-DOCSTART- (227508)

Naloxone	PROPN	O	I-Entity
reverses	VERB	O	O
the	DET	O	O
antihypertensive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
unanesthetized	ADJ	O	O
,	PUNCT	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
intravenous	ADJ	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
5	NUM	O	O
to	PART	O	O
20	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	ADV	O	O
,	PUNCT	O	O
was	VERB	O	O
inhibited	VERB	O	O
or	CCONJ	O	O
reversed	VERB	O	O
by	ADP	O	O
nalozone	NOUN	O	I-Entity
,	PUNCT	O	O
0.2	NUM	O	O
to	PART	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
hypotensive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
partially	ADV	O	O
reversed	VERB	O	O
by	ADP	O	O
naloxone	NOUN	O	I-Entity
.	PUNCT	O	O

Naloxone	PROPN	O	I-Entity
alone	ADV	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
either	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
or	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
brain	NOUN	O	O
membranes	NOUN	O	O
from	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
10(-8	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
10(-5	NUM	O	O
)	PUNCT	O	O

M	PROPN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
stereoselective	ADJ	O	O
binding	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
3H]-naloxone	NUM	O	I-Entity
(	PUNCT	O	O
8	NUM	O	O
nM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
naloxone	NOUN	O	I-Entity
,	PUNCT	O	O
10(-8	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
10(-4	NUM	O	O
)	PUNCT	O	O

M	PROPN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
suppressible	ADJ	O	O
binding	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
3H]-dihydroergocryptine	NUM	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
nM	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
stimulation	NOUN	O	O
involve	VERB	O	O
activation	NOUN	O	O
of	ADP	O	O
opiate	NOUN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
naloxone	NOUN	O	I-Entity
and	CCONJ	O	O
clonidine	NOUN	O	I-Entity
do	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
interact	VERB	O	O
with	ADP	O	O
the	DET	O	O
same	ADJ	O	O
receptor	NOUN	O	O
site	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
observed	VERB	O	O
functional	ADJ	O	O
antagonism	NOUN	O	O
suggests	VERB	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
an	DET	O	O
endogenous	ADJ	O	O
opiate	NOUN	O	O
by	ADP	O	O
clonidine	NOUN	O	I-Entity
or	CCONJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
opiate	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
sympathetic	ADJ	O	O
tone	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (354896)

Lidocaine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
asystole	NOUN	O	I-Entity
.	PUNCT	O	O

Intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
50-mg	NUM	O	O
bolus	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
67-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
profound	ADJ	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sinoatrial	ADJ	O	O
and	CCONJ	O	O
atrioventricular	ADJ	O	O
nodal	ADJ	O	O
pacemakers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
no	DET	O	O
apparent	ADJ	O	O
associated	ADJ	O	O
conditions	NOUN	O	O
which	ADJ	O	O
might	VERB	O	O
have	VERB	O	O
predisposed	VERB	O	O
him	PRON	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
bradyarrhythmias	NOUN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
thus	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
probably	ADV	O	O
represented	VERB	O	O
a	DET	O	O
true	ADJ	O	O
idiosyncrasy	NOUN	O	O
to	ADP	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (435349)

Suxamethonium	ADJ	O	I-Entity
infusion	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
observed	VERB	O	O
fasciculations	NOUN	O	I-Entity
.	PUNCT	O	O

Suxamethonium	PROPN	O	B-Entity
chloride	NOUN	O	I-Entity
(	PUNCT	O	O
Sch	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
to	ADP	O	O
36	NUM	O	O
adult	NOUN	O	O
males	NOUN	O	O
at	ADP	O	O
six	NUM	O	O
rates	NOUN	O	O
:	PUNCT	O	O

The	DET	O	O
infusion	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
either	CCONJ	O	O
when	ADV	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
muscular	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
tetanic	ADJ	O	I-Entity
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ulnar	ADJ	O	O
nerve	NOUN	O	O
or	CCONJ	O	O
when	ADV	O	O
Sch	PROPN	O	I-Entity
120	NUM	O	O
mg	NUM	O	O
was	VERB	O	O
exceeded	VERB	O	O
.	PUNCT	O	O

Fasciculations	NOUN	O	I-Entity
in	ADP	O	O
six	NUM	O	O
areas	NOUN	O	O
of	ADP	O	O
the	DET	O	O
body	NOUN	O	O
were	VERB	O	O
scored	VERB	O	O
from	ADP	O	O
0	NUM	O	O
to	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
summated	VERB	O	O
as	ADP	O	O
a	DET	O	O
total	ADJ	O	O
fasciculation	NOUN	O	I-Entity
score	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
times	NOUN	O	O
to	ADP	O	O
first	ADJ	O	O
fasciculation	NOUN	O	I-Entity
,	PUNCT	O	O
twitch	NOUN	O	I-Entity
suppression	NOUN	O	O
and	CCONJ	O	O
tetanus	NOUN	O	I-Entity
suppression	NOUN	O	O
were	VERB	O	O
inversely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
rates	NOUN	O	O
.	PUNCT	O	O

Fasciculations	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
six	NUM	O	O
areas	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
total	ADJ	O	O
fasciculation	NOUN	O	I-Entity
score	NOUN	O	O
were	VERB	O	O
related	VERB	O	O
directly	ADV	O	O
to	ADP	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
fasciculation	NOUN	O	I-Entity
scores	NOUN	O	O
in	ADP	O	O
the	DET	O	O
30-mg	PROPN	O	O
bolus	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
5-mg	NUM	O	O
s-1	NOUN	O	O
and	CCONJ	O	O
20-mg	NUM	O	O
s-1	ADJ	O	O
infusion	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (603022)

Galanthamine	PROPN	O	B-Entity
hydrobromide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
longer	ADV	O	O
acting	VERB	O	O
anticholinesterase	ADP	O	O
drug	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
central	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
Hyoscine	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Galanthamine	PROPN	O	B-Entity
hydrobromide	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
anticholinesterase	NOUN	O	O
drug	NOUN	O	O
capable	ADJ	O	O
of	ADP	O	O
penetrating	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	ADJ	O	O
demonstrating	VERB	O	O
central	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
hyoscine	NOUN	O	I-Entity
)	PUNCT	O	O

overdosage	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
longer	ADV	O	O
acting	VERB	O	O
than	ADP	O	O
physostigmine	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
anaesthesia	NOUN	O	O
to	PART	O	O
reverse	VERB	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
depolarizing	VERB	O	O
neuromuscular	ADJ	O	O
block	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
studies	NOUN	O	O
into	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
necessary	ADJ	O	O
to	ADP	O	O
combating	VERB	O	O
scopolamine	NOUN	O	I-Entity
intoxication	NOUN	O	O
are	VERB	O	O
indicated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1378968)

Effects	NOUN	O	O
of	ADP	O	O
uninephrectomy	NOUN	O	O
and	CCONJ	O	O
high	ADJ	O	O
protein	NOUN	O	O
feeding	VERB	O	O
on	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
high	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
HP	PROPN	O	O
)	PUNCT	O	O
feeding	NOUN	O	O
,	PUNCT	O	O
uninephrectomy	NOUN	O	O
(	PUNCT	O	O
NX	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
these	DET	O	O
,	PUNCT	O	O
in	ADP	O	O
an	DET	O	O
attempt	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
glomerular	ADJ	O	O
hyperfiltration	NOUN	O	O
and	CCONJ	O	O
further	ADJ	O	O
progression	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Newborn	ADJ	O	O
female	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
fed	VERB	O	O
a	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
diet	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
randomized	ADJ	O	O
to	ADP	O	O
normal	ADJ	O	O
diet	NOUN	O	O
,	PUNCT	O	O
HP	PROPN	O	O
diet	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
vs.	X	O	O
19%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
NX	NOUN	O	O
or	CCONJ	O	O
HP+NX	NOUN	O	O
for	ADP	O	O
another	DET	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Corresponding	VERB	O	O
non	ADV	O	O
-	PUNCT	O	O
lithium	NOUN	O	I-Entity
pretreated	ADJ	O	O
groups	NOUN	O	O
were	VERB	O	O
generated	VERB	O	O
.	PUNCT	O	O

When	ADV	O	O
comparing	VERB	O	O
all	DET	O	O
lithium	NOUN	O	I-Entity
treated	VERB	O	O
versus	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
groups	NOUN	O	O
,	PUNCT	O	O
lithium	NOUN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
GFR	PROPN	O	O
)	PUNCT	O	O
without	ADP	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
effective	ADJ	O	O
renal	ADJ	O	O
plasma	NOUN	O	O
flow	NOUN	O	O
(	PUNCT	O	O
as	ADP	O	O
determined	VERB	O	O
by	ADP	O	O
a	DET	O	O
marker	NOUN	O	O
secreted	VERB	O	O
into	ADP	O	O
the	DET	O	O
proximal	ADJ	O	O
tubules	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
lithium	NOUN	O	I-Entity
clearance	NOUN	O	O
.	PUNCT	O	O

Consequently	ADV	O	O
,	PUNCT	O	O
lithium	NOUN	O	I-Entity
pretreatment	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
filtration	NOUN	O	O
fraction	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
fractional	ADJ	O	O
Li	PROPN	O	I-Entity
excretion	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
also	ADV	O	O
caused	VERB	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
systolic	ADJ	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
absence	NOUN	O	O
of	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

HP	PROPN	O	O
failed	VERB	O	O
to	PART	O	O
accentuante	VERB	O	O
progression	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
fact	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
increase	VERB	O	O
GFR	PROPN	O	O
and	CCONJ	O	O
decrease	VERB	O	O
plasma	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
lithium	NOUN	O	I-Entity
pretreated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

NX+HP	PROPN	O	O
caused	VERB	O	O
a	DET	O	O
further	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
in	ADP	O	O
Li	PROPN	O	I-Entity
-	PUNCT	O	O
pretreated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
Li	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
when	ADV	O	O
the	DET	O	O
GFR	PROPN	O	O
is	VERB	O	O
only	ADV	O	O
modestly	ADV	O	O
reduced	VERB	O	O
,	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
arterial	ADJ	O	O
systolic	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
model	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
the	DET	O	O
decline	NOUN	O	O
in	ADP	O	O
GFR	PROPN	O	O
is	VERB	O	O
not	ADV	O	O
accompanied	VERB	O	O
by	ADP	O	O
a	DET	O	O
corresponding	VERB	O	O
fall	NOUN	O	O
in	ADP	O	O
effective	ADJ	O	O
renal	ADJ	O	O
plasma	NOUN	O	O
flow	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
functional	ADJ	O	O
expression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
nonfiltrating	VERB	O	O
atubular	ADJ	O	O
glomeruli	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1420741)

Treatment	NOUN	O	O
of	ADP	O	O
Crohn	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
with	ADP	O	O
fusidic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
antibiotic	NOUN	O	O
with	ADP	O	O
immunosuppressive	ADJ	O	O
properties	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
cyclosporin	VERB	O	I-Entity
.	PUNCT	O	O

Fusidic	PROPN	O	O
acid	NOUN	O	O
is	VERB	O	O
an	DET	O	O
antibiotic	NOUN	O	O
with	ADP	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	PROPN	O	O
specific	ADJ	O	O
immunosuppressive	ADJ	O	O
effects	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
cyclosporin	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
treatments	NOUN	O	O
for	ADP	O	O
Crohn	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
pharmacodynamics	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
fusidic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
active	ADJ	O	O
,	PUNCT	O	O
therapy	NOUN	O	O
-	PUNCT	O	O
resistant	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
Crohn	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

Fusidic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
orally	ADV	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
500	NUM	O	O
mg	NUM	O	O
t.d.s	NUM	O	O
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
8	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
63%	NUM	O	O
)	PUNCT	O	O
improved	VERB	O	O
during	ADP	O	O
fusidic	ADJ	O	B-Entity
acid	ADJ	O	I-Entity
treatment	NOUN	O	O
:	PUNCT	O	O
3	NUM	O	O
at	ADP	O	O
two	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
after	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
serious	ADJ	O	O
clinical	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
was	VERB	O	O
required	VERB	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
nausea	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
fusidic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
of	ADP	O	O
benefit	NOUN	O	O
in	ADP	O	O
selected	VERB	O	O
chronic	ADJ	O	O
active	ADJ	O	O
Crohn	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
conventional	ADJ	O	O
treatment	NOUN	O	O
is	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

Because	ADP	O	O
there	ADV	O	O
seems	VERB	O	O
to	PART	O	O
exist	VERB	O	O
a	DET	O	O
scientific	ADJ	O	O
rationale	NOUN	O	O
for	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
fusidic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
cytokine	NOUN	O	O
level	NOUN	O	O
in	ADP	O	O
inflammatory	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
this	DET	O	O
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
further	ADV	O	O
investigated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1601297)

Electrocardiographic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
psychiatrically	ADV	O	O
hospitalized	VERB	O	O
cocaine	NOUN	O	I-Entity
abusers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
electrocardiograms	NOUN	O	O
(	PUNCT	O	O
ECG	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
99	NUM	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
abusing	VERB	O	O
patients	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
ECGs	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
schizophrenic	ADJ	O	I-Entity
controls	NOUN	O	O
.	PUNCT	O	O

Eleven	NUM	O	O
of	ADP	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
abusers	NOUN	O	O
and	CCONJ	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
had	VERB	O	O
ECG	PROPN	O	O
evidence	NOUN	O	O
of	ADP	O	O
significant	ADJ	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
defined	VERB	O	O
as	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
,	PUNCT	O	O
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
bundle	ADJ	O	B-Entity
branch	NOUN	O	I-Entity
block	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1967484)

Sulpiride	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tardive	ADJ	O	B-Entity
dystonia	NOUN	O	I-Entity
.	PUNCT	O	O

Sulpiride	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
D2-receptor	NOUN	O	O
antagonist	NOUN	O	O
with	ADP	O	O
antipsychotic	ADJ	O	O
and	CCONJ	O	O
antidepressant	ADJ	O	I-Entity
properties	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
initially	ADV	O	O
thought	VERB	O	O
to	PART	O	O
be	VERB	O	O
free	ADJ	O	O
of	ADP	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
sulpiride	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
and	CCONJ	O	O
parkinsonism	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
occasionally	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
a	DET	O	O
37-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
persistent	ADJ	O	O
segmental	ADJ	O	O
dystonia	NOUN	O	I-Entity
within	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
starting	VERB	O	O
sulpiride	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
could	VERB	O	O
not	ADV	O	O
find	VERB	O	O
any	DET	O	O
previous	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
sulpiride	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tardive	ADJ	O	B-Entity
dystonia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2234245)

Ocular	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
auditory	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
hemodialyzed	ADJ	O	O
patients	NOUN	O	O
receiving	VERB	O	O
desferrioxamine	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
an	DET	O	O
18-month	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
41	NUM	O	O
hemodialyzed	VERB	O	O
patients	NOUN	O	O
receiving	VERB	O	O
desferrioxamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
BW/3	ADP	O	O
times	NOUN	O	O
weekly	ADV	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
were	VERB	O	O
monitored	VERB	O	O
for	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
audiovisual	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

6	NUM	O	O
patients	NOUN	O	O
presented	VERB	O	O
clinical	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-Entity
or	CCONJ	O	I-Entity
auditory	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Visual	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
of	ADP	O	O
retinal	ADJ	O	O
origin	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
a	DET	O	O
tritan	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
dyschromatopsy	NOUN	O	I-Entity
,	PUNCT	O	O
sometimes	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	B-Entity
loss	NOUN	O	I-Entity
of	ADP	O	I-Entity
visual	ADJ	O	I-Entity
acuity	NOUN	O	I-Entity
and	CCONJ	O	O
pigmentary	ADJ	O	B-Entity
retinal	ADJ	O	I-Entity
deposits	NOUN	O	I-Entity
.	PUNCT	O	O

Auditory	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
a	DET	O	O
mid-	NOUN	O	O
to	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
frequency	NOUN	O	O
neurosensorial	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
lesion	NOUN	O	O
was	VERB	O	O
of	ADP	O	O
the	DET	O	O
cochlear	ADJ	O	O
type	NOUN	O	O
.	PUNCT	O	O

Desferrioxamine	NOUN	O	I-Entity
withdrawal	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
complete	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
and	CCONJ	O	O
partial	ADJ	O	O
recovery	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
complete	ADJ	O	O
reversal	NOUN	O	O
of	ADP	O	O
hearing	VERB	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
and	CCONJ	O	O
partial	ADJ	O	O
recovery	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
.	PUNCT	O	O

This	DET	O	O
toxicity	NOUN	O	I-Entity
appeared	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
the	DET	O	O
higher	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
desferrioxamine	NOUN	O	I-Entity
or	CCONJ	O	O
coincided	VERB	O	O
with	ADP	O	O
the	DET	O	O
normalization	NOUN	O	O
of	ADP	O	O
ferritin	NOUN	O	O
or	CCONJ	O	O
aluminium	NOUN	O	I-Entity
serum	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
audiovisual	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
an	DET	O	O
infrequent	ADJ	O	O
complication	NOUN	O	O
in	ADP	O	O
hemodialyzed	VERB	O	O
patients	NOUN	O	O
receiving	VERB	O	O
desferrioxamine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2385256)

Myasthenia	PROPN	O	B-Entity
gravis	NOUN	O	I-Entity
presenting	VERB	O	O
as	ADP	O	O
weakness	NOUN	O	O
after	ADP	O	O
magnesium	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
no	DET	O	O
prior	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
neuromuscular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
became	VERB	O	O
virtually	ADV	O	O
quadriplegic	ADJ	O	I-Entity
after	ADP	O	O
parenteral	ADJ	O	O
magnesium	NOUN	O	I-Entity
administration	NOUN	O	O
for	ADP	O	O
preeclampsia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
magnesium	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
3.0	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
usually	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
magnesium	NOUN	O	I-Entity
was	VERB	O	O
stopped	VERB	O	O
and	CCONJ	O	O
she	PRON	O	O
recovered	VERB	O	O
over	ADP	O	O
a	DET	O	O
few	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
she	PRON	O	O
was	VERB	O	O
weak	ADJ	O	O
,	PUNCT	O	O
2-Hz	NUM	O	O
repetitive	ADJ	O	O
stimulation	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
decrement	NOUN	O	O
without	ADP	O	O
significant	ADJ	O	O
facilitation	NOUN	O	O
at	ADP	O	O
rapid	ADJ	O	O
rates	NOUN	O	O
or	CCONJ	O	O
after	ADP	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
postsynaptic	ADJ	O	B-Entity
neuromuscular	ADJ	O	I-Entity
blockade	NOUN	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
antibody	NOUN	O	O
level	NOUN	O	O
was	VERB	O	O
markedly	ADV	O	O
elevated	VERB	O	O
.	PUNCT	O	O

Although	ADP	O	O
paralysis	NOUN	O	I-Entity
after	ADP	O	O
magnesium	NOUN	O	I-Entity
administration	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
known	VERB	O	O
myasthenia	NOUN	O	B-Entity
gravis	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
has	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
or	CCONJ	O	O
only	ADJ	O	O
manifestation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
unusually	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
the	DET	O	O
neuromuscular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
magnesium	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
suspected	VERB	O	O
of	ADP	O	O
having	VERB	O	O
an	DET	O	O
underlying	ADJ	O	O
disorder	NOUN	O	B-Entity
of	ADP	O	I-Entity
neuromuscular	ADJ	O	I-Entity
transmission	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2505783)

Chloroacetaldehyde	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
contribution	NOUN	O	O
to	ADP	O	O
urotoxicity	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
or	CCONJ	O	O
ifosfamide	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
clinical	ADJ	O	O
data	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
chloroacetaldehyde	NOUN	O	I-Entity
(	PUNCT	O	O
CAA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
metabolite	NOUN	O	O
of	ADP	O	O
oxazaphosphorine	NOUN	O	O
cytostatics	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
experimental	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
elucidate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
CAA	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
CAA	PROPN	O	I-Entity
after	ADP	O	O
i.v	PROPN	O	O
.	PUNCT	O	O

administration	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
contribute	VERB	O	O
to	ADP	O	O
bladder	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
instilled	VERB	O	O
directly	ADV	O	O
into	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
,	PUNCT	O	O
CAA	PROPN	O	I-Entity
exerts	VERB	O	O
urotoxic	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
susceptible	ADJ	O	O
to	ADP	O	O
detoxification	NOUN	O	O
with	ADP	O	O
mesna	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2515254)

Source	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
and	CCONJ	O	O
primitive	ADJ	O	O
dysfunction	NOUN	O	O
in	ADP	O	O
migraine	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
identical	ADJ	O	O
site	NOUN	O	O
?	PUNCT	O	O

Twenty	NUM	O	O
common	ADJ	O	O
migraine	ADJ	O	I-Entity
patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
one	NUM	O	O
sided	VERB	O	O
frontotemporal	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
ointment	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Early	ADJ	O	O
onset	NOUN	O	O
migraine	ADJ	O	I-Entity
attacks	NOUN	O	O
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
in	ADP	O	O
seven	NUM	O	O
out	ADP	O	O
of	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
versus	ADP	O	O
no	DET	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Subsequently	ADV	O	O
20	NUM	O	O
migraine	ADJ	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
an	DET	O	O
early	ADJ	O	O
onset	NOUN	O	O
attack	NOUN	O	O
with	ADP	O	O
frontotemporal	ADJ	O	O
nitroglycerin	NOUN	O	I-Entity
,	PUNCT	O	O
received	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
a	DET	O	O
second	ADJ	O	O
induction	NOUN	O	O
test	NOUN	O	O
at	ADP	O	O
other	ADJ	O	O
body	NOUN	O	O
areas	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
early	ADJ	O	O
onset	NOUN	O	O
migraine	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Thus	ADV	O	O
the	DET	O	O
migraine	ADJ	O	I-Entity
-	PUNCT	O	O
inducing	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
depend	VERB	O	O
on	ADP	O	O
direct	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
habitual	ADJ	O	O
site	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
the	DET	O	O
frontotemporal	ADJ	O	O
region	NOUN	O	O
is	VERB	O	O
of	ADP	O	O
crucial	ADJ	O	O
importance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
a	DET	O	O
migraine	ADJ	O	I-Entity
crisis	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
not	ADV	O	O
consistent	ADJ	O	O
with	ADP	O	O
a	DET	O	O
CNS	PROPN	O	O
origin	NOUN	O	O
of	ADP	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2572625)

Clotiazepam	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
with	ADP	O	O
extensive	ADJ	O	B-Entity
hepatocellular	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
7	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
clotiazepam	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
thienodiazepine	NOUN	O	I-Entity
derivative	ADJ	O	O
.	PUNCT	O	O

Clotiazepam	PROPN	O	I-Entity
withdrawal	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
prompt	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
benzodiazepines	NOUN	O	I-Entity
,	PUNCT	O	O
chemically	ADV	O	O
related	VERB	O	O
to	ADP	O	O
clotiazepam	NOUN	O	I-Entity
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
interfere	VERB	O	O
with	ADP	O	O
recovery	NOUN	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
any	DET	O	O
relapse	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
clotiazepam	NOUN	O	I-Entity
can	VERB	O	O
induce	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
and	CCONJ	O	O
suggests	VERB	O	O
that	ADP	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
cross	NOUN	O	O
hepatotoxicity	NOUN	O	I-Entity
between	ADP	O	O
clotiazepam	NOUN	O	I-Entity
and	CCONJ	O	O
several	ADJ	O	O
benzodiazepines	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2632720)

Arterial	ADJ	O	O
hypertension	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
prolonged	ADJ	O	O
ketoconazole	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
of	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Cushing	PROPN	O	B-Entity
's	PART	O	I-Entity
syndrome	NOUN	O	I-Entity
treated	VERB	O	O
on	ADP	O	O
a	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
basis	NOUN	O	O
with	ADP	O	O
ketoconazole	NOUN	O	I-Entity
developed	VERB	O	O
sustained	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
cases	NOUN	O	O
normal	ADJ	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
free	ADJ	O	O
cortisol	NOUN	O	I-Entity
levels	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
achieved	VERB	O	O
following	VERB	O	O
ketoconazole	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
yet	ADV	O	O
continuous	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
monitoring	NOUN	O	O
demonstrated	VERB	O	O
hypertension	NOUN	O	I-Entity
31	NUM	O	O
(	PUNCT	O	O
patient	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
52	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
patient	ADJ	O	O
2	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patient	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
deoxycorticosterone	NOUN	O	I-Entity
and	CCONJ	O	O
11-deoxycortisol	NUM	O	I-Entity
were	VERB	O	O
elevated	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
patient	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
both	DET	O	O
deoxycorticosterone	NOUN	O	I-Entity
and	CCONJ	O	O
11-deoxycortisol	NUM	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
aldosterone	NOUN	O	I-Entity
values	NOUN	O	O
were	VERB	O	O
raised	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
concomitant	ADJ	O	O
suppression	NOUN	O	O
of	ADP	O	O
renin	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ketoconazole	NOUN	O	I-Entity
may	VERB	O	O
induce	VERB	O	O
enzyme	NOUN	O	O
blockade	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
mineralocorticoid	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2670794)

Effects	NOUN	O	O
of	ADP	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
Captopril	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
pulmonary	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
intravascular	ADJ	O	B-Entity
coagulation	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
of	ADP	O	O
intravascular	ADJ	O	B-Entity
coagulation	NOUN	O	I-Entity
and	CCONJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
fibrinolysis	NOUN	O	O
by	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
thrombin	NOUN	O	O
and	CCONJ	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
AMCA	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
gives	VERB	O	O
rise	VERB	O	O
to	ADP	O	O
pulmonary	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
resembling	VERB	O	O
that	DET	O	O
occurring	VERB	O	O
after	ADP	O	O
trauma	NOUN	O	I-Entity
or	CCONJ	O	O
sepsis	NOUN	O	I-Entity
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Injection	NOUN	O	O
of	ADP	O	O
Captopril	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
reduced	VERB	O	O
both	DET	O	O
pulmonary	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
contents	NOUN	O	O
of	ADP	O	O
albumin	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lungs	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
changed	VERB	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
Captopril	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
influence	VERB	O	O
the	DET	O	O
extravasation	NOUN	O	O
of	ADP	O	O
protein	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
as	ADP	O	O
reflected	VERB	O	O
by	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
urea	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
kidney	NOUN	O	O
weight	NOUN	O	O
was	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
Captopril	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
fibrin	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kidneys	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
considerably	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
animals	NOUN	O	O
which	ADJ	O	O
received	VERB	O	O
thrombin	NOUN	O	O
and	CCONJ	O	O
AMCA	PROPN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
Captopril	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
lungs	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
a	DET	O	O
vasodilatory	NOUN	O	O
effect	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
circulating	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
Angiotension	PROPN	O	B-Entity
II	PROPN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
prostacyclin	PROPN	O	I-Entity
(	PUNCT	O	O
secondary	ADJ	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
bradykinin	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Captopril	PROPN	O	I-Entity
may	VERB	O	O
,	PUNCT	O	O
by	ADP	O	O
the	DET	O	O
same	ADJ	O	O
mechanism	NOUN	O	O
,	PUNCT	O	O
reduce	VERB	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
occur	VERB	O	O
after	ADP	O	O
an	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
thrombin	NOUN	O	O
,	PUNCT	O	O
thereby	ADV	O	O
diminishing	VERB	O	O
the	DET	O	O
aggregation	NOUN	O	O
of	ADP	O	O
fibrin	NOUN	O	O
monomers	NOUN	O	O
in	ADP	O	O
the	DET	O	O
glomeruli	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
result	NOUN	O	O
that	ADJ	O	O
less	ADJ	O	O
fibrin	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
deposited	VERB	O	O
and	CCONJ	O	O
thus	ADV	O	O
less	ADJ	O	O
kidney	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
will	VERB	O	O
be	VERB	O	O
produced	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2696505)

A	DET	O	O
randomized	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
labetalol	NOUN	O	I-Entity
and	CCONJ	O	O
nitroprusside	NOUN	O	I-Entity
for	ADP	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
labetalol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
nitroprusside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
)	PUNCT	O	O
scheduled	VERB	O	O
for	ADP	O	O
major	ADJ	O	O
orthopedic	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
an	DET	O	O
identical	ADJ	O	O
anesthetic	NOUN	O	O
protocol	NOUN	O	O
and	CCONJ	O	O
similar	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
reductions	NOUN	O	B-Entity
in	ADP	O	I-Entity
mean	ADJ	O	I-Entity
arterial	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
(	PUNCT	O	O
BP	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
50	NUM	O	O
to	PART	O	O
55	NUM	O	O
mmHg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nitroprusside	PROPN	O	O
infusion	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
heart	NOUN	O	I-Entity
rate	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
cardiac	ADJ	O	I-Entity
output	NOUN	O	I-Entity
;	PUNCT	O	O
rebound	VERB	O	O
hypertension	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
nitroprusside	NOUN	O	I-Entity
.	PUNCT	O	O

Labetalol	PROPN	O	I-Entity
administration	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
any	DET	O	O
of	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Arterial	ADJ	O	O
PO2	PROPN	O	I-Entity
decreased	VERB	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
labetalol	NOUN	O	I-Entity
offers	VERB	O	O
advantages	NOUN	O	O
over	ADP	O	O
nitroprusside	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2924746)

Chronic	ADJ	O	O
carbamazepine	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
:	PUNCT	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
effect	NOUN	O	O
on	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
tissue	NOUN	O	O
folate	ADJ	O	I-Entity
concentrations	NOUN	O	O
.	PUNCT	O	O

Folate	PROPN	O	I-Entity
depletion	NOUN	O	O
has	VERB	O	O
often	ADV	O	O
been	VERB	O	O
a	DET	O	O
problem	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
(	PUNCT	O	O
AED	PROPN	O	O
)	PUNCT	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Carbamazepine	PROPN	O	I-Entity
(	PUNCT	O	O
CBZ	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
commonly	ADV	O	O
used	VERB	O	O
AED	PROPN	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
some	DET	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
CBZ	PROPN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
folate	NOUN	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
this	DET	O	O
model	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
common	ADJ	O	O
vehicle	NOUN	O	O
,	PUNCT	O	O
propylene	NOUN	O	B-Entity
glycol	NOUN	O	I-Entity
,	PUNCT	O	O
by	ADP	O	O
itself	PRON	O	O
in	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
to	ADP	O	O
exhibit	VERB	O	O
protective	ADJ	O	O
properties	NOUN	O	O
against	ADP	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
inhibited	VERB	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
hexafluorodiethyl	NOUN	O	B-Entity
ether	NOUN	O	I-Entity
(	PUNCT	O	O
HFDE	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
more	ADV	O	O
sensitive	ADJ	O	O
measure	NOUN	O	O
of	ADP	O	O
protection	NOUN	O	O
by	ADP	O	O
CBZ	PROPN	O	I-Entity
than	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
maximal	ADJ	O	O
electroshock	NOUN	O	O
(	PUNCT	O	O
MES	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
CBZ	PROPN	O	I-Entity
as	ADP	O	O
an	DET	O	O
aqueous	ADJ	O	O
suspension	NOUN	O	O
every	DET	O	O
8	NUM	O	O
h	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
250	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
was	VERB	O	O
continuously	ADV	O	O
protective	ADJ	O	O
against	ADP	O	O
HFDE	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
minimally	ADV	O	O
toxic	ADJ	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
over	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
CBZ	PROPN	O	I-Entity
levels	NOUN	O	O
measured	VERB	O	O
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
of	ADP	O	O
these	DET	O	O
animals	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
below	ADP	O	O
those	DET	O	O
normally	ADV	O	O
considered	VERB	O	O
protective	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
treatment	NOUN	O	O
with	ADP	O	O
CBZ	PROPN	O	I-Entity
had	VERB	O	O
no	DET	O	O
apparent	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
folate	NOUN	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
indeed	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
folate	NOUN	O	I-Entity
concentration	NOUN	O	O
increased	VERB	O	O
in	ADP	O	O
liver	NOUN	O	O
after	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
plasma	NOUN	O	O
at	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2951327)

In	ADP	O	O
six	NUM	O	O
conscious	ADJ	O	O
,	PUNCT	O	O
trained	VERB	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
maintained	VERB	O	O
on	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
sodium	NOUN	O	I-Entity
intake	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
to	ADP	O	O
4	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
sympathetic	ADJ	O	O
activity	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
as	ADP	O	O
the	DET	O	O
release	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
norepinephrine	NOUN	O	I-Entity
and	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
during	ADP	O	O
15-minute	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

6%	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
tachycardia	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
augmentation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
norepinephrine	ADJ	O	I-Entity
release	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
up	ADP	O	O
to	ADP	O	O
0.3	NUM	O	O
microgram	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
in	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
comparable	ADJ	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
hydralazine	NOUN	O	I-Entity
or	CCONJ	O	O
nitroglycerin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
release	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
6.7	NUM	O	O
+	X	O	O
/-	PUNCT	O	O


-DOCSTART- (3192036)

Death	NOUN	O	I-Entity
from	ADP	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
gestational	ADJ	O	B-Entity
trophoblastic	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Multiple	PROPN	O	O
cytotoxic	ADJ	O	O
drug	NOUN	O	O
administration	NOUN	O	O
is	VERB	O	O
the	DET	O	O
generally	ADV	O	O
accepted	VERB	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
stage	NOUN	O	O
of	ADP	O	O
choriocarcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
multiple	ADJ	O	O
drug	NOUN	O	O
schema	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
:	PUNCT	O	O
Etoposide	ADV	O	I-Entity
16.213	NUM	O	O
,	PUNCT	O	O
Methotrexate	PROPN	O	I-Entity
,	PUNCT	O	O
Cyclophosphamide	PROPN	O	I-Entity
,	PUNCT	O	O
Actomycin	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
D	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
Cisplatin	PROPN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
the	DET	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
moderate	ADJ	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
Methotrexate	PROPN	O	I-Entity
,	PUNCT	O	O
Etoposide	PROPN	O	I-Entity
and	CCONJ	O	O
Cyclophosphamide	PROPN	O	I-Entity
were	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Within	ADP	O	O
8	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
the	DET	O	O
patient	NOUN	O	O
died	VERB	O	O
with	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
picture	NOUN	O	O
resembling	VERB	O	O
massive	ADJ	O	O
pulmonary	ADJ	O	B-Entity
obstruction	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
choriocarcinomic	ADJ	O	O
tissue	NOUN	O	O
plugs	NOUN	O	O
,	PUNCT	O	O
probably	ADV	O	O
originating	VERB	O	O
from	ADP	O	O
the	DET	O	O
uterus	NOUN	O	O
.	PUNCT	O	O

Formation	NOUN	O	O
of	ADP	O	O
these	DET	O	O
plugs	NOUN	O	O
was	VERB	O	O
probably	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
extensive	ADJ	O	O
tumor	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
the	DET	O	O
walls	NOUN	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
uterine	NOUN	O	O
veins	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
open	ADJ	O	O
exchange	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
plugs	NOUN	O	O
to	ADP	O	O
the	DET	O	O
vascular	ADJ	O	O
spaces	NOUN	O	O
;	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
tumor	NOUN	O	I-Entity
tissue	NOUN	O	O
coherence	NOUN	O	O
secondary	ADJ	O	O
to	ADP	O	O
chemotherapy	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
further	ADV	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
emboli	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
view	NOUN	O	O
of	ADP	O	O
the	DET	O	O
close	ADJ	O	O
time	NOUN	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
acute	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
massive	ADJ	O	O
embolism	NOUN	O	I-Entity
other	ADJ	O	O
explanations	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
spontaneous	ADJ	O	O
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
must	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
less	ADV	O	O
likely	ADJ	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
large	ADJ	O	O
pelvic	ADJ	O	B-Entity
tumor	NOUN	O	I-Entity
loads	NOUN	O	O
are	VERB	O	O
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
existing	VERB	O	O
classifications	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
to	PART	O	O
die	VERB	O	O
and	CCONJ	O	O
to	PART	O	O
develop	VERB	O	O
drug	NOUN	O	O
resistance	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3409645)

Sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
relationship	NOUN	O	O
of	ADP	O	O
arthritis	NOUN	O	I-Entity
and	CCONJ	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
was	VERB	O	O
investigated	VERB	O	O
among	ADP	O	O
169	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
,	PUNCT	O	O
osteoarthritis	NOUN	O	I-Entity
and	CCONJ	O	O
spondyloarthropathy	NOUN	O	I-Entity
,	PUNCT	O	O
130	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
were	VERB	O	O
pair	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Assessments	NOUN	O	O
of	ADP	O	O
marital	ADJ	O	O
happiness	NOUN	O	O
and	CCONJ	O	O
depressed	ADJ	O	B-Entity
mood	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
made	VERB	O	O
using	VERB	O	O
the	DET	O	O
CES	PROPN	O	O
-	PUNCT	O	O
D	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
Azrin	PROPN	O	O
Marital	PROPN	O	O
Happiness	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
AMHS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Sexual	ADJ	O	B-Entity
dysfunctions	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
common	ADJ	O	O
among	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
controls	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
majority	NOUN	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
reporting	VERB	O	O
one	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
dysfunctions	NOUN	O	O
.	PUNCT	O	O

Impotence	NOUN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
among	ADP	O	O
male	ADJ	O	O
patients	NOUN	O	O
than	ADP	O	O
controls	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
co	NOUN	O	O
-	PUNCT	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
taking	NOUN	O	O
of	ADP	O	O
methotrexate	NOUN	O	I-Entity
.	PUNCT	O	O

Depressed	ADJ	O	B-Entity
mood	NOUN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
among	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
certain	ADJ	O	O
sexual	ADJ	O	O
difficulties	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
impotence	NOUN	O	I-Entity
.	PUNCT	O	O

Marital	ADJ	O	O
unhappiness	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
indicated	VERB	O	O
by	ADP	O	O
AMHS	PROPN	O	O
scores	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
arthritis	NOUN	O	I-Entity
but	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
sexual	ADJ	O	O
dissatisfaction	NOUN	O	O
and	CCONJ	O	O
being	VERB	O	O
female	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (3412544)

Does	VERB	O	O
paracetamol	NOUN	O	I-Entity
cause	VERB	O	O
urothelial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
or	CCONJ	O	O
renal	ADJ	O	B-Entity
papillary	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
?	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
renal	ADJ	O	B-Entity
papillary	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
or	CCONJ	O	O
cancer	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
renal	ADJ	O	I-Entity
pelvis	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
ureter	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
bladder	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
consumption	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
phenacetin	NOUN	O	I-Entity
or	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
was	VERB	O	O
calculated	VERB	O	O
from	ADP	O	O
data	NOUN	O	O
acquired	VERB	O	O
by	ADP	O	O
questionnaire	NOUN	O	O
from	ADP	O	O
381	NUM	O	O
cases	NOUN	O	O
and	CCONJ	O	O
808	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
papillary	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
was	VERB	O	O
increased	VERB	O	O
nearly	ADV	O	O
20-fold	ADV	O	O
by	ADP	O	O
consumption	NOUN	O	O
of	ADP	O	O
phenacetin	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
also	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
cancer	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
renal	ADJ	O	I-Entity
pelvis	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
bladder	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
ureteric	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

By	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
were	VERB	O	O
unable	ADJ	O	O
to	PART	O	O
substantiate	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
from	ADP	O	O
paracetamol	NOUN	O	I-Entity
consumption	NOUN	O	O
for	ADP	O	O
renal	ADJ	O	B-Entity
papillary	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
or	CCONJ	O	O
any	DET	O	O
of	ADP	O	O
these	DET	O	O
cancers	NOUN	O	I-Entity
although	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
suggestion	NOUN	O	O
of	ADP	O	O
an	DET	O	O
association	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
ureter	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3425586)

Dapsone	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
Heinz	PROPN	O	O
body	NOUN	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
Cambodian	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
hemoglobin	NOUN	O	O
E	NOUN	O	O
trait	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
Cambodian	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
hemoglobin	NOUN	O	O
E	NOUN	O	O
trait	NOUN	O	O
(	PUNCT	O	O
AE	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
leprosy	NOUN	O	I-Entity
developed	VERB	O	O
a	DET	O	O
Heinz	PROPN	O	O
body	NOUN	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
while	ADP	O	O
taking	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
dapsone	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
not	ADV	O	O
usually	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
clinical	ADJ	O	O
hemolysis	NOUN	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
(	PUNCT	O	O
RBCs	PROPN	O	O
)	PUNCT	O	O
had	VERB	O	O
increased	VERB	O	O
incubated	VERB	O	O
Heinz	PROPN	O	O
body	NOUN	O	O
formation	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
reduced	VERB	O	O
glutathione	NOUN	O	I-Entity
(	PUNCT	O	O
GSH	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
decreased	VERB	O	O
GSH	PROPN	O	I-Entity
stability	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pentose	ADJ	O	B-Entity
phosphate	NOUN	O	I-Entity
shunt	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dapsone	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
AE	PROPN	O	O
RBCs	PROPN	O	O
was	VERB	O	O
increased	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
RBCs	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
AE	PROPN	O	O
RBCs	PROPN	O	O
from	ADP	O	O
an	DET	O	O
individual	NOUN	O	O
not	ADV	O	O
taking	VERB	O	O
dapsone	NOUN	O	I-Entity
had	VERB	O	O
increased	VERB	O	O
incubated	VERB	O	O
Heinz	PROPN	O	O
body	NOUN	O	O
formation	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
GSH	PROPN	O	I-Entity
content	NOUN	O	O
and	CCONJ	O	O
GSH	PROPN	O	I-Entity
stability	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
pentose	ADJ	O	B-Entity
phosphate	NOUN	O	I-Entity
shunt	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
dapsone	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
AE	PROPN	O	O
RBCs	PROPN	O	O
was	VERB	O	O
decreased	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
RBCs	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
AE	PROPN	O	O
RBCs	PROPN	O	O
appear	VERB	O	O
to	PART	O	O
have	VERB	O	O
an	DET	O	O
increased	VERB	O	O
sensitivity	NOUN	O	O
to	PART	O	O
oxidant	VERB	O	O
stress	NOUN	O	O
both	CCONJ	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
since	ADP	O	O
dapsone	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
at	ADP	O	O
this	DET	O	O
dose	NOUN	O	O
in	ADP	O	O
hematologically	ADV	O	O
normal	ADJ	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
influx	NOUN	O	O
of	ADP	O	O
Southeast	PROPN	O	O
Asians	PROPN	O	O
into	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
,	PUNCT	O	O
oxidant	ADJ	O	O
medications	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
with	ADP	O	O
caution	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
if	ADP	O	O
an	DET	O	O
infection	NOUN	O	I-Entity
is	VERB	O	O
present	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
individuals	NOUN	O	O
of	ADP	O	O
ethnic	ADJ	O	O
backgrounds	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
an	DET	O	O
increased	VERB	O	O
prevalence	NOUN	O	O
of	ADP	O	O
hemoglobin	NOUN	O	O
E.	PROPN	O	O


-DOCSTART- (3437726)

Severe	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
antianginal	ADJ	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
identified	VERB	O	O
as	ADP	O	O
a	DET	O	O
poor	ADJ	O	O
metabolizer	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
,	PUNCT	O	O
propafenone	NOUN	O	I-Entity
,	PUNCT	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sparteine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
47-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
CCU	PROPN	O	O
in	ADP	O	O
shock	NOUN	O	I-Entity
with	ADP	O	O
III	PROPN	O	O
.	PUNCT	O	O

AV	NOUN	O	B-Entity
block	NOUN	O	I-Entity
,	PUNCT	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
ventricular	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
week	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
admission	NOUN	O	O
a	DET	O	O
therapy	NOUN	O	O
with	ADP	O	O
standard	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	NUM	O	O
t.i.d	NUM	O	O
.	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
100	NUM	O	O
mg	NUM	O	O
b.i.d	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
had	VERB	O	O
been	VERB	O	O
initiated	VERB	O	O
.	PUNCT	O	O

Two	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
admission	NOUN	O	O
diltiazem	NOUN	O	I-Entity
(	PUNCT	O	O
60	NUM	O	O
mg	NUM	O	O
b.i.d	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
prescribed	VERB	O	O
in	ADP	O	O
addition	NOUN	O	O
.	PUNCT	O	O

Analyses	NOUN	O	O
of	ADP	O	O
a	DET	O	O
blood	NOUN	O	O
sample	NOUN	O	O
revealed	VERB	O	O
unusually	ADV	O	O
high	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
(	PUNCT	O	O
greater	ADJ	O	O
than	ADP	O	O
3000	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
ml	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diltiazem	NOUN	O	I-Entity
(	PUNCT	O	O
526	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
ml	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
months	NOUN	O	O
later	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
,	PUNCT	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
propafenone	NOUN	O	I-Entity
(	PUNCT	O	O
since	ADP	O	O
he	PRON	O	O
had	VERB	O	O
received	VERB	O	O
this	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
the	DET	O	O
past	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sparteine	NOUN	O	I-Entity
(	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
probe	NOUN	O	O
for	ADP	O	O
the	DET	O	O
debrisoquine	NOUN	O	I-Entity
/	PUNCT	O	O
sparteine	ADJ	O	I-Entity
type	NOUN	O	O
polymorphism	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
drug	NOUN	O	O
metabolism	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
patients	NOUN	O	O
belonging	VERB	O	O
to	ADP	O	O
the	DET	O	O
poor	ADJ	O	O
-	PUNCT	O	O
metabolizer	NOUN	O	O
phenotype	NOUN	O	O
of	ADP	O	O
sparteine	NOUN	O	I-Entity
/	SYM	O	O
debrisoquine	NOUN	O	I-Entity
polymorphism	NOUN	O	O
in	ADP	O	O
drug	NOUN	O	O
metabolism	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
constitutes	VERB	O	O
6.4%	NUM	O	O
of	ADP	O	O
the	DET	O	O
German	ADJ	O	O
population	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
experience	VERB	O	O
adverse	ADJ	O	B-Entity
drug	NOUN	O	I-Entity
reactions	NOUN	O	I-Entity
when	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
standard	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
alone	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (3693336)

Triazolam	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
brief	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	O
mania	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
depressed	ADJ	O	I-Entity
patient	NOUN	O	O
.	PUNCT	O	O

Large	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
triazolam	NOUN	O	I-Entity
repeatedly	ADV	O	O
induced	VERB	O	O
brief	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
mania	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
depressed	ADJ	O	I-Entity
elderly	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O

Features	NOUN	O	O
of	ADP	O	O
organic	ADJ	O	B-Entity
mental	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
delirium	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
not	ADV	O	O
present	ADJ	O	O
.	PUNCT	O	O

Manic	ADJ	O	I-Entity
excitement	NOUN	O	O
was	VERB	O	O
coincident	ADJ	O	O
with	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
of	ADP	O	O
triazolam	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
contribution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
triazolo	NOUN	O	I-Entity
group	NOUN	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
affective	ADJ	O	O
status	NOUN	O	O
is	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3780846)

On	ADP	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
tolerance	NOUN	O	O
to	ADP	O	O
the	DET	O	O
muscular	ADJ	O	B-Entity
rigidity	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
tolerance	NOUN	O	O
to	ADP	O	O
the	DET	O	O
muscular	ADJ	O	B-Entity
rigidity	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Saline	PROPN	O	O
-	PUNCT	O	O
pretreated	ADJ	O	O
controls	NOUN	O	O
given	VERB	O	O
a	DET	O	O
test	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
showed	VERB	O	O
a	DET	O	O
pronounced	ADJ	O	O
rigidity	NOUN	O	I-Entity
recorded	VERB	O	O
as	ADP	O	O
tonic	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
electromyogram	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
11	NUM	O	O
days	NOUN	O	O
with	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
withdrawn	VERB	O	O
for	ADP	O	O
36	NUM	O	O
-	SYM	O	O
40	NUM	O	O
h	NOUN	O	O
showed	VERB	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
tolerance	NOUN	O	O
:	PUNCT	O	O
about	ADP	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
rigidity	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
test	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
that	ADJ	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
akinetic	ADJ	O	I-Entity
(	PUNCT	O	O
A	DET	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
other	ADJ	O	O
rats	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rigidity	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
stereotyped	ADJ	O	O
(	PUNCT	O	O
S	PROPN	O	O
)	PUNCT	O	O
licking	VERB	O	O
and/or	CCONJ	O	O
gnawing	VERB	O	O
in	ADP	O	O
presence	NOUN	O	O
of	ADP	O	O
akinetic	ADJ	O	I-Entity
or	CCONJ	O	O
hyperkinetic	ADJ	O	I-Entity
(	PUNCT	O	O
K	PROPN	O	O
)	PUNCT	O	O
behaviour	NOUN	O	O
(	PUNCT	O	O
AS	PROPN	O	O
/	SYM	O	O
KS	PROPN	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
dopaminergic	ADJ	O	O
activation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rigidity	NOUN	O	I-Entity
was	VERB	O	O
considerably	ADV	O	O
decreased	VERB	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
after	ADP	O	O
20	NUM	O	O
days	NOUN	O	O
'	PART	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
further	ADJ	O	O
series	NOUN	O	O
of	ADP	O	O
experiments	NOUN	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
0.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
block	VERB	O	O
the	DET	O	O
dopaminergic	ADJ	O	O
activation	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
real	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tolerance	NOUN	O	O
to	ADP	O	O
the	DET	O	O
rigidity	NOUN	O	I-Entity
without	ADP	O	O
any	DET	O	O
dopaminergic	ADJ	O	O
interference	NOUN	O	O
.	PUNCT	O	O

Haloperidol	PROPN	O	I-Entity
enhanced	VERB	O	O
the	DET	O	O
rigidity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
A	PROPN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
assumed	VERB	O	O
to	PART	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
action	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
can	VERB	O	O
be	VERB	O	O
antagonized	VERB	O	O
by	ADP	O	O
another	DET	O	O
process	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
dopaminergic	ADJ	O	O
activation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rapid	ADJ	O	O
alternations	NOUN	O	O
of	ADP	O	O
rigidity	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
dopaminergic	ADJ	O	O
activation	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
AS	PROPN	O	O
/	SYM	O	O
KS	PROPN	O	O
group	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
rapid	ADJ	O	O
shifts	NOUN	O	O
in	ADP	O	O
the	DET	O	O
predominance	NOUN	O	O
of	ADP	O	O
various	ADJ	O	O
DA	PROPN	O	O
-	PUNCT	O	O
innervated	VERB	O	O
structures	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3800626)

Compression	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
radial	ADJ	O	I-Entity
nerve	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
pentazocine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
fibrous	ADJ	O	B-Entity
myopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Fibrous	ADJ	O	B-Entity
myopathy	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
,	PUNCT	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
repeated	VERB	O	O
pentazocine	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
compression	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
fibrotic	ADJ	O	O
muscle	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
pentazocine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myopathy	NOUN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
37-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
documented	VERB	O	O
pentazocine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
fibrous	ADJ	O	B-Entity
myopathy	NOUN	O	I-Entity
of	ADP	O	O
triceps	NOUN	O	O
and	CCONJ	O	O
deltoid	ADJ	O	O
muscles	NOUN	O	O
bilaterally	ADV	O	O
and	CCONJ	O	O
a	DET	O	O
three	NUM	O	O
-	PUNCT	O	O
week	NOUN	O	O
history	NOUN	O	O
of	ADP	O	O
right	ADJ	O	O
wrist	NOUN	O	O
drop	NOUN	O	O
,	PUNCT	O	O
electrodiagnostic	ADJ	O	O
examination	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
severe	ADJ	O	O
but	CCONJ	O	O
partial	ADJ	O	O
lesion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
right	ADJ	O	O
radial	ADJ	O	O
nerve	NOUN	O	O
distal	NOUN	O	O
to	ADP	O	O
the	DET	O	O
branches	NOUN	O	O
to	ADP	O	O
the	DET	O	O
triceps	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
fibrous	ADJ	O	B-Entity
myopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3827439)

Recurrent	ADJ	O	O
reversible	ADJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
from	ADP	O	O
amphotericin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
cryptogenic	ADJ	O	O
cirrhosis	NOUN	O	I-Entity
and	CCONJ	O	O
disseminated	VERB	O	O
sporotrichosis	NOUN	O	I-Entity
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
immediately	ADV	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
on	ADP	O	O
four	NUM	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
abruptness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
reversibility	NOUN	O	O
within	ADP	O	O
days	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
functional	ADJ	O	O
component	NOUN	O	O
to	ADP	O	O
the	DET	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
propose	VERB	O	O
that	ADP	O	O
amphotericin	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
reduced	VERB	O	O
effective	ADJ	O	O
arterial	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
activate	VERB	O	O
tubuloglomerular	ADJ	O	O
feedback	NOUN	O	O
,	PUNCT	O	O
thereby	ADV	O	O
contributing	VERB	O	O
to	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3997294)

Pneumonitis	PROPN	O	O
with	ADP	O	O
pleural	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
pericardial	ADJ	O	I-Entity
effusion	NOUN	O	I-Entity
and	CCONJ	O	O
neuropathy	NOUN	O	I-Entity
during	ADP	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
sinuatrial	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
implanted	ADJ	O	O
pacemaker	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
amiodarone	NOUN	O	I-Entity
(	PUNCT	O	O
maximum	ADJ	O	O
dose	NOUN	O	O
1000	NUM	O	O
mg	INTJ	O	O
,	PUNCT	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
800	NUM	O	O
mg	NUM	O	O
daily	ADJ	O	O
)	PUNCT	O	O
for	ADP	O	O
10	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
supraventricular	ADJ	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
developed	VERB	O	O
pneumonitis	NOUN	O	I-Entity
,	PUNCT	O	O
pleural	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
pericardial	ADJ	O	I-Entity
effusions	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
predominantly	ADV	O	O
proximal	ADJ	O	B-Entity
motor	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Immediate	ADJ	O	O
but	CCONJ	O	O
gradual	ADJ	O	O
improvement	NOUN	O	O
followed	VERB	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
prednisolone	NOUN	O	I-Entity
.	PUNCT	O	O

Review	NOUN	O	O
of	ADP	O	O
this	DET	O	O
and	CCONJ	O	O
previously	ADV	O	O
reported	VERB	O	O
cases	NOUN	O	O
indicates	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
early	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
pneumonitis	NOUN	O	I-Entity
,	PUNCT	O	O
immediate	ADJ	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
prompt	VERB	O	O
but	CCONJ	O	O
continued	VERB	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
to	PART	O	O
ensure	VERB	O	O
full	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (4071154)

Indomethacin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
:	PUNCT	O	O
recurrence	NOUN	O	O
on	ADP	O	O
rechallenge	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
reported	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
oliguric	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
with	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
cirrhosis	NOUN	O	I-Entity
,	PUNCT	O	O
ascites	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cor	VERB	O	B-Entity
pulmonale	NOUN	O	I-Entity
after	ADP	O	O
indomethacin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Prompt	ADJ	O	O
restoration	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
followed	VERB	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
re	ADP	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
indomethacin	NOUN	O	I-Entity
caused	VERB	O	O
recurrence	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
reversible	ADJ	O	O
oliguria	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
case	NOUN	O	O
supports	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
endogenous	ADJ	O	O
renal	ADJ	O	O
prostaglandins	NOUN	O	I-Entity
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
when	ADV	O	O
circulating	VERB	O	O
plasma	NOUN	O	O
volume	NOUN	O	O
is	VERB	O	O
diminished	VERB	O	O
.	PUNCT	O	O

Since	ADP	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
agents	NOUN	O	O
interfere	VERB	O	O
with	ADP	O	O
this	DET	O	O
compensatory	NOUN	O	O
mechanism	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
cause	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
they	PRON	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
with	ADP	O	O
caution	NOUN	O	O
in	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6103707)

administration	NOUN	O	O
of	ADP	O	O
flunitrazepam	NOUN	O	I-Entity
in	ADP	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Flunitrazepam	PROPN	O	I-Entity
0.5	NUM	O	O
,	PUNCT	O	O
1.0	NUM	O	O
or	CCONJ	O	O
2.0	NUM	O	O
mg	PRON	O	O
was	VERB	O	O
given	VERB	O	O
by	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
or	CCONJ	O	O
i.m	ADJ	O	O
.	PUNCT	O	O

Dizziness	PROPN	O	I-Entity
was	VERB	O	O
less	ADJ	O	O
marked	ADJ	O	O
than	ADP	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
increased	VERB	O	O
with	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
pain	NOUN	O	I-Entity
on	ADP	O	O
i.m	NOUN	O	O
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
flunitrazepam	NOUN	O	I-Entity
significantly	ADV	O	O
more	ADV	O	O
often	ADV	O	O
than	ADP	O	O
with	ADP	O	O
isotonic	ADJ	O	O
saline	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6229975)

Changes	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
size	NOUN	O	O
during	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
timolol	NOUN	O	I-Entity
treatment	NOUN	O	O
after	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
timolol	NOUN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
heart	NOUN	O	O
size	NOUN	O	O
after	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
X	PROPN	O	O
-	PUNCT	O	O
ray	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
including	VERB	O	O
241	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
126	NUM	O	O
,	PUNCT	O	O
timolol	VERB	O	I-Entity
115	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
timolol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
small	ADJ	O	O
but	CCONJ	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
size	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
differences	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
timolol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
compensatory	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
timolol	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
size	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
and	CCONJ	O	O
borderline	ADJ	O	O
heart	NOUN	O	O
size	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cardiomegaly	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
size	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
re	ADV	O	O
-	PUNCT	O	O
infarction	NOUN	O	I-Entity
,	PUNCT	O	O
heart	NOUN	O	O
size	NOUN	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
in	ADP	O	O
the	DET	O	O
timolol	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6286738)

Vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
dairy	NOUN	O	O
cows	NOUN	O	O
.	PUNCT	O	O

Large	ADJ	O	O
parenteral	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
to	ADP	O	O
17.5	NUM	O	O
x	SYM	O	O
10(6	NUM	O	O
)	PUNCT	O	O

IU	PROPN	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
prolonged	ADJ	O	O
hypercalcemia	NOUN	O	I-Entity
,	PUNCT	O	O
hyperphosphatemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
large	ADJ	O	O
increases	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
plasma	NOUN	O	O
of	ADP	O	O
nonlactating	VERB	O	O
nonpregnant	NOUN	O	O
and	CCONJ	O	O
pregnant	ADJ	O	O
Jersey	PROPN	O	O
cows	NOUN	O	O
.	PUNCT	O	O

Calcium	NOUN	O	I-Entity
concentrations	NOUN	O	O
1	NUM	O	O
day	NOUN	O	O
postpartum	NOUN	O	O
were	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
cows	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
about	ADP	O	O
32	NUM	O	O
days	NOUN	O	O
prepartum	NOUN	O	O
(	PUNCT	O	O
8.8	NUM	O	O
mg/100	NUM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
control	NOUN	O	O
cows	NOUN	O	O
(	PUNCT	O	O
5.5	NUM	O	O
mg/100	NOUN	O	O
ml	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cows	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
showed	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
milk	NOUN	O	B-Entity
fever	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
peripartal	ADJ	O	O
period	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
22%	NUM	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
cows	NOUN	O	O
developed	VERB	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
milk	NOUN	O	B-Entity
fever	NOUN	O	I-Entity
during	ADP	O	O
this	DET	O	O
period	NOUN	O	O
.	PUNCT	O	O

Signs	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
nonlactating	VERB	O	O
nonpregnant	ADJ	O	O
cows	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
pregnant	ADJ	O	O
cows	NOUN	O	O
commonly	ADV	O	O
developed	VERB	O	O
severe	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
10	NUM	O	O
of	ADP	O	O
17	NUM	O	O
cows	NOUN	O	O
died	VERB	O	O
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
extreme	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
in	ADP	O	O
pregnant	ADJ	O	O
Jersey	PROPN	O	O
cows	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
low	ADJ	O	O
margin	NOUN	O	O
of	ADP	O	O
safety	NOUN	O	O
between	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
that	ADJ	O	O
prevent	VERB	O	O
milk	NOUN	O	B-Entity
fever	NOUN	O	I-Entity
and	CCONJ	O	O
doses	NOUN	O	O
that	ADJ	O	O
induce	VERB	O	O
milk	NOUN	O	B-Entity
fever	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
concluded	VERB	O	O
that	ADP	O	O
vitamin	NOUN	O	B-Entity
D3	NOUN	O	I-Entity
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
used	VERB	O	O
practically	ADV	O	O
to	PART	O	O
prevent	VERB	O	O
milk	NOUN	O	B-Entity
fever	NOUN	O	I-Entity
when	ADV	O	O
injected	VERB	O	O
several	ADJ	O	O
weeks	NOUN	O	O
prepartum	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6287825)

Diseases	NOUN	O	B-Entity
of	ADP	O	I-Entity
peripheral	ADJ	O	I-Entity
nerves	NOUN	O	I-Entity
as	ADP	O	O
seen	VERB	O	O
in	ADP	O	O
the	DET	O	O
Nigerian	ADJ	O	O
African	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
anatomical	ADJ	O	O
and	CCONJ	O	O
aetiological	ADJ	O	O
diagnoses	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
excluding	VERB	O	O
its	ADJ	O	O
primary	ADJ	O	O
benign	ADJ	O	O
and	CCONJ	O	O
malignant	ADJ	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
seen	VERB	O	O
in	ADP	O	O
358	NUM	O	O
Nigerians	PROPN	O	O
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

Sensori	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
motor	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
commonest	NOUN	O	O
presentation	NOUN	O	O
(	PUNCT	O	O
50%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Guillain	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Barr	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
commonest	NOUN	O	O
identifiable	ADJ	O	O
cause	NOUN	O	O
(	PUNCT	O	O
15.6%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
accounting	VERB	O	O
for	ADP	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
with	ADP	O	O
motor	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
nutritional	ADJ	O	B-Entity
deficiency	NOUN	O	I-Entity
of	ADP	O	O
thiamine	NOUN	O	I-Entity
and	CCONJ	O	O
riboflavin	NOUN	O	I-Entity
was	VERB	O	O
common	ADJ	O	O
(	PUNCT	O	O
10.1%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
presented	VERB	O	O
mainly	ADV	O	O
as	ADP	O	O
sensory	ADJ	O	O
and	CCONJ	O	O
sensori	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
motor	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Diabetes	NOUN	O	B-Entity
mellitus	VERB	O	I-Entity
was	VERB	O	O
the	DET	O	O
major	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
autonomic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Isoniazid	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
frequent	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Migraine	PROPN	O	I-Entity
(	PUNCT	O	O
20%	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
an	DET	O	O
uncommon	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
cranial	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
although	ADP	O	O
malignancies	NOUN	O	I-Entity
arising	VERB	O	O
from	ADP	O	O
the	DET	O	O
reticuloendothelial	ADJ	O	O
system	NOUN	O	O
or	CCONJ	O	O
related	ADJ	O	O
structures	NOUN	O	O
of	ADP	O	O
the	DET	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
frequent	ADJ	O	O
(	PUNCT	O	O
26%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
26.5%	NUM	O	O
of	ADP	O	O
all	ADJ	O	O
the	DET	O	O
cases	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
aetiology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
undetermined	ADJ	O	O
.	PUNCT	O	O

Heredofamilial	ADJ	O	O
and	CCONJ	O	O
connective	ADJ	O	B-Entity
tissue	NOUN	O	I-Entity
disorders	NOUN	O	I-Entity
were	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

Some	DET	O	O
of	ADP	O	O
the	DET	O	O
factors	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
presentation	NOUN	O	O
and	CCONJ	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neuropathies	NOUN	O	I-Entity
are	VERB	O	O
briefly	ADV	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (6386793)

A	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
dothiepin	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
major	ADJ	O	O
depressive	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
6-week	NUM	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
parallel	ADJ	O	O
treatment	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
dothiepin	NOUN	O	I-Entity
and	CCONJ	O	O
amitriptyline	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
33	NUM	O	O
depressed	ADJ	O	I-Entity
outpatients	NOUN	O	O
.	PUNCT	O	O

Dothiepin	PROPN	O	I-Entity
and	CCONJ	O	O
amitriptyline	NOUN	O	I-Entity
were	VERB	O	O
equally	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
alleviating	VERB	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
depressive	ADJ	O	B-Entity
illness	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
both	DET	O	O
were	VERB	O	O
significantly	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
blurred	ADJ	O	B-Entity
vision	NOUN	O	I-Entity
,	PUNCT	O	O
dry	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
drowsiness	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
with	ADP	O	O
dothiepin	NOUN	O	I-Entity
than	ADP	O	O
with	ADP	O	O
amitriptyline	NOUN	O	I-Entity
.	PUNCT	O	O

Dothiepin	PROPN	O	I-Entity
also	ADV	O	O
produced	VERB	O	O
fewer	ADJ	O	O
CNS	PROPN	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Dothiepin	PROPN	O	I-Entity
thus	ADV	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
antidepressant	NOUN	O	I-Entity
drug	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
fewer	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
than	ADP	O	O
amitriptyline	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
depressed	ADJ	O	I-Entity
outpatients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6387529)

Behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
and	CCONJ	O	O
propranolol	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
and	CCONJ	O	O
agoraphobia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
a	DET	O	O
median	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
mg	NUM	O	O
/	DET	O	O
day	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
propranolol	NOUN	O	I-Entity
(	PUNCT	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
80	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
a	DET	O	O
median	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
240	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
psychological	ADJ	O	O
performance	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
panic	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
and	CCONJ	O	O
agoraphobia	NOUN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
and	CCONJ	O	O
crossover	ADJ	O	O
design	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
drugs	NOUN	O	O
impaired	VERB	O	B-Entity
immediate	ADJ	O	I-Entity
free	ADJ	O	I-Entity
recall	NOUN	O	I-Entity
but	CCONJ	O	O
the	DET	O	O
decrease	NOUN	O	O
was	VERB	O	O
greater	ADJ	O	O
for	ADP	O	O
diazepam	NOUN	O	I-Entity
than	ADP	O	O
propranolol	NOUN	O	I-Entity
.	PUNCT	O	O

Delayed	VERB	O	B-Entity
free	ADJ	O	I-Entity
recall	NOUN	O	I-Entity
was	VERB	O	I-Entity
also	ADV	O	I-Entity
impaired	VERB	O	I-Entity
but	CCONJ	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
tapped	VERB	O	O
faster	ADJ	O	O
after	ADP	O	O
propranolol	NOUN	O	I-Entity
than	ADP	O	O
diazepam	NOUN	O	I-Entity
and	CCONJ	O	O
they	PRON	O	O
were	VERB	O	O
more	ADV	O	O
sedated	VERB	O	O
after	ADP	O	O
diazepam	NOUN	O	I-Entity
than	ADP	O	O
propranolol	NOUN	O	I-Entity
.	PUNCT	O	O

Accumulation	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
reflected	VERB	O	O
in	ADP	O	O
prolonged	VERB	O	O
behavioral	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6692345)

Effect	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
on	ADP	O	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epithelial	ADJ	O	O
proliferation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
and	CCONJ	O	O
forestomach	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
co	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
with	ADP	O	O
N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	PROPN	O	I-Entity
(	PUNCT	O	O
FANFT	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
rats	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
reduced	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
FANFT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bladder	NOUN	O	B-Entity
carcinomas	NOUN	O	I-Entity
but	CCONJ	O	O
a	DET	O	O
concomitant	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
forestomach	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
autoradiographic	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
male	ADJ	O	O
F-344	PROPN	O	O
rats	NOUN	O	O
fed	VERB	O	O
diet	NOUN	O	O
containing	VERB	O	O
FANFT	PROPN	O	I-Entity
at	ADP	O	O
a	DET	O	O
level	NOUN	O	O
of	ADP	O	O
0.2%	NUM	O	O
and/or	CCONJ	O	O
aspirin	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
level	NOUN	O	O
of	ADP	O	O
0.5%	NUM	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
increased	VERB	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
FANFT	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
forestomach	NOUN	O	O
and	CCONJ	O	O
bladder	NOUN	O	O
.	PUNCT	O	O

FANFT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
suppressed	VERB	O	O
by	ADP	O	O
aspirin	NOUN	O	I-Entity
co	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
after	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
after	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
forestomach	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
,	PUNCT	O	O
aspirin	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
FANFT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
labeling	VERB	O	O
index	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
results	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
carcinogenicity	NOUN	O	O
experiment	NOUN	O	O
suggesting	VERB	O	O
that	ADP	O	O
different	ADJ	O	O
mechanisms	NOUN	O	O
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
FANFT	PROPN	O	I-Entity
carcinogenesis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
and	CCONJ	O	O
forestomach	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
aspirin	NOUN	O	I-Entity
's	PART	O	O
effect	NOUN	O	O
on	ADP	O	O
FANFT	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
forestomach	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
irritant	NOUN	O	O
effect	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
adaptation	NOUN	O	O
by	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
to	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
ingestion	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6773726)

Provocation	NOUN	O	O
of	ADP	O	O
postural	ADJ	O	O
hypotension	NOUN	O	I-Entity
by	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
in	ADP	O	O
diabetic	ADJ	O	B-Entity
autonomic	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
?	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
on	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
5	NUM	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
diabetic	ADJ	O	I-Entity
subjects	NOUN	O	O
without	ADP	O	O
autonomic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
diabetic	ADJ	O	I-Entity
subjects	NOUN	O	O
with	ADP	O	O
autonomic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
magnitude	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
after	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
and	CCONJ	O	O
diabetic	ADJ	O	I-Entity
subjects	NOUN	O	O
without	ADP	O	O
autonomic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
a	DET	O	O
lesser	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
greater	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
diabetic	ADJ	O	I-Entity
subjects	NOUN	O	O
with	ADP	O	O
autonomic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
therefore	ADV	O	O
suggested	VERB	O	O
that	ADP	O	O
caution	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
exercised	VERB	O	O
when	ADV	O	O
prescribing	VERB	O	O
vasodilator	NOUN	O	O
drugs	NOUN	O	O
in	ADP	O	O
diabetic	ADJ	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
those	DET	O	O
with	ADP	O	O
autonomic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6888657)

Characterization	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
adenohypophyseal	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Fischer	PROPN	O	O
344	NUM	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Pituitary	ADJ	O	B-Entity
tumors	NOUN	O	I-Entity
were	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
F344	PROPN	O	O
female	ADJ	O	O
rats	NOUN	O	O
by	ADP	O	O
chronic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
diethylstilbestrol	NOUN	O	I-Entity
(	PUNCT	O	O
DES	PROPN	O	I-Entity
,	PUNCT	O	O
8	NUM	O	O
-	SYM	O	O
10	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
implanted	VERB	O	O
subcutaneously	ADV	O	O
in	ADP	O	O
silastic	ADJ	O	O
capsules	NOUN	O	O
.	PUNCT	O	O

Over	ADP	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
-	SYM	O	O
150	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
DES	PROPN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
pairs	NOUN	O	O
of	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
DES	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
were	VERB	O	O
sacrificed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
pituitaries	NOUN	O	O
dissociated	VERB	O	O
enzymatically	ADV	O	O
into	ADP	O	O
single	ADJ	O	O
-	PUNCT	O	O
cell	NOUN	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cell	NOUN	O	O
populations	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
regarding	VERB	O	O
total	ADJ	O	O
cell	NOUN	O	O
recovery	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
gland	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
intracellular	ADJ	O	O
prolactin	NOUN	O	O
(	PUNCT	O	O
PRL	PROPN	O	O
)	PUNCT	O	O
content	NOUN	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
release	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
culture	NOUN	O	O
,	PUNCT	O	O
immunocytochemical	ADJ	O	O
PRL	PROPN	O	O
staining	NOUN	O	O
,	PUNCT	O	O
density	NOUN	O	O
and/or	CCONJ	O	O
size	NOUN	O	O
alterations	NOUN	O	O
via	ADP	O	O
separation	NOUN	O	O
on	ADP	O	O
Ficoll	PROPN	O	O
-	PUNCT	O	O
Hypaque	PROPN	O	O
and	CCONJ	O	O
by	ADP	O	O
unit	NOUN	O	O
gravity	NOUN	O	O
sedimentation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cell	NOUN	O	O
cycle	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
acriflavine	ADJ	O	I-Entity
DNA	PROPN	O	O
staining	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
laser	NOUN	O	O
flow	NOUN	O	O
cytometry	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
cell	NOUN	O	O
yields	NOUN	O	O
from	ADP	O	O
DES	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
pituitaries	NOUN	O	O
increased	VERB	O	O
from	ADP	O	O
1.3	NUM	O	O
times	NOUN	O	O
control	NOUN	O	O
yields	NOUN	O	O
at	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
to	ADP	O	O
58.9	NUM	O	O
times	NOUN	O	O
control	NOUN	O	O
values	NOUN	O	O
by	ADP	O	O
day	NOUN	O	O
150	NUM	O	O
.	PUNCT	O	O

Intracellular	ADJ	O	O
PRL	PROPN	O	O
content	NOUN	O	O
ranged	VERB	O	O
from	ADP	O	O
1.9	NUM	O	O
to	ADP	O	O
9.4	NUM	O	O
times	NOUN	O	O
control	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
PRL	PROPN	O	O
release	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
and	CCONJ	O	O
consistently	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
at	ADV	O	O
least	ADJ	O	O
8	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
DES	PROPN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

Beyond	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
DES	PROPN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
immunochemically	ADV	O	O
PRL	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
cells	NOUN	O	O
increased	VERB	O	O
to	ADP	O	O
over	ADP	O	O
50%	NUM	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

All	ADJ	O	O
these	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
DES	PROPN	O	I-Entity
were	VERB	O	O
more	ADV	O	O
pronounced	VERB	O	O
among	ADP	O	O
previously	ADV	O	O
ovariectomized	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
extend	VERB	O	O
the	DET	O	O
findings	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
investigators	NOUN	O	O
,	PUNCT	O	O
further	ADV	O	O
establishing	VERB	O	O
the	DET	O	O
DES	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tumor	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
for	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
PRL	PROPN	O	O
cellular	ADJ	O	O
control	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7265370)

Triamterene	PROPN	O	I-Entity
nephrolithiasis	NOUN	O	I-Entity
complicating	VERB	O	O
dyazide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
triamterene	NOUN	O	I-Entity
nephrolithiasis	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
a	DET	O	O
man	NOUN	O	O
after	ADP	O	O
4	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
hydrochlorothiazide	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
triamterene	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
stone	NOUN	O	O
passed	VERB	O	O
spontaneously	ADV	O	O
and	CCONJ	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
contain	VERB	O	O
a	DET	O	O
triamterene	NOUN	O	I-Entity
metabolite	NOUN	O	O
admixed	NOUN	O	O
with	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
salts	NOUN	O	I-Entity
.	PUNCT	O	O

Factors	NOUN	O	O
affecting	VERB	O	O
triamterene	NOUN	O	I-Entity
nephrolithiasis	NOUN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
and	CCONJ	O	O
2	NUM	O	O
previously	ADV	O	O
reported	VERB	O	O
cases	NOUN	O	O
are	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (7423039)

Metabolic	ADJ	O	O
involvement	NOUN	O	O
in	ADP	O	O
adriamycin	ADJ	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
mammalian	ADJ	O	O
myocardial	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
culture	NOUN	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O

Adriamycin	PROPN	O	I-Entity
inhibited	VERB	O	O
cell	NOUN	O	O
growth	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
rhythmic	ADJ	O	O
contractions	NOUN	O	O
characteristic	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
culture	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
possible	ADJ	O	O
involvement	NOUN	O	O
of	ADP	O	O
energy	NOUN	O	O
metabolism	NOUN	O	O
was	VERB	O	O
suggested	VERB	O	O
previously	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
the	DET	O	O
adenylate	ADJ	O	O
energy	NOUN	O	O
charge	NOUN	O	O
and	CCONJ	O	O
phosphorylcreatine	NOUN	O	I-Entity
mole	NOUN	O	O
fraction	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
the	DET	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
cells	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
adenylate	ADJ	O	O
energy	NOUN	O	O
charge	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
phophorylcreatine	NOUN	O	I-Entity
mole	NOUN	O	O
fraction	NOUN	O	O
was	VERB	O	O
unchanged	ADJ	O	O
.	PUNCT	O	O

Such	ADJ	O	O
disparity	NOUN	O	O
suggests	VERB	O	O
an	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
mM	PROPN	O	O
adenosine	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
cell	NOUN	O	O
cultures	NOUN	O	O
markedly	ADV	O	O
increases	VERB	O	O
the	DET	O	O
ATP	PROPN	O	I-Entity
concentration	NOUN	O	O
through	ADP	O	O
a	DET	O	O
pathway	NOUN	O	O
reportedly	ADV	O	O
leading	VERB	O	O
to	ADP	O	O
a	DET	O	O
compartmentalized	ADJ	O	O
ATP	PROPN	O	I-Entity
pool	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
adriamycin	ADJ	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
cells	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
adenylate	NOUN	O	O
charge	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
concomitant	ADJ	O	O
with	ADP	O	O
this	DET	O	O
inrcease	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cells	NOUN	O	O
'	PART	O	O
functional	ADJ	O	O
integrity	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
percentage	NOUN	O	O
of	ADP	O	O
beating	VERB	O	O
cells	NOUN	O	O
and	CCONJ	O	O
rate	NOUN	O	O
of	ADP	O	O
contractions	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
maintained	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (7444978)

Age	PROPN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
to	ADP	O	O
neurotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
streptomycin	NOUN	O	I-Entity
.	PUNCT	O	O

Streptomycin	PROPN	O	I-Entity
sulfate	NOUN	O	O
(	PUNCT	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
for	ADP	O	O
various	ADJ	O	O
periods	NOUN	O	O
into	ADP	O	O
preweanling	VERB	O	O
rats	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
into	ADP	O	O
weanling	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Abnormal	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
and	CCONJ	O	O
deafness	NOUN	O	I-Entity
occurred	VERB	O	O
only	ADV	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
during	ADP	O	O
the	DET	O	O
preweaning	NOUN	O	O
period	NOUN	O	O
;	PUNCT	O	O
within	ADP	O	O
this	DET	O	O
period	NOUN	O	O
the	DET	O	O
greatest	ADJ	O	O
sensitivities	NOUN	O	O
for	ADP	O	O
these	DET	O	O
abnormalities	NOUN	O	O
occurred	VERB	O	O
from	ADP	O	O
2	NUM	O	O
to	ADP	O	O
11	NUM	O	O
-	SYM	O	O
17	NUM	O	O
and	CCONJ	O	O
5	NUM	O	O
to	PART	O	O
11	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
cochlea	NOUN	O	O
is	VERB	O	O
more	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
streptomycin	VERB	O	I-Entity
than	ADP	O	O
the	DET	O	O
site	NOUN	O	O
(	PUNCT	O	O
vestibular	ADJ	O	O
or	CCONJ	O	O
central	ADJ	O	O
)	PUNCT	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7834920)

Crescentic	ADJ	O	O
fibrillary	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
intermittent	ADJ	O	O
rifampin	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
pulmonary	ADJ	O	B-Entity
tuberculosis	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
study	NOUN	O	O
reveals	VERB	O	O
an	DET	O	O
unusual	ADJ	O	O
finding	NOUN	O	O
of	ADP	O	O
rapidly	ADV	O	O
proliferative	ADJ	O	O
crescentic	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
rifampin	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
no	DET	O	O
other	ADJ	O	O
identifiable	ADJ	O	O
causes	NOUN	O	O
for	ADP	O	O
developing	VERB	O	O
this	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
patient	NOUN	O	O
underwent	VERB	O	O
a	DET	O	O
10-month	ADJ	O	O
regimen	NOUN	O	O
of	ADP	O	O
rifampin	NOUN	O	I-Entity
and	CCONJ	O	O
isoniazid	NOUN	O	I-Entity
for	ADP	O	O
pulmonary	ADJ	O	B-Entity
tuberculosis	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
discovered	VERB	O	O
to	PART	O	O
have	VERB	O	O
developed	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
five	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
completion	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
biopsy	NOUN	O	O
revealed	VERB	O	O
severe	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
with	ADP	O	O
crescents	NOUN	O	O
,	PUNCT	O	O
electron	ADV	O	O
dense	ADJ	O	O
fibrillar	ADJ	O	O
deposits	NOUN	O	O
and	CCONJ	O	O
moderate	ADJ	O	O
lymphocytic	ADJ	O	O
interstitial	ADJ	O	O
infiltrate	NOUN	O	O
.	PUNCT	O	O

Other	ADJ	O	O
possible	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
rapidly	ADV	O	O
progressive	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
and	CCONJ	O	O
ruled	VERB	O	O
out	PART	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
documents	VERB	O	O
the	DET	O	O
unusual	ADJ	O	O
occurrence	NOUN	O	O
of	ADP	O	O
rapidly	ADV	O	O
progressive	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
with	ADP	O	O
crescents	NOUN	O	O
and	CCONJ	O	O
fibrillar	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
rifampin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7881871)

Time	PROPN	O	O
course	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
in	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN)-induced	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
antioxidants	NOUN	O	O
significantly	ADV	O	O
reducing	VERB	O	O
the	DET	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
temporal	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
lipid	NOUN	O	O
peroxidation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
IV	PROPN	O	O
injection	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
,	PUNCT	O	O
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
,	PUNCT	O	O
7.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
24	NUM	O	O
hour	NOUN	O	O
urine	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
prior	ADV	O	O
to	PART	O	O
sacrifice	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
3,5,7,10,17,27,41	NUM	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
-	SYM	O	O
10	NUM	O	O
per	ADP	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tissue	PROPN	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
whole	ADJ	O	O
homogenates	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
lipid	NOUN	O	O
extracts	NOUN	O	O
from	ADP	O	O
homogenates	NOUN	O	O
as	ADP	O	O
thiobarbituric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
reactive	ADJ	O	O
substances	NOUN	O	O
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
was	VERB	O	O
evident	ADJ	O	O
at	ADP	O	O
day	NOUN	O	O
5	NUM	O	O
,	PUNCT	O	O
peaked	VERB	O	O
at	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
and	CCONJ	O	O
persisted	VERB	O	O
to	ADP	O	O
day	NOUN	O	O
27	NUM	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
supports	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
in	ADP	O	O
mediating	VERB	O	O
the	DET	O	O
proteinuric	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
PAN	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7930386)

Clomipramine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sleep	NOUN	O	B-Entity
disturbance	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
impair	VERB	O	O
its	ADJ	O	O
prolactin	NOUN	O	O
-	PUNCT	O	O
releasing	VERB	O	O
action	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
sleep	NOUN	O	B-Entity
disturbance	NOUN	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
clomipramine	NOUN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
secretory	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
prolactin	NOUN	O	O
(	PUNCT	O	O
PRL	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
direct	ADJ	O	O
drug	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
subject	NOUN	O	O
received	VERB	O	O
a	DET	O	O
single	ADJ	O	O
50	NUM	O	O
mg	NUM	O	O
dose	NOUN	O	O
of	ADP	O	O
clomipramine	NOUN	O	I-Entity
given	VERB	O	O
orally	ADV	O	O
2	NUM	O	O
hours	NOUN	O	O
before	ADP	O	O
blood	NOUN	O	O
collection	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
night	NOUN	O	O
clomipramine	NOUN	O	I-Entity
ingestion	NOUN	O	O
altered	VERB	O	O
the	DET	O	O
complete	ADJ	O	O
sleep	NOUN	O	O
architecture	NOUN	O	O
in	ADP	O	O
that	DET	O	O
it	PRON	O	O
suppressed	VERB	O	O
REM	PROPN	O	O
sleep	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
sleep	NOUN	O	O
cycles	NOUN	O	O
and	CCONJ	O	O
induced	VERB	O	O
increased	VERB	O	O
wakefulness	NOUN	O	O
.	PUNCT	O	O

10%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
the	DET	O	O
observed	ADJ	O	O
sleep	NOUN	O	B-Entity
disturbance	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
interfere	VERB	O	O
with	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
action	NOUN	O	O
per	ADP	O	O
se	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
REM	PROPN	O	O
sleep	NOUN	O	O
was	VERB	O	O
shown	VERB	O	O
not	ADV	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
determining	VERB	O	O
factor	NOUN	O	O
either	CCONJ	O	O
for	ADP	O	O
secretory	NOUN	O	O
pulse	NOUN	O	O
amplitude	NOUN	O	O
and	CCONJ	O	O
frequency	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
,	PUNCT	O	O
for	ADP	O	O
both	DET	O	O
,	PUNCT	O	O
mean	ADJ	O	O
nocturnal	ADJ	O	O
values	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
prior	ADJ	O	O
clomipramine	NOUN	O	I-Entity
ingestion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7988234)

Angioedema	PROPN	O	I-Entity
following	VERB	O	O
the	DET	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
72-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
with	ADP	O	O
"	PUNCT	O	O
flash	NOUN	O	O
"	PUNCT	O	O
pulmonary	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
,	PUNCT	O	O
preceded	VERB	O	O
by	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
requiring	VERB	O	O
intubation	NOUN	O	O
.	PUNCT	O	O

Her	ADJ	O	O
medical	ADJ	O	O
history	NOUN	O	O
included	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
with	ADP	O	O
previous	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarctions	NOUN	O	I-Entity
,	PUNCT	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
diabetes	VERB	O	B-Entity
mellitus	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
history	NOUN	O	O
of	ADP	O	O
angioedema	DET	O	I-Entity
secondary	ADJ	O	O
to	PART	O	O
lisinopril	VERB	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
elicited	VERB	O	O
.	PUNCT	O	O

Current	ADJ	O	O
medications	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
include	VERB	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitors	NOUN	O	O
or	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
hospitalization	NOUN	O	O
(	PUNCT	O	O
while	ADP	O	O
intubated	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
metoprolol	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
severe	ADJ	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
angioedema	NOUN	O	I-Entity
resolved	VERB	O	O
after	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
intravenous	ADJ	O	O
steroids	NOUN	O	I-Entity
and	CCONJ	O	O
diphenhydramine	NOUN	O	I-Entity
hydrochloride	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8073369)

Effect	NOUN	O	O
of	ADP	O	O
coniine	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
developing	VERB	O	O
chick	NOUN	O	O
embryo	NOUN	O	O
.	PUNCT	O	O

Coniine	PROPN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
alkaloid	NOUN	O	O
from	ADP	O	O
Conium	PROPN	O	O
maculatum	NOUN	O	O
(	PUNCT	O	O
poison	NOUN	O	O
hemlock	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
teratogenic	ADJ	O	O
in	ADP	O	O
livestock	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
major	ADJ	O	O
teratogenic	ADJ	O	O
outcome	NOUN	O	O
is	VERB	O	O
arthrogryposis	NOUN	O	I-Entity
,	PUNCT	O	O
presumably	ADV	O	O
due	ADP	O	O
to	ADP	O	O
nicotinic	ADJ	O	O
receptor	NOUN	O	O
blockade	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
coniine	NOUN	O	I-Entity
has	VERB	O	O
failed	VERB	O	O
to	PART	O	O
produce	VERB	O	O
arthrogryposis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
or	CCONJ	O	O
mice	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
only	ADV	O	O
weakly	ADV	O	O
teratogenic	ADJ	O	O
in	ADP	O	O
rabbits	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
and	CCONJ	O	O
compare	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
coniine	NOUN	O	I-Entity
and	CCONJ	O	O
nicotine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
developing	VERB	O	O
chick	NOUN	O	O
.	PUNCT	O	O

Concentrations	NOUN	O	O
of	ADP	O	O
coniine	NOUN	O	I-Entity
and	CCONJ	O	O
nicotine	NOUN	O	I-Entity
sulfate	NOUN	O	O
were	VERB	O	O
0.015%	NUM	O	O
,	PUNCT	O	O
0.03%	NUM	O	O
,	PUNCT	O	O
0.075%	NUM	O	O
,	PUNCT	O	O
0.15%	NUM	O	O
,	PUNCT	O	O
0.75%	NUM	O	O
,	PUNCT	O	O
1.5%	NUM	O	O
,	PUNCT	O	O
3%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6%	NUM	O	O
and	CCONJ	O	O
1%	NUM	O	O
,	PUNCT	O	O
5%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Both	DET	O	O
compounds	NOUN	O	O
caused	VERB	O	O
deformations	NOUN	O	I-Entity
and	CCONJ	O	O
lethality	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
concentrations	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
sulfate	NOUN	O	O
caused	VERB	O	O
some	DET	O	O
lethality	NOUN	O	O
but	CCONJ	O	O
a	DET	O	O
no	DET	O	O
effect	NOUN	O	O
level	NOUN	O	O
for	ADP	O	O
coniine	NOUN	O	I-Entity
lethality	NOUN	O	O
was	VERB	O	O
0.75%	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
deformations	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
both	DET	O	O
coniine	NOUN	O	I-Entity
and	CCONJ	O	O
nicotine	NOUN	O	I-Entity
sulfate	NOUN	O	O
were	VERB	O	O
excessive	ADJ	O	B-Entity
flexion	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
extension	NOUN	O	I-Entity
of	ADP	O	I-Entity
one	NUM	O	I-Entity
or	CCONJ	O	I-Entity
more	ADJ	O	I-Entity
toes	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
histopathological	ADJ	O	O
alterations	NOUN	O	O
or	CCONJ	O	O
differences	NOUN	O	O
in	ADP	O	O
bone	NOUN	O	O
formation	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
the	DET	O	O
limbs	NOUN	O	O
or	CCONJ	O	O
toes	NOUN	O	O
of	ADP	O	O
any	DET	O	O
chicks	NOUN	O	O
from	ADP	O	O
any	DET	O	O
group	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
extensive	ADJ	O	O
cranial	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
all	DET	O	O
nicotine	NOUN	O	I-Entity
sulfate	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
chicks	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
movement	NOUN	O	O
in	ADP	O	O
coniine	NOUN	O	I-Entity
and	CCONJ	O	O
nicotine	NOUN	O	I-Entity
sulfate	NOUN	O	O
treated	VERB	O	O
chicks	NOUN	O	O
as	ADP	O	O
determined	VERB	O	O
by	ADP	O	O
ultrasound	NOUN	O	O
.	PUNCT	O	O

Control	NOUN	O	O
chicks	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
motion	NOUN	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
33.67%	NUM	O	O
of	ADP	O	O
the	DET	O	O
time	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
coniine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
chicks	NOUN	O	O
were	VERB	O	O
only	ADV	O	O
moving	VERB	O	O
8.95%	NUM	O	O
of	ADP	O	O
a	DET	O	O
5-min	NUM	O	O
interval	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
movement	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
nicotine	NOUN	O	I-Entity
sulfate	NOUN	O	O
treated	VERB	O	O
chicks	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
chick	NOUN	O	O
embryo	NOUN	O	O
provides	VERB	O	O
a	DET	O	O
reliable	ADJ	O	O
and	CCONJ	O	O
simple	ADJ	O	O
experimental	ADJ	O	O
animal	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
coniine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arthrogryposis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8302922)

Epidural	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
during	ADP	O	O
prostaglandin	NOUN	O	B-Entity
E1	NUM	O	I-Entity
or	CCONJ	O	O
trimethaphan	NOUN	O	I-Entity
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	B-Entity
E1	PROPN	O	I-Entity
(	PUNCT	O	O
PGE1	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
trimethaphan	NOUN	O	I-Entity
(	PUNCT	O	O
TMP	PROPN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
on	ADP	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
(	PUNCT	O	O
EBF	PROPN	O	O
)	PUNCT	O	O
during	ADP	O	O
spinal	ADJ	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
EBF	PROPN	O	O
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
the	DET	O	O
heat	NOUN	O	O
clearance	NOUN	O	O
method	NOUN	O	O
in	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
postero	NOUN	O	O
-	PUNCT	O	O
lateral	ADJ	O	O
interbody	NOUN	O	O
fusion	NOUN	O	O
under	ADP	O	O
isoflurane	NOUN	O	I-Entity
anaesthesia	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
initial	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
0.1	NUM	O	O
microgram.kg-1.min-1	NOUN	O	O
of	ADP	O	O
PGE1	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
10	NUM	O	O
micrograms.kg-1.min-1	NOUN	O	O
of	ADP	O	O
TMP	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
intravenously	ADV	O	O
after	ADP	O	O
the	DET	O	O
dural	ADJ	O	O
opening	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
dose	NOUN	O	O
was	VERB	O	O
adjusted	VERB	O	O
to	PART	O	O
maintain	VERB	O	O
the	DET	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
MAP	PROPN	O	O
)	PUNCT	O	O
at	ADP	O	O
about	ADV	O	O
60	NUM	O	O
mmHg	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hypotensive	ADJ	O	I-Entity
drug	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
at	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
operative	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
starting	VERB	O	O
PGE1	PROPN	O	I-Entity
or	CCONJ	O	O
TMP	PROPN	O	I-Entity
,	PUNCT	O	O
MAP	PROPN	O	O
and	CCONJ	O	O
rate	NOUN	O	O
pressure	NOUN	O	O
product	NOUN	O	O
(	PUNCT	O	O
RPP	PROPN	O	O
)	PUNCT	O	O
decreased	VERB	O	O
significantly	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
preinfusion	NOUN	O	O
values	NOUN	O	O

(	PUNCT	O	O
P	PROPN	O	O
<	PROPN	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
PGE1	PROPN	O	I-Entity
remained	VERB	O	O
constant	ADJ	O	O
until	ADP	O	O
60	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
its	ADJ	O	O
discontinuation	NOUN	O	O
.	PUNCT	O	O

EBFF	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
during	ADP	O	O
PGE1	NOUN	O	I-Entity
infusion	NOUN	O	O
whereas	ADP	O	O
in	ADP	O	O
the	DET	O	O
TMP	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
EBF	PROPN	O	O
decreased	VERB	O	O
significantly	ADV	O	O
at	ADP	O	O
30	NUM	O	O
and	CCONJ	O	O
60	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
TMP	PROPN	O	I-Entity
(	PUNCT	O	O
preinfusion	NOUN	O	O
:	PUNCT	O	O
45.9	NUM	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
PGE1	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
preferable	ADJ	O	O
to	PART	O	O
TMP	PROPN	O	I-Entity
for	ADP	O	O
hypotensive	ADJ	O	I-Entity
anaesthesia	NOUN	O	O
in	ADP	O	O
spinal	ADJ	O	O
surgery	NOUN	O	O
because	ADP	O	O
TMP	PROPN	O	I-Entity
decreased	VERB	O	O
EBF	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (8410052)

Immunohistochemical	ADJ	O	O
studies	NOUN	O	O
with	ADP	O	O
antibodies	NOUN	O	O
to	ADP	O	O
neurofilament	ADJ	O	O
proteins	NOUN	O	O
on	ADP	O	O
axonal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
experimental	ADJ	O	O
focal	ADJ	O	O
lesions	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Immunohistochemistry	PROPN	O	O
with	ADP	O	O
monoclonal	ADJ	O	O
antibodies	NOUN	O	O
against	ADP	O	O
neurofilament	NOUN	O	O
(	PUNCT	O	O
NF	PROPN	O	O
)	PUNCT	O	O
proteins	NOUN	O	O
of	ADP	O	O
middle	ADJ	O	O
and	CCONJ	O	O
high	ADJ	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
class	NOUN	O	O
,	PUNCT	O	O
NF	PROPN	O	O
-	PUNCT	O	O
M	PROPN	O	O
and	CCONJ	O	O
NF	PROPN	O	O
-	PUNCT	O	O
H	PROPN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
study	VERB	O	O
axonal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
borderzone	NOUN	O	O
of	ADP	O	O
focal	ADJ	O	O
lesions	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Focal	ADJ	O	O
injury	NOUN	O	B-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
cortex	NOUN	O	I-Entity
was	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
lactate	NOUN	O	I-Entity
at	ADP	O	O
acid	NOUN	O	O
pH	NOUN	O	O
or	CCONJ	O	O
by	ADP	O	O
stab	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
needle	NOUN	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

Infarcts	NOUN	O	B-Entity
in	ADP	O	I-Entity
substantia	NOUN	O	I-Entity
nigra	NOUN	O	I-Entity
pars	NOUN	O	I-Entity
reticulata	NOUN	O	I-Entity
were	VERB	O	O
evoked	VERB	O	O
by	ADP	O	O
prolonged	ADJ	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
immunohistochemical	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
NFs	NOUN	O	O
can	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
a	DET	O	O
marker	NOUN	O	O
for	ADP	O	O
axonal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
various	ADJ	O	O
experimental	ADJ	O	O
traumatic	ADJ	O	I-Entity
or	CCONJ	O	O
ischemic	ADJ	O	O
lesions	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8423889)

Increase	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
disability	NOUN	O	I-Entity
after	ADP	O	O
fluoxetine	NOUN	O	I-Entity
medication	NOUN	O	O
.	PUNCT	O	O

Depression	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
clinical	ADJ	O	O
feature	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
increased	VERB	O	O
amount	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	B-Entity
disability	NOUN	O	I-Entity
in	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
idiopathic	ADJ	O	B-Entity
Parkinson	PROPN	O	I-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
antidepressant	NOUN	O	I-Entity
fluoxetine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
a	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
dopamine	NOUN	O	I-Entity
-	PUNCT	O	O
antagonistic	ADJ	O	O
capacity	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8682684)

Acetaminophen	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Through	ADP	O	O
30	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
widespread	ADJ	O	O
use	NOUN	O	O
,	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
remarkably	ADV	O	O
safe	ADJ	O	O
medication	NOUN	O	O
in	ADP	O	O
therapeutic	ADJ	O	O
dosages	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
acetaminophen	NOUN	O	I-Entity
to	PART	O	O
produce	VERB	O	O
cardiovascular	ADJ	O	B-Entity
toxicities	NOUN	O	I-Entity
is	VERB	O	O
very	ADV	O	O
low	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
demonstrated	VERB	O	O
to	PART	O	O
produce	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
anaphylaxis	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
sensitive	ADJ	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
describes	VERB	O	O
two	NUM	O	O
critically	ADV	O	B-Entity
ill	ADJ	O	I-Entity
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
transient	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
reproducibly	ADV	O	O
developed	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
.	PUNCT	O	O

Other	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
allergic	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
clinically	ADV	O	O
detectable	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
hypotensive	ADJ	O	I-Entity
episodes	NOUN	O	O
were	VERB	O	O
severe	ADJ	O	O
enough	ADV	O	O
to	PART	O	O
require	VERB	O	O
vasopressor	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
reports	NOUN	O	O
illustrate	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
clinicians	NOUN	O	O
to	PART	O	O
consider	VERB	O	O
acetaminophen	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hypotension	NOUN	O	I-Entity
of	ADP	O	O
unknown	ADJ	O	O
origin	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9625142)

Acute	PROPN	O	O
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
autoimmune	ADJ	O	B-Entity
hemolytic	ADJ	O	I-Entity
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
erythroblastocytopenia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
ceftriaxone	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
80-yr	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
ingesting	VERB	O	O
oral	ADJ	O	O
ceftriaxone	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
transaminases	NOUN	O	O
gradually	ADV	O	O
returned	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
after	ADP	O	O
withholding	VERB	O	O
the	DET	O	O
beta	NOUN	O	B-Entity
lactam	NOUN	O	I-Entity
antibiotic	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
gradual	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
bilirubin	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
hemoglobin	NOUN	O	O
concentration	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
an	DET	O	O
autoimmune	ADJ	O	B-Entity
hemolytic	NOUN	O	I-Entity
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
erythroblastocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
responded	VERB	O	O
to	ADP	O	O
systemic	ADJ	O	O
steroids	NOUN	O	I-Entity
and	CCONJ	O	O
immunoglobulins	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
widespread	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
this	DET	O	O
triad	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
connection	NOUN	O	O
with	ADP	O	O
beta	NOUN	O	B-Entity
lactam	NOUN	O	I-Entity
antibiotics	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9766615)

Conventional	ADJ	O	O
agents	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
unwanted	ADJ	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
extrapyramidal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
(	PUNCT	O	O
EPS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
,	PUNCT	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
possible	ADJ	O	O
impairment	NOUN	O	O
of	ADP	O	O
some	DET	O	O
cognitive	ADJ	O	O
measures	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
cardiac	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
hepatic	ADJ	O	O
changes	NOUN	O	O
,	PUNCT	O	O
anticholinergic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
newer	NOUN	O	O
atypical	ADJ	O	O
agents	NOUN	O	O
have	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
EPS	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
are	VERB	O	O
associated	VERB	O	O
in	ADP	O	O
varying	VERB	O	O
degrees	NOUN	O	O
with	ADP	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
anticholinergic	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
,	PUNCT	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
hepatic	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
lowered	VERB	O	O
seizure	NOUN	O	I-Entity
threshold	NOUN	O	O
(	PUNCT	O	O
primarily	ADV	O	O
clozapine	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
agranulocytosis	NOUN	O	I-Entity
(	PUNCT	O	O
clozapine	NOUN	O	I-Entity
only	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (10193204)

Effects	NOUN	O	O
of	ADP	O	O
tetrandrine	NOUN	O	I-Entity
and	CCONJ	O	O
fangchinoline	NOUN	O	I-Entity
on	ADP	O	O
experimental	ADJ	O	O
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
and	CCONJ	O	O
human	ADJ	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
.	PUNCT	O	O

Tetrandrine	PROPN	O	I-Entity
(	PUNCT	O	O
TET	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
fangchinoline	NOUN	O	I-Entity
(	PUNCT	O	O
FAN	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
two	NUM	O	O
naturally	ADV	O	O
occurring	VERB	O	O
analogues	NOUN	O	O
with	ADP	O	O
a	DET	O	O
bisbenzylisoquinoline	NOUN	O	I-Entity
structure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
TET	PROPN	O	I-Entity
and	CCONJ	O	O
FAN	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
thrombosis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
collagen	NOUN	O	O
plus	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
EP	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
and	CCONJ	O	O
blood	NOUN	O	B-Entity
coagulation	NOUN	O	I-Entity
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
in	NOUN	O	O
vivo	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
administration	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
TET	PROPN	O	I-Entity
and	CCONJ	O	O
FAN	PROPN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
thrombosis	NOUN	O	I-Entity
by	ADP	O	O
55%	NUM	O	O
and	CCONJ	O	O
35%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
while	ADP	O	O
acetylsalicylic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
ASA	PROPN	O	I-Entity
,	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
positive	ADJ	O	O
control	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
only	ADV	O	O
30%	NUM	O	O
inhibition	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
vitro	NOUN	O	O
human	ADJ	O	O
platelet	NOUN	O	B-Entity
aggregations	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
agonists	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
tests	NOUN	O	O
,	PUNCT	O	O
TET	PROPN	O	I-Entity
and	CCONJ	O	O
FAN	PROPN	O	I-Entity
showed	VERB	O	O
the	DET	O	O
inhibitions	NOUN	O	O
dose	NOUN	O	O
dependently	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
neither	CCONJ	O	O
TET	PROPN	O	I-Entity
nor	CCONJ	O	O
FAN	PROPN	O	I-Entity
showed	VERB	O	O
any	DET	O	O
anticoagulation	NOUN	O	O
activities	NOUN	O	O
in	ADP	O	O
the	DET	O	O
measurement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
activated	VERB	O	O
partial	ADJ	O	O
thromboplastin	ADJ	O	O
time	NOUN	O	O
(	PUNCT	O	O
APTT	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
prothrombin	ADJ	O	O
time	NOUN	O	O
(	PUNCT	O	O
PT	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
thrombin	DET	O	O
time	NOUN	O	O
(	PUNCT	O	O
TT	PROPN	O	O
)	PUNCT	O	O
using	VERB	O	O
human	NOUN	O	O
-	PUNCT	O	O
citrated	VERB	O	O
plasma	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
antithrombosis	NOUN	O	O
of	ADP	O	O
TET	PROPN	O	I-Entity
and	CCONJ	O	O
FAN	PROPN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
mainly	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
antiplatelet	NOUN	O	O
aggregation	NOUN	O	O
activities	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10526274)

Gemcitabine	PROPN	O	I-Entity
plus	CCONJ	O	O
vinorelbine	NOUN	O	I-Entity
in	ADP	O	O
nonsmall	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
patients	NOUN	O	O
age	NOUN	O	O
70	NUM	O	O
years	NOUN	O	O
or	CCONJ	O	O
older	ADJ	O	O
or	CCONJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
receive	VERB	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
nonsmall	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
(	PUNCT	O	O
NSCLC	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
high	ADJ	O	O
among	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
few	ADJ	O	O
data	NOUN	O	O
are	VERB	O	O
available	ADJ	O	O
regarding	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
reports	NOUN	O	O
indicate	VERB	O	O
that	DET	O	O
single	ADJ	O	O
agent	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
vinorelbine	NOUN	O	I-Entity
(	PUNCT	O	O
VNB	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
gemcitabine	NOUN	O	I-Entity
(	PUNCT	O	O
GEM	PROPN	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
obtain	VERB	O	O
a	DET	O	O
response	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
-	PUNCT	O	O
30%	NUM	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
acceptable	ADJ	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
GEM	PROPN	O	I-Entity
and	CCONJ	O	O
VNB	PROPN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
NSCLC	PROPN	O	I-Entity
or	CCONJ	O	O
those	DET	O	O
with	ADP	O	O
some	DET	O	O
contraindication	NOUN	O	O
to	ADP	O	O
receiving	VERB	O	O
cisplatin	NOUN	O	I-Entity
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Forty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
NSCLC	PROPN	O	I-Entity
were	VERB	O	O
included	VERB	O	O
,	PUNCT	O	O
38	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
were	VERB	O	O
age	NOUN	O	O
>	X	O	O
/=	SYM	O	O
70	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
11	NUM	O	O
were	VERB	O	O
age	NOUN	O	O

<	X	O	O
70	NUM	O	O
years	NOUN	O	O
but	CCONJ	O	O
who	NOUN	O	O
had	VERB	O	O
some	DET	O	O
contraindication	NOUN	O	O
to	ADP	O	O
receiving	VERB	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluable	ADJ	O	O
for	ADP	O	O
response	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	PROPN	O	O
was	VERB	O	O
comprised	VERB	O	O
of	ADP	O	O
VNB	PROPN	O	I-Entity
,	PUNCT	O	O
25	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
plus	CCONJ	O	O
GEM	PROPN	O	I-Entity
,	PUNCT	O	O
1000	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
both	DET	O	O
on	ADP	O	O
Days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Toxicity	NOUN	O	I-Entity
was	VERB	O	O
mild	ADJ	O	O
.	PUNCT	O	O

Six	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
12%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
World	PROPN	O	O
Health	PROPN	O	O
Organization	PROPN	O	O
Grade	PROPN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
2	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
4%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
Grade	PROPN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
4%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
Grade	NOUN	O	O
3	NUM	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
6%	NUM	O	O
)	PUNCT	O	O
died	VERB	O	O
of	ADP	O	O
sepsis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
age	NOUN	O	O
of	ADP	O	O
those	DET	O	O
patients	NOUN	O	O
developing	VERB	O	O
Grade	PROPN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
75	NUM	O	O
years	NOUN	O	O
vs.	ADP	O	O
72	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.047	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
GEM	PROPN	O	I-Entity
and	CCONJ	O	O
VNB	PROPN	O	I-Entity
is	VERB	O	O
moderately	ADV	O	O
active	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
tolerated	VERB	O	O
except	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
age	NOUN	O	O
>	X	O	O
/=	SYM	O	O
75	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
age	NOUN	O	O
group	NOUN	O	O
had	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
myelosuppression	NOUN	O	I-Entity
.	PUNCT	O	O

New	ADJ	O	O
chemotherapy	NOUN	O	O
combinations	NOUN	O	O
with	ADP	O	O
higher	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
toxicity	NOUN	O	I-Entity
are	VERB	O	O
needed	VERB	O	O
for	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10669626)

Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
is	VERB	O	O
accelerated	VERB	O	O
by	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
D.	PROPN	O	I-Entity

The	DET	O	O
present	ADJ	O	O
studies	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
growth	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
treatment	NOUN	O	O
enhance	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
sufficient	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
Warfarin	PROPN	O	I-Entity
to	PART	O	O
inhibit	VERB	O	O
gamma	ADJ	O	O
-	PUNCT	O	O
carboxylation	NOUN	O	O
of	ADP	O	O
matrix	NOUN	O	O
Gla	PROPN	O	O
protein	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
calcification	NOUN	O	I-Entity
inhibitor	NOUN	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
expressed	VERB	O	O
by	ADP	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
macrophages	NOUN	O	O
in	ADP	O	O
the	DET	O	O
artery	NOUN	O	O
wall	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
series	NOUN	O	O
of	ADP	O	O
experiments	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
growth	NOUN	O	O
status	NOUN	O	O
on	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
in	ADP	O	O
Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
with	ADP	O	O
Warfarin	PROPN	O	I-Entity
caused	VERB	O	O
massive	ADJ	O	O
focal	ADJ	O	O
calcification	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
artery	NOUN	O	I-Entity
media	NOUN	O	O
in	ADP	O	O
20-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
and	CCONJ	O	O
less	ADV	O	O
extensive	ADJ	O	O
focal	ADJ	O	O
calcification	NOUN	O	I-Entity
in	ADP	O	O
42-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
10-month	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
adult	NOUN	O	O
rats	NOUN	O	O
even	ADV	O	O
after	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
Warfarin	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
directly	ADV	O	O
examine	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
growth	NOUN	O	O
to	ADP	O	O
Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
in	ADP	O	O
animals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
20-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
fed	VERB	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
either	CCONJ	O	O
an	DET	O	O
ad	NOUN	O	O
libitum	NOUN	O	O
diet	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
6-g	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
restricted	VERB	O	O
diet	NOUN	O	O
that	ADJ	O	O
maintains	VERB	O	O
weight	NOUN	O	O
but	CCONJ	O	O
prevents	VERB	O	O
growth	NOUN	O	O
.	PUNCT	O	O

Concurrent	PROPN	O	O
treatment	NOUN	O	O
of	ADP	O	O
both	DET	O	O
dietary	ADJ	O	O
groups	NOUN	O	O
with	ADP	O	O
Warfarin	PROPN	O	I-Entity
produced	VERB	O	O
massive	ADJ	O	O
focal	ADJ	O	O
calcification	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
artery	NOUN	O	I-Entity
media	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ad	NOUN	O	O
libitum	NOUN	O	O
-	PUNCT	O	O
fed	VERB	O	O
rats	NOUN	O	O
but	CCONJ	O	O
no	DET	O	O
detectable	ADJ	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
restricted	VERB	O	O
-	PUNCT	O	O
diet	NOUN	O	O
,	PUNCT	O	O
growth	NOUN	O	O
-	PUNCT	O	O
inhibited	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
explanation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
and	CCONJ	O	O
growth	NOUN	O	O
status	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
determined	VERB	O	O
from	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
higher	ADJ	O	O
serum	NOUN	O	O
phosphate	NOUN	O	I-Entity
and	CCONJ	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
30%	NUM	O	O
higher	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
phosphate	NOUN	O	I-Entity
in	ADP	O	O
young	ADJ	O	O
,	PUNCT	O	O
ad	NOUN	O	O
libitum	NOUN	O	O
-	PUNCT	O	O
fed	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
either	DET	O	O
of	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
resistant	ADJ	O	O
to	ADP	O	O
Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
,	PUNCT	O	O
ie	X	O	O
,	PUNCT	O	O
the	DET	O	O
10-month	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
restricted	VERB	O	O
-	PUNCT	O	O
diet	NOUN	O	O
,	PUNCT	O	O
growth	NOUN	O	O
-	PUNCT	O	O
inhibited	VERB	O	O
young	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
increased	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
higher	ADJ	O	O
serum	NOUN	O	O
phosphate	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
set	NOUN	O	O
of	ADP	O	O
experiments	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
synergy	NOUN	O	O
between	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
and	CCONJ	O	O
Warfarin	PROPN	O	I-Entity
in	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
.	PUNCT	O	O

High	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D	PROPN	O	I-Entity
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
calcification	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
artery	NOUN	O	I-Entity
media	NOUN	O	O
in	ADP	O	O
as	ADV	O	O
little	ADJ	O	O
as	ADP	O	O
3	NUM	O	O
to	PART	O	O
4	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vitamin	NOUN	O	B-Entity
K	PROPN	O	I-Entity
antagonist	NOUN	O	O
Warfarin	PROPN	O	I-Entity
are	VERB	O	O
also	ADV	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
calcification	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
artery	NOUN	O	I-Entity
media	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
at	ADP	O	O
treatment	NOUN	O	O
times	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
longer	ADV	O	O
yet	ADV	O	O
not	ADV	O	O
at	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
synergy	NOUN	O	O
between	ADP	O	O
these	DET	O	O
2	NUM	O	O
treatments	NOUN	O	O
and	CCONJ	O	O
found	VERB	O	O
that	ADP	O	O
concurrent	ADJ	O	O
Warfarin	PROPN	O	I-Entity
administration	NOUN	O	O
dramatically	ADV	O	O
increased	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
calcification	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
media	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
close	ADJ	O	O
parallel	NOUN	O	O
between	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
dose	NOUN	O	O
on	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
dose	NOUN	O	O
on	ADP	O	O
the	DET	O	O
elevation	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
suggests	VERB	O	O
that	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
may	VERB	O	O
induce	VERB	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
through	ADP	O	O
its	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
Warfarin	PROPN	O	I-Entity
treatment	NOUN	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
elevation	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
synergy	NOUN	O	O
between	ADP	O	O
Warfarin	PROPN	O	I-Entity
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
is	VERB	O	O
probably	ADV	O	O
best	ADJ	O	O
explained	VERB	O	O
by	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
Warfarin	PROPN	O	I-Entity
inhibits	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
matrix	NOUN	O	O
Gla	PROPN	O	O
protein	NOUN	O	O
as	ADP	O	O
a	DET	O	O
calcification	NOUN	O	I-Entity
inhibitor	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
matrix	NOUN	O	O
Gla	PROPN	O	O
protein	NOUN	O	O
are	VERB	O	O
found	VERB	O	O
at	ADP	O	O
sites	NOUN	O	O
of	ADP	O	O
artery	NOUN	O	B-Entity
calcification	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
plus	CCONJ	O	O
Warfarin	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
chemical	NOUN	O	O
analysis	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
protein	NOUN	O	O
that	ADJ	O	O
accumulated	VERB	O	O
was	VERB	O	O
indeed	ADV	O	O
not	ADV	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
carboxylated	VERB	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
although	ADP	O	O
the	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
carboxyglutamate	NOUN	O	I-Entity
residues	NOUN	O	O
of	ADP	O	O
matrix	NOUN	O	O
Gla	PROPN	O	O
protein	NOUN	O	O
are	VERB	O	O
apparently	ADV	O	O
required	VERB	O	O
for	ADP	O	O
its	ADJ	O	O
function	NOUN	O	O
as	ADP	O	O
a	DET	O	O
calcification	NOUN	O	I-Entity
inhibitor	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
are	VERB	O	O
not	ADV	O	O
required	VERB	O	O
for	ADP	O	O
its	ADJ	O	O
accumulation	NOUN	O	O
at	ADP	O	O
calcification	NOUN	O	I-Entity
sites	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11379838)

Antidepressant	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
mania	NOUN	O	I-Entity
in	ADP	O	O
bipolar	ADJ	O	I-Entity
patients	NOUN	O	O
:	PUNCT	O	O
identification	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Concerns	NOUN	O	O
about	ADP	O	O
possible	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
switching	VERB	O	O
to	ADP	O	O
mania	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
antidepressants	NOUN	O	I-Entity
continue	VERB	O	O
to	PART	O	O
interfere	VERB	O	O
with	ADP	O	O
the	DET	O	O
establishment	NOUN	O	O
of	ADP	O	O
an	DET	O	O
optimal	ADJ	O	O
treatment	NOUN	O	O
paradigm	NOUN	O	O
for	ADP	O	O
bipolar	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
of	ADP	O	O
44	NUM	O	O
patients	NOUN	O	O
meeting	VERB	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
criteria	NOUN	O	O
for	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
to	ADP	O	O
naturalistic	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
6	NUM	O	O
weeks	NOUN	O	O
using	VERB	O	O
the	DET	O	O
Montgomery	PROPN	O	O
-	PUNCT	O	O
Asberg	PROPN	O	O
Depression	PROPN	O	O
Rating	PROPN	O	O
Scale	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
Bech	PROPN	O	O
-	PUNCT	O	O
Rafaelson	PROPN	O	O
Mania	PROPN	O	O
Rating	PROPN	O	O
Scale	PROPN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
manic	ADJ	O	I-Entity
or	CCONJ	O	O
hypomanic	ADJ	O	I-Entity
switch	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
on	ADP	O	O
several	ADJ	O	O
variables	NOUN	O	O
including	VERB	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
diagnosis	NOUN	O	O
(	PUNCT	O	O
DSM	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
IV	PROPN	O	I-Entity
bipolar	NOUN	O	I-Entity
I	PRON	O	I-Entity
vs.	VERB	O	O
bipolar	ADJ	O	B-Entity
II	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
previous	ADJ	O	O
manic	ADJ	O	I-Entity
episodes	NOUN	O	O
,	PUNCT	O	O
type	NOUN	O	O
of	ADP	O	O
antidepressant	NOUN	O	I-Entity
therapy	NOUN	O	O
used	VERB	O	O
(	PUNCT	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
vs.	ADP	O	O
antidepressant	NOUN	O	I-Entity
drugs	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
more	ADV	O	O
particularly	ADV	O	O
,	PUNCT	O	O
selective	ADJ	O	O
serotonin	NOUN	O	B-Entity
reuptake	NOUN	O	I-Entity
inhibitors	NOUN	O	I-Entity
[	PUNCT	O	O
SSRIs	PROPN	O	I-Entity
]	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
use	NOUN	O	O
and	CCONJ	O	O
type	NOUN	O	O
of	ADP	O	O
mood	NOUN	O	O
stabilizers	NOUN	O	O
(	PUNCT	O	O
lithium	NOUN	O	I-Entity
vs.	X	O	O
anticonvulsants	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
temperament	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
assessed	VERB	O	O
during	ADP	O	O
a	DET	O	O
normothymic	ADJ	O	O
period	NOUN	O	O
using	VERB	O	O
the	DET	O	O
hyperthymia	NOUN	O	O
component	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Semi	PROPN	O	O
-	PUNCT	O	O
structured	VERB	O	O
Affective	ADJ	O	O
Temperament	PROPN	O	O
Interview	PROPN	O	O
.	PUNCT	O	O

Switches	NOUN	O	O
to	ADP	O	O
hypomania	VERB	O	I-Entity
or	CCONJ	O	O
mania	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
27%	NUM	O	O
of	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
24%	NUM	O	O
of	ADP	O	O
the	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
SSRIs	PROPN	O	I-Entity
[	PUNCT	O	O
8/33	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
16%	NUM	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
experienced	VERB	O	O
manic	ADJ	O	I-Entity
episodes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
11%	NUM	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
experienced	VERB	O	O
hypomanic	ADJ	O	I-Entity
episodes	NOUN	O	O
.	PUNCT	O	O

Sex	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
diagnosis	NOUN	O	O
(	PUNCT	O	O
bipolar	NOUN	O	B-Entity
I	PRON	O	I-Entity
vs.	VERB	O	O
bipolar	ADJ	O	B-Entity
II	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
additional	ADJ	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
switching	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
mood	NOUN	O	O
switches	NOUN	O	O
were	VERB	O	O
less	ADV	O	O
frequent	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
lithium	NOUN	O	I-Entity
(	PUNCT	O	O
15%	NUM	O	O
,	PUNCT	O	O
4/26	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
not	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
(	PUNCT	O	O
44%	NUM	O	O
,	PUNCT	O	O
8/18	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
previous	ADJ	O	O
manic	ADJ	O	I-Entity
episodes	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
probability	NOUN	O	O
of	ADP	O	O
switching	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
a	DET	O	O
high	ADJ	O	O
score	NOUN	O	O
on	ADP	O	O
the	DET	O	O
hyperthymia	NOUN	O	O
component	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Semistructured	PROPN	O	O
Affective	PROPN	O	O
Temperament	PROPN	O	O
Interview	PROPN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
switching	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.008	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
mood	NOUN	O	O
switching	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
antidepressant	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
lithium	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11419773)

Caffeine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
arrhythmia	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
unrecognised	ADJ	O	O
danger	NOUN	O	O
of	ADP	O	O
healthfood	NOUN	O	O
products	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
25-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
mitral	ADJ	O	B-Entity
valve	NOUN	O	I-Entity
prolapse	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
intractable	ADJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
after	ADP	O	O
consuming	VERB	O	O
a	DET	O	O
"	PUNCT	O	O
natural	ADJ	O	O
energy	NOUN	O	O
"	PUNCT	O	O
guarana	NOUN	O	O
health	NOUN	O	O
drink	NOUN	O	O
containing	VERB	O	O
a	DET	O	O
high	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11581460)

Bladder	NOUN	O	O
retention	NOUN	O	B-Entity
of	ADP	O	I-Entity
urine	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
:	PUNCT	O	O
2	NUM	O	O
case	NOUN	O	O
reports	NOUN	O	O
.	PUNCT	O	O

Sedation	PROPN	O	O
has	VERB	O	O
been	VERB	O	O
commonly	ADV	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
neonate	NOUN	O	O
to	PART	O	O
decrease	VERB	O	O
the	DET	O	O
stress	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
from	ADP	O	O
the	DET	O	O
noxious	ADJ	O	O
stimuli	NOUN	O	O
and	CCONJ	O	O
invasive	ADJ	O	O
procedures	NOUN	O	O
in	ADP	O	O
the	DET	O	O
neonatal	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
to	PART	O	O
facilitate	VERB	O	O
synchrony	NOUN	O	O
between	ADP	O	O
ventilator	NOUN	O	O
and	CCONJ	O	O
spontaneous	ADJ	O	O
breaths	NOUN	O	O
.	PUNCT	O	O

Fentanyl	PROPN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
opioid	ADJ	O	O
analgesic	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
frequently	ADV	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
neonatal	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
setting	VERB	O	O
for	ADP	O	O
these	DET	O	O
very	ADV	O	O
purposes	NOUN	O	O
.	PUNCT	O	O

Various	ADJ	O	O
reported	VERB	O	O
side	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
administration	NOUN	O	O
include	VERB	O	O
chest	NOUN	O	B-Entity
wall	NOUN	O	I-Entity
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
respiratory	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
2	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	B-Entity
bladder	NOUN	O	I-Entity
retention	NOUN	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
renal	ADJ	O	O

pelvocalyceal	ADJ	O	O
dilatation	NOUN	O	O
mimicking	VERB	O	O
hydronephrosis	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11706060)

Combined	VERB	O	O
antiretroviral	ADJ	O	O
therapy	NOUN	O	O
causes	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
and	CCONJ	O	O
elevates	VERB	O	O
plasma	NOUN	O	O
lactate	NOUN	O	I-Entity
in	ADP	O	O
transgenic	ADJ	O	O
AIDS	PROPN	O	I-Entity
mice	NOUN	O	O
.	PUNCT	O	O

Highly	ADV	O	O
active	ADJ	O	O
antiretroviral	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
HAART	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
CM	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
elevated	ADJ	O	O
plasma	NOUN	O	O
lactate	NOUN	O	I-Entity
(	PUNCT	O	O
LA	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
AIDS	PROPN	O	I-Entity
through	ADP	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
mitochondrial	ADJ	O	O
events	NOUN	O	O
from	ADP	O	O
HAART	PROPN	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
8-week	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
hemizygous	ADJ	O	O
transgenic	ADJ	O	O
AIDS	PROPN	O	I-Entity
mice	NOUN	O	O
(	PUNCT	O	O
NL4	PROPN	O	O
-	PUNCT	O	O
3Delta	PROPN	O	O
gag	NOUN	O	O
/	SYM	O	O
pol	NOUN	O	O
;	PUNCT	O	O
TG	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
FVB	PROPN	O	O
/	SYM	O	O

n	ADV	O	O
littermates	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
HAART	PROPN	O	O
combination	NOUN	O	O
of	ADP	O	O
zidovudine	NOUN	O	I-Entity
,	PUNCT	O	O
lamivudine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
indinavir	NOUN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
control	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
or	CCONJ	O	O
35	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
termination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
experiments	NOUN	O	O
,	PUNCT	O	O
mice	NOUN	O	O
underwent	VERB	O	O
echocardiography	NOUN	O	O
,	PUNCT	O	O
quantitation	NOUN	O	O
of	ADP	O	O
abundance	NOUN	O	O
of	ADP	O	O
molecular	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
CM	PROPN	O	I-Entity
(	PUNCT	O	O
ventricular	ADJ	O	O
mRNA	PROPN	O	O
encoding	VERB	O	O
atrial	NOUN	O	O
natriuretic	ADJ	O	O
factor	NOUN	O	O
[	PUNCT	O	O
ANF	PROPN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
sarcoplasmic	ADJ	O	O
calcium	NOUN	O	I-Entity
ATPase	NOUN	O	O
[	PUNCT	O	O
SERCA2	PROPN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
determination	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
LA	PROPN	O	I-Entity
.	PUNCT	O	O

Biochemically	PROPN	O	O
,	PUNCT	O	O
LA	PROPN	O	I-Entity
was	VERB	O	O
elevated	VERB	O	O
(	PUNCT	O	O
8.5	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
cumulative	ADJ	O	O
HAART	PROPN	O	O
caused	VERB	O	O
mitochondrial	ADJ	O	O
CM	PROPN	O	I-Entity
with	ADP	O	O
elevated	ADJ	O	O
LA	PROPN	O	I-Entity
in	ADP	O	O
AIDS	PROPN	O	I-Entity
transgenic	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11752354)

Oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
An	DET	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
found	VERB	O	O
in	ADP	O	O
some	DET	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
all	DET	O	O
,	PUNCT	O	O
studies	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
this	DET	O	O
association	NOUN	O	O
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
progestagen	NOUN	O	I-Entity
included	VERB	O	O
in	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
desogestrel	NOUN	O	I-Entity
or	CCONJ	O	O
gestodene	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
levonorgestrel	PUNCT	O	I-Entity
)	PUNCT	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity

,	PUNCT	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
prothrombotic	ADJ	O	O
mutations	NOUN	O	O
METHODS	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
a	DET	O	O
nationwide	NOUN	O	O
,	PUNCT	O	O
population	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
,	PUNCT	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
identified	VERB	O	O
and	CCONJ	O	O
enrolled	VERB	O	O
248	NUM	O	O
women	NOUN	O	O
18	NUM	O	O
through	ADP	O	O
49	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
had	VERB	O	O
a	DET	O	O
first	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
between	ADP	O	O
1990	NUM	O	O
and	CCONJ	O	O
1995	NUM	O	O
and	CCONJ	O	O
925	NUM	O	O
control	NOUN	O	O
women	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
not	ADV	O	O
had	VERB	O	O
a	DET	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
and	CCONJ	O	O
who	NOUN	O	O
were	VERB	O	O
matched	VERB	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
calendar	NOUN	O	O
year	NOUN	O	O
of	ADP	O	O
the	DET	O	O
index	NOUN	O	O
event	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
area	NOUN	O	O
of	ADP	O	O
residence	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
supplied	VERB	O	O
information	NOUN	O	O
on	ADP	O	O
oral	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
contraceptive	NOUN	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
major	ADJ	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
analysis	NOUN	O	O
for	ADP	O	O
factor	NOUN	O	O
V	PROPN	O	O
Leiden	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
G20210A	PROPN	O	O
mutation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prothrombin	NOUN	O	O
gene	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
217	NUM	O	O
patients	NOUN	O	O
and	CCONJ	O	O
763	NUM	O	O
controls	NOUN	O	O
RESULTS	PROPN	O	O
:	PUNCT	O	O
The	DET	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
for	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
among	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
any	DET	O	O
type	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
oral	ADJ	O	B-Entity
contraceptive	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
nonusers	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
2.0	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.5	NUM	O	O
to	PART	O	O
2.8	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
adjusted	ADJ	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
was	VERB	O	O
2.5	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.5	NUM	O	O
to	PART	O	O
4.1	NUM	O	O
)	PUNCT	O	O
among	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
and	CCONJ	O	O
1.3	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.7	NUM	O	O
to	ADP	O	O
2.5	NUM	O	O
)	PUNCT	O	O
among	ADP	O	O
those	DET	O	O
who	NOUN	O	O
used	VERB	O	O
third	ADV	O	O
-	PUNCT	O	O
generation	NOUN	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
was	VERB	O	O
2.1	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.5	NUM	O	O
to	PART	O	O
3.0	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
those	DET	O	O
without	ADP	O	O
a	DET	O	O
prothrombotic	ADJ	O	O
mutation	NOUN	O	O
and	CCONJ	O	O
1.9	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.6	NUM	O	O
to	ADP	O	O
5.5	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
those	DET	O	O
with	ADP	O	O
a	DET	O	O
mutation	NOUN	O	O
CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
was	VERB	O	O
increased	VERB	O	O
among	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
were	VERB	O	O
inconclusive	ADJ	O	O
but	CCONJ	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
was	VERB	O	O
lower	ADJ	O	O
than	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
among	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
whether	ADP	O	O
or	CCONJ	O	O
not	ADV	O	O
they	PRON	O	O
had	VERB	O	O
a	DET	O	O
prothrombotic	ADJ	O	O
mutation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12369736)

Effects	NOUN	O	O
of	ADP	O	O
5-HT1B	NUM	O	O
receptor	NOUN	O	O
ligands	NOUN	O	O
microinjected	VERB	O	O
into	ADP	O	O
the	DET	O	O
accumbal	ADJ	O	O
shell	NOUN	O	O
or	CCONJ	O	O
core	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
5-HT1B	NUM	O	O
receptor	NOUN	O	O
ligands	NOUN	O	O
microinjected	VERB	O	O
into	ADP	O	O
the	DET	O	O
subregions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nucleus	NOUN	O	O
accumbens	VERB	O	O
(	PUNCT	O	O
the	DET	O	O
shell	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
core	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
locomotor	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Male	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
implanted	VERB	O	O
bilaterally	ADV	O	O
with	ADP	O	O
cannulae	NOUN	O	O
into	ADP	O	O
the	DET	O	O
accumbens	NOUN	O	O
shell	NOUN	O	O
or	CCONJ	O	O
core	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
were	VERB	O	O
locally	ADV	O	O
injected	VERB	O	O
with	ADP	O	O
GR	PROPN	O	B-Entity
55562	NUM	O	I-Entity
(	PUNCT	O	O
an	DET	O	O
antagonist	NOUN	O	O
of	ADP	O	O
5-HT1B	NUM	O	O
receptors	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
CP	PROPN	O	B-Entity
93129	NUM	O	I-Entity
(	PUNCT	O	O
an	DET	O	O
agonist	NOUN	O	O
of	ADP	O	O
5-HT1B	NUM	O	O
receptors	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Given	VERB	O	O
alone	ADV	O	O
to	ADP	O	O
any	DET	O	O
accumbal	ADJ	O	O
subregion	NOUN	O	O
,	PUNCT	O	O
GR	PROPN	O	B-Entity
55562	NUM	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
CP	PROPN	O	B-Entity
93129	NUM	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
basal	ADJ	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Systemic	ADJ	O	O
cocaine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

GR	PROPN	O	B-Entity
55562	NUM	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
intra	NOUN	O	O
-	PUNCT	O	O
accumbens	NOUN	O	O
shell	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
psychostimulant	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
attenuation	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
found	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
which	ADJ	O	O
had	VERB	O	O
been	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
GR	PROPN	O	B-Entity
55562	NUM	O	I-Entity
into	ADP	O	O
the	DET	O	O
accumbens	NOUN	O	O
core	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
accumbens	NOUN	O	O
shell	NOUN	O	O
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
core	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
CP	PROPN	O	B-Entity
93129	NUM	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
-	SYM	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
)	PUNCT	O	O
enhanced	VERB	O	O
the	DET	O	O
locomotor	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
maximum	ADJ	O	O
effect	NOUN	O	O
being	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
of	ADP	O	O
the	DET	O	O
agonist	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
later	ADJ	O	O
enhancement	NOUN	O	O
was	VERB	O	O
attenuated	VERB	O	O
after	ADP	O	O
intra	ADV	O	O
-	PUNCT	O	O
accumbens	NOUN	O	O
shell	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
GR	PROPN	O	B-Entity
55562	NUM	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
cocaine	NOUN	O	I-Entity
induced	VERB	O	O
hyperlocomotion	NOUN	O	I-Entity
is	VERB	O	O
modified	VERB	O	O
by	ADP	O	O
5-HT1B	NUM	O	O
receptor	NOUN	O	O
ligands	NOUN	O	O
microinjected	VERB	O	O
into	ADP	O	O
the	DET	O	O
accumbens	NOUN	O	O
shell	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
core	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
modification	NOUN	O	O
consisting	VERB	O	O
in	ADP	O	O
inhibitory	NOUN	O	O
and	CCONJ	O	O
facilitatory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
5-HT1B	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
(	PUNCT	O	O
GR	PROPN	O	B-Entity
55562	NUM	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
agonist	NOUN	O	O
(	PUNCT	O	O
CP	PROPN	O	B-Entity
93129	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (12639165)

Ticlopidine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
2	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cholestatic	NOUN	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
investigate	VERB	O	O
its	ADJ	O	O
mechanism	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
compare	VERB	O	O
the	DET	O	O
observed	VERB	O	O
main	ADJ	O	O
characteristics	NOUN	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
the	DET	O	O
published	VERB	O	O
cases	NOUN	O	O
.	PUNCT	O	O

CASE	NOUN	O	O
SUMMARIES	NOUN	O	O
:	PUNCT	O	O
Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
prolonged	ADJ	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
after	ADP	O	O
receiving	VERB	O	O
ticlopidine	NOUN	O	I-Entity
following	VERB	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
during	ADP	O	O
the	DET	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

T	NOUN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
stimulation	NOUN	O	O
by	ADP	O	O
therapeutic	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	I-Entity
was	VERB	O	O
demonstrated	VERB	O	O
in	ADP	O	O
vitro	NOUN	O	O
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Cholestatic	PROPN	O	B-Entity
hepatitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antiplatelet	NOUN	O	O
agent	NOUN	O	O
ticlopidine	NOUN	O	I-Entity
;	PUNCT	O	O
several	ADJ	O	O
cases	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
but	CCONJ	O	O
few	ADJ	O	O
in	ADP	O	O
the	DET	O	O
English	ADJ	O	O
literature	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
patients	NOUN	O	O
developed	VERB	O	O
jaundice	ADV	O	I-Entity
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
ticlopidine	NOUN	O	I-Entity
and	CCONJ	O	O
showed	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
resolved	VERB	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Hepatitis	PROPN	O	I-Entity
may	VERB	O	O
develop	VERB	O	O
weeks	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
run	VERB	O	O
a	DET	O	O
prolonged	ADJ	O	O
course	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
complete	ADJ	O	O
remission	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
all	DET	O	O
reported	VERB	O	O
cases	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
objective	ADJ	O	O
causality	NOUN	O	O
assessment	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
event	NOUN	O	O
was	VERB	O	O
probably	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
this	DET	O	O
ticlopidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cholestasis	NOUN	O	I-Entity
are	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

Immune	ADJ	O	O
mechanisms	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
's	PART	O	O
hepatotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
suggested	VERB	O	O
by	ADP	O	O
the	DET	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
stimulation	NOUN	O	O
study	NOUN	O	O
reported	VERB	O	O
here	ADV	O	O
.	PUNCT	O	O

Cholestatic	PROPN	O	B-Entity
hepatitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
immune	ADJ	O	O
mediated	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
complication	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
observed	VERB	O	O
even	ADV	O	O
less	ADV	O	O
often	ADV	O	O
in	ADP	O	O
the	DET	O	O
future	NOUN	O	O
as	ADP	O	O
ticlopidine	NOUN	O	I-Entity
is	VERB	O	O
being	VERB	O	O
replaced	VERB	O	O
by	ADP	O	O
the	DET	O	O
newer	NOUN	O	O
antiplatelet	NOUN	O	O
agent	NOUN	O	O
clopidogrel	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12653683)

Epithelial	ADJ	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
(	PUNCT	O	O
ENaC	PROPN	O	O
)	PUNCT	O	O
subunit	NOUN	O	O
mRNA	NOUN	O	O
and	CCONJ	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
experimental	ADJ	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
is	VERB	O	O
decreased	VERB	O	O
during	ADP	O	O
the	DET	O	O
early	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
constituent	NOUN	O	O
of	ADP	O	O
collecting	VERB	O	O
duct	NOUN	O	O
sodium	NOUN	O	I-Entity
transport	NOUN	O	O
is	VERB	O	O
the	DET	O	O
epithelial	ADJ	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
(	PUNCT	O	O
ENaC	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
abundance	NOUN	O	O
of	ADP	O	O
ENaC	PROPN	O	O
subunit	NOUN	O	O
mRNAs	PROPN	O	O
and	CCONJ	O	O
proteins	NOUN	O	O
in	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN)-induced	VERB	O	I-Entity
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	O
courses	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
aldosterone	NOUN	O	I-Entity
concentration	NOUN	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
either	DET	O	O
PAN	PROPN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
kinetics	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
were	VERB	O	O
comparable	ADJ	O	O
with	ADP	O	O
those	DET	O	O
reported	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O

Sodium	ADJ	O	I-Entity
retention	NOUN	O	O
occurred	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
after	ADP	O	O
PAN	PROPN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
up	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
alphaENaC	PROPN	O	O
and	CCONJ	O	O
betaENaC	PROPN	O	O
mRNA	PROPN	O	O
abundance	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
preceded	VERB	O	O
sodium	NOUN	O	I-Entity
retention	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
.	PUNCT	O	O

Conversely	ADV	O	O
,	PUNCT	O	O
down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
alphaENaC	PROPN	O	O
,	PUNCT	O	O
betaENaC	PROPN	O	O
and	CCONJ	O	O
gammaENaC	PROPN	O	O
mRNA	PROPN	O	O
expression	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
3	NUM	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
aldosterone	NOUN	O	I-Entity
concentrations	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
return	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
to	PART	O	O
control	VERB	O	O
values	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
amounts	NOUN	O	O
of	ADP	O	O
alphaENaC	NOUN	O	O
,	PUNCT	O	O
betaENaC	PROPN	O	O
and	CCONJ	O	O
gammaENaC	PROPN	O	O
proteins	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
increased	VERB	O	O
during	ADP	O	O
PAN	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sodium	NOUN	O	I-Entity
retention	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
ENaC	PROPN	O	O
mRNA	PROPN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
alphaENaC	PROPN	O	O
,	PUNCT	O	O
is	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
very	ADV	O	O
early	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
PAN	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
appears	VERB	O	O
to	PART	O	O
escape	VERB	O	O
from	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
by	ADP	O	O
aldosterone	NOUN	O	I-Entity
after	ADP	O	O
day	NOUN	O	O
3	NUM	O	O
.	PUNCT	O	O


-DOCSTART- (14659530)

NO	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
:	PUNCT	O	O
strong	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
calcitonin	NOUN	O	B-Entity
gene	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
related	VERB	O	I-Entity
peptide	NOUN	O	I-Entity
(	PUNCT	O	O
CGRP	PROPN	O	I-Entity
)	PUNCT	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
negative	ADJ	O	O
correlation	NOUN	O	O
with	ADP	O	O
platelet	NOUN	O	O
serotonin	NOUN	O	I-Entity
release	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
calcitonin	NOUN	O	B-Entity
gene	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
related	VERB	O	I-Entity
peptide	NOUN	O	I-Entity
(	PUNCT	O	O
CGRP	PROPN	O	I-Entity
)	PUNCT	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
platelet	VERB	O	O
serotonin	NOUN	O	I-Entity
(	PUNCT	O	O
5-hydroxytriptamine	NOUN	O	I-Entity
,	PUNCT	O	O
5-HT	PUNCT	O	I-Entity
)	PUNCT	O	O
content	NOUN	O	O
during	ADP	O	O
the	DET	O	O
immediate	ADJ	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
delayed	VERB	O	O
genuine	ADJ	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
provoked	VERB	O	O
by	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
.	PUNCT	O	O

Fifteen	NUM	O	O
female	ADJ	O	O
migraineurs	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
without	ADP	O	I-Entity
aura	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	O
eight	NUM	O	O
controls	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Sublingual	ADJ	O	O
nitroglycerin	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
was	VERB	O	O
collected	VERB	O	O
from	ADP	O	O
the	DET	O	O
antecubital	NOUN	O	O
vein	NOUN	O	O
four	NUM	O	O
times	NOUN	O	O
:	PUNCT	O	O
60	NUM	O	O
min	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
nitroglycerin	NOUN	O	I-Entity
application	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
60	NUM	O	O
and	CCONJ	O	O
120	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
the	DET	O	O
beginning	NOUN	O	O
of	ADP	O	O
the	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
344	NUM	O	O
and	CCONJ	O	O
404	NUM	O	O
min	NOUN	O	O
;	PUNCT	O	O
12	NUM	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
those	DET	O	O
subjects	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
no	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
a	DET	O	O
similar	ADJ	O	O
time	NOUN	O	O
schedule	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
CGRP	PROPN	O	I-Entity
concentration	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P<0.01	PROPN	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
and	CCONJ	O	O
returned	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
after	ADP	O	O
the	DET	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
migraine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
change	NOUN	O	O
and	CCONJ	O	O
peak	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
significant	ADJ	O	O
positive	ADJ	O	O
correlations	NOUN	O	O
with	ADP	O	O
migraine	ADJ	O	I-Entity
headache	NOUN	O	I-Entity
intensity	NOUN	O	O
(	PUNCT	O	O
P<0.001	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
CGRP	PROPN	O	I-Entity
concentrations	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
change	VERB	O	O
during	ADP	O	O
immediate	ADJ	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
with	ADP	O	O
no	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
.	PUNCT	O	O

Basal	ADJ	O	O
CGRP	PROPN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
and	CCONJ	O	O
platelet	VERB	O	O
5-HT	NUM	O	I-Entity
content	NOUN	O	O
tended	VERB	O	O
to	PART	O	O
be	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
subjects	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
.	PUNCT	O	O

Platelet	PROPN	O	O
serotonin	NOUN	O	I-Entity
content	NOUN	O	O
decreased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P<0.01	PROPN	O	O
)	PUNCT	O	O
after	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
no	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
but	CCONJ	O	O
no	DET	O	O
consistent	ADJ	O	O
change	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
plasma	NOUN	O	O
CGRP	PROPN	O	I-Entity
concentration	NOUN	O	O
correlates	VERB	O	O
with	ADP	O	O
the	DET	O	O
timing	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
a	DET	O	O
migraine	ADJ	O	I-Entity
headache	NOUN	O	I-Entity
suggests	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
CGRP	PROPN	O	I-Entity
and	CCONJ	O	O
migraine	ADJ	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
serotonin	NOUN	O	I-Entity
release	NOUN	O	O
from	ADP	O	O
platelets	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
provoke	VERB	O	O
migraine	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
even	ADV	O	O
counteract	VERB	O	O
the	DET	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
concomitant	ADJ	O	O
CGRP	PROPN	O	I-Entity
release	NOUN	O	O
in	ADP	O	O
this	DET	O	O
model	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15804801)

Coronary	PROPN	O	B-Entity
aneurysm	NOUN	O	I-Entity
after	ADP	O	O
implantation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
paclitaxel	NOUN	O	I-Entity
-	PUNCT	O	O
eluting	VERB	O	O
stent	NOUN	O	O
.	PUNCT	O	O

Formation	PROPN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
aneurysm	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
stenting	VERB	O	O
with	ADP	O	O
bare	ADJ	O	O
metal	NOUN	O	O
stents	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
based	VERB	O	O
on	ADP	O	O
experimental	ADJ	O	O
studies	NOUN	O	O
drug	NOUN	O	O
-	PUNCT	O	O
eluting	VERB	O	O
stents	NOUN	O	O
may	VERB	O	O
induce	VERB	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
vessel	NOUN	O	O
wall	NOUN	O	O
with	ADP	O	O
incomplete	ADJ	O	O
stent	NOUN	O	O
apposition	NOUN	O	O
,	PUNCT	O	O
aneurysm	ADJ	O	I-Entity
formation	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
potential	NOUN	O	O
of	ADP	O	O
stent	NOUN	O	O
thrombosis	NOUN	O	I-Entity
or	CCONJ	O	O
vessel	NOUN	O	B-Entity
rupture	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
43-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
coronary	ADJ	O	B-Entity
aneurysm	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
6	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
receiving	VERB	O	O
a	DET	O	O
paclitaxel	NOUN	O	I-Entity
-	PUNCT	O	O
eluting	VERB	O	O
stent	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
asymptomatic	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
aneurysm	NOUN	O	I-Entity
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
a	DET	O	O
routine	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

Angiography	PROPN	O	O
and	CCONJ	O	O
intracoronary	ADJ	O	O
ultrasound	NOUN	O	O
demonstrated	VERB	O	O
lack	NOUN	O	O
of	ADP	O	O
contact	NOUN	O	O
between	ADP	O	O
stent	NOUN	O	O
and	CCONJ	O	O
vessel	NOUN	O	O
wall	NOUN	O	O
in	ADP	O	O
a	DET	O	O
15-mm	NUM	O	O
long	ADJ	O	O
segment	NOUN	O	O
with	ADP	O	O
maximal	ADJ	O	O
aneurysm	NOUN	O	I-Entity
diameter	NOUN	O	O
of	ADP	O	O
6.0	NUM	O	O
mm	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (16160878)

Behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
urotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
centrally	ADV	O	O
administered	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Urotensin	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
(	PUNCT	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
)	PUNCT	O	O
receptors	NOUN	O	O
are	VERB	O	O
widely	ADV	O	O
distributed	VERB	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

Intracerebroventricular	PROPN	O	O
(	PUNCT	O	O
i.c.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
injection	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
causes	VERB	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
stimulates	VERB	O	O
prolactin	ADJ	O	O
and	CCONJ	O	O
thyrotropin	ADJ	O	O
secretion	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
centrally	ADV	O	O
administered	VERB	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
have	VERB	O	O
received	VERB	O	O
little	ADJ	O	O
attention	NOUN	O	O
.	PUNCT	O	O

injections	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
on	ADP	O	O
behavioral	ADJ	O	O
,	PUNCT	O	O
metabolic	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
endocrine	NOUN	O	O
responses	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
graded	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
10,000	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
)	PUNCT	O	O
provoked	VERB	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
head	NOUN	O	O
dips	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hole	NOUN	O	O
-	PUNCT	O	O
board	NOUN	O	O
test	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
entries	NOUN	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
chamber	NOUN	O	O
in	ADP	O	O
the	DET	O	O
black	ADJ	O	O
-	PUNCT	O	O
and	CCONJ	O	O
-	PUNCT	O	O
white	ADJ	O	O
compartment	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
entries	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
platform	NOUN	O	O
and	CCONJ	O	O
open	ADJ	O	O
arms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plus	NOUN	O	O
-	PUNCT	O	O
maze	NOUN	O	O
test	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
immobility	NOUN	O	O
in	ADP	O	O
the	DET	O	O
forced	VERB	O	O
-	PUNCT	O	O
swimming	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
tail	NOUN	O	O
suspension	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Intracerebroventricular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
also	ADV	O	O
caused	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
:	PUNCT	O	O
food	NOUN	O	O
intake	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
and	CCONJ	O	O
1,000	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
,	PUNCT	O	O
water	NOUN	O	O
intake	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
-	SYM	O	O
10,000	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
horizontal	ADJ	O	O
locomotion	NOUN	O	O
activity	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
10,000	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
mouse	NOUN	O	O
.	PUNCT	O	O

Whatever	ADJ	O	O
was	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
central	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
body	NOUN	O	O
temperature	NOUN	O	O
,	PUNCT	O	O
nociception	NOUN	O	O
,	PUNCT	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
penile	ADJ	O	B-Entity
erection	NOUN	O	I-Entity
and	CCONJ	O	O
climbing	VERB	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
stress	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
plasma	NOUN	O	O
corticosterone	NOUN	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

Taken	VERB	O	O
together	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
the	DET	O	O
central	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
-	SYM	O	O
10,000	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
induces	VERB	O	O
anxiogenic-	ADJ	O	O
and	CCONJ	O	O
depressant	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
mouse	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
U	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
II	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
some	DET	O	O
aspects	NOUN	O	O
of	ADP	O	O
psychiatric	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16274958)

Recurrent	PROPN	O	O
dysphonia	NOUN	O	I-Entity
and	CCONJ	O	O
acitretin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
complaining	VERB	O	O
of	ADP	O	O
dysphonia	NOUN	O	I-Entity
while	ADP	O	O
she	PRON	O	O
was	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
acitretin	NOUN	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
symptoms	NOUN	O	O
totally	ADV	O	O
regressed	VERB	O	O
after	ADP	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
and	CCONJ	O	O
reappeared	VERB	O	O
when	ADV	O	O
acitretin	NOUN	O	I-Entity
was	VERB	O	O
reintroduced	VERB	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
acitretin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dysphonia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16330766)

Pharmacological	ADJ	O	O
modulation	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
brain	NOUN	O	O
activity	NOUN	O	O
during	ADP	O	O
normal	ADJ	O	O
and	CCONJ	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
states	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

Abnormal	ADJ	O	O
processing	NOUN	O	O
of	ADP	O	O
somatosensory	ADJ	O	O
inputs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
mechanism	NOUN	O	O
accounting	VERB	O	O
for	ADP	O	O
the	DET	O	O
enhanced	ADJ	O	O
pain	NOUN	O	I-Entity
sensitivity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
skin	NOUN	O	O
surrounding	VERB	O	O
tissue	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
secondary	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Secondary	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
shares	NOUN	O	O
clinical	ADJ	O	O
characteristics	NOUN	O	O
with	ADP	O	O
neurogenic	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Abnormal	ADJ	O	O
brain	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
somatosensory	ADJ	O	O
stimuli	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
found	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
during	ADP	O	O
experimental	ADJ	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
gabapentin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
drug	NOUN	O	O
effective	ADJ	O	O
in	ADP	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
brain	NOUN	O	O
processing	NOUN	O	O
of	ADP	O	O
nociceptive	ADJ	O	O
information	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
and	CCONJ	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
states	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
functional	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
fMRI	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
normal	ADJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
gabapentin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
modulation	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
nociceptive	ADJ	O	O
mechanical	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
skin	NOUN	O	O
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
secondary	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
gabapentin	NOUN	O	I-Entity
was	VERB	O	O
1,800	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
os	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	DET	O	O
(	PUNCT	O	O
i	PUNCT	O	O
)	PUNCT	O	O
gabapentin	NOUN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
activations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bilateral	ADJ	O	O
operculoinsular	ADJ	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
independently	ADV	O	O
of	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
ii	PUNCT	O	O
)	PUNCT	O	O
gabapentin	NOUN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
activation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brainstem	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
during	ADP	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
iii	PUNCT	O	O
)	PUNCT	O	O
gabapentin	NOUN	O	I-Entity
suppressed	VERB	O	O
stimulus	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
deactivations	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
during	ADP	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
;	PUNCT	O	O
this	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
robust	ADJ	O	O
than	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
brain	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
gabapentin	NOUN	O	I-Entity
has	VERB	O	O
a	DET	O	O
measurable	ADJ	O	O
antinociceptive	ADJ	O	O
effect	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
stronger	ADJ	O	O
antihyperalgesic	NOUN	O	O
effect	NOUN	O	O
most	ADJ	O	O
evident	ADJ	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
areas	NOUN	O	O
undergoing	VERB	O	O
deactivation	NOUN	O	O
,	PUNCT	O	O
thus	ADV	O	O
supporting	VERB	O	O
the	DET	O	O
concept	NOUN	O	O
that	ADP	O	O
gabapentin	NOUN	O	I-Entity
is	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
modulating	VERB	O	O
nociceptive	ADJ	O	O
transmission	NOUN	O	O
when	ADV	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
is	VERB	O	O
present	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (16574712)

MDMA	PROPN	O	I-Entity
polydrug	NOUN	O	O
users	NOUN	O	O
show	VERB	O	O
process	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
central	ADJ	O	O
executive	ADJ	O	O
impairments	NOUN	O	O
coupled	VERB	O	O
with	ADP	O	O
impaired	ADJ	O	B-Entity
social	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
emotional	ADJ	O	I-Entity
judgement	NOUN	O	I-Entity
processes	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
recent	ADJ	O	O
years	NOUN	O	O
working	VERB	O	O
memory	NOUN	O	B-Entity
deficits	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
MDMA	PROPN	O	I-Entity
(	PUNCT	O	O
3,4-methylenedioxymethamphetamine	NUM	O	I-Entity
,	PUNCT	O	O
ecstasy	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
MDMA	PROPN	O	I-Entity
use	NOUN	O	O
on	ADP	O	O
three	NUM	O	O
separate	ADJ	O	O
central	ADJ	O	O
executive	ADJ	O	O
processes	NOUN	O	O
(	PUNCT	O	O
set	VERB	O	O
shifting	VERB	O	O
,	PUNCT	O	O
inhibition	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
updating	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
on	ADP	O	O
"	PUNCT	O	O
prefrontal	ADJ	O	O
"	PUNCT	O	O
mediated	VERB	O	O
social	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
judgement	NOUN	O	O
processes	NOUN	O	O
.	PUNCT	O	O

Fifteen	NUM	O	O
polydrug	NOUN	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
and	CCONJ	O	O
15	NUM	O	O
polydrug	NOUN	O	O
non	NOUN	O	O
-	PUNCT	O	O
ecstasy	NOUN	O	I-Entity
user	NOUN	O	O
controls	NOUN	O	O
completed	VERB	O	O
a	DET	O	O
general	ADJ	O	O
drug	NOUN	O	O
use	NOUN	O	O
questionnaire	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Brixton	PROPN	O	O
Spatial	PROPN	O	O
Anticipation	PROPN	O	O
task	NOUN	O	O
(	PUNCT	O	O
set	VERB	O	O
shifting	VERB	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Backward	PROPN	O	O
Digit	PROPN	O	O
Span	PROPN	O	O
procedure	NOUN	O	O
(	PUNCT	O	O
memory	NOUN	O	O
updating	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Inhibition	NOUN	O	O
of	ADP	O	O
Return	PROPN	O	O
(	PUNCT	O	O
inhibition	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
emotional	ADJ	O	O
intelligence	NOUN	O	O
scale	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Tromso	PROPN	O	O
Social	PROPN	O	O
Intelligence	PROPN	O	O
Scale	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
Dysexecutive	PROPN	O	O
Questionnaire	PROPN	O	O
(	PUNCT	O	O
DEX	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
MDMA	PROPN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
polydrug	NOUN	O	O
controls	NOUN	O	O
,	PUNCT	O	O
MDMA	PROPN	O	I-Entity
polydrug	NOUN	O	O
users	NOUN	O	O
showed	VERB	O	O
impairments	NOUN	O	O
in	ADP	O	O
set	NOUN	O	O
shifting	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
updating	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
in	ADP	O	O
social	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
judgement	NOUN	O	O
processes	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
lend	VERB	O	O
further	ADJ	O	O
support	NOUN	O	O
to	ADP	O	O
the	DET	O	O
proposal	NOUN	O	O
that	ADP	O	O
cognitive	ADJ	O	O
processes	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
the	DET	O	O
prefrontal	ADJ	O	O
cortex	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
impaired	VERB	O	O
by	ADP	O	O
recreational	ADJ	O	O
ecstasy	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17111419)

Severe	ADJ	O	O
citrate	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
complicating	VERB	O	O
volunteer	NOUN	O	O
apheresis	NOUN	O	O
platelet	NOUN	O	O
donation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
citrate	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
during	ADP	O	O
volunteer	NOUN	O	O
donor	NOUN	O	O
apheresis	NOUN	O	O
platelet	NOUN	O	O
collection	NOUN	O	O
.	PUNCT	O	O

Past	ADJ	O	O
medical	ADJ	O	O
history	NOUN	O	O
was	VERB	O	O
remarkable	ADJ	O	O
for	ADP	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
hyperlipidemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O

Reported	VERB	O	O
medications	NOUN	O	O
included	VERB	O	O
bumetanide	NOUN	O	I-Entity
,	PUNCT	O	O
pravastatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
paroxetine	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
then	ADV	O	O
very	ADV	O	O
rapidly	ADV	O	O
developed	VERB	O	O
acute	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
facial	ADJ	O	O
and	CCONJ	O	O
extremity	NOUN	O	O
tetany	NOUN	O	I-Entity
.	PUNCT	O	O

Empirical	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
intravenous	ADJ	O	O
calcium	NOUN	O	B-Entity
gluconate	NOUN	O	I-Entity
was	VERB	O	O
initiated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
muscle	NOUN	O	B-Entity
contractions	NOUN	O	I-Entity
slowly	ADV	O	O
subsided	VERB	O	O
over	ADP	O	O
approximately	ADV	O	O
10	NUM	O	O
to	PART	O	O
15	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
events	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
a	DET	O	O
severe	ADJ	O	O
reaction	NOUN	O	O
to	ADP	O	O
calcium	NOUN	O	I-Entity
chelation	NOUN	O	O
by	ADP	O	O
sodium	NOUN	O	B-Entity
citrate	NOUN	O	I-Entity
anticoagulant	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
symptomatic	NOUN	O	O
systemic	ADJ	O	O
hypocalcemia	NOUN	O	I-Entity
.	PUNCT	O	O

Upon	ADP	O	O
additional	ADJ	O	O
retrospective	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
noted	VERB	O	O
that	ADP	O	O
bumetanide	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
loop	NOUN	O	B-Entity
diuretic	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
cause	VERB	O	O
significant	ADJ	O	O
hypocalcemia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
careful	ADJ	O	O
screening	NOUN	O	O
for	ADP	O	O
medications	NOUN	O	O
and	CCONJ	O	O
underlying	ADJ	O	O
conditions	NOUN	O	O
predisposing	VERB	O	O
to	ADP	O	O
hypocalcemia	NOUN	O	I-Entity
is	VERB	O	O
recommended	VERB	O	O
to	PART	O	O
help	VERB	O	O
prevent	VERB	O	O
severe	ADJ	O	O
reactions	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
citrate	VERB	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Laboratory	PROPN	O	O
measurement	NOUN	O	O
of	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
procedure	NOUN	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
selected	VERB	O	O
donors	NOUN	O	O
may	VERB	O	O
identify	VERB	O	O
cases	NOUN	O	O
requiring	VERB	O	O
heightened	VERB	O	O
vigilance	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17175308)

Proteinuria	PROPN	O	I-Entity
after	ADP	O	O
conversion	NOUN	O	O
to	ADP	O	O
sirolimus	VERB	O	I-Entity
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

Sirolimus	PROPN	O	I-Entity
(	PUNCT	O	O
SRL	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
new	ADJ	O	O
,	PUNCT	O	O
potent	ADJ	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

More	ADV	O	O
recently	ADV	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
mechanism	NOUN	O	O
has	VERB	O	O
remained	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
retrospectively	ADV	O	O
examined	VERB	O	O
the	DET	O	O
records	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
or	CCONJ	O	O
displayed	VERB	O	O
increased	VERB	O	O
proteinuria	NOUN	O	I-Entity
after	ADP	O	O
SRL	PROPN	O	I-Entity
conversion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	ADJ	O	O
cohort	NOUN	O	O
(	PUNCT	O	O
14	NUM	O	O
men	NOUN	O	O
,	PUNCT	O	O
11	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
SRL	PROPN	O	I-Entity
as	ADP	O	O
conversion	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
chronic	ADJ	O	B-Entity
allograft	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
CAN	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O

neoplasia	NOUN	O	I-Entity
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
8)	NUM	O	O
;	PUNCT	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
,	PUNCT	O	O
Four	NUM	O	O
skin	NOUN	O	B-Entity
cancers	NOUN	O	I-Entity
,	PUNCT	O	O
One	NUM	O	O
intestinal	ADJ	O	B-Entity
tumors	NOUN	O	I-Entity
,	PUNCT	O	O
One	NUM	O	O
renal	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
carsinom	NOUN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
BK	PROPN	O	O
virus	NOUN	O	O
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

SRL	PROPN	O	I-Entity
was	VERB	O	O
started	VERB	O	O
at	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
78	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

Mean	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
on	ADP	O	O
SRL	PROPN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
20	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
increased	VERB	O	O
from	ADP	O	O
0.445	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
to	ADP	O	O
1.5	NUM	O	O
)	PUNCT	O	O

Before	ADP	O	O
conversion	NOUN	O	O
8	NUM	O	O
(	PUNCT	O	O
32%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
had	VERB	O	O
no	DET	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
afterwards	ADV	O	O
all	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
28%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
proteinuria	ADV	O	I-Entity
remained	VERB	O	O
unchanged	ADJ	O	O
,	PUNCT	O	O
whereas	ADP	O	O
it	PRON	O	O
increased	VERB	O	O
in	ADP	O	O
68%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
showed	VERB	O	O
increased	VERB	O	O
proteinuria	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
nephrotic	ADJ	O	I-Entity
range	NOUN	O	O
.	PUNCT	O	O

Biopsies	NOUN	O	O
performed	VERB	O	O
in	ADP	O	O
five	NUM	O	O
patients	NOUN	O	O
revealed	VERB	O	O
new	ADJ	O	O
pathological	ADJ	O	O
changes	NOUN	O	O
:	PUNCT	O	O
One	NUM	O	O
membranoproliferative	NOUN	O	B-Entity
glomerulopathy	NOUN	O	I-Entity
and	CCONJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
.	PUNCT	O	O

Serum	PROPN	O	O
creatinine	NOUN	O	I-Entity
values	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
:	PUNCT	O	O
1.98	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

0.8	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
dL	PROPN	O	O
before	ADP	O	O
SRL	PROPN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
2.53	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
displayed	VERB	O	O
CAN	PROPN	O	I-Entity
and	CCONJ	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
.	PUNCT	O	O

Mean	ADJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
level	NOUN	O	O
before	ADP	O	O
conversion	NOUN	O	O
was	VERB	O	O
2.21	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
and	CCONJ	O	O
thereafter	ADV	O	O
,	PUNCT	O	O
4.93	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
dL	PROPN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Heavy	PROPN	O	O
proteinuria	NOUN	O	I-Entity
was	VERB	O	O
common	ADJ	O	O
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
SRL	PROPN	O	I-Entity
as	ADP	O	O
rescue	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
conversion	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
developed	VERB	O	O
advanced	ADJ	O	O
CAN	PROPN	O	I-Entity
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

glomerular	ADJ	O	O
pathology	NOUN	O	O
under	ADP	O	O
SRL	PROPN	O	I-Entity
treatment	NOUN	O	O
requires	VERB	O	O
further	ADJ	O	O
investigation	NOUN	O	O
by	ADP	O	O
renal	ADJ	O	O
biopsy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17244258)

In	ADP	O	O
vitro	ADJ	O	O
characterization	NOUN	O	O
of	ADP	O	O
parasympathetic	ADJ	O	O
and	CCONJ	O	O
sympathetic	ADJ	O	O
responses	NOUN	O	O
in	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
,	PUNCT	O	O
detrusor	NOUN	O	O
function	NOUN	O	O
is	VERB	O	O
impaired	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
and	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
muscarinic	NOUN	O	O
receptors	NOUN	O	O
altered	VERB	O	O
.	PUNCT	O	O

Whether	ADP	O	O
or	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
neuronal	ADJ	O	O
transmission	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
cystitis	NOUN	O	I-Entity
was	VERB	O	O
presently	ADV	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Responses	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	O
strip	NOUN	O	O
preparations	NOUN	O	O
from	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
pretreated	VERB	O	O
rats	NOUN	O	O
to	ADP	O	O
electrical	ADJ	O	O
field	NOUN	O	O
stimulation	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
agonists	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
and	CCONJ	O	O
presence	NOUN	O	O
of	ADP	O	O
muscarinic	NOUN	O	O
,	PUNCT	O	O
adrenergic	ADJ	O	O
and	CCONJ	O	O
purinergic	ADJ	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O

Generally	ADV	O	O
,	PUNCT	O	O
atropine	NOUN	O	I-Entity
reduced	VERB	O	O
contractions	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
also	ADV	O	O
reduced	VERB	O	O
responses	NOUN	O	O
to	PART	O	O
low	ADJ	O	O
electrical	ADJ	O	O
field	NOUN	O	O
stimulation	NOUN	O	O
intensity	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
5	NUM	O	O
Hz	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
inflamed	ADJ	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
types	NOUN	O	O
,	PUNCT	O	O
purinoceptor	NOUN	O	O
desensitization	NOUN	O	O
with	ADP	O	O
alpha	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
beta	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylene	NOUN	O	I-Entity
adenosine-5'-triphosphate	NOUN	O	I-Entity
(	PUNCT	O	O
alpha	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
beta	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
meATP	PROPN	O	I-Entity
)	PUNCT	O	O
caused	VERB	O	O
further	ADJ	O	O
reductions	NOUN	O	O
at	ADP	O	O
low	ADJ	O	O
frequencies	NOUN	O	O
(	PUNCT	O	O
<	SYM	O	O
10	NUM	O	O
Hz	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
muscarinic	ADJ	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
4-diphenylacetoxy	NUM	O	B-Entity
-	PUNCT	O	I-Entity
N	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylpiperidine	NOUN	O	I-Entity
(	PUNCT	O	O
4-DAMP	NUM	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
'	PUNCT	O	O
M(1)/M(3)/M(5)-selective	ADJ	O	O
'	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
methoctramine	NOUN	O	I-Entity
(	PUNCT	O	O
'	PUNCT	O	O
M(2)-selective	ADJ	O	O
'	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
pirenzepine	NOUN	O	I-Entity
(	PUNCT	O	O
'	PUNCT	O	O
M(1)-selective	ADJ	O	O
'	PUNCT	O	O
)	PUNCT	O	O
antagonized	VERB	O	O
the	DET	O	O
tonic	NOUN	O	O
component	NOUN	O	O
of	ADP	O	O
the	DET	O	O
electrical	ADJ	O	O
field	NOUN	O	O
stimulation	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
contractile	NOUN	O	O
response	NOUN	O	O
more	ADV	O	O
potently	ADV	O	O
than	ADP	O	O
the	DET	O	O
phasic	ADJ	O	O
component	NOUN	O	O
.	PUNCT	O	O

4-DAMP	NUM	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
tonic	NOUN	O	O
contractions	NOUN	O	O
in	ADP	O	O
controls	NOUN	O	O
more	ADV	O	O
potently	ADV	O	O
than	ADP	O	O
methoctramine	NOUN	O	I-Entity
and	CCONJ	O	O
pirenzepine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
inflamed	ADJ	O	O
preparations	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
muscarinic	ADJ	O	O
receptor	NOUN	O	O
antagonism	NOUN	O	O
on	ADP	O	O
the	DET	O	O
phasic	ADJ	O	O
component	NOUN	O	O
of	ADP	O	O
the	DET	O	O
electrical	ADJ	O	O
field	NOUN	O	O
stimulation	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
contraction	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
pirenzepine	NOUN	O	I-Entity
and	CCONJ	O	O
4-DAMP	NUM	O	I-Entity
antagonism	NOUN	O	O
on	ADP	O	O
the	DET	O	O
tonic	NOUN	O	O
component	NOUN	O	O
was	VERB	O	O
much	ADV	O	O
less	ADV	O	O
efficient	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
methoctramine	NOUN	O	I-Entity
increased	VERB	O	O
--	PUNCT	O	O
instead	ADV	O	O
of	ADP	O	O
decreased	VERB	O	O
--	PUNCT	O	O
the	DET	O	O
tonic	NOUN	O	O
responses	NOUN	O	O
at	ADP	O	O
high	ADJ	O	O
frequencies	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
contractions	NOUN	O	O
to	ADP	O	O
carbachol	VERB	O	I-Entity
and	CCONJ	O	O
ATP	PROPN	O	I-Entity
were	VERB	O	O
the	DET	O	O
same	ADJ	O	O
in	ADP	O	O
inflamed	VERB	O	O
and	CCONJ	O	O
in	ADP	O	O
control	NOUN	O	O
strips	NOUN	O	O
when	ADV	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
reference	NOUN	O	O
potassium	NOUN	O	I-Entity
response	NOUN	O	O
,	PUNCT	O	O
isoprenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
relaxations	NOUN	O	O
were	VERB	O	O
smaller	ADJ	O	O
in	ADP	O	O
inflamed	VERB	O	O
strips	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
cystitis	NOUN	O	I-Entity
substantial	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efferent	NOUN	O	O
functional	ADJ	O	O
responses	NOUN	O	O
occur	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18020536)

Associations	NOUN	O	O
between	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
benzodiazepines	NOUN	O	I-Entity
or	CCONJ	O	O
related	VERB	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
health	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
abilities	NOUN	O	O
and	CCONJ	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
randomised	ADJ	O	O
clinical	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
associations	NOUN	O	O
between	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
benzodiazepines	NOUN	O	I-Entity
or	CCONJ	O	O
related	VERB	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
BZDs	PROPN	O	I-Entity
/	SYM	O	O
RDs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
health	NOUN	O	O
,	PUNCT	O	O
functional	ADJ	O	O
abilities	NOUN	O	O
and	CCONJ	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
,	PUNCT	O	O
nearly	ADV	O	O
half	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
78	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
used	VERB	O	O
BZDs	NOUN	O	I-Entity
/	SYM	O	O
RDs	ADV	O	O
before	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
remainder	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
86	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
users	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
BZDs	PROPN	O	I-Entity
/	SYM	O	O
RDs	PROPN	O	O
before	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
current	ADJ	O	O
medications	NOUN	O	O
and	CCONJ	O	O
discharge	NOUN	O	O
diagnoses	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
from	ADP	O	O
medical	ADJ	O	O
records	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
residual	ADJ	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
oxazepam	NOUN	O	I-Entity
,	PUNCT	O	O
temazepam	NOUN	O	I-Entity
and	CCONJ	O	O
zopiclone	NOUN	O	I-Entity
were	VERB	O	O
analysed	VERB	O	O
.	PUNCT	O	O

Two	NUM	O	O
or	CCONJ	O	O
three	NUM	O	O
BZDs	NOUN	O	I-Entity
/	SYM	O	O
RDs	NOUN	O	O
were	VERB	O	O
concomitantly	ADV	O	O
taken	VERB	O	O
by	ADP	O	O
26%	NUM	O	O
of	ADP	O	O
users	NOUN	O	O
(	PUNCT	O	O
n	VERB	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
female	ADJ	O	O
sex	NOUN	O	O
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
with	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
CNS	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
tended	VERB	O	O
to	PART	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
diagnosed	VERB	O	O
dementia	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
these	DET	O	O
variables	NOUN	O	O
as	ADP	O	O
confounders	NOUN	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
BZDs	PROPN	O	I-Entity
/	SYM	O	O
RDs	PROPN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
MMSE	PROPN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
BZDs	PROPN	O	I-Entity
/	SYM	O	O
RDs	PROPN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
dizziness	NOUN	O	I-Entity
,	PUNCT	O	O
inability	NOUN	O	B-Entity
to	PART	O	I-Entity
sleep	VERB	O	I-Entity
after	ADP	O	O
awaking	VERB	O	O
at	ADP	O	O
night	NOUN	O	O
and	CCONJ	O	O
tiredness	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
mornings	NOUN	O	O
during	ADP	O	O
the	DET	O	O
week	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
admission	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
stronger	ADJ	O	O
depressive	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
beginning	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
stay	NOUN	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
BZDs	PROPN	O	I-Entity
/	SYM	O	O
RDs	PROPN	O	O
tended	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
reduced	VERB	O	O
ability	NOUN	O	O
to	PART	O	O
walk	VERB	O	O
and	CCONJ	O	O
shorter	ADJ	O	O
night	NOUN	O	O
-	PUNCT	O	O
time	NOUN	O	O
sleep	NOUN	O	O
during	ADP	O	O
the	DET	O	O
week	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
admission	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
higher	ADJ	O	O
residual	ADJ	O	O
serum	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
temazepam	NOUN	O	I-Entity
correlated	VERB	O	O
with	ADP	O	O
a	DET	O	O
lower	ADJ	O	O
MMSE	PROPN	O	O
sum	NOUN	O	O
score	NOUN	O	O
after	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
confounding	VERB	O	O
variables	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18023325)

Acute	PROPN	O	O
vocal	ADJ	O	B-Entity
fold	NOUN	O	I-Entity
palsy	NOUN	O	I-Entity
after	ADP	O	O
acute	ADJ	O	O
disulfiram	NOUN	O	I-Entity
intoxication	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
a	DET	O	O
disulfiram	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
is	VERB	O	O
very	ADV	O	O
rare	ADJ	O	O
and	CCONJ	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
report	NOUN	O	O
of	ADP	O	O
it	PRON	O	O
leading	VERB	O	O
to	ADP	O	O
vocal	ADJ	O	B-Entity
fold	NOUN	O	I-Entity
palsy	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
49-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
was	VERB	O	O
transferred	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
department	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
quadriparesis	NOUN	O	I-Entity
,	PUNCT	O	O
lancinating	VERB	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
sensory	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
paresthesia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
distal	ADJ	O	O
limbs	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
month	NOUN	O	O
previously	ADV	O	O
,	PUNCT	O	O
she	PRON	O	O
had	VERB	O	O
taken	VERB	O	O
a	DET	O	O
single	ADJ	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
disulfiram	NOUN	O	I-Entity
(	PUNCT	O	O
130	NUM	O	O
tablets	NOUN	O	O
of	ADP	O	O
ALCOHOL	PROPN	O	I-Entity
STOP	PROPN	O	O
TAB	PROPN	O	O
,	PUNCT	O	O
Shin	PROPN	O	O
-	PUNCT	O	O
Poong	PROPN	O	O
Pharm	PROPN	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
first	ADJ	O	O
few	ADJ	O	O
days	NOUN	O	O
after	ADP	O	O
ingestion	NOUN	O	O
,	PUNCT	O	O
she	PRON	O	O
was	VERB	O	O
in	ADP	O	O
a	DET	O	O
confused	ADJ	O	O
state	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
mild	ADJ	O	O
to	PART	O	O
moderate	ADJ	O	O
ataxia	NOUN	O	I-Entity
and	CCONJ	O	O
giddiness	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
noticed	VERB	O	O
hoarseness	NOUN	O	I-Entity
and	CCONJ	O	O
distally	ADV	O	O
accentuated	VERB	O	O
motor	NOUN	O	O
and	CCONJ	O	O
sensory	ADJ	O	O
dysfunction	NOUN	O	O
after	ADP	O	O
she	PRON	O	O
had	VERB	O	O
recovered	VERB	O	O
from	ADP	O	O
this	DET	O	O
state	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
nerve	NOUN	O	O
conduction	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
severe	ADJ	O	O
sensorimotor	NOUN	O	O
axonal	ADJ	O	O
polyneuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
palsy	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
recurrent	ADJ	O	O
laryngeal	ADJ	O	O
nerve	NOUN	O	O
and	CCONJ	O	O
superimposed	VERB	O	O
severe	ADJ	O	O
acute	ADJ	O	O
sensorimotor	NOUN	O	O
axonal	ADJ	O	O
polyneuropathy	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
disulfiram	NOUN	O	I-Entity
intoxication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18208574)

Higher	ADJ	O	O
optical	ADJ	O	O
density	NOUN	O	O
of	ADP	O	O
an	DET	O	O
antigen	NOUN	O	O
assay	NOUN	O	O
predicts	VERB	O	O
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
correlate	VERB	O	O
optical	ADJ	O	O
density	NOUN	O	O
and	CCONJ	O	O
percent	NOUN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
two	NUM	O	O
-	PUNCT	O	O
step	NOUN	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
(	PUNCT	O	O
HIT	PROPN	O	I-Entity
)	PUNCT	O	O
antigen	NOUN	O	O
assay	NOUN	O	O
with	ADP	O	O
thrombosis	NOUN	O	I-Entity

;	PUNCT	O	O
the	DET	O	O
assay	NOUN	O	O
utilizes	VERB	O	O
reaction	NOUN	O	O
inhibition	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high	ADJ	O	O
heparin	NOUN	O	I-Entity
concentration	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
50%	NUM	O	O
decrease	NOUN	O	O
in	ADP	O	O
platelet	NOUN	O	O
count	NOUN	O	O
or	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
(	PUNCT	O	O
<	SYM	O	O
150	NUM	O	O
x	SYM	O	O
10(9)/L	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
two	NUM	O	O
-	PUNCT	O	O
step	NOUN	O	O
antigen	NOUN	O	O
assay	NOUN	O	O
[	PUNCT	O	O
optical	ADJ	O	O
density	NOUN	O	O
(	PUNCT	O	O
OD	PROPN	O	O
)	PUNCT	O	O

0.4	NUM	O	O
and	CCONJ	O	O
>	SYM	O	O
50	NUM	O	O
inhibition	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
]	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
of	ADP	O	O
94	NUM	O	O
HIT	PROPN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
thrombosis	NOUN	O	I-Entity
at	ADP	O	O
diagnosis	NOUN	O	O
;	PUNCT	O	O
54/94	NUM	O	O
had	VERB	O	O
isolated	VERB	O	O
-	PUNCT	O	O
HIT	PART	O	I-Entity
without	ADP	O	O
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

Eight	NUM	O	O
of	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	PROPN	O	I-Entity
patients	NOUN	O	O
developed	VERB	O	O
thrombosis	NOUN	O	I-Entity
within	ADP	O	O
the	DET	O	O
next	ADJ	O	O
30	NUM	O	O
d	NOUN	O	O
;	PUNCT	O	O
thus	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
48	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
thrombosis	NOUN	O	I-Entity
at	ADP	O	O
day	NOUN	O	O
30	NUM	O	O
.	PUNCT	O	O

At	ADP	O	O
diagnosis	NOUN	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
OD	NOUN	O	O
between	ADP	O	O
HIT	PROPN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
and	CCONJ	O	O
those	DET	O	O
with	ADP	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
OD	PROPN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
48	NUM	O	O
,	PUNCT	O	O
1.34	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.89	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
including	VERB	O	O
isolated	VERB	O	O
-	PUNCT	O	O
HIT	PROPN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
later	ADV	O	O
developed	VERB	O	O
thrombosis	NOUN	O	I-Entity
within	ADP	O	O
30	NUM	O	O
d	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
8	NUM	O	O
,	PUNCT	O	O
1.84	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.64	PUNCT	O	O
)	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	VERB	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
develop	VERB	O	O
thrombosis	NOUN	O	I-Entity
(	PUNCT	O	O
0.96	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
Receiver	PROPN	O	O
Operative	PROPN	O	O
Characteristic	PROPN	O	O
Curve	PROPN	O	O
showed	VERB	O	O
that	ADP	O	O
OD	PROPN	O	O
>	SYM	O	O
1.27	NUM	O	O
in	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	PROPN	O	I-Entity
group	NOUN	O	O
had	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
higher	ADJ	O	O
chance	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
thrombosis	NOUN	O	I-Entity
by	ADP	O	O
day	NOUN	O	O
30	NUM	O	O
.	PUNCT	O	O

Multivariate	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
2.8-fold	NUM	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
females	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
thrombotic	ADJ	O	I-Entity
risk	NOUN	O	O
increased	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
OD	PROPN	O	O
values	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Higher	ADJ	O	O
OD	PROPN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significant	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
subsequent	ADJ	O	O
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
isolated	ADJ	O	O
-	PUNCT	O	O
HIT	PROPN	O	I-Entity
;	PUNCT	O	O
percent	NOUN	O	O
inhibition	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
predictive	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (18343374)

Central	ADJ	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
clomiphene	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ovulation	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
clomiphene	NOUN	O	B-Entity
citrate	NOUN	O	I-Entity
(	PUNCT	O	O
CC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

PATIENT(S	PUNCT	O	O
)	PUNCT	O	O
:	PUNCT	O	O
A	DET	O	O
36-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
referred	VERB	O	O
from	ADP	O	O
the	DET	O	O
infertility	NOUN	O	I-Entity
clinic	NOUN	O	O
for	ADP	O	O
blurred	ADJ	O	B-Entity
vision	NOUN	O	I-Entity
.	PUNCT	O	O

INTERVENTION(S	PUNCT	O	O
)	PUNCT	O	O
:	PUNCT	O	O
Ophthalmic	PROPN	O	O
examination	NOUN	O	O
after	ADP	O	O
CC	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

MAIN	PROPN	O	O
OUTCOME	PROPN	O	O
MEASURE(S	PROPN	O	O
)	PUNCT	O	O
:	PUNCT	O	O
Central	ADJ	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
after	ADP	O	O
ovulation	NOUN	O	O
induction	NOUN	O	O
with	ADP	O	O
CC	PROPN	O	I-Entity
.	PUNCT	O	O

RESULT(S	PUNCT	O	O
)	PUNCT	O	O
:	PUNCT	O	O
A	DET	O	O
36-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
Chinese	ADJ	O	O
woman	NOUN	O	O
developed	VERB	O	O
central	ADJ	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
after	ADP	O	O
eight	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
CC	PROPN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
search	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
on	ADP	O	O
the	DET	O	O
thromboembolic	ADJ	O	I-Entity
complications	NOUN	O	O
of	ADP	O	O
CC	PROPN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
include	VERB	O	O
this	DET	O	O
severe	ADJ	O	O
ophthalmic	ADJ	O	O
complication	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
mild	ADJ	O	O
visual	ADJ	O	B-Entity
disturbance	NOUN	O	I-Entity
after	ADP	O	O
CC	PROPN	O	I-Entity
intake	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
uncommon	ADJ	O	O
.	PUNCT	O	O

CONCLUSION(S	PUNCT	O	O
)	PUNCT	O	O
:	PUNCT	O	O
This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
retinal	ADJ	O	B-Entity
vein	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
CC	PROPN	O	I-Entity
.	PUNCT	O	O

Extra	PROPN	O	O
caution	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
in	ADP	O	O
treating	VERB	O	O
infertility	NOUN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
CC	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
well	ADJ	O	O
informed	VERB	O	O
of	ADP	O	O
this	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
before	ADP	O	O
commencement	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18417364)

Nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nystagmus	NOUN	O	I-Entity
correlates	NOUN	O	O
with	ADP	O	O
midpontine	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pathomechanism	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nystagmus	NOUN	O	I-Entity
(	PUNCT	O	O
NIN	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
delineate	VERB	O	O
brain	NOUN	O	O
structures	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
NIN	PROPN	O	I-Entity
generation	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
inhaled	VERB	O	O
nicotine	NOUN	O	I-Entity
in	ADP	O	O
darkness	NOUN	O	O
during	ADP	O	O
a	DET	O	O
functional	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
fMRI	PROPN	O	O
)	PUNCT	O	O
experiment	NOUN	O	O
;	PUNCT	O	O
eye	NOUN	O	O
movements	NOUN	O	O
were	VERB	O	O
registered	VERB	O	O
using	VERB	O	O
video	NOUN	O	O
-	PUNCT	O	O
oculography	NOUN	O	O
.	PUNCT	O	O

NIN	PROPN	O	I-Entity
correlated	VERB	O	O
with	ADP	O	O
blood	NOUN	O	O
oxygen	NOUN	O	I-Entity
level	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
(	PUNCT	O	O
BOLD	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
a	DET	O	O
midpontine	NOUN	O	O
site	NOUN	O	O
in	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
basis	NOUN	O	O
pontis	NOUN	O	O
.	PUNCT	O	O

NIN	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
midpontine	NOUN	O	O
activation	NOUN	O	O
may	VERB	O	O
correspond	VERB	O	O
to	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dorsomedial	ADJ	O	O
pontine	NOUN	O	O
nuclei	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
nucleus	NOUN	O	O
reticularis	NOUN	O	O
tegmenti	NOUN	O	O
pontis	NOUN	O	O
,	PUNCT	O	O
structures	NOUN	O	O
known	VERB	O	O
to	PART	O	O
participate	VERB	O	O
in	ADP	O	O
the	DET	O	O
generation	NOUN	O	O
of	ADP	O	O
multidirectional	ADJ	O	O
saccades	NOUN	O	O
and	CCONJ	O	O
smooth	ADJ	O	O
pursuit	NOUN	O	O
eye	NOUN	O	O
movements	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18442015)

Protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	I-Entity
on	ADP	O	O
gastric	ADJ	O	B-Entity
hemorrhagic	ADJ	O	I-Entity
ulcers	NOUN	O	I-Entity
in	ADP	O	O
severe	ADJ	O	O
atherosclerotic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
concerning	VERB	O	O
with	ADP	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
gastric	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
and	CCONJ	O	O
mucosal	NOUN	O	O
ulceration	NOUN	O	O
produced	VERB	O	O
in	ADP	O	O
atherosclerotic	ADJ	O	I-Entity
rats	NOUN	O	O
are	VERB	O	O
lacking	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
gastric	ADJ	O	O
acid	NOUN	O	O
back	ADV	O	O
-	PUNCT	O	O
diffusion	NOUN	O	O
,	PUNCT	O	O
mast	NOUN	O	O
cell	NOUN	O	O
histamine	NOUN	O	I-Entity
release	NOUN	O	O
,	PUNCT	O	O
lipid	ADJ	O	O
peroxide	NOUN	O	O
(	PUNCT	O	O
LPO	PROPN	O	O
)	PUNCT	O	O
generation	NOUN	O	O
and	CCONJ	O	O
mucosal	NOUN	O	O
microvascular	ADJ	O	O
permeability	NOUN	O	O
in	ADP	O	O
modulating	VERB	O	O
gastric	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
and	CCONJ	O	O
ulcer	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
atherosclerosis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
coadministration	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
D2	NOUN	O	I-Entity
and	CCONJ	O	O
cholesterol	NOUN	O	I-Entity
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	I-Entity
on	ADP	O	O
this	DET	O	O
ulcer	NOUN	O	I-Entity
model	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

kg	NOUN	O	O
of	ADP	O	O
corn	NOUN	O	O
oil	NOUN	O	O
containing	VERB	O	O
vitamin	NOUN	O	B-Entity
D2	NOUN	O	I-Entity
and	CCONJ	O	O
cholesterol	NOUN	O	I-Entity
to	PART	O	O
induce	VERB	O	O
atherosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

Gastric	ADJ	O	O
acid	NOUN	O	O
back	ADV	O	O
-	PUNCT	O	O
diffusion	NOUN	O	O
,	PUNCT	O	O
mucosal	NOUN	O	O
LPO	PROPN	O	O
generation	NOUN	O	O
,	PUNCT	O	O
histamine	ADJ	O	I-Entity
concentration	NOUN	O	O
,	PUNCT	O	O
microvascular	ADJ	O	O
permeability	NOUN	O	O
,	PUNCT	O	O
luminal	ADJ	O	I-Entity
hemoglobin	NOUN	O	O
content	NOUN	O	O
and	CCONJ	O	O
ulcer	NOUN	O	I-Entity
areas	NOUN	O	O
were	VERB	O	O
determined	ADJ	O	O
.	PUNCT	O	O

Elevated	ADJ	O	O
atherosclerotic	ADJ	O	I-Entity
parameters	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
,	PUNCT	O	O
total	ADJ	O	O
cholesterol	NOUN	O	I-Entity
and	CCONJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
density	NOUN	O	O
lipoprotein	NOUN	O	O
concentration	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
atherosclerotic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
gastric	ADJ	O	O
ulcers	NOUN	O	I-Entity
accompanied	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
ulcerogenic	ADJ	O	O
factors	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
gastric	ADJ	O	O
acid	NOUN	O	O
back	ADV	O	O
-	PUNCT	O	O
diffusion	NOUN	O	O
,	PUNCT	O	O
histamine	ADJ	O	I-Entity
release	NOUN	O	O
,	PUNCT	O	O
LPO	PROPN	O	O
generation	NOUN	O	O
and	CCONJ	O	O
luminal	ADJ	O	I-Entity
hemoglobin	NOUN	O	O
content	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
these	DET	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
positive	ADJ	O	O
correlation	NOUN	O	O
of	ADP	O	O
histamine	NOUN	O	I-Entity
to	ADP	O	O
gastric	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
and	CCONJ	O	O
to	ADP	O	O
ulcer	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
those	DET	O	O
atherosclerotic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
hemorrhagic	ADJ	O	I-Entity
ulcer	NOUN	O	I-Entity
and	CCONJ	O	O
various	ADJ	O	O
ulcerogenic	ADJ	O	O
parameters	NOUN	O	O
were	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
ameliorated	VERB	O	O
by	ADP	O	O
daily	ADJ	O	O
intragastric	NOUN	O	O
verapamil	NOUN	O	I-Entity
.	PUNCT	O	O

Atherosclerosis	NOUN	O	I-Entity
could	VERB	O	O
produce	VERB	O	O
gastric	ADJ	O	B-Entity
hemorrhagic	ADJ	O	I-Entity
ulcer	NOUN	O	I-Entity
via	ADP	O	O
aggravation	NOUN	O	O
of	ADP	O	O
gastric	ADJ	O	O
acid	NOUN	O	O
back	ADV	O	O
-	PUNCT	O	O
diffusion	NOUN	O	O
,	PUNCT	O	O
LPO	PROPN	O	O
generation	NOUN	O	O
,	PUNCT	O	O
histamine	ADJ	O	I-Entity
release	NOUN	O	O
and	CCONJ	O	O
microvascular	ADJ	O	O
permeability	NOUN	O	O
that	ADJ	O	O
could	VERB	O	O
be	VERB	O	O
ameliorated	VERB	O	O
by	ADP	O	O
verapamil	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18619688)

Adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
autophagic	ADJ	O	O
cardiomyocyte	NOUN	O	O
death	NOUN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
pathogenic	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanisms	NOUN	O	O
underlying	VERB	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
adriamycin	NOUN	O	I-Entity
are	VERB	O	O
very	ADV	O	O
complicated	ADJ	O	O
and	CCONJ	O	O
still	ADV	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
autophagy	NOUN	O	O
was	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
adriamycin	ADV	O	I-Entity
,	PUNCT	O	O
so	ADP	O	O
that	ADP	O	O
we	PRON	O	O
can	VERB	O	O
develop	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
treatment	NOUN	O	O
strategy	NOUN	O	O
for	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
3-methyladenine	NUM	O	I-Entity
(	PUNCT	O	O
3MA	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
specific	ADJ	O	O
inhibitor	NOUN	O	O
on	ADP	O	O
autophagy	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
in	ADP	O	O
a	DET	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
adriamycin	ADV	O	I-Entity
.	PUNCT	O	O

Neonatal	ADJ	O	O
cardiomyocytes	NOUN	O	O
were	VERB	O	O
isolated	VERB	O	O
from	ADP	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rat	NOUN	O	O
hearts	NOUN	O	O
and	CCONJ	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
adriamycin	ADJ	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
3MA	NOUN	O	I-Entity
plus	CCONJ	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
examined	VERB	O	O
the	DET	O	O
morphology	NOUN	O	O
,	PUNCT	O	O
expression	NOUN	O	O
of	ADP	O	O
beclin	NOUN	O	O
1	NUM	O	O
gene	NOUN	O	O
,	PUNCT	O	O
mitochondrial	ADJ	O	O
permeability	NOUN	O	O
transition	NOUN	O	O
(	PUNCT	O	O
MPT	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Na+-K+	PROPN	O	I-Entity
ATPase	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
3MA	NUM	O	I-Entity
significantly	ADV	O	O
improved	VERB	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
reduced	ADJ	O	O
mitochondrial	ADJ	O	O
injury	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
adriamycin	ADV	O	I-Entity
induced	VERB	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
autophagic	ADJ	O	O
vacuoles	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3MA	NUM	O	I-Entity
strongly	ADV	O	O
downregulated	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
beclin	NOUN	O	O
1	NUM	O	O
in	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
failing	VERB	O	O
heart	NOUN	O	O
and	CCONJ	O	O
inhibited	VERB	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
autophagic	ADJ	O	O
vacuoles	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Autophagic	PROPN	O	O
cardiomyocyte	NOUN	O	O
death	NOUN	O	I-Entity
plays	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
adriamycin	ADV	O	I-Entity
.	PUNCT	O	O

Mitochondrial	ADJ	O	O
injury	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
adriamycin	ADV	O	I-Entity
via	ADP	O	O
the	DET	O	O
autophagy	NOUN	O	O
pathway	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19308880)

Confusion	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
rather	ADV	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
with	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
French	ADJ	O	O
Pharmacovigilance	PROPN	O	O
database	NOUN	O	O
.	PUNCT	O	O

Confusion	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
frequently	ADV	O	O
observed	VERB	O	O
with	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
the	DET	O	O
French	ADJ	O	O
Pharmacovigilance	PROPN	O	O
database	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
selected	VERB	O	O
the	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
confusion	NOUN	O	I-Entity
reported	VERB	O	O
since	ADP	O	O
1985	NUM	O	O
with	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
272	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
confusion	NOUN	O	I-Entity
were	VERB	O	O
reported	VERB	O	O
with	ADP	O	O
valproic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
:	PUNCT	O	O
153	NUM	O	O
women	NOUN	O	O
and	CCONJ	O	O
119	NUM	O	O
men	NOUN	O	O
.	PUNCT	O	O

Confusion	NOUN	O	I-Entity
mostly	ADV	O	O
occurred	VERB	O	O
during	ADP	O	O
the	DET	O	O
two	NUM	O	O
first	ADJ	O	O
weeks	NOUN	O	O
following	VERB	O	O
valproic	ADP	O	B-Entity
acid	NOUN	O	I-Entity
exposure	NOUN	O	O
(	PUNCT	O	O
39.7%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
work	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
confusion	NOUN	O	I-Entity
with	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
serious	ADJ	O	O
,	PUNCT	O	O
rather	ADV	O	O
frequent	ADJ	O	O
but	CCONJ	O	O
reversible	ADJ	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19631624)

Learning	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
deficits	NOUN	O	I-Entity
in	ADP	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
neural	ADJ	O	O
correlates	NOUN	O	O
during	ADP	O	O
a	DET	O	O
face	NOUN	O	O
-	PUNCT	O	O
learning	VERB	O	O
task	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
consistently	ADV	O	O
shown	VERB	O	O
that	DET	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
display	VERB	O	O
impairments	NOUN	O	B-Entity
in	ADP	O	I-Entity
learning	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
performance	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
working	VERB	O	O
memory	NOUN	O	O
processing	NOUN	O	O
in	ADP	O	O
ecstasy	NOUN	O	I-Entity
users	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
neural	ADJ	O	O
alterations	NOUN	O	O
in	ADP	O	O
hippocampal	NOUN	O	O
and/or	CCONJ	O	O
cortical	ADJ	O	O
regions	NOUN	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
functional	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
fMRI	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Using	VERB	O	O
functional	ADJ	O	O
imaging	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
face	NOUN	O	O
-	PUNCT	O	O
learning	NOUN	O	O
task	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
neural	ADJ	O	O
correlates	NOUN	O	O
of	ADP	O	O
encoding	NOUN	O	O
and	CCONJ	O	O
recalling	VERB	O	O
face	NOUN	O	O
-	PUNCT	O	O
name	NOUN	O	O
associations	NOUN	O	O
in	ADP	O	O
20	NUM	O	O
recreational	ADJ	O	O
drug	NOUN	O	O
users	NOUN	O	O
whose	ADJ	O	O
predominant	ADJ	O	O
drug	NOUN	O	O
use	NOUN	O	O
was	VERB	O	O
ecstasy	NOUN	O	I-Entity
and	CCONJ	O	O
20	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
address	VERB	O	O
the	DET	O	O
potential	NOUN	O	O
confounding	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cannabis	ADJ	O	I-Entity
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ecstasy	NOUN	O	I-Entity
using	VERB	O	O
group	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
second	ADJ	O	O
analysis	NOUN	O	O
included	VERB	O	O
14	NUM	O	O
previously	ADV	O	O
tested	VERB	O	O
cannabis	NOUN	O	I-Entity
users	NOUN	O	O
(	PUNCT	O	O
Nestor	PROPN	O	O
,	PUNCT	O	O
L.	PROPN	O	O
,	PUNCT	O	O
Roberts	PROPN	O	O
,	PUNCT	O	O
G.	PROPN	O	O
,	PUNCT	O	O
Garavan	PROPN	O	O
,	PUNCT	O	O
H.	PROPN	O	O
,	PUNCT	O	O
Hester	PROPN	O	O
,	PUNCT	O	O
R.	PROPN	O	O
,	PUNCT	O	O
2008	NUM	O	O
.	PUNCT	O	O

Deficits	NOUN	O	B-Entity
in	ADP	O	I-Entity
learning	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
:	PUNCT	O	O
parahippocampal	ADJ	O	O
hyperactivity	NOUN	O	I-Entity
and	CCONJ	O	O
frontocortical	ADJ	O	O
hypoactivity	NOUN	O	O
in	ADP	O	O
cannabis	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

Ecstasy	PROPN	O	I-Entity
users	NOUN	O	O
performed	VERB	O	O
significantly	ADV	O	O
worse	ADJ	O	O
in	ADP	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
and	CCONJ	O	O
cannabis	ADJ	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
conjunction	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
encode	NOUN	O	O
and	CCONJ	O	O
recall	VERB	O	O
phases	NOUN	O	O
of	ADP	O	O
the	DET	O	O
task	NOUN	O	O
revealed	VERB	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
specific	ADJ	O	O
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
bilateral	ADJ	O	O
frontal	ADJ	O	O
regions	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
temporal	ADJ	O	O
,	PUNCT	O	O
right	ADJ	O	O
parietal	NOUN	O	O
,	PUNCT	O	O
bilateral	ADJ	O	O
temporal	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bilateral	ADJ	O	O
occipital	ADJ	O	O
brain	NOUN	O	O
regions	NOUN	O	O
.	PUNCT	O	O

Ecstasy	ADJ	O	I-Entity
-	PUNCT	O	O
specific	ADJ	O	O
hypoactivity	NOUN	O	O
was	VERB	O	O
evident	ADJ	O	O
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
dorsal	NOUN	O	O
anterior	ADV	O	O
cingulated	VERB	O	O
cortex	NOUN	O	O
(	PUNCT	O	O
ACC	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
left	VERB	O	O
posterior	ADJ	O	O
cingulated	VERB	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
ecstasy	NOUN	O	I-Entity
and	CCONJ	O	O
cannabis	ADJ	O	I-Entity
groups	NOUN	O	O
brain	NOUN	O	O
activation	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
medial	ADJ	O	O
frontal	NOUN	O	O
gyrus	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
parahippocampal	ADJ	O	O
gyrus	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
dorsal	NOUN	O	O
cingulate	ADJ	O	O
gyrus	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
left	VERB	O	O
caudate	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
elucidated	VERB	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
deficits	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
some	DET	O	O
of	ADP	O	O
which	ADJ	O	O
might	VERB	O	O
be	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
cannabis	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
ecstasy	NOUN	O	I-Entity
-	PUNCT	O	O
specific	ADJ	O	O
effects	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
vulnerability	NOUN	O	O
of	ADP	O	O
isocortical	ADJ	O	O
and	CCONJ	O	O
allocortical	ADJ	O	O
regions	NOUN	O	O
to	ADP	O	O
the	DET	O	O
neurotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
ecstasy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20003049)

Prolonged	VERB	O	O
elevation	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
argatroban	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
cardiac	ADJ	O	O
transplant	NOUN	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
suspected	VERB	O	O
history	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Direct	ADJ	O	O
thrombin	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
DTIs	PROPN	O	O
)	PUNCT	O	O
provide	VERB	O	O
an	DET	O	O
alternative	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
anticoagulation	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
(	PUNCT	O	O
HIT	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
HIT	PROPN	O	I-Entity
with	ADP	O	O
thrombosis	NOUN	O	I-Entity
(	PUNCT	O	O
HITT	PROPN	O	I-Entity
)	PUNCT	O	O
undergoing	VERB	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
(	PUNCT	O	O
CPB	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
following	VERB	O	O
report	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
65-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
critically	ADV	O	B-Entity
ill	ADJ	O	I-Entity
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
suspected	VERB	O	O
history	NOUN	O	O
of	ADP	O	O
HITT	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
argatroban	NOUN	O	I-Entity
for	ADP	O	O
anticoagulation	NOUN	O	O
on	ADP	O	O
bypass	NOUN	O	O
during	ADP	O	O
heart	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
required	VERB	O	O
massive	ADJ	O	O
transfusion	NOUN	O	O
support	NOUN	O	O
(	PUNCT	O	O
55	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
42	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
fresh	ADJ	O	O
-	PUNCT	O	O
frozen	ADJ	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
cryoprecipitate	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
units	NOUN	O	O
of	ADP	O	O
platelets	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
recombinant	NOUN	O	O
Factor	PROPN	O	O
VIIa	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
severe	ADJ	O	O
intraoperative	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
postoperative	ADJ	O	I-Entity
bleeding	NOUN	O	I-Entity
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
:	PUNCT	O	O
Plasma	VERB	O	O
samples	NOUN	O	O
from	ADP	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
CPB	PROPN	O	O
were	VERB	O	O
analyzed	VERB	O	O
postoperatively	ADV	O	O
for	ADP	O	O
argatroban	ADJ	O	I-Entity
concentration	NOUN	O	O
using	VERB	O	O
a	DET	O	O
modified	VERB	O	O
ecarin	NOUN	O	O
clotting	NOUN	O	O
time	NOUN	O	O
(	PUNCT	O	O
ECT	PROPN	O	O
)	PUNCT	O	O
assay	NOUN	O	O
.	PUNCT	O	O

Unexpectedly	ADV	O	O
high	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
argatroban	NOUN	O	I-Entity
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
these	DET	O	O
samples	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
32	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
prolonged	ADJ	O	O
plasma	NOUN	O	O
argatroban	ADJ	O	I-Entity
half	NOUN	O	O
life	NOUN	O	O
(	PUNCT	O	O
t(1/2	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
514	NUM	O	O
minutes	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
(	PUNCT	O	O
published	VERB	O	O
elimination	NOUN	O	O
t(1/2	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
39	NUM	O	O
-	SYM	O	O
51	NUM	O	O
minutes	NOUN	O	O
[	PUNCT	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
181	NUM	O	O
minutes	NOUN	O	O
with	ADP	O	O
hepatic	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Correlation	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
argatroban	ADJ	O	I-Entity
concentration	NOUN	O	O
versus	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
coagulation	NOUN	O	O
variables	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
course	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
prolonged	VERB	O	O
elevated	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
argatroban	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
extended	VERB	O	O
coagulopathy	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
to	PART	O	O
measure	VERB	O	O
plasma	NOUN	O	O
argatroban	ADJ	O	I-Entity
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
CPB	PROPN	O	O
and	CCONJ	O	O
extended	VERB	O	O
coagulopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20196116)

Antituberculosis	NOUN	O	I-Entity
therapy	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
:	PUNCT	O	O
magnitude	NOUN	O	O
,	PUNCT	O	O
profile	NOUN	O	O
,	PUNCT	O	O
prognosis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

Antituberculosis	NOUN	O	I-Entity
therapy	NOUN	O	O
(	PUNCT	O	O
ATT)-associated	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
commonest	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
in	ADP	O	O
South	PROPN	O	O
Asia	PROPN	O	O
.	PUNCT	O	O

Prospective	ADJ	O	O
studies	NOUN	O	O
on	ADP	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
are	VERB	O	O
lacking	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
magnitude	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
course	NOUN	O	O
,	PUNCT	O	O
outcome	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prognostic	ADJ	O	O
factors	NOUN	O	O
in	ADP	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
January	PROPN	O	O
1986	NUM	O	O
to	ADP	O	O
January	PROPN	O	O
2009	NUM	O	O
,	PUNCT	O	O
1223	NUM	O	O
consecutive	ADJ	O	O
ALF	NOUN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
:	PUNCT	O	O
ATT	PROPN	O	O
alone	ADV	O	O
was	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
in	ADP	O	O
70	NUM	O	O
(	PUNCT	O	O
5.7%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Another	DET	O	O
15	NUM	O	O
(	PUNCT	O	O
1.2%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
ATT	PROPN	O	O
and	CCONJ	O	O
simultaneous	ADJ	O	O
hepatitis	NOUN	O	B-Entity
virus	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
44	NUM	O	O
(	PUNCT	O	O
62.8%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
ATT	PROPN	O	O
was	VERB	O	O
prescribed	VERB	O	O
empirically	ADV	O	O
without	ADP	O	O
definitive	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
tuberculosis	NOUN	O	I-Entity
.	PUNCT	O	O

ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
younger	ADJ	O	O
(	PUNCT	O	O
32.87	NUM	O	O
[	PUNCT	O	O
+	SYM	O	O
/-15.8	PROPN	O	O
]	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
49	NUM	O	O
(	PUNCT	O	O
70%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
them	PRON	O	O
were	VERB	O	O
women	NOUN	O	O
.	PUNCT	O	O

Most	ADJ	O	O
had	VERB	O	O
hyperacute	ADJ	O	O
presentation	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
icterus	NOUN	O	I-Entity
encephalopathy	ADJ	O	I-Entity
interval	NOUN	O	O
was	VERB	O	O
4.5	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
ATT	PROPN	O	O
before	ADP	O	O
ALF	PROPN	O	I-Entity
was	VERB	O	O
30	NUM	O	O
(	PUNCT	O	O
7	NUM	O	O
-	SYM	O	O
350	NUM	O	O
)	PUNCT	O	O
days	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
advanced	ADJ	O	O
encephalopathy	ADJ	O	I-Entity
and	CCONJ	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
51	NUM	O	O
(	PUNCT	O	O
76%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
29	NUM	O	O
(	PUNCT	O	O
41.4%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Gastrointestinal	ADJ	O	B-Entity
bleed	NOUN	O	I-Entity
,	PUNCT	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
infection	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
were	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
seven	NUM	O	O
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
five	NUM	O	O
(	PUNCT	O	O
7.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
26	NUM	O	O
(	PUNCT	O	O
37.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
seven	NUM	O	O
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
hepatitis	NOUN	O	B-Entity
E	PROPN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HEV	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O

A	DET	O	O
non	NOUN	O	O
-	PUNCT	O	O
E	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
ALF	PROPN	O	I-Entity
,	PUNCT	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
nearly	ADV	O	O
similar	ADJ	O	O
presentations	NOUN	O	O
except	ADP	O	O
for	ADP	O	O
older	ADJ	O	O
age	NOUN	O	O
and	CCONJ	O	O
less	ADJ	O	O
elevation	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
enzymes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
was	VERB	O	O
high	ADJ	O	O
(	PUNCT	O	O
67.1%	NUM	O	O
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
47	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
only	ADV	O	O
23	NUM	O	O
(	PUNCT	O	O
32.9%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
recovered	VERB	O	O
with	ADP	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
multivariate	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
factors	NOUN	O	O
independently	ADV	O	O
predicted	VERB	O	O
mortality	NOUN	O	O
:	PUNCT	O	O
serum	NOUN	O	O
bilirubin	NOUN	O	I-Entity
(	PUNCT	O	O
>	PUNCT	O	O
or=10.8	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
prothrombin	ADJ	O	O
time	NOUN	O	O
(	PUNCT	O	O
PT	PROPN	O	O
)	PUNCT	O	O
prolongation	NOUN	O	O
(	PUNCT	O	O
>	PUNCT	O	O
or=26	ADJ	O	O
seconds	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
grade	NOUN	O	O
III	PROPN	O	O
/	SYM	O	O
IV	PROPN	O	O
encephalopathy	NOUN	O	I-Entity
at	ADP	O	O
presentation	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
ATT	PROPN	O	O
-	PUNCT	O	O
ALF	PROPN	O	I-Entity
constituted	VERB	O	O
5.7%	NUM	O	O
of	ADP	O	O
ALF	NOUN	O	I-Entity
at	ADP	O	O
our	ADJ	O	O
center	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
a	DET	O	O
high	ADJ	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20470218)

Central	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
complications	NOUN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
pediatric	ADJ	O	O
institution	NOUN	O	O
.	PUNCT	O	O

Central	PROPN	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
CNS	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
complications	NOUN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
childhood	NOUN	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
(	PUNCT	O	O
ALL	PROPN	O	I-Entity
)	PUNCT	O	O
remain	VERB	O	O
a	DET	O	O
challenging	VERB	O	O
clinical	ADJ	O	O
problem	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
analyzed	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
neurological	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
during	ADP	O	O
ALL	DET	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
pediatric	ADJ	O	O
institution	NOUN	O	O
,	PUNCT	O	O
focusing	VERB	O	O
on	ADP	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
radiological	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
electrophysiological	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Exclusion	NOUN	O	O
criteria	NOUN	O	O
included	VERB	O	O
CNS	PROPN	O	O
leukemic	ADJ	O	B-Entity
infiltration	NOUN	O	I-Entity
at	ADP	O	O
diagnosis	NOUN	O	O
,	PUNCT	O	O
therapy	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
late	ADV	O	O
-	PUNCT	O	O
onset	NOUN	O	O
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
neurocognitive	ADJ	O	B-Entity
defects	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
9-year	ADJ	O	O
period	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
retrospectively	ADV	O	O
collected	VERB	O	O
27	NUM	O	O
neurological	ADJ	O	O
events	NOUN	O	O
(	PUNCT	O	O
11%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
as	ADP	O	O
many	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
253	NUM	O	O
children	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
ALL	PROPN	O	I-Entity
front	NOUN	O	O
-	PUNCT	O	O
line	NOUN	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

CNS	NOUN	O	O
complications	NOUN	O	O
included	VERB	O	O
posterior	ADJ	O	O
reversible	ADJ	O	O
leukoencephalopathy	NOUN	O	I-Entity
syndrome	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methotrexate	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
syndrome	NOUN	O	O
of	ADP	O	O
inappropriate	ADJ	O	B-Entity
antidiuretic	ADJ	O	I-Entity
hormone	NOUN	O	I-Entity
secretion	NOUN	O	I-Entity
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
unclassified	ADJ	O	O
events	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
CNS	PROPN	O	O
complications	NOUN	O	O
are	VERB	O	O
frequent	ADJ	O	O
events	NOUN	O	O
during	ADP	O	O
ALL	DET	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
require	VERB	O	O
rapid	ADJ	O	O
detection	NOUN	O	O
and	CCONJ	O	O
prompt	ADJ	O	O
treatment	NOUN	O	O
to	PART	O	O
limit	VERB	O	O
permanent	ADJ	O	O
damage	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20722491)

Safety	NOUN	O	O
of	ADP	O	O
capecitabine	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
review	NOUN	O	O
.	PUNCT	O	O

IMPORTANCE	NOUN	O	O
OF	ADP	O	O
THE	DET	O	O
FIELD	NOUN	O	O
:	PUNCT	O	O
Fluoropyrimidines	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
particular	ADJ	O	O
5-fluorouracil	PROPN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
the	DET	O	O
mainstay	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
several	ADJ	O	O
solid	ADJ	O	O
tumors	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
colorectal	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
breast	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
head	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
cancers	NOUN	O	I-Entity
,	PUNCT	O	O
for	ADP	O	O
>	SYM	O	O
40	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
reviews	VERB	O	O
the	DET	O	O
pharmacology	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
capecitabine	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
special	ADJ	O	O
emphasis	NOUN	O	O
on	ADP	O	O
its	ADJ	O	O
safety	NOUN	O	O
.	PUNCT	O	O

WHAT	NOUN	O	O
THE	DET	O	O
READER	NOUN	O	O
WILL	VERB	O	O
GAIN	VERB	O	O
:	PUNCT	O	O
The	DET	O	O
reader	NOUN	O	O
will	VERB	O	O
gain	VERB	O	O
better	ADJ	O	O
insight	NOUN	O	O
into	ADP	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
capecitabine	NOUN	O	I-Entity
in	ADP	O	O
special	ADJ	O	O
populations	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
renal	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
kidney	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
explore	VERB	O	O
different	ADJ	O	O
dosing	NOUN	O	O
and	CCONJ	O	O
schedules	NOUN	O	O
of	ADP	O	O
capecitabine	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Capecitabine	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
oral	ADJ	O	O
prodrug	NOUN	O	O
of	ADP	O	O
5-FU	PROPN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
developed	VERB	O	O
to	PART	O	O
fulfill	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
a	DET	O	O
more	ADV	O	O
convenient	ADJ	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
provide	VERB	O	O
an	DET	O	O
improved	ADJ	O	O
safety	NOUN	O	O
/	SYM	O	O
efficacy	NOUN	O	O
profile	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
shown	VERB	O	O
promising	ADJ	O	O
results	NOUN	O	O
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
chemotherapeutic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
colorectal	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
breast	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
pancreaticobiliary	ADJ	O	I-Entity
,	PUNCT	O	I-Entity
gastric	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
renal	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
head	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
cancers	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
commonly	ADV	O	O
reported	VERB	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
capecitabine	NOUN	O	I-Entity
are	VERB	O	O
diarrhea	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
,	PUNCT	O	O
stomatitis	NOUN	O	I-Entity
and	CCONJ	O	O
hand	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
foot	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Capecitabine	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
established	VERB	O	O
safety	NOUN	O	O
profile	NOUN	O	O
and	CCONJ	O	O
can	VERB	O	O
be	VERB	O	O
given	VERB	O	O
safely	ADV	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
hepatic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
dysfunctions	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20882060)

Effects	NOUN	O	O
of	ADP	O	O
pallidal	NOUN	O	O
neurotensin	NOUN	O	I-Entity
on	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
parkinsonian	ADJ	O	B-Entity
catalepsy	NOUN	O	I-Entity
:	PUNCT	O	O
behavioral	ADJ	O	O
and	CCONJ	O	O
electrophysiological	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
indicated	VERB	O	O
that	ADP	O	O
the	DET	O	O
globus	NOUN	O	O
pallidus	NOUN	O	O
receives	VERB	O	O
neurotensinergic	ADJ	O	O
innervation	NOUN	O	O
from	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
neurotensin	NOUN	O	I-Entity
analog	NOUN	O	O
could	VERB	O	O
produce	VERB	O	O
antiparkinsonian	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
pallidal	NOUN	O	O
neurotensin	NOUN	O	I-Entity
on	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
parkinsonian	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

Bilateral	ADJ	O	O
infusions	NOUN	O	O
of	ADP	O	O
neurotensin	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
globus	NOUN	O	O
pallidus	NOUN	O	O
reversed	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
parkinsonian	ADJ	O	B-Entity
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Electrophysiological	ADJ	O	O
recordings	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
microinjection	NOUN	O	O
of	ADP	O	O
neurotensin	NOUN	O	I-Entity
induced	VERB	O	O
excitation	NOUN	O	O
of	ADP	O	O
pallidal	NOUN	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
haloperidol	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
neurotensin	NOUN	O	B-Entity
type-1	ADJ	O	I-Entity
receptor	NOUN	O	I-Entity
antagonist	NOUN	O	I-Entity
SR48692	NOUN	O	I-Entity
blocked	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
behavioral	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
electrophysiological	ADJ	O	O
effects	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
neurotensin	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Activation	NOUN	O	O
of	ADP	O	O
pallidal	NOUN	O	O
neurotensin	NOUN	O	I-Entity
receptors	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
neurotensin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
antiparkinsonian	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (26094)

Antihypertensive	ADJ	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
depression	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
reappraisal	NOUN	O	O
.	PUNCT	O	O

new	ADJ	O	O
referral	NOUN	O	O
hypertensive	ADJ	O	I-Entity
out	ADV	O	O
-	PUNCT	O	O
patients	NOUN	O	O
and	CCONJ	O	O
46	NUM	O	O
new	ADJ	O	O
referral	ADJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
hypertensive	ADJ	O	I-Entity
chronically	ADV	O	O
physically	ADV	O	O
ill	ADJ	O	O
out	PART	O	O
-	PUNCT	O	O
patients	NOUN	O	O
completed	VERB	O	O
a	DET	O	O
mood	NOUN	O	O
rating	VERB	O	O
scale	NOUN	O	O
at	ADP	O	O
regular	ADJ	O	O
intervals	NOUN	O	O
for	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
high	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
preponderance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Hypertensive	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
psychiatric	ADJ	O	I-Entity
histories	NOUN	O	O
had	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
depression	NOUN	O	I-Entity
than	ADP	O	O
the	DET	O	O
comparison	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
accounted	VERB	O	O
for	ADP	O	O
by	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
depressions	NOUN	O	I-Entity
occurring	VERB	O	O
in	ADP	O	O
methyl	NOUN	O	B-Entity
dopa	NOUN	O	I-Entity
treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
psychiatric	ADJ	O	I-Entity
histories	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (322550)

Pulmonary	ADJ	O	O
shunt	VERB	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
CPAP	PROPN	O	O
during	ADP	O	O
nitroprusside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
positive	ADJ	O	O
airway	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
CPAP	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
cardiovascular	ADJ	O	O
dynamics	NOUN	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	O
shunt	NOUN	O	O
(	PUNCT	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
12	NUM	O	O
dogs	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
during	ADP	O	O
sodium	NOUN	O	B-Entity
nitroprusside	ADJ	O	I-Entity
infusion	NOUN	O	O
that	ADJ	O	O
decreased	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
40	NUM	O	O
-	PUNCT	O	O
50	NUM	O	O
per	NOUN	O	O
cent	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
nitroprusside	ADJ	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
cm	SYM	O	O
H2O	PROPN	O	I-Entity
CPAP	PROPN	O	O
significantly	ADV	O	O
,	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
.05	NUM	O	O
,	PUNCT	O	O
decreased	VERB	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
alter	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
.	PUNCT	O	O

cm	X	O	O
H2O	NUM	O	I-Entity
CPAP	PROPN	O	O
before	ADP	O	O
nitroprusside	NOUN	O	I-Entity
infusion	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
further	ADJ	O	O
decrease	NOUN	O	B-Entity
in	ADP	O	I-Entity
arterial	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
and	CCONJ	O	O
significantly	ADV	O	O
increased	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	B-Entity
cardiac	ADJ	O	I-Entity
output	NOUN	O	I-Entity
and	CCONJ	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
.	PUNCT	O	O

Nitroprusside	ADV	O	I-Entity
caused	VERB	O	O
significant	ADJ	O	O
decreases	NOUN	O	B-Entity
in	ADP	O	I-Entity
arterial	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
and	CCONJ	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
increases	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
or	CCONJ	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
.	PUNCT	O	O

H2O	NUM	O	I-Entity
CPAP	NOUN	O	O
during	ADP	O	O
nitroprusside	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
further	ADV	O	O
alter	VERB	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
above	ADV	O	O
-	PUNCT	O	O
mentioned	VERB	O	O
variables	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
10	NUM	O	O
cm	NOUN	O	O
H2O	PROPN	O	I-Entity
CPAP	PROPN	O	O
decreased	VERB	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
nitroprusside	ADJ	O	I-Entity
infusion	NOUN	O	O
rates	NOUN	O	O
that	ADJ	O	O
decrease	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
by	ADP	O	O
40	NUM	O	O
-	SYM	O	O
50	NUM	O	O
per	NOUN	O	O
cent	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
change	VERB	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
or	CCONJ	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
.	PUNCT	O	O

During	ADP	O	O
nitroprusside	ADJ	O	I-Entity
infusion	NOUN	O	O
low	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
CPAP	PROPN	O	O
do	VERB	O	O
not	ADV	O	O
markedly	ADV	O	O
alter	VERB	O	O
cardiovascular	ADJ	O	O
dynamics	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
CPAP	PROPN	O	O
(	PUNCT	O	O
10	NUM	O	O
cm	NOUN	O	O
H2O	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
decreasing	VERB	O	O
QS	PROPN	O	O
/	SYM	O	O
QT	PROPN	O	O
,	PUNCT	O	O
produce	VERB	O	O
marked	VERB	O	O
decreases	NOUN	O	B-Entity
in	ADP	O	I-Entity
arterial	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
cardiac	ADJ	O	I-Entity
output	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (869641)

Mediation	PROPN	O	O
of	ADP	O	O
enhanced	VERB	O	O
reflex	NOUN	O	O
vagal	NOUN	O	O
bradycardia	NOUN	O	I-Entity
by	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
via	ADP	O	O
central	ADJ	O	O
dopamine	NOUN	O	I-Entity
formation	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Dopa	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
decreased	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
after	ADP	O	O
extracerebral	ADJ	O	O
decarboxylase	NOUN	O	O
inhibition	NOUN	O	O
with	ADP	O	O
MK-486	PROPN	O	I-Entity
(	PUNCT	O	O
25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O

anesthetize	VERB	O	O
MAO	PROPN	O	I-Entity
-	PUNCT	O	O
inhibited	VERB	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
injected	VERB	O	O
norepinephrine	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
enhanced	VERB	O	O
by	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
,	PUNCT	O	O
DL	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Threo	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
dihydroxyphenylserine	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
or	CCONJ	O	O
reflex	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
norepinephrine	VERB	O	I-Entity
.	PUNCT	O	O

FLA-63	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
dopamine	NOUN	O	I-Entity
-	PUNCT	O	O
beta	NOUN	O	O
-	PUNCT	O	O
oxidase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
any	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
bradycardia	NOUN	O	I-Entity
or	CCONJ	O	O
reflex	NOUN	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
.	PUNCT	O	O

Pimozide	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
actions	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
but	CCONJ	O	O
completely	ADV	O	O
blocked	VERB	O	O
the	DET	O	O
enhancement	NOUN	O	O
of	ADP	O	O
reflexes	NOUN	O	O
.	PUNCT	O	O

Removal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
carotid	ADJ	O	O
sinuses	NOUN	O	O
caused	VERB	O	O
an	DET	O	O
elevation	NOUN	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
abolished	VERB	O	O
the	DET	O	O
negative	ADJ	O	O
chronotropic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
restored	VERB	O	O
the	DET	O	O
bradycardia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
norepinephrine	NOUN	O	I-Entity
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
decreasing	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

5-HTP	NUM	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

decreased	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
the	DET	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
to	ADP	O	O
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
enhances	VERB	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
through	ADP	O	O
central	ADJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
receptor	NOUN	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
are	VERB	O	O
mediated	VERB	O	O
through	ADP	O	O
dopamine	NOUN	O	I-Entity
rather	ADV	O	O
than	ADP	O	O
norepinephrine	NOUN	O	I-Entity
and	CCONJ	O	O
do	VERB	O	O
not	ADV	O	O
require	VERB	O	O
the	DET	O	O
carotid	ADJ	O	O
sinus	NOUN	O	O
baroreceptors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1749407)

Cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
:	PUNCT	O	O
clinical	ADJ	O	O
observations	NOUN	O	O
and	CCONJ	O	O
pathogenetic	ADJ	O	O
considerations	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
data	NOUN	O	O
published	VERB	O	O
to	ADP	O	O
date	NOUN	O	O
suggest	VERB	O	O
several	ADJ	O	O
possible	ADJ	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
cocaine	NOUN	O	I-Entity
may	VERB	O	O
result	VERB	O	O
in	ADP	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
individuals	NOUN	O	O
with	ADP	O	O
preexisting	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
grade	NOUN	O	O
coronary	ADJ	O	O
arterial	NOUN	O	O
narrowing	NOUN	O	O
,	PUNCT	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
myocardial	ADJ	O	O
oxygen	NOUN	O	I-Entity
demand	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
rate	NOUN	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
product	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
other	ADJ	O	O
individuals	NOUN	O	O
with	ADP	O	O
no	DET	O	O
underlying	VERB	O	O
atherosclerotic	ADJ	O	B-Entity
obstruction	NOUN	O	I-Entity
,	PUNCT	O	O
coronary	ADJ	O	B-Entity
occlusion	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
spasm	NOUN	O	I-Entity
,	PUNCT	O	O
thrombus	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
.	PUNCT	O	O

With	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
spasm	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
clinical	ADJ	O	O
findings	NOUN	O	O
are	VERB	O	O
largely	ADV	O	O
circumstantial	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
locus	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasoconstriction	NOUN	O	O
remains	VERB	O	O
speculative	ADJ	O	O
.	PUNCT	O	O

Although	ADP	O	O
certain	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
spasm	NOUN	O	I-Entity
involves	VERB	O	O
the	DET	O	O
epicardial	ADJ	O	O
,	PUNCT	O	O
medium	NOUN	O	O
-	PUNCT	O	O
size	NOUN	O	O
vessels	NOUN	O	O
,	PUNCT	O	O
other	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
intramural	ADJ	O	O
vasoconstriction	NOUN	O	O
.	PUNCT	O	O

Diffuse	ADP	O	O
intramural	ADJ	O	O
vasoconstriction	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
consistent	ADJ	O	O
with	ADP	O	O
reports	NOUN	O	O
of	ADP	O	O
segmental	NOUN	O	O
,	PUNCT	O	O
discrete	ADJ	O	O
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
finding	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasoconstriction	NOUN	O	O
in	ADP	O	O
segments	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
noninnervated	ADJ	O	O
)	PUNCT	O	O
human	ADJ	O	O
umbilical	ADJ	O	O
artery	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
intact	ADJ	O	O
innervation	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
sufficient	ADJ	O	O
to	PART	O	O
explain	VERB	O	O
the	DET	O	O
discrepant	ADJ	O	O
data	NOUN	O	O
involving	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
,	PUNCT	O	O
thrombotic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1786266)

Rabbit	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
antidepressant	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cerebral	ADJ	O	O
perfusion	NOUN	O	O
SPECT	PROPN	O	O
scan	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rabbit	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
neuroleptic	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Its	ADJ	O	O
occurrence	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
imipramine	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
,	PUNCT	O	O
representing	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
antidepressants	NOUN	O	I-Entity
.	PUNCT	O	O

Repeated	VERB	O	O
cerebral	ADJ	O	O
perfusion	NOUN	O	O
SPECT	PROPN	O	O
scans	VERB	O	O
revealed	VERB	O	O
decreased	ADJ	O	B-Entity
basal	NOUN	O	I-Entity
ganglia	NOUN	O	I-Entity
perfusion	NOUN	O	I-Entity
while	ADP	O	O
the	DET	O	O
movement	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
was	VERB	O	O
present	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
return	NOUN	O	O
to	ADP	O	O
normal	ADJ	O	O
perfusion	NOUN	O	O
when	ADV	O	O
the	DET	O	O
rabbit	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
resolved	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1835291)

Acute	PROPN	O	O
bronchodilating	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
ipratropium	NOUN	O	B-Entity
bromide	NOUN	O	I-Entity
and	CCONJ	O	O
theophylline	NOUN	O	I-Entity
in	ADP	O	O
chronic	ADJ	O	B-Entity
obstructive	ADJ	O	I-Entity
pulmonary	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
bronchodilator	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ipratropium	NOUN	O	B-Entity
bromide	NOUN	O	I-Entity
aerosol	NOUN	O	O
(	PUNCT	O	O
36	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
theophylline	NOUN	O	I-Entity
tablets	NOUN	O	O
(	PUNCT	O	O
dose	NOUN	O	O
titrated	VERB	O	O
to	PART	O	O
produce	VERB	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
-	SYM	O	O
20	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
crossover	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
,	PUNCT	O	O
chronic	ADJ	O	B-Entity
obstructive	ADJ	O	I-Entity
pulmonary	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Mean	ADJ	O	O
peak	NOUN	O	O
forced	VERB	O	O
expiratory	NOUN	O	O
volume	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
second	NOUN	O	O
(	PUNCT	O	O
FEV1	PROPN	O	O
)	PUNCT	O	O
increases	VERB	O	O
over	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
attaining	VERB	O	O
at	ADP	O	O
least	ADJ	O	O
a	DET	O	O
15%	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
FEV1	PROPN	O	O
(	PUNCT	O	O
responders	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
31%	NUM	O	O
and	CCONJ	O	O
90%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
ipratropium	NOUN	O	I-Entity
and	CCONJ	O	O
17%	NUM	O	O
and	CCONJ	O	O
50%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
theophylline	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
FEV1	PROPN	O	O
increases	NOUN	O	O
during	ADP	O	O
the	DET	O	O
6-hour	NUM	O	O
observation	NOUN	O	O
period	NOUN	O	O
were	VERB	O	O
18%	NUM	O	O
for	ADP	O	O
ipratropium	NOUN	O	I-Entity
and	CCONJ	O	O
8%	NUM	O	O
for	ADP	O	O
theophylline	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
was	VERB	O	O
3.8	NUM	O	O
hours	NOUN	O	O
with	ADP	O	O
ipratropium	NOUN	O	I-Entity
and	CCONJ	O	O
2.4	NUM	O	O
hours	NOUN	O	O
with	ADP	O	O
theophylline	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
rare	ADJ	O	O
,	PUNCT	O	O
those	DET	O	O
experienced	VERB	O	O
after	ADP	O	O
theophylline	NOUN	O	I-Entity
use	NOUN	O	O
did	VERB	O	O
involve	VERB	O	O
the	DET	O	O
cardiovascular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
gastrointestinal	ADJ	O	I-Entity
systems	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
ipratropium	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
more	ADV	O	O
potent	ADJ	O	O
bronchodilator	NOUN	O	O
than	ADP	O	O
oral	ADJ	O	O
theophylline	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
airflow	NOUN	O	I-Entity
obstruction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1919871)

Irreversible	ADJ	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
medullary	ADJ	O	O
interstitium	NOUN	O	O
in	ADP	O	O
experimental	ADJ	O	O
analgesic	NOUN	O	O
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
F344	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
papillary	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
(	PUNCT	O	O
RPN	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
decreased	ADJ	O	O
urinary	NOUN	O	O
concentrating	VERB	O	O
ability	NOUN	O	O
developed	VERB	O	O
during	ADP	O	O
continuous	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
aspirin	NOUN	O	I-Entity
and	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
in	ADP	O	O
female	ADJ	O	O
Fischer	PROPN	O	O
344	NUM	O	O
rats	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
prolonged	ADJ	O	O
analgesic	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
Fischer	PROPN	O	O
344	NUM	O	O
rats	NOUN	O	O
causes	VERB	O	O
progressive	ADJ	O	O
and	CCONJ	O	O
irreversible	ADJ	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
interstitial	ADJ	O	O
matrix	NOUN	O	O
and	CCONJ	O	O
type	NOUN	O	O
1	NUM	O	O
interstitial	ADJ	O	O
cells	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
RPN	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1987816)

Less	ADV	O	O
frequent	ADJ	O	O
lithium	NOUN	O	I-Entity
administration	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
urine	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
patients	NOUN	O	O
maintained	VERB	O	O
on	ADP	O	O
a	DET	O	O
regimen	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
once	ADV	O	O
-	PUNCT	O	O
per	ADP	O	O
-	PUNCT	O	O
day	NOUN	O	O
schedule	NOUN	O	O
have	VERB	O	O
lower	ADJ	O	O
urine	NOUN	O	O
volumes	NOUN	O	O
than	ADP	O	O
do	VERB	O	O
patients	NOUN	O	O
receiving	VERB	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
a	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
85	NUM	O	O
patients	NOUN	O	O
from	ADP	O	O
a	DET	O	O
lithium	NOUN	O	I-Entity
clinic	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
different	ADJ	O	O
dose	NOUN	O	O
schedules	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
for	ADP	O	O
measurement	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
level	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
,	PUNCT	O	O
urine	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
maximum	ADJ	O	O
osmolality	NOUN	O	O
.	PUNCT	O	O

Multiple	ADJ	O	O
daily	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
higher	ADJ	O	O
urine	NOUN	O	O
volumes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dosing	NOUN	O	O
schedule	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
maximum	ADJ	O	O
osmolality	NOUN	O	O
or	CCONJ	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Urine	ADJ	O	O
volume	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
giving	VERB	O	O
lithium	NOUN	O	I-Entity
once	ADV	O	O
daily	ADV	O	O
and/or	CCONJ	O	O
by	ADP	O	O
lowering	VERB	O	O
the	DET	O	O
total	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polyuria	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
extrarenal	VERB	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
to	ADP	O	O
renal	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2054792)

Effect	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
whole	ADJ	O	O
body	NOUN	O	O
hyperthermia	NOUN	O	I-Entity
on	ADP	O	O
tumor	NOUN	O	I-Entity
and	CCONJ	O	O
normal	ADJ	O	O
tissues	NOUN	O	O
.	PUNCT	O	O

Thermal	ADJ	O	O
enhancement	NOUN	O	O
of	ADP	O	O
Adriamycin	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
antitumor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
normal	ADJ	O	O
tissue	NOUN	O	O
toxicities	NOUN	O	I-Entity
by	ADP	O	O
whole	ADJ	O	O
body	NOUN	O	O
hyperthermia	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
using	VERB	O	O
a	DET	O	O
F344	PROPN	O	O
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

Antitumor	ADJ	O	O
activity	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
using	VERB	O	O
a	DET	O	O
tumor	NOUN	O	I-Entity
growth	NOUN	O	O
delay	NOUN	O	O
assay	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
normal	ADJ	O	O
tissue	NOUN	O	O
toxicities	NOUN	O	I-Entity
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
leukopenia	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
late	ADJ	O	O
normal	ADJ	O	O
tissue	NOUN	O	O
toxicities	NOUN	O	I-Entity
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
myocardial	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
kidney	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
functional	ADJ	O	O
/	SYM	O	O
physiological	ADJ	O	O
assays	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
morphological	ADJ	O	O
techniques	NOUN	O	O
.	PUNCT	O	O

Whole	ADJ	O	O
body	NOUN	O	O
hyperthermia	NOUN	O	I-Entity
(	PUNCT	O	O
120	NUM	O	O
min	NOUN	O	O
at	ADP	O	O
41.5	NUM	O	O
degrees	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
enhanced	VERB	O	O
both	DET	O	O
Adriamycin	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
antitumor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
toxic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Thermal	ADJ	O	O
enhancement	NOUN	O	O
ratios	NOUN	O	O
estimated	VERB	O	O
for	ADP	O	O
"	PUNCT	O	O
acute	ADJ	O	O
"	PUNCT	O	O
hematological	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
1.3	NUM	O	O
,	PUNCT	O	O
whereas	ADP	O	O
those	DET	O	O
estimated	VERB	O	O
for	ADP	O	O
"	PUNCT	O	O
late	ADJ	O	O
"	PUNCT	O	O
damage	NOUN	O	O
(	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
morphological	ADJ	O	O
cardiac	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
renal	ADJ	O	I-Entity
lesions	NOUN	O	I-Entity
)	PUNCT	O	O
varied	VERB	O	O
between	ADP	O	O
2.4	NUM	O	O
and	CCONJ	O	O
4.3	NUM	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
while	ADP	O	O
whole	ADJ	O	O
body	NOUN	O	O
hyperthermia	NOUN	O	I-Entity
enhances	VERB	O	O
Adriamycin	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
antitumor	NOUN	O	O
effect	NOUN	O	O
,	PUNCT	O	O
normal	ADJ	O	O
tissue	NOUN	O	O
toxicity	NOUN	O	I-Entity
is	VERB	O	O
also	ADV	O	O
increased	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
potential	ADJ	O	O
therapeutic	ADJ	O	O
gain	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combined	ADJ	O	O
modality	NOUN	O	O
treatment	NOUN	O	O
is	VERB	O	O
eroded	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2304736)

Prazosin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
stress	NOUN	O	B-Entity
incontinence	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
genuine	ADJ	O	O
stress	NOUN	O	B-Entity
incontinence	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
prazosin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
common	ADJ	O	O
antihypertensive	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

Prazosin	PROPN	O	I-Entity
exerts	VERB	O	O
its	ADJ	O	O
antihypertensive	ADJ	O	O
effects	NOUN	O	O
through	ADP	O	O
vasodilatation	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
selective	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
postsynaptic	ADJ	O	O
alpha-1	ADJ	O	O
adrenergic	ADJ	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
clinical	ADJ	O	O
course	NOUN	O	O
is	VERB	O	O
described	VERB	O	O
and	CCONJ	O	O
correlated	VERB	O	O
with	ADP	O	O
initial	ADJ	O	O
urodynamic	ADJ	O	O
studies	NOUN	O	O
while	ADP	O	O
on	ADP	O	O
prazosin	NOUN	O	I-Entity
and	CCONJ	O	O
subsequent	ADJ	O	O
studies	NOUN	O	O
while	ADP	O	O
taking	VERB	O	O
verapamil	ADV	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
incontinence	NOUN	O	I-Entity
resolved	VERB	O	O
with	ADP	O	O
the	DET	O	O
change	NOUN	O	O
of	ADP	O	O
medication	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
present	VERB	O	O
with	ADP	O	O
stress	NOUN	O	B-Entity
incontinence	NOUN	O	I-Entity
while	ADP	O	O
taking	VERB	O	O
prazosin	NOUN	O	I-Entity
should	VERB	O	O
change	VERB	O	O
their	ADJ	O	O
antihypertensive	ADJ	O	O
medication	NOUN	O	O
before	ADP	O	O
considering	VERB	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
because	ADP	O	O
their	ADJ	O	O
incontinence	NOUN	O	I-Entity
may	VERB	O	O
resolve	VERB	O	O
spontaneously	ADV	O	O
with	ADP	O	O
a	DET	O	O
change	NOUN	O	O
in	ADP	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2312209)

Myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
following	VERB	O	O
sublingual	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
isosorbide	NOUN	O	B-Entity
dinitrate	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
78-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
with	ADP	O	O
healed	VERB	O	O
septal	ADJ	O	O
necrosis	NOUN	O	I-Entity
suffered	VERB	O	O
a	DET	O	O
recurrent	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
wall	NOUN	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
isosorbide	NOUN	O	B-Entity
dinitrate	NOUN	O	I-Entity
5	NUM	O	O
mg	NUM	O	O
sublingually	ADV	O	O
.	PUNCT	O	O

After	ADP	O	O
detailing	VERB	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
discuss	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
paradoxical	ADJ	O	O
coronary	ADJ	O	O
spasm	NOUN	O	I-Entity
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
occurring	VERB	O	O
downstream	NOUN	O	O
to	ADP	O	O
significant	ADJ	O	O
coronary	ADJ	O	B-Entity
arterial	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
coronary	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2549018)

Fluoxetine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
:	PUNCT	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
theoretical	ADJ	O	O
implications	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
fluoxetine	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
obsessive	ADJ	O	B-Entity
compulsive	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
or	CCONJ	O	O
major	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
developed	VERB	O	O
akathisia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
typical	ADJ	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
restlessness	NOUN	O	O
,	PUNCT	O	O
constant	ADJ	O	O
pacing	NOUN	O	O
,	PUNCT	O	O
purposeless	ADJ	O	O
movements	NOUN	O	O
of	ADP	O	O
the	DET	O	O
feet	NOUN	O	O
and	CCONJ	O	O
legs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
marked	VERB	O	O
anxiety	NOUN	O	I-Entity
were	VERB	O	O
indistinguishable	ADJ	O	O
from	ADP	O	O
those	DET	O	O
of	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
experienced	VERB	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
past	NOUN	O	O
reported	VERB	O	O
that	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
were	VERB	O	O
identical	ADJ	O	O
,	PUNCT	O	O
although	ADP	O	O
somewhat	ADV	O	O
milder	ADJ	O	O
.	PUNCT	O	O

Akathisia	PROPN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
common	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	I-Entity
and	CCONJ	O	O
generally	ADV	O	O
responded	VERB	O	O
well	ADV	O	O
to	PART	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
antagonist	NOUN	O	O
propranolol	NOUN	O	I-Entity
,	PUNCT	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
serotonergically	ADV	O	O
mediated	VERB	O	O
inhibition	NOUN	O	O
of	ADP	O	O
dopaminergic	ADJ	O	O
neurotransmission	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
and	CCONJ	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
"	PUNCT	O	O
jitteriness	NOUN	O	O
"	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
identical	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (2611118)

Chronic	ADJ	O	B-Entity
active	ADJ	O	I-Entity
hepatitis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
diclofenac	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Diclofenac	PROPN	O	B-Entity
sodium	NOUN	O	I-Entity
(	PUNCT	O	O
Voltarol	PROPN	O	I-Entity
,	PUNCT	O	O
Geigy	PROPN	O	O
Pharmaceuticals	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
steroidal	NOUN	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
derivative	NOUN	O	O
of	ADP	O	O
phenylacetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
generally	ADV	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
asymptomatic	ADJ	O	O
abnormalities	NOUN	O	B-Entity
of	ADP	O	I-Entity
liver	NOUN	O	I-Entity
function	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
recorded	VERB	O	O
and	CCONJ	O	O
,	PUNCT	O	O
less	ADV	O	O
commonly	ADV	O	O
,	PUNCT	O	O
severe	ADJ	O	O
hepatitis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
diclofenac	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
described	VERB	O	O
developed	VERB	O	O
chronic	ADJ	O	B-Entity
active	ADJ	O	I-Entity
hepatitis	NOUN	O	I-Entity
after	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
diclofenac	NOUN	O	B-Entity
sodium	NOUN	O	I-Entity
which	ADJ	O	O
progressed	VERB	O	O
despite	ADP	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
finding	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2673163)

Stroke	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
eight	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
stroke	NOUN	O	I-Entity
and	CCONJ	O	O
review	NOUN	O	O
39	NUM	O	O
cases	NOUN	O	O
from	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

Stroke	PROPN	O	I-Entity
followed	VERB	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
by	ADP	O	O
inhalation	NOUN	O	O
,	PUNCT	O	O
intranasal	NOUN	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intramuscular	ADJ	O	O
routes	NOUN	O	O
.	PUNCT	O	O

Intracranial	ADJ	O	B-Entity
aneurysms	NOUN	O	I-Entity
or	CCONJ	O	O
arteriovenous	ADJ	O	B-Entity
malformations	NOUN	O	I-Entity
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
17	NUM	O	O
of	ADP	O	O
32	NUM	O	O
patients	NOUN	O	O
studied	VERB	O	O
angiographically	ADV	O	O
or	CCONJ	O	O
at	ADP	O	O
autopsy	NOUN	O	O
;	PUNCT	O	O
cerebral	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
22%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
in	ADP	O	O
22	NUM	O	O
(	PUNCT	O	O
49%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
in	ADP	O	O
13	NUM	O	O
(	PUNCT	O	O
29%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
apparent	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
is	VERB	O	O
increasing	VERB	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
stroke	NOUN	O	I-Entity
occurs	VERB	O	O
primarily	ADV	O	O
in	ADP	O	O
young	ADJ	O	O
adults	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
stroke	NOUN	O	I-Entity
may	VERB	O	O
follow	VERB	O	O
any	DET	O	O
route	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
administration	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
stroke	NOUN	O	I-Entity
after	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
is	VERB	O	O
frequently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
intracranial	ADJ	O	B-Entity
aneurysms	NOUN	O	I-Entity
and	CCONJ	O	O
arteriovenous	ADJ	O	B-Entity
malformations	NOUN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O

(	PUNCT	O	O
5	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
stroke	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
intracranial	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
exceeds	VERB	O	O
that	ADP	O	O
of	ADP	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3107448)

Glyburide	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
common	ADJ	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
only	ADV	O	O
infrequently	ADV	O	O
with	ADP	O	O
sulfonylureas	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
glyburide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
second	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
sulfonylurea	NOUN	O	I-Entity
,	PUNCT	O	O
only	ADV	O	O
two	NUM	O	O
brief	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
exist	VERB	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	B-Entity
II	NUM	O	I-Entity
diabetes	NOUN	O	I-Entity
mellitus	NOUN	O	I-Entity
developed	VERB	O	O
an	DET	O	O
acute	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
soon	ADV	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
glyburide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
serologic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
viral	ADJ	O	B-Entity
infection	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
liver	NOUN	O	O
biopsy	NOUN	O	O
sample	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
histologic	ADJ	O	O
pattern	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
patients	NOUN	O	O
recovered	VERB	O	O
quickly	ADV	O	O
after	ADP	O	O
stopping	VERB	O	O
glyburide	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
have	VERB	O	O
remained	VERB	O	O
well	ADV	O	O
for	ADP	O	O
a	DET	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

Glyburide	PROPN	O	I-Entity
can	VERB	O	O
produce	VERB	O	O
an	DET	O	O
acute	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
illness	NOUN	O	I-Entity
in	ADP	O	O
some	DET	O	O
persons	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3341566)

Systolic	ADJ	O	O
pressure	NOUN	O	O
variation	NOUN	O	O
is	VERB	O	O
greater	ADJ	O	O
during	ADP	O	O
hemorrhage	NOUN	O	I-Entity
than	ADP	O	O
during	ADP	O	O
sodium	NOUN	O	B-Entity
nitroprusside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
ventilated	ADJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
systolic	ADJ	O	O
pressure	NOUN	O	O
variation	NOUN	O	O
(	PUNCT	O	O
SPV	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
the	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
maximal	ADJ	O	O
and	CCONJ	O	O
minimal	ADJ	O	O
values	NOUN	O	O
of	ADP	O	O
the	DET	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
SBP	PROPN	O	O
)	PUNCT	O	O
after	ADP	O	O
one	NUM	O	O
positive	ADJ	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
breath	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
ventilated	ADJ	O	O
dogs	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
to	ADP	O	O
50	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
for	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
either	CCONJ	O	O
by	ADP	O	O
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
HEM	PROPN	O	I-Entity
,	PUNCT	O	O
n	X	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
by	ADP	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	B-Entity
nitroprusside	NOUN	O	I-Entity
(	PUNCT	O	O
SNP	PROPN	O	I-Entity
,	PUNCT	O	O
n	X	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
HEM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
the	DET	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
higher	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
that	DET	O	O
in	ADP	O	O
the	DET	O	O
SNP	PROPN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
SPV	PROPN	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
15.7	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

6.7	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
in	ADP	O	O
the	DET	O	O
HEM	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
9.1	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

2.0	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
in	ADP	O	O
the	DET	O	O
SNP	PROPN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

3.8	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
in	ADP	O	O
the	DET	O	O
HEM	PROPN	O	I-Entity
and	CCONJ	O	O
SNP	PROPN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
increases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
SPV	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
delta	NOUN	O	O
down	ADV	O	O
are	VERB	O	O
characteristic	ADJ	O	O
of	ADP	O	O
a	DET	O	O
hypotensive	ADJ	O	I-Entity
state	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
predominant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
preload	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
are	VERB	O	O
thus	ADV	O	O
more	ADV	O	O
important	ADJ	O	O
during	ADP	O	O
absolute	ADJ	O	O
hypovolemia	NOUN	O	I-Entity
than	ADP	O	O
during	ADP	O	O
deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3564823)

Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
arterial	ADJ	O	O
spasm	NOUN	O	I-Entity
relieved	VERB	O	O
by	ADP	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
major	ADJ	O	O
intracranial	ADJ	O	O
surgery	NOUN	O	O
in	ADP	O	O
a	DET	O	O
35-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
,	PUNCT	O	O
sodium	NOUN	O	B-Entity
pentothal	NOUN	O	I-Entity
was	VERB	O	O
intravenously	ADV	O	O
infused	VERB	O	O
to	PART	O	O
minimize	VERB	O	O
cerebral	ADJ	O	B-Entity
ischaemia	NOUN	O	I-Entity
.	PUNCT	O	O

Intense	ADJ	O	O
vasospasm	NOUN	O	I-Entity
with	ADP	O	O
threatened	VERB	O	O
gangrene	NOUN	O	I-Entity
arose	VERB	O	O
in	ADP	O	O
the	DET	O	O
arm	NOUN	O	O
used	VERB	O	O
for	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
the	DET	O	O
cranial	ADJ	O	O
condition	NOUN	O	O
precluded	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
more	ADJ	O	O
usual	ADJ	O	O
methods	NOUN	O	O
,	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
intra	ADJ	O	O
-	PUNCT	O	O
arterially	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
careful	ADJ	O	O
cardiovascular	NOUN	O	O
monitoring	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
counteract	VERB	O	O
the	DET	O	O
vasospasm	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3676049)

Cerebral	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
and	CCONJ	O	O
metabolism	NOUN	O	O
during	ADP	O	O
isoflurane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
surgery	NOUN	O	O
for	ADP	O	O
cerebral	ADJ	O	B-Entity
aneurysms	NOUN	O	I-Entity
.	PUNCT	O	O

Cerebral	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
and	CCONJ	O	O
cerebral	ADJ	O	O
metabolic	NOUN	O	O
rate	NOUN	O	O
for	ADP	O	O
oxygen	NOUN	O	I-Entity
were	VERB	O	O
measured	VERB	O	O
during	ADP	O	O
isoflurane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
craniotomy	VERB	O	O
for	ADP	O	O
clipping	NOUN	O	O
of	ADP	O	O
a	DET	O	O
cerebral	ADJ	O	B-Entity
aneurysm	NOUN	O	I-Entity
.	PUNCT	O	O

Flow	VERB	O	O
and	CCONJ	O	O
metabolism	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
5	NUM	O	O
-	SYM	O	O
13	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
subarachnoid	NOUN	O	B-Entity
haemorrhage	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
modification	NOUN	O	O
of	ADP	O	O
the	DET	O	O
classical	ADJ	O	O
Kety	PROPN	O	O
-	PUNCT	O	O
Schmidt	PROPN	O	O
technique	NOUN	O	O
using	VERB	O	O
xenon-133	PROPN	O	I-Entity
i.v	PROPN	O	O
.	PUNCT	O	O

Anaesthesia	PROPN	O	O
was	VERB	O	O
maintained	VERB	O	O
with	ADP	O	O
an	DET	O	O
inspired	VERB	O	O
isoflurane	NOUN	O	I-Entity
concentration	NOUN	O	O
of	ADP	O	O
0.75%	NUM	O	O
(	PUNCT	O	O
plus	CCONJ	O	O
67%	NUM	O	O
nitrous	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
in	ADP	O	O
oxygen	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
during	ADP	O	O
which	ADJ	O	O
CBF	PROPN	O	O
and	CCONJ	O	O
CMRO2	PROPN	O	O
were	VERB	O	O
34.3	NUM	O	O
+	NUM	O	O
/-	PUNCT	O	O

Controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
to	ADP	O	O
an	DET	O	O
average	ADJ	O	O
MAP	PROPN	O	O
of	ADP	O	O
50	NUM	O	O
-	SYM	O	O
55	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
isoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
maintained	VERB	O	O
at	ADP	O	O
an	DET	O	O
inspired	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
2.2	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
clipping	NOUN	O	O
of	ADP	O	O
the	DET	O	O
aneurysm	NOUN	O	I-Entity
the	DET	O	O
isoflurane	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
0.75%	NUM	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
CBF	PROPN	O	O
,	PUNCT	O	O
although	ADP	O	O
CMRO2	PROPN	O	O
was	VERB	O	O
unchanged	ADJ	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
hypotensive	ADJ	O	I-Entity
values	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
changes	NOUN	O	O
might	VERB	O	O
offer	VERB	O	O
protection	NOUN	O	O
to	ADP	O	O
brain	NOUN	O	O
tissue	NOUN	O	O
during	ADP	O	O
periods	NOUN	O	O
of	ADP	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3719553)

Allergic	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
to	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
allergic	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
consisting	VERB	O	O
of	ADP	O	O
angioneurotic	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
5-fluorouracil	NUM	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
oral	ADJ	O	I-Entity
cavity	NOUN	O	I-Entity
,	PUNCT	O	O
cirrhosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
impaired	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

Oral	PROPN	O	O
diphenhydramine	NOUN	O	I-Entity
and	CCONJ	O	O
prednisone	NOUN	O	I-Entity
were	VERB	O	O
ineffective	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
allergic	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (4008111)

Amiodarone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sinoatrial	ADJ	O	B-Entity
block	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
sinoatrial	ADJ	O	B-Entity
block	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
chronic	ADJ	O	O
amiodarone	NOUN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
a	DET	O	O
5-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
Wolff	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Parkinson	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
White	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
supraventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dosage	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
disappearance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sinoatrial	ADJ	O	B-Entity
block	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
persistence	NOUN	O	O
of	ADP	O	O
asymptomatic	ADJ	O	O
sinus	ADJ	O	B-Entity
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6133211)

Possible	ADJ	O	O
teratogenicity	NOUN	O	O
of	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
infants	NOUN	O	O
,	PUNCT	O	O
born	VERB	O	O
of	ADP	O	O
two	NUM	O	O
mothers	NOUN	O	O
with	ADP	O	O
inflammatory	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
received	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
throughout	ADP	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
major	ADJ	O	O
congenital	ADJ	O	B-Entity
anomalies	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
singleton	NOUN	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mother	NOUN	O	O
had	VERB	O	O
ulcerative	ADJ	O	B-Entity
colitis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
infant	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
male	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
coarctation	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
aorta	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
ventricular	ADJ	O	B-Entity
septal	ADJ	O	I-Entity
defect	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
twin	ADJ	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mother	NOUN	O	O
had	VERB	O	O
Crohn	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
twin	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
female	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
left	ADJ	O	O
Potter	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
type	NOUN	O	I-Entity
IIa	NOUN	O	I-Entity
polycystic	ADJ	O	I-Entity
kidney	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
rudimentary	ADJ	O	B-Entity
left	NOUN	O	I-Entity
uterine	NOUN	O	I-Entity
cornu	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
twin	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
male	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
some	DET	O	O
features	NOUN	O	O
of	ADP	O	O
Potter	PROPN	O	B-Entity
's	PART	O	I-Entity
facies	NOUN	O	I-Entity
,	PUNCT	O	O
hypoplastic	ADJ	O	B-Entity
lungs	NOUN	O	I-Entity
,	PUNCT	O	O
absent	ADJ	O	B-Entity
kidneys	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
ureters	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
talipes	NOUN	O	B-Entity
equinovarus	NOUN	O	I-Entity
.	PUNCT	O	O

Despite	ADP	O	O
reports	NOUN	O	O
to	ADP	O	O
the	DET	O	O
contrary	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
teratogenic	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (6503301)

Veno	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
occlusive	ADJ	O	I-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
dacarbazine	NOUN	O	I-Entity
therapy	NOUN	O	O
(	PUNCT	O	O
DTIC	PROPN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
melanoma	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
veno	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
occlusive	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
with	ADP	O	O
fatal	ADJ	O	O
outcome	NOUN	O	O
after	ADP	O	O
dacarbazine	NOUN	O	I-Entity
(	PUNCT	O	O
DTIC	PROPN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
for	ADP	O	O
melanoma	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
fulminant	ADJ	O	O
clinical	ADJ	O	O
course	NOUN	O	O
from	ADP	O	O
start	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
until	ADP	O	O
death	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
autopsy	NOUN	O	O
the	DET	O	O
liver	NOUN	O	O
was	VERB	O	O
enlarged	VERB	O	O
and	CCONJ	O	O
firm	NOUN	O	O
with	ADP	O	O
signs	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
congestion	NOUN	O	I-Entity
.	PUNCT	O	O

Small-	PUNCT	O	O
and	CCONJ	O	O
medium	NOUN	O	O
-	PUNCT	O	O
sized	ADJ	O	O
hepatic	ADJ	O	O
veins	NOUN	O	O
were	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6727060)

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
metoclopramide	NOUN	O	I-Entity
.	PUNCT	O	O

Abnormal	PROPN	O	B-Entity
involuntary	ADJ	O	I-Entity
movements	NOUN	O	I-Entity
appeared	VERB	O	O
in	ADP	O	O
the	DET	O	O
mouth	NOUN	O	O
,	PUNCT	O	O
tongue	NOUN	O	O
,	PUNCT	O	O
neck	NOUN	O	O
and	CCONJ	O	O
abdomen	NOUN	O	O
of	ADP	O	O
a	DET	O	O
64-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
patient	NOUN	O	O
after	ADP	O	O
he	PRON	O	O
took	VERB	O	O
metoclopramide	NOUN	O	I-Entity
for	ADP	O	O
gastrointestinal	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
regimen	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
day	NOUN	O	O
for	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
about	ADP	O	O
260	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
the	DET	O	O
metoclopramide	NOUN	O	I-Entity
administration	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
abnormal	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
gradually	ADV	O	O
improved	VERB	O	O
to	ADP	O	O
a	DET	O	O
considerable	ADJ	O	O
extent	NOUN	O	O
.	PUNCT	O	O

Attention	NOUN	O	O
to	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
induction	NOUN	O	O
of	ADP	O	O
specific	ADJ	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
is	VERB	O	O
called	VERB	O	O
for	ADP	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7083920)

Further	ADJ	O	O
observations	NOUN	O	O
on	ADP	O	O
the	DET	O	O
electrophysiologic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
of	ADP	O	O
a	DET	O	O
reversible	ADJ	O	O
intra	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Hisian	PROPN	O	I-Entity
block	NOUN	O	I-Entity
occurring	VERB	O	O
under	ADP	O	O
amiodarone	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
atrial	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
without	ADP	O	O
clear	ADJ	O	O
intraventricular	ADJ	O	B-Entity
conduction	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

His	ADJ	O	O
bundle	NOUN	O	O
recordings	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
atrial	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
with	ADP	O	O
intermittent	ADJ	O	O
exit	NOUN	O	O
block	NOUN	O	O
and	CCONJ	O	O
greatly	ADV	O	O
prolonged	ADJ	O	O
BH	PROPN	O	O
and	CCONJ	O	O
HV	PROPN	O	O
intervals	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
msec	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
amiodarone	NOUN	O	I-Entity
discontinuation	NOUN	O	O
,	PUNCT	O	O
His	ADJ	O	O
bundle	NOUN	O	O
electrograms	NOUN	O	O
showed	VERB	O	O
atrial	ADJ	O	B-Entity
flutter	NOUN	O	I-Entity
without	ADP	O	O
intra	NOUN	O	O
-	PUNCT	O	O
Hisian	PROPN	O	O
or	CCONJ	O	O
infra	NOUN	O	O
-	PUNCT	O	O
Hisian	PROPN	O	O
delay	NOUN	O	O
.	PUNCT	O	O

Amiodarone	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
with	ADP	O	O
caution	NOUN	O	O
during	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
oral	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
clear	ADJ	O	O
intraventricular	ADJ	O	O
conduction	NOUN	O	O
defects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7269015)

Busulfan	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
busulfan	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhage	NOUN	O	B-Entity
cystitis	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
similarity	NOUN	O	O
between	ADP	O	O
the	DET	O	O
histologic	ADJ	O	O
appearances	NOUN	O	O
of	ADP	O	O
busulfan	NOUN	O	I-Entity
cystitis	NOUN	O	I-Entity
and	CCONJ	O	O
both	DET	O	O
radiation	NOUN	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
world	NOUN	O	O
literature	NOUN	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
view	NOUN	O	O
of	ADP	O	O
the	DET	O	O
known	VERB	O	O
tendency	NOUN	O	O
of	ADP	O	O
busulfan	NOUN	O	I-Entity
to	PART	O	O
induce	VERB	O	O
cellular	ADJ	O	O
atypia	NOUN	O	O
and	CCONJ	O	O
carcinoma	NOUN	O	I-Entity
in	ADP	O	O
other	ADJ	O	O
sites	NOUN	O	O
,	PUNCT	O	O
periodic	ADJ	O	O
urinary	ADJ	O	O
cytology	NOUN	O	O
is	VERB	O	O
suggested	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7352670)

Rebound	PROPN	O	O
hypertensive	ADJ	O	I-Entity
after	ADP	O	O
sodium	NOUN	O	B-Entity
nitroprusside	ADV	O	I-Entity
prevented	VERB	O	O
by	ADP	O	O
saralasin	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
--	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
during	ADP	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
and	CCONJ	O	O
sodium	NOUN	O	B-Entity
nitroprusside	NOUN	O	I-Entity
(	PUNCT	O	O
SNP)-induced	PROPN	O	I-Entity
hypotension	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Control	NOUN	O	O
rats	NOUN	O	O
received	VERB	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
MAC	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
one	NUM	O	O
hour	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
SNP	PROPN	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
30-min	NUM	O	O
recovery	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
identically	ADV	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
received	VERB	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
saralasin	NOUN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
competitive	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
)	PUNCT	O	O
throughout	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
each	DET	O	O
group	NOUN	O	O
,	PUNCT	O	O
SNP	PROPN	O	I-Entity
infusion	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
initial	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
from	ADP	O	O
86	NUM	O	O
torr	NOUN	O	O
and	CCONJ	O	O
83	NUM	O	O
torr	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
to	ADP	O	O
48	NUM	O	O
torr	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
SNP	PROPN	O	I-Entity
infusion	NOUN	O	O
the	DET	O	O
control	NOUN	O	O
animals	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
progressive	ADJ	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
to	ADP	O	O
61	NUM	O	O
torr	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
saralasin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
change	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
SNP	PROPN	O	I-Entity
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
animals	NOUN	O	O
rebounded	VERB	O	O
to	ADP	O	O
94	NUM	O	O
torr	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
78	NUM	O	O
torr	NOUN	O	O
in	ADP	O	O
the	DET	O	O
saralasin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
with	ADP	O	O
stable	ADJ	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
partial	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
during	ADP	O	O
SNP	PROPN	O	I-Entity
infusion	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
post	NOUN	O	O
-	PUNCT	O	O
SNP	PROPN	O	I-Entity
rebound	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
completely	ADV	O	O
blocked	VERB	O	O
by	ADP	O	O
saralasin	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
demonstrates	VERB	O	O
the	DET	O	O
participation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
--	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
antagonizing	VERB	O	O
the	DET	O	O
combined	VERB	O	O
hypotensive	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
halothane	NOUN	O	I-Entity
and	CCONJ	O	O
SNP	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7504976)

Toxic	PROPN	O	B-Entity
hepatitis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
antithyroid	ADJ	O	O
drugs	NOUN	O	O
:	PUNCT	O	O
four	NUM	O	O
cases	NOUN	O	O
including	VERB	O	O
one	NUM	O	O
with	ADP	O	O
cross	NOUN	O	O
-	PUNCT	O	O
reactivity	NOUN	O	O
between	ADP	O	O
carbimazole	NOUN	O	I-Entity
and	CCONJ	O	O
benzylthiouracil	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
adverse	ADJ	O	I-Entity
effects	NOUN	O	I-Entity
encountered	VERB	O	O
with	ADP	O	O
antithyroid	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Retrospective	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
medical	ADJ	O	O
records	NOUN	O	O
of	ADP	O	O
236	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
admitted	VERB	O	O
in	ADP	O	O
our	ADJ	O	O
department	NOUN	O	O
(	PUNCT	O	O
in-	NOUN	O	O
or	CCONJ	O	O
out	ADP	O	O
-	PUNCT	O	O
patients	NOUN	O	O
)	PUNCT	O	O
from	ADP	O	O
1986	NUM	O	O
to	ADP	O	O
1992	NUM	O	O
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
1.7%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
identified	VERB	O	O
with	ADP	O	O
toxic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
which	ADJ	O	O
could	VERB	O	O
reasonably	ADV	O	O
be	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
antithyroid	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
carbimazole	NOUN	O	I-Entity
(	PUNCT	O	O
N	PROPN	O	B-Entity
omercazole	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
others	NOUN	O	O
had	VERB	O	O
a	DET	O	O
mixed	ADJ	O	O
(	PUNCT	O	O
cholestatic	ADJ	O	I-Entity
and	CCONJ	O	O
cytolytic	ADJ	O	O
)	PUNCT	O	O
hepatitis	NOUN	O	I-Entity
following	VERB	O	O
carbimazole	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
of	ADP	O	O
the	DET	O	O
latter	ADJ	O	O
two	NUM	O	O
patients	NOUN	O	O
further	ADV	O	O
experienced	VERB	O	O
a	DET	O	O
cytolytic	NOUN	O	O
hepatitis	NOUN	O	I-Entity
which	ADJ	O	O
appeared	VERB	O	O
after	ADP	O	O
Benzylthiouracil	PROPN	O	I-Entity
(	PUNCT	O	O
Basd	PROPN	O	B-Entity
ne	INTJ	O	I-Entity
)	PUNCT	O	O
had	VERB	O	O
replaced	VERB	O	O
carbimazole	NOUN	O	I-Entity
.	PUNCT	O	O

Biological	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
disappeared	VERB	O	O
in	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
after	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
incriminated	VERB	O	O
drug	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
biliary	ADJ	O	O
,	PUNCT	O	O
viral	ADJ	O	O
and	CCONJ	O	O
immunological	ADJ	O	O
searches	NOUN	O	O
were	VERB	O	O
negative	ADJ	O	O
.	PUNCT	O	O

Only	ADV	O	O
2	NUM	O	O
patients	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
mild	ADJ	O	O
or	CCONJ	O	O
severe	ADJ	O	O
neutropenia	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Toxic	PROPN	O	B-Entity
hepatitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
antithyroid	ADJ	O	O
drugs	NOUN	O	O
which	ADJ	O	O
warrants	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
for	ADP	O	O
haematological	ADJ	O	O
disturbances	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
pre	NOUN	O	O
-	PUNCT	O	O
therapeutic	ADJ	O	O
determination	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
careful	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
relevant	ADJ	O	O
biological	ADJ	O	O
markers	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
hepatotoxicity	NOUN	O	I-Entity
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
restricted	VERB	O	O
to	ADP	O	O
one	NUM	O	O
class	NOUN	O	O
of	ADP	O	O
antithyroid	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7628595)

Study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
B12	PROPN	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
supplementation	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
hematologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
zidovudine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
B12	PROPN	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
supplementation	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
zidovudine	NOUN	O	I-Entity
(	PUNCT	O	O
ZDV)-induced	ADJ	O	I-Entity
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
suppression	NOUN	O	I-Entity
.	PUNCT	O	O

Seventy	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
HIV)-infected	VERB	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
CD4	PROPN	O	O
+	CCONJ	O	O
cell	NOUN	O	O
counts	VERB	O	O

<	X	O	O
500/mm3	NUM	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
either	CCONJ	O	O
ZDV	PROPN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
daily	ADJ	O	O
)	PUNCT	O	O
alone	ADJ	O	O
(	PUNCT	O	O
group	NOUN	O	O
I	PRON	O	O
,	PUNCT	O	O
n	VERB	O	O
=	SYM	O	O
38	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mg	NUM	O	O
daily	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
intramascular	ADJ	O	O
vitamin	NOUN	O	B-Entity
B12	PROPN	O	I-Entity
(	PUNCT	O	O
1000	NUM	O	O
micrograms	NOUN	O	O
monthly	ADJ	O	O
)	PUNCT	O	O
(	PUNCT	O	O
group	NOUN	O	O
II	PROPN	O	O
,	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
37	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
15	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
excluded	VERB	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
noncompliance	NOUN	O	O
14	NUM	O	O
,	PUNCT	O	O
death	NOUN	O	I-Entity
1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
thus	ADV	O	O
,	PUNCT	O	O
60	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
31	NUM	O	O
in	ADP	O	O
group	NOUN	O	O
I	PRON	O	O
and	CCONJ	O	O
29	NUM	O	O
in	ADP	O	O
group	NOUN	O	O
II	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
eligible	ADJ	O	O
for	ADP	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
vitamin	NOUN	O	B-Entity
B12	PROPN	O	I-Entity
and	CCONJ	O	O
folate	ADJ	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
patients	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
hemoglobin	NOUN	O	O
,	PUNCT	O	O
hematocrit	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
corpuscular	ADJ	O	O
volume	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
white	ADJ	O	O
-	PUNCT	O	O
cell	NOUN	O	O
,	PUNCT	O	O
neutrophil	NOUN	O	O
and	CCONJ	O	O
platelet	NOUN	O	O
counts	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
groups	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
hematologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
neutrophil	ADJ	O	O
count	NOUN	O	O
<	X	O	O
1000/mm3	NUM	O	O
and/or	CCONJ	O	O
hemoglobin	NOUN	O	O
<	X	O	O
8	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
4	NUM	O	O
patients	NOUN	O	O
assigned	VERB	O	O
to	ADP	O	O
group	NOUN	O	O
I	PRON	O	O
and	CCONJ	O	O
7	NUM	O	O
assigned	VERB	O	O
to	ADP	O	O
group	NOUN	O	O
II	PROPN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
vitamin	NOUN	O	B-Entity
B12	PROPN	O	I-Entity
or	CCONJ	O	O
folate	ADJ	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
development	NOUN	O	O
of	ADP	O	O
myelosuppression	NOUN	O	I-Entity
.	PUNCT	O	O

Vitamin	NOUN	O	B-Entity
B12	PROPN	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
supplementation	NOUN	O	O
of	ADP	O	O
ZDV	PROPN	O	I-Entity
therapy	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
seem	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
or	CCONJ	O	O
reducing	VERB	O	O
ZDV	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myelotoxicity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
treated	VERB	O	O
population	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
certain	ADJ	O	O
subgroups	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (7858459)

Acute	PROPN	O	O
confusion	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
61-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
combination	NOUN	O	O
chemotherapy	NOUN	O	O
incorporating	VERB	O	O
cisplatinum	NOUN	O	I-Entity
,	PUNCT	O	O
etoposide	ADV	O	I-Entity
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
2,250	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2/24	PROPN	O	O
hours	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
for	ADP	O	O
an	DET	O	O
inoperable	ADJ	O	O
gastric	NOUN	O	B-Entity
adenocarcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
developed	VERB	O	O
acute	ADJ	O	O
neurologic	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
disorientation	NOUN	O	I-Entity
and	CCONJ	O	O
irritability	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
lapsed	VERB	O	O
into	ADP	O	O
a	DET	O	O
deep	ADJ	O	O
coma	NOUN	O	I-Entity
,	PUNCT	O	O
lasting	VERB	O	O
for	ADP	O	O
approximately	ADV	O	O
40	NUM	O	O
hours	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
complication	NOUN	O	O
reappeared	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
25	NUM	O	O
during	ADP	O	O
the	DET	O	O
second	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
and	CCONJ	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
then	ADV	O	O
the	DET	O	O
only	ADJ	O	O
drugs	NOUN	O	O
given	VERB	O	O
.	PUNCT	O	O

Because	ADP	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
unlikely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
this	DET	O	O
condition	NOUN	O	O
,	PUNCT	O	O
neurotoxicity	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-fluorouracil	NOUN	O	I-Entity
was	VERB	O	O
highly	ADV	O	O
suspected	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
5-fluorouracil	NUM	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
Krebs	PROPN	O	O
cycle	NOUN	O	O
blockade	NOUN	O	O
by	ADP	O	O
fluoroacetate	NOUN	O	I-Entity
and	CCONJ	O	O
fluorocitrate	NOUN	O	I-Entity
,	PUNCT	O	O
thiamine	ADJ	O	I-Entity
deficiency	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
dihydrouracil	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
deficiency	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-fluorouracil	PROPN	O	I-Entity
/	SYM	O	O
folinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
infusion	NOUN	O	O
therapy	NOUN	O	O
has	VERB	O	O
recently	ADV	O	O
become	VERB	O	O
a	DET	O	O
popular	ADJ	O	O
regimen	NOUN	O	O
for	ADP	O	O
various	ADJ	O	O
cancers	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7862923)

Effect	NOUN	O	O
of	ADP	O	O
switching	VERB	O	O
carbamazepine	NOUN	O	I-Entity
to	ADP	O	O
oxcarbazepine	VERB	O	I-Entity
on	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
neuroleptics	NOUN	O	O
.	PUNCT	O	O

Carbamazepine	NOUN	O	I-Entity
was	VERB	O	O
switched	VERB	O	O
to	ADP	O	O
its	ADJ	O	O
10-keto	NUM	O	O
analogue	NOUN	O	O
oxcarbazepine	NOUN	O	I-Entity
among	ADP	O	O
six	NUM	O	O
difficult	ADJ	O	O
-	PUNCT	O	O
to	PART	O	O
-	PUNCT	O	O
treat	VERB	O	O
schizophrenic	ADJ	O	I-Entity
or	CCONJ	O	O
organic	ADJ	O	B-Entity
psychotic	ADJ	O	I-Entity
patients	NOUN	O	O
using	VERB	O	O
concomitantly	ADV	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
chlorpromazine	NOUN	O	I-Entity
or	CCONJ	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
change	NOUN	O	O
resulted	VERB	O	O
within	ADP	O	O
2	NUM	O	O
-	SYM	O	O
4	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
50	NUM	O	O
-	PUNCT	O	O
200%	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
these	DET	O	O
neuroleptics	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
extrapyramidal	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
case	NOUN	O	O
report	VERB	O	O
support	NOUN	O	O
the	DET	O	O
idea	NOUN	O	O
that	ADP	O	O
in	ADP	O	O
contrast	NOUN	O	O
with	ADP	O	O
carbamazepine	NOUN	O	I-Entity
oxcarbazepine	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
the	DET	O	O
hepatic	ADJ	O	O
microsomal	ADJ	O	O
enzyme	NOUN	O	O
systems	NOUN	O	O
regulating	VERB	O	O
the	DET	O	O
inactivation	NOUN	O	O
of	ADP	O	O
antipsychotic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7919560)

Erythema	PROPN	O	B-Entity
multiforme	NOUN	O	I-Entity
and	CCONJ	O	O
hypersensitivity	NOUN	O	B-Entity
myocarditis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
ampicillin	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
erythema	NOUN	O	B-Entity
multiforme	NOUN	O	I-Entity
and	CCONJ	O	O
hypersensitivity	NOUN	O	B-Entity
myocarditis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
ampicillin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
13-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
ampicillin	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
because	ADP	O	O
of	ADP	O	O
suspected	VERB	O	O
septicemia	NOUN	O	I-Entity
.	PUNCT	O	O

Medications	NOUN	O	O
were	VERB	O	O
discontinued	VERB	O	O
when	ADV	O	O
erythema	NOUN	O	B-Entity
multiforme	NOUN	O	I-Entity
and	CCONJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
myocarditis	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
and	CCONJ	O	O
gradually	ADV	O	O
improved	VERB	O	O
.	PUNCT	O	O

Macrophage	NOUN	O	O
-	PUNCT	O	O
migration	NOUN	O	O
inhibition	NOUN	O	O
(	PUNCT	O	O
MIF	PROPN	O	O
)	PUNCT	O	O
test	NOUN	O	O
with	ADP	O	O
ampicillin	NOUN	O	I-Entity
was	VERB	O	O
positive	ADJ	O	O
.	PUNCT	O	O

After	ADP	O	O
most	ADJ	O	O
infections	NOUN	O	I-Entity
causing	VERB	O	O
erythema	NOUN	O	B-Entity
multiforme	NOUN	O	I-Entity
and	CCONJ	O	O
myocarditis	NOUN	O	I-Entity
were	VERB	O	O
ruled	VERB	O	O
out	PART	O	O
,	PUNCT	O	O
a	DET	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
allergic	ADJ	O	I-Entity
reaction	NOUN	O	I-Entity
was	VERB	O	O
suspected	VERB	O	O
.	PUNCT	O	O

Positive	ADJ	O	O
MIF	PROPN	O	O
test	NOUN	O	O
for	ADP	O	O
ampicillin	NOUN	O	I-Entity
showed	VERB	O	O
sensitization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
lymphocytes	NOUN	O	O
to	ADP	O	O
ampicillin	NOUN	O	I-Entity
.	PUNCT	O	O

Hypersensitivity	PROPN	O	B-Entity
myocarditis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
and	CCONJ	O	O
dangerous	ADJ	O	O
manifestation	NOUN	O	O
of	ADP	O	O
allergy	NOUN	O	I-Entity
to	ADP	O	O
penicillins	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8092427)

Immediate	ADJ	O	O
allergic	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
to	ADP	O	O
amoxicillin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
large	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
allergic	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
to	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lactam	NOUN	O	I-Entity
antibiotics	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
detailed	ADJ	O	O
clinical	ADJ	O	O
history	NOUN	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
skin	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
RAST	PROPN	O	O
(	PUNCT	O	O
radioallergosorbent	ADJ	O	O
test	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
controlled	VERB	O	O
challenge	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
establish	VERB	O	O
whether	ADP	O	O
patients	NOUN	O	O
allergic	ADJ	O	I-Entity
to	ADP	O	O
beta	VERB	O	B-Entity
-	PUNCT	O	I-Entity
lactam	NOUN	O	I-Entity
antibiotics	NOUN	O	O
had	VERB	O	O
selective	ADJ	O	O
immediate	ADJ	O	O
allergic	ADJ	O	I-Entity
responses	NOUN	O	O
to	PART	O	O
amoxicillin	VERB	O	I-Entity
(	PUNCT	O	O
AX	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
were	VERB	O	O
cross	NOUN	O	O
-	PUNCT	O	O
reacting	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
penicillin	NOUN	O	I-Entity
derivatives	NOUN	O	O
.	PUNCT	O	O

Skin	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
benzylpenicilloyl	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
poly	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
lysine	NOUN	O	I-Entity
(	PUNCT	O	O
BPO	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
PLL	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
benzylpenicilloate	NOUN	O	I-Entity
,	PUNCT	O	O
benzylpenicillin	NOUN	O	I-Entity

(	PUNCT	O	O
PG	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
ampicillin	NOUN	O	I-Entity
(	PUNCT	O	O
AMP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
AX	PROPN	O	I-Entity
.	PUNCT	O	O

RAST	NOUN	O	O
for	ADP	O	O
BPO	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
PLL	PROPN	O	I-Entity
and	CCONJ	O	O
AX	PROPN	O	I-Entity
-	PUNCT	O	O
PLL	PROPN	O	O
was	VERB	O	O
done	VERB	O	O
.	PUNCT	O	O

When	ADV	O	O
both	DET	O	O
skin	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
RAST	PROPN	O	O
for	ADP	O	O
BPO	PROPN	O	I-Entity
were	VERB	O	O
negative	ADJ	O	O
,	PUNCT	O	O
single	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
challenge	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
done	VERB	O	O
to	PART	O	O
ensure	VERB	O	O
tolerance	NOUN	O	O
of	ADP	O	O
PG	PROPN	O	I-Entity
or	CCONJ	O	O
sensitivity	NOUN	O	O
to	PART	O	O
AX	PROPN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
177	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
diagnosed	VERB	O	O
as	ADP	O	O
allergic	ADJ	O	I-Entity
to	ADP	O	O
beta	VERB	O	B-Entity
-	PUNCT	O	I-Entity
lactam	NOUN	O	I-Entity
antibiotics	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
selected	VERB	O	O
the	DET	O	O
54	NUM	O	O
(	PUNCT	O	O
30.5%	NUM	O	O
)	PUNCT	O	O
cases	NOUN	O	O
of	ADP	O	O
immediate	ADJ	O	O
AX	PROPN	O	I-Entity
allergy	NOUN	O	I-Entity
with	ADP	O	O
good	ADJ	O	O
tolerance	NOUN	O	O
of	ADP	O	O
PG	PROPN	O	I-Entity
.	PUNCT	O	O

Anaphylaxis	PROPN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
69%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
other	ADJ	O	O
17	NUM	O	O
(	PUNCT	O	O
31%	NUM	O	O
)	PUNCT	O	O
having	VERB	O	O
urticaria	NOUN	O	I-Entity
and/or	CCONJ	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

All	ADJ	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
skin	ADJ	O	O
test	NOUN	O	O
negative	ADJ	O	O
to	ADP	O	O
BPO	PROPN	O	I-Entity
;	PUNCT	O	O
49	NUM	O	O
of	ADP	O	O
51	NUM	O	O
(	PUNCT	O	O
96%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
negative	ADJ	O	O
to	ADP	O	O
MDM	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
44	NUM	O	O
of	ADP	O	O
46	NUM	O	O
(	PUNCT	O	O
96%	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
PG	PROPN	O	I-Entity
.	PUNCT	O	O

Skin	NOUN	O	O
tests	NOUN	O	O
with	ADP	O	O
AX	PROPN	O	I-Entity
were	VERB	O	O
positive	ADJ	O	O
in	ADP	O	O
34	NUM	O	O
(	PUNCT	O	O
63%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

RAST	NOUN	O	O
was	VERB	O	O
positive	ADJ	O	O
for	ADP	O	O
AX	PROPN	O	I-Entity
in	ADP	O	O
22	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
41%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
BPO	PROPN	O	I-Entity
in	ADP	O	O
just	ADV	O	O
5	NUM	O	O
(	PUNCT	O	O
9%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sera	NOUN	O	O
with	ADP	O	O
negative	ADJ	O	O
RAST	PROPN	O	O
for	ADP	O	O
AX	PROPN	O	I-Entity
were	VERB	O	O
positive	ADJ	O	O
to	ADP	O	O
BPO	PROPN	O	I-Entity
.	PUNCT	O	O

Challenge	PROPN	O	O
tests	NOUN	O	O
with	ADP	O	O
AX	NOUN	O	I-Entity
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
23	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
43%	NUM	O	O
)	PUNCT	O	O
to	PART	O	O
establish	VERB	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
immediate	ADJ	O	O
allergic	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
to	ADP	O	O
AX	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
15	NUM	O	O
cases	NOUN	O	O
(	PUNCT	O	O
28%	NUM	O	O
)	PUNCT	O	O
both	DET	O	O
skin	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
RAST	PROPN	O	O
for	ADP	O	O
AX	PROPN	O	I-Entity
were	VERB	O	O
negative	ADJ	O	O
.	PUNCT	O	O

PG	NOUN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
by	ADP	O	O
all	DET	O	O
54	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
largest	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
AX	PROPN	O	I-Entity
-	PUNCT	O	O
allergic	ADJ	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
tolerated	VERB	O	O
PG	PROPN	O	I-Entity
reported	VERB	O	O
so	ADV	O	O
far	ADV	O	O
.	PUNCT	O	O

Diagnosis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
only	ADV	O	O
if	ADP	O	O
specific	ADJ	O	O
AX	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
reagents	NOUN	O	O
are	VERB	O	O
employed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8638206)

Persistent	ADJ	O	O
paralysis	NOUN	O	I-Entity
after	ADP	O	O
prolonged	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
atracurium	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
corticosteroids	NOUN	O	O
.	PUNCT	O	O

Reports	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
paralysis	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
discontinuance	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
have	VERB	O	O
most	ADV	O	O
often	ADV	O	O
involved	VERB	O	O
aminosteroid	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
NMBAs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
vecuronium	NOUN	O	B-Entity
bromide	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
when	ADV	O	O
used	VERB	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
corticosteroids	NOUN	O	O
.	PUNCT	O	O

Atracurium	NOUN	O	B-Entity
besylate	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
benzylisoquinolinium	NOUN	O	I-Entity
NMBA	PROPN	O	O
that	ADJ	O	O
is	VERB	O	O
eliminated	VERB	O	O
independently	ADV	O	O
of	ADP	O	O
renal	NOUN	O	O
or	CCONJ	O	O
hepatic	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
also	ADV	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
persistent	ADJ	O	O
paralysis	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
when	ADV	O	O
used	VERB	O	O
with	ADP	O	O
corticosteroids	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
atracurium	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
paralysis	NOUN	O	I-Entity
persisting	VERB	O	O
for	ADP	O	O
approximately	ADV	O	O
50	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
corticosteroids	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8669433)

Habitual	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
comparison	NOUN	O	O
with	ADP	O	O
phenacetin	NOUN	O	I-Entity
.	PUNCT	O	O

Six	NUM	O	O
epidemiologic	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
and	CCONJ	O	O
Europe	PROPN	O	O
indicate	VERB	O	O
that	ADP	O	O
habitual	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
phenacetin	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
end	VERB	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
ESRD	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
in	ADP	O	O
the	DET	O	O
range	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
to	PART	O	O
19	NUM	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
these	DET	O	O
and	CCONJ	O	O
other	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
phenacetin	NOUN	O	I-Entity
has	VERB	O	O
now	ADV	O	O
been	VERB	O	O
withdrawn	VERB	O	O
from	ADP	O	O
the	DET	O	O
market	NOUN	O	O
in	ADP	O	O
most	ADJ	O	O
countries	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
three	NUM	O	O
case	NOUN	O	O
control	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
each	DET	O	O
in	ADP	O	O
North	PROPN	O	O
Carolina	PROPN	O	O
,	PUNCT	O	O
northern	ADJ	O	O
Maryland	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
West	PROPN	O	O
Berlin	PROPN	O	O
,	PUNCT	O	O
Germany	PROPN	O	O
,	PUNCT	O	O
showed	VERB	O	O
that	ADP	O	O
habitual	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
is	VERB	O	O
also	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
ESRD	PROPN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
in	ADP	O	O
the	DET	O	O
range	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
to	ADP	O	O
4	NUM	O	O
.	PUNCT	O	O

These	DET	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
both	DET	O	O
phenacetin	NOUN	O	I-Entity
and	CCONJ	O	O
acetaminophen	NOUN	O	I-Entity
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
burden	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
the	DET	O	O
latter	ADJ	O	O
being	VERB	O	O
somewhat	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
former	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
apparent	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
risk	NOUN	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
nephrotoxic	ADJ	O	I-Entity
potential	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
themselves	PRON	O	O
.	PUNCT	O	O

A	DET	O	O
lower	ADJ	O	O
relative	ADJ	O	O
risk	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
expected	VERB	O	O
for	ADP	O	O
acetaminophen	NOUN	O	I-Entity
if	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
analgesics	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
either	DET	O	O
agent	NOUN	O	O
alone	ADV	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
both	DET	O	O
as	ADP	O	O
a	DET	O	O
single	ADJ	O	O
agent	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
analgesics	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
phenacetin	NOUN	O	I-Entity
was	VERB	O	O
available	ADJ	O	O
only	ADV	O	O
in	ADP	O	O
combinations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
habitual	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
alone	ADJ	O	O
increases	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
clearly	ADV	O	O
demonstrated	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
dismissed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8690168)

Reduction	NOUN	O	O
of	ADP	O	O
heparan	NOUN	O	B-Entity
sulphate	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
anionic	NOUN	O	O
sites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Heparan	PROPN	O	B-Entity
sulphate	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
anionic	NOUN	O	O
sites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
8	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	I-Entity
by	ADP	O	O
streptozotocin	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
age-	DET	O	O
adn	ADJ	O	O
sex	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
control	NOUN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
employing	VERB	O	O
the	DET	O	O
cationic	ADJ	O	O
dye	NOUN	O	O
cuprolinic	ADJ	O	B-Entity
blue	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
heparan	NOUN	O	B-Entity
sulphate	ADJ	O	I-Entity
specificity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cuprolinic	ADJ	O	B-Entity
blue	ADJ	O	I-Entity
staining	NOUN	O	O
was	VERB	O	O
demonstrated	VERB	O	O
by	ADP	O	O
glycosaminoglycan	ADJ	O	I-Entity
-	PUNCT	O	O
degrading	ADJ	O	O
enzymes	NOUN	O	O
,	PUNCT	O	O
showing	VERB	O	O
that	ADP	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sections	NOUN	O	O
with	ADP	O	O
heparitinase	NOUN	O	O
abolished	VERB	O	O
all	DET	O	O
staining	VERB	O	O
,	PUNCT	O	O
whereas	ADP	O	O
chondroitinase	NOUN	O	O
ABC	PROPN	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
anionic	ADJ	O	O
sites	NOUN	O	O
(	PUNCT	O	O
74%	NUM	O	O
in	ADP	O	O
diabetic	ADJ	O	I-Entity
and	CCONJ	O	O
81%	NUM	O	O
in	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
within	ADP	O	O
the	DET	O	O
lamina	NOUN	O	O
rara	NOUN	O	O
externa	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
minority	NOUN	O	O
of	ADP	O	O
anionic	NOUN	O	O
sites	NOUN	O	O
were	VERB	O	O
scattered	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
lamina	NOUN	O	O
densa	NOUN	O	O
and	CCONJ	O	O
lamina	NOUN	O	O
rara	NOUN	O	O
interna	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
significantly	ADV	O	O
smaller	ADJ	O	O
than	ADP	O	O
those	DET	O	O
in	ADP	O	O
the	DET	O	O
lamina	NOUN	O	O
rara	NOUN	O	O
externa	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
(	PUNCT	O	O
p<0.001	NOUN	O	O
and	CCONJ	O	O
p<0.01	NOUN	O	O
for	ADP	O	O
diabetic	ADJ	O	I-Entity
and	CCONJ	O	O
control	NOUN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
progressively	ADV	O	O
developed	VERB	O	O
albuminuria	NOUN	O	I-Entity
reaching	VERB	O	O
40.3	NUM	O	O
(	PUNCT	O	O
32.2	NUM	O	O
-	SYM	O	O
62.0	NUM	O	O
)	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
heparan	NOUN	O	B-Entity
sulphate	ADJ	O	I-Entity
anionic	NOUN	O	O
sites	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
total	ADJ	O	O
anionic	ADJ	O	O
site	NOUN	O	O
surface	NOUN	O	O
(	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
anionic	ADJ	O	O
sites	NOUN	O	O
x	SYM	O	O
mean	VERB	O	O
anionic	ADJ	O	O
site	NOUN	O	O
surface	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
lamina	NOUN	O	O
rara	NOUN	O	O
externa	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
19%	NUM	O	O
(	PUNCT	O	O
p<0.021	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
26%	NUM	O	O
(	PUNCT	O	O
p<0.02	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
in	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
urinary	NOUN	O	O
albumin	NOUN	O	O
excretion	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
reduced	VERB	O	O
heparan	NOUN	O	B-Entity
sulphate	NOUN	O	I-Entity
charge	NOUN	O	O
barrier	NOUN	O	O
/	SYM	O	O
density	NOUN	O	O
is	VERB	O	O
found	VERB	O	O
at	ADP	O	O
the	DET	O	O
lamina	NOUN	O	O
rara	NOUN	O	O
externa	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8739323)

Effect	NOUN	O	O
of	ADP	O	O
some	DET	O	O
anticancer	NOUN	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
combined	VERB	O	O
chemotherapy	NOUN	O	O
on	ADP	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
nephrotoxic	ADJ	O	I-Entity
action	NOUN	O	O
of	ADP	O	O
anticancer	NOUN	O	O
drugs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
nitrogranulogen	NOUN	O	I-Entity
(	PUNCT	O	O
NG	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
methotrexate	NOUN	O	I-Entity
(	PUNCT	O	O
MTX	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
5-fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O

CY	PROPN	O	I-Entity
)	PUNCT	O	O
administered	VERB	O	O
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
[	PUNCT	O	O
MTX	PROPN	O	I-Entity
+	PROPN	O	O
5-FU	NUM	O	I-Entity
+	CCONJ	O	O
CY	PROPN	O	I-Entity
(	PUNCT	O	O
CMF	PROPN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
experiments	NOUN	O	O
on	ADP	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
creatinine	ADJ	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
urine	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
MTX	PROPN	O	I-Entity
administration	NOUN	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0228	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
NG	PROPN	O	I-Entity
,	PUNCT	O	O
5-FU	NUM	O	I-Entity
and	CCONJ	O	O
CY	PROPN	O	I-Entity
neither	CCONJ	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
nor	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
group	NOUN	O	O
receiving	VERB	O	O
no	DET	O	O
cytostatics	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
polytherapy	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
CMF	PROPN	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0343	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
increase	VERB	O	O
significantly	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

CY	PROPN	O	I-Entity
caused	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
in	ADP	O	O
40%	NUM	O	O
of	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
this	DET	O	O
complication	NOUN	O	O
when	ADV	O	O
combined	VERB	O	O
with	ADP	O	O
5-FU	NUM	O	I-Entity
and	CCONJ	O	O
MTX	PROPN	O	I-Entity
.	PUNCT	O	O

Histologic	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
rat	NOUN	O	O
kidneys	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
MTX	PROPN	O	I-Entity
,	PUNCT	O	O
CY	PROPN	O	I-Entity
and	CCONJ	O	O
NG	PROPN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
no	DET	O	O
such	ADJ	O	O
change	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
5-FU	NUM	O	I-Entity
and	CCONJ	O	O
joint	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
MTX	PROPN	O	I-Entity
+	SYM	O	O
5-FU	NUM	O	I-Entity

+	CCONJ	O	O
CY	PROPN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
studies	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
of	ADP	O	O
MTX	PROPN	O	I-Entity
+	SYM	O	O
5-FU	NUM	O	I-Entity
+	CCONJ	O	O
CY	PROPN	O	I-Entity
administered	VERB	O	O
jointly	ADV	O	O
is	VERB	O	O
lower	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
monotherapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8752018)

Lithium	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
cognitive	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
functional	ADJ	O	I-Entity
deficits	NOUN	O	I-Entity
reduced	VERB	O	O
by	ADP	O	O
a	DET	O	O
switch	NOUN	O	O
to	ADP	O	O
divalproex	VERB	O	B-Entity
sodium	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
remains	VERB	O	O
a	DET	O	O
first	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
and	CCONJ	O	O
maintenance	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
much	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
written	VERB	O	O
about	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
the	DET	O	O
more	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
polyuria	NOUN	O	I-Entity
and	CCONJ	O	O
tremor	NOUN	O	I-Entity
,	PUNCT	O	O
more	ADV	O	O
subtle	ADJ	O	O
lithium	ADJ	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
,	PUNCT	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
creativity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
functional	ADJ	O	B-Entity
impairments	NOUN	O	I-Entity
remain	VERB	O	O
understudied	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
summarizes	VERB	O	O
our	ADJ	O	O
experience	NOUN	O	O
in	ADP	O	O
switching	VERB	O	O
bipolar	ADJ	O	I-Entity
patients	NOUN	O	O
from	ADP	O	O
lithium	NOUN	O	I-Entity
to	ADP	O	O
divalproex	VERB	O	B-Entity
sodium	NOUN	O	I-Entity
to	PART	O	O
alleviate	VERB	O	O
such	ADJ	O	O
cognitive	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
functional	ADJ	O	I-Entity
impairments	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
seven	NUM	O	O
cases	NOUN	O	O
where	ADV	O	O
substitution	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
,	PUNCT	O	O
either	CCONJ	O	O
fully	ADV	O	O
or	CCONJ	O	O
partially	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
divalproex	NOUN	O	B-Entity
sodium	NOUN	O	I-Entity
was	VERB	O	O
extremely	ADV	O	O
helpful	ADJ	O	O
in	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
cognitive	ADJ	O	B-Entity
,	PUNCT	O	I-Entity
motivational	ADJ	O	I-Entity
,	PUNCT	O	I-Entity
or	CCONJ	O	I-Entity
creative	ADJ	O	I-Entity
deficits	NOUN	O	I-Entity
attributed	VERB	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
bipolar	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
preliminary	ADJ	O	O
report	NOUN	O	O
,	PUNCT	O	O
divalproex	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
was	VERB	O	O
a	DET	O	O
superior	ADJ	O	O
alternative	NOUN	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
in	ADP	O	O
bipolar	ADJ	O	I-Entity
patients	NOUN	O	O
experiencing	VERB	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
,	PUNCT	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
creativity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
functional	ADJ	O	B-Entity
impairments	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9390208)

Treatment	NOUN	O	O
of	ADP	O	O
previously	ADV	O	O
treated	VERB	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
by	ADP	O	O
mitoxantrone	NOUN	O	I-Entity
and	CCONJ	O	O
48-hour	NUM	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-FU	NUM	O	I-Entity
and	CCONJ	O	O
leucovorin	NOUN	O	I-Entity
(	PUNCT	O	O
MFL	PROPN	O	I-Entity
)	PUNCT	O	O
:	PUNCT	O	O
low	ADJ	O	O
palliative	ADJ	O	O
benefit	NOUN	O	O
and	CCONJ	O	O
high	ADJ	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
previously	ADV	O	O
treated	VERB	O	O
advanced	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
standard	ADJ	O	O
second	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
mitoxantrone	NOUN	O	I-Entity
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
5-fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
leucovorin	NOUN	O	I-Entity
(	PUNCT	O	O
MFL	PROPN	O	B-Entity
regimen	NOUN	O	I-Entity
)	PUNCT	O	O
had	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
tolerated	VERB	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
October	PROPN	O	O
1993	NUM	O	O
to	ADP	O	O
November	PROPN	O	O
1995	NUM	O	O
,	PUNCT	O	O
we	PRON	O	O
treated	VERB	O	O
13	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
previously	ADV	O	O
chemotherapy	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
by	ADP	O	O
mitoxantrone	NOUN	O	I-Entity
,	PUNCT	O	O
12	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
5-FU	NUM	O	I-Entity
,	PUNCT	O	O
3000	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
leucovorin	NOUN	O	I-Entity
,	PUNCT	O	O
300	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
from	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
to	ADP	O	O
2	NUM	O	O
.	PUNCT	O	O

Seven	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
anthracycline	NOUN	O	I-Entity
.	PUNCT	O	O

Median	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
courses	NOUN	O	O
of	ADP	O	O
MFL	PROPN	O	B-Entity
regimen	NOUN	O	I-Entity
given	VERB	O	O
was	VERB	O	O
six	NUM	O	O
and	CCONJ	O	O
the	DET	O	O
median	ADJ	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
mitoxantrone	NOUN	O	I-Entity
was	VERB	O	O
68.35	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
.	PUNCT	O	O

Major	ADJ	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
leukopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Eight	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
dead	ADJ	O	O
in	ADP	O	O
the	DET	O	O
last	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
;	PUNCT	O	O
two	NUM	O	O
of	ADP	O	O
them	PRON	O	O
died	VERB	O	O
of	ADP	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
MFL	PROPN	O	B-Entity
regimen	NOUN	O	I-Entity
achieves	VERB	O	O
little	ADJ	O	O
palliative	ADJ	O	O
benefit	NOUN	O	O
and	CCONJ	O	O
induces	VERB	O	O
severe	ADJ	O	O
toxicity	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
fairly	ADV	O	O
high	ADJ	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
this	DET	O	O
regimen	NOUN	O	O
to	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
those	DET	O	O
with	ADP	O	O
impaired	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
function	NOUN	O	I-Entity
requires	VERB	O	O
careful	ADJ	O	O
attention	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9406968)

Upregulation	PROPN	O	O
of	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
vasopressin	NOUN	O	I-Entity
gene	NOUN	O	O
in	ADP	O	O
the	DET	O	O
paraventricular	NOUN	O	O
and	CCONJ	O	O
supraoptic	ADJ	O	O
nuclei	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
insipidus	ADJ	O	I-Entity
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
arginine	NOUN	O	B-Entity
vasopressin	NOUN	O	I-Entity
(	PUNCT	O	O
AVP	PROPN	O	I-Entity
)	PUNCT	O	O
gene	NOUN	O	O
in	ADP	O	O
the	DET	O	O
paraventricular	NOUN	O	O
(	PUNCT	O	O
PVN	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
supraoptic	ADJ	O	O
nuclei	NOUN	O	O
(	PUNCT	O	O
SON	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
(	PUNCT	O	O
Li)-induced	PROPN	O	I-Entity
polyuria	NOUN	O	I-Entity
,	PUNCT	O	O
using	VERB	O	O
in	ADP	O	O
situ	NOUN	O	O
hybridization	NOUN	O	O
histochemistry	NOUN	O	O
and	CCONJ	O	O
radioimmunoassay	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
male	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
consuming	VERB	O	O
a	DET	O	O
diet	NOUN	O	O
that	ADJ	O	O
contained	VERB	O	O
LiCl	PROPN	O	I-Entity
(	PUNCT	O	O
60	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
developed	VERB	O	O
marked	VERB	O	O
polyuria	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Li	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
large	ADJ	O	O
volume	NOUN	O	O
of	ADP	O	O
hypotonic	ADJ	O	O
urine	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
ionic	ADJ	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

Plasma	ADJ	O	O
sodium	NOUN	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
slightly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
Li	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
in	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
concentration	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	I-Entity
and	CCONJ	O	O
transcripts	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	I-Entity
gene	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PVN	PROPN	O	O
and	CCONJ	O	O
SON	PROPN	O	O
were	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
Li	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
dehydration	NOUN	O	I-Entity
and/or	CCONJ	O	O
the	DET	O	O
activation	NOUN	O	O
of	ADP	O	O
visceral	ADJ	O	O
afferent	NOUN	O	O
inputs	NOUN	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
elevation	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
AVP	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
upregulation	NOUN	O	O
of	ADP	O	O
AVP	PROPN	O	I-Entity
gene	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PVN	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
SON	PROPN	O	O
of	ADP	O	O
the	DET	O	O
Li	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
insipidus	ADJ	O	I-Entity
rat	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9587734)

Suxamethonium	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	I-Entity
following	VERB	O	O
5	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
immobilization	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
report	NOUN	O	O
describes	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
and	CCONJ	O	O
subsequent	ADJ	O	O
death	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
hyperkalaemia	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
23-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Malawian	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
meningitis	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
aspirated	VERB	O	O
stomach	NOUN	O	O
contents	NOUN	O	O
and	CCONJ	O	O
needed	VERB	O	O
endotracheal	ADJ	O	O
intubation	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
seconds	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
,	PUNCT	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
to	PART	O	O
be	VERB	O	O
8.4	NUM	O	O
mequiv	NOUN	O	O

Apart	ADV	O	O
from	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
level	NOUN	O	O
of	ADP	O	O
consciousness	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
neurone	NOUN	O	O
damage	NOUN	O	O
or	CCONJ	O	O
of	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
known	VERB	O	O
predisposing	NOUN	O	O
conditions	NOUN	O	O
for	ADP	O	O
hyperkalaemia	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
postulated	VERB	O	O
that	ADP	O	O
her	ADJ	O	O
death	NOUN	O	I-Entity
was	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
hypersensitivity	NOUN	O	I-Entity
to	ADP	O	O
suxamethonium	NOUN	O	I-Entity
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
her	PRON	O	O
5-day	PROPN	O	O
immobilization	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9698967)

An	DET	O	O
unusual	ADJ	O	O
toxic	ADJ	O	O
reaction	NOUN	O	O
to	ADP	O	O
axillary	ADJ	O	O
block	NOUN	O	O
by	ADP	O	O
mepivacaine	NOUN	O	I-Entity
with	ADP	O	O
adrenaline	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
,	PUNCT	O	O
accompanied	VERB	O	O
by	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
,	PUNCT	O	O
agitation	NOUN	O	I-Entity
,	PUNCT	O	O
incomprehensible	ADJ	O	B-Entity
shouts	NOUN	O	I-Entity
and	CCONJ	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
consciousness	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
an	DET	O	O
elderly	ADJ	O	O
,	PUNCT	O	O
ASA	PROPN	O	O
classification	NOUN	O	O
group	NOUN	O	O
II	PROPN	O	O
,	PUNCT	O	O
cardiovascularly	ADV	O	O
medicated	VERB	O	O
male	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
performance	NOUN	O	O
of	ADP	O	O
axillary	ADJ	O	O
block	NOUN	O	O
with	ADP	O	O
mepivacaine	NOUN	O	I-Entity
850	NUM	O	O
mg	NUM	O	O
containing	VERB	O	O
adrenaline	NOUN	O	I-Entity
0.225	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
for	ADP	O	O
correction	NOUN	O	O
of	ADP	O	O
Dupuytren	PROPN	O	B-Entity
's	PART	O	I-Entity
contracture	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
labetalol	NOUN	O	I-Entity
,	PUNCT	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
midazolam	NOUN	O	I-Entity
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
condition	NOUN	O	O
improved	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
min	NOUN	O	O
later	ADV	O	O
he	PRON	O	O
woke	VERB	O	O
up	PART	O	O
.	PUNCT	O	O

The	DET	O	O
block	NOUN	O	O
was	VERB	O	O
successful	ADJ	O	O
and	CCONJ	O	O
surgery	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
as	ADP	O	O
scheduled	VERB	O	O
despite	ADP	O	O
persisting	VERB	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
temporal	ADJ	O	O
relationship	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
response	NOUN	O	O
to	PART	O	O
treatment	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
rapid	ADJ	O	O
systemic	ADJ	O	O
absorption	NOUN	O	O
of	ADP	O	O
mepivacaine	NOUN	O	I-Entity
with	ADP	O	O
adrenaline	NOUN	O	I-Entity
and/or	CCONJ	O	O
interaction	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
with	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
cardiovascular	NOUN	O	O
medications	NOUN	O	O
were	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
perioperative	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9855119)

Clinical	ADJ	O	O
and	CCONJ	O	O
histopathologic	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
renal	NOUN	O	O
allografts	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
tacrolimus	NOUN	O	I-Entity
(	PUNCT	O	O
FK506	PROPN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
one	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
clinically	ADV	O	O
and	CCONJ	O	O
pathologically	ADV	O	O
analyzed	VERB	O	O
renal	ADJ	O	O
allografts	NOUN	O	O
from	ADP	O	O
1	NUM	O	O
9	NUM	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
tacrolimus	NOUN	O	I-Entity
(	PUNCT	O	O
FK506	PROPN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
pathologic	ADJ	O	O
diagnoses	NOUN	O	O
(	PUNCT	O	O
some	DET	O	O
overlap	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
acute	ADJ	O	O
rejection	NOUN	O	O
(	PUNCT	O	O
AR	PROPN	O	O
;	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
chronic	ADJ	O	O
rejection	NOUN	O	O
(	PUNCT	O	O
CR	PROPN	O	O
;	PUNCT	O	O
n=5	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
AR+CR	PROPN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
recurrent	ADJ	O	O
IgA	PROPN	O	B-Entity
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
normal	ADJ	O	O
findings	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
minimal	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
chronic	ADJ	O	O
FK506	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
FK506	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
11	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
nonepisode	NOUN	O	O
biopsies	NOUN	O	O
,	PUNCT	O	O
7	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
biopsies	NOUN	O	O
showed	VERB	O	O
minimal	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
and	CCONJ	O	O
mild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
chronic	ADJ	O	O
FK506	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
FK506	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
consisted	VERB	O	O
of	ADP	O	O
rough	ADJ	O	O
and	CCONJ	O	O
foamy	ADJ	O	O
tubular	ADJ	O	O
vacuolization	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
biopsies	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
arteriolopathy	NOUN	O	O
(	PUNCT	O	O
angiodegeneration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arteriolar	ADJ	O	O
wall	NOUN	O	O
;	PUNCT	O	O
20	NUM	O	O
biopsies	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
focal	ADJ	O	B-Entity
segmental	ADJ	O	I-Entity
glomerulosclerosis	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
biopsies	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
striped	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
interstitial	ADJ	O	B-Entity
fibrosis	NOUN	O	I-Entity
(	PUNCT	O	O
11	NUM	O	O
biopsies	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
chronic	ADJ	O	O
FK506	NOUN	O	I-Entity
nephropathy	ADJ	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
included	VERB	O	O
7	NUM	O	O
episode	NOUN	O	O
biopsies	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
statistically	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
those	DET	O	O
in	ADP	O	O
the	DET	O	O
minimum	NOUN	O	O
-	PUNCT	O	O
type	NOUN	O	O
chronic	ADJ	O	O
FK506-nephropathy	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O

This	DET	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
chronic	ADJ	O	O
FK506	NUM	O	I-Entity
nephropathy	NOUN	O	I-Entity
consists	VERB	O	O
primarily	ADV	O	O
of	ADP	O	O
arteriolopathy	ADJ	O	O
manifesting	NOUN	O	O
as	ADP	O	O
insudative	ADJ	O	O
hyalinosis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arteriolar	ADJ	O	O
wall	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
suggests	VERB	O	O
that	ADP	O	O
mild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
chronic	ADJ	O	O
FK506	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
condition	NOUN	O	O
which	ADJ	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
deterioration	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
allograft	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9869257)

Memory	NOUN	O	O
facilitation	NOUN	O	O
and	CCONJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
endogenous	ADJ	O	O
nerve	NOUN	O	O
growth	NOUN	O	O
factor	NOUN	O	O
synthesis	NOUN	O	O
by	ADP	O	O
the	DET	O	O
acetylcholine	NOUN	O	I-Entity
releaser	NOUN	O	O
PG-9	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
PG-9	PROPN	O	I-Entity
(	PUNCT	O	O
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
tropyl	NOUN	O	I-Entity
2-(p	NUM	O	I-Entity
-	PUNCT	O	I-Entity
bromophenyl)propionate	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
acetylcholine	NOUN	O	I-Entity
releaser	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
memory	NOUN	O	O
processes	NOUN	O	O
and	CCONJ	O	O
nerve	NOUN	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
NGF	PROPN	O	O
)	PUNCT	O	O
synthesis	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
mouse	NOUN	O	O
passive	ADJ	O	O
-	PUNCT	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
PG-9	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
20	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
training	NOUN	O	O
session	NOUN	O	O
,	PUNCT	O	O
prevented	VERB	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
both	DET	O	O
the	DET	O	O
non	ADJ	O	O
selective	ADJ	O	O
antimuscarinic	ADJ	O	O
drug	NOUN	O	O
scopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
M1-selective	ADJ	O	O
antagonist	NOUN	O	O
S-(-)-ET-126	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
same	ADJ	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
PG-9	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
-	SYM	O	O
20	NUM	O	O
microg	NOUN	O	O
per	ADP	O	O
mouse	NOUN	O	O
,	PUNCT	O	O
i.c.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
able	ADJ	O	O
to	PART	O	O
prevent	VERB	O	O
antimuscarine	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
,	PUNCT	O	O
demonstrating	VERB	O	O
a	DET	O	O
central	ADJ	O	O
localization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
effective	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
PG-9	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
any	DET	O	O
collateral	ADJ	O	O
symptoms	NOUN	O	O
as	ADP	O	O
revealed	VERB	O	O
by	ADP	O	O
the	DET	O	O
Irwin	PROPN	O	O
test	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
modify	VERB	O	O
spontaneous	ADJ	O	O
motility	NOUN	O	O
and	CCONJ	O	O
inspection	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
revealed	VERB	O	O
by	ADP	O	O
the	DET	O	O
hole	NOUN	O	O
-	PUNCT	O	O
board	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O
PG-9	PUNCT	O	I-Entity

The	DET	O	O
maximal	ADJ	O	O
NGF	PROPN	O	O
contents	NOUN	O	O
obtained	VERB	O	O
by	ADP	O	O
PG-9	NOUN	O	I-Entity
were	VERB	O	O
17.6-fold	NUM	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
value	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
culture	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
morphological	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
at	ADP	O	O
effective	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
PG-9	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
work	NOUN	O	O
indicates	VERB	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
PG-9	PROPN	O	I-Entity
to	PART	O	O
induce	VERB	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
cognitive	ADJ	O	O
processes	NOUN	O	O
and	CCONJ	O	O
stimulate	VERB	O	O
activity	NOUN	O	O
of	ADP	O	O
NGF	PROPN	O	O
synthesis	NOUN	O	O
in	ADP	O	O
astroglial	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
PG-9	PROPN	O	I-Entity
could	VERB	O	O
represent	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
useful	ADJ	O	O
drug	NOUN	O	O
able	ADJ	O	O
to	PART	O	O
improve	VERB	O	O
the	DET	O	O
function	NOUN	O	O
of	ADP	O	O
impaired	VERB	O	O
cognitive	ADJ	O	O
processes	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10342929)

Angioedema	PROPN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
ACE	PROPN	O	B-Entity
inhibitors	NOUN	O	I-Entity
:	PUNCT	O	O
common	ADJ	O	O
and	CCONJ	O	O
inadequately	ADV	O	O
diagnosed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
estimated	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
angioedema	NOUN	O	I-Entity
during	ADP	O	O
angiotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
ACE	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
inhibitor	NOUN	O	I-Entity
treatment	NOUN	O	O
is	VERB	O	O
between	ADP	O	O
1	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
per	ADP	O	O
thousand	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10457883)

Accumulation	NOUN	O	O
of	ADP	O	O
atracurium	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
intravenous	ADJ	O	O
line	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
recurarization	NOUN	O	O
after	ADP	O	O
flushing	VERB	O	O
the	DET	O	O
line	NOUN	O	O
in	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
room	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
respiratory	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
with	ADP	O	O
severe	ADJ	O	O
desaturation	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

Circumstances	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
this	DET	O	O
event	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
mechanisms	NOUN	O	O
enabling	VERB	O	O
a	DET	O	O
neuromuscular	ADJ	O	B-Entity
blockade	NOUN	O	I-Entity
to	PART	O	O
occur	VERB	O	O
,	PUNCT	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
small	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
relaxant	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (10739826)

Recurrent	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
newer	ADJ	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
epidemiological	ADJ	O	O
studies	NOUN	O	O
that	ADJ	O	O
assessed	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
VTE	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
newer	ADJ	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
(	PUNCT	O	O
OC	PROPN	O	I-Entity
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
distinguish	VERB	O	O
between	ADP	O	O
patterns	NOUN	O	O
of	ADP	O	O
OC	PROPN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
namely	ADV	O	O
first	ADJ	O	O
-	PUNCT	O	O
time	NOUN	O	O
users	NOUN	O	O
,	PUNCT	O	O
repeaters	NOUN	O	O
and	CCONJ	O	O
switchers	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
from	ADP	O	O
a	DET	O	O
Transnational	PROPN	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
for	ADP	O	O
the	DET	O	O
latter	ADJ	O	O
patterns	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
accounting	VERB	O	O
for	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
use	NOUN	O	O
.	PUNCT	O	O

Over	ADP	O	O
the	DET	O	O
period	NOUN	O	O
1993	NUM	O	O
-	SYM	O	O
1996	NUM	O	O
,	PUNCT	O	O
551	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
were	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
Germany	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
UK	PROPN	O	O
along	ADP	O	O
with	ADP	O	O
2066	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
adjusted	ADJ	O	O
rate	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
for	ADP	O	O
repeat	NOUN	O	O
users	NOUN	O	O
of	ADP	O	O
third	ADJ	O	O
generation	NOUN	O	O
OC	PROPN	O	I-Entity
was	VERB	O	O
0.6	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI:0.3	NUM	O	O
-	PUNCT	O	O
1.2	NUM	O	O
)	PUNCT	O	O
relative	ADJ	O	O
to	PART	O	O
repeat	VERB	O	O
users	NOUN	O	O
of	ADP	O	O
second	ADJ	O	O
generation	NOUN	O	O
pills	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
it	PRON	O	O
was	VERB	O	O
1.3	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI:0.7	NUM	O	O
-	PUNCT	O	O
2.4	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
switchers	NOUN	O	O
from	ADP	O	O
second	ADJ	O	O
to	ADP	O	O
third	ADJ	O	O
generation	NOUN	O	O
pills	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
switchers	NOUN	O	O
from	ADP	O	O
third	ADJ	O	O
to	ADP	O	O
second	ADJ	O	O
generation	NOUN	O	O
pills	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
second	ADJ	O	O
and	CCONJ	O	O
third	ADJ	O	O
generation	NOUN	O	O
agents	NOUN	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
equivalent	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
when	ADV	O	O
the	DET	O	O
same	ADJ	O	O
agent	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
repeatedly	ADV	O	O
after	ADP	O	O
interruption	NOUN	O	O
periods	NOUN	O	O
or	CCONJ	O	O
when	ADV	O	O
users	NOUN	O	O
are	VERB	O	O
switched	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
generations	NOUN	O	O
of	ADP	O	O
pills	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
analyses	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
risk	NOUN	O	O
observed	VERB	O	O
for	ADP	O	O
the	DET	O	O
newer	ADJ	O	O
OC	PROPN	O	I-Entity
in	ADP	O	O
other	ADJ	O	O
studies	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
inadequate	ADJ	O	O
comparisons	NOUN	O	O
of	ADP	O	O
pill	NOUN	O	O
users	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
patterns	NOUN	O	O
of	ADP	O	O
pill	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10791295)

Development	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
:	PUNCT	O	O
comparison	NOUN	O	O
of	ADP	O	O
adult	NOUN	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
(	PUNCT	O	O
1.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O

once	ADV	O	O
daily	ADV	O	O
)	PUNCT	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
of	ADP	O	O
adult	NOUN	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
obtained	VERB	O	O
from	ADP	O	O
the	DET	O	O
same	ADJ	O	O
breeder	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
sets	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
male	ADJ	O	O
animals	NOUN	O	O
,	PUNCT	O	O
repeated	VERB	O	O
apomorphine	NOUN	O	I-Entity
treatment	NOUN	O	O
induced	VERB	O	O
a	DET	O	O
gradual	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
as	ADP	O	O
evidenced	VERB	O	O
by	ADP	O	O
the	DET	O	O
increased	VERB	O	O
intensity	NOUN	O	O
of	ADP	O	O
aggressiveness	NOUN	O	I-Entity
and	CCONJ	O	O
shortened	VERB	O	O
latency	NOUN	O	O
before	ADP	O	O
the	DET	O	O
first	ADJ	O	O
attack	NOUN	O	O
toward	ADP	O	O
the	DET	O	O
opponent	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
a	DET	O	O
weak	ADJ	O	O
tendency	NOUN	O	O
toward	ADP	O	O
aggressiveness	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
gender	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
the	DET	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
and	CCONJ	O	O
indicates	VERB	O	O
that	ADP	O	O
the	DET	O	O
female	ADJ	O	O
rats	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
fill	VERB	O	O
the	DET	O	O
validation	NOUN	O	O
criteria	NOUN	O	O
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
this	DET	O	O
method	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11147747)

Serotonergic	ADJ	O	B-Entity
antidepressants	NOUN	O	I-Entity
and	CCONJ	O	O
urinary	ADJ	O	B-Entity
incontinence	NOUN	O	I-Entity
.	PUNCT	O	O

Many	ADJ	O	O
new	ADJ	O	O
serotonergic	ADJ	O	B-Entity
antidepressants	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
introduced	VERB	O	O
over	ADP	O	O
the	DET	O	O
past	ADJ	O	O
decade	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
urinary	ADJ	O	B-Entity
incontinence	NOUN	O	I-Entity
is	VERB	O	O
listed	VERB	O	O
as	ADP	O	O
one	NUM	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
package	NOUN	O	O
inserts	NOUN	O	O
there	ADV	O	O
is	VERB	O	O
only	ADV	O	O
one	NUM	O	O
report	NOUN	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
concerns	VERB	O	O
2	NUM	O	O
male	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
incontinence	NOUN	O	I-Entity
while	ADP	O	O
taking	VERB	O	O
venlafaxine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
paper	NOUN	O	O
the	DET	O	O
authors	NOUN	O	O
describe	VERB	O	O
2	NUM	O	O
female	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
incontinence	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
the	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
paroxetine	VERB	O	I-Entity
and	CCONJ	O	O
sertraline	VERB	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
a	DET	O	O
third	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
this	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
on	ADP	O	O
venlafaxine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
2	NUM	O	O
of	ADP	O	O
the	DET	O	O
3	NUM	O	O
cases	NOUN	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
taking	VERB	O	O
lithium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
and	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
both	DET	O	O
of	ADP	O	O
which	ADJ	O	O
could	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
incontinence	NOUN	O	I-Entity
.	PUNCT	O	O

Animal	ADJ	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
incontinence	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
serotonergic	ADJ	O	B-Entity
antidepressants	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
the	DET	O	O
5HT4	NUM	O	O
receptors	NOUN	O	O
found	VERB	O	O
on	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11198499)

Hypotension	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
tizanidine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
an	DET	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Centrally	ADV	O	O
acting	VERB	O	O
alpha-2	ADJ	O	O
adrenergic	ADJ	O	O
agonists	NOUN	O	O
are	VERB	O	O
one	NUM	O	O
of	ADP	O	O
several	ADJ	O	O
pharmacologic	ADJ	O	O
agents	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
spasticity	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
disorders	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
central	ADJ	O	I-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
their	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
spasticity	NOUN	O	I-Entity
,	PUNCT	O	O
certain	ADJ	O	O
adverse	ADJ	O	O
cardiorespiratory	NOUN	O	O
effects	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Adults	NOUN	O	O
chronically	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitors	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
limited	VERB	O	O
ability	NOUN	O	O
to	PART	O	O
respond	VERB	O	O
to	ADP	O	O
hypotension	NOUN	O	I-Entity
when	ADV	O	O
the	DET	O	O
sympathetic	ADJ	O	O
response	NOUN	O	O
is	VERB	O	O
simultaneously	ADV	O	O
blocked	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
present	VERB	O	O
a	DET	O	O
10-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
chronically	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
lisinopril	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
control	VERB	O	O
hypertension	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
hypotension	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
tizanidine	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
alpha-2	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
spasticity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
interaction	NOUN	O	O
of	ADP	O	O
tizanidine	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
antihypertensive	ADJ	O	O
agents	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
kept	VERB	O	O
in	ADP	O	O
mind	NOUN	O	O
when	ADV	O	O
prescribing	VERB	O	O
therapy	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
either	CCONJ	O	O
hypertension	NOUN	O	I-Entity
or	CCONJ	O	O
spasticity	NOUN	O	I-Entity
in	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11391224)

Peritubular	ADJ	O	O
capillary	ADJ	O	O
basement	NOUN	O	O
membrane	NOUN	O	O
reduplication	NOUN	O	O
in	ADP	O	O
allografts	NOUN	O	O
and	CCONJ	O	O
native	ADJ	O	O
kidney	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
clinicopathologic	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
278	NUM	O	O
consecutive	ADJ	O	O
renal	ADJ	O	O
specimens	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
An	DET	O	O
association	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
found	VERB	O	O
between	ADP	O	O
transplant	NOUN	O	B-Entity
glomerulopathy	NOUN	O	I-Entity
(	PUNCT	O	O
TG	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
reduplication	NOUN	O	O
of	ADP	O	O
peritubular	ADJ	O	O
capillary	ADJ	O	O
basement	NOUN	O	O
membranes	NOUN	O	O
(	PUNCT	O	O
PTCR	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
renal	ADJ	O	O
allografts	NOUN	O	O
with	ADP	O	O
TG	PROPN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
also	ADV	O	O
examined	VERB	O	O
grafts	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
rejection	NOUN	O	O
,	PUNCT	O	O
recurrent	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
,	PUNCT	O	O
chronic	ADJ	O	B-Entity
allograft	NOUN	O	I-Entity
nephropathy	ADJ	O	I-Entity
and	CCONJ	O	O
stable	ADJ	O	O
grafts	NOUN	O	O
(	PUNCT	O	O
"	PUNCT	O	O
protocol	NOUN	O	O
biopsies	NOUN	O	O
"	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Native	ADJ	O	O
kidney	NOUN	O	O
specimens	NOUN	O	O
included	VERB	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
glomerulopathies	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
,	PUNCT	O	O
malignant	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
acute	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
PTCR	PROPN	O	O
in	ADP	O	O
14	NUM	O	O
of	ADP	O	O
15	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
TG	PROPN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
7	NUM	O	O
transplant	NOUN	O	O
biopsy	NOUN	O	O
specimens	NOUN	O	O
without	ADP	O	O
TG	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
13	NUM	O	O
of	ADP	O	O
143	NUM	O	O
native	ADJ	O	O
kidney	NOUN	O	O
biopsy	NOUN	O	O
specimens	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
13	NUM	O	O
included	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
,	PUNCT	O	O
lupus	NOUN	O	B-Entity
nephritis	NOUN	O	I-Entity
,	PUNCT	O	O
Henoch	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Schonlein	PROPN	O	I-Entity
nephritis	NOUN	O	I-Entity
,	PUNCT	O	O
crescentic	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Mild	PROPN	O	O
PTCR	PROPN	O	O
in	ADP	O	O
allografts	NOUN	O	O
without	ADP	O	O
TG	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
predict	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
or	CCONJ	O	O
significant	ADJ	O	O
proteinuria	NOUN	O	I-Entity
after	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
periods	NOUN	O	O
of	ADP	O	O
between	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
in	ADP	O	O
transplants	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
well	ADV	O	O
-	PUNCT	O	O
developed	VERB	O	O
PTCR	PROPN	O	O
and	CCONJ	O	O
TG	PROPN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
significance	NOUN	O	O
of	ADP	O	O
mild	ADJ	O	O
PTCR	PROPN	O	O
and	CCONJ	O	O
its	ADJ	O	O
predictive	ADJ	O	O
value	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
TG	PROPN	O	I-Entity
is	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

PTCR	PROPN	O	O
also	ADV	O	O
occurs	VERB	O	O
in	ADP	O	O
certain	ADJ	O	O
native	ADJ	O	O
kidney	NOUN	O	B-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
though	ADP	O	O
the	DET	O	O
association	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
as	ADV	O	O
strong	ADJ	O	O
as	ADP	O	O
that	DET	O	O
for	ADP	O	O
TG	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
repeated	VERB	O	O
endothelial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
immunologic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
this	DET	O	O
lesion	NOUN	O	O
both	CCONJ	O	O
in	ADP	O	O
allografts	NOUN	O	O
and	CCONJ	O	O
native	ADJ	O	O
kidneys	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11426838)

Conformationally	PROPN	O	O
restricted	VERB	O	O
analogs	NOUN	O	O
of	ADP	O	O
BD1008	PROPN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
antisense	NOUN	O	O
oligodeoxynucleotide	NOUN	O	I-Entity
targeting	VERB	O	O
sigma1	NOUN	O	O
receptors	NOUN	O	O
produce	VERB	O	O
anti	ADJ	O	O
-	PUNCT	O	O
cocaine	NOUN	O	I-Entity
effects	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Cocaine	PROPN	O	I-Entity
's	PART	O	O
ability	NOUN	O	O
to	PART	O	O
interact	VERB	O	O
with	ADP	O	O
sigma	NOUN	O	O
receptors	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
these	DET	O	O
proteins	NOUN	O	O
mediate	VERB	O	O
some	DET	O	O
of	ADP	O	O
its	ADJ	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
three	NUM	O	O
novel	NOUN	O	O
sigma	NOUN	O	O
receptor	NOUN	O	O
ligands	VERB	O	O
with	ADP	O	O
antagonist	NOUN	O	O
activity	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
Swiss	PROPN	O	O
Webster	PROPN	O	O
mice	NOUN	O	O
:	PUNCT	O	O
BD1018	NOUN	O	I-Entity
(	PUNCT	O	O
3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
BD1063	PROPN	O	I-Entity
(	PUNCT	O	O
1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
LR132	PROPN	O	I-Entity
(	PUNCT	O	O
1R,2S-(+)-cis	NUM	O	O
-	PUNCT	O	O
N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
three	NUM	O	O
compounds	NOUN	O	O
vary	VERB	O	O
in	ADP	O	O
their	ADJ	O	O
affinities	NOUN	O	O
for	ADP	O	O
sigma2	NOUN	O	O
receptors	NOUN	O	O
and	CCONJ	O	O
exhibit	NOUN	O	O
negligible	ADJ	O	O
affinities	NOUN	O	O
for	ADP	O	O
dopamine	NOUN	O	I-Entity
,	PUNCT	O	O
opioid	ADJ	O	O
,	PUNCT	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
behavioral	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
pre	ADJ	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
BD1018	PROPN	O	I-Entity
,	PUNCT	O	O
BD1063	PROPN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
LR132	PROPN	O	I-Entity
significantly	ADV	O	O
attenuated	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
lethality	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
post	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
LR132	PROPN	O	I-Entity
prevented	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
lethality	NOUN	O	O
in	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
the	DET	O	O
protection	NOUN	O	O
provided	VERB	O	O
by	ADP	O	O
the	DET	O	O
putative	ADJ	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
characterized	VERB	O	O
sigma	NOUN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
di	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
o	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
tolylguanidine	NOUN	O	I-Entity
(	PUNCT	O	O
DTG	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
novel	NOUN	O	O
sigma	NOUN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
BD1031	NOUN	O	I-Entity
(	PUNCT	O	O
3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	NOUN	O	I-Entity
)	PUNCT	O	O
each	DET	O	O
worsened	VERB	O	O
the	DET	O	O
behavioral	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
doses	NOUN	O	O
where	ADV	O	O
alone	ADV	O	O
,	PUNCT	O	O
they	PRON	O	O
produced	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
locomotion	NOUN	O	O
,	PUNCT	O	O
BD1018	PROPN	O	I-Entity
,	PUNCT	O	O
BD1063	PROPN	O	I-Entity
and	CCONJ	O	O
LR132	PROPN	O	I-Entity
significantly	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
locomotor	NOUN	O	O
stimulatory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
further	ADV	O	O
validate	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
cocaine	NOUN	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
novel	NOUN	O	O
ligands	NOUN	O	O
involved	VERB	O	O
antagonism	NOUN	O	O
of	ADP	O	O
sigma	NOUN	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
antisense	NOUN	O	O
oligodeoxynucleotide	NOUN	O	I-Entity
against	ADP	O	O
sigma1	NOUN	O	O
receptors	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
shown	VERB	O	O
to	ADP	O	O
significantly	ADV	O	O
attenuate	VERB	O	O
the	DET	O	O
convulsive	ADJ	O	I-Entity
and	CCONJ	O	O
locomotor	NOUN	O	O
stimulatory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Together	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
data	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
functional	ADJ	O	O
antagonism	NOUN	O	O
of	ADP	O	O
sigma	NOUN	O	O
receptors	NOUN	O	O
is	VERB	O	O
capable	ADJ	O	O
of	ADP	O	O
attenuating	VERB	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
behaviors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11569530)

Pharmacokinetic	PROPN	O	O
/	SYM	O	O
pharmacodynamic	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
E4031	PROPN	O	I-Entity
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
,	PUNCT	O	O
terfenadine	NOUN	O	I-Entity
and	CCONJ	O	O
terodiline	NOUN	O	I-Entity
on	ADP	O	O
monophasic	ADJ	O	O
action	NOUN	O	O
potential	ADJ	O	O
duration	NOUN	O	O
in	ADP	O	O
dog	NOUN	O	O

Torsades	PROPN	O	B-Entity
de	X	O	I-Entity
pointes	X	O	I-Entity
(	PUNCT	O	O
TDP	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
fatal	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
increases	NOUN	O	O
in	ADP	O	O
QT	PROPN	O	O
interval	NOUN	O	O
and	CCONJ	O	O
monophasic	ADJ	O	O
action	NOUN	O	O
potential	ADJ	O	O
duration	NOUN	O	O
(	PUNCT	O	O
MAPD	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

TDP	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
led	VERB	O	O
to	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
drugs	NOUN	O	O
from	ADP	O	O
the	DET	O	O
market	NOUN	O	O
(	PUNCT	O	O
e.g.	X	O	O
terfenadine	NOUN	O	I-Entity
and	CCONJ	O	O
terodiline	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
potential	NOUN	O	O
of	ADP	O	O
compounds	NOUN	O	O
to	PART	O	O
cause	VERB	O	O
TDP	PROPN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
monitoring	VERB	O	O
their	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
MAPD	PROPN	O	O
in	ADP	O	O
dog	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
compounds	NOUN	O	O
known	VERB	O	O
to	PART	O	O
increase	VERB	O	O
QT	PROPN	O	O
interval	NOUN	O	O
and	CCONJ	O	O
cause	VERB	O	O
TDP	PROPN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
:	PUNCT	O	O
terfenadine	NOUN	O	I-Entity
,	PUNCT	O	O
terodiline	NOUN	O	I-Entity
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
and	CCONJ	O	O
E4031	PROPN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
free	ADJ	O	O
ED50	PROPN	O	O
in	ADP	O	O
plasma	NOUN	O	O
for	ADP	O	O
terfenadine	NOUN	O	I-Entity
(	PUNCT	O	O
1.9	NUM	O	O
nM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
terodiline	NOUN	O	I-Entity
(	PUNCT	O	O
76	NUM	O	O
nM	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
(	PUNCT	O	O
11	NUM	O	O
nM	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
E4031	PROPN	O	I-Entity
(	PUNCT	O	O
1.9	NUM	O	O
nM	NOUN	O	O
)	PUNCT	O	O
closely	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
the	DET	O	O
free	ADJ	O	O
concentration	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
causing	VERB	O	O
QT	PROPN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
compounds	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
shown	VERB	O	O
TDP	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
clinic	NOUN	O	O
(	PUNCT	O	O
terfenadine	NOUN	O	I-Entity
,	PUNCT	O	O
terodiline	NOUN	O	I-Entity
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
)	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
little	ADJ	O	O
differentiation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
ED50	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
efficacious	ADJ	O	O
free	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
(	PUNCT	O	O
<	X	O	O
10-fold	NUM	O	O
)	PUNCT	O	O
reflecting	VERB	O	O
their	ADJ	O	O
limited	ADJ	O	O
safety	NOUN	O	O
margins	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
underline	VERB	O	O
the	DET	O	O
need	NOUN	O	O
to	PART	O	O
maximize	VERB	O	O
the	DET	O	O
therapeutic	ADJ	O	O
ratio	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
TDP	PROPN	O	I-Entity
in	ADP	O	O
potential	ADJ	O	O
development	NOUN	O	O
candidates	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
using	VERB	O	O
free	ADJ	O	O
drug	NOUN	O	O
concentrations	NOUN	O	O
in	ADP	O	O
pharmacokinetic	ADJ	O	O
/	SYM	O	O
pharmacodynamic	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11587867)

Fatal	ADJ	O	O
myeloencephalopathy	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
accidental	ADJ	O	O
intrathecal	ADJ	O	O
vincristin	ADJ	O	I-Entity
administration	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
report	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
two	NUM	O	O
fatal	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
accidental	ADJ	O	O
intrathecal	ADJ	O	O
vincristine	NOUN	O	I-Entity
instillation	NOUN	O	O
in	ADP	O	O
a	DET	O	O
5-year	ADJ	O	O
old	ADJ	O	O
girl	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leucemia	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
57-year	ADJ	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
lymphoblastic	ADJ	O	B-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
girl	NOUN	O	O
died	VERB	O	O
seven	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
man	NOUN	O	O
four	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
intrathecal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
vincristine	NOUN	O	I-Entity
.	PUNCT	O	O

Clinically	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
onset	NOUN	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
the	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
opistothonus	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
sensory	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
motor	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
ascending	VERB	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

Histological	ADJ	O	O
and	CCONJ	O	O
immunohistochemical	ADJ	O	O
investigations	NOUN	O	O
(	PUNCT	O	O
HE	PROPN	O	O
-	PUNCT	O	O
LFB	PROPN	O	O
,	PUNCT	O	O
CD-68	PROPN	O	O
,	PUNCT	O	O
Neurofilament	PROPN	O	O
)	PUNCT	O	O
revealed	VERB	O	O
degeneration	NOUN	O	B-Entity
of	ADP	O	I-Entity
myelin	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
axons	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
pseudocystic	ADJ	O	B-Entity
transformation	NOUN	O	I-Entity
in	ADP	O	O
areas	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
vincristine	NOUN	O	I-Entity
,	PUNCT	O	O
accompanied	VERB	O	O
by	ADP	O	O
secondary	ADJ	O	O
changes	NOUN	O	O
with	ADP	O	O
numerous	ADJ	O	O
prominent	ADJ	O	O
macrophages	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
better	ADJ	O	O
controlled	VERB	O	O
regimen	NOUN	O	O
for	ADP	O	O
administering	VERB	O	O
vincristine	NOUN	O	I-Entity
and	CCONJ	O	O


-DOCSTART- (11679859)

Intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
prochlorperazine	NOUN	O	I-Entity
by	ADP	O	O
15-minute	ADJ	O	O
infusion	NOUN	O	O
versus	ADP	O	O
2-minute	NUM	O	O
bolus	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
akathisia	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
sought	VERB	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
akathisia	NOUN	O	I-Entity
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
prochlorperazine	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
2-minute	NUM	O	O
bolus	NOUN	O	O
or	CCONJ	O	O
15-minute	ADJ	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
aged	VERB	O	O
18	NUM	O	O
years	NOUN	O	O
or	CCONJ	O	O
older	ADJ	O	O
treated	VERB	O	O
with	ADP	O	O
prochlorperazine	NOUN	O	I-Entity
for	ADP	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
vomiting	VERB	O	I-Entity
were	VERB	O	O
eligible	ADJ	O	O
for	ADP	O	O
inclusion	NOUN	O	O
.	PUNCT	O	O

Study	NOUN	O	O
participants	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
10	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
prochlorperazine	NOUN	O	I-Entity
administered	VERB	O	O
intravenously	ADV	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
2-minute	NUM	O	O
push	NOUN	O	O
(	PUNCT	O	O
bolus	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
diluted	VERB	O	O
in	ADP	O	O
50	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
solution	NOUN	O	O
administered	VERB	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
during	ADP	O	O
a	DET	O	O
15-minute	ADJ	O	O
period	NOUN	O	O
(	PUNCT	O	O
infusion	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
participants	NOUN	O	O
experiencing	VERB	O	O
akathisia	NOUN	O	I-Entity
within	ADP	O	O
60	NUM	O	O
minutes	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Akathisia	PROPN	O	O
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
either	DET	O	O
a	DET	O	O
spontaneous	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
restlessness	NOUN	O	O
or	CCONJ	O	O
agitation	NOUN	O	I-Entity
or	CCONJ	O	O
a	DET	O	O
change	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
-	PUNCT	O	O
reported	VERB	O	O
akathisia	ADJ	O	I-Entity
rating	NOUN	O	O
scale	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
change	NOUN	O	O
of	ADP	O	O
at	ADV	O	O
least	ADJ	O	O
1	NUM	O	O
in	ADP	O	O
the	DET	O	O
investigator	NOUN	O	O
-	PUNCT	O	O
observed	VERB	O	O
akathisia	NOUN	O	I-Entity
rating	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
nausea	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
a	DET	O	O
100-mm	NUM	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Seventy	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
73/99	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
participants	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
70%	NUM	O	O
(	PUNCT	O	O
70/99	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
nausea	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
bolus	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
26.0%	NUM	O	O
(	PUNCT	O	O
13/50	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
akathisia	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
32.7%	NUM	O	O
(	PUNCT	O	O
16/49	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
group	NOUN	O	O

The	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
bolus	NOUN	O	O
and	CCONJ	O	O
infusion	NOUN	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
participants	NOUN	O	O
who	NOUN	O	O
saw	VERB	O	O
a	DET	O	O
50%	NUM	O	O
reduction	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
headache	NOUN	O	I-Entity
intensity	NOUN	O	O
within	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
was	VERB	O	O
11.8%	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
-9.6%	PROPN	O	O
to	ADP	O	O
33.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
50%	NUM	O	O
reduction	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
nausea	NOUN	O	I-Entity
was	VERB	O	O
12.6%	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
-4.6%	PROPN	O	O
to	ADP	O	O
29.8%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
50%	NUM	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
akathisia	NOUN	O	I-Entity
when	ADV	O	O
prochlorperazine	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
15-minute	ADJ	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
versus	ADP	O	O
a	DET	O	O
2-minute	NUM	O	O
intravenous	ADJ	O	O
push	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
detected	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
prochlorperazine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
nausea	NOUN	O	I-Entity
likewise	ADV	O	O
did	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
no	DET	O	O
formal	ADJ	O	O
statistical	ADJ	O	O
comparisons	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (12041669)

Antithymocyte	PROPN	O	B-Entity
globulin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
antithymocyte	NOUN	O	B-Entity
globulin	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
antithymocyte	NOUN	O	B-Entity
globulin	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
optimal	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12198388)

The	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
hippocampal	ADJ	O	O
acetylcholine	NOUN	O	I-Entity
release	NOUN	O	O
and	CCONJ	O	O
cholinergic	ADJ	O	O
convulsant	ADJ	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
withdrawal	NOUN	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
prone	ADJ	O	O
and	CCONJ	O	O
withdrawal	NOUN	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
selected	VERB	O	O
mouse	NOUN	O	O
lines	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
septo	NOUN	O	O
-	PUNCT	O	O
hippocampal	ADJ	O	O
cholinergic	ADJ	O	O
pathway	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
epileptogenesis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
genetic	ADJ	O	O
factors	NOUN	O	O
influence	VERB	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
cholinergic	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
limited	ADJ	O	O
data	NOUN	O	O
are	VERB	O	O
available	ADJ	O	O
on	ADP	O	O
cholinergic	ADJ	O	O
involvement	NOUN	O	O
in	ADP	O	O
alcohol	NOUN	O	I-Entity
withdrawal	NOUN	O	O
severity	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
cholinergic	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
responsiveness	NOUN	O	O
and	CCONJ	O	O
alcohol	NOUN	O	I-Entity
withdrawal	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
a	DET	O	O
genetic	ADJ	O	O
animal	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
ethanol	NOUN	O	I-Entity
withdrawal	NOUN	O	O
severity	NOUN	O	O
.	PUNCT	O	O

Cholinergic	PROPN	O	O
convulsant	NOUN	O	O
sensitivity	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
alcohol	NOUN	O	I-Entity
-	PUNCT	O	O
na	NOUN	O	O
ve	ADP	O	O

Withdrawal	PROPN	O	O
Seizure	PROPN	O	I-Entity
-	PUNCT	O	O
Prone	PROPN	O	O
(	PUNCT	O	O
WSP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
-	PUNCT	O	O
Resistant	PROPN	O	O
(	PUNCT	O	O
WSR	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
nicotine	NOUN	O	I-Entity
,	PUNCT	O	O
carbachol	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
neostigmine	ADV	O	I-Entity
via	ADP	O	O
timed	VERB	O	O
tail	NOUN	O	O
vein	NOUN	O	O
infusion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
latencies	NOUN	O	O
to	PART	O	O
onset	NOUN	O	O
of	ADP	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
clonus	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
and	CCONJ	O	O
converted	VERB	O	O
to	ADP	O	O
threshold	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
used	VERB	O	O
microdialysis	NOUN	O	O
to	PART	O	O
measure	VERB	O	O
basal	NOUN	O	O
and	CCONJ	O	O
potassium	NOUN	O	I-Entity
-	PUNCT	O	O
stimulated	VERB	O	O
acetylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
ACh	PROPN	O	I-Entity
)	PUNCT	O	O
release	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CA1	PROPN	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
.	PUNCT	O	O

Potassium	NOUN	O	I-Entity
was	VERB	O	O
applied	VERB	O	O
by	ADP	O	O
reverse	ADJ	O	O
dialysis	NOUN	O	O
twice	ADV	O	O
,	PUNCT	O	O
separated	VERB	O	O
by	ADP	O	O
75	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Hippocampal	PROPN	O	O
ACh	PROPN	O	I-Entity
also	ADV	O	O
was	VERB	O	O
measured	VERB	O	O
during	ADP	O	O
testing	NOUN	O	O
for	ADP	O	O
handling	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Sensitivity	NOUN	O	O
to	ADP	O	O
several	ADJ	O	O
convulsion	NOUN	O	I-Entity
endpoints	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
nicotine	NOUN	O	I-Entity
,	PUNCT	O	O
carbachol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
neostigmine	NOUN	O	I-Entity
were	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
in	ADP	O	O
WSR	PROPN	O	O
versus	ADP	O	O
WSP	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
microdialysis	NOUN	O	O
experiments	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
lines	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
in	ADP	O	O
basal	ADJ	O	O
release	NOUN	O	O
of	ADP	O	O
ACh	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
50	NUM	O	O
mM	NOUN	O	O
KCl	NOUN	O	I-Entity
increased	VERB	O	O
ACh	NOUN	O	I-Entity
output	NOUN	O	O
in	ADP	O	O
both	DET	O	O
lines	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
ACh	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
the	DET	O	O
first	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
KCl	PROPN	O	I-Entity
was	VERB	O	O
2-fold	NUM	O	O
higher	ADJ	O	O
in	ADP	O	O
WSP	PROPN	O	O
versus	ADP	O	O
WSR	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
hippocampal	ADJ	O	O
ACh	PROPN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
during	ADP	O	O
testing	NOUN	O	O
for	ADP	O	O
handling	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
,	PUNCT	O	O
extracellular	ADJ	O	O
ACh	PROPN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
elevated	ADJ	O	O
(	PUNCT	O	O
192%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
WSP	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
nonsignificantly	ADV	O	O
elevated	ADJ	O	O
(	PUNCT	O	O
59%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
WSR	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
cholinergic	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
postsynaptic	ADJ	O	O
sensitivity	NOUN	O	O
to	PART	O	O
cholinergic	VERB	O	O
convulsants	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
ethanol	NOUN	O	I-Entity
withdrawal	NOUN	O	O
severity	NOUN	O	O
and	CCONJ	O	O
implicate	VERB	O	O
cholinergic	ADJ	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
alcohol	NOUN	O	I-Entity
withdrawal	NOUN	O	O
.	PUNCT	O	O

Specifically	ADV	O	O
,	PUNCT	O	O
WSP	PROPN	O	O
mice	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
lower	ADJ	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
cholinergic	VERB	O	O
convulsants	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
WSR	PROPN	O	O
because	ADP	O	O
of	ADP	O	O
postsynaptic	ADJ	O	O
receptor	NOUN	O	O
desensitization	NOUN	O	O
brought	VERB	O	O
on	PART	O	O
by	ADP	O	O
higher	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
cholinergic	ADJ	O	O
neurons	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12574103)

Prenatal	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
programs	NOUN	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
prenatal	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
programmed	VERB	O	O
a	DET	O	O
progressive	ADJ	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Pregnant	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
either	DET	O	O
vehicle	NOUN	O	O
or	CCONJ	O	O
2	NUM	O	O
daily	ADJ	O	O
intraperitoneal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
0.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
gestational	ADJ	O	O
days	NOUN	O	O
11	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
,	PUNCT	O	O
13	NUM	O	O
and	CCONJ	O	O
14	NUM	O	O
,	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
,	PUNCT	O	O
17	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
19	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
.	PUNCT	O	O

Offspring	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
administered	VERB	O	O
dexamethasone	NOUN	O	I-Entity
on	ADP	O	O
days	NOUN	O	O
15	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
gestation	NOUN	O	O
had	VERB	O	O
a	DET	O	O
20%	NUM	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
glomerular	ADJ	O	I-Entity
number	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
to	PART	O	O
9	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
(	PUNCT	O	O
22	NUM	O	O
527+/-509	NUM	O	O
versus	ADP	O	O
28	NUM	O	O
050+/-561	NOUN	O	O
,	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
percent	NOUN	O	O
reduction	NOUN	O	O
in	ADP	O	O
glomeruli	NOUN	O	O
measured	VERB	O	O
at	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

Six-	NOUN	O	O
to	ADP	O	O
9-month	ADJ	O	O
old	ADJ	O	O
rats	NOUN	O	O
receiving	VERB	O	O
prenatal	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
on	ADP	O	O
days	NOUN	O	O
17	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
of	ADP	O	O
gestation	NOUN	O	O
had	VERB	O	O
a	DET	O	O
17%	NUM	O	O
reduction	NOUN	O	O
in	ADP	O	O
glomeruli	NOUN	O	O
(	PUNCT	O	O
23	NUM	O	O
380+/-587	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Male	NOUN	O	O
rats	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
prenatal	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
on	ADP	O	O
days	NOUN	O	O
15	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
,	PUNCT	O	O
17	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
13	NUM	O	O
and	CCONJ	O	O
14	NUM	O	O
of	ADP	O	O
gestation	NOUN	O	O
had	VERB	O	O
elevated	VERB	O	B-Entity
blood	NOUN	O	I-Entity
pressures	NOUN	O	I-Entity
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
latter	ADJ	O	O
group	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
a	DET	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
glomerular	ADJ	O	I-Entity
number	NOUN	O	I-Entity
.	PUNCT	O	O

Adult	NOUN	O	O
rats	NOUN	O	O
given	VERB	O	O
dexamethasone	NOUN	O	I-Entity
on	ADP	O	O
days	NOUN	O	O
15	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
of	ADP	O	O
gestation	NOUN	O	O
had	VERB	O	O
more	ADV	O	O
glomeruli	NOUN	O	O
with	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
than	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
prenatal	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
a	DET	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
glomerular	ADJ	O	I-Entity
number	NOUN	O	I-Entity
,	PUNCT	O	O
glomerulosclerosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hypertension	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
at	ADP	O	O
specific	ADJ	O	O
points	NOUN	O	O
during	ADP	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

Hypertension	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
that	ADJ	O	O
had	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
glomeruli	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
a	DET	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
glomerular	ADJ	O	I-Entity
number	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
a	DET	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
glomerular	ADJ	O	I-Entity
number	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
the	DET	O	O
sole	ADJ	O	O
cause	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12615818)

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
prescribed	VERB	O	O
cyproterone	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
nested	VERB	O	O
cohort	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Cyproterone	PROPN	O	B-Entity
acetate	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
(	PUNCT	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
licensed	VERB	O	O
in	ADP	O	O
the	DET	O	O
UK	PROPN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
acne	NOUN	O	I-Entity
and	CCONJ	O	O
hirsutism	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
also	ADV	O	O
a	DET	O	O
treatment	NOUN	O	O
option	NOUN	O	O
for	ADP	O	O
polycystic	ADJ	O	B-Entity
ovary	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
PCOS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
VTE	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
conventional	ADJ	O	O
combined	ADJ	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
(	PUNCT	O	O
COCs	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Using	VERB	O	O
the	DET	O	O
General	PROPN	O	O
Practice	PROPN	O	O
Research	PROPN	O	O
Database	PROPN	O	O
we	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
cohort	NOUN	O	O
analysis	NOUN	O	O
and	CCONJ	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
nested	VERB	O	O
within	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
aged	VERB	O	O
between	ADP	O	O
15	NUM	O	O
and	CCONJ	O	O
39	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
acne	NOUN	O	I-Entity
,	PUNCT	O	O
hirsutism	NOUN	O	I-Entity
or	CCONJ	O	O
PCOS	PROPN	O	I-Entity
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
age	NOUN	O	O
-	PUNCT	O	O
adjusted	VERB	O	O
incidence	NOUN	O	O
rate	NOUN	O	O
ratio	NOUN	O	O
for	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
versus	ADP	O	O
conventional	ADJ	O	O
COCs	NOUN	O	O
was	VERB	O	O
2.20	NUM	O	O
[	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	PROPN	O	O
)	PUNCT	O	O
1.35	NUM	O	O
-	SYM	O	O
3.58	NUM	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Using	VERB	O	O
as	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
group	NOUN	O	O
women	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
using	VERB	O	O
oral	ADJ	O	O
contraception	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
no	DET	O	O
recent	ADJ	O	O
pregnancy	NOUN	O	O
or	CCONJ	O	O
menopausal	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
analysis	NOUN	O	O
gave	VERB	O	O
an	DET	O	O
adjusted	ADJ	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
OR(adj	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
7.44	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
3.67	NUM	O	O
-	SYM	O	O
15.08	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
use	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
an	DET	O	O
OR(adj	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
2.58	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.60	NUM	O	O
-	SYM	O	O
4.18	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
conventional	ADJ	O	O
COCs	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
have	VERB	O	O
demonstrated	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
acne	NOUN	O	I-Entity
,	PUNCT	O	O
hirsutism	NOUN	O	I-Entity
or	CCONJ	O	O
PCOS	PROPN	O	I-Entity
although	ADP	O	O
residual	ADJ	O	O
confounding	NOUN	O	O
by	ADP	O	O
indication	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (12789195)

Pseudoacromegaly	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
minoxidil	NOUN	O	I-Entity
.	PUNCT	O	O

Acromegaly	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
endocrine	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
excessive	ADJ	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
secretion	NOUN	O	O
from	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
pituitary	ADJ	O	O
gland	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
disfiguring	ADJ	O	O
changes	NOUN	O	O
occur	VERB	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
,	PUNCT	O	O
cartilage	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
soft	ADJ	O	O
tissue	NOUN	O	O
hypertrophy	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
thickening	NOUN	O	O
of	ADP	O	O
the	DET	O	O
skin	NOUN	O	O
,	PUNCT	O	O
coarsening	NOUN	O	O
of	ADP	O	O
facial	ADJ	O	O
features	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cutis	NOUN	O	B-Entity
verticis	NOUN	O	I-Entity
gyrata	NOUN	O	I-Entity
.	PUNCT	O	O

Pseudoacromegaly	PROPN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
similar	ADJ	O	O
acromegaloid	NOUN	O	O
features	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
elevated	ADJ	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
or	CCONJ	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
pseudoacromegaly	NOUN	O	I-Entity
that	ADJ	O	O
resulted	VERB	O	O
from	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
minoxidil	NOUN	O	I-Entity
at	ADP	O	O
an	DET	O	O
unusually	ADV	O	O
high	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
pseudoacromegaly	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
minoxidil	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12820454)

Combined	VERB	O	O
androgen	NOUN	O	O
blockade	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
in	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
without	ADP	O	O
bone	NOUN	O	O
involvement	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
and	CCONJ	O	O
extent	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
androgen	NOUN	O	O
blockade	NOUN	O	O
(	PUNCT	O	O
CAB)-induced	VERB	O	O
anemia	NOUN	O	I-Entity
in	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
without	ADP	O	O
bone	NOUN	O	O
involvement	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
biopsy	NOUN	O	O
-	PUNCT	O	O
proven	VERB	O	O
prostatic	ADJ	O	B-Entity
adenocarcinoma	NOUN	O	I-Entity
[	PUNCT	O	O
26	NUM	O	O
with	ADP	O	O
stage	NOUN	O	O
C	PROPN	O	O
(	PUNCT	O	O
T3N0M0	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
16	NUM	O	O
with	ADP	O	O
stage	NOUN	O	O
D1	PROPN	O	O
(	PUNCT	O	O
T3N1M0	PROPN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
CAB	PROPN	O	O
[	PUNCT	O	O
leuprolide	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
LHRH	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
A	PROPN	O	I-Entity
)	PUNCT	O	O
3.75	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
intramuscularly	ADV	O	O
,	PUNCT	O	O
every	DET	O	O
28	NUM	O	O
days	NOUN	O	O
plus	CCONJ	O	O
250	NUM	O	O
mg	NUM	O	O
flutamide	NOUN	O	I-Entity
,	PUNCT	O	O
tid	NOUN	O	O
,	PUNCT	O	O
per	ADP	O	O
Os	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
anemia	NOUN	O	I-Entity
by	ADP	O	O
physical	ADJ	O	O
examination	NOUN	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
tests	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
subsequent	ADJ	O	O
intervals	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
CAB	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Hb	PROPN	O	O
,	PUNCT	O	O
PSA	PROPN	O	O
and	CCONJ	O	O
Testosterone	NOUN	O	I-Entity
measurements	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
and	CCONJ	O	O
clinically	ADV	O	O
evident	ADJ	O	O
anemia	NOUN	O	I-Entity
of	ADP	O	O
Hb	PROPN	O	O
<	X	O	O
11	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
symptoms	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
6	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
14.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
CAB	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
normochromic	ADJ	O	O
and	CCONJ	O	O
normocytic	ADJ	O	O
.	PUNCT	O	O

At	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
CAB	PROPN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
anemia	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
Hb	PROPN	O	O
mean	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
10.2	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

SE	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
other	ADJ	O	O
patients	NOUN	O	O
had	VERB	O	O
mild	ADJ	O	O
anemia	NOUN	O	I-Entity
with	ADP	O	O
Hb	PROPN	O	O
mean	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
13.2	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
anemia	NOUN	O	I-Entity
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
CAB	PROPN	O	O
was	VERB	O	O
predictable	ADJ	O	O
by	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
Hb	PROPN	O	O
baseline	NOUN	O	O
value	NOUN	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
2.5	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
after	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
CAB	PROPN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
CAB	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
in	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
T	NOUN	O	O
baseline	NOUN	O	O
values	NOUN	O	O
(	PUNCT	O	O
T	PROPN	O	O
<	X	O	O
3	NUM	O	O

Severe	ADJ	O	O
and	CCONJ	O	O
clinically	ADV	O	O
evident	ADJ	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
easily	ADV	O	O
corrected	VERB	O	O
by	ADP	O	O
subcutaneous	ADJ	O	O
injections	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
times	NOUN	O	O
/	SYM	O	O
week	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
recombinant	NOUN	O	O
erythropoietin	NOUN	O	O
(	PUNCT	O	O
rHuEPO	PROPN	O	O
-	PUNCT	O	O
beta	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
rHuEPO	PROPN	O	O
-	PUNCT	O	O
beta	NOUN	O	O
correctable	ADJ	O	O
CAB	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
occurs	VERB	O	O
in	ADP	O	O
14.3%	NUM	O	O
of	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
after	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14657095)

Reversible	ADJ	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
dilated	ADJ	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
and	CCONJ	O	O
clinical	ADJ	O	O
congestive	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
(	PUNCT	O	O
AmB	PROPN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
disseminated	VERB	O	O
coccidioidomycosis	NOUN	O	I-Entity
.	PUNCT	O	O

His	ADJ	O	O
echocardiographic	ADJ	O	O
abnormalities	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
resolved	VERB	O	O
after	ADP	O	O
posaconazole	NOUN	O	I-Entity
was	VERB	O	O
substituted	VERB	O	O
for	ADP	O	O
AmB.	PROPN	O	I-Entity
It	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
recognize	VERB	O	O
the	DET	O	O
rare	ADJ	O	O
and	CCONJ	O	O
potentially	ADV	O	O
reversible	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
AmB.	PROPN	O	I-Entity


-DOCSTART- (14765563)

Risks	NOUN	O	O
of	ADP	O	O
the	DET	O	O
consumption	NOUN	O	O
of	ADP	O	O
beverages	NOUN	O	O
containing	VERB	O	O
quinine	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
Food	PROPN	O	O
and	CCONJ	O	O
Drug	PROPN	O	O
Administration	PROPN	O	O
banned	VERB	O	O
its	ADJ	O	O
use	NOUN	O	O
for	ADP	O	O
nocturnal	ADJ	O	B-Entity
leg	NOUN	O	I-Entity
cramps	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
lack	NOUN	O	O
of	ADP	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
quinine	NOUN	O	I-Entity
is	VERB	O	O
widely	ADV	O	O
available	ADJ	O	O
in	ADP	O	O
beverages	NOUN	O	O
including	VERB	O	O
tonic	NOUN	O	O
water	NOUN	O	O
and	CCONJ	O	O
bitter	ADJ	O	O
lemon	NOUN	O	O
.	PUNCT	O	O

Numerous	ADJ	O	O
anecdotal	ADJ	O	O
reports	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
products	NOUN	O	O
containing	VERB	O	O
quinine	NOUN	O	I-Entity
may	VERB	O	O
produce	VERB	O	O
neurological	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
altered	VERB	O	O
mental	ADJ	O	O
status	NOUN	O	O
,	PUNCT	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
coma	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
older	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

Psychologists	NOUN	O	O
need	VERB	O	O
to	PART	O	O
inquire	VERB	O	O
about	ADP	O	O
consumption	NOUN	O	O
of	ADP	O	O
quinine	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
beverages	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
an	DET	O	O
evaluation	NOUN	O	O
process	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15036754)

Organophosphate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
neuropathological	ADJ	O	B-Entity
damages	NOUN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
organophosphorus	NOUN	O	I-Entity
(	PUNCT	O	O
OP	PROPN	O	I-Entity
)	PUNCT	O	O
compounds	NOUN	O	O
as	ADP	O	O
diisopropylfluorophosphate	NOUN	O	I-Entity
(	PUNCT	O	O
DFP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
sarin	NOUN	O	I-Entity
and	CCONJ	O	O
soman	NOUN	O	I-Entity
are	VERB	O	O
potent	ADJ	O	O
inhibitors	NOUN	O	O
of	ADP	O	O
acetylcholinesterases	NOUN	O	O
(	PUNCT	O	O
AChEs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
butyrylcholinesterases	NOUN	O	O
(	PUNCT	O	O
BChEs	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
acute	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
OPs	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
irreversible	ADJ	O	O
binding	NOUN	O	O
with	ADP	O	O
AChEs	PROPN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
elevates	VERB	O	O
acetylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
ACh	PROPN	O	I-Entity
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
protective	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
subcutaneously	NOUN	O	O
(	PUNCT	O	O
SC	NOUN	O	O
)	PUNCT	O	O
administered	ADJ	O	O
antidotes	NOUN	O	O
or	CCONJ	O	O
their	ADJ	O	O
combinations	NOUN	O	O
in	ADP	O	O
DFP	PROPN	O	I-Entity
(	PUNCT	O	O
2.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
intoxication	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
9	NUM	O	O
-	PUNCT	O	O
10-weeks	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Han	PROPN	O	O
-	PUNCT	O	O
Wistar	PROPN	O	O
male	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rats	NOUN	O	O
received	VERB	O	O
AChE	PROPN	O	O
reactivator	NOUN	O	O
pralidoxime-2-chloride	NOUN	O	I-Entity
(	PUNCT	O	O
2PAM	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
30.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
anticonvulsant	ADJ	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
2.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
A(1)-adenosine	ADJ	O	I-Entity
receptor	NOUN	O	O
agonist	NOUN	O	O

N(6)-cyclopentyl	PROPN	O	B-Entity
adenosine	NOUN	O	I-Entity
(	PUNCT	O	O
CPA	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
2.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
NMDA	PROPN	O	I-Entity
-	PUNCT	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
dizocilpine	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
(	PUNCT	O	O
+	SYM	O	O
-MK801	NUM	O	O
hydrogen	NOUN	O	O
maleate	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
2.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
their	ADJ	O	O
combinations	NOUN	O	O
with	ADP	O	O
cholinolytic	ADJ	O	O
drug	NOUN	O	O
atropine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
(	PUNCT	O	O
50.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
immediately	ADV	O	O
or	CCONJ	O	O
30	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
the	DET	O	O
single	ADJ	O	O
SC	NOUN	O	O
injection	NOUN	O	O
of	ADP	O	O
DFP	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
rats	NOUN	O	O
received	VERB	O	O
atropine	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
also	ADV	O	O
saline	ADJ	O	O
and	CCONJ	O	O
olive	ADJ	O	O
oil	NOUN	O	O
instead	ADV	O	O
of	ADP	O	O
other	ADJ	O	O
antidotes	NOUN	O	O
and	CCONJ	O	O
DFP	PROPN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

All	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
terminated	VERB	O	O
either	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
or	CCONJ	O	O
3	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
DFP	PROPN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
DFP	PROPN	O	I-Entity
-	PUNCT	O	O
atropine	NOUN	O	I-Entity
showed	VERB	O	O
severe	ADJ	O	O
typical	ADJ	O	O
OP	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
toxicity	NOUN	O	I-Entity
signs	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
CPA	PROPN	O	I-Entity
,	PUNCT	O	O
diazepam	NOUN	O	I-Entity
or	CCONJ	O	O
2PAM	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
DFP	PROPN	O	I-Entity
-	PUNCT	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
these	DET	O	O
treatments	NOUN	O	O
prevented	VERB	O	O
,	PUNCT	O	O
delayed	VERB	O	O
or	CCONJ	O	O
shortened	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
poisoning	NOUN	O	I-Entity
.	PUNCT	O	O

Atropine	NOUN	O	I-Entity
-	PUNCT	O	O
MK801	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
offer	VERB	O	O
any	DET	O	O
additional	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
DFP	PROPN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
CPA	PROPN	O	I-Entity
,	PUNCT	O	O
diazepam	NOUN	O	I-Entity
and	CCONJ	O	O
2PAM	NUM	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
atropine	NOUN	O	I-Entity
prevented	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
poisoning	NOUN	O	I-Entity
and	CCONJ	O	O
thus	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
DFP	PROPN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15145918)

Differential	ADJ	O	O
modulation	NOUN	O	O
by	ADP	O	O
estrogen	NOUN	O	I-Entity
of	ADP	O	O
alpha2-adrenergic	ADJ	O	O
and	CCONJ	O	O
I1-imidazoline	ADJ	O	I-Entity
receptor	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
recently	ADV	O	O
shown	VERB	O	O
that	ADP	O	O
estrogen	NOUN	O	I-Entity
negatively	ADV	O	O
modulates	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
(	PUNCT	O	O
mixed	ADJ	O	O
alpha2-/I1-receptor	NOUN	O	O
agonist	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
and	CCONJ	O	O
implicates	VERB	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
autonomic	ADJ	O	O
control	NOUN	O	O
in	ADP	O	O
this	DET	O	O
interaction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
investigated	VERB	O	O
whether	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
involves	VERB	O	O
interaction	NOUN	O	O
with	ADP	O	O
alpha2-	NOUN	O	O
and/or	CCONJ	O	O
I1-receptors	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
evoked	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
intraperitoneal	NOUN	O	O
injection	NOUN	O	O
of	ADP	O	O
rilmenidine	NOUN	O	I-Entity
(	PUNCT	O	O
600	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
selective	ADJ	O	O
I1-	NOUN	O	O
and	CCONJ	O	O
alpha2-receptor	NOUN	O	O
agonists	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
hemodynamic	ADJ	O	O
variability	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
radiotelemetered	VERB	O	O
sham	NOUN	O	O
-	PUNCT	O	O
operated	VERB	O	O
and	CCONJ	O	O
ovariectomized	VERB	O	O
(	PUNCT	O	O
Ovx	PROPN	O	O
)	PUNCT	O	O

Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
female	ADJ	O	O
rats	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
12-wk	NUM	O	O
estrogen	NOUN	O	I-Entity
replacement	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
sham	NOUN	O	O
-	PUNCT	O	O
operated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
rilmenidine	NOUN	O	I-Entity
or	CCONJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
elicited	VERB	O	O
similar	ADJ	O	O
hypotension	NOUN	O	I-Entity
that	ADJ	O	O
lasted	VERB	O	O
at	ADP	O	O
least	ADJ	O	O
5	NUM	O	O
h	PROPN	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
reductions	NOUN	O	O
in	ADP	O	O
standard	ADJ	O	O
deviation	NOUN	O	O
of	ADP	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

SDRR	PROPN	O	O
was	VERB	O	O
reduced	VERB	O	O
only	ADV	O	O
by	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
.	PUNCT	O	O

Ovx	PROPN	O	O
significantly	ADV	O	O
enhanced	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
to	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
rilmenidine	NOUN	O	I-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
enhanced	ADJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
hypotension	NOUN	O	I-Entity
in	ADP	O	O
Ovx	PROPN	O	O
rats	NOUN	O	O
was	VERB	O	O
paralleled	VERB	O	O
with	ADP	O	O
further	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
SDRR	PROPN	O	O
and	CCONJ	O	O
a	DET	O	B-Entity
reduced	ADJ	O	I-Entity
locomotor	NOUN	O	I-Entity
activity	NOUN	O	I-Entity
.	PUNCT	O	O

Estrogen	NOUN	O	O
replacement	NOUN	O	O
(	PUNCT	O	O
17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
estradiol	NOUN	O	I-Entity
subcutaneous	ADJ	O	O
pellet	NOUN	O	O
,	PUNCT	O	O
14.2	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
wk	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
Ovx	PROPN	O	O
rats	NOUN	O	O
restored	VERB	O	O
the	DET	O	O
hemodynamic	NOUN	O	O
and	CCONJ	O	O
locomotor	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
to	ADP	O	O
sham	VERB	O	O
-	PUNCT	O	O
operated	VERB	O	O
levels	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
estrogen	NOUN	O	I-Entity
downregulates	NOUN	O	O
alpha2-	X	O	O
but	CCONJ	O	O
not	ADV	O	O
I1-receptor	NUM	O	O
-	PUNCT	O	O
mediated	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
highlight	VERB	O	O
a	DET	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
cardiac	ADJ	O	O
autonomic	NOUN	O	O
control	NOUN	O	O
in	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyldopa	NOUN	O	I-Entity
-	PUNCT	O	O
estrogen	NOUN	O	I-Entity
interaction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15233872)

Cardioprotective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
tincture	NOUN	O	B-Entity
of	ADP	O	I-Entity
Crataegus	PROPN	O	I-Entity
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Tincture	NOUN	O	B-Entity
of	ADP	O	I-Entity
Crataegus	PROPN	O	I-Entity
(	PUNCT	O	O
TCR	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
alcoholic	ADJ	O	B-Entity
extract	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
berries	NOUN	O	I-Entity
of	ADP	O	I-Entity
hawthorn	NOUN	O	I-Entity
(	PUNCT	O	O
Crataegus	PROPN	O	B-Entity
oxycantha	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
herbal	ADJ	O	O
and	CCONJ	O	O
homeopathic	ADJ	O	O
medicine	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
done	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
TCR	PROPN	O	I-Entity
on	ADP	O	O
experimentally	ADV	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
of	ADP	O	O
TCR	PROPN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mL/100	PROPN	O	O
g	INTJ	O	O
bodyweight	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
orally	ADV	O	O
for	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
prevented	VERB	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
marker	NOUN	O	O
enzymes	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
85	NUM	O	O
mg	NUM	O	O
kg(-1	NOUN	O	O
)	PUNCT	O	O
s.	NOUN	O	O
c.	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
at	ADP	O	O
an	DET	O	O
interval	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
h	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

TCR	PROPN	O	I-Entity
prevented	VERB	O	O
the	DET	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
decrease	NOUN	O	O
in	ADP	O	O
antioxidant	NOUN	O	O
enzymes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
ADP	PROPN	O	I-Entity
-	PUNCT	O	O
stimulated	VERB	O	O
oxygen	NOUN	O	I-Entity
uptake	NOUN	O	O
and	CCONJ	O	O
respiratory	ADJ	O	O
coupling	NOUN	O	O
ratio	NOUN	O	O
.	PUNCT	O	O

TCR	NOUN	O	I-Entity
protected	VERB	O	O
against	ADP	O	O
pathological	ADJ	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
heart	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
TCR	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
the	DET	O	O
damage	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
heart	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15458908)

Safety	NOUN	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
raloxifene	NOUN	O	I-Entity
:	PUNCT	O	O
multiple	ADJ	O	O
outcomes	NOUN	O	O
of	ADP	O	O
raloxifene	ADJ	O	I-Entity
evaluation	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
examine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
raloxifene	NOUN	O	I-Entity
on	ADP	O	O
major	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
that	ADJ	O	O
occur	VERB	O	O
with	ADP	O	O
postmenopausal	NOUN	O	O
estrogen	NOUN	O	I-Entity
therapy	NOUN	O	O
or	CCONJ	O	O
tamoxifen	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Multiple	PROPN	O	O
Outcomes	PROPN	O	O
of	ADP	O	O
Raloxifene	PROPN	O	I-Entity
Evaluation	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
enrolled	VERB	O	O
7,705	NUM	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
with	ADP	O	O
osteoporosis	NOUN	O	I-Entity
.	PUNCT	O	O

Women	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
raloxifene	VERB	O	I-Entity
60	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
or	CCONJ	O	O
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Outcomes	NOUN	O	O
included	VERB	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
,	PUNCT	O	O
cataracts	NOUN	O	I-Entity
,	PUNCT	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
endometrial	ADJ	O	B-Entity
hyperplasia	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
3.3	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
raloxifene	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
[	PUNCT	O	O
RR	PROPN	O	O
]	PUNCT	O	O
2.1	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	PROPN	O	O
]	PUNCT	O	O
1.2	NUM	O	O
-	SYM	O	O
3.8	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Risk	NOUN	O	O
in	ADP	O	O
the	DET	O	O
raloxifene	NOUN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
decreased	VERB	O	O
to	ADP	O	O
about	ADP	O	O
the	DET	O	O
same	ADJ	O	O
rate	NOUN	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
thereafter	ADV	O	O
.	PUNCT	O	O

Raloxifene	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
increase	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
cataracts	NOUN	O	I-Entity
(	PUNCT	O	O
RR	PROPN	O	O
0.9	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.8	NUM	O	O
-	SYM	O	O
1.1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
RR	PROPN	O	O
1.0	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.7	NUM	O	O
-	SYM	O	O
1.3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
endometrial	ADJ	O	B-Entity
hyperplasia	NOUN	O	I-Entity
(	PUNCT	O	O
RR	PROPN	O	O
1.3	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.4	NUM	O	O
-	SYM	O	O
5.1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
RR	PROPN	O	O
0.9	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.3	NUM	O	O
-	SYM	O	O
2.7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Raloxifene	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
cataracts	NOUN	O	I-Entity
,	PUNCT	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
endometrial	ADJ	O	B-Entity
hyperplasia	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15737522)

Ceftriaxone	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
biliary	NOUN	O	B-Entity
pseudolithiasis	NOUN	O	I-Entity
in	ADP	O	O
paediatric	ADJ	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
well	ADV	O	O
known	VERB	O	O
that	ADP	O	O
ceftriaxone	NOUN	O	I-Entity
leads	VERB	O	O
to	ADP	O	O
pseudolithiasis	NOUN	O	I-Entity
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
studies	NOUN	O	O
also	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
situations	NOUN	O	O
causing	VERB	O	O
gallbladder	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
fasting	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
pseudolithiasis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
importance	NOUN	O	O
of	ADP	O	O
pseudolithiasis	NOUN	O	I-Entity
in	ADP	O	O
paediatric	ADJ	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
receiving	VERB	O	O
ceftriaxone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
often	ADV	O	O
had	VERB	O	O
to	PART	O	O
fast	VERB	O	O
in	ADP	O	O
the	DET	O	O
post	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Fifty	NUM	O	O
children	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
ceftriaxone	NOUN	O	I-Entity
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
serial	ADJ	O	O
abdominal	ADJ	O	O
sonograms	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
pseudolithiasis	NOUN	O	I-Entity
revealed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
starvation	NOUN	O	O
variables	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
pseudolithiasis	NOUN	O	I-Entity
resolved	VERB	O	O
spontaneously	ADV	O	O
within	ADP	O	O
a	DET	O	O
short	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
pseudolithiasis	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
fasting	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (16005948)

Evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anticocaine	ADJ	O	O
monoclonal	ADJ	O	O
antibody	NOUN	O	O
GNC92H2	PROPN	O	I-Entity
as	ADP	O	O
an	DET	O	O
immunotherapy	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	B-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
illicit	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
continues	VERB	O	O
in	ADP	O	O
epidemic	NOUN	O	O
proportions	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	B-Entity
overdose	NOUN	O	I-Entity
remains	VERB	O	O
elusive	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
therapeutic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anticocaine	NOUN	O	O
antibody	NOUN	O	O
GNC92H2	PROPN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
using	VERB	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	B-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

Swiss	ADJ	O	O
albino	ADJ	O	O
mice	NOUN	O	O
prepared	VERB	O	O
with	ADP	O	O
intrajugular	ADJ	O	O
catheters	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
photocell	NOUN	O	O
cages	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
93	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
(	PUNCT	O	O
LD50	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
GNC92H2	PROPN	O	I-Entity
infusions	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
30	NUM	O	O
to	ADP	O	O
190	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

GNC92H2	PROPN	O	I-Entity
was	VERB	O	O
delivered	VERB	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADV	O	O
,	PUNCT	O	O
concomitantly	ADV	O	O
or	CCONJ	O	O
3	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
cocaine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
GNC92H2	PROPN	O	I-Entity
(	PUNCT	O	O
190	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
where	ADV	O	O
premorbid	ADJ	O	O
behaviors	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
up	PART	O	O
to	ADP	O	O
40%	NUM	O	O
,	PUNCT	O	O
seizures	VERB	O	I-Entity
up	PART	O	O
to	ADP	O	O
77%	NUM	O	O
and	CCONJ	O	O
death	NOUN	O	I-Entity
by	ADP	O	O
72%	NUM	O	O
.	PUNCT	O	O

Importantly	ADV	O	O
,	PUNCT	O	O
GNC92H2	PROPN	O	I-Entity
prevented	VERB	O	O
death	NOUN	O	I-Entity
even	ADV	O	O
post	NOUN	O	O
-	PUNCT	O	O
cocaine	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
support	VERB	O	O
the	DET	O	O
important	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
GNC92H2	PROPN	O	I-Entity
as	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
tool	NOUN	O	O
against	ADP	O	O
cocaine	NOUN	O	B-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16167916)

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
raloxifene	NOUN	O	I-Entity
therapy	NOUN	O	O
on	ADP	O	O
fibrinolysis	NOUN	O	O
markers	NOUN	O	O
:	PUNCT	O	O
TAFI	PROPN	O	O
,	PUNCT	O	O
tPA	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
PAI-1	PROPN	O	O
.	PUNCT	O	O

inhibitor-1	PROPN	O	O
(	PUNCT	O	O
PAI-1	PROPN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
the	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
raloxifene	NOUN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Thirty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
with	ADP	O	O
osteopenia	NOUN	O	I-Entity
or	CCONJ	O	O
osteoporosis	NOUN	O	I-Entity
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
this	DET	O	O
prospective	NOUN	O	O
,	PUNCT	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
raloxifene	ADJ	O	B-Entity
hydrochloride	NOUN	O	I-Entity
(	PUNCT	O	O
60	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
calcium	NOUN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Age	PROPN	O	O
-	PUNCT	O	O
matched	VERB	O	O
controls	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
14	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
only	ADV	O	O
calcium	NOUN	O	I-Entity
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Three	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
raloxifene	NOUN	O	I-Entity
treatment	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
TAFI	PROPN	O	O
antigen	NOUN	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
16%	NUM	O	O
change	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
tPA	PROPN	O	O
antigen	NOUN	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
25%	NUM	O	O
change	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
baseline	NOUN	O	O
TAFI	PROPN	O	O
antigen	NOUN	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
amenorrhea	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
;	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.33	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
raloxifene	NOUN	O	I-Entity
treatment	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
increased	VERB	O	O
tPA	PROPN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
TAFI	DET	O	O
levels	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16403073)

Ketoconazole	PROPN	O	I-Entity
induced	VERB	O	O
torsades	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
without	ADP	O	O
concomitant	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
QT	PROPN	O	O
interval	NOUN	O	O
-	PUNCT	O	O
prolonging	VERB	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Ketoconazole	PROPN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
proarrhythmic	ADJ	O	O
without	ADP	O	O
concomitant	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
QT	PROPN	O	O
interval	NOUN	O	O
-	PUNCT	O	O
prolonging	VERB	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
woman	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
markedly	ADV	O	O
prolonged	VERB	O	B-Entity
QT	PROPN	O	I-Entity
interval	NOUN	O	I-Entity
and	CCONJ	O	O
torsades	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
(	PUNCT	O	O
TdP	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
taking	VERB	O	O
ketoconazole	NOUN	O	I-Entity
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
fungal	ADJ	O	B-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
QT	PROPN	O	O
interval	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
upon	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
ketoconazole	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
postulate	VERB	O	O
that	DET	O	O
by	ADP	O	O
virtue	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
direct	ADJ	O	O
blocking	VERB	O	O
action	NOUN	O	O
on	ADP	O	O
IKr	PROPN	O	O
,	PUNCT	O	O
ketoconazole	NOUN	O	I-Entity
alone	ADV	O	O
may	VERB	O	O
prolong	VERB	O	O
QT	PROPN	O	O
interval	NOUN	O	O
and	CCONJ	O	O
induce	VERB	O	O
TdP.	PROPN	O	I-Entity

This	DET	O	O
calls	VERB	O	O
for	ADP	O	O
attention	NOUN	O	O
when	ADV	O	O
ketoconazole	NOUN	O	I-Entity
is	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
acquired	VERB	O	O
long	ADJ	O	B-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16755009)

Pharmacological	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
the	DET	O	O
potential	NOUN	O	O
of	ADP	O	O
Daucus	PROPN	O	O
carota	PROPN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
dysfunctions	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
aimed	VERB	O	O
at	ADP	O	O
investigating	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
Daucus	PROPN	O	O
carota	PROPN	O	O
seeds	NOUN	O	O
on	ADP	O	O
cognitive	ADJ	O	O
functions	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
serum	NOUN	O	O
cholesterol	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
cholinesterase	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ethanolic	ADJ	O	O
extract	NOUN	O	B-Entity
of	ADP	O	I-Entity
Daucus	PROPN	O	I-Entity
carota	PROPN	O	I-Entity
seeds	NOUN	O	I-Entity
(	PUNCT	O	O
DCE	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
orally	ADV	O	O
in	ADP	O	O
three	NUM	O	O
doses	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
,	PUNCT	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
seven	NUM	O	O
successive	ADJ	O	O
days	NOUN	O	O
to	ADP	O	O
different	ADJ	O	O
groups	NOUN	O	O
of	ADP	O	O
young	ADJ	O	O
and	CCONJ	O	O
aged	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Diazepam-	NOUN	O	I-Entity
,	PUNCT	O	O
scopolamine-	ADJ	O	I-Entity
and	CCONJ	O	O
ageing	VERB	O	O
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
served	VERB	O	O
as	ADP	O	O
the	DET	O	O
interoceptive	ADJ	O	O
behavioral	ADJ	O	O
models	NOUN	O	O
.	PUNCT	O	O

DCE	PROPN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
,	PUNCT	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
showed	VERB	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
memory	NOUN	O	O
scores	NOUN	O	O
of	ADP	O	O
young	ADJ	O	O
and	CCONJ	O	O
aged	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
improvement	NOUN	O	O
evoked	VERB	O	O
by	ADP	O	O
DCE	PROPN	O	I-Entity
was	VERB	O	O
23%	NUM	O	O
at	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
and	CCONJ	O	O
35%	NUM	O	O
at	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	VERB	O	O
in	ADP	O	O
young	ADJ	O	O
mice	NOUN	O	O
using	VERB	O	O
elevated	ADJ	O	O
plus	CCONJ	O	O
maze	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
DCE	PROPN	O	I-Entity
reversed	VERB	O	O
the	DET	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
0.4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O

kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Daucus	PROPN	O	B-Entity
carota	X	O	I-Entity
extract	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
,	PUNCT	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

reduced	VERB	O	O
significantly	ADV	O	O
the	DET	O	O
brain	NOUN	O	O
acetylcholinesterase	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
cholesterol	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
and	CCONJ	O	O
aged	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
cholinesterase	NOUN	O	O
activity	NOUN	O	O
evoked	VERB	O	O
by	ADP	O	O
DCE	PROPN	O	I-Entity
at	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
400	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
was	VERB	O	O
22%	NUM	O	O
in	ADP	O	O
young	ADJ	O	O
and	CCONJ	O	O
19%	NUM	O	O
in	ADP	O	O
aged	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
remarkable	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
cholesterol	NOUN	O	I-Entity
level	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
,	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
23%	NUM	O	O
in	ADP	O	O
young	ADJ	O	O
and	CCONJ	O	O
21%	NUM	O	O
in	ADP	O	O
aged	VERB	O	O
animals	NOUN	O	O
with	ADP	O	O
this	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
DCE	PROPN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
DCE	PROPN	O	I-Entity
may	VERB	O	O
prove	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
remedy	NOUN	O	O
for	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
dysfunctions	NOUN	O	I-Entity
on	ADP	O	O
account	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
multifarious	ADJ	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
,	PUNCT	O	O
memory	NOUN	O	O
improving	VERB	O	O
property	NOUN	O	O
,	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
lowering	VERB	O	O
property	NOUN	O	O
and	CCONJ	O	O
anticholinesterase	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16904497)

Cauda	PROPN	O	B-Entity
equina	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
after	ADP	O	O
epidural	ADJ	O	O
steroid	NOUN	O	I-Entity
injection	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

Conventional	ADJ	O	O
treatment	NOUN	O	O
methods	NOUN	O	O
of	ADP	O	O
lumbusacral	ADJ	O	O
radiculopathy	NOUN	O	I-Entity
are	VERB	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
epidural	ADJ	O	O
steroid	NOUN	O	I-Entity
injections	NOUN	O	O
,	PUNCT	O	O
oral	ADJ	O	O
medications	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
spinal	ADJ	O	O
manipulative	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Cauda	PROPN	O	B-Entity
equina	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
epidural	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
following	VERB	O	O
case	NOUN	O	O
is	VERB	O	O
a	DET	O	O
report	NOUN	O	O
of	ADP	O	O
cauda	NOUN	O	B-Entity
equina	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
possibly	ADV	O	O
caused	VERB	O	O
by	ADP	O	O
epidural	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
triamcinolone	NOUN	O	I-Entity
and	CCONJ	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
50-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
low	ADJ	O	B-Entity
back	ADV	O	I-Entity
and	CCONJ	O	I-Entity
right	ADJ	O	I-Entity
leg	NOUN	O	I-Entity
pain	NOUN	O	I-Entity
was	VERB	O	O
scheduled	VERB	O	O
for	ADP	O	O
epidural	ADJ	O	O
steroid	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
verifying	VERB	O	O
the	DET	O	O
epidural	ADJ	O	O
space	NOUN	O	O
,	PUNCT	O	O
bupivacaine	NOUN	O	I-Entity
and	CCONJ	O	O
triamcinolone	NOUN	O	B-Entity
diacetate	NOUN	O	I-Entity
were	VERB	O	O
injected	VERB	O	O
.	PUNCT	O	O

Three	NUM	O	O
hours	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
she	PRON	O	O
complained	VERB	O	O
of	ADP	O	O
perineal	ADJ	O	O
numbness	NOUN	O	I-Entity
and	CCONJ	O	O
lower	ADJ	O	B-Entity
extremity	NOUN	O	I-Entity
weakness	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
neurologic	ADJ	O	O
evaluation	NOUN	O	O
revealed	VERB	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
sensation	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
saddle	NOUN	O	O
area	NOUN	O	O
and	CCONJ	O	O
medial	ADJ	O	O
aspect	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
right	ADJ	O	O
leg	NOUN	O	O
.	PUNCT	O	O

Complications	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
epidural	ADJ	O	O
steroid	NOUN	O	I-Entity
injections	NOUN	O	O
are	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
examination	NOUN	O	O
and	CCONJ	O	O
continued	VERB	O	O
vigilance	NOUN	O	O
for	ADP	O	O
neurologic	ADJ	O	B-Entity
deterioration	NOUN	O	I-Entity
after	ADP	O	O
epidural	ADJ	O	O
steroid	NOUN	O	I-Entity
injections	NOUN	O	O
is	VERB	O	O
important	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (16938416)

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
testosterone	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
atherosclerosis	NOUN	O	I-Entity
in	ADP	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
androgen	NOUN	O	O
treatment	NOUN	O	O
on	ADP	O	O
atherosclerosis	NOUN	O	I-Entity
in	ADP	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
population	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
study	NOUN	O	O
in	ADP	O	O
513	NUM	O	O
naturally	ADV	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
aged	VERB	O	O
54	NUM	O	O
-	SYM	O	O
67	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
self	NOUN	O	O
-	PUNCT	O	O
reported	VERB	O	O
intramuscularly	ADV	O	O
administered	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
testosterone	NOUN	O	I-Entity
therapy	NOUN	O	O
(	PUNCT	O	O
estradiol-	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
testosterone	NOUN	O	I-Entity
esters	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
aortic	ADJ	O	O
atherosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

Aortic	ADJ	O	O
atherosclerosis	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
by	ADP	O	O
radiographic	ADJ	O	O
detection	NOUN	O	O
of	ADP	O	O
calcified	VERB	O	O
deposits	NOUN	O	O
in	ADP	O	O
the	DET	O	O
abdominal	ADJ	O	O
aorta	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
reflect	VERB	O	O
intima	ADJ	O	O
atherosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
almost	ADV	O	O
half	NOUN	O	O
of	ADP	O	O
these	DET	O	O
women	NOUN	O	O
severe	ADJ	O	O
atherosclerosis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
aorta	NOUN	O	O
was	VERB	O	O
present	ADJ	O	O
(	PUNCT	O	O
n=11	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
in	ADP	O	O
women	NOUN	O	O
without	ADP	O	O
hormone	NOUN	O	O
use	NOUN	O	O
severe	ADJ	O	O
atherosclerosis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
aorta	NOUN	O	O
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
20%	NUM	O	O
(	PUNCT	O	O
OR	CCONJ	O	O
3.1	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.1	NUM	O	O
-	SYM	O	O
8.5	NUM	O	O
,	PUNCT	O	O
adjusted	VERB	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
years	NOUN	O	O
since	ADP	O	O
menopause	NOUN	O	O
,	PUNCT	O	O
smoking	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
remained	VERB	O	O
after	ADP	O	O
additional	ADJ	O	O
adjustment	NOUN	O	O
for	ADP	O	O
diabetes	NOUN	O	I-Entity
,	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
level	NOUN	O	O
,	PUNCT	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
testosterone	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
adversely	ADV	O	O
affect	VERB	O	O
atherosclerosis	NOUN	O	I-Entity
in	ADP	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
and	CCONJ	O	O
indicate	VERB	O	O
that	ADP	O	O
androgen	NOUN	O	O
replacement	NOUN	O	O
in	ADP	O	O
these	DET	O	O
women	NOUN	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
harmless	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (17147461)

Sirolimus	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Sirolimus	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
immunosuppressant	NOUN	O	O
with	ADP	O	O
potent	ADJ	O	O
antiproliferative	ADJ	O	O
actions	NOUN	O	O
through	ADP	O	O
its	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
inhibit	VERB	O	O
the	DET	O	O
raptor	NOUN	O	O
-	PUNCT	O	O
containing	VERB	O	O
mammalian	ADJ	O	O
target	NOUN	O	O
of	ADP	O	O
rapamycin	NOUN	O	I-Entity
protein	NOUN	O	O
kinase	NOUN	O	O
.	PUNCT	O	O

Sirolimus	PROPN	O	I-Entity
represents	VERB	O	O
a	DET	O	O
major	ADJ	O	O
therapeutic	ADJ	O	O
advance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
renal	ADJ	O	O
allograft	NOUN	O	O
rejection	NOUN	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
allograft	NOUN	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Its	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
therapy	NOUN	O	O
of	ADP	O	O
glomerulonephritis	NOUN	O	I-Entity
,	PUNCT	O	O
autoimmunity	NOUN	O	I-Entity
,	PUNCT	O	O
cystic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
diseases	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
is	VERB	O	O
under	ADP	O	O
investigation	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
sirolimus	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
share	VERB	O	O
the	DET	O	O
vasomotor	NOUN	O	O
renal	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
exhibited	VERB	O	O
by	ADP	O	O
calcineurin	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
has	VERB	O	O
been	VERB	O	O
designated	VERB	O	O
a	DET	O	O
'	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
nephrotoxic	ADJ	O	I-Entity
drug	NOUN	O	O
'	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
reports	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
under	ADP	O	O
some	DET	O	O
circumstances	NOUN	O	O
,	PUNCT	O	O
sirolimus	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
common	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
presence	NOUN	O	O
of	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
proteinuria	NOUN	O	I-Entity
are	VERB	O	O
multifactorial	ADJ	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
capillary	ADJ	O	O
pressure	NOUN	O	O
following	VERB	O	O
calcineurin	NOUN	O	O
inhibitor	NOUN	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
also	ADV	O	O
been	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
sirolimus	NOUN	O	I-Entity
directly	ADV	O	O
causes	VERB	O	O
increased	VERB	O	O
glomerular	ADJ	O	O
permeability	NOUN	O	O
/	SYM	O	O
injury	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
this	DET	O	O
mechanism	NOUN	O	O
is	VERB	O	O
currently	ADV	O	O
inconclusive	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sirolimus	NOUN	O	I-Entity
(	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
in	ADP	O	O
delayed	VERB	O	O
graft	NOUN	O	O
function	NOUN	O	O
)	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
compensatory	ADJ	O	O
renal	ADJ	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
and	CCONJ	O	O
survival	NOUN	O	O
/	SYM	O	O
repair	NOUN	O	O
processes	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
these	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
occur	VERB	O	O
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
their	ADJ	O	O
occurrence	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
minimised	VERB	O	O
by	ADP	O	O
knowledge	NOUN	O	O
of	ADP	O	O
the	DET	O	O
molecular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
in	ADP	O	O
appropriate	ADJ	O	O
patient	NOUN	O	O
populations	NOUN	O	O
,	PUNCT	O	O
close	ADJ	O	O
monitoring	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitors	NOUN	O	O
or	CCONJ	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
blockers	NOUN	O	O
if	ADP	O	O
proteinuria	NOUN	O	I-Entity
occurs	VERB	O	O
and	CCONJ	O	O
withdrawal	NOUN	O	O
if	ADP	O	O
needed	VERB	O	O
.	PUNCT	O	O

Further	ADV	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
allograft	NOUN	O	O
studies	NOUN	O	O
using	VERB	O	O
sirolimus	NOUN	O	I-Entity
as	ADP	O	O
de	X	O	O
novo	X	O	O


-DOCSTART- (17241784)

Progressive	ADJ	O	O
myopathy	NOUN	O	I-Entity
with	ADP	O	O
up	ADP	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
MHC	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
associated	VERB	O	O
with	ADP	O	O
statin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Statins	NOUN	O	I-Entity
can	VERB	O	O
cause	VERB	O	O
a	DET	O	O
necrotizing	NOUN	O	O
myopathy	NOUN	O	I-Entity
and	CCONJ	O	O
hyperCKaemia	NOUN	O	I-Entity
which	ADJ	O	O
is	VERB	O	O
reversible	ADJ	O	O
on	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

What	NOUN	O	O
is	VERB	O	O
less	ADV	O	O
well	ADV	O	O
known	VERB	O	O
is	VERB	O	O
a	DET	O	O
phenomenon	NOUN	O	O
whereby	ADV	O	O
statins	NOUN	O	I-Entity
may	VERB	O	O
induce	VERB	O	O
a	DET	O	O
myopathy	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
persists	VERB	O	O
or	CCONJ	O	O
may	VERB	O	O
progress	VERB	O	O
after	ADP	O	O
stopping	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
had	VERB	O	O
myofibre	ADJ	O	O
necrosis	NOUN	O	I-Entity
but	CCONJ	O	O
only	ADV	O	O
3	NUM	O	O
had	VERB	O	O
an	DET	O	O
inflammatory	ADJ	O	O
infiltrate	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
there	ADV	O	O
was	VERB	O	O
diffuse	NOUN	O	O
or	CCONJ	O	O
multifocal	ADJ	O	O
up	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
MHC	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
expression	VERB	O	O
even	ADV	O	O
in	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
necrotic	ADJ	O	I-Entity
fibres	NOUN	O	O
.	PUNCT	O	O

Progressive	ADJ	O	O
improvement	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
7	NUM	O	O
cases	NOUN	O	O
after	ADP	O	O
commencement	NOUN	O	O
of	ADP	O	O
prednisolone	NOUN	O	I-Entity
and	CCONJ	O	O
methotrexate	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
one	NUM	O	O
case	NOUN	O	O
spontaneously	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
statins	NOUN	O	I-Entity
may	VERB	O	O
initiate	VERB	O	O
an	DET	O	O
immune	ADJ	O	O
-	PUNCT	O	O
mediated	VERB	O	O
myopathy	NOUN	O	I-Entity
that	ADJ	O	O
persists	VERB	O	O
after	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
responds	VERB	O	O
to	ADP	O	O
immunosuppressive	VERB	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
this	DET	O	O
myopathy	NOUN	O	I-Entity
is	VERB	O	O
uncertain	ADJ	O	O
but	CCONJ	O	O
may	VERB	O	O
involve	VERB	O	O
the	DET	O	O
induction	NOUN	O	O
by	ADP	O	O
statins	NOUN	O	I-Entity
of	ADP	O	O
an	DET	O	O
endoplasmic	NOUN	O	O
reticulum	NOUN	O	O
stress	NOUN	O	O
response	NOUN	O	O
with	ADP	O	O
associated	VERB	O	O
up	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
MHC	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
expression	NOUN	O	O
and	CCONJ	O	O
antigen	NOUN	O	O
presentation	NOUN	O	O
by	ADP	O	O
muscle	NOUN	O	O
fibres	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17261653)

Direct	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
hyperpolarization	NOUN	O	O
-	PUNCT	O	O
activated	VERB	O	O
cyclic	ADJ	O	B-Entity
nucleotide	ADV	O	I-Entity
-	PUNCT	O	O
gated	ADJ	O	O
pacemaker	NOUN	O	O
channels	NOUN	O	O
by	ADP	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	PROPN	O	O
:	PUNCT	O	O
Inhibition	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
sympathetic	ADJ	O	O
tone	NOUN	O	O
represents	VERB	O	O
an	DET	O	O
important	ADJ	O	O
strategy	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
arrhythmia	NOUN	O	I-Entity
,	PUNCT	O	O
coronary	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Activation	NOUN	O	O
of	ADP	O	O
presynaptic	ADJ	O	O
alpha2-adrenoceptors	NOUN	O	O
is	VERB	O	O
the	DET	O	O
most	ADV	O	O
widely	ADV	O	O
accepted	VERB	O	O
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antisympathetic	ADJ	O	O
drug	NOUN	O	O
clonidine	NOUN	O	I-Entity
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
other	ADJ	O	O
target	NOUN	O	O
proteins	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
postulated	VERB	O	O
to	PART	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
in	ADP	O	O
vivo	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
test	VERB	O	O
whether	ADP	O	O
clonidine	NOUN	O	I-Entity
elicits	VERB	O	O
pharmacological	ADJ	O	O
effects	NOUN	O	O
independent	ADJ	O	O
of	ADP	O	O
alpha2-adrenoceptors	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
generated	VERB	O	O
mice	NOUN	O	O
with	ADP	O	O
a	DET	O	O
targeted	ADJ	O	O
deletion	NOUN	O	O
of	ADP	O	O
all	DET	O	O
3	NUM	O	O
alpha2-adrenoceptor	NOUN	O	O
subtypes	NOUN	O	O
(	PUNCT	O	O
alpha2ABC-/-	X	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Alpha2ABC-/-	DET	O	O
mice	NOUN	O	O
were	VERB	O	O
completely	ADV	O	O
unresponsive	ADJ	O	O
to	ADP	O	O
the	DET	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
hypnotic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
clonidine	NOUN	O	I-Entity
significantly	ADV	O	O
lowered	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
alpha2ABC-/-	ADJ	O	O
mice	NOUN	O	O
by	ADP	O	O
up	ADP	O	O
to	PART	O	O
150	NUM	O	O
bpm	NOUN	O	O
.	PUNCT	O	O

Clonidine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
alpha2ABC-/-	ADJ	O	O
mice	NOUN	O	O
was	VERB	O	O
32.3%	NUM	O	O
(	PUNCT	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
26.6%	NUM	O	O
(	PUNCT	O	O
100	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
in	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
similar	ADJ	O	O
bradycardic	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
isolated	ADJ	O	O
spontaneously	ADV	O	O
beating	VERB	O	O
right	ADJ	O	O
atria	NOUN	O	O
from	ADP	O	O
alpha2ABC	NUM	O	O
-	PUNCT	O	O
knockout	NOUN	O	O
and	CCONJ	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Clonidine	PROPN	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
native	ADJ	O	O
pacemaker	NOUN	O	O
current	NOUN	O	O
(	PUNCT	O	O
I(f	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
isolated	ADJ	O	O
sinoatrial	ADJ	O	O
node	NOUN	O	O
pacemaker	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
I(f)-generating	VERB	O	O
hyperpolarization	NOUN	O	O
-	PUNCT	O	O
activated	VERB	O	O
cyclic	ADJ	O	B-Entity
nucleotide	ADV	O	I-Entity
-	PUNCT	O	O
gated	ADJ	O	O
(	PUNCT	O	O
HCN	PROPN	O	O
)	PUNCT	O	O
2	NUM	O	O
and	CCONJ	O	O
HCN4	ADJ	O	O
channels	NOUN	O	O
in	ADP	O	O
transfected	VERB	O	O
HEK293	PROPN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
blocking	VERB	O	O
I(f	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
clonidine	NOUN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
slope	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diastolic	ADJ	O	O
depolarization	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
pacemaker	NOUN	O	O
potentials	NOUN	O	O
in	ADP	O	O
sinoatrial	ADJ	O	O
node	NOUN	O	O
cells	NOUN	O	O
from	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
and	CCONJ	O	O
alpha2ABC	NOUN	O	O
-	PUNCT	O	O
knockout	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Direct	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
HCN	PROPN	O	O
pacemaker	NOUN	O	O
channels	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
the	DET	O	O
bradycardic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
gene	NOUN	O	O
-	PUNCT	O	O
targeted	VERB	O	O
mice	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thus	ADV	O	O
,	PUNCT	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
drugs	NOUN	O	O
represent	VERB	O	O
novel	ADJ	O	O
structures	NOUN	O	O
for	ADP	O	O
future	ADJ	O	O
HCN	PROPN	O	O
channel	NOUN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17343925)

Influence	NOUN	O	O
of	ADP	O	O
smoking	NOUN	O	I-Entity
on	ADP	O	O
developing	VERB	O	O
cochlea	NOUN	O	O
.	PUNCT	O	O

Does	VERB	O	O
smoking	NOUN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
affect	VERB	O	O
the	DET	O	O
amplitudes	NOUN	O	O
of	ADP	O	O
transient	NOUN	O	O
evoked	VERB	O	O
otoacoustic	ADJ	O	O
emissions	NOUN	O	O
in	ADP	O	O
newborns	NOUN	O	O
?	PUNCT	O	O

Maternal	ADJ	O	O
tobacco	NOUN	O	O
smoking	NOUN	O	I-Entity
has	VERB	O	O
negative	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
fetal	ADJ	O	O
growth	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
smoking	NOUN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
on	ADP	O	O
the	DET	O	O
developing	VERB	O	O
cochlea	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
estimated	VERB	O	O
,	PUNCT	O	O
although	ADP	O	O
smoking	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
positively	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
adults	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
smoking	NOUN	O	I-Entity
on	ADP	O	O
transient	ADJ	O	O
evoked	VERB	O	O
otoacoustic	ADJ	O	O
emissions	NOUN	O	O
(	PUNCT	O	O
TEOAEs	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
healthy	ADJ	O	O
neonates	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
neonatal	ADJ	O	O
screening	NOUN	O	O
for	ADP	O	O
hearing	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
involved	VERB	O	O
both	DET	O	O
ears	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
newborns	NOUN	O	O
.	PUNCT	O	O

Newborns	PROPN	O	O
whose	ADJ	O	O
mothers	NOUN	O	O
reported	VERB	O	O
smoking	NOUN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
(	PUNCT	O	O
n=200	ADJ	O	O
ears	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
newborns	NOUN	O	O
(	PUNCT	O	O
n=200	ADJ	O	O
ears	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whose	ADJ	O	O
mothers	NOUN	O	O
were	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
smokers	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
by	ADP	O	O
comparing	VERB	O	O
each	DET	O	O
subgroup	NOUN	O	O
to	PART	O	O
control	VERB	O	O
group	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
decreases	NOUN	O	B-Entity
of	ADP	O	I-Entity
TEOAEs	PROPN	O	I-Entity
amplitudes	NOUN	O	I-Entity
at	ADP	O	O
4000Hz	NUM	O	O
for	ADP	O	O
all	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
utero	NOUN	O	O
,	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
tobacco	NOUN	O	O
smoking	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
small	ADJ	O	O
impact	NOUN	O	O
on	ADP	O	O
outer	ADJ	O	O
hair	NOUN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
establish	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
negative	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
smoking	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
neonate	NOUN	O	O
's	PART	O	O
hearing	NOUN	O	O
acuity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17400887)

Neuroinflammation	PROPN	O	I-Entity
and	CCONJ	O	O
behavioral	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
after	ADP	O	O
neonatal	ADJ	O	O
terbutaline	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
:	PUNCT	O	O
implications	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	I-Entity
.	PUNCT	O	O

Autism	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
neurodevelopmental	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
presenting	VERB	O	O
before	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
with	ADP	O	O
deficits	NOUN	O	B-Entity
in	ADP	O	I-Entity
communication	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
social	ADJ	O	I-Entity
skills	NOUN	O	I-Entity
and	CCONJ	O	O
repetitive	ADJ	O	B-Entity
behaviors	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
genetic	ADJ	O	O
influences	NOUN	O	O
,	PUNCT	O	O
recent	ADJ	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
prenatal	ADJ	O	O
drug	NOUN	O	O
or	CCONJ	O	O
chemical	NOUN	O	O
exposures	NOUN	O	O
are	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	I-Entity
.	PUNCT	O	O

Terbutaline	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
beta2-adrenoceptor	NOUN	O	O
agonist	NOUN	O	O
used	VERB	O	O
to	PART	O	O
arrest	VERB	O	O
preterm	NOUN	O	B-Entity
labor	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
concordance	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	I-Entity
in	ADP	O	O
dizygotic	ADJ	O	O
twins	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
terbutaline	NOUN	O	I-Entity
on	ADP	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
in	ADP	O	O
different	ADJ	O	O
brain	NOUN	O	O
regions	NOUN	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
outcomes	NOUN	O	O
in	ADP	O	O
developing	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Newborn	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
terbutaline	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
daily	ADV	O	O
on	ADP	O	O
postnatal	ADJ	O	O
days	NOUN	O	O
(	PUNCT	O	O
PN	PROPN	O	O
)	PUNCT	O	O
2	NUM	O	O
to	PART	O	O
5	NUM	O	O
or	CCONJ	O	O
PN	PROPN	O	O
11	NUM	O	O
to	ADP	O	O
14	NUM	O	O
and	CCONJ	O	O
examined	VERB	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
dose	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
PN	PROPN	O	O
30	NUM	O	O
.	PUNCT	O	O

Immunohistochemical	ADJ	O	O
studies	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
terbutaline	NOUN	O	I-Entity
on	ADP	O	O
PN	PROPN	O	O
2	NUM	O	O
to	ADP	O	O
5	NUM	O	O
produced	VERB	O	O
a	DET	O	O
robust	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
on	ADP	O	O
PN	PROPN	O	O
30	NUM	O	O
in	ADP	O	O
the	DET	O	O
cerebral	ADJ	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
cerebellar	NOUN	O	O
and	CCONJ	O	O
cerebrocortical	ADJ	O	O
white	ADJ	O	O
matter	NOUN	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
these	DET	O	O
effects	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
given	VERB	O	O
terbutaline	NOUN	O	I-Entity
on	ADP	O	O
PN	PROPN	O	O
11	NUM	O	O
to	ADP	O	O
14	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
behavioral	ADJ	O	O
tests	NOUN	O	O
,	PUNCT	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
terbutaline	NOUN	O	I-Entity
on	ADP	O	O
PN	PROPN	O	O
2	NUM	O	O
to	ADP	O	O
5	NUM	O	O
showed	VERB	O	O
consistent	ADJ	O	O
patterns	NOUN	O	O
of	ADP	O	O
hyper	ADJ	O	O
-	PUNCT	O	O
reactivity	NOUN	O	O
to	PART	O	O
novelty	NOUN	O	O
and	CCONJ	O	O
aversive	ADJ	O	O
stimuli	NOUN	O	O
when	ADV	O	O
assessed	VERB	O	O
in	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
open	ADJ	O	O
field	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
acoustic	ADJ	O	O
startle	NOUN	O	O
response	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
beta2-adrenoceptor	NOUN	O	O
overstimulation	NOUN	O	O
during	ADP	O	O
an	DET	O	O
early	ADJ	O	O
critical	ADJ	O	O
period	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
innate	ADJ	O	O
neuroinflammatory	NOUN	O	O
pathways	NOUN	O	O
and	CCONJ	O	O
behavioral	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
,	PUNCT	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
described	VERB	O	O
in	ADP	O	O
autism	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
provides	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
animal	NOUN	O	O
model	NOUN	O	O
for	ADP	O	O
understanding	VERB	O	O
the	DET	O	O
neuropathological	ADJ	O	O
processes	NOUN	O	O
underlying	VERB	O	O
autism	NOUN	O	B-Entity
spectrum	NOUN	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17612891)

Acute	PROPN	O	O
myocarditis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
myocarditis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
commencement	NOUN	O	O
of	ADP	O	O
clozapine	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
,	PUNCT	O	O
highlighting	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
,	PUNCT	O	O
course	NOUN	O	O
and	CCONJ	O	O
possible	ADJ	O	O
contributing	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
an	DET	O	O
urgent	ADJ	O	O
need	NOUN	O	O
to	PART	O	O
raise	VERB	O	O
awareness	NOUN	O	O
about	ADP	O	O
this	DET	O	O
potentially	ADV	O	O
fatal	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
clozapine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
20-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
developed	VERB	O	O
a	DET	O	O
sudden	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
myocarditis	NOUN	O	I-Entity
after	ADP	O	O
commencement	NOUN	O	O
of	ADP	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
symptoms	NOUN	O	O
occurred	VERB	O	O
around	ADV	O	O
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
starting	VERB	O	O
clozapine	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
inpatient	NOUN	O	O
setting	NOUN	O	O
.	PUNCT	O	O

Possible	ADJ	O	O
contributing	NOUN	O	O
factors	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
concomitant	ADJ	O	O
antidepressant	NOUN	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
unaccustomed	ADJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Myocarditis	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
increasingly	ADV	O	O
recognized	VERB	O	O
complication	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O

Considering	VERB	O	O
that	ADP	O	O
clozapine	NOUN	O	I-Entity
remains	VERB	O	O
the	DET	O	O
gold	ADJ	O	O
standard	NOUN	O	O
in	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
resistant	ADJ	O	O
psychosis	NOUN	O	I-Entity
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
an	DET	O	O
urgent	ADJ	O	O
need	NOUN	O	O
to	PART	O	O
raise	VERB	O	O
awareness	NOUN	O	O
among	ADP	O	O
medical	ADJ	O	O
and	CCONJ	O	O
paramedical	ADJ	O	O
staff	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
care	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
are	VERB	O	O
also	ADV	O	O
implications	NOUN	O	O
for	ADP	O	O
recommendations	NOUN	O	O
and	CCONJ	O	O
regulations	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18081909)

Encephalopathy	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
levetiracetam	NOUN	O	I-Entity
added	VERB	O	O
to	ADP	O	O
valproate	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
the	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
levetiracetam	NOUN	O	I-Entity
(	PUNCT	O	O
LEV)-induced	VERB	O	I-Entity
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
28-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
idiopathic	ADJ	O	B-Entity
epilepsy	NOUN	O	I-Entity
with	ADP	O	O
generalized	ADJ	O	O
seizures	NOUN	O	I-Entity
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
LEV	PROPN	O	I-Entity
(	PUNCT	O	O
3000	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
added	VERB	O	O
to	ADP	O	O
valproate	VERB	O	I-Entity
(	PUNCT	O	O
VPA	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
2000	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Frequency	PROPN	O	O
of	ADP	O	O
generalized	ADJ	O	O
tonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clonic	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
increased	VERB	O	O
from	ADP	O	O
one	NUM	O	O
per	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
to	ADP	O	O
two	NUM	O	O
per	ADP	O	O
month	NOUN	O	O
.	PUNCT	O	O

Neuropsychological	ADJ	O	O
testing	NOUN	O	O
showed	VERB	O	O
impaired	ADJ	O	B-Entity
word	NOUN	O	I-Entity
fluency	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
psychomotor	NOUN	O	I-Entity
speed	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
working	VERB	O	I-Entity
memory	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
LEV	PROPN	O	I-Entity
,	PUNCT	O	O
EEG	PROPN	O	O
and	CCONJ	O	O
neuropsychological	ADJ	O	O
findings	NOUN	O	O
improved	VERB	O	O
and	CCONJ	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
decreased	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18083142)

Norepinephrine	PROPN	O	I-Entity
signaling	VERB	O	O
through	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
receptors	NOUN	O	O
is	VERB	O	O
critical	ADJ	O	O
for	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
widely	ADV	O	O
abused	VERB	O	O
psychostimulant	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
both	DET	O	O
rewarding	ADJ	O	O
and	CCONJ	O	O
aversive	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
mechanisms	NOUN	O	O
underlying	VERB	O	O
cocaine	NOUN	O	I-Entity
's	PART	O	O
rewarding	ADJ	O	O
effects	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
studied	VERB	O	O
extensively	ADV	O	O
,	PUNCT	O	O
less	ADJ	O	O
attention	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
paid	VERB	O	O
to	ADP	O	O
the	DET	O	O
unpleasant	ADJ	O	O
behavioral	ADJ	O	O
states	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

:	PUNCT	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
performance	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
beta	NOUN	O	O
-	PUNCT	O	O
hydroxylase	NOUN	O	O
knockout	NOUN	O	O
(	PUNCT	O	O
Dbh	PROPN	O	O
-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
lack	VERB	O	O
norepinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
NE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
elevated	ADJ	O	O
plus	CCONJ	O	O
maze	NOUN	O	O
(	PUNCT	O	O
EPM	PROPN	O	O
)	PUNCT	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
noradrenergic	ADJ	O	O
signaling	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
cocaine	NOUN	O	I-Entity
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
increased	VERB	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
control	NOUN	O	O
(	PUNCT	O	O
Dbh	PROPN	O	O
+	SYM	O	O
/-	PUNCT	O	O

mice	NOUN	O	O
had	VERB	O	O
normal	ADJ	O	O
baseline	NOUN	O	O
performance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
EPM	PROPN	O	O
but	CCONJ	O	O
were	VERB	O	O
completely	ADV	O	O
resistant	ADJ	O	O
to	ADP	O	O
the	DET	O	O
anxiogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
attenuated	VERB	O	O
in	ADP	O	O
Dbh	PROPN	O	O
+	SYM	O	O
/-	PUNCT	O	O

mice	NOUN	O	O
following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
disulfiram	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
dopamine	NOUN	O	I-Entity
beta	NOUN	O	O
-	PUNCT	O	O
hydroxylase	NOUN	O	O
(	PUNCT	O	O
DBH	PROPN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
experiments	NOUN	O	O
using	VERB	O	O
specific	ADJ	O	O
adrenergic	ADJ	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
that	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
propranolol	NOUN	O	I-Entity
blocked	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
Dbh	PROPN	O	O
+	SYM	O	O
/-	PUNCT	O	O

and	CCONJ	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
C57BL6/J	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
alpha(1	NOUN	O	O
)	PUNCT	O	O
antagonist	NOUN	O	O
prazosin	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
alpha(2	PROPN	O	O
)	PUNCT	O	O
antagonist	NOUN	O	O
yohimbine	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
noradrenergic	ADJ	O	O
signaling	VERB	O	O
via	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
receptors	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
for	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiety	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18182964)

Clonidine	NOUN	O	I-Entity
for	ADP	O	O
attention	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
deficit	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
hyperactivity	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
:	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
examine	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
used	VERB	O	O
alone	ADV	O	O
or	CCONJ	O	O
with	ADP	O	O
methylphenidate	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
attention	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
deficit	NOUN	O	I-Entity
/	PUNCT	O	I-Entity
hyperactivity	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
ADHD	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
16-week	ADJ	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
122	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
ADHD	PROPN	O	I-Entity
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
clonidine	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
31	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O

methylphenidate	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
29	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
methylphenidate	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
32	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O

Doses	NOUN	O	O
were	VERB	O	O
flexibly	ADV	O	O
titrated	VERB	O	O
up	PART	O	O
to	ADP	O	O
0.6	NUM	O	O
mg	NUM	O	O
/	DET	O	O
day	NOUN	O	O
for	ADP	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
60	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
methylphenidate	NOUN	O	I-Entity
(	PUNCT	O	O
both	DET	O	O
with	ADP	O	O
divided	VERB	O	O
dosing	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
more	ADJ	O	O
incidents	NOUN	O	O
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
clonidine	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
not	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
clonidine	NOUN	O	I-Entity
(	PUNCT	O	O
17.5%	NUM	O	O
versus	ADP	O	O
3.4%	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
other	ADJ	O	O
significant	ADJ	O	O
group	NOUN	O	O
differences	NOUN	O	O
regarding	VERB	O	O
electrocardiogram	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
cardiovascular	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
suggestions	NOUN	O	O
of	ADP	O	O
interactions	NOUN	O	O
between	ADP	O	O
clonidine	NOUN	O	I-Entity
and	CCONJ	O	O
methylphenidate	NOUN	O	I-Entity
regarding	VERB	O	O
cardiovascular	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Moderate	NUM	O	O
or	CCONJ	O	O
severe	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
subjects	NOUN	O	O
on	ADP	O	O
clonidine	NOUN	O	I-Entity
(	PUNCT	O	O
79.4%	NUM	O	O
versus	ADP	O	O
49.2%	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.0006	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
higher	ADJ	O	O
rates	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
study	NOUN	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O

Drowsiness	NOUN	O	I-Entity
was	VERB	O	O
common	ADJ	O	O
on	ADP	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
generally	ADV	O	O
resolved	VERB	O	O
by	ADP	O	O
6	NUM	O	O
to	PART	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
used	VERB	O	O
alone	ADV	O	O
or	CCONJ	O	O
with	ADP	O	O
methylphenidate	NOUN	O	I-Entity
,	PUNCT	O	O
appears	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
tolerated	VERB	O	O
in	ADP	O	O
childhood	NOUN	O	O
ADHD	PROPN	O	I-Entity
.	PUNCT	O	O

Physicians	NOUN	O	O
prescribing	VERB	O	O
clonidine	NOUN	O	I-Entity
should	VERB	O	O
monitor	VERB	O	O
for	ADP	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
advise	VERB	O	O
patients	NOUN	O	O
about	ADP	O	O
the	DET	O	O
high	ADJ	O	O
likelihood	NOUN	O	O
of	ADP	O	O
initial	ADJ	O	O
drowsiness	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18217897)

Thalidomide	PROPN	O	I-Entity
has	VERB	O	O
limited	VERB	O	O
single	ADJ	O	O
-	PUNCT	O	O
agent	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
relapsed	VERB	O	O
or	CCONJ	O	O
refractory	ADJ	O	O
indolent	ADJ	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
Hodgkin	PROPN	O	I-Entity
lymphomas	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
trial	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Cancer	PROPN	O	I-Entity
and	CCONJ	O	O
Leukemia	PROPN	O	I-Entity
Group	PROPN	O	O
B.	PROPN	O	O
Thalidomide	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
immunomodulatory	ADJ	O	O
agent	NOUN	O	O
with	ADP	O	O
demonstrated	VERB	O	O
activity	NOUN	O	O
in	ADP	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
,	PUNCT	O	O
mantle	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
lymphoma	NOUN	O	I-Entity
and	CCONJ	O	O
lymphoplasmacytic	ADJ	O	B-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

Its	ADJ	O	O
activity	NOUN	O	O
is	VERB	O	O
believed	VERB	O	O
to	PART	O	O
be	VERB	O	O
due	ADJ	O	O
modulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tumour	NOUN	O	I-Entity
milieu	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
downregulation	NOUN	O	O
of	ADP	O	O
angiogenesis	NOUN	O	O
and	CCONJ	O	O
inflammatory	ADJ	O	O
cytokines	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
July	PROPN	O	O
2001	NUM	O	O
and	CCONJ	O	O
April	PROPN	O	O
2004	NUM	O	O
,	PUNCT	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O
refractory	ADJ	O	O
indolent	ADJ	O	O
lymphomas	NOUN	O	I-Entity
received	VERB	O	O
thalidomide	ADV	O	I-Entity
200	NUM	O	O
mg	NUM	O	O
daily	ADJ	O	O
with	ADP	O	O
escalation	NOUN	O	O
by	ADP	O	O
100	NUM	O	O
mg	NUM	O	O
daily	NOUN	O	O
every	DET	O	O
1	NUM	O	O
-	SYM	O	O
2	NUM	O	O
weeks	NOUN	O	O
as	ADP	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
800	NUM	O	O
mg	NUM	O	O
daily	ADV	O	O
.	PUNCT	O	O

included	VERB	O	O
myelosuppression	NOUN	O	I-Entity
,	PUNCT	O	O
fatigue	NOUN	O	I-Entity
,	PUNCT	O	O
somnolence	NOUN	O	I-Entity
/	PUNCT	O	O
depressed	ADJ	O	B-Entity
mood	NOUN	O	I-Entity
,	PUNCT	O	O
neuropathy	NOUN	O	I-Entity
and	CCONJ	O	O
dyspnea	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
concern	NOUN	O	O
was	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
thromboembolic	ADJ	O	I-Entity
events	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
demonstrate	VERB	O	O
an	DET	O	O
important	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
to	ADP	O	O
single	ADJ	O	O
agent	NOUN	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
indolent	ADJ	O	O
lymphomas	NOUN	O	I-Entity
and	CCONJ	O	O
contrast	NOUN	O	O
with	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
activity	NOUN	O	O
level	NOUN	O	O
reported	VERB	O	O
with	ADP	O	O
the	DET	O	O
second	ADJ	O	O
generation	NOUN	O	O
immunomodulatory	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
lenalidomide	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18996674)

Intracavernous	ADJ	O	O
epinephrine	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
minimally	ADV	O	O
invasive	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
priapism	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
.	PUNCT	O	O

Priapism	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
prolonged	ADJ	O	O
erection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
penis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	O
arousal	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
45-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
admitted	VERB	O	O
frequent	ADJ	O	O
cocaine	NOUN	O	I-Entity
user	NOUN	O	O
,	PUNCT	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
Emergency	PROPN	O	O
Department	PROPN	O	O
(	PUNCT	O	O
ED	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
two	NUM	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
priapism	NOUN	O	I-Entity
after	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
management	NOUN	O	O
options	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ED	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
exemplified	VERB	O	O
by	ADP	O	O
four	NUM	O	O
individual	ADJ	O	O
case	NOUN	O	O
reports	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
particular	ADJ	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
minimally	ADV	O	O
invasive	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
intracorporal	ADJ	O	O
epinephrine	NOUN	O	I-Entity
instillation	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19058010)

Effect	PROPN	O	O
of	ADP	O	O
green	ADJ	O	B-Entity
tea	NOUN	O	I-Entity
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
combination	NOUN	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
combined	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
green	ADJ	O	B-Entity
tea	NOUN	O	I-Entity
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
on	ADP	O	O
heart	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
marker	NOUN	O	O
enzymes	NOUN	O	O
,	PUNCT	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
,	PUNCT	O	O
endogenous	ADJ	O	O
antioxidants	NOUN	O	O
and	CCONJ	O	O
membrane	NOUN	O	O
bound	VERB	O	O
ATPases	NOUN	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
ISO)-induced	VERB	O	I-Entity
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Adult	ADJ	O	O
male	ADJ	O	O
albino	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
ISO	PROPN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
s.c	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
at	ADP	O	O
an	DET	O	O
interval	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
elevation	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
marker	NOUN	O	O
enzymes	NOUN	O	O
,	PUNCT	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
and	CCONJ	O	O
Ca+2	PROPN	O	I-Entity
ATPase	PROPN	O	O
level	NOUN	O	O
whereas	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
endogenous	ADJ	O	O
antioxidants	NOUN	O	O
,	PUNCT	O	O
Na+/	PROPN	O	I-Entity
K+	PROPN	O	I-Entity
ATPase	PROPN	O	O
and	CCONJ	O	O
Mg+2	PROPN	O	I-Entity
ATPase	PROPN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
green	ADJ	O	B-Entity
tea	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

together	ADV	O	O
for	ADP	O	O
30	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
and	CCONJ	O	O
challenged	VERB	O	O
with	ADP	O	O
ISO	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
day	NOUN	O	O
29th	NOUN	O	O
and	CCONJ	O	O
30th	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
decrease	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
marker	NOUN	O	O
enzymes	NOUN	O	O
,	PUNCT	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
,	PUNCT	O	O
Ca+2	PROPN	O	I-Entity
ATPase	PROPN	O	O
and	CCONJ	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
body	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
endogenous	ADJ	O	O
antioxidants	NOUN	O	O
,	PUNCT	O	O
Na+/K+	PROPN	O	I-Entity
ATPase	PROPN	O	O
and	CCONJ	O	O
Mg+2	PROPN	O	I-Entity
ATPase	PROPN	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
ISO	PROPN	O	I-Entity
treated	VERB	O	O
group	NOUN	O	O
and	CCONJ	O	O
green	ADJ	O	B-Entity
tea	NOUN	O	I-Entity
or	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
alone	ADV	O	O
treated	VERB	O	O
groups	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
the	DET	O	O
synergistic	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
green	ADJ	O	B-Entity
tea	NOUN	O	I-Entity
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
during	ADP	O	O
ISO	PROPN	O	I-Entity
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19581773)

Development	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	B-Entity
myasthenia	NOUN	O	I-Entity
during	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C.	PROPN	O	I-Entity

A	DET	O	O
63-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	ADJ	O	O
experienced	ADJ	O	O
sudden	ADJ	O	O
diplopia	NOUN	O	I-Entity
after	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
IFN	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
alpha-2b	X	O	I-Entity
and	CCONJ	O	O
ribavirin	VERB	O	I-Entity
for	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	PROPN	O	I-Entity
(	PUNCT	O	O
CHC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Ophthalmologic	ADJ	O	O
examinations	NOUN	O	O
showed	VERB	O	O
ptosis	NOUN	O	B-Entity
on	ADP	O	I-Entity
the	DET	O	I-Entity
right	ADJ	O	I-Entity
upper	ADJ	O	I-Entity
lid	NOUN	O	I-Entity
and	CCONJ	O	O
restricted	VERB	O	B-Entity
right	ADJ	O	I-Entity
eye	NOUN	O	I-Entity
movement	NOUN	O	I-Entity
without	ADP	O	O
any	DET	O	O
other	ADJ	O	O
neurological	ADJ	O	O
signs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
antibody	NOUN	O	O
titer	NOUN	O	O
and	CCONJ	O	O
response	NOUN	O	O
to	ADP	O	O
acetylcholinesterase	NOUN	O	O
inhibitors	NOUN	O	O
were	VERB	O	O
negative	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
thyroid	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
ophthalmological	ADJ	O	O
symptoms	NOUN	O	O
improved	VERB	O	O
rapidly	ADV	O	O
3	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
pegylated	VERB	O	B-Entity
IFN	PROPN	O	I-Entity
alpha-2b	PROPN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
ocular	ADJ	O	B-Entity
myasthenia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
pegylated	VERB	O	B-Entity
IFN	PROPN	O	I-Entity
alpha-2b	PROPN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
for	ADP	O	O
CHC	PROPN	O	I-Entity
is	VERB	O	O
very	ADV	O	O
rarely	ADV	O	O
reported	VERB	O	O
;	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
present	VERB	O	O
this	DET	O	O
case	NOUN	O	O
with	ADP	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
various	ADJ	O	O
eye	NOUN	O	O
complications	NOUN	O	O
of	ADP	O	O
IFN	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19759529)

The	DET	O	O
glycine	NOUN	O	I-Entity
transporter-1	ADJ	O	O
inhibitor	NOUN	O	O
SSR103800	NOUN	O	I-Entity
displays	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
and	CCONJ	O	O
specific	ADJ	O	O
antipsychotic	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
profile	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
and	CCONJ	O	O
transgenic	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Schizophrenia	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
initially	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
dysfunction	NOUN	O	O
in	ADP	O	O
dopamine	NOUN	O	I-Entity
neurotransmission	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
observation	NOUN	O	O
that	ADJ	O	O
antagonists	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glutamate	NOUN	O	I-Entity
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
produce	VERB	O	O
schizophrenic	ADJ	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
has	VERB	O	O
led	VERB	O	O
to	ADP	O	O
the	DET	O	O
idea	NOUN	O	O
of	ADP	O	O
a	DET	O	O
dysfunctioning	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glutamatergic	ADJ	O	O
system	NOUN	O	O
via	ADP	O	O
its	ADJ	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
growing	VERB	O	O
interest	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
pharmacological	ADJ	O	O
agents	NOUN	O	O
with	ADP	O	O
potential	ADJ	O	O
antipsychotic	ADJ	O	O
properties	NOUN	O	O
that	ADJ	O	O
enhance	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glutamatergic	ADJ	O	O
system	NOUN	O	O
via	ADP	O	O
a	DET	O	O
modulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
them	PRON	O	O
are	VERB	O	O
glycine	ADJ	O	I-Entity
transporter-1	NOUN	O	O
(	PUNCT	O	O
GlyT1	PROPN	O	O
)	PUNCT	O	O

inhibitors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
SSR103800	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
indirectly	ADV	O	O
enhance	VERB	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
function	NOUN	O	O
by	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
glycine	NOUN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
co	NOUN	O	O
-	PUNCT	O	O
agonist	NOUN	O	O
for	ADP	O	O
the	DET	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
synapse	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
aimed	VERB	O	O
at	ADP	O	O
investigating	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
antipsychotic	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
SSR103800	PROPN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
particular	ADJ	O	O
focus	NOUN	O	O
on	ADP	O	O
models	NOUN	O	O
of	ADP	O	O
hyperactivity	NOUN	O	I-Entity
,	PUNCT	O	O
involving	VERB	O	O
either	CCONJ	O	O
drug	NOUN	O	O
challenge	NOUN	O	O
(	PUNCT	O	O
ie	X	O	O
,	PUNCT	O	O
amphetamine	NOUN	O	I-Entity
and	CCONJ	O	O
MK-801	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
transgenic	ADJ	O	O
mice	NOUN	O	O
(	PUNCT	O	O
ie	ADV	O	O
,	PUNCT	O	O
NMDA	PROPN	O	I-Entity
Nr1(neo-/-	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
DAT(-/-	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
SSR103800	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

blocked	VERB	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
competitive	ADJ	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
MK-801	PROPN	O	I-Entity
and	CCONJ	O	O
partially	ADV	O	O
reversed	VERB	O	O
spontaneous	ADJ	O	O
hyperactivity	NOUN	O	I-Entity
of	ADP	O	O
NMDA	PROPN	O	I-Entity
Nr1(neo-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
SSR103800	PROPN	O	I-Entity
failed	VERB	O	O
to	PART	O	O
affect	VERB	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
amphetamine	NOUN	O	I-Entity
or	CCONJ	O	O
naturally	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
dopamine	NOUN	O	I-Entity
transporter	NOUN	O	O
(	PUNCT	O	O
DAT(-/-	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
knockout	NOUN	O	O
mice	NOUN	O	O

Importantly	ADV	O	O
,	PUNCT	O	O
both	DET	O	O
classical	ADJ	O	O
(	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
atypical	ADJ	O	O
(	PUNCT	O	O
olanzapine	NOUN	O	I-Entity
,	PUNCT	O	O
clozapine	NOUN	O	I-Entity
and	CCONJ	O	O
aripiprazole	NOUN	O	I-Entity
)	PUNCT	O	O

antipsychotics	NOUN	O	O
were	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
all	ADJ	O	O
these	DET	O	O
models	NOUN	O	O
of	ADP	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
unlike	ADP	O	O
these	DET	O	O
latter	ADJ	O	O
,	PUNCT	O	O
SSR103800	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
catalepsy	NOUN	O	I-Entity
(	PUNCT	O	O
retention	NOUN	O	O
on	ADP	O	O
the	DET	O	O
bar	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O

Together	ADV	O	O
these	DET	O	O
findings	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
GlyT1	PROPN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
SSR103800	PROPN	O	I-Entity
,	PUNCT	O	O
produces	VERB	O	O
antipsychotic	ADJ	O	O
-	PUNCT	O	O
like	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
differ	VERB	O	O
from	ADP	O	O
those	DET	O	O
observed	VERB	O	O
with	ADP	O	O
compounds	NOUN	O	O
primarily	ADV	O	O
targeting	VERB	O	O
the	DET	O	O
dopaminergic	ADJ	O	O
system	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
has	VERB	O	O
a	DET	O	O
reduced	VERB	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
potential	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
these	DET	O	O
latter	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19957053)

Phenylephrine	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
ephedrine	ADJ	O	I-Entity
reduces	VERB	O	B-Entity
frontal	ADJ	O	I-Entity
lobe	NOUN	O	I-Entity
oxygenation	NOUN	O	I-Entity
following	VERB	O	O
anesthesia	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Vasopressor	PROPN	O	O
agents	NOUN	O	O
are	VERB	O	O
used	VERB	O	O
to	PART	O	O
correct	VERB	O	O
anesthesia	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	I-Entity
and	CCONJ	O	O
ephedrine	NOUN	O	I-Entity
on	ADP	O	O
frontal	ADJ	O	O
lobe	NOUN	O	O
oxygenation	NOUN	O	O
(	PUNCT	O	O
S(c)O(2	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
following	VERB	O	O
anesthesia	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
by	ADP	O	O
fentanyl	NOUN	O	I-Entity
(	PUNCT	O	O
0.15	NUM	O	O
mg	NUM	O	O
kg(-1	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
propofol	NOUN	O	I-Entity
(	PUNCT	O	O
2.0	NUM	O	O
mg	NUM	O	O
kg(-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
13	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
phenylephrine	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
mg	NUM	O	O
iv	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
ephedrine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
iv	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
restore	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
MAP	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MAP	PROPN	O	O
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
volume	NOUN	O	O
(	PUNCT	O	O
SV	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
(	PUNCT	O	O
CO	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
frontal	ADJ	O	O
lobe	NOUN	O	O
oxygenation	NOUN	O	O
(	PUNCT	O	O
S(c)O(2	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
registered	VERB	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	B-Entity
decrease	NOUN	O	I-Entity
in	ADP	O	I-Entity
MAP	PROPN	O	I-Entity
,	PUNCT	O	I-Entity
HR	PROPN	O	I-Entity
,	PUNCT	O	I-Entity
SV	PROPN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
CO	PROPN	O	I-Entity
concomitant	ADJ	O	O
with	ADP	O	O
an	DET	O	O
elevation	NOUN	O	O
in	ADP	O	O
S(c)O(2	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	I-Entity
,	PUNCT	O	O
MAP	PROPN	O	O
increased	VERB	O	O
(	PUNCT	O	O
51	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
MAP	PROPN	O	O
(	PUNCT	O	O
53	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
utilization	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	I-Entity
to	PART	O	O
correct	VERB	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
anesthesia	NOUN	O	O
has	VERB	O	O
a	DET	O	O
negative	ADJ	O	O
impact	NOUN	O	O
on	ADP	O	O
S(c)O(2	PROPN	O	O
)	PUNCT	O	O
while	ADP	O	O
ephedrine	NOUN	O	I-Entity
maintains	VERB	O	O
frontal	ADJ	O	O
lobe	NOUN	O	O
oxygenation	NOUN	O	O
potentially	ADV	O	O
related	VERB	O	O
to	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
CO	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (20619828)

A	DET	O	O
novel	NOUN	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
symptom	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
obsessive	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
compulsive	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
behaviors	NOUN	O	I-Entity
in	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Current	ADJ	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
obsessive	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
compulsive	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
OCD	PROPN	O	I-Entity
)	PUNCT	O	O
typically	ADV	O	O
involve	VERB	O	O
acute	ADJ	O	O
,	PUNCT	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
symptom	NOUN	O	O
provocation	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
genetic	ADJ	O	O
association	NOUN	O	O
with	ADP	O	O
stereotypies	NOUN	O	O
or	CCONJ	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
these	DET	O	O
current	ADJ	O	O
models	NOUN	O	O
demonstrate	VERB	O	O
multiple	ADJ	O	O
OCD	ADV	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
behaviors	NOUN	O	O
.	PUNCT	O	O

Neonatal	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	I-Entity
clomipramine	NOUN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
between	ADP	O	O
days	NOUN	O	O
9	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
and	CCONJ	O	O
behaviorally	ADV	O	O
tested	VERB	O	O
in	ADP	O	O
adulthood	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Clomipramine	NOUN	O	I-Entity
exposure	NOUN	O	O
in	ADP	O	O
immature	ADJ	O	O
rats	NOUN	O	O
produced	VERB	O	O
significant	ADJ	O	O
behavioral	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
changes	NOUN	O	O
that	ADJ	O	O
include	VERB	O	O
enhanced	ADJ	O	O
anxiety	NOUN	O	I-Entity
(	PUNCT	O	O
elevated	VERB	O	O
plus	CCONJ	O	O
maze	NOUN	O	O
and	CCONJ	O	O
marble	NOUN	O	O
burying	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
behavioral	ADJ	O	B-Entity
inflexibility	NOUN	O	I-Entity
(	PUNCT	O	O
perseveration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
spontaneous	ADJ	O	O
alternation	NOUN	O	O
task	NOUN	O	O
and	CCONJ	O	O
impaired	ADJ	O	O
reversal	NOUN	O	O
learning	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
working	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
(	PUNCT	O	O
e.g.	NOUN	O	O
,	PUNCT	O	O
win	VERB	O	O
-	PUNCT	O	O
shift	NOUN	O	O
paradigm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hoarding	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
corticostriatal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Dopamine	PROPN	O	I-Entity
D2	NOUN	O	O
receptors	NOUN	O	O
were	VERB	O	O
elevated	VERB	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
serotonin	NOUN	O	I-Entity
2C	NUM	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
serotonin	ADJ	O	I-Entity
1A	NOUN	O	O
,	PUNCT	O	O
receptors	NOUN	O	O
were	VERB	O	O
elevated	VERB	O	O
in	ADP	O	O
the	DET	O	O
orbital	ADJ	O	O
frontal	NOUN	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
demonstration	NOUN	O	O
of	ADP	O	O
multiple	ADJ	O	O
symptoms	NOUN	O	O
consistent	ADJ	O	O
with	ADP	O	O
an	DET	O	O
OCD	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
profile	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
behaviors	NOUN	O	O
are	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
biochemical	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
regions	NOUN	O	O
previously	ADV	O	O
identified	VERB	O	O
as	ADP	O	O
relevant	ADJ	O	O
to	ADP	O	O
OCD	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
novel	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
OCD	PROPN	O	I-Entity
demonstrates	VERB	O	O
that	ADP	O	O
drug	NOUN	O	O
exposure	NOUN	O	O
during	ADP	O	O
a	DET	O	O
sensitive	ADJ	O	O
period	NOUN	O	O
can	VERB	O	O
program	VERB	O	O
disease	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
systems	NOUN	O	O
permanently	ADV	O	O
,	PUNCT	O	O
which	ADJ	O	O
could	VERB	O	O
have	VERB	O	O
implications	NOUN	O	O
for	ADP	O	O
current	ADJ	O	O
and	CCONJ	O	O
future	ADJ	O	O
therapeutic	ADJ	O	O
strategies	NOUN	O	O
for	ADP	O	O
this	DET	O	O
and	CCONJ	O	O
other	ADJ	O	O
psychiatric	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (891050)

Late	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
with	ADP	O	O
the	DET	O	O
hemolytic	ADJ	O	B-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
of	ADP	O	O
the	DET	O	O
hemolytic	ADJ	O	B-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
HUS	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
taking	VERB	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
dipyridamole	NOUN	O	I-Entity
and	CCONJ	O	O
hemodialysis	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
her	ADJ	O	O
urinary	ADJ	O	O
output	NOUN	O	O
rose	VERB	O	O
above	ADP	O	O
500	NUM	O	O
ml	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
six	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
anuria	NOUN	O	I-Entity
,	PUNCT	O	O
dialysis	NOUN	O	O
treatment	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
emphasizes	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
HUS	PROPN	O	I-Entity
in	ADP	O	O
adults	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
invariably	ADV	O	O
irreversible	ADJ	O	O
and	CCONJ	O	O
that	DET	O	O
,	PUNCT	O	O
despite	ADP	O	O
prolonged	VERB	O	O
oliguria	NOUN	O	I-Entity
,	PUNCT	O	O
recovery	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
obtained	VERB	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
adult	NOUN	O	O
patients	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
HUS	PROPN	O	I-Entity
,	PUNCT	O	O
dialysis	NOUN	O	O
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
discontinued	VERB	O	O
prematurely	ADV	O	O
;	PUNCT	O	O
moreover	ADV	O	O
,	PUNCT	O	O
bilateral	ADJ	O	O
nephrectomy	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
microangiopathic	ADJ	O	B-Entity
hemolytic	ADJ	O	I-Entity
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
should	VERB	O	O
be	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
caution	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (983936)

Effects	NOUN	O	O
of	ADP	O	O
acetylsalicylic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
dipyridamole	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hydrocortisone	NOUN	O	I-Entity
on	ADP	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
reproducible	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
producing	VERB	O	O
diffuse	NOUN	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
(	PUNCT	O	O
epinephrine	ADJ	O	I-Entity
infusion	NOUN	O	O
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
developed	VERB	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
cardioprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
agents	NOUN	O	O
or	CCONJ	O	O
maneuvers	NOUN	O	O
which	ADJ	O	O
might	VERB	O	O
alter	VERB	O	O
the	DET	O	O
evolution	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Infusions	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mug	NOUN	O	O
per	ADP	O	O
kilogram	NOUN	O	O
per	ADP	O	O
minute	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
radiocalcium	NOUN	O	I-Entity
uptakes	NOUN	O	O
into	ADP	O	O
intact	ADJ	O	O
myocardium	NOUN	O	O
and	CCONJ	O	O
each	DET	O	O
of	ADP	O	O
its	ADJ	O	O
subcellular	ADJ	O	O
components	NOUN	O	O
with	ADP	O	O
the	DET	O	O
mitochondrial	ADJ	O	O
fraction	NOUN	O	O
showing	VERB	O	O
the	DET	O	O
most	ADV	O	O
consistent	ADJ	O	O
changes	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
saline	NOUN	O	O
-	PUNCT	O	O
infused	VERB	O	O
control	NOUN	O	O
animals	NOUN	O	O
(	PUNCT	O	O
4,957	NUM	O	O
vs.	ADP	O	O
827	NUM	O	O
counts	NOUN	O	O
per	ADP	O	O
minute	NOUN	O	O
per	ADP	O	O
gram	NOUN	O	O
of	ADP	O	O
dried	VERB	O	O
tissue	NOUN	O	O
or	CCONJ	O	O
fraction	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Myocardial	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
also	ADV	O	O
increased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
12.0	NUM	O	O
vs.	NOUN	O	O
5.0	NUM	O	O
mg.per	NOUN	O	O
100	NUM	O	O
Gm	PROPN	O	O
.	PUNCT	O	O

Infusions	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
sufficient	ADJ	O	O
to	PART	O	O
raise	VERB	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
concentrations	NOUN	O	O
2	NUM	O	O
mEq	PROPN	O	O
.	PUNCT	O	O

per	ADP	O	O
liter	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
increase	VERB	O	O
calcium	NOUN	O	I-Entity
influx	NOUN	O	O
into	ADP	O	O
the	DET	O	O
myocardial	ADJ	O	O
cell	NOUN	O	O
.	PUNCT	O	O

Mitochondrial	ADJ	O	O
radiocalcium	NOUN	O	I-Entity
uptakes	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
acetylsalicylic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
or	CCONJ	O	O
dipyridamole	NOUN	O	I-Entity
or	CCONJ	O	O
when	ADV	O	O
hydrocortisone	NOUN	O	I-Entity
was	VERB	O	O
added	VERB	O	O
to	ADP	O	O
the	DET	O	O
epinephrine	NOUN	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
2,682,2,803	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3,424	NUM	O	O
counts	NOUN	O	O
per	ADP	O	O
minute	NOUN	O	O
per	ADP	O	O
gram	NOUN	O	O
of	ADP	O	O
dried	VERB	O	O
fraction	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Myocardial	ADJ	O	O
calcium	NOUN	O	I-Entity
concentrations	NOUN	O	O
also	ADV	O	O
were	VERB	O	O
decreased	VERB	O	O
(	PUNCT	O	O
11.2	NUM	O	O
,	PUNCT	O	O
8.3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
8.9	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

Acetylsalicylic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
dipyridamole	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hydrocortisone	NOUN	O	I-Entity
all	DET	O	O
appear	VERB	O	O
to	PART	O	O
have	VERB	O	O
cardioprotective	ADJ	O	O
effects	NOUN	O	O
when	ADV	O	O
tested	VERB	O	O
in	ADP	O	O
this	DET	O	O
model	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1428568)

Changes	NOUN	O	O
in	ADP	O	O
depressive	ADJ	O	I-Entity
status	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
topical	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

Depression	NOUN	O	I-Entity
and	CCONJ	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
preliminary	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
any	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
a	DET	O	O
non	ADJ	O	O
selective	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
(	PUNCT	O	O
timolol	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
selective	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
(	PUNCT	O	O
betaxolol	NOUN	O	I-Entity
)	PUNCT	O	O
regarding	VERB	O	O
CNS	PROPN	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
glaucomatous	ADJ	O	I-Entity
patients	NOUN	O	O
chronically	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
timolol	NOUN	O	I-Entity
0.5%/12h	NUM	O	O
,	PUNCT	O	O
suffering	VERB	O	O
from	ADP	O	O
depression	NOUN	O	I-Entity
diagnosed	VERB	O	O
through	ADP	O	O
DMS	PROPN	O	O
-	PUNCT	O	O
III	PROPN	O	O
-	PUNCT	O	O
R	PROPN	O	O
criteria	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
six	NUM	O	O
-	PUNCT	O	O
month	NOUN	O	O
follow	NOUN	O	O
up	PART	O	O
,	PUNCT	O	O
depression	NOUN	O	I-Entity
was	VERB	O	O
quantified	VERB	O	O
through	ADP	O	O
the	DET	O	O
Beck	PROPN	O	O
and	CCONJ	O	O
Zung	PROPN	O	O
-	PUNCT	O	O
Conde	PROPN	O	O
scales	VERB	O	O
every	DET	O	O
two	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
cross	NOUN	O	O
-	PUNCT	O	O
over	PART	O	O
study	NOUN	O	O
with	ADP	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
under	ADP	O	O
timolol	ADJ	O	I-Entity
treatment	NOUN	O	O
presented	VERB	O	O
higher	ADJ	O	O
depression	NOUN	O	I-Entity
values	NOUN	O	O
measured	VERB	O	O
through	ADP	O	O
the	DET	O	O
Beck	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
Zung	PROPN	O	O
-	PUNCT	O	O
Conde	PROPN	O	O
scales	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
betaxolol	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
less	ADJ	O	O
of	ADP	O	O
a	DET	O	O
depression	NOUN	O	I-Entity
-	PUNCT	O	O
inducer	NOUN	O	O
than	ADP	O	O
timolol	NOUN	O	I-Entity
in	ADP	O	O
predisposed	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1720453)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
ifosfamide	ADJ	O	I-Entity
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
malignant	ADJ	O	B-Entity
mesenchymal	ADJ	O	I-Entity
tumors	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
International	PROPN	O	O
Society	PROPN	O	O
of	ADP	O	O
Pediatric	PROPN	O	O
Oncology	PROPN	O	O
report	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
renal	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
74	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
malignant	ADJ	O	B-Entity
mesenchymal	ADJ	O	I-Entity
tumors	NOUN	O	I-Entity
in	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
and	CCONJ	O	O
who	NOUN	O	O
have	VERB	O	O
received	VERB	O	O
the	DET	O	O
same	ADJ	O	O
ifosfamide	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
protocol	NOUN	O	O
(	PUNCT	O	O
International	PROPN	O	O
Society	PROPN	O	O
of	ADP	O	O
Pediatric	PROPN	O	O
Oncology	PROPN	O	O
Malignant	PROPN	O	B-Entity
Mesenchymal	PROPN	O	I-Entity
Tumor	PROPN	O	I-Entity
Study	PROPN	O	O
84	NUM	O	O
[	PUNCT	O	O
SIOP	PROPN	O	O
MMT	PROPN	O	O
84	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
1	NUM	O	O
year	NOUN	O	O
after	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
cumulative	ADJ	O	O
doses	NOUN	O	O
were	VERB	O	O
36	NUM	O	O
or	CCONJ	O	O
60	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
(	PUNCT	O	O
six	NUM	O	O
or	CCONJ	O	O
10	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
vincristine	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
dactinomycin	NOUN	O	I-Entity
[	PUNCT	O	O
IVA	PROPN	O	I-Entity
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
them	PRON	O	O
had	VERB	O	O
received	VERB	O	O
cisplatin	ADJ	O	I-Entity
chemotherapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
primary	ADJ	O	O
tumor	NOUN	O	I-Entity
site	NOUN	O	O
was	VERB	O	O
the	DET	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
electrolytes	NOUN	O	O
,	PUNCT	O	O
glucosuria	NOUN	O	I-Entity
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
aminoaciduria	NOUN	O	I-Entity
,	PUNCT	O	O
urinary	ADJ	O	O
pH	NOUN	O	O
,	PUNCT	O	O
osmolarity	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
,	PUNCT	O	O
phosphate	ADJ	O	I-Entity
tubular	ADJ	O	O
reabsorption	NOUN	O	O
,	PUNCT	O	O
beta	NOUN	O	O
2	NUM	O	O
microglobulinuria	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lysozymuria	NOUN	O	O
.	PUNCT	O	O

Fifty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
78%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
normal	ADJ	O	O
renal	ADJ	O	O
tests	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
22%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
renal	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

the	DET	O	O
first	ADJ	O	O
included	VERB	O	O
four	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
5%	NUM	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
population	NOUN	O	O
)	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
major	ADJ	O	O
toxicity	NOUN	O	I-Entity
resulting	VERB	O	O
in	ADP	O	O
Fanconi	PROPN	O	B-Entity
's	PART	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
TDFS	PROPN	O	I-Entity
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
included	VERB	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
elevated	ADJ	O	O
beta	NOUN	O	O
2	NUM	O	O
microglobulinuria	NOUN	O	O
and	CCONJ	O	O
low	ADJ	O	O
phosphate	NOUN	O	I-Entity
reabsorption	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
toxicity	NOUN	O	I-Entity
was	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
younger	ADJ	O	O
age	NOUN	O	O
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
2	NUM	O	O
1/2	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
predominance	NOUN	O	O
of	ADP	O	O
vesicoprostatic	ADJ	O	O
tumor	NOUN	O	I-Entity
involvement	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
low	ADJ	O	O
percentage	NOUN	O	O
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
TDFS	PROPN	O	O
must	VERB	O	O
be	VERB	O	O
evaluated	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
mesenchymal	ADJ	O	B-Entity
tumors	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1833784)

Evidence	NOUN	O	O
for	ADP	O	O
an	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
D1	PROPN	O	O
and	CCONJ	O	O
D2	PROPN	O	O
dopamine	NOUN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
mediating	VERB	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
repeated	VERB	O	O
exposure	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
environment	NOUN	O	O
is	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
observe	VERB	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
habituation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
environment	NOUN	O	O
on	ADP	O	O
the	DET	O	O
stimulant	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
mediating	VERB	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
stimulation	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
by	ADP	O	O
examining	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
selective	ADJ	O	O
D1	PROPN	O	O
and	CCONJ	O	O
D2	PROPN	O	O
dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
on	ADP	O	O
activity	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
nicotine	NOUN	O	I-Entity
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
1.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
locomotor	NOUN	O	I-Entity
activity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
habituated	VERB	O	O
to	ADP	O	O
the	DET	O	O
test	NOUN	O	O
environment	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
had	VERB	O	O
only	ADV	O	O
a	DET	O	O
weak	ADJ	O	O
and	CCONJ	O	O
delayed	ADJ	O	O
stimulant	NOUN	O	O
action	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
unfamiliar	ADJ	O	O
with	ADP	O	O
the	DET	O	O
test	NOUN	O	O
environment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
stimulant	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
was	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nicotinic	ADJ	O	O
antagonist	NOUN	O	O
mecamylamine	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nicotinic	NOUN	O	O
blocker	NOUN	O	O
hexamethonium	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
response	NOUN	O	O
is	VERB	O	O
probably	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
central	ADJ	O	O
nicotinic	ADJ	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
was	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
the	DET	O	O
selective	ADJ	O	O
D1	NOUN	O	O
antagonist	NOUN	O	O
SCH	PROPN	O	B-Entity
23390	NUM	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
selective	ADJ	O	O
D2	NOUN	O	O
antagonist	NOUN	O	O
raclopride	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
D1/D2	PROPN	O	O
antagonist	NOUN	O	O
fluphenazine	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
D2	NOUN	O	O
agonist	NOUN	O	O
PHNO	PROPN	O	I-Entity
enhanced	VERB	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
D1	NOUN	O	O
agonist	NOUN	O	O
SKF	PROPN	O	B-Entity
38393	NUM	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
acute	ADJ	O	O
nicotine	NOUN	O	I-Entity
injection	NOUN	O	O
induces	VERB	O	O
a	DET	O	O
pronounced	ADJ	O	O
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
habituated	VERB	O	O
to	ADP	O	O
the	DET	O	O
test	NOUN	O	O
environment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
central	ADJ	O	O
nicotine	NOUN	O	I-Entity
receptors	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
located	VERB	O	O
on	ADP	O	O
dopaminergic	ADJ	O	O
neurons	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
requires	VERB	O	O
the	DET	O	O
activation	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
D1	PROPN	O	O
and	CCONJ	O	O
D2	PROPN	O	O
dopamine	NOUN	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1867351)

Neuropsychiatric	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
mefloquine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
describes	VERB	O	O
neuropsychiatric	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
mefloquine	NOUN	O	I-Entity
.	PUNCT	O	O

Reactions	NOUN	O	O
consisted	VERB	O	O
mainly	ADV	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	O
psychoses	NOUN	O	I-Entity
,	PUNCT	O	O
anxiety	NOUN	O	B-Entity
neurosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
major	ADJ	O	O
disturbances	NOUN	O	B-Entity
of	ADP	O	I-Entity
sleep	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
wake	NOUN	O	I-Entity
rhythm	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
risk	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
neuropsychiatric	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
Germany	PROPN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
estimated	VERB	O	O
that	ADP	O	O
one	NUM	O	O
of	ADP	O	O
8,000	NUM	O	O
mefloquine	NOUN	O	I-Entity
users	NOUN	O	O
suffers	VERB	O	O
from	ADP	O	O
such	ADJ	O	O
reactions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
calculation	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
one	NUM	O	O
of	ADP	O	O
215	NUM	O	O
therapeutic	ADJ	O	O
users	NOUN	O	O
had	VERB	O	O
reactions	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
one	NUM	O	O
of	ADP	O	O
13,000	NUM	O	O
in	ADP	O	O
the	DET	O	O
prophylaxis	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
making	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
neuropsychiatric	ADJ	O	O
reactions	NOUN	O	O
after	ADP	O	O
mefloquine	NOUN	O	I-Entity
treatment	NOUN	O	O
60	NUM	O	O
times	NOUN	O	O
higher	ADJ	O	O
than	ADP	O	O
after	ADP	O	O
prophylaxis	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
certain	ADJ	O	O
limitations	NOUN	O	O
for	ADP	O	O
malaria	NOUN	O	I-Entity
prophylaxis	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
mefloquine	NOUN	O	I-Entity
are	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2070391)

Reduction	NOUN	O	O
in	ADP	O	O
injection	NOUN	O	O
pain	NOUN	O	I-Entity
using	VERB	O	O
buffered	VERB	O	O
lidocaine	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
before	ADP	O	O
cardiac	ADJ	O	O
catheterization	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
reports	NOUN	O	O
have	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
pain	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
acidic	ADJ	O	O
pH	NOUN	O	O
of	ADP	O	O
the	DET	O	O
solution	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
if	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
buffering	NOUN	O	O
solution	NOUN	O	O
to	PART	O	O
adjust	VERB	O	O
the	DET	O	O
pH	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
physiologic	ADJ	O	O
range	NOUN	O	O
would	VERB	O	O
reduce	VERB	O	O
pain	NOUN	O	I-Entity
during	ADP	O	O
injection	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
performed	VERB	O	O
a	DET	O	O
blinded	VERB	O	O
randomized	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
catheterization	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
asked	VERB	O	O
to	PART	O	O
quantify	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
after	ADP	O	O
receiving	VERB	O	O
standard	ADJ	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
femoral	ADJ	O	O
area	NOUN	O	O
and	CCONJ	O	O
buffered	VERB	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
opposite	ADJ	O	O
femoral	ADJ	O	O
area	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
pain	NOUN	O	I-Entity
score	NOUN	O	O
for	ADP	O	O
buffered	VERB	O	O
lidocaine	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
the	DET	O	O
mean	ADJ	O	O
score	NOUN	O	O
for	ADP	O	O
standard	ADJ	O	O
lidocaine	NOUN	O	I-Entity
(	PUNCT	O	O
2.7	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
pH	PROPN	O	O
adjustment	NOUN	O	O
of	ADP	O	O
standard	ADJ	O	O
lidocaine	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
accomplished	VERB	O	O
easily	ADV	O	O
in	ADP	O	O
the	DET	O	O
catheterization	NOUN	O	O
laboratory	NOUN	O	O
before	ADP	O	O
injection	NOUN	O	O
and	CCONJ	O	O
results	NOUN	O	O
in	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
occurring	VERB	O	O
during	ADP	O	O
the	DET	O	O
infiltration	NOUN	O	O
of	ADP	O	O
tissues	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2266990)

Randomized	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
mazindol	NOUN	O	I-Entity
in	ADP	O	O
Duchenne	PROPN	O	B-Entity
dystrophy	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
evidence	NOUN	O	O
that	ADP	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
weakness	NOUN	O	I-Entity
in	ADP	O	O
Duchenne	PROPN	O	B-Entity
dystrophy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
12-month	NUM	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
mazindol	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
putative	ADJ	O	O
growth	NOUN	O	O
hormone	NOUN	O	O
secretion	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
83	NUM	O	O
boys	NOUN	O	O
with	ADP	O	O
Duchenne	PROPN	O	B-Entity
dystrophy	NOUN	O	I-Entity
.	PUNCT	O	O

Muscle	PROPN	O	O
strength	NOUN	O	O
,	PUNCT	O	O
contractures	NOUN	O	O
,	PUNCT	O	O
functional	ADJ	O	O
ability	NOUN	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	O
function	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
mazindol	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
power	NOUN	O	O
of	ADP	O	O
greater	ADJ	O	O
than	ADP	O	O
0.90	NUM	O	O
to	PART	O	O
detect	VERB	O	O
a	DET	O	O
slowing	NOUN	O	O
to	ADP	O	O
25%	NUM	O	O
of	ADP	O	O
the	DET	O	O
expected	VERB	O	O
rate	NOUN	O	O
of	ADP	O	O
progression	NOUN	O	O
of	ADP	O	O
weakness	NOUN	O	I-Entity
at	ADP	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
.	PUNCT	O	O

Mazindol	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
benefit	VERB	O	O
strength	NOUN	O	O
at	ADP	O	O
any	DET	O	O
point	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Side	ADJ	O	O
effects	NOUN	O	O
attributable	ADJ	O	O
to	ADP	O	O
mazindol	NOUN	O	I-Entity
included	VERB	O	O
decreased	VERB	O	B-Entity
appetite	NOUN	O	I-Entity
(	PUNCT	O	O
36%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
dry	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
behavioral	ADJ	O	O
change	NOUN	O	O
(	PUNCT	O	O
22%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
gastrointestinal	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
(	PUNCT	O	O
18%	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
mazindol	NOUN	O	I-Entity
dosage	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
43%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
mazindol	NOUN	O	I-Entity
on	ADP	O	O
GH	PROPN	O	O
secretion	NOUN	O	O
was	VERB	O	O
estimated	VERB	O	O
indirectly	ADV	O	O
by	ADP	O	O
comparing	VERB	O	O
the	DET	O	O
postabsorptive	ADJ	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
levels	NOUN	O	O
obtained	VERB	O	O
following	VERB	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mazindol	NOUN	O	I-Entity
treated	VERB	O	O
to	ADP	O	O
those	DET	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
mazindol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
gained	VERB	O	O
less	ADJ	O	O
weight	NOUN	O	O
and	CCONJ	O	O
height	NOUN	O	O
than	ADP	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
levels	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Mazindol	PROPN	O	I-Entity
doses	VERB	O	O
not	ADV	O	O
slow	VERB	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
weakness	NOUN	O	I-Entity
in	ADP	O	O
Duchenne	PROPN	O	B-Entity
dystrophy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2348231)

Pentoxifylline	PROPN	O	I-Entity
(	PUNCT	O	O
Trental	PROPN	O	I-Entity
)	PUNCT	O	O
does	VERB	O	O
not	ADV	O	O
inhibit	VERB	O	O
dipyridamole	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
coronary	ADJ	O	O
hyperemia	NOUN	O	I-Entity
:	PUNCT	O	O
implications	NOUN	O	O
for	ADP	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
thallium-201	NOUN	O	I-Entity
myocardial	ADJ	O	O
imaging	NOUN	O	O
.	PUNCT	O	O

Dipyridamole	PROPN	O	I-Entity
-	PUNCT	O	O
thallium-201	PROPN	O	I-Entity
imaging	NOUN	O	O
is	VERB	O	O
often	ADV	O	O
performed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
unable	ADJ	O	O
to	PART	O	O
exercise	VERB	O	O
because	ADP	O	O
of	ADP	O	O
peripheral	ADJ	O	B-Entity
vascular	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Many	ADJ	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
are	VERB	O	O
taking	VERB	O	O
pentoxifylline	NOUN	O	I-Entity
(	PUNCT	O	O
Trental	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
methylxanthine	NOUN	O	I-Entity
derivative	ADJ	O	O
which	ADJ	O	O
may	VERB	O	O
improve	VERB	O	O
intermittent	ADJ	O	B-Entity
claudication	NOUN	O	I-Entity
.	PUNCT	O	O

Whether	ADP	O	O
pentoxifylline	NOUN	O	I-Entity
inhibits	VERB	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
coronary	ADJ	O	O
hyperemia	NOUN	O	I-Entity
like	ADP	O	O
other	ADJ	O	O
methylxanthines	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
theophylline	NOUN	O	I-Entity
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
stopped	VERB	O	O
prior	ADV	O	O
to	ADP	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
thallium-201	NOUN	O	I-Entity
imaging	NOUN	O	O
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
hyperemic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
dipyridamole	NOUN	O	I-Entity
in	ADP	O	O
seven	NUM	O	O
open	ADJ	O	O
-	PUNCT	O	O
chest	NOUN	O	O
anesthetized	VERB	O	O
dogs	NOUN	O	O
after	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
either	DET	O	O
pentoxifylline	NOUN	O	I-Entity
(	PUNCT	O	O
0	PUNCT	O	O
,	PUNCT	O	O

7.5	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
15	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
theophylline	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Dipyridamole	NOUN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
coronary	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
7.5	NUM	O	O
or	CCONJ	O	O
15	NUM	O	O
mm	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

pentoxifylline	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Neither	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
pentoxifylline	NOUN	O	I-Entity
significantly	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperemia	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
peak	ADJ	O	O
coronary	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
after	ADP	O	O
theophylline	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
pentoxyifylline	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
inhibit	VERB	O	O
dipyridamole	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
coronary	ADJ	O	O
hyperemia	NOUN	O	I-Entity
even	ADV	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2355241)

Cause	PROPN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
rare	ADJ	O	O
mortality	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

Causes	NOUN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
special	ADJ	O	O
reference	NOUN	O	O
to	ADP	O	O
cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
among	ADP	O	O
240	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
pathologically	ADV	O	O
verified	VERB	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
using	VERB	O	O
the	DET	O	O
Annuals	PROPN	O	O
of	ADP	O	O
the	DET	O	O
Pathological	ADJ	O	O
Autopsy	PROPN	O	O
Cases	PROPN	O	O
in	ADP	O	O
Japan	PROPN	O	O
from	ADP	O	O
1981	NUM	O	O
to	ADP	O	O
1985	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
leading	VERB	O	O
causes	NOUN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
were	VERB	O	O
pneumonia	NOUN	O	I-Entity
and	CCONJ	O	O
bronchitis	NOUN	O	I-Entity
(	PUNCT	O	O
44.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
malignant	ADJ	O	O
neoplasms	NOUN	O	I-Entity
(	PUNCT	O	O
11.6%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
heart	NOUN	O	B-Entity
diseases	NOUN	O	I-Entity
(	PUNCT	O	O
4.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
3.7%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
septicaemia	NOUN	O	I-Entity
(	PUNCT	O	O
3.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
11th	ADJ	O	O
most	ADV	O	O
frequent	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
,	PUNCT	O	O
accounting	VERB	O	O
for	ADP	O	O
only	ADV	O	O
0.8%	NUM	O	O
of	ADP	O	O
deaths	NOUN	O	I-Entity
among	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
it	PRON	O	O
was	VERB	O	O
the	DET	O	O
5th	ADJ	O	O
most	ADV	O	O
common	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
among	ADP	O	O
the	DET	O	O
Japanese	ADJ	O	O
general	ADJ	O	O
population	NOUN	O	O
in	ADP	O	O
1985	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
low	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
may	VERB	O	O
reflect	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
hypotensive	ADJ	O	I-Entity
mechanism	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
reduced	VERB	O	O
noradrenaline	NOUN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
parkinsonian	ADJ	O	I-Entity
brain	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2445283)

Tolerance	NOUN	O	O
and	CCONJ	O	O
antiviral	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Argentine	ADJ	O	B-Entity
hemorrhagic	ADJ	O	I-Entity
fever	NOUN	O	I-Entity
.	PUNCT	O	O

Tolerance	PROPN	O	O
and	CCONJ	O	O
antiviral	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
6	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Argentine	ADJ	O	B-Entity
hemorrhagic	ADJ	O	I-Entity
fever	NOUN	O	I-Entity
(	PUNCT	O	O
AHF	PROPN	O	I-Entity
)	PUNCT	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
evolution	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
neutralization	NOUN	O	O
of	ADP	O	O
viremia	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
drop	NOUN	O	O
of	ADP	O	O
endogenous	ADJ	O	O
interferon	NOUN	O	O
titers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
time	NOUN	O	O
of	ADP	O	O
death	NOUN	O	I-Entity
was	VERB	O	O
delayed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
reversible	ADJ	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
only	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
observed	VERB	O	O
.	PUNCT	O	O

From	ADP	O	O
these	DET	O	O
results	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
ribavirin	NOUN	O	I-Entity
has	VERB	O	O
an	DET	O	O
antiviral	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
AHF	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
that	DET	O	O
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
only	ADJ	O	O
secondary	ADJ	O	O
reaction	NOUN	O	O
observed	VERB	O	O
,	PUNCT	O	O
can	VERB	O	O
be	VERB	O	O
easily	ADV	O	O
managed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
days	NOUN	O	O
of	ADP	O	O
AHF	PROPN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2950248)

Dipyridamole	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

Angina	PROPN	O	I-Entity
and	CCONJ	O	O
ischemic	ADJ	O	O
electrocardiographic	ADJ	O	O
changes	NOUN	O	O
occurred	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
dipyridamole	NOUN	O	I-Entity
in	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
awaiting	VERB	O	O
urgent	ADJ	O	O
myocardial	ADJ	O	O
revascularization	NOUN	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
has	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
a	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
preoperative	ADJ	O	O
dipyridamole	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
demonstrated	VERB	O	O
to	PART	O	O
occur	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
and	CCONJ	O	O
humans	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Epicardial	ADJ	O	O
coronary	ADJ	O	O
collateral	NOUN	O	O
vessels	NOUN	O	O
were	VERB	O	O
demonstrated	VERB	O	O
in	ADP	O	O
all	DET	O	O
four	NUM	O	O
patients	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
coronary	ADJ	O	O
"	PUNCT	O	O
steal	VERB	O	O
"	PUNCT	O	O
phenomenon	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ischemia	NOUN	O	I-Entity
observed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3015567)

Nitroprusside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
evokes	VERB	O	O
ACTH	PROPN	O	O
secretion	NOUN	O	O
which	ADJ	O	O
is	VERB	O	O
primarily	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
enhanced	ADJ	O	O
secretion	NOUN	O	O
of	ADP	O	O
immunoreactive	ADJ	O	O
corticotropin	NOUN	O	O
-	PUNCT	O	O
releasing	VERB	O	O
factor	NOUN	O	O
(	PUNCT	O	O
irCRF	PROPN	O	O
)	PUNCT	O	O
into	ADP	O	O
the	DET	O	O
hypophysial	ADJ	O	O
-	PUNCT	O	O
portal	ADJ	O	O
circulation	NOUN	O	O
.	PUNCT	O	O

Portal	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
neither	DET	O	O
arginine	NOUN	O	B-Entity
vasopressin	NOUN	O	I-Entity
nor	CCONJ	O	O
oxytocin	NOUN	O	I-Entity
are	VERB	O	O
significantly	ADV	O	O
altered	VERB	O	O
in	ADP	O	O
this	DET	O	O
paradigm	NOUN	O	O
.	PUNCT	O	O

Application	NOUN	O	O
of	ADP	O	O
a	DET	O	O
delayed	VERB	O	O
feedback	NOUN	O	O
signal	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
a	DET	O	O
2-h	NUM	O	O
systemic	ADJ	O	O
corticosterone	NOUN	O	I-Entity
infusion	NOUN	O	O
in	ADP	O	O
urethane	NOUN	O	I-Entity
-	PUNCT	O	O
anesthetized	ADJ	O	O
rats	NOUN	O	O
with	ADP	O	O
pharmacological	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
glucocorticoid	ADJ	O	O
synthesis	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
without	ADP	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
resting	VERB	O	O
secretion	NOUN	O	O
of	ADP	O	O
arginine	NOUN	O	B-Entity
vasopressin	NOUN	O	I-Entity
and	CCONJ	O	O
oxytocin	NOUN	O	I-Entity
at	ADP	O	O
any	DET	O	O
corticosterone	NOUN	O	I-Entity
feedback	NOUN	O	O
dose	NOUN	O	O
tested	VERB	O	O
.	PUNCT	O	O

Resting	VERB	O	O
irCRF	PROPN	O	O
levels	NOUN	O	O
are	VERB	O	O
suppressed	VERB	O	O
only	ADV	O	O
at	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
corticosterone	NOUN	O	I-Entity
infusion	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
systemic	ADJ	O	O
corticosterone	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
40	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
.	PUNCT	O	O

Suppression	NOUN	O	O
of	ADP	O	O
irCRF	PROPN	O	O
secretion	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
nitroprusside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
is	VERB	O	O
observed	VERB	O	O
and	CCONJ	O	O
occurs	VERB	O	O
at	ADP	O	O
a	DET	O	O
plasma	NOUN	O	O
corticosterone	NOUN	O	I-Entity
level	NOUN	O	O
between	ADP	O	O
8	NUM	O	O
-	SYM	O	O
12	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3031535)

Noradrenergic	ADJ	O	O
involvement	NOUN	O	O
in	ADP	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
delta	NOUN	O	B-Entity
9-tetrahydrocannabinol	NUM	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
elucidate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
catecholaminergic	ADJ	O	O
system	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cataleptogenic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
delta	NOUN	O	B-Entity
9-tetrahydrocannabinol	NUM	O	I-Entity
(	PUNCT	O	O
THC	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
6-hydroxydopamine	NUM	O	I-Entity
(	PUNCT	O	O
6-OHDA	NUM	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
desipramine	NOUN	O	I-Entity
and	CCONJ	O	O
6-OHDA	NUM	O	I-Entity
and	CCONJ	O	O
lesions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
locus	NOUN	O	O
coeruleus	NOUN	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cataleptogenic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
THC	PROPN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
6-OHDA	NUM	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
lesions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
locus	NOUN	O	O
coeruleus	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
desipramine	NOUN	O	I-Entity
and	CCONJ	O	O
6-OHDA	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
contrary	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cataleptogenic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
desipramine	NOUN	O	I-Entity
and	CCONJ	O	O
6-OHDA	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
6-OHDA	NUM	O	I-Entity
or	CCONJ	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
lesions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
locus	NOUN	O	O
coeruleus	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
noradrenergic	ADJ	O	O
neurons	NOUN	O	O
have	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
THC	PROPN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
dopaminergic	ADJ	O	O
neurons	NOUN	O	O
are	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3125768)

Intracranial	ADJ	O	O
pressure	NOUN	O	O
increases	NOUN	O	O
during	ADP	O	O
alfentanil	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rigidity	NOUN	O	I-Entity
.	PUNCT	O	O

Intracranial	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
ICP	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
measured	VERB	O	O
during	ADP	O	O
alfentanil	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rigidity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
rats	NOUN	O	O
had	VERB	O	O
arterial	ADJ	O	O
,	PUNCT	O	O
central	ADJ	O	O
venous	ADJ	O	O
(	PUNCT	O	O
CVP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
subdural	ADJ	O	O
cannulae	NOUN	O	O
inserted	VERB	O	O
under	ADP	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
instrumentation	NOUN	O	O
,	PUNCT	O	O
halothane	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
alfentanil	NOUN	O	I-Entity
(	PUNCT	O	O
125	NUM	O	O
mu	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
administered	VERB	O	O
iv	NOUN	O	O
during	ADP	O	O
emergence	NOUN	O	O
from	ADP	O	O
halothane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
five	NUM	O	O
rats	NOUN	O	O
that	ADJ	O	O
developed	VERB	O	O
somatic	ADJ	O	B-Entity
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
ICP	PROPN	O	O
and	CCONJ	O	O
CVP	PROPN	O	O
increased	VERB	O	O
significantly	ADV	O	O
above	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
delta	NOUN	O	O
ICP	PROPN	O	O
7.5	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

These	DET	O	O
variables	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
when	ADV	O	O
rigidity	NOUN	O	I-Entity
was	VERB	O	O
abolished	VERB	O	O
with	ADP	O	O
metocurine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
five	NUM	O	O
rats	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
become	VERB	O	O
rigid	ADJ	O	O
,	PUNCT	O	O
ICP	PROPN	O	O
and	CCONJ	O	O
CVP	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
following	VERB	O	O
alfentanil	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
rigidity	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
prevented	VERB	O	O
when	ADV	O	O
alfentanil	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
presumably	ADV	O	O
,	PUNCT	O	O
other	ADJ	O	O
opiates	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
anesthetic	ADJ	O	O
management	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ICP	PROPN	O	O
problems	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3187073)

Adverse	ADJ	O	O
cardiac	ADJ	O	O
effects	NOUN	O	O
during	ADP	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
platin	NOUN	O	I-Entity
and	CCONJ	O	O
5-fluorouracil	NOUN	O	I-Entity
.	PUNCT	O	O

Survival	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
head	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
and	CCONJ	O	O
esophageal	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
is	VERB	O	O
poor	ADJ	O	O
with	ADP	O	O
radiotherapy	ADJ	O	O
and/or	CCONJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
cis	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
platin	PROPN	O	I-Entity
(	PUNCT	O	O
80	NUM	O	O
-	SYM	O	O
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2BSA	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
5-FU	NUM	O	I-Entity
(	PUNCT	O	O
1000	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2BSA	ADJ	O	O
daily	ADV	O	O
as	ADP	O	O
a	DET	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
during	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
given	VERB	O	O
to	ADP	O	O
76	NUM	O	O
patients	NOUN	O	O
before	ADV	O	O
radiotherapy	ADJ	O	O
and	CCONJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
evaluation	NOUN	O	O
,	PUNCT	O	O
signs	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
33	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
43%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
signs	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
those	DET	O	O
without	ADP	O	O
in	ADP	O	O
the	DET	O	O
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
were	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
ST	PROPN	O	O
-	PUNCT	O	O
T	PROPN	O	O
wave	NOUN	O	O
changes	NOUN	O	O
and	CCONJ	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
and	CCONJ	O	O
sudden	ADJ	O	B-Entity
death	NOUN	O	I-Entity
in	ADP	O	O
another	DET	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
5-FU	NUM	O	I-Entity
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
under	ADP	O	O
close	ADJ	O	O
supervision	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
discontinued	VERB	O	O
if	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
or	CCONJ	O	O
tachyarrhythmia	NOUN	O	I-Entity
is	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3371379)

Verapamil	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
carbamazepine	NOUN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
signs	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
after	ADP	O	O
combined	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
verapamil	NOUN	O	I-Entity
showed	VERB	O	O
complete	ADJ	O	O
recovery	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
calcium	NOUN	O	I-Entity
entry	NOUN	O	O
blocker	NOUN	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
carbamazepine	NOUN	O	I-Entity
should	VERB	O	O
either	DET	O	O
be	VERB	O	O
avoided	VERB	O	O
or	CCONJ	O	O
prescribed	VERB	O	O
only	ADV	O	O
with	ADP	O	O
appropriate	ADJ	O	O
adjustment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
carbamazepine	NOUN	O	I-Entity
dose	NOUN	O	O
(	PUNCT	O	O
usually	ADV	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
carbamazepine	NOUN	O	I-Entity
dose	NOUN	O	O
by	ADP	O	O
one	NUM	O	O
half	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (3503576)

Serial	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
auditory	ADJ	O	B-Entity
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
deferoxamine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Visual	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
auditory	ADJ	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
was	VERB	O	O
previously	ADV	O	O
documented	VERB	O	O
in	ADP	O	O
42	NUM	O	O
of	ADP	O	O
89	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
transfusion	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
anemia	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
iron	NOUN	O	I-Entity
chelation	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
daily	ADJ	O	O
subcutaneous	ADJ	O	O
deferoxamine	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
affected	VERB	O	O
group	NOUN	O	O
had	VERB	O	O
abnormal	ADJ	O	B-Entity
audiograms	NOUN	O	I-Entity
with	ADP	O	I-Entity
deficits	NOUN	O	I-Entity
mostly	ADV	O	I-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
high	ADJ	O	I-Entity
frequency	NOUN	O	I-Entity
range	NOUN	O	I-Entity
of	ADP	O	I-Entity
4,000	NUM	O	I-Entity
to	PART	O	I-Entity
8,000	NUM	O	I-Entity
Hz	PROPN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
hearing	NOUN	O	O
threshold	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
to	PART	O	O
100	NUM	O	O
decibels	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
deferoxamine	NOUN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
serial	ADJ	O	O
studies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
,	PUNCT	O	O
audiograms	NOUN	O	O
in	ADP	O	O
seven	NUM	O	O
cases	NOUN	O	O
reverted	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
or	CCONJ	O	O
near	ADP	O	O
normal	ADJ	O	O
within	ADP	O	O
two	NUM	O	O
to	PART	O	O
three	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
nine	NUM	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
symptoms	NOUN	O	O
became	VERB	O	O
asymptomatic	ADJ	O	O
.	PUNCT	O	O

Audiograms	PROPN	O	O
from	ADP	O	O
15	NUM	O	O
patients	NOUN	O	O
remained	VERB	O	O
abnormal	ADJ	O	O
and	CCONJ	O	O
four	NUM	O	O
patients	NOUN	O	O
required	VERB	O	O
hearing	NOUN	O	O
aids	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
permanent	ADJ	O	B-Entity
disability	NOUN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
18	NUM	O	O
of	ADP	O	O
the	DET	O	O
22	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
initially	ADV	O	O
receiving	VERB	O	O
deferoxamine	NOUN	O	I-Entity
doses	NOUN	O	O
in	ADP	O	O
excess	NOUN	O	O
of	ADP	O	O
the	DET	O	O
commonly	ADV	O	O
recommended	VERB	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
dose	NOUN	O	O
,	PUNCT	O	O
therapy	NOUN	O	O
was	VERB	O	O
restarted	VERB	O	O
with	ADP	O	O
lower	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
usually	ADV	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
dose	NOUN	O	O
or	CCONJ	O	O
less	ADJ	O	O
depending	VERB	O	O
on	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
auditory	ADJ	O	B-Entity
abnormality	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
cases	NOUN	O	O
no	DET	O	O
further	ADJ	O	O
toxicity	NOUN	O	I-Entity
was	VERB	O	O
demonstrated	VERB	O	O
.	PUNCT	O	O

Auditory	ADJ	O	O
deterioration	NOUN	O	O
and	CCONJ	O	O
improvement	NOUN	O	O
,	PUNCT	O	O
demonstrated	VERB	O	O
serially	ADV	O	O
in	ADP	O	O
individual	ADJ	O	O
patients	NOUN	O	O
receiving	VERB	O	O
and	CCONJ	O	O
not	ADV	O	O
receiving	VERB	O	O
deferoxamine	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
provided	VERB	O	O
convincing	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
-	PUNCT	O	O
and	CCONJ	O	O
-	PUNCT	O	O
effect	NOUN	O	O
relation	NOUN	O	O
between	ADP	O	O
deferoxamine	NOUN	O	I-Entity
administration	NOUN	O	O
and	CCONJ	O	O
ototoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
plan	NOUN	O	O
of	ADP	O	O
management	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
that	ADJ	O	O
allows	VERB	O	O
effective	ADJ	O	O
yet	ADV	O	O
safe	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
deferoxamine	NOUN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
mild	ADJ	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
reduction	NOUN	O	O
to	ADP	O	O
30	NUM	O	O
or	CCONJ	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
dose	NOUN	O	O
should	VERB	O	O
result	VERB	O	O
in	ADP	O	O
a	DET	O	O
reversal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
abnormal	ADJ	O	O
results	NOUN	O	O
to	ADP	O	O
normal	ADJ	O	O
within	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Moderate	ADJ	O	O
abnormalities	NOUN	O	O
require	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
deferoxamine	NOUN	O	I-Entity
to	ADP	O	O
25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
per	ADP	O	O
dose	NOUN	O	O
with	ADP	O	O
careful	ADJ	O	O
monitoring	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
those	DET	O	O
with	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
drug	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
stopped	VERB	O	O
for	ADP	O	O
four	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
when	ADV	O	O
the	DET	O	O
audiogram	NOUN	O	O
is	VERB	O	O
stable	ADJ	O	O
or	CCONJ	O	O
improved	ADJ	O	O
,	PUNCT	O	O
therapy	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
restarted	VERB	O	O
at	ADP	O	O
10	NUM	O	O
to	PART	O	O
25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
per	ADP	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Serial	ADJ	O	O
audiograms	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
performed	VERB	O	O
every	DET	O	O
six	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
those	DET	O	O
without	ADP	O	O
problems	NOUN	O	O
and	CCONJ	O	O
more	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
young	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
serum	NOUN	O	O
ferritin	NOUN	O	O
values	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
those	DET	O	O
with	ADP	O	O
auditory	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3560095)

Flurbiprofen	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
juvenile	NOUN	O	B-Entity
rheumatoid	NOUN	O	I-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
juvenile	NOUN	O	B-Entity
rheumatoid	NOUN	O	I-Entity
arthritis	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
flurbiprofen	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
maximum	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
6	NUM	O	O
arthritis	NOUN	O	I-Entity
indices	NOUN	O	O
after	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Improvements	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
tender	ADJ	O	B-Entity
joints	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
swelling	VERB	O	I-Entity
and	CCONJ	O	O
tenderness	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
walk	NOUN	O	O
50	NUM	O	O
feet	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
morning	NOUN	O	B-Entity
stiffness	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
circumference	NOUN	O	O
of	ADP	O	O
the	DET	O	O
left	ADJ	O	O
knee	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
frequently	ADV	O	O
observed	VERB	O	O
side	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
fecal	ADJ	O	B-Entity
occult	NOUN	O	I-Entity
blood	NOUN	O	I-Entity
(	PUNCT	O	O
25%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
other	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
gastrointestinal	ADJ	O	B-Entity
(	PUNCT	O	I-Entity
GI	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
bleeding	VERB	O	I-Entity
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
was	VERB	O	O
prematurely	ADV	O	O
discontinued	VERB	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
for	ADP	O	O
severe	ADJ	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3714122)

The	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
neurotoxic	NOUN	O	I-Entity
esterase	NOUN	O	O
inhibition	NOUN	O	O
and	CCONJ	O	O
mipafox	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neuropathic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
neuropathic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
and	CCONJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
neurotoxic	NOUN	O	I-Entity
esterase	NOUN	O	O
or	CCONJ	O	O
neuropathy	ADJ	O	I-Entity
target	NOUN	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
NTE	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
acutely	ADV	O	O
exposed	VERB	O	O
to	ADP	O	O
Mipafox	PROPN	O	I-Entity
(	PUNCT	O	O
N	PROPN	O	B-Entity
,	PUNCT	O	I-Entity
N'-diisopropylphosphorodiamidofluoridate	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
neurotoxic	NOUN	O	I-Entity
organophosphate	NOUN	O	I-Entity
.	PUNCT	O	O

Brain	NOUN	O	O
and	CCONJ	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
NTE	PROPN	O	O
activities	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
Long	PROPN	O	O
-	PUNCT	O	O
Evans	PROPN	O	O
male	NOUN	O	O
rats	NOUN	O	O
1	NUM	O	O
hr	INTJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
various	ADJ	O	O
dosages	NOUN	O	O
of	ADP	O	O
Mipafox	PROPN	O	I-Entity
(	PUNCT	O	O
ip	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
were	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
histologically	ADV	O	O
scored	VERB	O	O
cervical	ADJ	O	O
cord	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
separate	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
similarly	ADV	O	O
dosed	VERB	O	O
rats	NOUN	O	O
sampled	VERB	O	O
14	NUM	O	O
-	SYM	O	O
21	NUM	O	O
days	NOUN	O	O
post	ADV	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
dosages	NOUN	O	O
of	ADP	O	O
Mipafox	PROPN	O	I-Entity
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	PART	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
which	ADJ	O	O
inhibited	VERB	O	O
mean	ADJ	O	O
NTE	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
61%	NUM	O	O
and	CCONJ	O	O
brain	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	PART	O	O
60%	NUM	O	O
produced	VERB	O	O
this	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
cord	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
only	ADV	O	O
9%	NUM	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
a	DET	O	O
critical	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
NTE	PROPN	O	O
inhibition	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
and	CCONJ	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
sampled	VERB	O	O
shortly	ADV	O	O
after	ADP	O	O
Mipafox	PROPN	O	I-Entity
exposure	NOUN	O	O
can	VERB	O	O
predict	VERB	O	O
neuropathic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
several	ADJ	O	O
weeks	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (3828020)

Cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
phenylpropanolamine	NOUN	O	I-Entity
.	PUNCT	O	O

Phenylpropanolamine	PROPN	O	I-Entity
(	PUNCT	O	O
PPA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
synthetic	ADJ	O	O
sympathomimetic	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
structurally	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
available	ADJ	O	O
over	ADP	O	O
the	DET	O	O
counter	NOUN	O	O
in	ADP	O	O
anorectics	NOUN	O	O
,	PUNCT	O	O
nasal	ADJ	O	O
congestants	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cold	ADJ	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

Its	ADJ	O	O
prolonged	ADJ	O	O
use	NOUN	O	O
or	CCONJ	O	O
overuse	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
neuropsychiatric	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nonhemorrhagic	ADJ	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
young	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
suffered	VERB	O	O
a	DET	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
after	ADP	O	O
taking	VERB	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (4812392)

Treatment	NOUN	O	O
of	ADP	O	O
psoriasis	NOUN	O	I-Entity
with	ADP	O	O
azathioprine	NOUN	O	I-Entity
.	PUNCT	O	O

Azathioprine	PROPN	O	I-Entity
treatment	NOUN	O	O
benefited	VERB	O	O
19	NUM	O	O
(	PUNCT	O	O
66%	NUM	O	O
)	PUNCT	O	O
out	ADP	O	O
of	ADP	O	O
29	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
severe	ADJ	O	O
psoriasis	NOUN	O	I-Entity
.	PUNCT	O	O

Minimal	ADJ	O	O
cholestasis	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
two	NUM	O	O
cases	NOUN	O	O
and	CCONJ	O	O
portal	ADJ	O	O
fibrosis	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
reversible	ADJ	O	O
degree	NOUN	O	O
in	ADP	O	O
eight	NUM	O	O
.	PUNCT	O	O

Liver	ADJ	O	O
biopsies	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
undertaken	VERB	O	O
at	ADP	O	O
regular	ADJ	O	O
intervals	NOUN	O	O
if	ADP	O	O
azathioprine	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
continued	VERB	O	O
so	ADP	O	O
that	ADP	O	O
structural	ADJ	O	O
liver	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
detected	VERB	O	O
at	ADP	O	O
an	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
reversible	ADJ	O	O
stage	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6518066)

Maternal	ADJ	O	O
lithium	NOUN	O	I-Entity
and	CCONJ	O	O
neonatal	ADJ	O	O

Ebstein	PROPN	O	B-Entity
's	PART	O	I-Entity
anomaly	NOUN	O	I-Entity
:	PUNCT	O	O
evaluation	NOUN	O	O
with	ADP	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Cross	PROPN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
echocardiography	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
two	NUM	O	O
neonates	NOUN	O	O
whose	ADJ	O	O
mothers	NOUN	O	O
ingested	VERB	O	O
lithium	NOUN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
infant	NOUN	O	O
,	PUNCT	O	O
Ebstein	PROPN	O	B-Entity
's	PART	O	I-Entity
anomaly	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
tricuspid	NOUN	O	O
valve	NOUN	O	O
was	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
other	ADJ	O	O
infant	NOUN	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
echocardiography	NOUN	O	O
provided	VERB	O	O
reassurance	NOUN	O	O
that	ADP	O	O
the	DET	O	O
infant	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
Ebstein	PROPN	O	B-Entity
's	PART	O	I-Entity
anomaly	NOUN	O	I-Entity
.	PUNCT	O	O

Cross	PROPN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
echocardiographic	ADJ	O	O
screening	NOUN	O	O
of	ADP	O	O
newborns	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
during	ADP	O	O
gestation	NOUN	O	O
can	VERB	O	O
provide	VERB	O	O
highly	ADV	O	O
accurate	ADJ	O	O
,	PUNCT	O	O
noninvasive	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
malformations	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6534871)

Effects	NOUN	O	O
of	ADP	O	O
training	NOUN	O	O
on	ADP	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
aging	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
on	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
female	ADJ	O	O
albino	ADJ	O	O
rats	NOUN	O	O
of	ADP	O	O
20,40,60	NUM	O	O
and	CCONJ	O	O
80	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
infarcts	NOUN	O	I-Entity
were	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
histological	ADJ	O	O
methods	NOUN	O	O
.	PUNCT	O	O

Elevations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
GOT	PROPN	O	O
and	CCONJ	O	O
GPT	PROPN	O	O
were	VERB	O	O
maximum	ADJ	O	O
in	ADP	O	O
the	DET	O	O
sedentary	ADJ	O	O
-	PUNCT	O	O
isoproterenols	NOUN	O	I-Entity
and	CCONJ	O	O
minimum	NOUN	O	O
in	ADP	O	O
the	DET	O	O
exercise	NOUN	O	O
-	PUNCT	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
dealing	VERB	O	O
with	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
are	VERB	O	O
more	ADV	O	O
informative	ADJ	O	O
when	ADV	O	O
dealt	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6538499)

Effect	NOUN	O	O
of	ADP	O	O
polyethylene	NOUN	O	B-Entity
glycol	NOUN	O	I-Entity
400	NUM	O	I-Entity
on	ADP	O	O
adriamycin	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
organic	ADJ	O	O
solvent	NOUN	O	O
,	PUNCT	O	O
polyethylene	NOUN	O	B-Entity
glycol	NOUN	O	I-Entity
400	NUM	O	I-Entity
(	PUNCT	O	O
PEG	PROPN	O	B-Entity
400	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
toxic	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
or	CCONJ	O	O
chronic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
adriamycin	ADJ	O	I-Entity
(	PUNCT	O	O
ADR	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

PEG	PROPN	O	B-Entity
400	NUM	O	I-Entity
impressively	ADV	O	O
decreased	VERB	O	O
both	DET	O	O
acute	ADJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
-	PUNCT	O	O
ADR	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
lethality	NOUN	O	O
.	PUNCT	O	O

Light	NOUN	O	O
microscopic	ADJ	O	O
analysis	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
ADR	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
morphological	ADJ	O	I-Entity
alterations	NOUN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
diminish	VERB	O	O
the	DET	O	O
ADR	PROPN	O	I-Entity
antitumor	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
L1210	PROPN	O	B-Entity
leukemia	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
Ehrlich	PROPN	O	B-Entity
ascites	VERB	O	I-Entity
tumor	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6747681)

Intra	PROPN	O	O
-	PUNCT	O	O
arterial	ADJ	O	O
BCNU	PROPN	O	I-Entity
chemotherapy	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	B-Entity
gliomas	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
rapid	ADJ	O	O
systemic	ADJ	O	O
clearance	NOUN	O	O
of	ADP	O	O
BCNU	PROPN	O	I-Entity
(	PUNCT	O	O
1,3-bis-(2-chloroethyl)-1-nitrosourea	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterial	ADJ	O	O
administration	NOUN	O	O
should	VERB	O	O
provide	VERB	O	O
a	DET	O	O
substantial	ADJ	O	O
advantage	NOUN	O	O
over	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	B-Entity
gliomas	NOUN	O	I-Entity
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
BCNU	PROPN	O	I-Entity
every	DET	O	O
6	NUM	O	O
to	PART	O	O
8	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
either	ADV	O	O
by	ADP	O	O
transfemoral	ADJ	O	O
catheterization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
internal	ADJ	O	O
carotid	ADJ	O	O
or	CCONJ	O	O
vertebral	ADJ	O	O
artery	NOUN	O	O
or	CCONJ	O	O
through	ADP	O	O
a	DET	O	O
fully	ADV	O	O
implantable	ADJ	O	O
intracarotid	ADJ	O	O
drug	NOUN	O	O
delivery	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
beginning	VERB	O	O
with	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
sq	PROPN	O	O
m	NOUN	O	O
body	NOUN	O	O
surface	NOUN	O	O
area	NOUN	O	O
.	PUNCT	O	O

Twelve	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Grade	PROPN	O	O
III	PROPN	O	O
or	CCONJ	O	O
IV	PROPN	O	O
astrocytomas	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
after	ADP	O	O
partial	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tumor	NOUN	O	I-Entity
without	ADP	O	O
prior	ADJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
two	NUM	O	O
to	PART	O	O
seven	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
nine	NUM	O	O
patients	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
tumor	NOUN	O	I-Entity
size	NOUN	O	O
and	CCONJ	O	O
surrounding	VERB	O	O
edema	NOUN	O	I-Entity
on	ADP	O	O
contrast	NOUN	O	O
-	PUNCT	O	O
enhanced	VERB	O	O
computerized	ADJ	O	O
tomography	NOUN	O	O
scans	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
recurrent	ADJ	O	O
Grade	PROPN	O	O
I	PRON	O	O
to	ADP	O	O
IV	PROPN	O	O
astrocytomas	NOUN	O	I-Entity
,	PUNCT	O	O
whose	ADJ	O	O
resection	NOUN	O	O
and	CCONJ	O	O
irradiation	NOUN	O	O
therapy	NOUN	O	O
had	VERB	O	O
failed	VERB	O	O
,	PUNCT	O	O
received	VERB	O	O
two	NUM	O	O
to	PART	O	O
eight	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterial	NOUN	O	O
BCNU	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
catheterization	NOUN	O	O
procedure	NOUN	O	O
is	VERB	O	O
safe	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
immediate	ADJ	O	O
complication	NOUN	O	O
in	ADP	O	O
111	NUM	O	O
infusions	NOUN	O	O
of	ADP	O	O
BCNU	PROPN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
delayed	VERB	O	O
complication	NOUN	O	O
in	ADP	O	O
nine	NUM	O	O
patients	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
unilateral	ADJ	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
vision	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
a	DET	O	O
retinal	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
decreased	VERB	O	O
after	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ethanol	NOUN	O	I-Entity
diluent	NOUN	O	O
was	VERB	O	O
lowered	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (6861444)

Blood	NOUN	O	O
pressure	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
chronic	ADJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intrarenal	ADJ	O	O
noradrenaline	NOUN	O	I-Entity
infusion	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
solution	NOUN	O	O
(	PUNCT	O	O
0.9%	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O

noradrenaline	NOUN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
and	CCONJ	O	O
36	NUM	O	O

Intrarenal	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
noradrenaline	NOUN	O	I-Entity
caused	VERB	O	O
hypertension	NOUN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
which	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
do	VERB	O	O
so	ADV	O	O
when	ADV	O	O
infused	VERB	O	O
intravenously	ADV	O	O
.	PUNCT	O	O

Intrarenal	ADJ	O	O
compared	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
noradrenaline	NOUN	O	I-Entity
caused	VERB	O	O
higher	ADJ	O	O
plasma	NOUN	O	O
noradrenaline	NOUN	O	I-Entity
concentrations	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
shift	NOUN	O	O
of	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
noradrenaline	ADJ	O	I-Entity
concentration	NOUN	O	O
-	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
effect	NOUN	O	O
curve	NOUN	O	O
towards	ADP	O	O
lower	ADJ	O	O
plasma	NOUN	O	O
noradrenaline	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
hypertension	NOUN	O	I-Entity
after	ADP	O	O
chronic	ADJ	O	O
intrarenal	ADJ	O	O
noradrenaline	NOUN	O	I-Entity
infusion	NOUN	O	O
is	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
relatively	ADV	O	O
higher	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
circulating	VERB	O	O
noradrenaline	NOUN	O	I-Entity
and	CCONJ	O	O
by	ADP	O	O
triggering	VERB	O	O
of	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
intrarenal	ADJ	O	O
pressor	NOUN	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7053303)

Age	PROPN	O	O
and	CCONJ	O	O
renal	ADJ	O	O
clearance	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
35	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
ages	NOUN	O	O
20	NUM	O	O
to	PART	O	O
86	NUM	O	O
yr	INTJ	O	O
)	PUNCT	O	O
receiving	VERB	O	O
cimetidine	NOUN	O	I-Entity
therapeutically	ADV	O	O
two	NUM	O	O
serum	NOUN	O	O
samples	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
urine	NOUN	O	O
formed	VERB	O	O
in	ADP	O	O
the	DET	O	O
interim	ADJ	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
analysis	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
by	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
creatinine	NOUN	O	I-Entity
.	PUNCT	O	O

Cimetidine	NOUN	O	I-Entity
clearance	NOUN	O	O
decreased	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
extrapolated	VERB	O	O
6-hr	NOUN	O	O
serum	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
per	ADP	O	O
unit	NOUN	O	O
dose	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
intravenous	ADJ	O	O
cimetidine	NOUN	O	I-Entity
,	PUNCT	O	O
increased	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
clearance	NOUN	O	O
to	ADP	O	O
creatinine	VERB	O	I-Entity
clearance	NOUN	O	O
(	PUNCT	O	O
Rc	PROPN	O	O
)	PUNCT	O	O
averaged	VERB	O	O
4.8	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

2.0	PUNCT	O	O
,	PUNCT	O	O
indicating	VERB	O	O
net	ADJ	O	O
tubular	NOUN	O	O
secretion	NOUN	O	O
for	ADP	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O

Rc	PROPN	O	O
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
independent	ADJ	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
with	ADP	O	O
increasing	VERB	O	O
serum	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
secretion	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
saturable	ADJ	O	O
process	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
only	ADV	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
dementia	NOUN	O	I-Entity
possibly	ADV	O	O
due	ADP	O	O
to	ADP	O	O
cimetidine	NOUN	O	I-Entity
(	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
1.9	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
ml	ADV	O	O
6	NUM	O	O

hr	NOUN	O	O
after	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
liver	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
kidney	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
cimetidine	NOUN	O	I-Entity
levels	NOUN	O	O
above	ADP	O	O
1.25	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
ml	ADV	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
high	ADJ	O	O
cimetidine	NOUN	O	I-Entity
levels	NOUN	O	O
alone	ADV	O	O
do	VERB	O	O
not	ADV	O	O
always	ADV	O	O
induce	VERB	O	O
dementia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7088431)

Development	PROPN	O	O
of	ADP	O	O
clear	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
adenocarcinoma	NOUN	O	I-Entity
in	ADP	O	O
DES	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
offspring	NOUN	O	O
under	ADP	O	O
observation	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
clear	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
adenocarcinoma	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
vagina	NOUN	O	I-Entity
detected	VERB	O	O
at	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
women	NOUN	O	O
exposed	VERB	O	O
in	ADP	O	O
utero	NOUN	O	O
to	ADP	O	O
diethylstilbestrol	NOUN	O	I-Entity
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
23	NUM	O	O
,	PUNCT	O	O
had	VERB	O	O
been	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
before	ADP	O	O
carcinoma	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
;	PUNCT	O	O
the	DET	O	O
second	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
22	NUM	O	O
,	PUNCT	O	O
had	VERB	O	O
been	VERB	O	O
seen	VERB	O	O
on	ADP	O	O
a	DET	O	O
regular	ADJ	O	O
basis	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
instances	NOUN	O	O
,	PUNCT	O	O
suspicion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
carcinoma	NOUN	O	I-Entity
was	VERB	O	O
aroused	VERB	O	O
by	ADP	O	O
the	DET	O	O
palpation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
small	ADJ	O	O
nodule	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vaginal	ADJ	O	O
fornix	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7248170)

Phenobarbitone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
enlargement	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
:	PUNCT	O	O
its	ADJ	O	O
relationship	NOUN	O	O
to	ADP	O	O
carbon	NOUN	O	B-Entity
tetrachloride	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cirrhosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
yield	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
cirrhosis	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
(	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
shrunken	ADV	O	O
finely	ADV	O	O
nodular	ADJ	O	O
liver	NOUN	O	O
with	ADP	O	O
micronodular	ADJ	O	O
histology	NOUN	O	O
,	PUNCT	O	O
ascites	VERB	O	I-Entity
greater	ADJ	O	O
than	ADP	O	O
30	NUM	O	O
ml	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
albumin	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
2.2	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O
splenomegaly	NOUN	O	I-Entity
2	NUM	O	O
-	SYM	O	O
3	NUM	O	O
times	NOUN	O	O
normal	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
testicular	ADJ	O	O
atrophy	NOUN	O	I-Entity
approximately	ADV	O	O
half	ADJ	O	O
normal	ADJ	O	O
weight	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
12	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
carbon	NOUN	O	B-Entity
tetrachloride	NOUN	O	I-Entity
given	VERB	O	O
intragastrically	ADV	O	O
in	ADP	O	O
the	DET	O	O
phenobarbitone	NOUN	O	I-Entity
-	PUNCT	O	O
primed	VERB	O	O
rat	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
25%	NUM	O	O
to	ADP	O	O
56%	NUM	O	O
by	ADP	O	O
giving	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
"	PUNCT	O	O
calibrating	VERB	O	O
"	PUNCT	O	O
dose	NOUN	O	O
of	ADP	O	O
carbon	NOUN	O	B-Entity
tetrachloride	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
peak	NOUN	O	O
of	ADP	O	O
the	DET	O	O
phenobarbitone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
enlargement	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
this	DET	O	O
point	NOUN	O	O
it	PRON	O	O
was	VERB	O	O
assumed	VERB	O	O
that	ADP	O	O
the	DET	O	O
cytochrome	NOUN	O	O
P450/CCl4	PROPN	O	I-Entity
toxic	ADJ	O	O
state	NOUN	O	O
was	VERB	O	O
both	DET	O	O
maximal	ADJ	O	O
and	CCONJ	O	O
stable	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
optimal	ADJ	O	O
rat	NOUN	O	O
size	NOUN	O	O
to	PART	O	O
begin	VERB	O	O
phenobarbitone	NOUN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
as	ADP	O	O
100	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
size	NOUN	O	O
as	ADP	O	O
a	DET	O	O
group	NOUN	O	O
had	VERB	O	O
a	DET	O	O
mean	ADJ	O	O
maximum	ADJ	O	O
relative	ADJ	O	O
liver	NOUN	O	O
weight	NOUN	O	O
increase	NOUN	O	O
47%	NUM	O	O
greater	ADJ	O	O
than	ADP	O	O
normal	ADJ	O	O
rats	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
optimal	ADJ	O	O
time	NOUN	O	O
for	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
carbon	NOUN	O	B-Entity
tetrachloride	NOUN	O	I-Entity
was	VERB	O	O
after	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
on	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7453952)

Attenuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
insipidus	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
by	ADP	O	O
amiloride	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
amiloride	NOUN	O	I-Entity
on	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polydipsia	NOUN	O	I-Entity
and	CCONJ	O	O
polyuria	NOUN	O	I-Entity
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
brain	NOUN	O	O
,	PUNCT	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
thyroid	NOUN	O	O
and	CCONJ	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
chronically	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
LiCl	PROPN	O	I-Entity
.	PUNCT	O	O

Amiloride	PROPN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
drinking	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
volume	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
in	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
(	PUNCT	O	O
6	NUM	O	O
or	CCONJ	O	O
12	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
subacute	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
experiment	NOUN	O	O
.	PUNCT	O	O

6	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
amiloride	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
reduction	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
content	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
medulla	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
organs	NOUN	O	O
studied	VERB	O	O
.	PUNCT	O	O

At	ADP	O	O
12	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
all	ADJ	O	O
the	DET	O	O
tissues	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
slight	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
lithium	ADJ	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
marked	ADJ	O	O
elevation	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
tissue	NOUN	O	O
lithium	NOUN	O	I-Entity
levels	NOUN	O	O
accompanied	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
water	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	ADJ	O	O
the	DET	O	O
experiments	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
attenuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
insipidus	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
by	ADP	O	O
amiloride	NOUN	O	I-Entity
was	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ratio	NOUN	O	O
between	ADP	O	O
the	DET	O	O
lithium	ADJ	O	I-Entity
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
medulla	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
elevation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
potassium	NOUN	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
acute	ADJ	O	O
amiloride	ADJ	O	I-Entity
administration	NOUN	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
polydipsia	NOUN	O	I-Entity
and	CCONJ	O	O
polyuria	NOUN	O	I-Entity
might	VERB	O	O
relieve	VERB	O	O
these	DET	O	O
patients	NOUN	O	O
but	CCONJ	O	O
prolonged	ADJ	O	O
amiloride	NOUN	O	I-Entity
supplementation	NOUN	O	O
would	VERB	O	O
result	VERB	O	O
in	ADP	O	O
elevated	VERB	O	O
lithium	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
might	VERB	O	O
be	VERB	O	O
hazardous	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (7802851)

Safety	NOUN	O	O
and	CCONJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
of	ADP	O	O
alprazolam	NOUN	O	I-Entity
.	PUNCT	O	O

Controlled	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
agoraphobia	NOUN	O	I-Entity
with	ADP	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
widespread	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
benzodiazepines	NOUN	O	I-Entity
has	VERB	O	O
led	VERB	O	O
to	ADP	O	O
increasing	VERB	O	O
recognition	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
unwanted	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
alprazolam	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
with	ADP	O	O
agoraphobia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
profiles	NOUN	O	O
of	ADP	O	O
both	DET	O	O
drug	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
London	PROPN	O	O
and	CCONJ	O	O
Toronto	PROPN	O	O
154	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
met	VERB	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
III	PROPN	O	O
criteria	NOUN	O	O
for	ADP	O	O
panic	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
with	ADP	O	O
agoraphobia	NOUN	O	I-Entity
were	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
alprazolam	NOUN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Mean	VERB	O	O
alprazolam	NOUN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
5	NUM	O	O
mg	NUM	O	O
daily	ADV	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
alprazolam	NOUN	O	I-Entity
patients	NOUN	O	O
developed	VERB	O	O
more	ADV	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
(	PUNCT	O	O
21%	NUM	O	O
v.	NOUN	O	O
0%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
depression	NOUN	O	I-Entity
,	PUNCT	O	O
enuresis	NOUN	O	I-Entity
,	PUNCT	O	O
disinhibition	NOUN	O	O
and	CCONJ	O	O
aggression	NOUN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O
more	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
irritability	NOUN	O	I-Entity
,	PUNCT	O	O
impaired	ADJ	O	B-Entity
memory	NOUN	O	I-Entity
,	PUNCT	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
and	CCONJ	O	O
ataxia	NOUN	O	I-Entity
.	PUNCT	O	O

Alprazolam	PROPN	O	I-Entity
caused	VERB	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
but	CCONJ	O	O
many	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
willing	ADJ	O	O
to	PART	O	O
accept	VERB	O	O
these	DET	O	O
.	PUNCT	O	O


-DOCSTART- (8319760)

Dup	PROPN	O	B-Entity
753	NUM	O	I-Entity
prevents	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndromes	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
hypoalbuminemia	NOUN	O	I-Entity
,	PUNCT	O	O
hypercholesterolemia	NOUN	O	I-Entity
and	CCONJ	O	O
increase	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	B-Entity
nitrogen	NOUN	O	I-Entity
urea	NOUN	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
was	VERB	O	O
markedly	ADV	O	O
inhibited	VERB	O	O
by	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
Dup	PROPN	O	B-Entity
753	NUM	O	I-Entity
(	PUNCT	O	O
losartan	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
novel	NOUN	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
involvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8386779)

Sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
alleviates	VERB	O	O
penile	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
intracavernous	ADJ	O	O
injections	NOUN	O	O
for	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
an	DET	O	O
attempt	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
penile	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
intracorporeal	ADJ	O	O
injections	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
the	DET	O	O
acidity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
performed	VERB	O	O
a	DET	O	O
randomized	ADJ	O	O
study	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
penile	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
following	VERB	O	O
intracorporeal	ADJ	O	O
injections	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
intracorporeal	NOUN	O	O
medications	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
38	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
presented	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
clinic	NOUN	O	O
with	ADP	O	O
impotence	NOUN	O	I-Entity
received	VERB	O	O
0.2	NUM	O	O
ml	NOUN	O	O
.	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
drugs	NOUN	O	O
:	PUNCT	O	O
6	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

papaverine	NOUN	O	I-Entity
,	PUNCT	O	O
100	NUM	O	O
micrograms	NOUN	O	O
.	PUNCT	O	O

phentolamine	NOUN	O	I-Entity
and	CCONJ	O	O
10	NUM	O	O
micrograms	NOUN	O	O
.	PUNCT	O	O

prostaglandin	NOUN	O	B-Entity
E1	NOUN	O	I-Entity
with	ADP	O	O
(	PUNCT	O	O
pH	PROPN	O	O
7.05	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
without	ADP	O	O
(	PUNCT	O	O
pH	NOUN	O	O
4.17	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
(	PUNCT	O	O
0.03	NUM	O	O
mEq	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
19	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
added	VERB	O	O
to	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
11	NUM	O	O
(	PUNCT	O	O
58%	NUM	O	O
)	PUNCT	O	O
complained	VERB	O	O
of	ADP	O	O
penile	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
only	ADV	O	O
1	NUM	O	O
of	ADP	O	O
the	DET	O	O
19	NUM	O	O
men	NOUN	O	O
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
who	NOUN	O	O
received	VERB	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
complained	VERB	O	O
of	ADP	O	O
penile	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
these	DET	O	O
data	NOUN	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
penile	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
following	VERB	O	O
intracorporeal	ADJ	O	O
injections	NOUN	O	O
is	VERB	O	O
most	ADV	O	O
likely	ADJ	O	O
due	ADJ	O	O
to	ADP	O	O
the	DET	O	O
acidity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
can	VERB	O	O
be	VERB	O	O
overcome	VERB	O	O
by	ADP	O	O
elevating	VERB	O	O
the	DET	O	O
pH	NOUN	O	O
to	ADP	O	O
a	DET	O	O
neutral	ADJ	O	O
level	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8421099)

Prospective	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
somatostatin	NOUN	O	O
analog	NOUN	O	O
(	PUNCT	O	O
octreotide	NOUN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
gallbladder	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
gallstone	NOUN	O	I-Entity
formation	NOUN	O	O
in	ADP	O	O
Chinese	ADJ	O	O
acromegalic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
reports	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
gallbladder	NOUN	O	O
function	NOUN	O	O
examined	VERB	O	O
by	ADP	O	O
ultrasonography	NOUN	O	O
in	ADP	O	O
20	NUM	O	O
Chinese	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
active	ADJ	O	O
acromegaly	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
sc	NOUN	O	O
injection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
somatostatin	NOUN	O	O
analog	NOUN	O	O
octreotide	NOUN	O	I-Entity
in	ADP	O	O
dosages	NOUN	O	O
of	ADP	O	O
300	NUM	O	O
-	SYM	O	O
1500	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
24.2	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

During	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
octreotide	NOUN	O	I-Entity
,	PUNCT	O	O
17	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
sludge	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
had	VERB	O	O
gallstones	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
cholecystitis	NOUN	O	I-Entity
requiring	VERB	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
8	NUM	O	O
patients	NOUN	O	O
followed	VERB	O	O
for	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
gallbladder	NOUN	O	O
contractility	NOUN	O	O
remained	VERB	O	O
depressed	ADJ	O	I-Entity
throughout	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
octreotide	NOUN	O	I-Entity
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
gallstones	NOUN	O	I-Entity
,	PUNCT	O	O
8	NUM	O	O
patients	NOUN	O	O
assessed	VERB	O	O
had	VERB	O	O
return	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
gallbladder	NOUN	O	O
contractility	NOUN	O	O
within	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
8	NUM	O	O
of	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
10	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
gallstones	NOUN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
gallbladder	NOUN	O	O
contractility	NOUN	O	O
normalized	ADJ	O	O
in	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
has	VERB	O	O
disappearance	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
stones	NOUN	O	O
within	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
remained	VERB	O	O
depressed	ADJ	O	I-Entity
in	ADP	O	O
3	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
had	VERB	O	O
stones	NOUN	O	O
present	ADJ	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
suppression	NOUN	O	O
of	ADP	O	O
gallbladder	NOUN	O	O
contractility	NOUN	O	O
is	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
successive	ADJ	O	O
formation	NOUN	O	O
of	ADP	O	O
bile	NOUN	O	O
sludge	NOUN	O	O
,	PUNCT	O	O
gallstones	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cholecystitis	NOUN	O	I-Entity
during	ADP	O	O
octreotide	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
Chinese	ADJ	O	O
acromegalic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
therefore	ADV	O	O
very	ADV	O	O
important	ADJ	O	O
to	PART	O	O
follow	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
of	ADP	O	O
gallbladder	NOUN	O	O
function	NOUN	O	O
during	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
octreotide	NOUN	O	I-Entity
therapy	NOUN	O	O
of	ADP	O	O
acromegalic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8649546)

Improvement	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
by	ADP	O	O
propranolol	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Seven	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
severely	ADV	O	O
disabling	VERB	O	O
dyskinesia	NOUN	O	I-Entity
received	VERB	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
propranolol	NOUN	O	I-Entity
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
to	ADP	O	O
the	DET	O	O
currently	ADV	O	O
used	VERB	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
40%	NUM	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dyskinesia	NOUN	O	I-Entity
score	NOUN	O	O
without	ADP	O	O
increase	NOUN	O	O
of	ADP	O	O
parkinsonian	ADJ	O	I-Entity
motor	NOUN	O	B-Entity
disability	NOUN	O	I-Entity
.	PUNCT	O	O

Ballistic	ADJ	O	O
and	CCONJ	O	O
choreic	ADJ	O	O
dyskinesia	NOUN	O	I-Entity
were	VERB	O	O
markedly	ADV	O	O
ameliorated	VERB	O	O
,	PUNCT	O	O
whereas	ADP	O	O
dystonia	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
may	VERB	O	O
improve	VERB	O	O
levodopa	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ballistic	ADJ	O	O
and	CCONJ	O	O
choreic	ADJ	O	O
dyskinesia	NOUN	O	I-Entity
in	ADP	O	O
PD	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8919272)

Morphological	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
encephalopathy	NOUN	O	I-Entity
after	ADP	O	O
chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
valproate	NOUN	O	I-Entity
to	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
intragastric	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
sodium	NOUN	O	B-Entity
valproate	NOUN	O	I-Entity
(	PUNCT	O	O
Vupral	PROPN	O	O
"	PUNCT	O	O
Polfa	PROPN	O	O
"	PUNCT	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
effective	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
b.	NOUN	O	O
w.	PROPN	O	O
once	ADV	O	O
daily	ADV	O	O
to	ADP	O	O
rats	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
revealed	VERB	O	O
neurological	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
indicating	VERB	O	O
cerebellum	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
(	PUNCT	O	O
"	PUNCT	O	O
valproate	ADJ	O	I-Entity
encephalopathy	NOUN	O	I-Entity
"	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Lesions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
capillary	ADJ	O	O
included	VERB	O	O
necrosis	NOUN	O	I-Entity
of	ADP	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Reduced	ADJ	O	O
size	NOUN	O	O
of	ADP	O	O
capillary	ADJ	O	O
lumen	NOUN	O	O
and	CCONJ	O	O
occlusion	NOUN	O	O
were	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
swollen	ADJ	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
which	ADJ	O	O
had	VERB	O	O
luminal	ADJ	O	I-Entity
protrusions	NOUN	O	O
and	CCONJ	O	O
swollen	ADJ	O	O
microvilli	NOUN	O	O
.	PUNCT	O	O

Fragments	NOUN	O	O
of	ADP	O	O
necrotic	ADJ	O	I-Entity
endothelial	ADJ	O	O
cells	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
the	DET	O	O
vascular	ADJ	O	O
lumens	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
these	DET	O	O
there	ADV	O	O
was	VERB	O	O
loosening	VERB	O	O
and	CCONJ	O	O
breaking	VERB	O	O
of	ADP	O	O
tight	ADJ	O	O
cellular	ADJ	O	O
junctions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
electron	NOUN	O	O
micrographs	NOUN	O	O
both	CCONJ	O	O
luminal	ADJ	O	I-Entity
and	CCONJ	O	O
antiluminal	ADJ	O	O
sides	NOUN	O	O
of	ADP	O	O
the	DET	O	O
BBB	PROPN	O	O
of	ADP	O	O
the	DET	O	O
cerebellar	ADJ	O	O
cortex	NOUN	O	O
had	VERB	O	O
similar	ADJ	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
influence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hepatic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
mainly	ADV	O	O
hyperammonemia	NOUN	O	I-Entity
,	PUNCT	O	O
upon	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	I-Entity
encephalopathy	NOUN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9199746)

Macula	PROPN	O	O
toxicity	NOUN	O	I-Entity
after	ADP	O	O
intravitreal	ADJ	O	O
amikacin	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
intravitreal	ADJ	O	O
aminoglycosides	NOUN	O	I-Entity
have	VERB	O	O
substantially	ADV	O	O
improved	VERB	O	O
visual	ADJ	O	O
prognosis	NOUN	O	O
in	ADP	O	O
endophthalmitis	NOUN	O	I-Entity
,	PUNCT	O	O
macular	ADJ	O	O
infarction	NOUN	O	I-Entity
may	VERB	O	O
impair	VERB	O	O
full	ADJ	O	O
visual	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
presumed	VERB	O	O
amikacin	ADJ	O	I-Entity
retinal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
amikacin	NOUN	O	I-Entity
and	CCONJ	O	O
vancomycin	NOUN	O	I-Entity
for	ADP	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
haemolytic	ADJ	O	O
streptococcal	ADJ	O	B-Entity
endophthalmitis	NOUN	O	I-Entity
.	PUNCT	O	O

Endophthalmitis	PROPN	O	I-Entity
resolved	VERB	O	O
with	ADP	O	O
improvement	NOUN	O	O
in	ADP	O	O
visual	ADJ	O	O
acuity	NOUN	O	O
to	ADP	O	O
6/24	NUM	O	O
at	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Fundus	PROPN	O	O
fluorescein	NOUN	O	I-Entity
angiography	NOUN	O	O
confirmed	VERB	O	O
macular	ADJ	O	O
capillary	ADJ	O	O
closure	NOUN	O	O
and	CCONJ	O	O
telangiectasis	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Currently	ADV	O	O
accepted	VERB	O	O
intravitreal	NOUN	O	O
antibiotic	NOUN	O	O
regimens	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
retinal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
macular	ADJ	O	O
ischaemia	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	NOUN	O	O
strategies	NOUN	O	O
aimed	VERB	O	O
at	ADP	O	O
avoiding	VERB	O	O
retinal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9249847)

Iatrogenically	ADV	O	O
induced	VERB	O	O
intractable	ADJ	O	O
atrioventricular	ADJ	O	B-Entity
reentrant	ADJ	O	I-Entity
tachycardia	NOUN	O	I-Entity
after	ADP	O	O
verapamil	ADV	O	I-Entity
and	CCONJ	O	O
catheter	NOUN	O	O
ablation	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
Wolff	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Parkinson	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
White	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
idiopathic	ADJ	O	B-Entity
dilated	ADJ	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
WPW	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
idiopathic	ADJ	O	B-Entity
dilated	VERB	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
intractable	ADJ	O	O
atrioventricular	ADJ	O	B-Entity
reentrant	ADJ	O	I-Entity
tachycardia	NOUN	O	I-Entity
(	PUNCT	O	O
AVRT	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
iatrogenically	ADV	O	O
induced	VERB	O	O
.	PUNCT	O	O

QRS	NOUN	O	O
without	ADP	O	O
preexcitation	NOUN	O	O
,	PUNCT	O	O
caused	VERB	O	O
by	ADP	O	O
junctional	ADJ	O	O
escape	NOUN	O	O
beats	NOUN	O	O
after	ADP	O	O
verapamil	ADV	O	I-Entity
or	CCONJ	O	O
unidirectional	ADJ	O	O
antegrade	NOUN	O	O
block	NOUN	O	O
of	ADP	O	O
accessory	NOUN	O	O
pathway	NOUN	O	O
after	ADP	O	O
catheter	NOUN	O	O
ablation	NOUN	O	O
,	PUNCT	O	O
established	VERB	O	O
frequent	ADJ	O	O
AVRT	PROPN	O	I-Entity
attack	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9284778)

Epidemic	PROPN	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
hydrochlorofluorocarbons	NOUN	O	I-Entity
used	VERB	O	O
as	ADP	O	O
ozone	NOUN	O	I-Entity
-	PUNCT	O	O
sparing	VERB	O	O
substitutes	NOUN	O	O
of	ADP	O	O
chlorofluorocarbons	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Hydrochlorofluorocarbons	NOUN	O	I-Entity
(	PUNCT	O	O
HCFCs	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
used	VERB	O	O
increasingly	ADV	O	O
in	ADP	O	O
industry	NOUN	O	O
as	ADP	O	O
substitutes	NOUN	O	O
for	ADP	O	O
ozone	NOUN	O	I-Entity
-	PUNCT	O	O
depleting	VERB	O	O
chlorofluorocarbons	NOUN	O	I-Entity
(	PUNCT	O	O
CFCs	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Limited	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
indicate	VERB	O	O
potential	ADJ	O	O
hepatotoxicity	NOUN	O	I-Entity
of	ADP	O	O
some	DET	O	O
of	ADP	O	O
these	DET	O	O
compounds	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
an	DET	O	O
epidemic	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
nine	NUM	O	O
industrial	ADJ	O	O
workers	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
had	VERB	O	O
repeated	VERB	O	O
accidental	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
1,1-dichloro-2,2,2-trifluoroethane	NUM	O	I-Entity
(	PUNCT	O	O
HCFC	PROPN	O	B-Entity
123	NUM	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
1-chloro-1,2,2,2-tetrafluoroethane	NUM	O	I-Entity

(	PUNCT	O	O
HCFC	PROPN	O	B-Entity
124	NUM	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
compounds	NOUN	O	O
are	VERB	O	O
metabolised	VERB	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
way	NOUN	O	O
as	ADP	O	O
1-bromo-1-chloro-2,2,2-trifluoroethane	NUM	O	I-Entity
(	PUNCT	O	O
halothane	NOUN	O	I-Entity
)	PUNCT	O	O
to	PART	O	O
form	VERB	O	O
reactive	ADJ	O	O
trifluoroacetyl	NOUN	O	I-Entity
halide	NOUN	O	O
intermediates	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
hepatotoxicity	NOUN	O	I-Entity
of	ADP	O	O
halothane	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
test	VERB	O	O
whether	ADP	O	O
HCFCs	PROPN	O	B-Entity
123	NUM	O	I-Entity
and	CCONJ	O	I-Entity
124	NUM	O	I-Entity
can	VERB	O	O
result	VERB	O	O
in	ADP	O	O
serious	ADJ	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
For	ADP	O	O
one	NUM	O	O
severely	ADV	O	O
affected	VERB	O	O
worker	NOUN	O	O
liver	NOUN	O	O
biopsy	NOUN	O	O
and	CCONJ	O	O
immunohistochemical	ADJ	O	O
stainings	NOUN	O	O
for	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
trifluoroacetyl	DET	O	I-Entity
protein	NOUN	O	O
adducts	NOUN	O	O
were	VERB	O	O
done	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
liver	NOUN	O	O
biopsy	NOUN	O	O
sample	NOUN	O	O
showed	VERB	O	O
hepatocellular	ADJ	O	O
necrosis	NOUN	O	I-Entity
which	ADJ	O	O
was	VERB	O	O
prominent	ADJ	O	O
in	ADP	O	O
perivenular	ADJ	O	O
zone	NOUN	O	O
three	NUM	O	O
and	CCONJ	O	O
extended	VERB	O	O
focally	ADV	O	O
from	ADP	O	O
portal	ADJ	O	O
tracts	NOUN	O	O
to	ADP	O	O
portal	ADJ	O	O
tracts	NOUN	O	O
and	CCONJ	O	O
centrilobular	ADJ	O	O
areas	NOUN	O	O
(	PUNCT	O	O
bridging	VERB	O	O
necrosis	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Trifluoroacetyl	PROPN	O	I-Entity
-	PUNCT	O	O
adducted	VERB	O	O
proteins	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
surviving	VERB	O	O
hepatocytes	NOUN	O	O
.	PUNCT	O	O

Autoantibodies	NOUN	O	O
against	ADP	O	O
P450	PROPN	O	O
2E1	NUM	O	O
or	CCONJ	O	O
P58	PROPN	O	O
,	PUNCT	O	O
previously	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
halothane	NOUN	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
affected	VERB	O	O
workers	NOUN	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
:	PUNCT	O	O
Repeated	VERB	O	O
exposure	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
beings	NOUN	O	O
to	ADP	O	O
HCFCs	VERB	O	B-Entity
123	NUM	O	I-Entity
and	CCONJ	O	I-Entity
124	NUM	O	I-Entity
can	VERB	O	O
result	VERB	O	O
in	ADP	O	O
serious	ADJ	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
exposed	VERB	O	O
population	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
exact	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
of	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
trifluoroacetyl	NOUN	O	I-Entity
-	PUNCT	O	O
altered	VERB	O	O
liver	NOUN	O	O
proteins	NOUN	O	O
are	VERB	O	O
involved	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9522143)

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
anaesthetic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
following	VERB	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
after	ADP	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

Up	ADP	O	O
until	ADP	O	O
now	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
only	ADJ	O	O
factor	NOUN	O	O
studied	VERB	O	O
has	VERB	O	O
been	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diameter	NOUN	O	O
of	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
needle	NOUN	O	O
on	ADP	O	O
post	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
sensorineural	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
describe	VERB	O	O
this	DET	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
investigate	VERB	O	O
other	ADJ	O	O
factors	NOUN	O	O
influencing	VERB	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

prilocaine	NOUN	O	I-Entity
2%	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
received	VERB	O	O
3	NUM	O	O
mL	PROPN	O	O
bupivacaine	NOUN	O	I-Entity
0.5%	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
given	VERB	O	O
prilocaine	NOUN	O	I-Entity
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
develop	VERB	O	O
hearing	VERB	O	B-Entity
loss	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
out	ADP	O	O
of	ADP	O	O
22	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
those	DET	O	O
given	VERB	O	O
bupivacaine	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
out	ADP	O	O
of	ADP	O	O
22	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
for	ADP	O	O
speech	NOUN	O	O
frequencies	NOUN	O	O
was	VERB	O	O
about	ADV	O	O
10	NUM	O	O
dB	NOUN	O	O
after	ADP	O	O
prilocaine	NOUN	O	I-Entity
and	CCONJ	O	O
15	NUM	O	O
dB	NOUN	O	O
after	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
complained	VERB	O	O
of	ADP	O	O
subjective	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9522152)

A	DET	O	O
transient	ADJ	O	O
neurological	ADJ	O	B-Entity
deficit	NOUN	O	I-Entity
following	VERB	O	O
intrathecal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
1%	NUM	O	O
hyperbaric	ADJ	O	O
bupivacaine	NOUN	O	I-Entity
for	ADP	O	O
unilateral	ADJ	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
neurological	ADJ	O	B-Entity
deficit	NOUN	O	I-Entity
that	ADJ	O	O
occurred	VERB	O	O
after	ADP	O	O
unilateral	ADJ	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
8	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
1%	NUM	O	O
hyperbaric	ADJ	O	O
bupivacaine	NOUN	O	I-Entity
slowly	ADV	O	O
injected	VERB	O	O
through	ADP	O	O
a	DET	O	O
25-gauge	NUM	O	O
pencil	NOUN	O	O
-	PUNCT	O	O
point	NOUN	O	O
spinal	ADJ	O	O
needle	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
anaesthesia	NOUN	O	O
were	VERB	O	O
uneventful	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
3	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
reported	VERB	O	O
an	DET	O	O
area	NOUN	O	O
of	ADP	O	O
hypoaesthesia	NOUN	O	O
over	ADP	O	O
L3-L4	PROPN	O	O
dermatomes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
leg	NOUN	O	O
which	ADJ	O	O
had	VERB	O	O
been	VERB	O	O
operated	VERB	O	O
on	ADP	O	O
(	PUNCT	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
pinprick	NOUN	O	I-Entity
sensation	NOUN	O	I-Entity
)	PUNCT	O	O
without	ADP	O	O
reduction	NOUN	O	O
in	ADP	O	O
muscular	ADJ	O	O
strength	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
low	ADJ	O	O
solution	NOUN	O	O
concentration	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
preferred	VERB	O	O
for	ADP	O	O
unilateral	ADJ	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
a	DET	O	O
hyperbaric	ADJ	O	O
anaesthetic	ADJ	O	O
solution	NOUN	O	O
(	PUNCT	O	O
if	ADP	O	O
pencil	NOUN	O	O
-	PUNCT	O	O
point	NOUN	O	O
needle	NOUN	O	O
and	CCONJ	O	O
slow	ADJ	O	O
injection	NOUN	O	O
rate	NOUN	O	O
are	VERB	O	O
employed	VERB	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
minimize	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
a	DET	O	O
localized	ADJ	O	O
high	ADJ	O	O
peak	NOUN	O	O
anaesthetic	ADJ	O	O
concentration	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
might	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
transient	ADJ	O	O
neurological	ADJ	O	B-Entity
deficit	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9672936)

Pethidine	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
seizure	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
healthy	ADJ	O	O
adolescent	NOUN	O	O
receiving	VERB	O	O
pethidine	NOUN	O	I-Entity
for	ADP	O	O
postoperative	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
control	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
healthy	ADJ	O	O
17-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
received	VERB	O	O
standard	ADJ	O	O
intermittent	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
via	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
analgesia	NOUN	O	O
(	PUNCT	O	O
PCA	PROPN	O	O
)	PUNCT	O	O
pump	NOUN	O	O
for	ADP	O	O
management	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
control	NOUN	O	O
.	PUNCT	O	O

postoperatively	ADV	O	O
he	PRON	O	O
developed	VERB	O	O
a	DET	O	O
brief	ADJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
limited	ADJ	O	O
seizure	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
plasma	NOUN	O	O
pethidine	NOUN	O	I-Entity
and	CCONJ	O	O
norpethidine	NOUN	O	I-Entity
were	VERB	O	O
elevated	VERB	O	O
in	ADP	O	O
the	DET	O	O
range	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
clinical	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
excitation	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
other	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
CNS	PROPN	O	O
toxicity	NOUN	O	I-Entity
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
method	NOUN	O	O
allowed	VERB	O	O
frequent	ADJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
dosing	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
at	ADP	O	O
short	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
and	CCONJ	O	O
rapid	ADJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
and	CCONJ	O	O
norpethidine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
routine	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
pethidine	NOUN	O	I-Entity
via	ADP	O	O
PCA	PROPN	O	O
even	ADV	O	O
for	ADP	O	O
a	DET	O	O
brief	ADJ	O	O
postoperative	ADJ	O	O
analgesia	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
reconsidered	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9721172)

Drug	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
acute	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
vanishing	VERB	O	B-Entity
bile	NOUN	O	I-Entity
duct	NOUN	O	I-Entity
and	CCONJ	O	O
Stevens	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Johnson	PROPN	O	I-Entity
syndromes	VERB	O	I-Entity
in	ADP	O	O
a	DET	O	O
child	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
vanishing	VERB	O	B-Entity
bile	NOUN	O	I-Entity
duct	NOUN	O	I-Entity
syndrome	NOUN	O	O
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
but	CCONJ	O	O
established	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
progressive	ADJ	O	O
cholestasis	NOUN	O	I-Entity
in	ADP	O	O
adults	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
most	ADV	O	O
often	ADV	O	O
drug	NOUN	O	O
or	CCONJ	O	O
toxin	NOUN	O	O
related	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
is	VERB	O	O
of	ADP	O	O
unknown	ADJ	O	O
pathogenesis	NOUN	O	O
.	PUNCT	O	O

Stevens	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Johnson	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
recognized	VERB	O	O
immune	ADJ	O	O
complex	ADJ	O	O
-	PUNCT	O	O
mediated	VERB	O	O
hypersensitivity	ADJ	O	I-Entity
reaction	NOUN	O	O
that	ADJ	O	O
affects	VERB	O	O
all	DET	O	O
age	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
drug	NOUN	O	O
or	CCONJ	O	O
infection	NOUN	O	I-Entity
induced	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
has	VERB	O	O
classic	ADJ	O	O
systemic	ADJ	O	O
,	PUNCT	O	O
mucosal	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
dermatologic	ADJ	O	O
manifestations	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
previously	ADV	O	O
healthy	ADJ	O	O
child	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
,	PUNCT	O	O
severe	ADJ	O	O
,	PUNCT	O	O
rapidly	ADV	O	O
progressive	ADJ	O	O
vanishing	VERB	O	B-Entity
bile	NOUN	O	I-Entity
duct	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
Stevens	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Johnson	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
;	PUNCT	O	O
this	DET	O	O
was	VERB	O	O
temporally	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
ibuprofen	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
ursodeoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
prednisone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
tacrolimus	NOUN	O	I-Entity
,	PUNCT	O	O
her	ADJ	O	O
cholestatic	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
was	VERB	O	O
unrelenting	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
cirrhosis	NOUN	O	I-Entity
shown	VERB	O	O
by	ADP	O	O
biopsy	NOUN	O	O
6	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
presentation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
documents	VERB	O	O
acute	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
vanishing	VERB	O	B-Entity
bile	NOUN	O	I-Entity
duct	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
pediatric	ADJ	O	O
age	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
suggests	VERB	O	O
shared	VERB	O	O
immune	ADJ	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
both	DET	O	O
Stevens	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Johnson	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
vanishing	VERB	O	B-Entity
bile	ADJ	O	I-Entity
duct	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9727773)

High	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
in	ADP	O	O
Belgium	PROPN	O	O
.	PUNCT	O	O

Primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
,	PUNCT	O	O
progressive	ADJ	O	O
and	CCONJ	O	O
incurable	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
intake	NOUN	O	O
of	ADP	O	O
appetite	NOUN	O	B-Entity
suppressant	ADJ	O	I-Entity
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
this	DET	O	O
association	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
Belgium	PROPN	O	O
while	ADP	O	O
this	DET	O	O
country	NOUN	O	O
still	ADV	O	O
had	VERB	O	O
no	DET	O	O
restriction	NOUN	O	O
on	ADP	O	O
the	DET	O	O
prescription	NOUN	O	O
of	ADP	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
85	NUM	O	O
matched	VERB	O	O
controls	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
over	ADP	O	O
32	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
1992	NUM	O	O
-	SYM	O	O
1994	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
Belgium	PROPN	O	O
.	PUNCT	O	O

Exposure	NOUN	O	O
to	ADP	O	O
appetite	VERB	O	B-Entity
-	PUNCT	O	I-Entity
suppressants	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
hospital	NOUN	O	O
records	NOUN	O	O
and	CCONJ	O	O
standardized	ADJ	O	O
interview	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
previously	ADV	O	O
taken	VERB	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
,	PUNCT	O	O
mainly	ADV	O	O
fenfluramines	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
only	ADV	O	O
5	NUM	O	O
of	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
(	PUNCT	O	O
66	NUM	O	O
versus	NOUN	O	O
6%	NUM	O	O
,	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
died	VERB	O	O
before	ADP	O	O
the	DET	O	O
interview	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
of	ADP	O	O
them	PRON	O	O
had	VERB	O	O
taken	VERB	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
8	NUM	O	O
patients	NOUN	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
was	VERB	O	O
uncertain	ADJ	O	O
,	PUNCT	O	O
5	NUM	O	O
of	ADP	O	O
them	PRON	O	O
had	VERB	O	O
taken	VERB	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
tended	VERB	O	O
to	PART	O	O
be	VERB	O	O
on	ADP	O	O
average	ADJ	O	O
more	ADV	O	O
severely	ADV	O	O
ill	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
shorter	ADJ	O	O
median	ADJ	O	O
delay	NOUN	O	O
between	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
diagnosis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
policy	NOUN	O	O
of	ADP	O	O
unrestricted	ADJ	O	O
prescription	NOUN	O	O
of	ADP	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
associated	VERB	O	O
primary	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Intake	PROPN	O	O
of	ADP	O	O
appetite	NOUN	O	B-Entity
suppressants	NOUN	O	I-Entity
may	VERB	O	O
accelerate	VERB	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9754849)

Choreoathetoid	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
rapid	ADJ	O	O
adjustment	NOUN	O	O
to	ADP	O	O
methadone	NOUN	O	I-Entity
.	PUNCT	O	O

Choreatiform	PROPN	O	B-Entity
hyperkinesias	NOUN	O	I-Entity
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
occasional	ADJ	O	O
movement	NOUN	O	B-Entity
abnormalities	NOUN	O	I-Entity
during	ADP	O	O
intoxications	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
opiates	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
euphoria	NOUN	O	O
and	CCONJ	O	O
choreoathetoid	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
both	DET	O	O
transiently	ADV	O	O
induced	VERB	O	O
by	ADP	O	O
rapid	ADJ	O	O
adjustment	NOUN	O	O
to	ADP	O	O
the	DET	O	O
selective	ADJ	O	O
mu	NOUN	O	O
-	PUNCT	O	O
opioid	ADJ	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
methadone	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
inpatient	NOUN	O	O
previously	ADV	O	O
abusing	VERB	O	O
heroine	NOUN	O	I-Entity
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10365197)

Cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
mood	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
:	PUNCT	O	O
prevalence	NOUN	O	O
rates	NOUN	O	O
and	CCONJ	O	O
psychiatric	ADJ	O	I-Entity
symptoms	NOUN	O	O
in	ADP	O	O
an	DET	O	O
outpatient	ADJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
sample	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
paper	NOUN	O	O
attempts	VERB	O	O
to	PART	O	O
examine	VERB	O	O
and	CCONJ	O	O
compare	VERB	O	O
prevalence	NOUN	O	O
rates	NOUN	O	O
and	CCONJ	O	O
symptom	NOUN	O	O
patterns	NOUN	O	O
of	ADP	O	O
DSM	PROPN	O	O
substance	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
and	CCONJ	O	O
other	ADJ	O	O
mood	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

243	NUM	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
outpatients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
mood	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
CIMD	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
other	ADJ	O	O
mood	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
mood	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
on	ADP	O	O
measures	NOUN	O	O
of	ADP	O	O
psychiatric	ADJ	O	I-Entity
symptoms	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prevalence	NOUN	O	O
rate	NOUN	O	O
for	ADP	O	O
CIMD	PROPN	O	I-Entity
was	VERB	O	O
12%	NUM	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Introduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
CIMD	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
substantially	ADV	O	O
affect	VERB	O	O
rates	NOUN	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
depressive	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
CIMD	PROPN	O	I-Entity
had	VERB	O	O
symptom	NOUN	O	O
severity	NOUN	O	O
levels	NOUN	O	O
between	ADP	O	O
those	DET	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
a	DET	O	O
mood	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
some	DET	O	O
validity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
new	ADJ	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
CIMD	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
also	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
it	PRON	O	O
requires	VERB	O	O
further	ADJ	O	O
specification	NOUN	O	O
and	CCONJ	O	O
replication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10704919)

Hemolysis	PROPN	O	I-Entity
of	ADP	O	O
human	ADJ	O	O
erythrocytes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
tamoxifen	NOUN	O	I-Entity
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
disruption	NOUN	O	O
of	ADP	O	O
membrane	NOUN	O	O
structure	NOUN	O	O
.	PUNCT	O	O

Tamoxifen	PROPN	O	I-Entity
(	PUNCT	O	O
TAM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
antiestrogenic	ADJ	O	O
drug	NOUN	O	O
most	ADV	O	O
widely	ADV	O	O
prescribed	VERB	O	O
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
induces	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
discoid	ADJ	O	O
shape	NOUN	O	O
of	ADP	O	O
erythrocytes	NOUN	O	O
and	CCONJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
work	NOUN	O	O
evaluates	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
TAM	PROPN	O	I-Entity
on	ADP	O	O
isolated	ADJ	O	O
human	ADJ	O	O
erythrocytes	NOUN	O	O
,	PUNCT	O	O
attempting	VERB	O	O
to	PART	O	O
identify	VERB	O	O
the	DET	O	O
underlying	VERB	O	O
mechanisms	NOUN	O	O
on	ADP	O	O
TAM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
biomembranes	NOUN	O	O
in	ADP	O	O
its	ADJ	O	O
cytostatic	ADJ	O	O
action	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

TAM	PROPN	O	I-Entity
induces	VERB	O	O
hemolysis	NOUN	O	I-Entity
of	ADP	O	O
erythrocytes	NOUN	O	O
as	ADP	O	O
a	DET	O	O
function	NOUN	O	O
of	ADP	O	O
concentration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
extension	NOUN	O	O
of	ADP	O	O
hemolysis	NOUN	O	I-Entity
is	VERB	O	O
variable	ADJ	O	O
with	ADP	O	O
erythrocyte	NOUN	O	O
samples	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
12.5	NUM	O	O
microM	PROPN	O	O
TAM	PROPN	O	I-Entity
induces	VERB	O	O
total	ADJ	O	O
hemolysis	NOUN	O	I-Entity
of	ADP	O	O
all	DET	O	O
tested	VERB	O	O
suspensions	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
inducing	VERB	O	O
extensive	ADJ	O	O
erythrocyte	NOUN	O	O
lysis	NOUN	O	O
,	PUNCT	O	O
TAM	PROPN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
shift	VERB	O	O
the	DET	O	O
osmotic	ADJ	O	O
fragility	NOUN	O	O
curves	NOUN	O	O
of	ADP	O	O
erythrocytes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hemolytic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
TAM	PROPN	O	I-Entity
is	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
low	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tocopherol	NOUN	O	I-Entity
(	PUNCT	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
T	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tocopherol	NOUN	O	I-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
TAc	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
inactivated	VERB	O	O
functional	ADJ	O	O
hydroxyl	NOUN	O	I-Entity
)	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
TAM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolysis	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
related	VERB	O	O
to	ADP	O	O
oxidative	ADJ	O	O
membrane	NOUN	O	O
damage	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
further	ADV	O	O
evidenced	VERB	O	O
by	ADP	O	O
absence	NOUN	O	O
of	ADP	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
and	CCONJ	O	O
hemoglobin	NOUN	O	O
oxidation	NOUN	O	O
both	CCONJ	O	O
determined	VERB	O	O
in	ADP	O	O
parallel	ADJ	O	O
with	ADP	O	O
TAM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolysis	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
observed	VERB	O	O
that	ADP	O	O
TAM	PROPN	O	I-Entity
inhibits	VERB	O	O
the	DET	O	O
peroxidation	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
erythrocytes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
AAPH	PROPN	O	I-Entity
,	PUNCT	O	O
thus	ADV	O	O
ruling	VERB	O	O
out	PART	O	O
TAM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cell	NOUN	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Hemolysis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
TAM	PROPN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
preceded	VERB	O	O
by	ADP	O	O
the	DET	O	O
leakage	NOUN	O	O
of	ADP	O	O
K(+	PROPN	O	I-Entity
)	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
cells	NOUN	O	O
,	PUNCT	O	O
also	ADV	O	O
excluding	VERB	O	O
a	DET	O	O
colloid	NOUN	O	O
-	PUNCT	O	O
osmotic	ADJ	O	O
type	NOUN	O	O
mechanism	NOUN	O	O
of	ADP	O	O
hemolysis	NOUN	O	I-Entity
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
osmotic	ADJ	O	O
fragility	NOUN	O	O
curves	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
TAM	PROPN	O	I-Entity
induces	VERB	O	O
release	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	O
proteins	NOUN	O	O
of	ADP	O	O
membrane	NOUN	O	O
-	PUNCT	O	O
cytoskeleton	NOUN	O	O
and	CCONJ	O	O
cytosol	NOUN	O	O
proteins	NOUN	O	O
essentially	ADV	O	O
bound	VERB	O	O
to	PART	O	O
band	VERB	O	O
3	NUM	O	O
.	PUNCT	O	O

Either	ADV	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
T	NOUN	O	I-Entity
or	CCONJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
TAc	PROPN	O	I-Entity
increases	VERB	O	O
membrane	NOUN	O	O
packing	NOUN	O	O
and	CCONJ	O	O
prevents	VERB	O	O
TAM	PROPN	O	I-Entity
partition	NOUN	O	O
into	ADP	O	O
model	NOUN	O	O
membranes	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
protection	NOUN	O	O
from	ADP	O	O
hemolysis	NOUN	O	I-Entity
by	ADP	O	O
tocopherols	NOUN	O	I-Entity
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
decreased	ADJ	O	O
TAM	PROPN	O	I-Entity
incorporation	NOUN	O	O
in	ADP	O	O
condensed	VERB	O	O
membranes	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
structural	ADJ	O	O
damage	NOUN	O	O
of	ADP	O	O
the	DET	O	O
erythrocyte	NOUN	O	O
membrane	NOUN	O	O
is	VERB	O	O
consequently	ADV	O	O
avoided	VERB	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
TAM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolysis	NOUN	O	I-Entity
results	NOUN	O	O
from	ADP	O	O
a	DET	O	O
structural	ADJ	O	O
perturbation	NOUN	O	O
of	ADP	O	O
red	ADJ	O	O
cell	NOUN	O	O
membrane	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
framework	NOUN	O	O
of	ADP	O	O
the	DET	O	O
erythrocyte	NOUN	O	O
membrane	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
cytoskeleton	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
its	ADJ	O	O
high	ADJ	O	O
partition	NOUN	O	O
in	ADP	O	O
the	DET	O	O
membrane	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
defects	NOUN	O	O
explain	VERB	O	O
the	DET	O	O
abnormal	ADJ	O	O
erythrocyte	NOUN	O	O
shape	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
mechanical	ADJ	O	O
stability	NOUN	O	O
promoted	VERB	O	O
by	ADP	O	O
TAM	PROPN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
since	ADP	O	O
membrane	NOUN	O	O
leakage	NOUN	O	O
is	VERB	O	O
a	DET	O	O
final	ADJ	O	O
stage	NOUN	O	O
of	ADP	O	O
cytotoxicity	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
structural	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
biomembranes	NOUN	O	O
by	ADP	O	O
TAM	PROPN	O	I-Entity
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
multiple	ADJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
anticancer	NOUN	O	O
action	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10706004)

Changes	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
ATP	PROPN	O	I-Entity
affinities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardiac	NOUN	O	O
(	PUNCT	O	O
Na	PROPN	O	I-Entity
,	PUNCT	O	O
K)-ATPase	PROPN	O	I-Entity
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
deficient	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
cardiovascular	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
NO	PROPN	O	I-Entity
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
functions	NOUN	O	O
.	PUNCT	O	O

Inhibition	NOUN	O	O
of	ADP	O	O
NO	DET	O	I-Entity
synthesis	NOUN	O	O
induces	VERB	O	O
sustained	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
several	ADJ	O	O
models	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
elevation	NOUN	O	O
of	ADP	O	O
intracellular	ADJ	O	O
sodium	NOUN	O	I-Entity
level	NOUN	O	O
was	VERB	O	O
documented	VERB	O	O
in	ADP	O	O
cardiac	ADJ	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
molecular	ADJ	O	O
basis	NOUN	O	O
of	ADP	O	O
disturbances	NOUN	O	O
in	ADP	O	O
transmembraneous	ADJ	O	O
transport	NOUN	O	O
of	ADP	O	O
Na+	PROPN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
response	NOUN	O	O
of	ADP	O	O
cardiac	NOUN	O	O
(	PUNCT	O	O
Na	PROPN	O	I-Entity
,	PUNCT	O	O
K)-ATPase	PROPN	O	I-Entity
to	ADP	O	O
NO	PROPN	O	I-Entity
-	PUNCT	O	O
deficient	ADJ	O	O
hypertension	NOUN	O	I-Entity
induced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
NO	PROPN	O	I-Entity
-	PUNCT	O	O
synthase	NOUN	O	O
inhibition	NOUN	O	O
with	ADP	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O

N(G)-nitro	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
methyl	NOUN	O	I-Entity
ester	NOUN	O	I-Entity
(	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	PROPN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
4	NUM	O	O
four	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
4-week	NUM	O	O
administration	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
SBP	PROPN	O	O
)	PUNCT	O	O
increased	VERB	O	O
by	ADP	O	O
36%	NUM	O	O
.	PUNCT	O	O

When	ADV	O	O
activating	VERB	O	O
the	DET	O	O
(	PUNCT	O	O
Na	PROPN	O	I-Entity
,	PUNCT	O	O
K)-ATPase	PROPN	O	I-Entity
with	ADP	O	O
its	ADJ	O	O
substrate	NOUN	O	O
ATP	PROPN	O	I-Entity
,	PUNCT	O	O
no	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
Km	PROPN	O	O
and	CCONJ	O	O
Vmax	PROPN	O	O
values	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
NO	PROPN	O	I-Entity
-	PUNCT	O	O
deficient	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
activation	NOUN	O	O
with	ADP	O	O
Na+	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
Vmax	PROPN	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
,	PUNCT	O	O
however	ADV	O	O
the	DET	O	O
K(Na	PROPN	O	I-Entity
)	PUNCT	O	O
increased	VERB	O	O
by	ADP	O	O
50%	NUM	O	O
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
profound	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
affinity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Na+-binding	VERB	O	I-Entity
site	NOUN	O	O
in	ADP	O	O
NO	PROPN	O	I-Entity
-	PUNCT	O	O
deficient	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
recovery	NOUN	O	O
from	ADP	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
Na	PROPN	O	I-Entity
,	PUNCT	O	O
K)-ATPase	PROPN	O	I-Entity
increased	VERB	O	O
,	PUNCT	O	O
due	ADP	O	O
to	ADP	O	O
higher	ADJ	O	O
affinity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ATP	PROPN	O	I-Entity
-	PUNCT	O	O
binding	VERB	O	O
site	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
revealed	VERB	O	O
from	ADP	O	O
the	DET	O	O
lowered	VERB	O	O
Km	PROPN	O	O
value	NOUN	O	O
for	ADP	O	O
ATP	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
K(Na	PROPN	O	I-Entity
)	PUNCT	O	O
value	NOUN	O	O
for	ADP	O	O
Na+	PROPN	O	I-Entity
returned	VERB	O	O
to	PART	O	O
control	VERB	O	O
value	NOUN	O	O
.	PUNCT	O	O

Inhibition	NOUN	O	O
of	ADP	O	O
NO	PROPN	O	I-Entity
-	PUNCT	O	O
synthase	PROPN	O	O
induced	VERB	O	O
a	DET	O	O
reversible	ADJ	O	O
hypertension	NOUN	O	I-Entity
accompanied	VERB	O	O
by	ADP	O	O
depressed	ADJ	O	I-Entity
Na+-extrusion	NOUN	O	I-Entity
from	ADP	O	O
cardiac	ADJ	O	O
cells	NOUN	O	O
as	ADP	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
deteriorated	VERB	O	O
Na+-binding	VERB	O	I-Entity
properties	NOUN	O	O
of	ADP	O	O
the	DET	O	O
(	PUNCT	O	O
Na	PROPN	O	I-Entity
,	PUNCT	O	O
K)-ATPase	PROPN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
recovery	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
to	PART	O	O
control	VERB	O	O
values	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
extrusion	NOUN	O	O
of	ADP	O	O
Na+	PROPN	O	I-Entity
from	ADP	O	O
cardiac	ADJ	O	O
cells	NOUN	O	O
was	VERB	O	O
normalized	ADJ	O	O
,	PUNCT	O	O
as	ADP	O	O
revealed	VERB	O	O
by	ADP	O	O
restoration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
(	PUNCT	O	O
Na	PROPN	O	I-Entity
,	PUNCT	O	O
K)-ATPase	PROPN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10721819)

Effects	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
isoproterenol	NOUN	O	I-Entity
on	ADP	O	O
bromocriptine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
bromocriptine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
persisted	VERB	O	O
after	ADP	O	O
adrenalectomy	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
(	PUNCT	O	O
i	PUNCT	O	O
)	PUNCT	O	O
mediated	VERB	O	O
by	ADP	O	O
central	ADJ	O	O
dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
receptor	NOUN	O	O
activation	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
ii	PUNCT	O	O
)	PUNCT	O	O
reduced	VERB	O	O
by	ADP	O	O
5-day	PROPN	O	O
isoproterenol	NOUN	O	I-Entity
pretreatment	NOUN	O	O
,	PUNCT	O	O
supporting	VERB	O	O
therefore	ADV	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
is	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
sympathetic	ADJ	O	O
outflow	NOUN	O	O
to	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
examine	VERB	O	O
whether	ADP	O	O
prolonged	VERB	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
isoproterenol	NOUN	O	I-Entity
could	VERB	O	O
abolish	VERB	O	O
bromocriptine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Isoproterenol	ADJ	O	I-Entity
pretreatment	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
caused	VERB	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
without	ADP	O	O
affecting	VERB	O	O
baseline	NOUN	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
bromocriptine	NOUN	O	I-Entity
(	PUNCT	O	O
150	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
induced	VERB	O	O
significant	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Bromocriptine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
pretreatment	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
tachycardia	NOUN	O	I-Entity
was	VERB	O	O
reversed	VERB	O	O
to	ADP	O	O
significant	ADJ	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
effect	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
partly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
i.v	PROPN	O	O
.	PUNCT	O	O

domperidone	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Neither	DET	O	O
cardiac	ADJ	O	O
vagal	NOUN	O	O
nor	CCONJ	O	O
sympathetic	ADJ	O	O
tone	NOUN	O	O
was	VERB	O	O
altered	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
pretreatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
isolated	ADJ	O	O
perfused	ADJ	O	O
heart	NOUN	O	O
preparations	NOUN	O	O
from	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
pretreated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
maximal	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
left	VERB	O	O
ventricular	ADJ	O	O
systolic	ADJ	O	O
pressure	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
-	PUNCT	O	O
pretreated	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
EC50	PROPN	O	O
of	ADP	O	O
the	DET	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
left	VERB	O	O
ventricular	ADJ	O	O
systolic	ADJ	O	O
pressure	NOUN	O	O
was	VERB	O	O
enhanced	VERB	O	O
approximately	ADV	O	O
22-fold	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
15-day	NUM	O	O
isoproterenol	NOUN	O	I-Entity
pretreatment	NOUN	O	O
not	ADV	O	O
only	ADV	O	O
abolished	VERB	O	O
but	CCONJ	O	O
reversed	VERB	O	O
bromocriptine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
to	ADP	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
effect	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
mainly	ADV	O	O
related	VERB	O	O
to	ADP	O	O
further	ADJ	O	O
cardiac	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
desensitization	NOUN	O	O
rather	ADV	O	O
than	ADP	O	O
to	ADP	O	O
impairment	NOUN	O	O
of	ADP	O	O
autonomic	ADJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
normal	ADJ	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
central	ADJ	O	O
tachycardia	NOUN	O	I-Entity
of	ADP	O	O
bromocriptine	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
predominate	VERB	O	O
and	CCONJ	O	O
to	PART	O	O
mask	VERB	O	O
the	DET	O	O
bradycardia	NOUN	O	I-Entity
of	ADP	O	O
this	DET	O	O
agonist	NOUN	O	O
at	ADP	O	O
peripheral	NOUN	O	O
dopamine	NOUN	O	I-Entity
D2	NOUN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10737864)

A	DET	O	O
developmental	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
's	PART	O	O
effects	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	O
rate	NOUN	O	O
and	CCONJ	O	O
ultrasound	ADJ	O	O
production	NOUN	O	O
in	ADP	O	O
infant	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

adrenoceptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O

Previous	ADJ	O	O
investigations	NOUN	O	O
have	VERB	O	O
determined	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
ultrasound	ADJ	O	O
production	NOUN	O	O
increases	NOUN	O	O
through	ADP	O	O
the	DET	O	O
2nd	ADJ	O	O
-	PUNCT	O	O
week	NOUN	O	O
postpartum	NOUN	O	O
and	CCONJ	O	O
decreases	VERB	O	O
thereafter	ADV	O	O
.	PUNCT	O	O

Given	VERB	O	O
that	DET	O	O
sympathetic	ADJ	O	O
neural	ADJ	O	O
dominance	NOUN	O	O
exhibits	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
developmental	ADJ	O	O
pattern	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
given	VERB	O	O
that	ADP	O	O
clonidine	NOUN	O	I-Entity
induces	VERB	O	O
sympathetic	ADJ	O	O
withdrawal	NOUN	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
clonidine	NOUN	O	I-Entity
's	PART	O	O
developmental	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	O
rate	NOUN	O	O
and	CCONJ	O	O
ultrasound	ADJ	O	O
production	NOUN	O	O
would	VERB	O	O
mirror	VERB	O	O
each	DET	O	O
other	ADJ	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
experiment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
cardiac	ADJ	O	O
rate	NOUN	O	O
and	CCONJ	O	O
ultrasound	ADJ	O	O
production	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
2-	PROPN	O	O
,	PUNCT	O	O
8-	NUM	O	O
,	PUNCT	O	O
15-	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
20-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Age	PROPN	O	O
-	PUNCT	O	O
related	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
ultrasound	ADJ	O	O
production	NOUN	O	O
corresponded	VERB	O	O
with	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
cardiovascular	ADJ	O	O
variables	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
baseline	NOUN	O	O
cardiac	ADJ	O	O
rate	NOUN	O	O
and	CCONJ	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
experiment	NOUN	O	O
is	VERB	O	O
discussed	VERB	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
ultrasound	ADJ	O	O
production	NOUN	O	O
is	VERB	O	O
the	DET	O	O
acoustic	ADJ	O	O
by	ADP	O	O
-	PUNCT	O	O
product	NOUN	O	O
of	ADP	O	O
a	DET	O	O
physiological	ADJ	O	O
maneuver	NOUN	O	O
that	ADJ	O	O
compensates	VERB	O	O
for	ADP	O	O
clonidine	NOUN	O	I-Entity
's	PART	O	O
detrimental	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
cardiovascular	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10743446)

Differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
systemically	ADV	O	O
administered	VERB	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
lidocaine	NOUN	O	I-Entity
on	ADP	O	O
dynamic	ADJ	O	O
and	CCONJ	O	O
static	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
intradermal	ADJ	O	O
capsaicin	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
lidocaine	NOUN	O	I-Entity
on	ADP	O	O
brush	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
(	PUNCT	O	O
dynamic	ADJ	O	O
)	PUNCT	O	O
pain	NOUN	O	I-Entity
and	CCONJ	O	O
punctate	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
(	PUNCT	O	O
static	ADJ	O	O
)	PUNCT	O	O

hyperalgesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
capsaicin	NOUN	O	I-Entity
.	PUNCT	O	O

Capsaicin	PROPN	O	I-Entity
100	NUM	O	O
micrograms	NOUN	O	O
was	VERB	O	O
injected	VERB	O	O
intradermally	ADV	O	O
on	ADP	O	O
the	DET	O	O
volar	ADJ	O	O
forearm	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

infusion	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
(	PUNCT	O	O
bolus	NOUN	O	O
0.1	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
over	ADP	O	O
10	NUM	O	O
min	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
micrograms	NOUN	O	O
kg-1	SYM	O	O

min-1	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
5	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
or	CCONJ	O	O
saline	NOUN	O	O
for	ADP	O	O
50	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Infusion	PROPN	O	O
started	VERB	O	O
15	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
following	VERB	O	O
were	VERB	O	O
measured	VERB	O	O
:	PUNCT	O	O
spontaneous	ADJ	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
pain	NOUN	O	I-Entity
evoked	VERB	O	O
by	ADP	O	O
punctate	NOUN	O	O
and	CCONJ	O	O
brush	NOUN	O	O
stimuli	NOUN	O	O
(	PUNCT	O	O
VAS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
areas	NOUN	O	O
of	ADP	O	O
brush	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
and	CCONJ	O	O
punctate	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
reduced	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
area	NOUN	O	O
of	ADP	O	O
brush	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
and	CCONJ	O	O
punctate	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O

hyperalgesia	NOUN	O	I-Entity
significantly	ADV	O	O

and	CCONJ	O	O
it	PRON	O	O
tended	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
brush	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Lidocaine	PROPN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
area	NOUN	O	O
of	ADP	O	O
punctate	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
significantly	ADV	O	O
.	PUNCT	O	O

It	PRON	O	O
tended	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
VAS	PROPN	O	O
scores	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
pain	NOUN	O	I-Entity
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
evoked	VERB	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
lidocaine	NOUN	O	I-Entity
on	ADP	O	O
static	ADJ	O	O
and	CCONJ	O	O
dynamic	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
two	NUM	O	O
types	NOUN	O	O
of	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
are	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
separate	ADJ	O	O
mechanisms	NOUN	O	O
and	CCONJ	O	O
have	VERB	O	O
a	DET	O	O
distinct	ADJ	O	O
pharmacology	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11007689)

Cyclosporine	PROPN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
(	PUNCT	O	O
TMA	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
well	ADV	O	O
documented	VERB	O	O
.	PUNCT	O	O

Treatments	NOUN	O	O
have	VERB	O	O
included	VERB	O	O
discontinuation	NOUN	O	O
or	CCONJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
dose	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
concurrent	ADJ	O	O
plasma	NOUN	O	O
exchange	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
infusion	NOUN	O	O
,	PUNCT	O	O
anticoagulation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
immunoglobulin	NOUN	O	O
G	PROPN	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
last	ADJ	O	O
decade	NOUN	O	O
has	VERB	O	O
seen	VERB	O	O
the	DET	O	O
emergence	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
potent	ADJ	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
with	ADP	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
virtually	ADV	O	O
identical	ADJ	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
,	PUNCT	O	O
switching	VERB	O	O
to	ADP	O	O
tacrolimus	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
viable	ADJ	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
TMA	PROPN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
the	DET	O	O
more	ADV	O	O
widespread	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
in	ADP	O	O
organ	NOUN	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
TMA	PROPN	O	I-Entity
has	VERB	O	O
also	ADV	O	O
been	VERB	O	O
recognized	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
literature	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
TMA	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
exposed	VERB	O	O
sequentially	ADV	O	O
to	ADP	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
is	VERB	O	O
limited	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
living	VERB	O	O
donor	NOUN	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
cyclosporine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
TMA	PROPN	O	I-Entity
that	ADJ	O	O
responded	VERB	O	O
to	ADP	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
plasmapheresis	NOUN	O	O
and	CCONJ	O	O
fresh	ADJ	O	O
frozen	ADJ	O	O
plasma	NOUN	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Introduction	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
as	ADP	O	O
an	DET	O	O
alternative	NOUN	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
TMA	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
subsequent	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
allograft	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
switched	VERB	O	O
from	ADP	O	O
cyclosporine	NOUN	O	I-Entity
to	ADP	O	O
tacrolimus	NOUN	O	I-Entity
or	CCONJ	O	O
vice	NOUN	O	O
versa	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
closely	ADV	O	O
monitored	VERB	O	O
for	ADP	O	O
the	DET	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	O
TMA	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11256525)

Repeated	VERB	O	O
transient	ADJ	O	O
anuria	NOUN	O	I-Entity
following	VERB	O	O
losartan	ADJ	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
solitary	ADJ	O	O
kidney	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
70-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
hypertensive	ADJ	O	I-Entity
man	NOUN	O	O
with	ADP	O	O
a	DET	O	O
solitary	ADJ	O	O
kidney	NOUN	O	O
and	CCONJ	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
two	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
anuria	NOUN	O	I-Entity
after	ADP	O	O
losartan	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
hospitalized	VERB	O	O
for	ADP	O	O
a	DET	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
with	ADP	O	O
pulmonary	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
diuretics	NOUN	O	O
.	PUNCT	O	O

Due	ADP	O	O
to	ADP	O	O
severe	ADJ	O	O
systolic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
losartan	NOUN	O	I-Entity
was	VERB	O	O
prescribed	VERB	O	O
.	PUNCT	O	O

Surprisingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
losartan	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
sudden	ADJ	O	O
anuria	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
lasted	VERB	O	O
eight	NUM	O	O
hours	NOUN	O	O
despite	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
furosemide	NOUN	O	I-Entity
and	CCONJ	O	O
amine	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
week	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
by	ADP	O	O
mistake	NOUN	O	O
,	PUNCT	O	O
losartan	NOUN	O	I-Entity
was	VERB	O	O
prescribed	VERB	O	O
again	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
second	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
second	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
anuria	NOUN	O	I-Entity
lasting	VERB	O	O
10	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
these	DET	O	O
two	NUM	O	O
episodes	NOUN	O	O
,	PUNCT	O	O
his	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
diminished	VERB	O	O
but	CCONJ	O	O
no	DET	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

Ultimately	ADV	O	O
,	PUNCT	O	O
an	DET	O	O
arteriography	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
70	NUM	O	O
-	PUNCT	O	O
80%	NUM	O	O
renal	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
renal	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
diuretic	NOUN	O	O
therapy	NOUN	O	O
certainly	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
strong	ADJ	O	O
activation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
(	PUNCT	O	O
RAS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Under	ADP	O	O
such	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
blockade	NOUN	O	O
by	ADP	O	O
losartan	NOUN	O	I-Entity
probably	ADV	O	O
induced	VERB	O	O
a	DET	O	O
critical	ADJ	O	O
fall	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
highlights	VERB	O	O
the	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
the	DET	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
losartan	NOUN	O	I-Entity
can	VERB	O	O
cause	VERB	O	O
serious	ADJ	O	O
unexpected	ADJ	O	O
complications	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
renovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
with	ADP	O	O
extreme	ADJ	O	O
caution	NOUN	O	O
in	ADP	O	O
this	DET	O	O
setting	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11334364)

In	ADP	O	O
vivo	ADJ	O	O
protection	NOUN	O	O
of	ADP	O	O
dna	NOUN	O	O
damage	NOUN	O	O
associated	VERB	O	O
apoptotic	NOUN	O	O
and	CCONJ	O	O
necrotic	ADJ	O	I-Entity
cell	NOUN	O	O
deaths	NOUN	O	O
during	ADP	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
lung	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
IH636	NOUN	O	B-Entity
grape	NOUN	O	I-Entity
seed	NOUN	O	I-Entity
proanthocyanidin	NOUN	O	I-Entity
extract	NOUN	O	I-Entity
.	PUNCT	O	O

Grape	PROPN	O	B-Entity
seed	NOUN	O	I-Entity
extract	NOUN	O	I-Entity
,	PUNCT	O	O
primarily	ADV	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
proanthocyanidins	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
modulate	VERB	O	O
a	DET	O	O
wide	ADJ	O	O
-	PUNCT	O	O
range	NOUN	O	O
of	ADP	O	O
biological	ADJ	O	O
,	PUNCT	O	O
pharmacological	ADJ	O	O
and	CCONJ	O	O
toxicological	ADJ	O	O
effects	NOUN	O	O
which	ADJ	O	O
are	VERB	O	O
mainly	ADV	O	O
cytoprotective	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
IH636	PROPN	O	B-Entity
grape	NOUN	O	I-Entity
seed	NOUN	O	I-Entity
proanthocyanidin	NOUN	O	I-Entity
extract	NOUN	O	I-Entity
(	PUNCT	O	O
GSPE	PROPN	O	I-Entity
)	PUNCT	O	O
to	PART	O	O
prevent	VERB	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
AAP)-induced	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
(	PUNCT	O	O
AMI)-induced	ADJ	O	I-Entity
lung	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity

(	PUNCT	O	O
DOX)-induced	VERB	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Experimental	ADJ	O	O
design	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
control	NOUN	O	O
(	PUNCT	O	O
vehicle	NOUN	O	O
alone	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
GSPE	PROPN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
drug	NOUN	O	O
alone	ADV	O	O
and	CCONJ	O	O
GSPE+drug	PROPN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
cytoprotection	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
animals	NOUN	O	O
were	VERB	O	O
orally	ADV	O	O
gavaged	VERB	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
Kg	PROPN	O	O
GSPE	PROPN	O	I-Entity
for	ADP	O	O
7	NUM	O	O
-	SYM	O	O
10	NUM	O	O
days	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

injections	NOUN	O	O
of	ADP	O	O
organ	NOUN	O	O
specific	ADJ	O	O
three	NUM	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
AAP	PROPN	O	I-Entity
:	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
Kg	PROPN	O	O
for	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
;	PUNCT	O	O
AMI	PROPN	O	I-Entity
:	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
Kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
four	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O

DOX	PROPN	O	I-Entity
:	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
Kg	PROPN	O	O
for	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
GSPE	PROPN	O	I-Entity
preexposure	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
AAP	PROPN	O	I-Entity
,	PUNCT	O	O
AMI	PROPN	O	I-Entity
and	CCONJ	O	O
DOX	PROPN	O	I-Entity
,	PUNCT	O	O
provided	VERB	O	O
near	ADP	O	O
complete	ADJ	O	O
protection	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
chemistry	NOUN	O	O
changes	NOUN	O	O
(	PUNCT	O	O
ALT	PROPN	O	O
,	PUNCT	O	O
BUN	PROPN	O	O
and	CCONJ	O	O
CPK	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
reduced	VERB	O	O
DNA	PROPN	O	O
fragmentation	NOUN	O	O
.	PUNCT	O	O

Histopathological	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
and	CCONJ	O	O
lung	NOUN	O	O
sections	NOUN	O	O
revealed	VERB	O	O
moderate	ADJ	O	O
to	ADP	O	O
massive	ADJ	O	O
tissue	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
morphological	ADJ	O	O
aberrations	NOUN	O	O
by	ADP	O	O
all	ADJ	O	O
the	DET	O	O
three	NUM	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
GSPE	PROPN	O	I-Entity
preexposure	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
its	ADJ	O	O
presence	NOUN	O	O
.	PUNCT	O	O

GSPE+drug	NOUN	O	I-Entity
exposed	VERB	O	O
tissues	NOUN	O	O
exhibited	VERB	O	O
minor	ADJ	O	O
residual	ADJ	O	O
damage	NOUN	O	O
or	CCONJ	O	O
near	ADP	O	O
total	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

Interestingly	ADV	O	O
,	PUNCT	O	O
all	ADJ	O	O
the	DET	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
,	PUNCT	O	O
AAP	PROPN	O	I-Entity
,	PUNCT	O	O
AMI	PROPN	O	I-Entity
and	CCONJ	O	O
DOX	PROPN	O	I-Entity
induced	VERB	O	O
apoptotic	ADJ	O	O
death	NOUN	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
necrosis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
respective	ADJ	O	O
organs	NOUN	O	O
which	ADJ	O	O
was	VERB	O	O
very	ADV	O	O
effectively	ADV	O	O
blocked	VERB	O	O
by	ADP	O	O
GSPE	PROPN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
AAP	PROPN	O	I-Entity
,	PUNCT	O	O
AMI	PROPN	O	I-Entity
and	CCONJ	O	O
DOX	PROPN	O	I-Entity
undergo	VERB	O	O
biotransformation	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
produce	VERB	O	O
damaging	ADJ	O	O
radicals	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
protection	NOUN	O	O
by	ADP	O	O
GSPE	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
linked	VERB	O	O
to	ADP	O	O
both	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
metabolism	NOUN	O	O
and/or	CCONJ	O	O
detoxification	NOUN	O	O
of	ADP	O	O
cytotoxic	ADJ	O	O
radicals	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
on	ADP	O	O
AMI	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
apoptotic	ADJ	O	O
death	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lung	NOUN	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

Taken	VERB	O	O
together	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
events	NOUN	O	O
undoubtedly	ADV	O	O
establish	VERB	O	O
GSPE	PROPN	O	I-Entity
's	PART	O	O
abundant	ADJ	O	O
bioavailability	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
power	NOUN	O	O
to	PART	O	O
defend	VERB	O	O
multiple	ADJ	O	O
target	NOUN	O	O
organs	NOUN	O	O
from	ADP	O	O
toxic	ADJ	O	O
assaults	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
structurally	ADV	O	O
diverse	ADJ	O	O
and	CCONJ	O	O
functionally	ADV	O	O
different	ADJ	O	O
entities	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11642480)

Palpebral	PROPN	O	B-Entity
twitching	VERB	O	I-Entity
in	ADP	O	O
a	DET	O	O
depressed	ADJ	O	I-Entity
adolescent	NOUN	O	O
on	ADP	O	O
citalopram	NOUN	O	I-Entity
.	PUNCT	O	O

Current	ADJ	O	O
estimates	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
between	ADP	O	O
0.4%	NUM	O	O
and	CCONJ	O	O
8.3%	NUM	O	O
of	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
are	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
major	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
favorable	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
citalopram	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
15-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
boy	NOUN	O	O
with	ADP	O	O
major	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
who	NOUN	O	O
exhibited	VERB	O	O
palpebral	ADJ	O	B-Entity
twitching	NOUN	O	I-Entity
during	ADP	O	O
his	ADJ	O	O
first	ADJ	O	O
2	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
a	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
citalopram	NOUN	O	I-Entity
as	ADP	O	O
it	PRON	O	O
remitted	VERB	O	O
with	ADP	O	O
redistribution	NOUN	O	O
of	ADP	O	O
doses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12063090)

Metamizol	PROPN	O	I-Entity
potentiates	VERB	O	O
morphine	ADJ	O	I-Entity
antinociception	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
constipation	NOUN	O	I-Entity
after	ADP	O	O
chronic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
work	NOUN	O	O
evaluates	VERB	O	O
the	DET	O	O
antinociceptive	ADJ	O	O
and	CCONJ	O	O
constipating	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
3.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O

morphine	NOUN	O	I-Entity
with	ADP	O	O
177.8	NUM	O	O
mg	NUM	O	O

metamizol	NOUN	O	I-Entity
in	ADP	O	O
acutely	ADV	O	O
and	CCONJ	O	O
chronically	ADV	O	O
treated	VERB	O	O
(	PUNCT	O	O
once	ADV	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
13th	ADJ	O	O
day	NOUN	O	O
,	PUNCT	O	O
antinociceptive	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
using	VERB	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
nociception	NOUN	O	O
,	PUNCT	O	O
pain	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
functional	ADJ	O	O
impairment	NOUN	O	O
model	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
charcoal	ADJ	O	I-Entity
meal	NOUN	O	O
test	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
intestinal	ADJ	O	O
transit	NOUN	O	O
.	PUNCT	O	O

Simultaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
with	ADP	O	O
metamizol	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
markedly	ADV	O	O
antinociceptive	ADJ	O	O
potentiation	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
increasing	NOUN	O	O
of	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
after	ADP	O	O
a	DET	O	O
single	ADJ	O	O
(	PUNCT	O	O
298+/-7	NOUN	O	O
vs.	X	O	O
139+/-36	NUM	O	O
units	NOUN	O	O
area	NOUN	O	O
(	PUNCT	O	O
ua	INTJ	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P<0.001	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
repeated	VERB	O	O
administration	NOUN	O	O
(	PUNCT	O	O
280+/-17	NUM	O	O
vs.	ADP	O	O
131+/-22	NUM	O	O

Antinociceptive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
chronically	ADV	O	O
treated	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
39+/-10	NUM	O	O
vs.	X	O	O
18+/-5	NUM	O	O
au	INTJ	O	O
)	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
antinociception	NOUN	O	O
was	VERB	O	O
remained	VERB	O	O
similar	ADJ	O	O
as	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
298+/-7	NOUN	O	O
vs.	X	O	O
280+/-17	NUM	O	O
au	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
antinociceptive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
were	VERB	O	O
partially	ADV	O	O
prevented	VERB	O	O
by	ADP	O	O
3.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
naloxone	NOUN	O	I-Entity
s.c	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
independent	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
morphine	NOUN	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
intestinal	ADJ	O	O
transit	NOUN	O	O
in	ADP	O	O
48+/-4%	NUM	O	O
and	CCONJ	O	O
38+/-4%	NUM	O	O
after	ADP	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
tolerance	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
develop	VERB	O	O
to	ADP	O	O
the	DET	O	O
constipating	NOUN	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
inhibited	VERB	O	O
intestinal	ADJ	O	O
transit	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
produced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
regardless	ADV	O	O
of	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
metamizol	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
potentiate	VERB	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
constipation	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
show	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
metamizol	NOUN	O	I-Entity
in	ADP	O	O
chronically	ADV	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
this	DET	O	O
combination	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12084448)

Ifosfamide	PROPN	O	I-Entity
encephalopathy	NOUN	O	I-Entity
presenting	VERB	O	O
with	ADP	O	O
asterixis	NOUN	O	I-Entity
.	PUNCT	O	O

CNS	PROPN	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antineoplastic	ADJ	O	O
agent	NOUN	O	O
ifosfamide	NOUN	O	I-Entity
(	PUNCT	O	O
IFX	PROPN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
frequent	ADJ	O	O
and	CCONJ	O	O
include	VERB	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
neurological	ADJ	O	O
symptoms	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
limit	VERB	O	O
drug	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
51-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
severe	ADJ	O	O
,	PUNCT	O	O
disabling	VERB	O	O
negative	ADJ	O	O
myoclonus	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
and	CCONJ	O	O
lower	ADJ	O	O
extremities	NOUN	O	O
after	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
for	ADP	O	O
plasmacytoma	NOUN	O	I-Entity
.	PUNCT	O	O

Cranial	ADJ	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
and	CCONJ	O	O
extensive	ADJ	O	O
laboratory	NOUN	O	O
studies	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
reveal	VERB	O	O
structural	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
brain	NOUN	O	I-Entity
and	CCONJ	O	O
metabolic	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
electroencephalogram	NOUN	O	O
showed	VERB	O	O
continuous	ADJ	O	O
,	PUNCT	O	O
generalized	ADJ	O	O
irregular	ADJ	O	O
slowing	NOUN	O	O
with	ADP	O	O
admixed	NOUN	O	O
periodic	ADJ	O	O
triphasic	NOUN	O	O
waves	NOUN	O	O
indicating	VERB	O	O
symptomatic	ADJ	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
within	ADP	O	O
12	NUM	O	O
h	PRON	O	O
the	DET	O	O
asterixis	NOUN	O	I-Entity
resolved	VERB	O	O
completely	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
described	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
asterixis	NOUN	O	I-Entity
during	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
,	PUNCT	O	O
normal	ADJ	O	O
laboratory	NOUN	O	O
findings	NOUN	O	O
and	CCONJ	O	O
imaging	VERB	O	O
studies	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
resolution	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
following	VERB	O	O
the	DET	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
negative	ADJ	O	O
myoclonus	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
IFX	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12684739)

Sub	PROPN	O	O
-	PUNCT	O	O
chronic	ADJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
vinyl	NOUN	O	I-Entity
GABA	PROPN	O	I-Entity
(	PUNCT	O	O
vigabatrin	NOUN	O	I-Entity
)	PUNCT	O	O
inhibits	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
nucleus	NOUN	O	O
accumbens	VERB	O	O
dopamine	NOUN	O	I-Entity
.	PUNCT	O	O

RATIONALE	NOUN	O	O
:	PUNCT	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Vinyl	PROPN	O	I-Entity
GABA	PROPN	O	I-Entity
(	PUNCT	O	O
GVG	PROPN	O	I-Entity
)	PUNCT	O	O
irreversibly	ADV	O	O
inhibits	VERB	O	O
GABA	PROPN	O	I-Entity
-	PUNCT	O	O
transaminase	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
receptor	NOUN	O	O
mediated	VERB	O	O
inhibition	NOUN	O	O
requires	VERB	O	O
de	X	O	O
novo	X	O	O
synthesis	NOUN	O	O
for	ADP	O	O
restoration	NOUN	O	O
of	ADP	O	O
functional	ADJ	O	O
GABA	PROPN	O	I-Entity
catabolism	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
its	ADJ	O	O
preclinical	ADJ	O	O
success	NOUN	O	O
for	ADP	O	O
treating	VERB	O	O
substance	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
(	PUNCT	O	O
VFD	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
cumulative	ADJ	O	O
lifetime	NOUN	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
explored	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
sub	NOUN	O	O
-	PUNCT	O	O
chronic	ADJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
GVG	NOUN	O	I-Entity
on	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
nucleus	NOUN	O	O
accumbens	NOUN	O	O
(	PUNCT	O	O
NAcc	PROPN	O	O
)	PUNCT	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Sub	VERB	O	O
-	PUNCT	O	O
chronic	ADJ	O	O
GVG	PROPN	O	I-Entity
exposure	NOUN	O	O
inhibited	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
exceeded	VERB	O	O
in	ADP	O	O
magnitude	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
the	DET	O	O
identical	ADJ	O	O
acute	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Sub	VERB	O	O
-	PUNCT	O	O
chronic	ADJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
GVG	PROPN	O	I-Entity
potentiates	NOUN	O	O
and	CCONJ	O	O
extends	VERB	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
dopamine	NOUN	O	I-Entity
,	PUNCT	O	O
effectively	ADV	O	O
reducing	VERB	O	O
cumulative	ADJ	O	O
exposures	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
VFDS	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (12716030)

Amount	PROPN	O	O
of	ADP	O	O
bleeding	VERB	O	I-Entity
and	CCONJ	O	O
hematoma	NOUN	O	I-Entity
size	NOUN	O	O
in	ADP	O	O
the	DET	O	O
collagenase	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aggravated	VERB	O	O
risk	NOUN	O	O
on	ADP	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
ICH	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
drugs	NOUN	O	O
used	VERB	O	O
for	ADP	O	O
stroke	NOUN	O	I-Entity
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
estimated	VERB	O	O
carefully	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
established	VERB	O	O
sensitive	ADJ	O	O
quantification	NOUN	O	O
methods	NOUN	O	O
and	CCONJ	O	O
provided	VERB	O	O
a	DET	O	O
rat	NOUN	O	O
ICH	PROPN	O	I-Entity
model	NOUN	O	O
for	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
ICH	PROPN	O	I-Entity
deterioration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
ICH	PROPN	O	I-Entity
intrastriatally	ADV	O	O
induced	VERB	O	O
by	ADP	O	O
0.014-unit	NOUN	O	O
,	PUNCT	O	O
0.070-unit	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0.350-unit	NUM	O	O
collagenase	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
bleeding	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
a	DET	O	O
hemoglobin	NOUN	O	O
assay	NOUN	O	O
developed	VERB	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
morphologically	NOUN	O	O
determined	VERB	O	O
hematoma	NOUN	O	I-Entity
volume	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
blood	NOUN	O	O
amounts	VERB	O	O
and	CCONJ	O	O
hematoma	NOUN	O	I-Entity
volumes	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
correlated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
hematoma	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
0.014-unit	NUM	O	O
collagenase	NOUN	O	O
was	VERB	O	O
adequate	ADJ	O	O
to	PART	O	O
detect	VERB	O	O
ICH	PROPN	O	I-Entity
deterioration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
ICH	PROPN	O	I-Entity
induction	NOUN	O	O
using	VERB	O	O
0.014-unit	NOUN	O	O
collagenase	NOUN	O	O
,	PUNCT	O	O
heparin	NOUN	O	I-Entity
enhanced	VERB	O	O
the	DET	O	O
hematoma	NOUN	O	I-Entity
volume	NOUN	O	O
3.4-fold	VERB	O	O
over	ADP	O	O
that	DET	O	O
seen	VERB	O	O
in	ADP	O	O
control	NOUN	O	O
ICH	PROPN	O	I-Entity
animals	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
bleeding	NOUN	O	I-Entity
7.6-fold	NUM	O	O
.	PUNCT	O	O

Data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
this	DET	O	O
sensitive	ADJ	O	O
hemoglobin	NOUN	O	O
assay	NOUN	O	O
is	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
ICH	PROPN	O	I-Entity
detection	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
a	DET	O	O
model	NOUN	O	O
with	ADP	O	O
a	DET	O	O
small	ADJ	O	O
ICH	PROPN	O	I-Entity
induced	VERB	O	O
with	ADP	O	O
a	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
collagenase	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
for	ADP	O	O
evaluation	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
affect	VERB	O	O
ICH	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12757899)

Estradiol	PROPN	O	I-Entity
reduces	VERB	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hippocampal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
ovariectomized	ADJ	O	O
female	ADJ	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
male	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Estrogens	PROPN	O	O
protect	VERB	O	O
ovariectomized	VERB	O	O
rats	NOUN	O	O
from	ADP	O	O
hippocampal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
kainic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
SE	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
estradiol	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
male	NOUN	O	O
and	CCONJ	O	O
ovariectomized	ADJ	O	O
female	ADJ	O	O
rats	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

Rats	NOUN	O	O
received	VERB	O	O
subcutaneous	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
estradiol	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
rat	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
oil	NOUN	O	O
once	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
four	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

SE	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
20	NUM	O	O
h	NOUN	O	O
following	VERB	O	O
the	DET	O	O
second	ADJ	O	O
injection	NOUN	O	O
and	CCONJ	O	O
terminated	VERB	O	O
3	NUM	O	O
h	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
silver	NOUN	O	I-Entity
-	PUNCT	O	O
stained	VERB	O	O
CA3	NOUN	O	O
and	CCONJ	O	O
CA1	PROPN	O	O
hippocampal	ADJ	O	O
neurons	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
2	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
Estradiol	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
first	ADJ	O	O
clonus	NOUN	O	O
in	ADP	O	O
ovariectomized	VERB	O	O
rats	NOUN	O	O
but	CCONJ	O	O
accelerated	VERB	O	O
it	PRON	O	O
in	ADP	O	O
males	NOUN	O	O
.	PUNCT	O	O

17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
Estradiol	PROPN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
argyrophilic	ADJ	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
CA1	PROPN	O	O
and	CCONJ	O	O
CA3-C	PROPN	O	O
sectors	NOUN	O	O
of	ADP	O	O
ovariectomized	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
males	NOUN	O	O
,	PUNCT	O	O
estradiol	ADV	O	I-Entity
increased	VERB	O	O
the	DET	O	O
total	ADJ	O	O
damage	NOUN	O	O
score	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
estradiol	NOUN	O	I-Entity
on	ADP	O	O
seizure	NOUN	O	I-Entity
threshold	NOUN	O	O
and	CCONJ	O	O
damage	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
altered	VERB	O	O
by	ADP	O	O
sex	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hormonal	ADJ	O	O
environment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12905102)

Delirium	NOUN	O	I-Entity
during	ADP	O	O
clozapine	NOUN	O	I-Entity
treatment	NOUN	O	O
:	PUNCT	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
associated	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Incidence	NOUN	O	O
and	CCONJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
delirium	NOUN	O	I-Entity
during	ADP	O	O
clozapine	NOUN	O	I-Entity
treatment	NOUN	O	O
require	VERB	O	O
further	ADJ	O	O
clarification	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
computerized	NOUN	O	O
pharmacy	NOUN	O	O
records	NOUN	O	O
to	PART	O	O
identify	VERB	O	O
all	DET	O	O
adult	NOUN	O	O
psychiatric	ADJ	O	I-Entity
inpatients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
clozapine	NOUN	O	I-Entity
(	PUNCT	O	O
1995	NUM	O	O
-	SYM	O	O
96	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
reviewed	VERB	O	O
their	ADJ	O	O
medical	ADJ	O	O
records	NOUN	O	O
to	PART	O	O
score	VERB	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
delirium	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
tested	VERB	O	O
associations	NOUN	O	O
with	ADP	O	O
potential	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

23.3	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
given	VERB	O	O
clozapine	NOUN	O	I-Entity
,	PUNCT	O	O
gradually	ADV	O	O
increased	VERB	O	O
to	ADP	O	O
an	DET	O	O
average	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
282	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Delirium	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
in	ADP	O	O
14	NUM	O	O
(	PUNCT	O	O
10.1	NUM	O	O
%	NOUN	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
1.48	NUM	O	O
cases	NOUN	O	O
/	SYM	O	O
person	NOUN	O	O
-	PUNCT	O	O
years	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
71.4	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
were	VERB	O	O
moderate	ADJ	O	O
or	CCONJ	O	O
severe	ADJ	O	O
.	PUNCT	O	O

Associated	ADJ	O	O
factors	NOUN	O	O
were	VERB	O	O
co	ADJ	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
centrally	ADV	O	O
antimuscarinic	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
poor	ADJ	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
,	PUNCT	O	O
older	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
longer	ADJ	O	O
hospitalization	NOUN	O	O
(	PUNCT	O	O
by	ADP	O	O
17.5	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
increasing	VERB	O	O
cost	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
diagnosis	NOUN	O	O
or	CCONJ	O	O
medical	ADJ	O	O
co	NOUN	O	O
-	PUNCT	O	O
morbidity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
daily	ADJ	O	O
clozapine	NOUN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
fell	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
unrelated	ADJ	O	O
.	PUNCT	O	O

Delirium	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
10	NUM	O	O
%	NOUN	O	O
of	ADP	O	O
clozapine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
inpatients	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
older	ADJ	O	O
patients	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
other	ADJ	O	O
central	ADJ	O	O
anticholinergics	NOUN	O	O
.	PUNCT	O	O

Delirium	NOUN	O	I-Entity
was	VERB	O	O
inconsistently	ADV	O	O
recognized	VERB	O	O
clinically	ADV	O	O
in	ADP	O	O
milder	ADJ	O	O
cases	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
length	NOUN	O	O
-	PUNCT	O	O
of	ADP	O	O
-	PUNCT	O	O
stay	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
costs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
inferior	ADJ	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14513889)

Ketoconazole	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurologic	ADJ	O	B-Entity
sequelae	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
77-y	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
developed	VERB	O	O
weakness	NOUN	O	B-Entity
of	ADP	O	I-Entity
extremities	NOUN	O	I-Entity
,	PUNCT	O	O
legs	NOUN	O	B-Entity
paralysis	NOUN	O	I-Entity
,	PUNCT	O	O
dysarthria	NOUN	O	I-Entity
and	CCONJ	O	O
tremor	NOUN	O	I-Entity
1	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
ingestion	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
ketoconazole	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
in	ADP	O	O
his	ADJ	O	O
life	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
complaints	NOUN	O	O
faded	VERB	O	O
away	ADV	O	O
within	ADP	O	O
24	NUM	O	O
h.	NOUN	O	O
Few	ADJ	O	O
days	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
used	VERB	O	O
another	DET	O	O
200	NUM	O	O
mg	VERB	O	O
ketoconazole	NOUN	O	I-Entity
tablet	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
within	ADP	O	O
an	DET	O	O
hour	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
clinical	ADJ	O	O
picture	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
resolved	VERB	O	O
again	ADV	O	O
spontaneously	ADV	O	O
within	ADP	O	O
hours	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
illustrates	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
close	ADJ	O	O
vigilance	NOUN	O	O
in	ADP	O	O
adverse	ADJ	O	B-Entity
drug	NOUN	O	I-Entity
reactions	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (15009014)

Noxious	ADJ	O	O
chemical	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
rat	NOUN	O	O
facial	ADJ	O	O
mucosa	NOUN	O	O
increases	NOUN	O	O
intracranial	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
through	ADP	O	O
a	DET	O	O
trigemino	NOUN	O	O
-	PUNCT	O	O
parasympathetic	ADJ	O	O
reflex	NOUN	O	O
--	PUNCT	O	O
an	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
vascular	ADJ	O	B-Entity
dysfunctions	NOUN	O	I-Entity
in	ADP	O	O
cluster	NOUN	O	B-Entity
headache	NOUN	O	I-Entity
.	PUNCT	O	O

Cluster	NOUN	O	B-Entity
headache	NOUN	O	I-Entity
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
typical	ADJ	O	O
autonomic	ADJ	O	O
dysfunctions	NOUN	O	O
including	VERB	O	O
facial	ADJ	O	O
and	CCONJ	O	O
intracranial	ADJ	O	B-Entity
vascular	ADJ	O	I-Entity
disturbances	NOUN	O	I-Entity
.	PUNCT	O	O

Capsaicin	PROPN	O	I-Entity
(	PUNCT	O	O
0.01	NUM	O	O
-	SYM	O	O
1	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
applied	VERB	O	O
to	ADP	O	O
oral	ADJ	O	O
or	CCONJ	O	O
nasal	ADJ	O	O
mucosa	NOUN	O	O
induced	VERB	O	O
increases	NOUN	O	B-Entity
in	ADP	O	I-Entity
dural	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
cortical	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
flow	NOUN	O	I-Entity
and	CCONJ	O	O
provoked	VERB	O	O
lacrimation	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
responses	NOUN	O	O
were	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
systemic	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
hexamethonium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
evoked	VERB	O	O
increases	NOUN	O	B-Entity
in	ADP	O	I-Entity
dural	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
flow	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
abolished	VERB	O	O
by	ADP	O	O
topical	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
atropine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mm	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
[	PUNCT	O	O
Lys1	PROPN	O	O
,	PUNCT	O	O
Pro2,5	PROPN	O	O
,	PUNCT	O	O
Arg3,4	PROPN	O	O
,	PUNCT	O	O
Tyr6]-VIP	PROPN	O	O
(	PUNCT	O	O
0.1	NUM	O	O
mm	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
vasoactive	ADJ	O	O
intestinal	ADJ	O	O
polypeptide	NOUN	O	O
(	PUNCT	O	O
VIP	PROPN	O	O
)	PUNCT	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
onto	ADP	O	O
the	DET	O	O
exposed	VERB	O	O
dura	NOUN	O	O
mater	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
blood	NOUN	O	O
flow	NOUN	O	O
responses	NOUN	O	O
seem	VERB	O	O
to	PART	O	O
be	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
acetylcholine	NOUN	O	I-Entity
and	CCONJ	O	O
VIP	NOUN	O	O
within	ADP	O	O
the	DET	O	O
meninges	NOUN	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
mechanisms	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
cluster	NOUN	O	B-Entity
headache	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15120741)

Recurrent	ADJ	O	O
excitation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
of	ADP	O	O
a	DET	O	O
murine	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Similar	ADJ	O	O
to	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
pilocarpine	NOUN	O	I-Entity
injection	NOUN	O	O
causes	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
SE	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
eventual	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
mossy	NOUN	O	O
fiber	NOUN	O	O
sprouting	VERB	O	O
in	ADP	O	O
C57BL/6	PROPN	O	O
and	CCONJ	O	O
CD1	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
physiological	ADJ	O	O
correlates	NOUN	O	O
of	ADP	O	O
these	DET	O	O
events	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Population	NOUN	O	O
responses	NOUN	O	O
in	ADP	O	O
granule	NOUN	O	O
cells	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
transverse	ADJ	O	O
slices	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ventral	ADJ	O	O
hippocampus	NOUN	O	O
from	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
and	CCONJ	O	O
untreated	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Mg(2+)-free	PROPN	O	I-Entity
bathing	VERB	O	O
medium	NOUN	O	O
containing	VERB	O	O
bicuculline	NOUN	O	I-Entity
,	PUNCT	O	O
conditions	NOUN	O	O
designed	VERB	O	O
to	PART	O	O
increase	VERB	O	O
excitability	NOUN	O	O
in	ADP	O	O
the	DET	O	O
slices	NOUN	O	O
,	PUNCT	O	O
electrical	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hilus	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
population	NOUN	O	O
spike	NOUN	O	O
in	ADP	O	O
granule	NOUN	O	O
cells	NOUN	O	O
from	ADP	O	O
control	NOUN	O	O
mice	NOUN	O	O
and	CCONJ	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
mice	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
experience	VERB	O	O
SE	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
SE	PROPN	O	I-Entity
survivors	NOUN	O	O
,	PUNCT	O	O
similar	ADJ	O	O
stimulation	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
spike	NOUN	O	O
followed	VERB	O	O
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
variable	ADJ	O	O
latency	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
negative	ADJ	O	O
DC	PROPN	O	O
shifts	NOUN	O	O
and	CCONJ	O	O
repetitive	ADJ	O	O
afterdischarges	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
-	SYM	O	O
60	NUM	O	O
s	PART	O	O
duration	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
ionotropic	ADJ	O	O
glutamate	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O

Focal	ADJ	O	O
glutamate	NOUN	O	I-Entity
photostimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
granule	NOUN	O	O
cell	NOUN	O	O
layer	NOUN	O	O
at	ADP	O	O
sites	NOUN	O	O
distant	ADJ	O	O
from	ADP	O	O
the	DET	O	O
recording	NOUN	O	O
pipette	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
population	NOUN	O	O
responses	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
-	SYM	O	O
30	NUM	O	O
s	NOUN	O	O
duration	NOUN	O	O
in	ADP	O	O
slices	NOUN	O	O
from	ADP	O	O
SE	PROPN	O	I-Entity
survivors	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
other	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
support	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
SE	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
mossy	NOUN	O	O
fiber	NOUN	O	O
sprouting	NOUN	O	O
and	CCONJ	O	O
synaptic	ADJ	O	O
reorganization	NOUN	O	O
are	VERB	O	O
relevant	ADJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
development	NOUN	O	O
in	ADP	O	O
these	DET	O	O
murine	ADJ	O	O
strains	NOUN	O	O
,	PUNCT	O	O
resembling	VERB	O	O
rat	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15275829)

The	DET	O	O
alpha3	NOUN	O	O
and	CCONJ	O	O
beta4	ADJ	O	O
nicotinic	ADJ	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
subunits	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
for	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
hypolocomotion	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Binding	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
to	ADP	O	O
nicotinic	ADJ	O	O
acetylcholine	NOUN	O	I-Entity
receptors	NOUN	O	O
(	PUNCT	O	O
nAChRs	PROPN	O	O
)	PUNCT	O	O
elicits	VERB	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
behaviors	NOUN	O	O
that	ADJ	O	O
go	VERB	O	O
from	ADP	O	O
altered	VERB	O	O
exploration	NOUN	O	O
,	PUNCT	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tremors	NOUN	O	I-Entity
,	PUNCT	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
beta4	NOUN	O	O
subunits	NOUN	O	O
in	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
hypolocomotion	NOUN	O	I-Entity
in	ADP	O	O
beta4	PROPN	O	O
homozygous	ADJ	O	O
null	ADJ	O	O
(	PUNCT	O	O
beta4	NOUN	O	O
-/-	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
alpha3	ADJ	O	O
heterozygous	ADJ	O	O
(	PUNCT	O	O
+	X	O	O
/-	PUNCT	O	O

mice	NOUN	O	O
were	VERB	O	O
less	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
both	CCONJ	O	O
at	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
as	ADP	O	O
decreased	VERB	O	O
exploration	NOUN	O	O
in	ADP	O	O
an	DET	O	O
open	ADJ	O	O
field	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
as	ADP	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

mice	NOUN	O	O
were	VERB	O	O
partially	ADV	O	O
resistant	ADJ	O	O
to	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
littermates	NOUN	O	O
.	PUNCT	O	O

Together	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
beta4	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
alpha3	NOUN	O	O
subunits	NOUN	O	O
are	VERB	O	O
mediators	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
hypolocomotion	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15602202)

Recurrent	PROPN	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
azithromycin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
14-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
with	ADP	O	O
recurrent	ADJ	O	O
,	PUNCT	O	O
azithromycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
,	PUNCT	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
most	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
antibiotic	ADJ	O	O
induced	VERB	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
are	VERB	O	O
benign	ADJ	O	O
and	CCONJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
limited	VERB	O	O
,	PUNCT	O	O
some	DET	O	O
patients	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
permanent	ADJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16181582)

Valproate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Valproate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
syndrome	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
manifest	VERB	O	O
in	ADP	O	O
otherwise	ADV	O	O
normal	ADJ	O	O
epileptic	ADJ	O	I-Entity
individuals	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
usually	ADV	O	O
but	CCONJ	O	O
not	ADV	O	O
necessarily	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
hyperammonemia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (16298782)

Nitro	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
methyl	NOUN	O	I-Entity
ester	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
potential	ADJ	O	O
protector	NOUN	O	O
against	ADP	O	O
gentamicin	NOUN	O	I-Entity
ototoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
inhibitor	NOUN	O	O
nitro	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
methyl	NOUN	O	I-Entity
ester	NOUN	O	I-Entity
(	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	PROPN	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
act	VERB	O	O
as	ADP	O	O
an	DET	O	O
otoprotectant	NOUN	O	O
against	ADP	O	O
high	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
frequency	NOUN	O	I-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
gentamicin	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
confirm	VERB	O	O
this	DET	O	O
.	PUNCT	O	O

Aminoglycoside	ADP	O	I-Entity
antibiotics	NOUN	O	O
are	VERB	O	O
still	ADV	O	O
widely	ADV	O	O
used	VERB	O	O
by	ADP	O	O
virtue	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
low	ADJ	O	O
cost	NOUN	O	O
.	PUNCT	O	O

Their	ADJ	O	O
ototoxicity	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
serious	ADJ	O	O
health	NOUN	O	O
problem	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
as	ADP	O	O
their	ADJ	O	O
ototoxic	ADJ	O	I-Entity
mechanism	NOUN	O	O
involves	VERB	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
NO	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
need	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
NO	DET	O	I-Entity
inhibitors	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sensorineural	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
experimental	ADJ	O	O
study	NOUN	O	O
we	PRON	O	O
used	VERB	O	O
30	NUM	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
27	NUM	O	O
of	ADP	O	O
which	ADJ	O	O
had	VERB	O	O
gentamicin	NOUN	O	I-Entity
instilled	VERB	O	O
into	ADP	O	O
the	DET	O	O
middle	ADJ	O	O
ear	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
otoprotectant	ADJ	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
topically	ADV	O	O
to	ADP	O	O
12/27	NUM	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Its	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
attenuation	NOUN	O	O
of	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
shifts	NOUN	O	O
in	ADP	O	O
the	DET	O	O
auditory	ADJ	O	O
brainstem	NOUN	O	O
response	NOUN	O	O
threshold	NOUN	O	O
.	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	PROPN	O	I-Entity
reduced	VERB	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
frequency	NOUN	O	O
range	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
gave	VERB	O	O
no	DET	O	O
protection	NOUN	O	O
in	ADP	O	O
the	DET	O	O
middle	NOUN	O	O
or	CCONJ	O	O
low	ADJ	O	O
frequencies	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16428221)

Cerebral	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
following	VERB	O	O
oral	ADJ	O	O
methylphenidate	NOUN	O	I-Entity
intake	NOUN	O	O
in	ADP	O	O
an	DET	O	O
adult	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

Methylphenidate	PROPN	O	I-Entity
is	VERB	O	O
structurally	ADV	O	O
and	CCONJ	O	O
functionally	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

Cerebral	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
amphetamine	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
is	VERB	O	O
well	ADV	O	O
documented	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
rare	ADJ	O	O
cases	NOUN	O	O
ischaemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
after	ADP	O	O
methylphenidate	NOUN	O	I-Entity
intake	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
63-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
methylphenidate	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
hyperactivity	NOUN	O	I-Entity
and	CCONJ	O	O
suffered	VERB	O	O
from	ADP	O	O
multiple	ADJ	O	O
ischaemic	ADJ	O	B-Entity
strokes	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
consider	VERB	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
cerebral	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
most	ADV	O	O
likely	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	O
ischaemic	ADJ	O	B-Entity
strokes	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
any	DET	O	O
pathological	ADJ	O	O
findings	NOUN	O	O
during	ADP	O	O
the	DET	O	O
diagnostic	ADJ	O	O
work	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
methylphenidate	NOUN	O	I-Entity
mediated	VERB	O	O
vasculitis	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
neurological	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
methylphenidate	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
potential	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
,	PUNCT	O	O
though	ADP	O	O
very	ADV	O	O
rare	ADJ	O	O
,	PUNCT	O	O
represents	VERB	O	O
one	NUM	O	O
more	ADJ	O	O
reason	NOUN	O	O
to	PART	O	O
be	VERB	O	O
very	ADV	O	O
restrictive	ADJ	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
methylphenidate	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16858720)

Cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
,	PUNCT	O	O
severity	NOUN	O	O
and	CCONJ	O	O
preventability	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cerebral	ADJ	O	B-Entity
haemorrhages	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
warfarin	NOUN	O	I-Entity
and	CCONJ	O	O
warfarin	VERB	O	I-Entity
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
living	VERB	O	O
in	ADP	O	O
the	DET	O	O
county	NOUN	O	O
of	ADP	O	O
Osterg	PROPN	O	O
tland	NOUN	O	O
,	PUNCT	O	O
Sweden	PROPN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
diagnosed	VERB	O	O
cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
at	ADP	O	O
three	NUM	O	O
hospitals	NOUN	O	O
during	ADP	O	O
the	DET	O	O
period	NOUN	O	O
2000	NUM	O	O
-	SYM	O	O
2002	NUM	O	O
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

Medical	ADJ	O	O
records	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
retrospectively	ADV	O	O
to	PART	O	O
evaluate	VERB	O	O
whether	ADP	O	O
warfarin	NOUN	O	I-Entity
and	CCONJ	O	O
warfarin	VERB	O	I-Entity
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
could	VERB	O	O
have	VERB	O	O
caused	VERB	O	O
the	DET	O	O
cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
593	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cerebral	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
59	NUM	O	O
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
assessed	VERB	O	O
as	ADP	O	O
related	VERB	O	O
to	ADP	O	O
warfarin	VERB	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
59	NUM	O	O
cases	NOUN	O	O
,	PUNCT	O	O
26	NUM	O	O
(	PUNCT	O	O
44%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
fatal	ADJ	O	O
outcome	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
136	NUM	O	O
(	PUNCT	O	O
25%	NUM	O	O
)	PUNCT	O	O
among	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
warfarin	NOUN	O	I-Entity
patients	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
warfarin	ADJ	O	I-Entity
-	PUNCT	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
could	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
haemorrhage	NOUN	O	I-Entity
in	ADP	O	O
24	NUM	O	O
(	PUNCT	O	O
41%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
warfarin	NOUN	O	I-Entity
patients	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
7	NUM	O	O
of	ADP	O	O
these	DET	O	O
(	PUNCT	O	O
12%	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
bleeding	NOUN	O	I-Entity
complication	NOUN	O	O
was	VERB	O	O
considered	VERB	O	O
being	VERB	O	O
possible	ADJ	O	O
to	PART	O	O
avoid	VERB	O	O
.	PUNCT	O	O

Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cerebral	ADJ	O	B-Entity
haemorrhages	NOUN	O	I-Entity
are	VERB	O	O
a	DET	O	O
major	ADJ	O	O
clinical	ADJ	O	O
problem	NOUN	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
fatality	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Almost	ADV	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
cerebral	ADJ	O	B-Entity
haemorrhages	NOUN	O	I-Entity
might	VERB	O	O
have	VERB	O	O
been	VERB	O	O
prevented	VERB	O	O
if	ADP	O	O
greater	ADJ	O	O
caution	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
taken	VERB	O	O
when	ADV	O	O
prescribing	VERB	O	O
drugs	NOUN	O	O
known	VERB	O	O
to	PART	O	O
interact	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17466854)

Side	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
sub	NOUN	O	O
-	PUNCT	O	O
Tenon	PROPN	O	O
's	PART	O	O
space	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
emetic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
sub	NOUN	O	O
-	PUNCT	O	O
Tenon	PROPN	O	O
's	PART	O	O
space	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
routine	ADJ	O	O
cataract	ADJ	O	I-Entity
surgery	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
double	ADJ	O	O
-	PUNCT	O	O
armed	ADJ	O	O
prospective	ADJ	O	O
study	NOUN	O	O
comprised	VERB	O	O
40	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
uneventful	ADJ	O	O
sutureless	NOUN	O	O
phacoemulsification	NOUN	O	O
under	ADP	O	O
sub	NOUN	O	O
-	PUNCT	O	O
Tenon	PROPN	O	O
's	PART	O	O
local	ADJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
mL	PROPN	O	O
of	ADP	O	O
plain	ADJ	O	O
lignocaine	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
,	PUNCT	O	O
Group	PROPN	O	O
A	PROPN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
20	NUM	O	O
mg/0.5	NOUN	O	O
mL	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
and	CCONJ	O	O
10	NUM	O	O
mg/0.5	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
gentamicin	NOUN	O	I-Entity
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
sub	NOUN	O	O

Postoperatively	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
nausea	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	I-Entity
.	PUNCT	O	O

Sixty	NUM	O	O
percent	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
A	PROPN	O	O
developed	VERB	O	O
postoperative	ADJ	O	B-Entity
emetic	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
;	PUNCT	O	O
1	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
B	PROPN	O	O
developed	VERB	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
sub	NOUN	O	O
-	PUNCT	O	O
Tenon	PROPN	O	O
's	PART	O	O
space	NOUN	O	O
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
including	VERB	O	O
nausea	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17562951)

Cardiac	PROPN	O	O
Angiography	PROPN	O	O
in	ADP	O	O
Renally	PROPN	O	O
Impaired	PROPN	O	O
Patients	PROPN	O	O
(	PUNCT	O	O
CARE	PROPN	O	O
)	PUNCT	O	O
study	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	ADJ	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
direct	ADJ	O	O
comparisons	NOUN	O	O
exist	VERB	O	O
of	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
osmolality	NOUN	O	O
contrast	NOUN	O	B-Entity
medium	NOUN	O	I-Entity
iopamidol	NOUN	O	I-Entity
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
iso	NOUN	O	O
-	PUNCT	O	O
osmolality	NOUN	O	O
contrast	NOUN	O	B-Entity
medium	NOUN	O	I-Entity
iodixanol	NOUN	O	I-Entity
in	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
iopamidol	NOUN	O	I-Entity
and	CCONJ	O	O
iodixanol	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
estimated	VERB	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
to	PART	O	O
59	NUM	O	O
mL	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
who	NOUN	O	O
underwent	VERB	O	O
cardiac	ADJ	O	O
angiography	NOUN	O	O
or	CCONJ	O	O
percutaneous	ADJ	O	O
coronary	ADJ	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
creatinine	NOUN	O	I-Entity
(	PUNCT	O	O
SCr	PROPN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
and	CCONJ	O	O
estimated	VERB	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
to	PART	O	O
5	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
receiving	VERB	O	O
medications	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
414	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
contrast	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
presence	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	B-Entity
mellitus	NOUN	O	I-Entity
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
acetylcysteine	NOUN	O	I-Entity
,	PUNCT	O	O
mean	VERB	O	O
baseline	NOUN	O	O
SCr	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
estimated	VERB	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
4.4%	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
of	ADP	O	O
204	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
iopamidol	NOUN	O	I-Entity
and	CCONJ	O	O
6.7%	NUM	O	O
(	PUNCT	O	O
14	NUM	O	O
of	ADP	O	O
210	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
iodixanol	NOUN	O	I-Entity
(	PUNCT	O	O
P=0.39	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
rates	NOUN	O	O
of	ADP	O	O
SCr	PROPN	O	O
increases	VERB	O	O
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
25%	NUM	O	O
were	VERB	O	O
9.8%	NUM	O	O
and	CCONJ	O	O
12.4%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P=0.44	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	I-Entity
,	PUNCT	O	O
SCr	PROPN	O	O
increases	VERB	O	O
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
were	VERB	O	O
5.1%	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
of	ADP	O	O
78	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
iopamidol	NOUN	O	I-Entity
and	CCONJ	O	O
13.0%	NUM	O	O
(	PUNCT	O	O
12	NUM	O	O
of	ADP	O	O
92	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
iodixanol	NOUN	O	I-Entity
(	PUNCT	O	O
P=0.11	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
SCr	PROPN	O	O
increases	VERB	O	O
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
25%	NUM	O	O
were	VERB	O	O
10.3%	NUM	O	O
and	CCONJ	O	O
15.2%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P=0.37	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
SCr	PROPN	O	O
increases	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
with	ADP	O	O
iopamidol	NOUN	O	I-Entity
(	PUNCT	O	O
all	DET	O	O
patients	NOUN	O	O
:	PUNCT	O	O
0.07	NUM	O	O
versus	ADP	O	O
0.12	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
,	PUNCT	O	O
6.2	NUM	O	O
versus	ADP	O	O
10.6	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
,	PUNCT	O	O
P=0.03	NOUN	O	O
;	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	I-Entity
:	PUNCT	O	O
0.07	NUM	O	O
versus	ADP	O	O
0.16	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
,	PUNCT	O	O
6.2	NUM	O	O
versus	ADP	O	O
14.1	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
,	PUNCT	O	O
P=0.01	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
defined	VERB	O	O
by	ADP	O	O
multiple	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
different	ADJ	O	O
after	ADP	O	O
the	DET	O	O
intraarterial	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
iopamidol	NOUN	O	I-Entity
or	CCONJ	O	O
iodixanol	NOUN	O	I-Entity
to	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
diabetes	NOUN	O	B-Entity
mellitus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17600377)

A	DET	O	O
novel	NOUN	O	O
compound	NOUN	O	O
,	PUNCT	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
,	PUNCT	O	O
attenuates	VERB	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
and	CCONJ	O	O
shows	NOUN	O	O
neuroprotective	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
dementia	NOUN	O	I-Entity
models	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
develop	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
and	CCONJ	O	O
effective	ADJ	O	O
drug	NOUN	O	O
that	ADJ	O	O
could	VERB	O	O
enhance	VERB	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
neuroprotection	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
newly	ADV	O	O
synthesized	VERB	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
by	ADP	O	O
the	DET	O	O
esterification	NOUN	O	O
of	ADP	O	O
maltol	NOUN	O	I-Entity
and	CCONJ	O	O
p	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
coumaric	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
could	VERB	O	O
improve	VERB	O	O
cognitive	ADJ	O	B-Entity
decline	NOUN	O	I-Entity
in	ADP	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
rats	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
amyloid	NOUN	O	B-Entity
beta	NOUN	O	I-Entity
peptide(1	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
42)-infused	VERB	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Maltolyl	PROPN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
to	ADP	O	O
attenuate	VERB	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
rat	NOUN	O	O
models	NOUN	O	O
using	VERB	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
reduce	VERB	O	O
apoptotic	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
of	ADP	O	O
the	DET	O	O
amyloid	NOUN	O	B-Entity
beta	NOUN	O	I-Entity
peptide(1	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
42)-infused	VERB	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
examined	VERB	O	O
the	DET	O	O
neuroprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
in	ADP	O	O
vitro	NOUN	O	O
using	VERB	O	O
SH	PROPN	O	O
-	PUNCT	O	O
SY5Y	PROPN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Cells	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
,	PUNCT	O	O
before	ADP	O	O
exposed	VERB	O	O
to	ADP	O	O
amyloid	NOUN	O	B-Entity
beta	NOUN	O	I-Entity
peptide(1	NUM	O	I-Entity
-	PUNCT	O	I-Entity
42	NUM	O	I-Entity
)	PUNCT	O	I-Entity
,	PUNCT	O	O
glutamate	NOUN	O	I-Entity
or	CCONJ	O	O
H2O2	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
significantly	ADV	O	O
decreased	VERB	O	O
apoptotic	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	O
species	NOUN	O	O
,	PUNCT	O	O
cytochrome	VERB	O	O
c	PROPN	O	O
release	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
caspase	NOUN	O	O
3	NUM	O	O
activation	NOUN	O	O
.	PUNCT	O	O

Taking	VERB	O	O
these	DET	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
results	NOUN	O	O
together	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
maltolyl	NOUN	O	B-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
coumarate	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
effective	ADJ	O	O
candidate	NOUN	O	O
against	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
that	ADJ	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
wide	ADJ	O	O
spread	VERB	O	O
neuronal	ADJ	O	B-Entity
death	NOUN	O	I-Entity
and	CCONJ	O	O
progressive	ADJ	O	O
decline	NOUN	O	B-Entity
of	ADP	O	I-Entity
cognitive	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17639754)

Interaction	NOUN	O	O
between	ADP	O	O
warfarin	NOUN	O	I-Entity
and	CCONJ	O	O
levofloxacin	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

Warfarin	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
most	ADV	O	O
widely	ADV	O	O
used	ADJ	O	O
oral	ADJ	O	O
anticoagulant	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
indicated	VERB	O	O
for	ADP	O	O
many	ADJ	O	O
clinical	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Levofloxacin	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
fluoroquinolone	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
commonly	ADV	O	O
prescribed	VERB	O	O
antibiotics	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
effective	ADJ	O	O
against	ADP	O	O
Gram	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
,	PUNCT	O	O
Gram	PROPN	O	O
-	PUNCT	O	O
negative	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
atypical	ADJ	O	O
bacteria	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
small	ADJ	O	O
prospective	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
revealed	VERB	O	O
any	DET	O	O
significant	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
between	ADP	O	O
warfarin	NOUN	O	I-Entity
and	CCONJ	O	O
levofloxacin	NOUN	O	I-Entity
,	PUNCT	O	O
several	ADJ	O	O
case	NOUN	O	O
reports	NOUN	O	O
have	VERB	O	O
indicated	VERB	O	O
that	ADP	O	O
levofloxacin	NOUN	O	I-Entity
may	VERB	O	O
significantly	ADV	O	O
potentiate	VERB	O	O
the	DET	O	O
anticoagulation	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
3	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
bleeding	NOUN	O	I-Entity
complications	NOUN	O	O
that	ADJ	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
warfarin	NOUN	O	I-Entity
and	CCONJ	O	O
levofloxacin	NOUN	O	I-Entity
.	PUNCT	O	O

Physicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
potential	ADJ	O	O
interaction	NOUN	O	O
and	CCONJ	O	O
use	VERB	O	O
caution	NOUN	O	O
when	ADV	O	O
prescribing	VERB	O	O
levofloxacin	NOUN	O	I-Entity
to	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17854040)

Mutations	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
resistance	NOUN	O	O
in	ADP	O	O
therapy	NOUN	O	O
-	PUNCT	O	O
na	NOUN	O	I-Entity
ve	NOUN	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
HBV	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
infected	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
HIV	PROPN	O	B-Entity
co	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infection	NOUN	O	I-Entity
:	PUNCT	O	O
implications	NOUN	O	O
for	ADP	O	O
antiretroviral	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
HBV	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
HIV	PROPN	O	I-Entity
co	ADV	O	I-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
South	ADJ	O	O
African	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
an	DET	O	O
exploratory	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HBV	PROPN	O	O
)	PUNCT	O	O
strains	NOUN	O	O
in	ADP	O	O
selected	VERB	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
na	NOUN	O	I-Entity
ve	ADP	O	O
HBV	PROPN	O	O
carriers	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
HIV	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
co	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infection	NOUN	O	I-Entity
in	ADP	O	O
South	ADJ	O	O
African	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
na	NOUN	O	I-Entity

ve	X	O	O
HBV	PROPN	O	B-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
HIV	PROPN	O	B-Entity
co	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infection	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
:	PUNCT	O	O
15	NUM	O	O
chronic	ADJ	O	O
HBV	PROPN	O	B-Entity
mono	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
and	CCONJ	O	O
20	NUM	O	O
HBV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
HIV	PROPN	O	I-Entity
co	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
latter	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
further	ADJ	O	O
sub	NOUN	O	O
-	PUNCT	O	O
divided	VERB	O	O
into	ADP	O	O
13	NUM	O	O
occult	NOUN	O	O
HBV	PROPN	O	O
(	PUNCT	O	O
HBsAg	PROPN	O	I-Entity
-	PUNCT	O	O
negative	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
7	NUM	O	O
overt	ADJ	O	O
HBV	NOUN	O	O
(	PUNCT	O	O
HBsAg-	PROPN	O	I-Entity
positive	ADJ	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

HBsAg	PROPN	O	I-Entity
,	PUNCT	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HBs	NOUN	O	O
,	PUNCT	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HBc	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HIV	NOUN	O	O
1/2	NUM	O	O
were	VERB	O	O
determined	VERB	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
routine	ADJ	O	O
diagnosis	NOUN	O	O
using	VERB	O	O
Axsym	PROPN	O	O
assays	NOUN	O	O
(	PUNCT	O	O
Abbott	PROPN	O	O
Laboratories	PROPN	O	O
,	PUNCT	O	O
North	PROPN	O	O
Chicago	PROPN	O	O
,	PUNCT	O	O
IL	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Serum	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
PCR	PROPN	O	O
amplified	VERB	O	O
with	ADP	O	O
HBV	PROPN	O	O
reverse	NOUN	O	O
transcriptase	NOUN	O	O
(	PUNCT	O	O
RT	PROPN	O	O
)	PUNCT	O	O
primers	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
direct	ADJ	O	O
sequencing	NOUN	O	O
across	ADP	O	O
the	DET	O	O
tyrosine	NOUN	O	I-Entity
-	PUNCT	O	O
methionine	NOUN	O	I-Entity
-	PUNCT	O	O
aspartate	NOUN	O	I-Entity
-	PUNCT	O	O
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
YMDD	PROPN	O	O
)	PUNCT	O	O
motif	NOUN	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
catalytic	ADJ	O	O
region	NOUN	O	O
in	ADP	O	O
the	DET	O	O
C	PROPN	O	O
domain	NOUN	O	O
of	ADP	O	O
the	DET	O	O
HBV	PROPN	O	O
RT	PROPN	O	O
enzyme	NOUN	O	O
.	PUNCT	O	O

HBV	PROPN	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
strains	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
3	NUM	O	O
of	ADP	O	O
15	NUM	O	O
mono	NOUN	O	O
-	PUNCT	O	O
infected	VERB	O	O
chronic	ADJ	O	O
hepatitis	NOUN	O	B-Entity
B	NOUN	O	I-Entity
patients	NOUN	O	O
and	CCONJ	O	O
10	NUM	O	O
of	ADP	O	O
20	NUM	O	O
HBV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
HIV	PROPN	O	I-Entity
co	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
the	DET	O	O
best	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
constitutes	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
strains	NOUN	O	O
in	ADP	O	O
therapy	NOUN	O	O
-	PUNCT	O	O
na	NOUN	O	I-Entity
ve	ADP	O	O
HBV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
HIV	PROPN	O	I-Entity
co	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
remains	VERB	O	O
to	PART	O	O
be	VERB	O	O
seen	VERB	O	O
whether	ADP	O	O
such	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
antiviral	ADJ	O	O
mutations	NOUN	O	O
could	VERB	O	O
result	VERB	O	O
in	ADP	O	O
widespread	ADJ	O	O
emergence	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
resistant	ADJ	O	O
strains	NOUN	O	O
when	ADV	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
highly	ADV	O	O
active	ADJ	O	O
antiretroviral	ADJ	O	O
(	PUNCT	O	O
ARV	PROPN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
HAART	PROPN	O	O
)	PUNCT	O	O
regimens	VERB	O	O
become	VERB	O	O
widely	ADV	O	O
applied	VERB	O	O
in	ADP	O	O
South	PROPN	O	O
Africa	PROPN	O	O
,	PUNCT	O	O
as	ADP	O	O
this	DET	O	O
is	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
potential	ADJ	O	O
implications	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
HIV	PROPN	O	I-Entity
co	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18221780)

Sex	NOUN	O	O
differences	NOUN	O	O
in	ADP	O	O
NMDA	PROPN	O	I-Entity
antagonist	NOUN	O	O
enhancement	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
antihyperalgesia	NOUN	O	O
in	ADP	O	O
a	DET	O	O
capsaicin	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
pain	NOUN	O	I-Entity
:	PUNCT	O	O
comparisons	NOUN	O	O
to	ADP	O	O
two	NUM	O	O
models	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
acute	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
models	NOUN	O	O
,	PUNCT	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
antagonists	NOUN	O	O
enhance	VERB	O	O
the	DET	O	O
antinociceptive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
extent	NOUN	O	O
in	ADP	O	O
males	NOUN	O	O
than	ADP	O	O
females	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
investigation	NOUN	O	O
was	VERB	O	O
to	PART	O	O
extend	VERB	O	O
these	DET	O	O
findings	NOUN	O	O
to	ADP	O	O
a	DET	O	O
persistent	ADJ	O	O
pain	NOUN	O	I-Entity
model	NOUN	O	O
which	ADJ	O	O
could	VERB	O	O
be	VERB	O	O
distinguished	VERB	O	O
from	ADP	O	O
acute	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
models	NOUN	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nociceptive	ADJ	O	O
fibers	NOUN	O	O
activated	VERB	O	O
,	PUNCT	O	O
neurochemical	ADJ	O	O
substrates	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nociceptive	ADJ	O	O
stimulus	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
this	DET	O	O
end	NOUN	O	O
,	PUNCT	O	O
persistent	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
tail	NOUN	O	O
of	ADP	O	O
gonadally	NOUN	O	O
intact	ADJ	O	O
F344	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
following	VERB	O	O
which	ADJ	O	O
the	DET	O	O
tail	NOUN	O	O
was	VERB	O	O
immersed	VERB	O	O
in	ADP	O	O
a	DET	O	O
mildly	ADV	O	O
noxious	ADJ	O	O
thermal	ADJ	O	O
stimulus	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tail	NOUN	O	O
-	PUNCT	O	O
withdrawal	NOUN	O	O
latencies	NOUN	O	O
measured	VERB	O	O
.	PUNCT	O	O

For	ADP	O	O
comparison	NOUN	O	O
,	PUNCT	O	O
tests	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
two	NUM	O	O
acute	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
models	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
hotplate	NOUN	O	O
and	CCONJ	O	O
warm	ADJ	O	O
water	NOUN	O	O
tail	NOUN	O	O
-	PUNCT	O	O
withdrawal	NOUN	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
males	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
competitive	ADJ	O	O
NMDA	PROPN	O	I-Entity
antagonist	NOUN	O	O
dextromethorphan	ADP	O	I-Entity
enhanced	VERB	O	O
the	DET	O	O
antihyperalgesic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
to	PART	O	O
moderate	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
and	CCONJ	O	O
time	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

Enhancement	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
antinociception	NOUN	O	O
by	ADP	O	O
dextromethorphan	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
both	DET	O	O
males	NOUN	O	O
and	CCONJ	O	O
females	NOUN	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
models	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
being	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
males	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
demonstrate	VERB	O	O
a	DET	O	O
sexually	ADV	O	O
-	PUNCT	O	O
dimorphic	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
NMDA	PROPN	O	I-Entity
antagonists	NOUN	O	O
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
persistent	ADJ	O	O
pain	NOUN	O	I-Entity
model	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
be	VERB	O	O
distinguished	VERB	O	O
from	ADP	O	O
those	DET	O	O
observed	VERB	O	O
in	ADP	O	O
acute	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
models	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18261172)

Development	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
after	ADP	O	O
switch	NOUN	O	O
to	ADP	O	O
sirolimus	VERB	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
immunosuppression	NOUN	O	O
in	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
cardiac	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Calcineurin	PROPN	O	O
-	PUNCT	O	O
inhibitor	NOUN	O	O
therapy	NOUN	O	O
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
heart	NOUN	O	O
transplantation	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
novel	NOUN	O	O
immunosuppressive	NOUN	O	O
(	PUNCT	O	O
IS	PROPN	O	O
)	PUNCT	O	O
drug	NOUN	O	O
sirolmus	NOUN	O	I-Entity
(	PUNCT	O	O
Srl	PROPN	O	I-Entity
)	PUNCT	O	O
lacks	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
Srl	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
following	VERB	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
cardiac	ADJ	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
Srl	PROPN	O	I-Entity
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
cardiac	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
switched	VERB	O	O
from	ADP	O	O
cyclosporine	NOUN	O	I-Entity
to	ADP	O	O
Srl	PROPN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
IS	PROPN	O	O
.	PUNCT	O	O

Concomitant	ADJ	O	O
IS	VERB	O	O
consisted	VERB	O	O
of	ADP	O	O
mycophenolate	NOUN	O	B-Entity
mofetil	NOUN	O	I-Entity

steroids	NOUN	O	I-Entity
.	PUNCT	O	O

Before	ADP	O	O
the	DET	O	O
switch	NOUN	O	O
,	PUNCT	O	O
11.5%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
had	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
grade	NOUN	O	O
proteinuria	NOUN	O	I-Entity
(	PUNCT	O	O
>	SYM	O	O
1.0	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
this	DET	O	O
increased	VERB	O	O
to	ADP	O	O
22.9%	NUM	O	O
postswitch	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.006	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ACE	PROPN	O	B-Entity
inhibitor	NOUN	O	I-Entity
and	CCONJ	O	O
angiotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
releasing	VERB	O	I-Entity
blocker	NOUN	O	I-Entity
(	PUNCT	O	O
ARB	PROPN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
reduced	VERB	O	O
proteinuria	NOUN	O	I-Entity
development	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
without	ADP	O	O
proteinuria	NOUN	O	I-Entity
had	VERB	O	O
increased	VERB	O	O
renal	ADJ	O	O
function	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
42.5	NUM	O	O
vs.	ADP	O	O
64.1	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.25	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
grade	NOUN	O	O
proteinuria	NOUN	O	I-Entity
showed	VERB	O	O
decreased	VERB	O	O
renal	ADJ	O	O
function	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
39.6	NUM	O	O
vs.	ADP	O	O
29.2	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.125	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
may	VERB	O	O
develop	VERB	O	O
in	ADP	O	O
cardiac	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
after	ADP	O	O
switch	NOUN	O	O
to	ADP	O	O
Srl	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
have	VERB	O	O
an	DET	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Srl	PROPN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
with	ADP	O	O
ACEi	PROPN	O	I-Entity
/	SYM	O	O
ARB	PROPN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
monitored	VERB	O	O
for	ADP	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18329269)

Synthesis	NOUN	O	O
of	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
pyrimidinyl-2-phenoxyacetamides	NOUN	O	I-Entity
as	ADP	O	O
adenosine	NOUN	O	I-Entity
A2A	PROPN	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
series	NOUN	O	O
of	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
pyrimidinyl-2-phenoxyacetamide	PROPN	O	I-Entity
adenosine	NOUN	O	I-Entity
A(2A	PROPN	O	O
)	PUNCT	O	O
antagonists	NOUN	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

>	X	O	O
100	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
(	PUNCT	O	O
MED	PROPN	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
model	NOUN	O	O
for	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18410508)

Methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
fractalkine	NOUN	O	O
receptor	NOUN	O	O
signaling	VERB	O	O
.	PUNCT	O	O

Methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
METH	PROPN	O	I-Entity
)	PUNCT	O	O
damages	VERB	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O
nerve	NOUN	O	O
endings	NOUN	O	O
by	ADP	O	O
a	DET	O	O
process	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
linked	VERB	O	O
to	ADP	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
signaling	VERB	O	O
pathways	NOUN	O	O
that	ADJ	O	O
mediate	VERB	O	O
this	DET	O	O
response	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
yet	ADV	O	O
been	VERB	O	O
delineated	VERB	O	O
.	PUNCT	O	O

Neurosci	PROPN	O	O
.	PUNCT	O	O
9	NUM	O	O
(	PUNCT	O	O
2006	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
917	NUM	O	O
]	PUNCT	O	O
recently	ADV	O	O
identified	VERB	O	O
the	DET	O	O
microglial	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
fractalkine	NOUN	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
CX3CR1	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
important	ADJ	O	O
mediator	NOUN	O	O
of	ADP	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurodegeneration	NOUN	O	I-Entity
of	ADP	O	O
DA	PROPN	O	I-Entity
neurons	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
the	DET	O	O
CNS	PROPN	O	B-Entity
damage	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
METH	PROPN	O	I-Entity
and	CCONJ	O	O
MPTP	PROPN	O	I-Entity
is	VERB	O	O
highly	ADV	O	O
selective	ADJ	O	O
for	ADP	O	O
the	DET	O	O
DA	PROPN	O	I-Entity
neuronal	ADJ	O	O
system	NOUN	O	O
in	ADP	O	O
mouse	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
the	DET	O	O
CX3CR1	PROPN	O	O
plays	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
.	PUNCT	O	O

Mice	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
the	DET	O	O
CX3CR1	PROPN	O	O
gene	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
deleted	VERB	O	O
and	CCONJ	O	O
replaced	VERB	O	O
with	ADP	O	O
a	DET	O	O
cDNA	NOUN	O	O
encoding	VERB	O	O
enhanced	VERB	O	O
green	ADJ	O	O
fluorescent	NOUN	O	O
protein	NOUN	O	O
(	PUNCT	O	O
eGFP	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
METH	PROPN	O	I-Entity
and	CCONJ	O	O
examined	VERB	O	O
for	ADP	O	O
striatal	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

METH	PROPN	O	I-Entity
depleted	VERB	O	O
DA	PROPN	O	I-Entity
,	PUNCT	O	O
caused	VERB	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
body	NOUN	O	O
temperature	NOUN	O	O
in	ADP	O	O
CX3CR1	PROPN	O	O
knockout	NOUN	O	O
mice	NOUN	O	O
to	ADP	O	O
the	DET	O	O
same	ADJ	O	O
extent	NOUN	O	O
and	CCONJ	O	O
over	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
course	NOUN	O	O
seen	VERB	O	O
in	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
in	ADP	O	O
CX3CR1	PROPN	O	O
knockout	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
gender	NOUN	O	O
-	PUNCT	O	O
dependent	NOUN	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
extend	VERB	O	O
beyond	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

Striatal	ADJ	O	O
microglia	NOUN	O	O
expressing	VERB	O	O
eGFP	PROPN	O	O
constitutively	ADV	O	O
show	VERB	O	O
morphological	ADJ	O	O
changes	NOUN	O	O
after	ADP	O	O
METH	PROPN	O	I-Entity
that	ADJ	O	O
are	VERB	O	O
characteristic	ADJ	O	O
of	ADP	O	O
activation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
response	NOUN	O	O
was	VERB	O	O
restricted	VERB	O	O
to	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
and	CCONJ	O	O
contrasted	VERB	O	O
sharply	ADV	O	O
with	ADP	O	O
unresponsive	ADJ	O	O
eGFP	NOUN	O	O
-	PUNCT	O	O
microglia	NOUN	O	O
in	ADP	O	O
surrounding	VERB	O	O
brain	NOUN	O	O
areas	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
not	ADV	O	O
damaged	VERB	O	O
by	ADP	O	O
METH	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
from	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
that	ADJ	O	O
CX3CR1	PROPN	O	O
signaling	VERB	O	O
does	VERB	O	O
not	ADV	O	O
modulate	VERB	O	O
METH	PROPN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
or	CCONJ	O	O
microglial	ADJ	O	O
activation	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
appears	VERB	O	O
that	ADP	O	O
striatal	ADJ	O	O
-	PUNCT	O	O
resident	NOUN	O	O
microglia	NOUN	O	O
respond	VERB	O	O
to	ADP	O	O
METH	PROPN	O	I-Entity
with	ADP	O	O
an	DET	O	O
activation	NOUN	O	O
cascade	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
return	VERB	O	O
to	ADP	O	O
a	DET	O	O
surveying	VERB	O	O
state	NOUN	O	O
without	ADP	O	O
undergoing	VERB	O	O
apoptosis	NOUN	O	O
or	CCONJ	O	O
migration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18503483)

Recovery	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
brachial	NOUN	O	B-Entity
neuritis	NOUN	O	I-Entity
after	ADP	O	O
conversion	NOUN	O	O
to	ADP	O	O
everolimus	VERB	O	I-Entity
in	ADP	O	O
a	DET	O	O
pediatric	ADJ	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipient	NOUN	O	O
--	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

TAC	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
potent	ADJ	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
for	ADP	O	O
solid	ADJ	O	O
organ	ADJ	O	O
transplantation	NOUN	O	O
in	ADP	O	O
pediatrics	NOUN	O	O
.	PUNCT	O	O

Neurotoxicity	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
serious	ADJ	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
headaches	NOUN	O	I-Entity
,	PUNCT	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
neurological	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
.	PUNCT	O	O

MRI	PROPN	O	O
demonstrated	VERB	O	O
hyperintense	NOUN	O	O
T2	ADJ	O	O
signals	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cervical	ADJ	O	O
cord	NOUN	O	O
and	CCONJ	O	O
right	ADJ	O	O
brachial	NOUN	O	O
plexus	NOUN	O	O
roots	NOUN	O	O
indicative	ADJ	O	O
of	ADP	O	O
both	DET	O	O
myelitis	NOUN	O	I-Entity
and	CCONJ	O	O
right	ADJ	O	O
brachial	NOUN	O	B-Entity
plexitis	NOUN	O	I-Entity
.	PUNCT	O	O

Symptoms	NOUN	O	O
persisted	VERB	O	O
for	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
despite	ADP	O	O
TAC	PROPN	O	I-Entity
dose	NOUN	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
IVIG	PROPN	O	O
and	CCONJ	O	O
four	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
pulse	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Improvement	NOUN	O	O
and	CCONJ	O	O
eventually	ADV	O	O
full	ADJ	O	O
recovery	NOUN	O	O
only	ADV	O	O
occurred	VERB	O	O
after	ADP	O	O
TAC	PROPN	O	I-Entity
was	VERB	O	O
completely	ADV	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
successfully	ADV	O	O
replaced	VERB	O	O
by	ADP	O	O
everolimus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18560792)

Valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
.	PUNCT	O	O

Valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
estimate	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
abnormality	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
possible	ADJ	O	O
reversibility	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
in	ADP	O	O
a	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
PD	NOUN	O	I-Entity
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Amiens	PROPN	O	O
area	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
were	VERB	O	O
invited	VERB	O	O
to	PART	O	O
attend	VERB	O	O
a	DET	O	O
cardiologic	ADJ	O	O
assessment	NOUN	O	O
including	VERB	O	O
transthoracic	NOUN	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
PD	NOUN	O	I-Entity
patients	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
second	ADJ	O	O
echocardiography	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
(	PUNCT	O	O
median	ADJ	O	O
interval	NOUN	O	O
:	PUNCT	O	O
13	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
pergolide	NOUN	O	I-Entity
withdrawal	NOUN	O	O
(	PUNCT	O	O
n=10	ADJ	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Controls	NOUN	O	O
were	VERB	O	O
age-	ADJ	O	O
and	CCONJ	O	O
sex	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
PD	NOUN	O	I-Entity
patients	NOUN	O	O
referred	VERB	O	O
to	ADP	O	O
the	DET	O	O
cardiology	NOUN	O	O
department	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
aortic	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
:	PUNCT	O	O
3.1	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
IC	NOUN	O	O
:	PUNCT	O	O
1.1	NUM	O	O
-	PUNCT	O	O
8.8	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
mitral	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
:	PUNCT	O	O
10.7	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
IC	NOUN	O	O
:	PUNCT	O	O
2.1	NUM	O	O
-	SYM	O	O
53	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
more	ADJ	O	O
frequent	ADJ	O	O
in	ADP	O	O
PD	NOUN	O	I-Entity
patients	NOUN	O	O
(	PUNCT	O	O
tricuspid	NOUN	O	O
:	PUNCT	O	O
NS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
affected	VERB	O	O
valves	NOUN	O	O
(	PUNCT	O	O
n=2.4+/-0.7	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
sum	NOUN	O	O
of	ADP	O	O
regurgitation	NOUN	O	O
grades	NOUN	O	O
(	PUNCT	O	O
n=2.8+/-1.09	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
higher	ADJ	O	O
(	PUNCT	O	O
p=0.008	NOUN	O	O
and	CCONJ	O	O
p=0.006	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
pergolide	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Severity	NOUN	O	O
of	ADP	O	O
regurgitation	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
cumulative	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
restrictive	ADJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
valvular	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
,	PUNCT	O	O
suggestive	ADJ	O	O
of	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
pergolide	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
12/30	NUM	O	O
(	PUNCT	O	O
40%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
including	VERB	O	O
two	NUM	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Pergolide	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
a	DET	O	O
lower	ADJ	O	O
regurgitation	NOUN	O	O
grade	NOUN	O	O
(	PUNCT	O	O
p=0.01	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
second	ADJ	O	O
transthoracic	NOUN	O	O
echocardiography	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
returned	VERB	O	O
to	ADP	O	O
nearly	ADV	O	O
normal	ADJ	O	O
clinical	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
supports	VERB	O	O
the	DET	O	O
high	ADJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
restrictive	ADJ	O	O
valve	NOUN	O	B-Entity
regurgitation	NOUN	O	I-Entity
in	ADP	O	O
PD	PROPN	O	I-Entity
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
pergolide	NOUN	O	I-Entity
and	CCONJ	O	O
reveals	VERB	O	O
that	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
is	VERB	O	O
usual	ADJ	O	O
when	ADV	O	O
the	DET	O	O
treatment	NOUN	O	O
is	VERB	O	O
converted	VERB	O	O
to	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
ergot	NOUN	O	O
dopamine	NOUN	O	I-Entity
agonists	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18726058)

Adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
topical	ADJ	O	O
papaverine	NOUN	O	I-Entity
on	ADP	O	O
auditory	ADJ	O	O
nerve	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Papaverine	PROPN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
vasodilator	NOUN	O	O
used	VERB	O	O
to	PART	O	O
manage	VERB	O	O
vasospasm	NOUN	O	I-Entity
during	ADP	O	O
various	ADJ	O	O
neurosurgical	ADJ	O	O
operations	NOUN	O	O
.	PUNCT	O	O

Transient	PROPN	O	O
cranial	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
in	ADP	O	O
a	DET	O	O
few	ADJ	O	O
cases	NOUN	O	O
with	ADP	O	O
topical	ADJ	O	O
papaverine	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
retrospective	NOUN	O	O
review	NOUN	O	O
of	ADP	O	O
70	NUM	O	O
consecutive	ADJ	O	O
microvascular	ADJ	O	O
decompression	NOUN	O	O
operations	NOUN	O	O
and	CCONJ	O	O
studied	VERB	O	O
those	DET	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
topical	ADJ	O	O
papaverine	NOUN	O	I-Entity
for	ADP	O	O
vasospasm	NOUN	O	I-Entity
.	PUNCT	O	O

Topical	ADJ	O	O
papaverine	NOUN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
direct	ADJ	O	O
therapeutic	ADJ	O	O
action	NOUN	O	O
to	PART	O	O
manage	VERB	O	O
vasospasm	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
timing	NOUN	O	O
of	ADP	O	O
papaverine	NOUN	O	I-Entity
application	NOUN	O	O
and	CCONJ	O	O
ongoing	ADJ	O	O
operative	ADJ	O	O
events	NOUN	O	O
was	VERB	O	O
reviewed	VERB	O	O
relative	ADJ	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
neurophysiological	ADJ	O	O
recordings	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
temporal	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
topical	ADJ	O	O
papaverine	NOUN	O	I-Entity
and	CCONJ	O	O
BAEP	PROPN	O	O
changes	NOUN	O	O
leading	VERB	O	O
to	PART	O	O
complete	VERB	O	O
waveform	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
temporal	ADJ	O	O
delay	NOUN	O	O
between	ADP	O	O
papaverine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
an	DET	O	O
adverse	ADJ	O	O
BAEP	NOUN	O	O
change	NOUN	O	O
was	VERB	O	O
5	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
10	NUM	O	O
of	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
BAEP	PROPN	O	O
waves	NOUN	O	O
II	PROPN	O	O
/	SYM	O	O
III	PROPN	O	O
-	PUNCT	O	O
V	PROPN	O	O
completely	ADV	O	O
disappeared	VERB	O	O
within	ADP	O	O
2	NUM	O	O
to	ADP	O	O
25	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
papaverine	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
recovery	NOUN	O	O
of	ADP	O	O
later	ADV	O	O
waves	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
delayed	VERB	O	O
profound	ADJ	O	O
sensorineural	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
recovery	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
BAEP	PROPN	O	O
waveforms	NOUN	O	O
to	ADP	O	O
pre	VERB	O	O
-	PUNCT	O	O
papaverine	NOUN	O	I-Entity
baseline	NOUN	O	O
values	NOUN	O	O
was	VERB	O	O
39	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Topical	ADJ	O	O
papaverine	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
vasospasm	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
a	DET	O	O
transient	ADJ	O	O
disturbance	NOUN	O	O
in	ADP	O	O
neurophysiological	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ascending	VERB	O	O
auditory	ADJ	O	O
brainstem	NOUN	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
complete	ADJ	O	O
disappearance	NOUN	O	O
of	ADP	O	O
BAEP	PROPN	O	O
waveforms	NOUN	O	O
with	ADP	O	O
a	DET	O	O
consistent	ADJ	O	O
temporal	ADJ	O	O
delay	NOUN	O	O
suggests	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
adverse	ADJ	O	B-Entity
effect	NOUN	O	I-Entity
on	ADP	O	I-Entity
the	DET	O	I-Entity
proximal	ADJ	O	I-Entity
eighth	ADJ	O	I-Entity
nerve	NOUN	O	I-Entity
.	PUNCT	O	O

Recommendations	NOUN	O	O
to	PART	O	O
avoid	VERB	O	O
potential	ADJ	O	O
cranial	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
deficits	NOUN	O	I-Entity
from	ADP	O	O
papaverine	NOUN	O	I-Entity
are	VERB	O	O
provided	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18754075)

Massive	ADJ	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
oral	ADJ	O	O
bisphosphonate	NOUN	O	I-Entity
(	PUNCT	O	O
alendronate	NOUN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
focal	ADJ	O	B-Entity
segmental	ADJ	O	I-Entity
glomerulosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
61-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Japanese	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
focal	ADJ	O	B-Entity
segmental	ADJ	O	I-Entity
glomerulosclerosis	NOUN	O	I-Entity
was	VERB	O	O
initially	ADV	O	O
responding	VERB	O	O
well	ADV	O	O
to	ADP	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Within	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
bisphosphonate	NOUN	O	I-Entity
(	PUNCT	O	O
alendronate	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
urinary	NOUN	O	O
protein	NOUN	O	O
increased	VERB	O	O
rapidly	ADV	O	O
up	ADP	O	O
to	ADP	O	O
12.8	NUM	O	O
g	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
discontinuing	VERB	O	O
the	DET	O	O
oral	ADJ	O	O
alendronate	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
underwent	VERB	O	O
six	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
hemodialysis	NOUN	O	O
and	CCONJ	O	O
four	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
LDL	PROPN	O	O
apheresis	NOUN	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
volume	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
recovered	VERB	O	O
to	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
range	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
urinary	ADJ	O	O
protein	NOUN	O	O
disappearing	VERB	O	O
completely	ADV	O	O
within	ADP	O	O
40	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
not	ADV	O	O
only	ADV	O	O
intravenous	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
also	ADV	O	O
oral	ADJ	O	O
bisphosphonates	NOUN	O	I-Entity
can	VERB	O	O
aggravate	VERB	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18768591)

Serum-	NOUN	O	O
and	CCONJ	O	O
glucocorticoid	NOUN	O	O
-	PUNCT	O	O
inducible	ADJ	O	O
kinase	NOUN	O	O
1	NUM	O	O
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Doxorubicin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
leads	VERB	O	O
to	ADP	O	O
epithelial	ADJ	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
(	PUNCT	O	O
ENaC)-dependent	NOUN	O	O
volume	NOUN	O	B-Entity
retention	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	O
fibrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aldosterone	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
serum-	NOUN	O	O
and	CCONJ	O	O
glucocorticoid	NOUN	O	O

-	PUNCT	O	O
inducible	ADJ	O	O
kinase	NOUN	O	O
SGK1	PROPN	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
participate	VERB	O	O
in	ADP	O	O
the	DET	O	O
stimulation	NOUN	O	O
of	ADP	O	O
ENaC	PROPN	O	O
and	CCONJ	O	O
to	PART	O	O
mediate	VERB	O	O
renal	ADJ	O	O
fibrosis	NOUN	O	I-Entity
following	VERB	O	O
mineralocorticoid	NOUN	O	O
and	CCONJ	O	O
salt	NOUN	O	O
excess	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
elucidate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
SGK1	PROPN	O	O
in	ADP	O	O
the	DET	O	O
volume	NOUN	O	B-Entity
retention	NOUN	O	I-Entity
and	CCONJ	O	O
fibrosis	NOUN	O	I-Entity
during	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
this	DET	O	O
end	NOUN	O	O
,	PUNCT	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mug	NOUN	O	O
/	SYM	O	O
g	NOUN	O	O
body	NOUN	O	O
wt	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
intravenously	ADV	O	O
into	ADP	O	O
gene	NOUN	O	O
-	PUNCT	O	O
targeted	VERB	O	O
mice	NOUN	O	O
lacking	VERB	O	O
SGK1	PROPN	O	O
(	PUNCT	O	O
sgk1(-/-	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
littermates	NOUN	O	O
(	PUNCT	O	O
sgk1(+/+	PUNCT	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Doxorubicin	PROPN	O	I-Entity
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
heavy	ADJ	O	O
proteinuria	NOUN	O	I-Entity
(	PUNCT	O	O
>	SYM	O	O
100	NUM	O	O
mg	NUM	O	O
protein	NOUN	O	O
/	SYM	O	O
mg	X	O	O
crea	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
15/44	NUM	O	O
of	ADP	O	O
sgk1(+/+	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
15/44	NUM	O	O
of	ADP	O	O
sgk1(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
severe	ADJ	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
with	ADP	O	O
ascites	NOUN	O	I-Entity
,	PUNCT	O	O
lipidemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hypoalbuminemia	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
genotypes	NOUN	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
aldosterone	NOUN	O	I-Entity
levels	NOUN	O	O
increased	VERB	O	O
in	ADP	O	O
nephrotic	ADJ	O	I-Entity
mice	NOUN	O	O
of	ADP	O	O
both	DET	O	O
genotypes	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
increased	VERB	O	O
SGK1	PROPN	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
sgk1(+/+	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
reached	VERB	O	O
signficantly	ADV	O	O
lower	ADJ	O	O
values	NOUN	O	O
in	ADP	O	O
sgk1(+/+	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

5	NUM	O	O
mumol	PROPN	O	O
/	SYM	O	O
mg	INTJ	O	O
crea	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
higher	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	B-Entity
gain	NOUN	O	I-Entity
in	ADP	O	O
sgk1(+/+	PROPN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
sgk1(-/-	NOUN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
6.6	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
serum	NOUN	O	O
urea	NOUN	O	I-Entity
concentrations	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
faster	ADV	O	O
in	ADP	O	O
sgk1(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
sgk1(+/+	PROPN	O	O
)	PUNCT	O	O

mice	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
uremia	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
reduced	ADJ	O	O
median	ADJ	O	O
survival	NOUN	O	O
in	ADP	O	O
sgk1(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
(	PUNCT	O	O
29	NUM	O	O
vs.	SYM	O	O
40	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
sgk1(+/+	NUM	O	O
)	PUNCT	O	O
mice	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
gene	NOUN	O	O
-	PUNCT	O	O
targeted	VERB	O	O
mice	NOUN	O	O
lacking	VERB	O	O
SGK1	PROPN	O	O
showed	VERB	O	O
blunted	VERB	O	O
volume	NOUN	O	B-Entity
retention	NOUN	O	I-Entity
,	PUNCT	O	O
yet	CCONJ	O	O
were	VERB	O	O
not	ADV	O	O
protected	VERB	O	O
against	ADP	O	O
renal	ADJ	O	O
fibrosis	NOUN	O	I-Entity
during	ADP	O	O
experimental	ADJ	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19299179)

Severe	ADJ	O	O
and	CCONJ	O	O
long	ADJ	O	O
lasting	ADJ	O	O
cholestasis	NOUN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
co	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
trimoxazole	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
Pneumocystis	PROPN	O	B-Entity
pneumonia	NOUN	O	I-Entity
in	ADP	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
report	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Pneumocystis	PROPN	O	B-Entity
pneumonia	NOUN	O	I-Entity
(	PUNCT	O	O
PCP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
common	ADJ	O	O
opportunistic	ADJ	O	B-Entity
infection	NOUN	O	I-Entity
in	ADP	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
individuals	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
generally	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
co	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
trimoxazole	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
report	VERB	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
severely	ADV	O	O
immunocompromised	VERB	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
severe	ADJ	O	O
intrahepatic	ADJ	O	B-Entity
cholestasis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
lesions	NOUN	O	O
mimicking	VERB	O	O
liver	NOUN	O	B-Entity
abscess	ADJ	O	I-Entity
formation	NOUN	O	O
on	ADP	O	O
radiologic	ADJ	O	O
exams	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
co	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
trimoxazole	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
PCP	PROPN	O	I-Entity
.	PUNCT	O	O

Whereas	ADP	O	O
patient	NOUN	O	O
1	NUM	O	O
showed	VERB	O	O
lesions	NOUN	O	O
of	ADP	O	O
up	ADP	O	O
to	PART	O	O
1	NUM	O	O
cm	X	O	O
readily	ADV	O	O
detectable	ADJ	O	O
on	ADP	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
under	ADP	O	O
prolonged	ADJ	O	O
co	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
trimoxazole	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
therapy	NOUN	O	O
of	ADP	O	O
patient	NOUN	O	O
2	NUM	O	O
was	VERB	O	O
switched	VERB	O	O
early	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (19356053)

Clinically	PROPN	O	O
significant	ADJ	O	O
proteinuria	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
to	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

Sirolimus	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
latest	ADJ	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
used	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
rejection	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
have	VERB	O	O
less	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
than	ADP	O	O
calcineurin	ADJ	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
CNI)-based	VERB	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
date	NOUN	O	O
there	ADV	O	O
has	VERB	O	O
been	VERB	O	O
little	ADJ	O	O
documentation	NOUN	O	O
of	ADP	O	O
clinically	ADV	O	O
significant	ADJ	O	O
proteinuria	NOUN	O	I-Entity
linked	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
encountered	VERB	O	O
several	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
substantial	ADJ	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sirolimus	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
close	ADJ	O	O
temporal	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
commencement	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
implicated	VERB	O	O
sirolimus	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
most	ADV	O	O
likely	ADJ	O	O
etiology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
analyzed	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
laboratory	ADJ	O	O
information	NOUN	O	O
available	ADJ	O	O
for	ADP	O	O
all	DET	O	O
119	NUM	O	O
patients	NOUN	O	O
transplanted	VERB	O	O
at	ADP	O	O
the	DET	O	O
Washington	PROPN	O	O
Hospital	PROPN	O	O
Center	PROPN	O	O
between	ADP	O	O
1999	NUM	O	O
-	SYM	O	O
2003	NUM	O	O
for	ADP	O	O
whom	NOUN	O	O
sirolimus	NOUN	O	I-Entity
was	VERB	O	O
a	DET	O	O
component	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
immunosuppressant	ADJ	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
on	ADP	O	O
morning	NOUN	O	O
urine	NOUN	O	O
samples	NOUN	O	O
by	ADP	O	O
turbidometric	ADJ	O	O
measurement	NOUN	O	O
or	CCONJ	O	O
random	ADJ	O	O
urine	NOUN	O	O
protein	NOUN	O	O
:	PUNCT	O	O
creatinine	NOUN	O	I-Entity
ratios	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
estimate	NOUN	O	O
of	ADP	O	O
grams	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
/	SYM	O	O
day	NOUN	O	O
.	PUNCT	O	O

Laboratory	NOUN	O	O
results	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
between	ADP	O	O
prior	ADV	O	O
,	PUNCT	O	O
during	ADP	O	O
and	CCONJ	O	O
following	VERB	O	O
sirolimus	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
24%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
increased	VERB	O	O
proteinuria	NOUN	O	I-Entity
from	ADP	O	O
baseline	NOUN	O	O
during	ADP	O	O
their	ADJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
transplantation	NOUN	O	O
course	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
an	DET	O	O
alternative	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
was	VERB	O	O
either	CCONJ	O	O
obvious	ADJ	O	O
or	CCONJ	O	O
insufficient	ADJ	O	O
data	NOUN	O	O
was	VERB	O	O
available	ADJ	O	O
to	PART	O	O
be	VERB	O	O
conclusive	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
7	NUM	O	O
of	ADP	O	O
the	DET	O	O
28	NUM	O	O
patients	NOUN	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
striking	ADJ	O	O
temporal	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
nephrotic	ADJ	O	I-Entity
-	PUNCT	O	O
range	NOUN	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
correlated	VERB	O	O
most	ADV	O	O
strongly	ADV	O	O
with	ADP	O	O
sirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
other	ADJ	O	O
demographic	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
most	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
resolution	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Sirolimus	PROPN	O	I-Entity
induces	VERB	O	O
or	CCONJ	O	O
aggravates	VERB	O	O
pre	ADV	O	O
-	PUNCT	O	O
existing	VERB	O	O
proteinuria	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
unpredictable	ADJ	O	O
subset	NOUN	O	O
of	ADP	O	O
renal	NOUN	O	O
allograft	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
may	VERB	O	O
improve	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
resolve	VERB	O	O
,	PUNCT	O	O
when	ADV	O	O
sirolimus	NOUN	O	I-Entity
is	VERB	O	O
withdrawn	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19729346)

Comparative	ADJ	O	O
cognitive	ADJ	O	O
and	CCONJ	O	O
subjective	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
immediate	ADJ	O	O
-	PUNCT	O	O
release	NOUN	O	O
oxycodone	NOUN	O	I-Entity
in	ADP	O	O
healthy	ADJ	O	O
middle	NOUN	O	O
-	PUNCT	O	O
aged	ADJ	O	O
and	CCONJ	O	O
older	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
measured	VERB	O	O
the	DET	O	O
objective	NOUN	O	O
and	CCONJ	O	O
subjective	ADJ	O	O
neurocognitive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
10-mg	NUM	O	O
dose	NOUN	O	O
of	ADP	O	O
immediate	ADJ	O	O
-	PUNCT	O	O
release	NOUN	O	O
oxycodone	NOUN	O	I-Entity
in	ADP	O	O
healthy	ADJ	O	O
,	PUNCT	O	O
older	ADJ	O	O
(	PUNCT	O	O
>	SYM	O	O
65	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
middle	NOUN	O	O
-	PUNCT	O	O
aged	ADJ	O	O
(	PUNCT	O	O
35	NUM	O	O
to	ADP	O	O
55	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
adults	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
suffering	VERB	O	O
from	ADP	O	O
chronic	ADJ	O	O
or	CCONJ	O	O
significant	ADJ	O	O
daily	ADJ	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Seventy	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
participants	NOUN	O	O
completed	VERB	O	O
2	NUM	O	O
separate	ADJ	O	O
study	NOUN	O	O
days	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
blind	ADJ	O	O
to	ADP	O	O
medication	NOUN	O	O
condition	NOUN	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
10-mg	NUM	O	O
oxycodone	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
oxycodone	NOUN	O	I-Entity
concentration	NOUN	O	O
peaked	VERB	O	O
between	ADP	O	O
60	NUM	O	O
and	CCONJ	O	O
90	NUM	O	O
minutes	NOUN	O	O
postdose	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
pupil	NOUN	O	O
size	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
indication	NOUN	O	O
of	ADP	O	O
physiological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
,	PUNCT	O	O
peaked	VERB	O	O
at	ADP	O	O
approximately	ADV	O	O
90	NUM	O	O
to	PART	O	O
120	NUM	O	O
minutes	NOUN	O	O
postdose	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
declines	NOUN	O	B-Entity
in	ADP	O	I-Entity
simple	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
sustained	ADJ	O	I-Entity
attention	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
working	VERB	O	I-Entity
memory	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
verbal	ADJ	O	I-Entity
memory	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
postdose	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
for	ADP	O	O
both	DET	O	O
age	NOUN	O	O
groups	NOUN	O	O
with	ADP	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
return	NOUN	O	O
to	ADP	O	O
baseline	NOUN	O	O
by	ADP	O	O
5	NUM	O	O
hours	NOUN	O	O
postdose	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
for	ADP	O	O
healthy	ADJ	O	O
older	ADJ	O	O
adults	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
suffering	VERB	O	O
from	ADP	O	O
chronic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
neurocognitive	ADJ	O	O
and	CCONJ	O	O
pharmacodynamic	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
a	DET	O	O
10-mg	NUM	O	O
dose	NOUN	O	O
of	ADP	O	O
immediate	ADJ	O	O
-	PUNCT	O	O
release	NOUN	O	O
oxycodone	NOUN	O	I-Entity
are	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
observed	VERB	O	O
for	ADP	O	O
middle	NOUN	O	O
-	PUNCT	O	O
aged	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

Study	VERB	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
metabolism	NOUN	O	O
,	PUNCT	O	O
neurocognitive	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
oxycodone	NOUN	O	I-Entity
are	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
healthy	ADJ	O	O
middle	NOUN	O	O
-	PUNCT	O	O
aged	ADJ	O	O
and	CCONJ	O	O
older	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20080983)

Normalizing	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
modafinil	NOUN	O	I-Entity
on	ADP	O	O
sleep	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
morning	NOUN	O	O
-	PUNCT	O	O
dosed	VERB	O	O
modafinil	NOUN	O	I-Entity
on	ADP	O	O
sleep	NOUN	O	O
and	CCONJ	O	O
daytime	NOUN	O	B-Entity
sleepiness	NOUN	O	I-Entity
in	ADP	O	O
chronic	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
participants	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	VERB	O	O
modafinil	NOUN	O	I-Entity
,	PUNCT	O	O
400	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
N=10	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
N=10	PROPN	O	O
)	PUNCT	O	O
every	DET	O	O
morning	NOUN	O	O
at	ADP	O	O
7:30	NUM	O	O
a.m.	NOUN	O	O
for	ADP	O	O
16	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
an	DET	O	O
inpatient	NOUN	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
randomized	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Progressive	ADJ	O	O
abstinence	NOUN	O	O
from	ADP	O	O
cocaine	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
worsening	NOUN	O	O
of	ADP	O	O
all	DET	O	O
measured	VERB	O	O
polysomnographic	ADJ	O	O
sleep	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
modafinil	NOUN	O	I-Entity
decreased	VERB	O	O
nighttime	ADJ	O	O
sleep	NOUN	O	O
latency	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
slow	ADJ	O	O
-	PUNCT	O	O
wave	NOUN	O	O
sleep	NOUN	O	O
time	NOUN	O	O
in	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
participants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
modafinil	NOUN	O	I-Entity
interacted	VERB	O	O
with	ADP	O	O
the	DET	O	O
abstinence	NOUN	O	O
week	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
longer	ADJ	O	O
total	ADJ	O	O
sleep	NOUN	O	O
time	NOUN	O	O
and	CCONJ	O	O
shorter	ADJ	O	O
REM	PROPN	O	O
sleep	NOUN	O	O
latency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
third	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
abstinence	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
slow	ADJ	O	O
-	PUNCT	O	O
wave	NOUN	O	O
sleep	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
sleep	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sleep	VERB	O	O
latency	NOUN	O	O
in	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
and	CCONJ	O	O
healthy	ADJ	O	O
participants	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
normalizing	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
modafinil	NOUN	O	I-Entity
in	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
participants	NOUN	O	O
.	PUNCT	O	O

Modafinil	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
daytime	NOUN	O	O
sleep	NOUN	O	O
latency	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
Multiple	PROPN	O	O
Sleep	PROPN	O	O
Latency	PROPN	O	O
Test	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
nearly	ADV	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
subjective	ADJ	O	O
daytime	NOUN	O	B-Entity
sleepiness	NOUN	O	I-Entity
.	PUNCT	O	O

Morning	NOUN	O	O
-	PUNCT	O	O
dosed	VERB	O	O
modafinil	NOUN	O	I-Entity
promotes	VERB	O	O
nocturnal	ADJ	O	O
sleep	NOUN	O	O
,	PUNCT	O	O
normalizes	VERB	O	O
sleep	NOUN	O	O
architecture	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
decreases	VERB	O	O
daytime	NOUN	O	B-Entity
sleepiness	NOUN	O	I-Entity
in	ADP	O	O
abstinent	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
relevant	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
dependence	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20520283)

Efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
asenapine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
placebo-	NOUN	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
exacerbation	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

Asenapine	PROPN	O	I-Entity
is	VERB	O	O
approved	VERB	O	O
by	ADP	O	O
the	DET	O	O
Food	PROPN	O	O
and	CCONJ	O	O
Drugs	PROPN	O	O
Administration	PROPN	O	O
in	ADP	O	O
adults	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
or	CCONJ	O	O
of	ADP	O	O
manic	ADJ	O	I-Entity
or	CCONJ	O	O
mixed	ADJ	O	O
episodes	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
bipolar	NOUN	O	B-Entity
I	PRON	O	I-Entity
disorder	VERB	O	I-Entity
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
psychotic	ADJ	O	I-Entity
features	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
6-week	PROPN	O	O
trial	NOUN	O	O
,	PUNCT	O	O
458	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
schizophrenia	NOUN	O	I-Entity
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
fixed	VERB	O	O
-	PUNCT	O	O
dose	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
(	PUNCT	O	O
BID	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
at	ADP	O	O
4	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
(	PUNCT	O	O
to	PART	O	O
verify	VERB	O	O
assay	NOUN	O	O
sensitivity	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

With	ADP	O	O
last	ADJ	O	O
observations	NOUN	O	O
carried	VERB	O	O
forward	ADV	O	O
(	PUNCT	O	O
LOCF	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mean	VERB	O	O
Positive	ADJ	O	O
and	CCONJ	O	O
Negative	ADJ	O	O
Syndrome	PROPN	O	O
Scale	PROPN	O	O
total	ADJ	O	O
score	NOUN	O	O
reductions	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
endpoint	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
with	ADP	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
(	PUNCT	O	O
-16.2	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
-15.4	PROPN	O	O
)	PUNCT	O	O
than	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
-10.7	PROPN	O	O
;	PUNCT	O	O
both	DET	O	O
P	PROPN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
using	VERB	O	O
mixed	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
repeated	VERB	O	O
measures	NOUN	O	O
(	PUNCT	O	O
MMRM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
changes	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
42	NUM	O	O
were	VERB	O	O
significantly	ADV	O	O
greater	ADJ	O	O
with	ADP	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
(	PUNCT	O	O
-21.3	PUNCT	O	O
and	CCONJ	O	O
-19.4	PROPN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
-20.0	PROPN	O	O
)	PUNCT	O	O
than	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
-14.6	PROPN	O	O
;	PUNCT	O	O
all	DET	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
Positive	ADJ	O	O
and	CCONJ	O	O
Negative	ADJ	O	O
Syndrome	PROPN	O	O
Scale	PROPN	O	O
positive	ADJ	O	O
subscale	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
treatments	NOUN	O	O
were	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
with	ADP	O	O
LOCF	PROPN	O	O
and	CCONJ	O	O
MMRM	PROPN	O	O
;	PUNCT	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
placebo	NOUN	O	O
on	ADP	O	O
the	DET	O	O
negative	ADJ	O	O
subscale	NOUN	O	O
with	ADP	O	O
MMRM	PROPN	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
general	ADJ	O	O
psychopathology	NOUN	O	O
subscale	NOUN	O	O
with	ADP	O	O
LOCF	PROPN	O	O
and	CCONJ	O	O
MMRM	PROPN	O	O
.	PUNCT	O	O

Treatment	PROPN	O	O
-	PUNCT	O	O
related	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
(	PUNCT	O	O
AEs	PROPN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
44%	NUM	O	O
and	CCONJ	O	O
52%	NUM	O	O
,	PUNCT	O	O
57%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
41%	NUM	O	O
of	ADP	O	O
the	DET	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Extrapyramidal	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
reported	VERB	O	O
as	ADP	O	O
AEs	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
15%	NUM	O	O
and	CCONJ	O	O
18%	NUM	O	O
,	PUNCT	O	O
34%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10%	NUM	O	O
of	ADP	O	O
the	DET	O	O
asenapine	NOUN	O	I-Entity
at	ADP	O	O
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
BID	NOUN	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Post	PROPN	O	O
hoc	NOUN	O	O
analyses	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
efficacy	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
asenapine	NOUN	O	I-Entity
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
;	PUNCT	O	O
greater	ADJ	O	O
contrasts	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
AEs	PROPN	O	O
,	PUNCT	O	O
especially	ADV	O	O
extrapyramidal	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20588063)

Permeability	NOUN	O	O
,	PUNCT	O	O
ultrastructural	ADJ	O	O
changes	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
distribution	NOUN	O	O
of	ADP	O	O
novel	NOUN	O	O
proteins	NOUN	O	O
in	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
barrier	NOUN	O	O
in	ADP	O	O
early	ADJ	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	PROPN	O	O
/	SYM	O	O
AIMS	PROPN	O	O
:	PUNCT	O	O
It	PRON	O	O
is	VERB	O	O
still	ADV	O	O
unclear	ADJ	O	O
what	NOUN	O	O
happens	VERB	O	O
in	ADP	O	O
the	DET	O	O
glomerulus	NOUN	O	O
when	ADV	O	O
proteinuria	NOUN	O	I-Entity
starts	VERB	O	O
.	PUNCT	O	O

Using	VERB	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
nephrosis	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
early	ADJ	O	O
ultrastructural	ADJ	O	O
and	CCONJ	O	O
permeability	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
podocyte	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
molecules	NOUN	O	O
nephrin	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
-	PUNCT	O	O
actinin	NOUN	O	O
,	PUNCT	O	O
dendrin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
plekhh2	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
last	ADJ	O	O
two	NUM	O	O
of	ADP	O	O
which	ADJ	O	O
were	VERB	O	O
only	ADV	O	O
recently	ADV	O	O
discovered	VERB	O	O
in	ADP	O	O
podocytes	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
some	DET	O	O
patchy	ADJ	O	O
foot	NOUN	O	O
process	NOUN	O	O
effacement	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
appeared	VERB	O	O
.	PUNCT	O	O

By	ADP	O	O
day	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
foot	NOUN	O	O
process	NOUN	O	O
effacement	NOUN	O	O
was	VERB	O	O
complete	ADJ	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
appeared	VERB	O	O
in	ADP	O	O
parallel	ADJ	O	O
with	ADP	O	O
signs	NOUN	O	O
of	ADP	O	O
size	NOUN	O	O
barrier	NOUN	O	O
damage	NOUN	O	O
.	PUNCT	O	O

PAN	PROPN	O	O
glomeruli	NOUN	O	O
already	ADV	O	O
showed	VERB	O	O
significant	ADJ	O	O
pathology	NOUN	O	O
by	ADP	O	O
day	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
despite	ADP	O	O
relatively	ADV	O	O
mild	ADJ	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19820426)

Twin	PROPN	O	O
preterm	NOUN	O	O
neonates	VERB	O	O
with	ADP	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
lopinavir	VERB	O	B-Entity
/	SYM	O	I-Entity
ritonavir	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
twin	ADJ	O	O
neonates	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
born	VERB	O	O
prematurely	ADV	O	O
at	ADP	O	O
32	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
gestation	NOUN	O	O
to	ADP	O	O
a	DET	O	O
mother	NOUN	O	O
with	ADP	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
of	ADP	O	O
the	DET	O	O
twins	NOUN	O	O
developed	VERB	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
and	CCONJ	O	O
dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
lopinavir	VERB	O	B-Entity
/	SYM	O	I-Entity
ritonavir	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
boosted	VERB	O	O
protease	NOUN	O	O
-	PUNCT	O	O
inhibitor	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
other	ADJ	O	O
twin	NOUN	O	O
developed	VERB	O	O
mild	ADJ	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
recommend	VERB	O	O
caution	NOUN	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
lopinavir	NOUN	O	B-Entity
/	SYM	O	I-Entity
ritonavir	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
immediate	ADJ	O	O
neonatal	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1616457)

Learning	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
under	ADP	O	O
amnesia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
pentobarbital	NOUN	O	I-Entity
.	PUNCT	O	O

Dissociated	VERB	O	O
learning	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
state	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
state	NOUN	O	O
of	ADP	O	O
amnesia	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
pentobarbital	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
,	PUNCT	O	O
ip	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	PROPN	O	O
1	NUM	O	O
the	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
trained	VERB	O	O
under	ADP	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
pentobarbital	ADJ	O	I-Entity
to	PART	O	O
run	VERB	O	O
to	ADP	O	O
the	DET	O	O
same	ADJ	O	O
shelf	NOUN	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
state	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
memory	NOUN	O	B-Entity
dissociation	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
parameters	NOUN	O	O
of	ADP	O	O
training	NOUN	O	O
under	ADP	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
pentobarbital	NOUN	O	I-Entity
between	ADP	O	O
Groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
were	VERB	O	O
revealed	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
-	PUNCT	O	O
dissociated	VERB	O	O
state	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
pentobarbital	NOUN	O	I-Entity
is	VERB	O	O
formed	VERB	O	O
with	ADP	O	O
the	DET	O	O
participation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
information	NOUN	O	O
perception	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (567256)

Angiosarcoma	PROPN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
diethylstilbestrol	NOUN	O	I-Entity
.	PUNCT	O	O

Angiosarcoma	PROPN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
76-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
differentiated	VERB	O	O
adenocarcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
with	ADP	O	O
diethylstilbestrol	NOUN	O	I-Entity
for	ADP	O	O
13	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Angiosarcoma	PROPN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
present	ADJ	O	O
within	ADP	O	O
pulmonary	ADJ	O	O
and	CCONJ	O	O
renal	ADJ	O	O
arteries	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
the	DET	O	O
intraarterial	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
might	VERB	O	O
represent	VERB	O	O
independent	ADJ	O	O
primary	ADJ	O	O
tumors	NOUN	O	I-Entity
is	VERB	O	O
considered	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (17439425)

Role	NOUN	O	O
of	ADP	O	O
xanthine	NOUN	O	I-Entity
oxidase	NOUN	O	O
in	ADP	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O
1	NUM	O	O
.	PUNCT	O	O

Glucocorticoid	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
(	PUNCT	O	O
GC	PROPN	O	O
-	PUNCT	O	O
HT	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
-	PUNCT	O	O
redox	NOUN	O	O
imbalance	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
xanthine	NOUN	O	I-Entity
oxidase	NOUN	O	O
(	PUNCT	O	O
XO	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	O
species	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
(	PUNCT	O	O
dex	NOUN	O	I-Entity
-	PUNCT	O	O
HT	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
randomly	ADV	O	O
into	ADP	O	O
four	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
saline	NOUN	O	O
,	PUNCT	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
dex	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
allopurinol	NOUN	O	I-Entity
plus	CCONJ	O	O
saline	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
allopurinol	NOUN	O	I-Entity
plus	CCONJ	O	O
dex	NOUN	O	I-Entity
.	PUNCT	O	O

Thymus	PROPN	O	O
weight	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
marker	NOUN	O	O
of	ADP	O	O
glucocorticoid	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
serum	NOUN	O	O
urate	NOUN	O	I-Entity
to	PART	O	O
assess	VERB	O	O
XO	PROPN	O	O
inhibition	NOUN	O	O
.	PUNCT	O	O

Dex	PROPN	O	I-Entity
increased	VERB	O	B-Entity
SBP	PROPN	O	I-Entity
(	PUNCT	O	O
110	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

3	NUM	O	O
mmHg	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
decreased	VERB	O	B-Entity
thymus	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
P	NOUN	O	I-Entity
<	X	O	I-Entity
0.001	NUM	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
bodyweights	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
"	PUNCT	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Allopurinol	PROPN	O	I-Entity
decreased	VERB	O	O
serum	NOUN	O	O
urate	NOUN	O	I-Entity
from	ADP	O	O
76	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

/	SYM	O	O
L	NOUN	O	O
in	ADP	O	O
dex	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Allopurinol	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
dex	NOUN	O	I-Entity
-	PUNCT	O	O
HT	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
our	ADJ	O	O
previous	ADJ	O	O
findings	NOUN	O	O
that	ADJ	O	O
allopurinol	VERB	O	I-Entity
failed	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
adrenocorticotrophic	ADJ	O	O
hormone	NOUN	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
suggests	VERB	O	O
that	ADP	O	O
XO	PROPN	O	O
activity	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
major	ADJ	O	O
determinant	NOUN	O	O
of	ADP	O	O
GC	PROPN	O	O
-	PUNCT	O	O
HT	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9351491)

Extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
at	ADP	O	O
comparable	ADJ	O	O
D2	NOUN	O	O
receptor	NOUN	O	O
occupancy	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Risperidone	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
antipsychotic	ADJ	O	O
drug	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
affinity	NOUN	O	O
at	ADP	O	O
dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
and	CCONJ	O	O
serotonin	NOUN	O	B-Entity
5-HT2	NUM	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
proposed	VERB	O	O
that	ADP	O	O
risperidone	NOUN	O	I-Entity
's	PART	O	O
pharmacologic	NOUN	O	O
profile	NOUN	O	O
may	VERB	O	O
produce	VERB	O	O
improved	VERB	O	O
efficacy	NOUN	O	O
for	ADP	O	O
negative	ADJ	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
and	CCONJ	O	O
decreased	VERB	O	O
propensity	NOUN	O	O
for	ADP	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
;	PUNCT	O	O
features	NOUN	O	O
shared	VERB	O	O
by	ADP	O	O
so	ADV	O	O
-	PUNCT	O	O
called	VERB	O	O
'	PUNCT	O	O
atypical	ADJ	O	O
'	PUNCT	O	O
neuroleptics	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
if	ADP	O	O
routine	ADJ	O	O
risperidone	NOUN	O	I-Entity
treatment	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
unique	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
D2	PROPN	O	O
receptor	NOUN	O	O
occupancy	NOUN	O	O
and	CCONJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
used	VERB	O	O
[	PUNCT	O	O
123I]IBZM	NUM	O	O
SPECT	PROPN	O	O
to	PART	O	O
determine	VERB	O	O
D2	PROPN	O	O
occupancy	NOUN	O	O
in	ADP	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
routine	ADJ	O	O
clinical	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
produced	VERB	O	O
D2	PROPN	O	O
occupancy	NOUN	O	O
levels	NOUN	O	O
between	ADP	O	O
approximately	ADV	O	O
60	NUM	O	O
and	CCONJ	O	O
90%	NUM	O	O
at	ADP	O	O
standard	ADJ	O	O
clinical	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
occupancy	NOUN	O	O
levels	NOUN	O	O
obtained	VERB	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
or	CCONJ	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

Drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
parkinsonism	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
(	PUNCT	O	O
42%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
29%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
occupancy	NOUN	O	O
levels	NOUN	O	O
above	ADV	O	O
60%	NUM	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
observations	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
5-HT2	NUM	O	O
blockade	NOUN	O	O
obtained	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
at	ADP	O	O
D2	PROPN	O	O
occupancy	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
60%	NUM	O	O
and	CCONJ	O	O
above	ADP	O	O
does	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
protect	VERB	O	O
against	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18752389)

Simvastatin	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
ezetimibe	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatic	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
necessitating	VERB	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
reductase	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
statin	NOUN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
hepatotoxic	ADJ	O	I-Entity
events	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
widely	ADV	O	O
published	VERB	O	O
with	ADP	O	O
ezetimibe	NOUN	O	I-Entity
or	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
agent	NOUN	O	O
simvastatin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ezetimibe	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
70-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
Hispanic	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
fulminant	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
necessitating	VERB	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
10	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
conversion	NOUN	O	O
from	ADP	O	O
simvastatin	ADV	O	I-Entity
40	NUM	O	O
mg	NUM	O	O
/	DET	O	O
day	NOUN	O	O
to	ADP	O	O
simvastatin	VERB	O	B-Entity
10	NUM	O	I-Entity
mg	NUM	O	I-Entity
-	PUNCT	O	I-Entity
ezetimibe	NOUN	O	I-Entity
40	NUM	O	I-Entity
mg	NUM	O	I-Entity
/	SYM	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
lipid	ADJ	O	O
panel	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
maintained	VERB	O	O
with	ADP	O	O
simvastatin	NOUN	O	I-Entity
for	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
before	ADP	O	O
the	DET	O	O
conversion	NOUN	O	O
without	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Simvastatinezetimibe	PROPN	O	I-Entity
and	CCONJ	O	O
escitalopram	NOUN	O	I-Entity
(	PUNCT	O	O
which	ADJ	O	O
she	PRON	O	O
was	VERB	O	O
taking	VERB	O	O
for	ADP	O	O
depression	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
potential	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
repeat	NOUN	O	O
work	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
revealed	VERB	O	O
further	ADJ	O	O
elevations	NOUN	O	O
in	ADP	O	O
aminotransferase	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
liver	NOUN	O	O
biopsy	NOUN	O	O
revealed	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
moderate	ADJ	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
severe	ADJ	O	O
drug	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Ezetimibe	PROPN	O	I-Entity
undergoes	VERB	O	O
extensive	ADJ	O	O
glucuronidation	NOUN	O	O
by	ADP	O	O
uridine	ADJ	O	B-Entity
diphosphate	NOUN	O	I-Entity
glucoronosyltransferases	NOUN	O	O
(	PUNCT	O	O
UGT	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
intestine	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
have	VERB	O	O
inhibited	VERB	O	O
the	DET	O	O
glucuronidation	NOUN	O	O
of	ADP	O	O
simvastatin	NOUN	O	B-Entity
hydroxy	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
increased	VERB	O	O
simvastatin	NOUN	O	I-Entity
exposure	NOUN	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
hepatotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
simvastatin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ezetimibe	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
that	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
postulate	VERB	O	O
that	ADP	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
the	DET	O	O
simvastatinezetimibe	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
is	VERB	O	O
the	DET	O	O
increased	VERB	O	O
simvastatin	NOUN	O	I-Entity
exposure	NOUN	O	O
by	ADP	O	O
ezetimibe	NOUN	O	I-Entity
inhibition	NOUN	O	O
of	ADP	O	O
UGT	PROPN	O	O
enzymes	NOUN	O	O
.	PUNCT	O	O

Clinicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
potential	ADJ	O	O
hepatotoxicity	NOUN	O	I-Entity
with	ADP	O	O
simvastatin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ezetimibe	NOUN	O	I-Entity
especially	ADV	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
should	VERB	O	O
carefully	ADV	O	O
monitor	VERB	O	O
serum	NOUN	O	O
aminotransferase	NOUN	O	O
levels	NOUN	O	O
when	ADV	O	O
starting	VERB	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
titrating	VERB	O	O
the	DET	O	O
dosage	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20098969)

Oral	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
meth	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
"	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
documentation	NOUN	O	O
of	ADP	O	O
this	DET	O	O
clinical	ADJ	O	O
case	NOUN	O	O
is	VERB	O	O
to	PART	O	O
make	VERB	O	O
clinicians	NOUN	O	O
aware	ADJ	O	O
of	ADP	O	O
"	PUNCT	O	O
meth	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
"	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
medical	ADJ	O	O
risks	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
this	DET	O	O
serious	ADJ	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Methamphetamine	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
very	ADV	O	O
addictive	ADJ	O	O
,	PUNCT	O	O
powerful	ADJ	O	O
stimulant	NOUN	O	O
that	ADJ	O	O
increases	VERB	O	O
wakefulness	NOUN	O	O
and	CCONJ	O	O
physical	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
can	VERB	O	O
produce	VERB	O	O
other	ADJ	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
cardiac	ADJ	O	B-Entity
dysrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
hallucinations	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
violent	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
.	PUNCT	O	O

Dental	ADJ	O	O
patients	NOUN	O	O
abusing	VERB	O	O
methamphetamine	NOUN	O	I-Entity
can	VERB	O	O
present	VERB	O	O
with	ADP	O	O
poor	ADJ	O	O
oral	ADJ	O	O
hygiene	NOUN	O	O
,	PUNCT	O	O
xerostomia	NOUN	O	I-Entity
,	PUNCT	O	O
rampant	ADJ	O	O
caries	NOUN	O	I-Entity
(	PUNCT	O	O
"	PUNCT	O	O
meth	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
"	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
excessive	ADJ	O	O
tooth	NOUN	O	B-Entity
wear	NOUN	O	I-Entity
.	PUNCT	O	O

Oral	ADJ	O	O
rehabilitation	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
using	VERB	O	O
methamphetamine	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
challenging	VERB	O	O
.	PUNCT	O	O

CASE	NOUN	O	O
DESCRIPTION	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
30-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Caucasian	ADJ	O	O
woman	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
dental	ADJ	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
bad	ADJ	O	B-Entity
breath	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
reported	VERB	O	O
poor	ADJ	O	O
esthetics	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comprehensive	ADJ	O	O
examination	NOUN	O	O
including	VERB	O	O
her	ADJ	O	O
medical	ADJ	O	O
history	NOUN	O	O
,	PUNCT	O	O
panoramic	ADJ	O	O
radiograph	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intraoral	ADJ	O	O
examination	NOUN	O	O
revealed	VERB	O	O
19	NUM	O	O
carious	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
not	ADV	O	O
very	ADV	O	O
common	ADJ	O	O
for	ADP	O	O
a	DET	O	O
healthy	ADJ	O	O
adult	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
reported	VERB	O	O
her	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
for	ADP	O	O
five	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
not	ADV	O	O
experienced	VERB	O	O
any	DET	O	O
major	ADJ	O	O
carious	ADJ	O	B-Entity
episodes	NOUN	O	I-Entity
before	ADP	O	O
she	PRON	O	O
started	VERB	O	O
using	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
medical	ADJ	O	O
and	CCONJ	O	O
dental	ADJ	O	O
histories	NOUN	O	O
along	ADP	O	O
with	ADP	O	O
radiographic	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
findings	NOUN	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
meth	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
clinical	ADJ	O	O
case	NOUN	O	O
showing	VERB	O	O
oral	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
meth	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
was	VERB	O	O
presented	VERB	O	O
to	PART	O	O
help	VERB	O	O
dental	ADJ	O	O
practitioners	NOUN	O	O
recognize	VERB	O	O
and	CCONJ	O	O
manage	VERB	O	O
patients	NOUN	O	O
who	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
abusing	VERB	O	O
methamphetamines	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9653867)

Thyroxine	PROPN	O	I-Entity
abuse	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
unusual	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
thyrotoxicosis	NOUN	O	I-Entity
in	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Eating	VERB	O	B-Entity
disorders	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
associated	VERB	O	O
behavioural	NOUN	O	O
problems	NOUN	O	O
and	CCONJ	O	O
drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
are	VERB	O	O
uncommon	ADJ	O	O
in	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
illustrates	VERB	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
problems	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
encountered	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
eating	VERB	O	B-Entity
disorders	NOUN	O	I-Entity
in	ADP	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
prolonged	ADJ	O	O
and	CCONJ	O	O
recurrent	ADJ	O	O
metabolic	NOUN	O	O
disturbances	NOUN	O	O
and	CCONJ	O	O
diuretic	NOUN	O	O
abuse	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	ADJ	O	O
it	PRON	O	O
illustrates	VERB	O	O
the	DET	O	O
derangements	NOUN	O	O
of	ADP	O	O
thyroid	NOUN	O	O
function	NOUN	O	O
seen	VERB	O	O
in	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
eating	VERB	O	B-Entity
disorders	NOUN	O	I-Entity
and	CCONJ	O	O
reminds	VERB	O	O
us	PRON	O	O
that	ADP	O	O
when	ADV	O	O
a	DET	O	O
cause	NOUN	O	O
for	ADP	O	O
thyrotoxicosis	NOUN	O	I-Entity
remains	VERB	O	O
obscure	ADJ	O	O
,	PUNCT	O	O
thyroxine	ADJ	O	I-Entity
abuse	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
and	CCONJ	O	O
explored	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (17608141)

Attenuation	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nigrostriatal	ADJ	O	O
dopaminergic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
by	ADP	O	O
lipopolysaccharide	NOUN	O	I-Entity
pretreatment	NOUN	O	O
.	PUNCT	O	O

Immunological	ADJ	O	O
activation	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
to	PART	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dopaminergic	ADJ	O	B-Entity
terminal	ADJ	O	I-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
examined	VERB	O	O
the	DET	O	O
roles	NOUN	O	O
of	ADP	O	O
lipopolysaccharide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
pro	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
and	CCONJ	O	O
inflammatory	ADJ	O	O
factor	NOUN	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
in	ADP	O	O
modulating	VERB	O	O
the	DET	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nigrostriatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Lipopolysaccharide	PROPN	O	I-Entity
pretreatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
basal	NOUN	O	O
body	NOUN	O	O
temperature	NOUN	O	O
or	CCONJ	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
elicited	VERB	O	O
hyperthermia	NOUN	O	I-Entity
three	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

Such	ADJ	O	O
systemic	ADJ	O	O
lipopolysaccharide	NOUN	O	I-Entity
treatment	NOUN	O	O
mitigated	VERB	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
striatal	NOUN	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
3,4-dihydroxyphenylacetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
depletions	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
the	DET	O	O
most	ADV	O	O
potent	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
lipopolysaccharide	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
two	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
day	NOUN	O	O
before	ADV	O	O
or	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
methamphetamine	NOUN	O	I-Entity
dosing	VERB	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
striatal	NOUN	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
3,4-dihydroxyphenylacetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
depletions	NOUN	O	O
remained	VERB	O	O
unaltered	ADJ	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
lipopolysaccharide	NOUN	O	I-Entity
pretreatment	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
attenuated	ADJ	O	O
local	ADJ	O	O
methamphetamine	NOUN	O	I-Entity
infusion	NOUN	O	O
-	PUNCT	O	O
produced	VERB	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
3,4-dihydroxyphenylacetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
depletions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
lipopolysaccharide	NOUN	O	I-Entity
is	VERB	O	O
less	ADV	O	O
likely	ADJ	O	O
due	ADJ	O	O
to	ADP	O	O
interrupted	VERB	O	O
peripheral	ADJ	O	O
distribution	NOUN	O	O
or	CCONJ	O	O
metabolism	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
concluded	VERB	O	O
a	DET	O	O
critical	ADJ	O	O
time	NOUN	O	O
window	NOUN	O	O
for	ADP	O	O
systemic	ADJ	O	O
lipopolysaccharide	NOUN	O	I-Entity
pretreatment	NOUN	O	O
in	ADP	O	O
exerting	VERB	O	O
effective	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nigrostriatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2559236)

Effect	NOUN	O	O
of	ADP	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibition	NOUN	O	O
on	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
CEI	PROPN	O	O
)	PUNCT	O	O
enalapril	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
Munich	PROPN	O	O
-	PUNCT	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
with	ADP	O	O
established	VERB	O	O
adriamycin	ADJ	O	I-Entity
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
adriamycin	ADJ	O	I-Entity
and	CCONJ	O	O
one	NUM	O	O
month	NOUN	O	O
later	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
matched	VERB	O	O
for	ADP	O	O
albuminuria	NOUN	O	I-Entity
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
albumin	NOUN	O	O
concentration	NOUN	O	O
.	PUNCT	O	O

Groups	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
remained	VERB	O	O
untreated	ADJ	O	O
while	ADP	O	O
groups	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
received	VERB	O	O
enalapril	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
studies	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
enalapril	NOUN	O	I-Entity
reduced	VERB	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
101	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

2	PUNCT	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
,	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
without	ADP	O	O
reducing	VERB	O	O
albuminuria	NOUN	O	I-Entity
(	PUNCT	O	O
617	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O
50	NUM	O	O
vs.	CCONJ	O	O
570	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O
47	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
GFR	PROPN	O	O
(	PUNCT	O	O
1.03	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Groups	NOUN	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
were	VERB	O	O
studied	VERB	O	O
at	ADP	O	O
four	NUM	O	O
and	CCONJ	O	O
at	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
enalapril	NOUN	O	I-Entity
on	ADP	O	O
progression	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
adriamycin	ADJ	O	I-Entity
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Chronic	ADJ	O	O
enalapril	NOUN	O	I-Entity
treatment	NOUN	O	O
reduced	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
without	ADP	O	O
reducing	VERB	O	O
albuminuria	NOUN	O	I-Entity
in	ADP	O	O
group	NOUN	O	O
4	NUM	O	O
.	PUNCT	O	O

Enalapril	PROPN	O	I-Entity
treatment	NOUN	O	O
blunted	VERB	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
reduction	NOUN	O	O
in	ADP	O	O
GFR	PROPN	O	O
in	ADP	O	O
group	NOUN	O	O
4	NUM	O	O
(	PUNCT	O	O
0.86	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Reduction	NOUN	O	O
in	ADP	O	O
GFR	PROPN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
treated	VERB	O	O
and	CCONJ	O	O
untreated	ADJ	O	O
rats.(ABSTRACT	ADJ	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (21029050)

Butyrylcholinesterase	PROPN	O	O
gene	NOUN	O	O
mutations	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prolonged	ADJ	O	O
apnea	NOUN	O	I-Entity
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
for	ADP	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

patients	NOUN	O	O
undergoing	VERB	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ECT	PROPN	O	O
)	PUNCT	O	O
often	ADV	O	O
receive	VERB	O	O
succinylcholine	NOUN	O	I-Entity
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anesthetic	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
genetic	ADJ	O	O
variants	NOUN	O	O
in	ADP	O	O
butyrylcholinesterase	NOUN	O	O
gene	NOUN	O	O
(	PUNCT	O	O
BCHE	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
suspected	VERB	O	O
prolonged	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
after	ADP	O	O
ECT	PROPN	O	O
.	PUNCT	O	O

We	PRON	O	O
determined	VERB	O	O
the	DET	O	O
BChE	PROPN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
BCHE	PROPN	O	O
genotype	NOUN	O	O
using	VERB	O	O
molecular	ADJ	O	O
genetic	ADJ	O	O
methods	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
apnea	NOUN	O	I-Entity
,	PUNCT	O	O
time	NOUN	O	O
to	PART	O	O
sufficient	ADJ	O	O
spontaneous	ADJ	O	O
ventilation	NOUN	O	O
and	CCONJ	O	O
whether	ADP	O	O
neuromuscular	ADJ	O	O
monitoring	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
apnea	NOUN	O	I-Entity
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
published	VERB	O	O
data	NOUN	O	O
on	ADP	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
apnea	NOUN	O	I-Entity
was	VERB	O	O
5	NUM	O	O
-	SYM	O	O
15	NUM	O	O
min	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
3	NUM	O	O
-	SYM	O	O
5.3	NUM	O	O
min	NOUN	O	O
from	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
eleven	NUM	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
prolonged	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
had	VERB	O	O
mutations	NOUN	O	O
in	ADP	O	O
BCHE	PROPN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
reason	NOUN	O	O
for	ADP	O	O
a	DET	O	O
prolonged	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
apnea	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10901305)

Ketamine	PROPN	O	I-Entity
sedation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
's	PART	O	O
fractures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
recently	ADV	O	O
has	VERB	O	O
been	VERB	O	O
a	DET	O	O
resurgence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
utilization	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
unique	ADJ	O	O
anesthetic	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
emergency	NOUN	O	O
-	PUNCT	O	O
department	NOUN	O	O
procedures	NOUN	O	O
requiring	VERB	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
for	ADP	O	O
sedation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
's	PART	O	O
fractures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
fourteen	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
average	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
5.3	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
twelve	NUM	O	O
months	NOUN	O	O
to	ADP	O	O
ten	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
ten	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
who	NOUN	O	O
underwent	VERB	O	O
closed	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
an	DET	O	O
isolated	ADJ	O	O
fracture	NOUN	O	I-Entity
or	CCONJ	O	O
dislocation	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
at	ADP	O	O
a	DET	O	O
level	NOUN	O	O
-	PUNCT	O	O
I	PRON	O	O
trauma	VERB	O	I-Entity
center	NOUN	O	O
were	VERB	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Ketamine	PROPN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
intravenously	ADV	O	O
(	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
milligrams	NOUN	O	O
per	ADP	O	O
kilogram	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
ninety	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
intramuscularly	ADV	O	O
(	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
milligrams	NOUN	O	O
per	ADP	O	O
kilogram	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
fifteen	NUM	O	O
.	PUNCT	O	O

Any	DET	O	O
pain	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
was	VERB	O	O
rated	VERB	O	O
by	ADP	O	O
the	DET	O	O
orthopaedic	NOUN	O	O
surgeon	NOUN	O	O
treating	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
Children	PROPN	O	O
's	PART	O	O
Hospital	PROPN	O	O
of	ADP	O	O
Eastern	PROPN	O	O
Ontario	PROPN	O	O
Pain	PROPN	O	I-Entity
Scale	PROPN	O	O
(	PUNCT	O	O
CHEOPS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
time	NOUN	O	O
from	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
to	ADP	O	O
manipulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fracture	NOUN	O	I-Entity
or	CCONJ	O	O
dislocation	NOUN	O	I-Entity
was	VERB	O	O
one	NUM	O	O
minute	NOUN	O	O
and	CCONJ	O	O
thirty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
seconds	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
twenty	NUM	O	O
seconds	NOUN	O	O
to	ADP	O	O
five	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
average	ADJ	O	O
time	NOUN	O	O
from	ADP	O	O
intramuscular	ADJ	O	O
administration	NOUN	O	O
to	ADP	O	O
manipulation	NOUN	O	O
was	VERB	O	O
four	NUM	O	O
minutes	NOUN	O	O
and	CCONJ	O	O
forty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
seconds	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
sixty	ADJ	O	O
seconds	NOUN	O	O
to	ADP	O	O
fifteen	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
score	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
Children	PROPN	O	O
's	PART	O	O
Hospital	PROPN	O	O
of	ADP	O	O
Eastern	PROPN	O	O
Ontario	PROPN	O	O
Pain	PROPN	O	I-Entity
Scale	PROPN	O	O
was	VERB	O	O
6.4	NUM	O	O
points	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
to	PART	O	O
10	NUM	O	O
points	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
reflecting	VERB	O	O
minimal	ADJ	O	O
or	CCONJ	O	O
no	DET	O	O
pain	NOUN	O	I-Entity
during	ADP	O	O
fracture	NOUN	O	I-Entity
reduction	NOUN	O	O
.	PUNCT	O	O

Adequate	ADJ	O	O
fracture	NOUN	O	I-Entity
reduction	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
111	NUM	O	O
of	ADP	O	O
the	DET	O	O
children	NOUN	O	O
.	PUNCT	O	O

Minor	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
included	VERB	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
thirteen	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
emesis	NOUN	O	I-Entity
(	PUNCT	O	O
eight	NUM	O	O
of	ADP	O	O
the	DET	O	O
thirteen	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
nausea	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
clumsiness	NOUN	O	I-Entity
(	PUNCT	O	O
evident	ADJ	O	O
as	ADP	O	O
ataxic	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
in	ADP	O	O
ten	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
dysphoric	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
(	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
sequelae	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
hallucinations	NOUN	O	I-Entity
or	CCONJ	O	O
nightmares	NOUN	O	O
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
reliably	ADV	O	O
,	PUNCT	O	O
safely	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
quickly	ADV	O	O
provided	VERB	O	O
adequate	ADJ	O	O
sedation	NOUN	O	O
to	PART	O	O
effectively	ADV	O	O
facilitate	VERB	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
's	PART	O	O
fractures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
at	ADP	O	O
our	ADJ	O	O
institution	NOUN	O	O
.	PUNCT	O	O

Ketamine	PRON	O	I-Entity
should	VERB	O	O
only	ADV	O	O
be	VERB	O	O
used	VERB	O	O
in	ADP	O	O
an	DET	O	O
environment	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
,	PUNCT	O	O
where	ADV	O	O
proper	ADJ	O	O
one	NUM	O	O
-	PUNCT	O	O
on	ADP	O	O
-	PUNCT	O	O
one	NOUN	O	O
monitoring	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
and	CCONJ	O	O
board	NOUN	O	O
-	PUNCT	O	O
certified	VERB	O	O
physicians	NOUN	O	O
skilled	VERB	O	O
in	ADP	O	O
airway	NOUN	O	O
management	NOUN	O	O
are	VERB	O	O
directly	ADV	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
care	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19037603)

Prophylactic	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
with	ADP	O	O
chronic	ADJ	O	O
immunosuppressive	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
rheumatologic	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
report	VERB	O	O
our	ADJ	O	O
experience	NOUN	O	O
concerning	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
in	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
(	PUNCT	O	O
HBs	PROPN	O	B-Entity
Ag	PROPN	O	I-Entity
)	PUNCT	O	O
positive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatologic	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
June	PROPN	O	O
2004	NUM	O	O
to	ADP	O	O
October	PROPN	O	O
2006	NUM	O	O
,	PUNCT	O	O
11	NUM	O	O
HBs	PROPN	O	B-Entity
Ag	PROPN	O	I-Entity
positive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatologic	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
were	VERB	O	O
on	ADP	O	O
both	DET	O	O
immunosuppressive	ADJ	O	O
and	CCONJ	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
therapies	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
retrospectively	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Liver	ADJ	O	O
function	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HBV	PROPN	O	O
)	PUNCT	O	O
serologic	ADJ	O	O
markers	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
HBV	PROPN	O	O
DNA	PROPN	O	O
levels	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
during	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
from	ADP	O	O
hospital	NOUN	O	O
file	NOUN	O	O
records	NOUN	O	O
.	PUNCT	O	O

Lamivudine	PROPN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
3	NUM	O	O
-	SYM	O	O
7	NUM	O	O
days	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
immunosuppressive	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Shortly	ADV	O	O
after	ADP	O	O
treatment	NOUN	O	O
their	ADJ	O	O
tests	NOUN	O	O
normalized	ADJ	O	O
and	CCONJ	O	O
during	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
abnormal	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
function	NOUN	O	I-Entity
tests	NOUN	O	O
.	PUNCT	O	O

Lamivudine	PROPN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
was	VERB	O	O
continued	VERB	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Prophylactic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
required	VERB	O	O
immunosuppressive	NOUN	O	O
therapy	NOUN	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
safe	ADJ	O	O
,	PUNCT	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
effective	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
HBV	PROPN	O	O
reactivation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20084309)

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
to	PART	O	O
analyze	VERB	O	O
aspects	NOUN	O	O
of	ADP	O	O
TEE	PROPN	O	O
safety	NOUN	O	O
associated	VERB	O	O
to	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
Midazolan	PROPN	O	I-Entity
(	PUNCT	O	O
MZ	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
Flumazenil	PROPN	O	I-Entity
(	PUNCT	O	O
FL	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
on	ADP	O	O
the	DET	O	O
event	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
prospective	ADJ	O	O
study	NOUN	O	O
with	ADP	O	O
137	NUM	O	O
patients	NOUN	O	O
that	ADJ	O	O
underwent	VERB	O	O
TEE	PROPN	O	O
with	ADP	O	O
MZ	PROPN	O	I-Entity
associated	VERB	O	O
to	ADP	O	O
moderate	ADJ	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
analyzed	VERB	O	O
the	DET	O	O
following	ADJ	O	O
events	NOUN	O	O
:	PUNCT	O	O
complications	NOUN	O	O
related	VERB	O	O
with	ADP	O	O
the	DET	O	O
topical	ADJ	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
MZ	PROPN	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

Uni-	PUNCT	O	O
and	CCONJ	O	O
multivariate	NOUN	O	O
analyses	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
test	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
:	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
,	PUNCT	O	O
myocardiopathy	ADJ	O	I-Entity
(	PUNCT	O	O
MP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
test	NOUN	O	O
,	PUNCT	O	O
mitral	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
(	PUNCT	O	O
MR	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
MZ	PROPN	O	I-Entity
dose	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
MZ	PROPN	O	I-Entity
and	CCONJ	O	O
FL	PROPN	O	I-Entity
were	VERB	O	O
4.3+/-1.9	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
0.28+/-0.2	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Mild	PROPN	O	O
hypoxia	NOUN	O	I-Entity
(	PUNCT	O	O
SO2<90%	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
event	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
3	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
2%	NUM	O	O
)	PUNCT	O	O
presented	VERB	O	O
transient	ADJ	O	O
hypoxia	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
upper	ADJ	O	O
airway	NOUN	O	B-Entity
obstruction	NOUN	O	I-Entity
by	ADP	O	O
probe	NOUN	O	O
introduction	NOUN	O	O
and	CCONJ	O	O
8	NUM	O	O
(	PUNCT	O	O
5.8%	NUM	O	O
)	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
hypoxia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
MZ	PROPN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Transient	PROPN	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
SAP<90mmHg	PROPN	O	O
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
(	PUNCT	O	O
0.7%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
multivariate	NOUN	O	O
analysis	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
severe	ADJ	O	O
MR	PROPN	O	I-Entity
,	PUNCT	O	O
MP	PROPN	O	I-Entity
(	PUNCT	O	O
EF<45%	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
MZ	PROPN	O	I-Entity
(	PUNCT	O	O
>	SYM	O	O
5	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
events	NOUN	O	O
(	PUNCT	O	O
p<0.001	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
EF	PROPN	O	O
was	VERB	O	O
40%	NUM	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
with	ADP	O	O
MP	PROPN	O	I-Entity
and	CCONJ	O	O
44%	NUM	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
MR	PROPN	O	I-Entity
and	CCONJ	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
a	DET	O	O
factor	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
clinical	ADJ	O	O
events	NOUN	O	O
in	ADP	O	O
the	DET	O	O
last	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8231633)

Effects	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
on	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
on	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
each	DET	O	O
of	ADP	O	O
the	DET	O	O
three	NUM	O	O
tested	VERB	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
(	PUNCT	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
verapamil	ADV	O	I-Entity
and	CCONJ	O	O
bepridil	NOUN	O	I-Entity
)	PUNCT	O	O
6	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
i.e.	X	O	O
2	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
an	DET	O	O
equal	ADJ	O	O
volume	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
15	NUM	O	O
minutes	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
all	ADJ	O	O
the	DET	O	O
animals	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
i.p	PROPN	O	O
.	PUNCT	O	O

dose	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
mortality	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
by	ADP	O	O
the	DET	O	O
three	NUM	O	O
different	ADJ	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
convulsant	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
modified	VERB	O	O
but	CCONJ	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
decreased	VERB	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
latency	NOUN	O	O
to	PART	O	O
obtain	VERB	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
;	PUNCT	O	O
this	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
pronounced	VERB	O	O
with	ADP	O	O
bepridil	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10091617)

Selegiline	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
postural	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
longitudinal	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
United	PROPN	O	O
Kingdom	PROPN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Research	PROPN	O	O
Group	PROPN	O	O
(	PUNCT	O	O
UKPDRG	PROPN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
found	VERB	O	O
an	DET	O	O
increased	VERB	O	O
mortality	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
randomized	ADJ	O	O
to	PART	O	O
receive	VERB	O	O
10	NUM	O	O
mg	NUM	O	O
selegiline	NOUN	O	I-Entity
per	ADP	O	O
day	NOUN	O	O
and	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
taking	VERB	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
that	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
selegiline	NOUN	O	I-Entity
and	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
selective	ADJ	O	O
systolic	NOUN	O	B-Entity
orthostatic	ADJ	O	I-Entity
hypotension	NOUN	O	I-Entity
which	ADJ	O	O
was	VERB	O	O
abolished	VERB	O	O
by	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
selegiline	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aims	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
confirm	VERB	O	O
our	ADJ	O	O
previous	ADJ	O	O
findings	NOUN	O	O
in	ADP	O	O
a	DET	O	O
separate	ADJ	O	O
cohort	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
consequences	NOUN	O	O
of	ADP	O	O
stopping	VERB	O	O
selegiline	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
expectation	NOUN	O	O
that	ADP	O	O
this	DET	O	O
might	VERB	O	O
shed	VERB	O	O
light	NOUN	O	O
on	ADP	O	O
the	DET	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
the	DET	O	O
drug	NOUN	O	O
causes	VERB	O	O
orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiovascular	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
standing	VERB	O	O
and	CCONJ	O	O
head	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
tilt	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
repeatedly	ADV	O	O
in	ADP	O	O
PD	PROPN	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
selegiline	NOUN	O	I-Entity
and	CCONJ	O	O
as	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
was	VERB	O	O
withdrawn	VERB	O	O
.	PUNCT	O	O

Head	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
tilt	NOUN	O	O
caused	VERB	O	O
systolic	NOUN	O	B-Entity
orthostatic	ADJ	O	I-Entity
hypotension	NOUN	O	I-Entity
which	ADJ	O	O
was	VERB	O	O
marked	VERB	O	O
in	ADP	O	O
six	NUM	O	O
of	ADP	O	O
20	NUM	O	O
PD	NOUN	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
selegiline	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
lost	VERB	O	O
consciousness	NOUN	O	O
with	ADP	O	O
unrecordable	ADJ	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
lesser	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
occurred	VERB	O	O
with	ADP	O	O
standing	NOUN	O	O
.	PUNCT	O	O

Orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
was	VERB	O	O
ameliorated	VERB	O	O
4	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
selegiline	NOUN	O	I-Entity
and	CCONJ	O	O
totally	ADV	O	O
abolished	VERB	O	O
7	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Stopping	VERB	O	O
selegiline	NOUN	O	I-Entity
also	ADV	O	O
significantly	ADV	O	O
reduced	VERB	O	B-Entity
the	DET	O	I-Entity
supine	NOUN	O	I-Entity
systolic	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
diastolic	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressures	NOUN	O	I-Entity
consistent	ADJ	O	O
with	ADP	O	O
a	DET	O	O
previously	ADV	O	O
undescribed	VERB	O	O
supine	ADJ	O	O
pressor	NOUN	O	O
action	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
confirms	VERB	O	O
our	ADJ	O	O
previous	ADJ	O	O
finding	NOUN	O	O
that	ADP	O	O
selegiline	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
selective	ADJ	O	O
orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possibilities	NOUN	O	O
that	ADJ	O	O
these	DET	O	O
cardiovascular	ADJ	O	O
findings	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
monoamine	NOUN	O	O
oxidase	NOUN	O	O
or	CCONJ	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
and	CCONJ	O	O
metamphetamine	NOUN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19269743)

Explicit	PROPN	O	O
episodic	ADJ	O	O
memory	NOUN	O	O
for	ADP	O	O
sensory	ADJ	O	O
-	PUNCT	O	O
discriminative	ADJ	O	O
components	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
pain	NOUN	O	I-Entity
:	PUNCT	O	O
immediate	ADJ	O	O
and	CCONJ	O	O
delayed	ADJ	O	O
ratings	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
memory	NOUN	O	O
is	VERB	O	O
thought	VERB	O	O
to	PART	O	O
affect	VERB	O	O
future	ADJ	O	O
pain	NOUN	O	I-Entity
sensitivity	NOUN	O	O
and	CCONJ	O	O
thus	ADV	O	O
contribute	VERB	O	O
to	ADP	O	O
clinical	ADJ	O	O
pain	NOUN	O	I-Entity
conditions	NOUN	O	O
.	PUNCT	O	O

Systematic	ADJ	O	O
investigations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
human	ADJ	O	O
capacity	NOUN	O	O
to	PART	O	O
remember	VERB	O	O
sensory	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
pain	NOUN	O	I-Entity
are	VERB	O	O
sparse	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
address	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
pain	NOUN	O	I-Entity
memory	NOUN	O	O
,	PUNCT	O	O
nine	NUM	O	O
healthy	ADJ	O	O
male	ADJ	O	O
volunteers	NOUN	O	O
received	VERB	O	O
intradermal	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
microg	NOUN	O	O
,	PUNCT	O	O
separated	VERB	O	O
by	ADP	O	O
15	NUM	O	O
min	NOUN	O	O
breaks	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
each	DET	O	O
given	VERB	O	O
three	NUM	O	O
times	NOUN	O	O
in	ADP	O	O
a	DET	O	O
balanced	ADJ	O	O
design	NOUN	O	O
across	ADP	O	O
three	NUM	O	O
sessions	NOUN	O	O
at	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
rating	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
a	DET	O	O
computerized	ADJ	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
100	NUM	O	O
)	PUNCT	O	O
digitized	NOUN	O	O
at	ADP	O	O
1/s	NUM	O	O
,	PUNCT	O	O
either	CCONJ	O	O
immediately	ADV	O	O
online	ADV	O	O
or	CCONJ	O	O
one	NUM	O	O
hour	NOUN	O	O
or	CCONJ	O	O
one	NUM	O	O
day	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
also	ADV	O	O
recalled	VERB	O	O
their	ADJ	O	O
pains	NOUN	O	I-Entity
one	NUM	O	O
week	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

Capsaicin	PROPN	O	I-Entity
injection	NOUN	O	O
reliably	ADV	O	O
induced	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
flare	NOUN	O	O
(	PUNCT	O	O
p<0.001	PROPN	O	O
)	PUNCT	O	O
without	ADP	O	O
any	DET	O	O
difference	NOUN	O	O
within	ADP	O	O
or	CCONJ	O	O
across	ADP	O	O
sessions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
strong	ADJ	O	O
burning	VERB	O	O
pain	NOUN	O	I-Entity
decayed	NOUN	O	O
exponentially	ADV	O	O
within	ADP	O	O
a	DET	O	O
few	ADJ	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
able	ADJ	O	O
to	PART	O	O
reliably	ADV	O	O
discriminate	VERB	O	O
pain	NOUN	O	I-Entity
magnitude	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
across	ADP	O	O
capsaicin	NOUN	O	I-Entity
doses	NOUN	O	O
(	PUNCT	O	O
both	CCONJ	O	O
p<0.001	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
regardless	ADV	O	O
of	ADP	O	O
whether	ADP	O	O
first	ADV	O	O
-	PUNCT	O	O
time	NOUN	O	O
ratings	NOUN	O	O
were	VERB	O	O
requested	VERB	O	O
immediately	ADV	O	O
,	PUNCT	O	O
after	ADP	O	O
one	NUM	O	O
hour	NOUN	O	O
or	CCONJ	O	O
after	ADP	O	O
one	NUM	O	O
day	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
recall	NOUN	O	O
after	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
was	VERB	O	O
similarly	ADV	O	O
precise	ADJ	O	O
(	PUNCT	O	O
magnitude	NOUN	O	O
:	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
reliable	ADJ	O	O
memory	NOUN	O	O
for	ADP	O	O
magnitude	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
experimentally	ADV	O	O
induced	VERB	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3070035)

Reversibility	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
after	ADP	O	O
prolonged	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
an	DET	O	O
unusual	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
renovascular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypertension	NOUN	O	I-Entity
with	ADP	O	O
an	DET	O	O
occluded	ADJ	O	O
renal	NOUN	O	O
artery	NOUN	O	O
to	ADP	O	O
a	DET	O	O
solitary	ADJ	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
sudden	ADJ	O	B-Entity
deterioration	NOUN	O	I-Entity
of	ADP	O	I-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
captopril	NOUN	O	I-Entity
.	PUNCT	O	O

His	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
remained	VERB	O	O
impaired	ADJ	O	O
but	CCONJ	O	O
stable	ADJ	O	O
during	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
'	PART	O	O
treatment	NOUN	O	O
with	ADP	O	O
captopril	NOUN	O	I-Entity
but	CCONJ	O	O
returned	VERB	O	O
to	ADP	O	O
pre	VERB	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
levels	NOUN	O	O
soon	ADV	O	O
after	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
indicates	VERB	O	O
reversibility	NOUN	O	O
in	ADP	O	O
captopril	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
even	ADV	O	O
after	ADP	O	O
its	ADJ	O	O
prolonged	ADJ	O	O
use	NOUN	O	O
and	CCONJ	O	O
suggests	VERB	O	O
that	ADP	O	O
no	DET	O	O
organic	ADJ	O	O
damage	NOUN	O	O
occurs	VERB	O	O
to	ADP	O	O
glomerular	ADJ	O	O
arterioles	NOUN	O	O
following	VERB	O	O
chronic	ADJ	O	O
ACE	PROPN	O	O
inhibition	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1147734)

Liver	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
presents	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
laboratory	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
light	NOUN	O	O
and	CCONJ	O	O
electron	NOUN	O	O
microscopic	ADJ	O	O
observations	NOUN	O	O
on	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
active	ADJ	O	I-Entity
(	PUNCT	O	I-Entity
aggressive	ADJ	O	I-Entity
)	PUNCT	O	I-Entity
hepatitis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
an	DET	O	O
addition	NOUN	O	O
to	ADP	O	O
the	DET	O	O
list	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
must	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
the	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12202650)

Capsaicin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
alters	VERB	O	O
the	DET	O	O
excitability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
human	ADJ	O	O
jaw	NOUN	O	O
-	PUNCT	O	O
stretch	NOUN	O	O
reflex	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
painful	ADJ	O	O
temporomandibular	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
fully	ADV	O	O
understood	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
evidence	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
muscle	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
modulates	VERB	O	O
motor	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
characteristic	ADJ	O	O
ways	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
tested	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
nociceptive	ADJ	O	B-Entity
muscle	NOUN	O	I-Entity
afferent	NOUN	O	O
fibers	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
linked	VERB	O	O
to	ADP	O	O
an	DET	O	O
increased	VERB	O	O
excitability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
human	ADJ	O	O
jaw	NOUN	O	O
-	PUNCT	O	O
stretch	NOUN	O	O
reflex	NOUN	O	O
and	CCONJ	O	O
whether	ADP	O	O
this	DET	O	O
process	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
sensitive	ADJ	O	O
to	ADP	O	O
length	NOUN	O	O
and	CCONJ	O	O
velocity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
stretch	NOUN	O	O
.	PUNCT	O	O

Capsaicin	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micro	NOUN	O	O
g	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
masseter	NOUN	O	O
muscle	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
11	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Short	ADJ	O	O
-	PUNCT	O	O
latency	NOUN	O	O
reflex	NOUN	O	O
responses	NOUN	O	O
were	VERB	O	O
evoked	VERB	O	O
in	ADP	O	O
the	DET	O	O
masseter	NOUN	O	O
and	CCONJ	O	O
temporalis	NOUN	O	O
muscles	NOUN	O	O
by	ADP	O	O
a	DET	O	O
stretch	NOUN	O	O
device	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
velocities	NOUN	O	O
and	CCONJ	O	O
displacements	NOUN	O	O
before	ADP	O	O
,	PUNCT	O	O
during	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
normalized	ADJ	O	O
reflex	NOUN	O	O
amplitude	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
during	ADP	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
at	ADP	O	O
faster	ADJ	O	O
stretches	NOUN	O	O
in	ADP	O	O
the	DET	O	O
painful	ADJ	O	B-Entity
muscle	NOUN	O	I-Entity
.	PUNCT	O	O

Increased	VERB	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fusimotor	NOUN	O	O
system	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
muscle	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
one	NUM	O	O
likely	ADJ	O	O
mechanism	NOUN	O	O
to	PART	O	O
explain	VERB	O	O
the	DET	O	O
findings	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18951540)

Repetitive	ADJ	O	O
transcranial	ADJ	O	O
magnetic	ADJ	O	O
stimulation	NOUN	O	O
for	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
single	ADV	O	O
-	PUNCT	O	O
blinded	VERB	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
real	ADJ	O	O
"	PUNCT	O	O
repetitive	ADJ	O	O
transcranial	ADJ	O	O
magnetic	ADJ	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
rTMS	PROPN	O	O
)	PUNCT	O	O
versus	ADP	O	O
"	PUNCT	O	O
sham	ADJ	O	O
"	PUNCT	O	O
rTMS	NOUN	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
peak	NOUN	O	O
dose	NOUN	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Ten	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
PD	PROPN	O	I-Entity
and	CCONJ	O	O
prominent	ADJ	O	O
dyskinesias	NOUN	O	I-Entity
had	VERB	O	O
rTMS	PROPN	O	O
(	PUNCT	O	O
1,800	NUM	O	O
pulses	NOUN	O	O
;	PUNCT	O	O
1	NUM	O	O
Hz	INTJ	O	O
rate	NOUN	O	O
)	PUNCT	O	O
delivered	VERB	O	O
over	ADP	O	O
the	DET	O	O
motor	NOUN	O	O
cortex	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
twice	ADV	O	O
,	PUNCT	O	O
once	ADV	O	O
real	ADJ	O	O
stimuli	NOUN	O	O
and	CCONJ	O	O
once	ADP	O	O
sham	ADJ	O	O
stimulation	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
;	PUNCT	O	O
evaluations	NOUN	O	O
were	VERB	O	O
done	VERB	O	O
at	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
day	NOUN	O	O
after	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
each	DET	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

Direct	ADJ	O	O
comparison	NOUN	O	O
between	ADP	O	O
sham	NOUN	O	O
and	CCONJ	O	O
real	ADJ	O	O
rTMS	NOUN	O	O
effects	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
clinician	NOUN	O	O
-	PUNCT	O	O
assessed	VERB	O	O
dyskinesia	NOUN	O	I-Entity
severity	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
showed	VERB	O	O
small	ADJ	O	O
but	CCONJ	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
dyskinesia	NOUN	O	I-Entity
severity	NOUN	O	O
following	VERB	O	O
real	ADJ	O	O
rTMS	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
major	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
on	ADP	O	O
dystonia	NOUN	O	I-Entity
subscore	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
patient	NOUN	O	O
diaries	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
both	DET	O	O
treatments	NOUN	O	O
caused	VERB	O	O
reduction	NOUN	O	O
in	ADP	O	O
subjective	ADJ	O	O
dyskinesia	NOUN	O	I-Entity
scores	NOUN	O	O
during	ADP	O	O
the	DET	O	O
days	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
sustained	VERB	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
for	ADP	O	O
the	DET	O	O
real	ADJ	O	O
rTMS	PROPN	O	O
only	ADV	O	O
.	PUNCT	O	O

Following	VERB	O	O
rTMS	PROPN	O	O
,	PUNCT	O	O
no	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
no	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
motor	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
PD	NOUN	O	I-Entity
symptoms	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
the	DET	O	O
existence	NOUN	O	O
of	ADP	O	O
residual	ADJ	O	O
beneficial	ADJ	O	O
clinical	ADJ	O	O
aftereffects	NOUN	O	O
of	ADP	O	O
consecutive	ADJ	O	O
daily	ADJ	O	O
applications	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
frequency	NOUN	O	O
rTMS	NOUN	O	O
on	ADP	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
PD	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19657887)

Disulfiram	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
syndrome	NOUN	O	O
after	ADP	O	O
hydrogen	NOUN	O	B-Entity
cyanamide	NOUN	O	I-Entity
professional	ADJ	O	O
skin	NOUN	O	O
exposure	NOUN	O	O
:	PUNCT	O	O
two	NUM	O	O
case	NOUN	O	O
reports	VERB	O	O
in	ADP	O	O
France	PROPN	O	O
.	PUNCT	O	O

Hydrogen	NOUN	O	B-Entity
cyanamide	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
plant	NOUN	O	O
growth	NOUN	O	O
regulator	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
agriculture	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
bud	NOUN	O	O
break	NOUN	O	O
in	ADP	O	O
fruit	NOUN	O	O
trees	NOUN	O	O
.	PUNCT	O	O

Contact	NOUN	O	O
with	ADP	O	O
the	DET	O	O
skin	NOUN	O	O
can	VERB	O	O
result	VERB	O	O
in	ADP	O	O
percutaneous	ADJ	O	O
absorption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
substance	NOUN	O	O
that	ADJ	O	O
inhibits	VERB	O	O
aldehyde	ADJ	O	I-Entity
dehydrogenase	NOUN	O	O
and	CCONJ	O	O
can	VERB	O	O
induce	VERB	O	O
acetaldehyde	NOUN	O	I-Entity
syndrome	NOUN	O	O
in	ADP	O	O
case	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
report	NOUN	O	O
is	VERB	O	O
to	PART	O	O
describe	VERB	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
a	DET	O	O
disulfiram	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
syndrome	NOUN	O	O
following	VERB	O	O
occupational	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
hydrogen	NOUN	O	B-Entity
cyanamide	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
involved	VERB	O	O
a	DET	O	O
59-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
Dormex	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
contains	VERB	O	O
hydrogen	NOUN	O	B-Entity
cyanamide	NOUN	O	I-Entity
,	PUNCT	O	O
without	ADP	O	O
protection	NOUN	O	O
after	ADP	O	O
consuming	VERB	O	O
a	DET	O	O
large	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
during	ADP	O	O
a	DET	O	O
meal	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
after	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
,	PUNCT	O	O
he	PRON	O	O
developed	VERB	O	O
malaise	NOUN	O	O
with	ADP	O	O
flushing	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
face	NOUN	O	I-Entity
,	PUNCT	O	O
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dyspnea	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
case	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
55-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
farmer	NOUN	O	O
following	VERB	O	O
cutaneous	ADJ	O	O
contact	NOUN	O	O
with	ADP	O	O
Dormex	PROPN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
developed	VERB	O	O
disulfiram	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
syndrome	NOUN	O	O
with	ADP	O	O
flushing	NOUN	O	I-Entity
,	PUNCT	O	O
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
arterial	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
after	ADP	O	O
consuming	VERB	O	O
three	NUM	O	O
glasses	NOUN	O	O
of	ADP	O	O
wine	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
cases	NOUN	O	O
confirm	VERB	O	O
the	DET	O	O
necessity	NOUN	O	O
of	ADP	O	O
avoiding	VERB	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
as	ADP	O	O
recommended	VERB	O	O
in	ADP	O	O
the	DET	O	O
instructions	NOUN	O	O
for	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
Dormex	PROPN	O	I-Entity
and	CCONJ	O	O
of	ADP	O	O
preventing	VERB	O	O
cutaneous	ADJ	O	O
contact	NOUN	O	O
during	ADP	O	O
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9660111)

Repeated	VERB	O	O
trimipramine	NOUN	O	I-Entity
induces	VERB	O	O
dopamine	NOUN	O	I-Entity
D2/D3	NOUN	O	O
and	CCONJ	O	O
alpha1-adrenergic	VERB	O	O
up	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
.	PUNCT	O	O

Trimipramine	PROPN	O	I-Entity
(	PUNCT	O	O
TRI	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
shows	VERB	O	O
a	DET	O	O
clinical	ADJ	O	O
antidepressant	NOUN	O	I-Entity
activity	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
chemically	ADV	O	O
related	VERB	O	O
to	ADP	O	O
imipramine	NOUN	O	I-Entity
but	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
inhibit	VERB	O	O
the	DET	O	O
reuptake	NOUN	O	O
of	ADP	O	O
noradrenaline	NOUN	O	I-Entity
and	CCONJ	O	O
5-hydroxytryptamine	NUM	O	I-Entity
,	PUNCT	O	O
nor	CCONJ	O	O
does	VERB	O	O
it	PRON	O	O
induce	VERB	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
antidepressant	NOUN	O	I-Entity
activity	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
find	VERB	O	O
out	PART	O	O
whether	ADP	O	O
TRI	PROPN	O	I-Entity
given	VERB	O	O
repeatedly	ADV	O	O
was	VERB	O	O
able	ADJ	O	O
to	PART	O	O
induce	VERB	O	O
adaptive	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dopaminergic	NOUN	O	O
and	CCONJ	O	O
alpha1-adrenergic	ADJ	O	O
systems	NOUN	O	O
,	PUNCT	O	O
demonstrated	VERB	O	O
by	ADP	O	O
us	PRON	O	O
previously	ADV	O	O
for	ADP	O	O
various	ADJ	O	O
antidepressants	NOUN	O	I-Entity
.	PUNCT	O	O

TRI	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
male	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
and	CCONJ	O	O
male	ADJ	O	O
Albino	PROPN	O	O
Swiss	ADJ	O	O
mice	NOUN	O	O
perorally	ADV	O	O
twice	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
experiment	NOUN	O	O
TRI	PROPN	O	I-Entity
(	PUNCT	O	O
given	VERB	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

does	VERB	O	O
not	ADV	O	O
antagonize	VERB	O	O
the	DET	O	O
reserpine	NOUN	O	I-Entity
hypothermia	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
and	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
potentiate	VERB	O	O
the	DET	O	O
5-hydroxytryptophan	PROPN	O	I-Entity
head	NOUN	O	O
twitches	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

TRI	PROPN	O	I-Entity
given	VERB	O	O
repeatedly	ADV	O	O
to	ADP	O	O
rats	NOUN	O	O
increases	VERB	O	O
the	DET	O	O
locomotor	NOUN	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
amphetamine	NOUN	O	I-Entity
,	PUNCT	O	O
quinpirole	NOUN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-7-hydroxy	PUNCT	O	O
-	PUNCT	O	O
dipropyloaminotetralin	NOUN	O	O
(	PUNCT	O	O

dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
and	CCONJ	O	O
D3	PROPN	O	O
effects	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
stereotypies	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
amphetamine	NOUN	O	I-Entity
or	CCONJ	O	O
apomorphine	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
potentiated	VERB	O	O
by	ADP	O	O
TRI	PROPN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
increases	VERB	O	O
the	DET	O	O
behaviour	NOUN	O	O
stimulation	NOUN	O	O
evoked	VERB	O	O
by	ADP	O	O
phenylephrine	NOUN	O	I-Entity
(	PUNCT	O	O
given	VERB	O	O
intraventricularly	ADV	O	O
)	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
evaluated	VERB	O	O
in	ADP	O	O
the	DET	O	O
open	ADJ	O	O
field	NOUN	O	O
test	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
aggressiveness	NOUN	O	I-Entity
evoked	VERB	O	O
by	ADP	O	O
clonidine	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
these	DET	O	O
effects	NOUN	O	O
being	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
an	DET	O	O
alpha1-adrenergic	ADJ	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
may	VERB	O	O
be	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
like	ADP	O	O
other	ADJ	O	O
tricyclic	NOUN	O	O
antidepressants	NOUN	O	I-Entity
studied	VERB	O	O
previously	ADV	O	O
,	PUNCT	O	O
TRI	PROPN	O	I-Entity
given	VERB	O	O
repeatedly	ADV	O	O
increases	VERB	O	O
the	DET	O	O
responsiveness	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
dopamine	NOUN	O	I-Entity
D2	NOUN	O	O
and	CCONJ	O	O
D3	PROPN	O	O
(	PUNCT	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
stereotypy	VERB	O	O
)	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
alpha1-adrenergic	ADJ	O	O
receptors	NOUN	O	O
to	ADP	O	O
their	ADJ	O	O
agonists	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
question	NOUN	O	O
arises	VERB	O	O
whether	ADP	O	O
the	DET	O	O
reuptake	NOUN	O	O
inhibition	NOUN	O	O
is	VERB	O	O
of	ADP	O	O
any	DET	O	O
importance	NOUN	O	O
to	ADP	O	O
the	DET	O	O
adaptive	ADJ	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
repeated	VERB	O	O
antidepressants	NOUN	O	I-Entity
,	PUNCT	O	O
suggested	VERB	O	O
to	PART	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
antidepressant	NOUN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11431197)

Ranitidine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
cadaveric	ADJ	O	O
renal	ADJ	O	O
allograft	NOUN	O	O
.	PUNCT	O	O

Ranitidine	PROPN	O	I-Entity
frequently	ADV	O	O
is	VERB	O	O
used	VERB	O	O
for	ADP	O	O
preventing	VERB	O	O
peptic	ADJ	O	O
ulceration	NOUN	O	O
after	ADP	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
drug	NOUN	O	O
occasionally	ADV	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
in	ADP	O	O
native	ADJ	O	O
kidneys	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
ranitidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
recipient	NOUN	O	O
of	ADP	O	O
a	DET	O	O
cadaveric	ADJ	O	O
renal	ADJ	O	O
allograft	NOUN	O	O
presenting	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
allograft	NOUN	O	O
dysfunction	NOUN	O	O
within	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7449470)

Late	ADV	O	O
,	PUNCT	O	O
late	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiac	PROPN	O	B-Entity
toxicity	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
complication	NOUN	O	O
which	ADJ	O	O
limits	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
as	ADP	O	O
a	DET	O	O
chemotherapeutic	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Cardiomyopathy	PROPN	O	I-Entity
is	VERB	O	O
frequent	ADJ	O	O
when	ADV	O	O
the	DET	O	O
total	ADJ	O	O
dose	NOUN	O	O
exceeds	VERB	O	O
600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
and	CCONJ	O	O
occurs	VERB	O	O
within	ADP	O	O
one	NUM	O	O
to	PART	O	O
six	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
who	NOUN	O	O
developed	VERB	O	O
progressive	ADJ	O	O
cardiomyopathy	ADJ	O	I-Entity
two	NUM	O	O
and	CCONJ	O	O
one	NUM	O	O
-	PUNCT	O	O
half	NOUN	O	O
years	NOUN	O	O
after	ADP	O	O
receiving	VERB	O	O
580	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
which	ADJ	O	O
apparently	ADV	O	O
represents	VERB	O	O
late	ADJ	O	O
,	PUNCT	O	O
late	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8170551)

Acetazolamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrolithiasis	NOUN	O	I-Entity
:	PUNCT	O	O
implications	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
neuromuscular	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Carbonic	ADJ	O	O
anhydrase	NOUN	O	O
inhibitors	NOUN	O	O
can	VERB	O	O
cause	VERB	O	O
nephrolithiasis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
20	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
carbonic	ADJ	O	O
anhydrase	NOUN	O	O
inhibitor	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
periodic	ADJ	O	O
paralysis	NOUN	O	I-Entity
and	CCONJ	O	O
myotonia	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
on	ADP	O	O
acetazolamide	NOUN	O	I-Entity
(	PUNCT	O	O
15%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
calculi	NOUN	O	I-Entity
.	PUNCT	O	O

Extracorporeal	ADJ	O	O
lithotripsy	NOUN	O	O
successfully	ADV	O	O
removed	VERB	O	O
a	DET	O	O
renal	ADJ	O	B-Entity
calculus	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
and	CCONJ	O	O
surgery	NOUN	O	O
removed	VERB	O	O
a	DET	O	O
staghorn	ADJ	O	O
calculus	NOUN	O	I-Entity
in	ADP	O	O
another	DET	O	O
,	PUNCT	O	O
permitting	VERB	O	O
continued	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Nephrolithiasis	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
acetazolamide	NOUN	O	I-Entity
but	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
preclude	VERB	O	O
its	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2476560)

Is	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
scabies	NOUN	O	I-Entity
hazardous	ADJ	O	O
?	PUNCT	O	O

Treatment	PROPN	O	O
for	ADP	O	O
scabies	NOUN	O	I-Entity
is	VERB	O	O
usually	ADV	O	O
initiated	VERB	O	O
by	ADP	O	O
general	ADJ	O	O
practitioners	NOUN	O	O
;	PUNCT	O	O
most	ADJ	O	O
consider	VERB	O	O
lindane	NOUN	O	I-Entity
(	PUNCT	O	O
gamma	ADJ	O	B-Entity
benzene	NOUN	O	I-Entity
hexachloride	NOUN	O	I-Entity
)	PUNCT	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
.	PUNCT	O	O

Lindane	PROPN	O	I-Entity
is	VERB	O	O
also	ADV	O	O
widely	ADV	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
agricultural	ADJ	O	O
and	CCONJ	O	O
industrial	ADJ	O	O
pesticide	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
the	DET	O	O
toxic	ADJ	O	O
profile	NOUN	O	O
of	ADP	O	O
this	DET	O	O
insecticide	NOUN	O	O
is	VERB	O	O
well	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

Evidence	NOUN	O	O
is	VERB	O	O
accumulating	VERB	O	O
that	DET	O	O
lindane	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
toxic	ADJ	O	B-Entity
to	ADP	O	I-Entity
the	DET	O	I-Entity
central	ADJ	O	I-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
aplastic	ADJ	O	B-Entity
anaemia	NOUN	O	I-Entity
.	PUNCT	O	O

Preparations	NOUN	O	O
containing	VERB	O	O
lindane	NOUN	O	I-Entity
continue	VERB	O	O
to	PART	O	O
be	VERB	O	O
sold	VERB	O	O
over	ADP	O	O
the	DET	O	O
counter	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
represent	VERB	O	O
a	DET	O	O
hazard	NOUN	O	O
to	PART	O	O
poorly	ADV	O	O
informed	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
literature	NOUN	O	O
review	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
general	ADJ	O	O
practitioners	NOUN	O	O
should	VERB	O	O
prescribe	VERB	O	O
scabicides	NOUN	O	O
with	ADP	O	O
increased	VERB	O	O
caution	NOUN	O	O
for	ADP	O	O
certain	ADJ	O	O
at	ADP	O	O
-	PUNCT	O	O
risk	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
give	VERB	O	O
adequate	ADJ	O	O
warnings	NOUN	O	O
regarding	VERB	O	O
potential	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19803309)

Anaesthetists	NOUN	O	O
'	PART	O	O
nightmare	NOUN	O	O
:	PUNCT	O	O
masseter	NOUN	O	B-Entity
spasm	NOUN	O	I-Entity
after	ADP	O	O
induction	NOUN	O	O
in	ADP	O	O
an	DET	O	O
undiagnosed	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
myotonia	NOUN	O	B-Entity
congenita	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
an	DET	O	O
undiagnosed	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
myotonia	NOUN	O	B-Entity
congenita	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
24-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
previously	ADV	O	O
healthy	ADJ	O	O
primigravida	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
life	NOUN	O	O
threatening	VERB	O	O
masseter	NOUN	O	B-Entity
spasm	NOUN	O	I-Entity
following	VERB	O	O
a	DET	O	O
standard	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
suxamethonium	NOUN	O	I-Entity
for	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18821488)

Toxicity	NOUN	O	I-Entity
in	ADP	O	O
rhesus	ADJ	O	O
monkeys	NOUN	O	O
following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
8-aminoquinoline	NUM	O	I-Entity

8-[(4-amino	NUM	O	B-Entity
-	PUNCT	O	I-Entity
l	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylbutyl)amino]-	NOUN	O	I-Entity
5-(l	NUM	O	I-Entity
-	PUNCT	O	I-Entity
hexyloxy)-6-methoxy-4-methylquinoline	NOUN	O	I-Entity
(	PUNCT	O	O
WR242511	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
:	PUNCT	O	O
Many	ADJ	O	O
substances	NOUN	O	O
that	ADJ	O	O
form	VERB	O	O
methemoglobin	NOUN	O	O
(	PUNCT	O	O
MHb	PROPN	O	O
)	PUNCT	O	O
effectively	ADV	O	O
counter	VERB	O	O
cyanide	NOUN	O	O
(	PUNCT	O	O
CN	PROPN	O	O
)	PUNCT	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
MHb	PROPN	O	O
formers	NOUN	O	O
are	VERB	O	O
generally	ADV	O	O
applied	VERB	O	O
as	ADP	O	O
treatments	NOUN	O	O
for	ADP	O	O
CN	NOUN	O	O
poisoning	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
has	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
that	ADP	O	O
a	DET	O	O
stable	ADJ	O	O
,	PUNCT	O	O
long	ADV	O	O
-	PUNCT	O	O
acting	VERB	O	O
MHb	PROPN	O	O
former	ADJ	O	O
could	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
a	DET	O	O
CN	NOUN	O	O
pretreatment	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
this	DET	O	O
rationale	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
8-aminoquinoline	NUM	O	I-Entity
WR242511	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
potent	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
lasting	VERB	O	O
MHb	NOUN	O	O
former	ADJ	O	O
in	ADP	O	O
rodents	NOUN	O	O
and	CCONJ	O	O
beagle	ADJ	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
the	DET	O	O
rhesus	ADJ	O	O
monkey	NOUN	O	O
for	ADP	O	O
advanced	ADJ	O	O
development	NOUN	O	O
as	ADP	O	O
a	DET	O	O
potential	ADJ	O	O
CN	NOUN	O	O
pretreatment	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
WR242511	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
intravenously	ADV	O	O
(	PUNCT	O	O
IV	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
2	NUM	O	O
female	ADJ	O	O
and	CCONJ	O	O
4	NUM	O	O
male	ADJ	O	O
rhesus	ADJ	O	O
monkeys	NOUN	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
3.5	NUM	O	O
and/or	CCONJ	O	O
7.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
single	ADJ	O	O
male	NOUN	O	O
also	ADV	O	O
received	VERB	O	O
WR242511	PROPN	O	I-Entity
orally	ADV	O	O
(	PUNCT	O	O
PO	PROPN	O	O
)	PUNCT	O	O
at	ADP	O	O
7.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
selected	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
WR242511	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
produced	VERB	O	O
significant	ADJ	O	O
methemoglobinemia	NOUN	O	I-Entity
in	ADP	O	O
beagle	NOUN	O	O
dogs	NOUN	O	O
in	ADP	O	O
earlier	ADJ	O	O
studies	NOUN	O	O
conducted	VERB	O	O
elsewhere	ADV	O	O
,	PUNCT	O	O
produced	VERB	O	O
very	ADV	O	O
little	ADJ	O	O
MHb	PROPN	O	O
(	PUNCT	O	O
mean	VERB	O	O
<	PROPN	O	O
2.0%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
rhesus	ADJ	O	O
monkey	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
transient	ADJ	O	O
hemoglobinuria	NOUN	O	I-Entity
was	VERB	O	O
noted	VERB	O	O
approximately	ADV	O	O
60	NUM	O	O
minutes	NOUN	O	O
postinjection	NOUN	O	O
of	ADP	O	O
WR242511	PROPN	O	I-Entity
(	PUNCT	O	O
3.5	NUM	O	O
or	CCONJ	O	O
7.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
lethalities	NOUN	O	O
occurred	VERB	O	O
(	PUNCT	O	O
one	NUM	O	O
IV	PROPN	O	O
and	CCONJ	O	O
one	NUM	O	O
PO	NOUN	O	O
)	PUNCT	O	O
following	VERB	O	O
the	DET	O	O
7.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Myoglobinuria	PROPN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
following	VERB	O	O
the	DET	O	O
7.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Histopathology	NOUN	O	O
analyses	NOUN	O	O
in	ADP	O	O
the	DET	O	O
2	NUM	O	O
animals	NOUN	O	O
that	ADJ	O	O
died	VERB	O	O
revealed	VERB	O	O
liver	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
kidney	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
greater	ADJ	O	O
severity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
orally	ADV	O	O
-	PUNCT	O	O
treated	VERB	O	O
animal	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
demonstrate	VERB	O	O
direct	ADJ	O	O
and/or	CCONJ	O	O
indirect	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
WR242511	PRON	O	I-Entity
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
pursued	VERB	O	O
as	ADP	O	O
a	DET	O	O
pretreatment	NOUN	O	O
for	ADP	O	O
CN	NOUN	O	O
poisoning	NOUN	O	I-Entity
unless	ADP	O	O
the	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
CN	NOUN	O	O
characteristics	NOUN	O	O
of	ADP	O	O
this	DET	O	O
compound	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
successfully	ADV	O	O
dissociated	VERB	O	O
from	ADP	O	O
those	DET	O	O
producing	VERB	O	O
undesirable	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8372922)

Neuroplasticity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
primate	NOUN	O	O
auditory	ADJ	O	O
cortex	NOUN	O	O
following	VERB	O	O
cochlear	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
changes	NOUN	O	O
occur	VERB	O	O
in	ADP	O	O
this	DET	O	O
tonotopic	NOUN	O	O
organization	NOUN	O	O
following	VERB	O	O
cochlear	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
recovery	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
monkeys	NOUN	O	O
were	VERB	O	O
selectively	ADV	O	O
deafened	VERB	O	O
for	ADP	O	O
high	ADJ	O	O
frequencies	NOUN	O	O
using	VERB	O	O
kanamycin	NOUN	O	I-Entity
and	CCONJ	O	O
furosemide	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
region	NOUN	O	O
of	ADP	O	O
cortex	NOUN	O	O
that	ADJ	O	O
represents	VERB	O	O
the	DET	O	O
low	ADJ	O	O
frequencies	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
obviously	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
the	DET	O	O
cochlear	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9195768)

The	DET	O	O
site	NOUN	O	O
of	ADP	O	O
common	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
sumatriptan	NOUN	O	I-Entity
.	PUNCT	O	O

Atypical	ADJ	O	B-Entity
sensations	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
subcutaneous	ADJ	O	O
sumatriptan	NOUN	O	I-Entity
are	VERB	O	O
common	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
of	ADP	O	O
uncertain	ADJ	O	O
origin	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
with	ADP	O	O
tingling	VERB	O	B-Entity
or	CCONJ	O	I-Entity
burning	VERB	O	I-Entity
sensations	NOUN	O	I-Entity
limited	VERB	O	O
to	ADP	O	O
areas	NOUN	O	O
of	ADP	O	O
heat	NOUN	O	O
exposure	NOUN	O	O
or	CCONJ	O	O
sunburn	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15338796)

Tremor	NOUN	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
salbutamol	NOUN	O	I-Entity
,	PUNCT	O	O
quantified	VERB	O	O
by	ADP	O	O
a	DET	O	O
laser	NOUN	O	O
pointer	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
tremor	NOUN	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
salbutamol	NOUN	O	I-Entity
an	DET	O	O
easily	ADV	O	O
applicable	ADJ	O	O
,	PUNCT	O	O
quick	ADJ	O	O
and	CCONJ	O	O
low	ADV	O	O
-	PUNCT	O	O
priced	VERB	O	O
method	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Tremor	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
a	DET	O	O
laser	NOUN	O	O
pointer	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
sensitivity	NOUN	O	O
we	PRON	O	O
assessed	VERB	O	O
tremor	NOUN	O	I-Entity
in	ADP	O	O
44	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
obstructive	ADJ	O	B-Entity
lung	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
cumulative	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
salbutamol	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
another	DET	O	O
series	NOUN	O	O
of	ADP	O	O
measurements	NOUN	O	O
,	PUNCT	O	O
reproducibility	NOUN	O	O
and	CCONJ	O	O
reference	NOUN	O	O
values	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tremor	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
65	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
sessions	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
9	NUM	O	O
a.m.	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
p.m.	NOUN	O	O
and	CCONJ	O	O
9	NUM	O	O
a.m.	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
1	NUM	O	O
week	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

Postural	PROPN	O	O
tremor	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
the	DET	O	O
arm	NOUN	O	O
horizontally	ADV	O	O
outstretched	ADJ	O	O
rest	NOUN	O	O
tremor	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
arm	NOUN	O	O
supported	VERB	O	O
by	ADP	O	O
an	DET	O	O
armrest	NOUN	O	O
and	CCONJ	O	O
finally	ADV	O	O
tremor	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
after	ADP	O	O
holding	VERB	O	O
a	DET	O	O
2-kg	NUM	O	O
weight	NOUN	O	O
until	ADP	O	O
exhaustion	NOUN	O	O
.	PUNCT	O	O

Tremor	NOUN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
simultaneously	ADV	O	O
by	ADP	O	O
two	NUM	O	O
independent	ADJ	O	O
observers	NOUN	O	O
.	PUNCT	O	O

Salbutamol	NOUN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
tremor	NOUN	O	I-Entity
severity	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
way	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
agreement	NOUN	O	O
between	ADP	O	O
the	DET	O	O
questionnaire	NOUN	O	O
and	CCONJ	O	O
tremor	NOUN	O	I-Entity
severity	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.093	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.53	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postural	PROPN	O	O
tremor	NOUN	O	I-Entity
showed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
first	ADJ	O	O
and	CCONJ	O	O
third	ADJ	O	O
session	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.07	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Support	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arm	NOUN	O	O
decreased	VERB	O	O
tremor	NOUN	O	I-Entity
severity	NOUN	O	O
,	PUNCT	O	O
exhaustion	NOUN	O	O
increased	VERB	O	O
tremor	NOUN	O	I-Entity
severity	NOUN	O	O
significantly	ADV	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Quantifying	VERB	O	O
tremor	NOUN	O	I-Entity
by	ADP	O	O
using	VERB	O	O
an	DET	O	O
inexpensive	ADJ	O	O
laser	NOUN	O	O
pointer	NOUN	O	O
is	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
(	PUNCT	O	O
<	SYM	O	O
12	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
a	DET	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
reproducible	ADJ	O	O
method	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12627929)

Increased	ADJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
docetaxel	NOUN	O	I-Entity
and	CCONJ	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
androgen	NOUN	O	O
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
VTE	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
androgen	NOUN	O	O
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
docetaxel	NOUN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
thalidomide	NOUN	O	I-Entity
.	PUNCT	O	O

PATIENTS	NOUN	O	O
:	PUNCT	O	O
Seventy	NUM	O	O
men	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
50	NUM	O	O
-	SYM	O	O
80	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
advanced	ADJ	O	O
androgen	NOUN	O	O
-	PUNCT	O	O
independent	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Each	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
intravenous	ADJ	O	O
docetaxel	ADJ	O	I-Entity
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/week	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
consecutive	ADJ	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
off	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
oral	ADJ	O	O
thalidomide	NOUN	O	I-Entity
200	NUM	O	O
mg	NUM	O	O
every	DET	O	O
evening	NOUN	O	O
plus	CCONJ	O	O
the	DET	O	O
same	ADJ	O	O
docetaxel	NOUN	O	I-Entity
regimen	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
4-week	NOUN	O	O
cycle	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
until	ADP	O	O
there	ADV	O	O
was	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
excessive	ADJ	O	O
toxicity	NOUN	O	I-Entity
or	CCONJ	O	O
disease	NOUN	O	O
progression	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	NOUN	O	O
AND	CCONJ	O	O
MAIN	PROPN	O	O
RESULTS	PROPN	O	O
:	PUNCT	O	O
None	NOUN	O	O
of	ADP	O	O
23	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
docetaxel	ADV	O	I-Entity
alone	ADV	O	O
developed	VERB	O	O
VTE	PROPN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
9	NUM	O	O
of	ADP	O	O
47	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
19%	NUM	O	O
)	PUNCT	O	O
who	NOUN	O	O
received	VERB	O	O
docetaxel	NOUN	O	I-Entity
plus	CCONJ	O	O
thalidomide	NOUN	O	I-Entity
developed	VERB	O	O
VTE	PROPN	O	I-Entity
(	PUNCT	O	O
p=0.025	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
to	ADP	O	O
docetaxel	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
significantly	ADV	O	O
increases	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
.	PUNCT	O	O

Clinicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
potential	ADJ	O	O
complication	NOUN	O	O
when	ADV	O	O
adding	VERB	O	O
thalidomide	NOUN	O	I-Entity
to	ADP	O	O
chemotherapeutic	ADJ	O	O
regimens	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6634932)

Sublingual	ADJ	O	O
absorption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
quaternary	ADJ	O	B-Entity
ammonium	NOUN	O	I-Entity
antiarrhythmic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
UM-272	PROPN	O	I-Entity
.	PUNCT	O	O

UM-272	PROPN	O	I-Entity
(	PUNCT	O	O
N	PROPN	O	B-Entity
,	PUNCT	O	I-Entity
N	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
dimethylpropranolol	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
quaternary	ADJ	O	O
antiarrhythmic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
sublingually	ADV	O	O
to	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
ouabain	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardias	NOUN	O	I-Entity
.	PUNCT	O	O

Sublingual	PROPN	O	O
UM-272	PROPN	O	I-Entity
converted	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
to	ADP	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
in	ADP	O	O
all	DET	O	O
5	NUM	O	O
dogs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18791946)

Severe	ADJ	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
haemolytic	ADJ	O	B-Entity
anaemia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
with	ADP	O	O
fatal	ADJ	O	O
outcome	NOUN	O	O
.	PUNCT	O	O

Haematological	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
fatal	ADJ	O	O
outcome	NOUN	O	O
are	VERB	O	O
rare	ADJ	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
30-year	ADJ	O	O
old	ADJ	O	O
Caucasian	ADJ	O	O
man	NOUN	O	O
reported	VERB	O	O
with	ADP	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
jaundice	ADV	O	I-Entity
after	ADP	O	O
3-day	NUM	O	O
administration	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
ciprofloxacin	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
suspect	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	B-Entity
tract	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
evaluations	NOUN	O	O
suggested	VERB	O	O
an	DET	O	O
initial	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
haemolysis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
progressively	ADV	O	O
developed	VERB	O	O
petechiae	NOUN	O	I-Entity
and	CCONJ	O	O
purpura	NOUN	O	I-Entity
on	ADP	O	O
thorax	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
limbs	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
accurate	ADJ	O	O
autopsy	NOUN	O	O
revealed	VERB	O	O
most	ADV	O	O
organs	NOUN	O	O
with	ADP	O	O
diffuse	NOUN	O	O
petechial	ADJ	O	O
haemorrhages	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
depression	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
thrombi	NOUN	O	I-Entity
or	CCONJ	O	O
signs	NOUN	O	O
of	ADP	O	O
microangiopathies	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
arterial	ADJ	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
shows	VERB	O	O
that	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
may	VERB	O	O
precipitate	VERB	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
haemolytic	ADJ	O	B-Entity
anaemia	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
phases	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
without	ADP	O	O
apparent	ADJ	O	O
previous	ADJ	O	O
exposures	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17344566)

Simvastatin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bilateral	ADJ	O	O
leg	NOUN	O	O
compartment	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
myonecrosis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
hypothyroidism	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
54-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
hypothyroid	ADJ	O	I-Entity
male	ADJ	O	O
taking	VERB	O	O
thyroxine	NOUN	O	I-Entity
and	CCONJ	O	O
simvastatin	NOUN	O	I-Entity
presented	VERB	O	O
with	ADP	O	O
bilateral	ADJ	O	O
leg	NOUN	O	O
compartment	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
myonecrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Urgent	ADJ	O	O
fasciotomies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
made	VERB	O	O
an	DET	O	O
uneventful	ADJ	O	O
recovery	NOUN	O	O
with	ADP	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
simvastatin	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
likely	ADJ	O	O
that	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
seen	VERB	O	O
more	ADV	O	O
often	ADV	O	O
with	ADP	O	O
the	DET	O	O
increased	VERB	O	O
worldwide	ADV	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
approval	NOUN	O	O
for	ADP	O	O
all	DET	O	O
arteriopathic	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9293063)

Bile	ADJ	O	B-Entity
duct	NOUN	O	I-Entity
hamartoma	NOUN	O	I-Entity
occurring	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
danazol	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
bile	NOUN	O	B-Entity
duct	NOUN	O	I-Entity
hamartoma	NOUN	O	I-Entity
which	ADJ	O	O
developed	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
danazol	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
develops	VERB	O	O
a	DET	O	O
liver	NOUN	O	B-Entity
mass	NOUN	O	I-Entity
,	PUNCT	O	O
because	ADP	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
clinical	ADJ	O	O
features	NOUN	O	O
and	CCONJ	O	O
imaging	NOUN	O	O
appearances	NOUN	O	O
,	PUNCT	O	O
biopsy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
only	ADJ	O	O
way	NOUN	O	O
to	PART	O	O
achieve	VERB	O	O
a	DET	O	O
definitive	ADJ	O	O
diagnosis	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1728522)

Granulomatous	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
combination	NOUN	O	B-Entity
of	ADP	O	I-Entity
amoxicillin	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
clavulanic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
amoxicillin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clavulanic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatitis	NOUN	O	I-Entity
with	ADP	O	O
histologic	ADJ	O	O
multiple	ADJ	O	O
granulomas	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
type	NOUN	O	O
of	ADP	O	O
lesion	NOUN	O	O
broadens	VERB	O	O
the	DET	O	O
spectrum	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
combination	NOUN	O	O
,	PUNCT	O	O
mainly	ADV	O	O
represented	VERB	O	O
by	ADP	O	O
a	DET	O	O
benign	ADJ	O	O
cholestatic	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
of	ADP	O	O
granulomas	NOUN	O	I-Entity
and	CCONJ	O	O
eosinophilia	NOUN	O	I-Entity
favor	VERB	O	O
an	DET	O	O
immunoallergic	ADJ	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
penicillin	NOUN	O	I-Entity
derivatives	NOUN	O	O
and	CCONJ	O	O
amoxicillin	NOUN	O	I-Entity
alone	ADV	O	O
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
induce	VERB	O	O
such	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
lesions	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
amoxicillin	NOUN	O	I-Entity
component	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
a	DET	O	O
potentiating	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
clavulanic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
might	VERB	O	O
have	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10807237)

Intracranial	ADJ	O	B-Entity
aneurysms	NOUN	O	I-Entity
and	CCONJ	O	O
cocaine	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
:	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
prognostic	ADJ	O	O
indicators	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
cocaine	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
is	VERB	O	O
reportedly	ADV	O	O
poor	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
review	NOUN	O	O
of	ADP	O	O
admissions	NOUN	O	O
during	ADP	O	O
a	DET	O	O
6-year	NUM	O	O
period	NOUN	O	O
revealed	VERB	O	O
14	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
aneurysms	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
group	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
135	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
ruptured	NOUN	O	B-Entity
aneurysms	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
history	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
.	PUNCT	O	O

Age	PROPN	O	O
at	ADP	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
of	ADP	O	O
ictus	NOUN	O	O
after	ADP	O	O
intoxication	NOUN	O	O
,	PUNCT	O	O
Hunt	PROPN	O	O
and	CCONJ	O	O
Hess	PROPN	O	O
grade	NOUN	O	O
of	ADP	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
size	NOUN	O	O
of	ADP	O	O
the	DET	O	O
aneurysm	NOUN	O	I-Entity
,	PUNCT	O	O
location	NOUN	O	O
of	ADP	O	O
the	DET	O	O
aneurysm	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Glasgow	PROPN	O	O
Outcome	PROPN	O	O
Scale	PROPN	O	O
score	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
and	CCONJ	O	O
compared	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
aneurysms	NOUN	O	I-Entity
were	VERB	O	O
located	VERB	O	O
in	ADP	O	O
the	DET	O	O
anterior	ADJ	O	O
circulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
these	DET	O	O
aneurysms	NOUN	O	I-Entity
were	VERB	O	O
smaller	ADJ	O	O
than	ADP	O	O
those	DET	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
+	NUM	O	O
/-	PUNCT	O	O

0.007	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
significant	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
outcome	NOUN	O	O
for	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
aneurysms	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Cocaine	PROPN	O	I-Entity
use	NOUN	O	O
predisposed	ADJ	O	O
aneurysmal	ADJ	O	B-Entity
rupture	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
earlier	ADJ	O	O
age	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
much	ADV	O	O
smaller	ADJ	O	O
aneurysms	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12536034)

Anti	PROPN	O	O
-	PUNCT	O	O
epileptic	ADJ	O	I-Entity
drugs	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
de	NOUN	O	O
novo	ADJ	O	O
absence	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
present	ADJ	O	O
three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
de	PROPN	O	O
novo	ADJ	O	O
absence	NOUN	O	B-Entity
epilepsy	NOUN	O	I-Entity
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
and	CCONJ	O	O
vigabatrin	NOUN	O	I-Entity
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
underlying	ADJ	O	O
diseases	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
prognosis	NOUN	O	O
for	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
de	NOUN	O	O
novo	ADJ	O	O
absence	NOUN	O	B-Entity
seizure	NOUN	O	I-Entity
is	VERB	O	O
good	ADJ	O	O
because	ADP	O	O
it	PRON	O	O
subsides	VERB	O	O
rapidly	ADV	O	O
after	ADP	O	O
discontinuing	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
offending	VERB	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
transmitted	VERB	O	O
thalamocortical	ADJ	O	O
circuitry	NOUN	O	O
accounts	NOUN	O	O
for	ADP	O	O
a	DET	O	O
major	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
underlying	VERB	O	O
neurophysiology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
absence	NOUN	O	B-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
de	NOUN	O	O
novo	ADJ	O	O
absence	NOUN	O	B-Entity
seizure	NOUN	O	I-Entity
is	VERB	O	O
rare	ADJ	O	O
,	PUNCT	O	O
pro	ADJ	O	O
-	PUNCT	O	O
absence	NOUN	O	O
drugs	NOUN	O	O
can	VERB	O	O
only	ADV	O	O
be	VERB	O	O
considered	VERB	O	O
a	DET	O	O
promoting	VERB	O	O
factor	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
underlying	VERB	O	O
epileptogenecity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
synergistic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
accompanying	ADJ	O	O
drugs	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
to	PART	O	O
trigger	VERB	O	O
the	DET	O	O
de	NOUN	O	O
novo	ADJ	O	O
absence	NOUN	O	B-Entity
seizure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
aggravation	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
whenever	ADV	O	O
an	DET	O	O
unexpected	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
and/or	CCONJ	O	O
new	ADJ	O	O
seizure	NOUN	O	I-Entity
types	NOUN	O	O
appear	VERB	O	O
following	VERB	O	O
a	DET	O	O
change	NOUN	O	O
in	ADP	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
understanding	VERB	O	O
the	DET	O	O
underlying	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
absence	NOUN	O	B-Entity
epilepsy	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
can	VERB	O	O
avoid	VERB	O	O
the	DET	O	O
inappropriate	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
anticonvulsants	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
epilepsy	NOUN	O	I-Entity
and	CCONJ	O	O
prevent	VERB	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
absence	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7234705)

Procainamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polymorphous	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Seven	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
procainamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polymorphous	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
polymorphous	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
appeared	VERB	O	O
after	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
to	PART	O	O
400	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
procainamide	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
sustained	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
three	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
procainamide	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
orally	ADV	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
premature	ADJ	O	B-Entity
ventricular	ADJ	O	I-Entity
contractions	NOUN	O	I-Entity
or	CCONJ	O	O
atrial	ADJ	O	B-Entity
flutter	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
Q	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
T	PROPN	O	I-Entity
prolongation	NOUN	O	I-Entity
and	CCONJ	O	O
recurrent	ADJ	O	O
syncope	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
polymorphous	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
was	VERB	O	O
rapidly	ADV	O	O
diagnosed	VERB	O	O
and	CCONJ	O	O
treated	VERB	O	O
with	ADP	O	O
disappearance	NOUN	O	O
of	ADP	O	O
further	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
degenerated	VERB	O	O
into	ADP	O	O
irreversible	ADJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
and	CCONJ	O	O
both	DET	O	O
patients	NOUN	O	O
died	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
seventh	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
permanent	ADJ	O	O
ventricular	ADJ	O	O
pacemaker	NOUN	O	O
was	VERB	O	O
inserted	VERB	O	O
and	CCONJ	O	O
,	PUNCT	O	O
despite	ADP	O	O
continuation	NOUN	O	O
of	ADP	O	O
procainamide	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
polymorphous	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
reoccur	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
seven	NUM	O	O
cases	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
procainamide	NOUN	O	I-Entity
can	VERB	O	O
produce	VERB	O	O
an	DET	O	O
acquired	VERB	O	O
prolonged	VERB	O	B-Entity
Q	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
T	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
with	ADP	O	O
polymorphous	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8955532)

Role	NOUN	O	O
of	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
B2	NOUN	O	O
receptors	NOUN	O	O
in	ADP	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Cellular	ADJ	O	O
mechanisms	NOUN	O	O
which	ADJ	O	O
account	VERB	O	O
for	ADP	O	O
disruption	NOUN	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
clear	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
synthesis	NOUN	O	O
/	SYM	O	O
release	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
to	PART	O	O
activate	VERB	O	O
B2	NOUN	O	O
receptors	NOUN	O	O
in	ADP	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Permeability	PROPN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
was	VERB	O	O
quantitated	VERB	O	O
by	ADP	O	O
clearance	NOUN	O	O
of	ADP	O	O
fluorescent	NOUN	O	O
-	PUNCT	O	O
labeled	VERB	O	O
dextran	NOUN	O	I-Entity
before	ADP	O	O
and	CCONJ	O	O
during	ADP	O	O
phenylephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
vehicle	NOUN	O	O
and	CCONJ	O	O
Hoe-140	PROPN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
microM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Phenylephrine	PROPN	O	I-Entity
infusion	NOUN	O	O
increased	VERB	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
arteriolar	ADJ	O	O
diameter	NOUN	O	O
and	CCONJ	O	O
clearance	NOUN	O	O
of	ADP	O	O
fluorescent	NOUN	O	O
dextran	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
magnitude	NOUN	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
disruption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
synthesis	NOUN	O	O
/	PUNCT	O	O
release	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
to	PART	O	O
activate	VERB	O	O
B2	NOUN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2578334)

5-azacytidine	NUM	O	I-Entity
potentiates	NOUN	O	O
initiation	NOUN	O	B-Entity
induced	VERB	O	I-Entity
by	ADP	O	I-Entity
carcinogens	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
liver	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
test	VERB	O	O
the	DET	O	O
validity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
hypomethylation	NOUN	O	O
of	ADP	O	O
DNA	NOUN	O	O
plays	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
initiation	NOUN	O	B-Entity
of	ADP	O	I-Entity
carcinogenic	ADJ	O	I-Entity
process	NOUN	O	I-Entity
,	PUNCT	O	O
5-azacytidine	NUM	O	I-Entity
(	PUNCT	O	O
5-AzC	NUM	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
DNA	PROPN	O	O
methylation	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
rats	NOUN	O	O
during	ADP	O	O
the	DET	O	O
phase	NOUN	O	O
of	ADP	O	O
repair	NOUN	O	O
synthesis	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
three	NUM	O	O
carcinogens	NOUN	O	O
,	PUNCT	O	O
benzo[a]-pyrene	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
N	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
nitrosourea	NOUN	O	I-Entity
(	PUNCT	O	O
60	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
1,2-dimethylhydrazine	NUM	O	I-Entity
(	PUNCT	O	O
1,2-DMH	NUM	O	I-Entity
)	PUNCT	O	O

The	DET	O	O
initiated	VERB	O	O
hepatocytes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
were	VERB	O	O
assayed	VERB	O	O
as	ADP	O	O
the	DET	O	O
gamma	NOUN	O	O
-	PUNCT	O	O
glutamyltransferase	NOUN	O	O
(	PUNCT	O	O
gamma	NOUN	O	O
-	PUNCT	O	O
GT	PROPN	O	O
)	PUNCT	O	O
positive	ADJ	O	O
foci	NOUN	O	O
formed	VERB	O	O
following	VERB	O	O
a	DET	O	O
2-week	NUM	O	O
selection	NOUN	O	O
regimen	NOUN	O	O
consisting	VERB	O	O
of	ADP	O	O
dietary	ADJ	O	O
0.02%	NUM	O	O
2-acetylaminofluorene	NUM	O	I-Entity
coupled	VERB	O	O
with	ADP	O	O
a	DET	O	O
necrogenic	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
CCl4	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
obtained	VERB	O	O
indicate	VERB	O	O
that	ADP	O	O
with	ADP	O	O
all	DET	O	O
three	NUM	O	O
carcinogens	NOUN	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
5-AzC	PROPN	O	I-Entity
during	ADP	O	O
repair	NOUN	O	O
synthesis	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
initiated	VERB	O	O
hepatocytes	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
example	NOUN	O	O
10	NUM	O	O
-	SYM	O	O
20	NUM	O	O
foci	NOUN	O	O
/	SYM	O	O
cm2	NOUN	O	O
in	ADP	O	O
5-AzC	NUM	O	I-Entity
and	CCONJ	O	O
carcinogen	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
3	NUM	O	O
-	SYM	O	O
5	NUM	O	O
foci	NOUN	O	O
/	SYM	O	O
cm2	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
carcinogen	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
3H]-5-azadeoxycytidine	NUM	O	I-Entity
during	ADP	O	O
the	DET	O	O
repair	NOUN	O	O
synthesis	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
1,2-DMH	NUM	O	I-Entity
further	ADV	O	O
showed	VERB	O	O
that	ADP	O	O
0.019	NUM	O	O
mol	NOUN	O	O
%	NOUN	O	O
of	ADP	O	O
cytosine	NOUN	O	I-Entity
residues	NOUN	O	O
in	ADP	O	O
DNA	NOUN	O	O
were	VERB	O	O
substituted	VERB	O	O
by	ADP	O	O
the	DET	O	O
analogue	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
incorporation	NOUN	O	O
of	ADP	O	O
5-AzC	NUM	O	I-Entity
occurs	NOUN	O	O
during	ADP	O	O
repair	NOUN	O	O
synthesis	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
carcinogen	NOUN	O	O
,	PUNCT	O	O
5-AzC	PROPN	O	I-Entity
given	VERB	O	O
after	ADP	O	O
a	DET	O	O
two	NUM	O	O
thirds	NOUN	O	O
partial	ADJ	O	O
hepatectomy	NOUN	O	O
,	PUNCT	O	O
when	ADV	O	O
its	ADJ	O	O
incorporation	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
maximum	ADJ	O	O
,	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
induce	VERB	O	O
any	DET	O	O
gamma	NOUN	O	O
-	PUNCT	O	O
GT	PROPN	O	O
positive	ADJ	O	O
foci	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11532387)

Withdrawal	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
emergent	ADJ	O	I-Entity
rabbit	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
during	ADP	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

Rabbit	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
RS	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
prolonged	ADJ	O	O
neuroleptic	ADJ	O	O
medication	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
withdrawal	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
emergent	ADJ	O	I-Entity
RS	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
of	ADP	O	O
its	ADJ	O	O
kind	NOUN	O	O
to	PART	O	O
be	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
RS	NOUN	O	I-Entity
during	ADP	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
symptom	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
successfully	ADV	O	O
with	ADP	O	O
trihexyphenidyl	ADJ	O	I-Entity
anticholinergic	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
underlying	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
withdrawal	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
emergent	ADJ	O	I-Entity
RS	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
case	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
pharmacological	ADJ	O	O
profile	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
serotonin	NOUN	O	I-Entity
-	PUNCT	O	O
dopamine	NOUN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
the	DET	O	O
pathophysiologic	ADJ	O	O
influence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
serotonin	NOUN	O	I-Entity
system	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
RS	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3173179)

Verapamil	PROPN	O	I-Entity
withdrawal	NOUN	O	O
as	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
hypertensive	ADJ	O	I-Entity
woman	NOUN	O	O
with	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
coronary	ADJ	O	O
angiogram	NOUN	O	O
.	PUNCT	O	O

Verapamil	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
relatively	ADV	O	O
-	PUNCT	O	O
safe	ADJ	O	O
antihypertensive	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Serious	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
are	VERB	O	O
uncommon	ADJ	O	O
and	CCONJ	O	O
mainly	ADV	O	O
have	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
cardiac	ADJ	O	O
contractility	NOUN	O	O
and	CCONJ	O	O
conduction	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
when	ADV	O	O
the	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
combined	VERB	O	O
with	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
coincided	VERB	O	O
with	ADP	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
verapamil	X	O	I-Entity
in	ADP	O	O
a	DET	O	O
previously	ADV	O	O
asymptomatic	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Possible	ADJ	O	O
mechanisms	NOUN	O	O
that	ADJ	O	O
involve	VERB	O	O
a	DET	O	O
verapamil	ADV	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
platelet	NOUN	O	O
and/or	CCONJ	O	O
vascular	ADJ	O	O
alpha	NOUN	O	O
2-adrenoreceptor	NOUN	O	O
affinity	NOUN	O	O
for	ADP	O	O
catecholamines	NOUN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3856631)

Remission	NOUN	O	O
induction	NOUN	O	O
of	ADP	O	O
meningeal	ADJ	O	B-Entity
leukemia	NOUN	O	I-Entity
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
methotrexate	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
meningeal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
methotrexate	NOUN	O	I-Entity
regimen	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
achieve	VERB	O	O
and	CCONJ	O	O
maintain	VERB	O	O
CSF	PROPN	O	O
methotrexate	ADJ	O	I-Entity
concentrations	NOUN	O	O
of	ADP	O	O
10(-5	NUM	O	O
)	PUNCT	O	O

The	DET	O	O
methotrexate	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
loading	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
6,000	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	NOUN	O	O
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
hour	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
1,200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2/h	PROPN	O	O
for	ADP	O	O
23	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Leucovorin	PROPN	O	I-Entity
rescue	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
12	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
with	ADP	O	O
a	DET	O	O
loading	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
12	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	NOUN	O	O
every	DET	O	O
three	NUM	O	O
hours	NOUN	O	O
for	ADP	O	O
six	NUM	O	O
doses	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
every	DET	O	O
six	NUM	O	O
hours	NOUN	O	O
until	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
methotrexate	NOUN	O	I-Entity
level	NOUN	O	O
decreased	VERB	O	O
to	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
1	NUM	O	O
X	NOUN	O	O
10(-7	NUM	O	O
)	PUNCT	O	O
mol	NOUN	O	O
/	SYM	O	O
L.	PROPN	O	O

The	DET	O	O
mean	VERB	O	O
steady	ADJ	O	O
-	PUNCT	O	O
state	NOUN	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
CSF	PROPN	O	O
methotrexate	VERB	O	I-Entity
concentrations	NOUN	O	O
achieved	VERB	O	O
were	VERB	O	O
1.1	NUM	O	O
X	NOUN	O	O
10(-3	NUM	O	O
)	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
toxicities	NOUN	O	I-Entity
encountered	VERB	O	O
were	VERB	O	O
transient	ADJ	O	O
serum	NOUN	O	O
transaminase	NOUN	O	O
and	CCONJ	O	O
bilirubin	NOUN	O	I-Entity
elevations	NOUN	O	O
,	PUNCT	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
mucositis	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
had	VERB	O	O
focal	ADJ	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
transient	ADJ	O	B-Entity
hemiparesis	NOUN	O	I-Entity
but	CCONJ	O	O
recovered	VERB	O	O
completely	ADV	O	O
.	PUNCT	O	O

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
methotrexate	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
remission	NOUN	O	O
after	ADP	O	O
meningeal	NOUN	O	O
relapse	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	B-Entity
lymphoblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2522601)

Hypersensitivity	NOUN	O	I-Entity
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
presenting	VERB	O	O
with	ADP	O	O
a	DET	O	O
leukemoid	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
,	PUNCT	O	O
eosinophilia	NOUN	O	I-Entity
,	PUNCT	O	O
erythroderma	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
hypersensitivity	NOUN	O	I-Entity
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
presented	VERB	O	O
with	ADP	O	O
generalized	ADJ	O	O
erythroderma	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
severe	ADJ	O	O
leukemoid	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
,	PUNCT	O	O
eosinophilia	NOUN	O	I-Entity
,	PUNCT	O	O
hyponatremia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
such	ADJ	O	O
an	DET	O	O
unusual	ADJ	O	O
reaction	NOUN	O	O
to	ADP	O	O
carbamazepine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8741744)

The	DET	O	O
interpeduncular	ADJ	O	O
nucleus	NOUN	O	O
regulates	VERB	O	O
nicotine	NOUN	O	I-Entity
's	PART	O	O
effects	NOUN	O	O
on	ADP	O	O
free	ADJ	O	O
-	PUNCT	O	O
field	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Partial	ADJ	O	O
lesions	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
with	ADP	O	O
kainic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
interpeduncular	ADJ	O	O
nucleus	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ventral	ADJ	O	O
midbrain	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
sham	NOUN	O	O
-	PUNCT	O	O
operated	VERB	O	O
controls	NOUN	O	O
,	PUNCT	O	O
lesions	NOUN	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.25	NUM	O	O
)	PUNCT	O	O
blunted	VERB	O	O
the	DET	O	O
early	ADJ	O	O
(	PUNCT	O	O
<	SYM	O	O
60	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
free	ADJ	O	O
-	PUNCT	O	O
field	NOUN	O	O
locomotor	NOUN	O	B-Entity
hypoactivity	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	NUM	O	O
kg(-1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
i.m	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
enhanced	VERB	O	O
the	DET	O	O
later	ADV	O	O
(	PUNCT	O	O
60	NUM	O	O
-	SYM	O	O
120	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
raised	VERB	O	O
spontaneous	ADJ	O	O
nocturnal	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Lesions	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
immunohistological	ADJ	O	O
staining	NOUN	O	O
for	ADP	O	O
choline	NOUN	O	I-Entity
acetyltransferase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
interpeduncular	ADJ	O	O
nucleus	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.025	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
tyrosine	NOUN	O	I-Entity
hydroxylase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
surrounding	VERB	O	O
catecholaminergic	ADJ	O	O
A10	ADJ	O	O
region	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
interpeduncular	ADJ	O	O
nucleus	NOUN	O	O
mediates	VERB	O	O
nicotinic	ADJ	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
dampens	ADJ	O	O
nicotinic	ADJ	O	O
arousal	NOUN	O	O
mechanisms	NOUN	O	O
located	VERB	O	O
elsewhere	ADV	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17491223)

Assessment	PROPN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
invasive	ADJ	O	O
index	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
performance	NOUN	O	O
for	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
dobutamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

Electrocardiography	PROPN	O	O
has	VERB	O	O
a	DET	O	O
very	ADV	O	O
low	ADJ	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
detecting	VERB	O	O
dobutamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
added	VERB	O	O
diagnostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
cardiac	ADJ	O	O
performance	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
dP	PROPN	O	O
/	SYM	O	O
dtejc	NOUN	O	O
)	PUNCT	O	O
measurement	NOUN	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
brachial	ADJ	O	O
artery	NOUN	O	O
flow	NOUN	O	O
changes	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
standard	ADJ	O	O
12-lead	NUM	O	O
ECG	PROPN	O	O
,	PUNCT	O	O
for	ADP	O	O
detecting	VERB	O	O
dobutamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
using	VERB	O	O
Tc99m	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Sestamibi	PROPN	O	I-Entity
single	ADJ	O	O
-	PUNCT	O	O
photon	NOUN	O	O
emission	NOUN	O	O
computed	VERB	O	O
tomography	NOUN	O	O
as	ADP	O	O
the	DET	O	O
gold	NOUN	O	O
standard	NOUN	O	O
of	ADP	O	O
comparison	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

:	PUNCT	O	O
The	DET	O	O
study	NOUN	O	O
group	NOUN	O	O
comprised	VERB	O	O
40	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
Sestamibi	PROPN	O	I-Entity
-	PUNCT	O	O
SPECT	PROPN	O	O
/	PUNCT	O	O
dobutamine	ADJ	O	I-Entity
stress	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

dtejc	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
each	DET	O	O
dobutamine	ADJ	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
19	NUM	O	O
of	ADP	O	O
the	DET	O	O
40	NUM	O	O
patients	NOUN	O	O
perfusion	NOUN	O	O
defects	NOUN	O	O
compatible	ADJ	O	O
with	ADP	O	O
ischemia	NOUN	O	I-Entity
were	VERB	O	O
detected	VERB	O	O
on	ADP	O	O
SPECT	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
dP	PROPN	O	O
/	SYM	O	O
dtejc	NOUN	O	O
during	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
dobutamine	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
was	VERB	O	O
severely	ADV	O	O
impaired	VERB	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
ischemic	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
ECG	PROPN	O	O
alone	ADV	O	O
is	VERB	O	O
used	VERB	O	O
for	ADP	O	O
specificity	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
combination	NOUN	O	O
with	ADP	O	O
dP	PROPN	O	O
/	SYM	O	O
dtejc	ADV	O	O
improved	VERB	O	O
the	DET	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
test	NOUN	O	O
and	CCONJ	O	O
could	VERB	O	O
be	VERB	O	O
a	DET	O	O
cost	NOUN	O	O
-	PUNCT	O	O
savings	NOUN	O	O
alternative	NOUN	O	O
to	ADP	O	O
cardiac	ADJ	O	O
imaging	NOUN	O	O
or	CCONJ	O	O
perfusion	NOUN	O	O
studies	NOUN	O	O
to	PART	O	O
detect	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
unable	ADJ	O	O
to	PART	O	O
exercise	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18004067)

Acute	PROPN	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
regular	ADJ	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
ingesting	VERB	O	O
paracetamol	NOUN	O	I-Entity
at	ADP	O	O
therapeutic	ADJ	O	O
dosage	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
paracetamol	NOUN	O	I-Entity
(	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
currently	ADV	O	O
debated	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
2	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
regular	ADJ	O	O
consumers	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
and	CCONJ	O	O
who	NOUN	O	O
developed	VERB	O	O
liver	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
within	ADP	O	O
3	NUM	O	O
-	SYM	O	O
5	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
hospitalization	NOUN	O	O
and	CCONJ	O	O
stopping	VERB	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
while	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
4	NUM	O	O
g	NOUN	O	O
paracetamol	ADV	O	I-Entity
/	SYM	O	O
day	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
paracetamol	NOUN	O	I-Entity
serum	NOUN	O	O
level	NOUN	O	O
obtained	VERB	O	O
in	ADP	O	O
one	NUM	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
toxic	ADJ	O	O
range	NOUN	O	O
.	PUNCT	O	O

Possible	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
paracetamol	NOUN	O	I-Entity
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
,	PUNCT	O	O
e.g.	ADV	O	O
regular	ADJ	O	O
consumption	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
,	PUNCT	O	O
liver	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
is	VERB	O	O
possible	ADJ	O	O
when	ADV	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
are	VERB	O	O
ingested	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
propose	VERB	O	O
that	ADP	O	O
the	DET	O	O
paracetamol	NOUN	O	I-Entity
dose	NOUN	O	O
should	VERB	O	O
not	ADV	O	O
exceed	VERB	O	O
2	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
in	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
their	ADJ	O	O
liver	NOUN	O	O
function	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
monitored	VERB	O	O
closely	ADV	O	O
while	ADP	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
paracetamol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12443032)

Cocaine	NOUN	O	I-Entity
related	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
:	PUNCT	O	O

The	DET	O	O
recreational	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
is	VERB	O	O
on	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
emergency	NOUN	O	O
nurse	NOUN	O	O
ought	VERB	O	O
to	PART	O	O
be	VERB	O	O
familiar	ADJ	O	O
with	ADP	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
consequences	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
tendency	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
to	PART	O	O
produce	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
ought	VERB	O	O
to	PART	O	O
be	VERB	O	O
in	ADP	O	O
the	DET	O	O
mind	NOUN	O	O
of	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
nurse	NOUN	O	O
when	ADV	O	O
faced	VERB	O	O
with	ADP	O	O
a	DET	O	O
young	ADJ	O	O
victim	NOUN	O	O
of	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
who	NOUN	O	O
is	VERB	O	O
otherwise	ADV	O	O
at	ADP	O	O
low	ADJ	O	O
risk	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
is	VERB	O	O
discussed	VERB	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
dilemmas	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
moral	ADJ	O	O
issues	NOUN	O	O
relating	VERB	O	O
to	ADP	O	O
the	DET	O	O
testing	NOUN	O	O
of	ADP	O	O
potential	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
addressed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (17615423)

Severe	ADJ	O	O
rhabdomyolysis	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
concomitant	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
simvastatin	NOUN	O	I-Entity
,	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
atazanavir	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
severe	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
simvastatin	NOUN	O	I-Entity
,	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
atazanavir	NOUN	O	I-Entity
resulting	VERB	O	O
in	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
and	CCONJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
72-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
white	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
underlying	VERB	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
,	PUNCT	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
,	PUNCT	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hyperlipidemia	NOUN	O	I-Entity
presented	VERB	O	O
with	ADP	O	O
generalized	ADJ	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
fatigue	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dark	ADJ	O	O
orange	ADJ	O	O
urine	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
taking	VERB	O	O
80	NUM	O	O
mg	NUM	O	O
simvastatin	NOUN	O	I-Entity
at	ADP	O	O
bedtime	NOUN	O	O
(	PUNCT	O	O
initiated	VERB	O	O
27	NUM	O	O
days	NOUN	O	O
earlier	ADV	O	O
)	PUNCT	O	O
;	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
400	NUM	O	O
mg	NUM	O	O
daily	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
200	NUM	O	O
mg	NUM	O	O
daily	NOUN	O	O
(	PUNCT	O	O
initiated	VERB	O	O
19	NUM	O	O
days	NOUN	O	O
earlier	ADV	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NUM	O	O
atazanavir	ADJ	O	I-Entity
daily	ADJ	O	O
(	PUNCT	O	O
initiated	VERB	O	O
at	ADP	O	O
least	ADV	O	O
2	NUM	O	O
years	NOUN	O	O
previously	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Laboratory	PROPN	O	O
evaluation	NOUN	O	O
revealed	VERB	O	O
66,680	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
,	PUNCT	O	O
93	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
blood	NOUN	O	B-Entity
urea	NOUN	O	I-Entity
nitrogen	NOUN	O	I-Entity
,	PUNCT	O	O
4.6	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
1579	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
aspartate	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
738	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
.	PUNCT	O	O

Simvastatin	PROPN	O	I-Entity
,	PUNCT	O	O
amiodarone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
human	ADJ	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	I-Entity
medications	NOUN	O	O
were	VERB	O	O
all	DET	O	O
temporarily	ADV	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
forced	VERB	O	O
alkaline	ADJ	O	O
diuresis	NOUN	O	O
and	CCONJ	O	O
started	VERB	O	O
on	ADP	O	O
dialysis	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
had	VERB	O	O
dropped	VERB	O	O
to	ADP	O	O
1695	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
was	VERB	O	O
3.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL.	NOUN	O	O
The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
discharged	VERB	O	O
and	CCONJ	O	O
continued	VERB	O	O
outpatient	ADJ	O	O
dialysis	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
until	ADP	O	O
his	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
recovered	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
is	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
concomitant	ADJ	O	O
drugs	NOUN	O	O
that	ADJ	O	O
inhibit	VERB	O	O
simvastatin	ADJ	O	I-Entity
metabolism	NOUN	O	O
.	PUNCT	O	O

Simvastatin	PROPN	O	I-Entity
is	VERB	O	O
metabolized	VERB	O	O
by	ADP	O	O
CYP3A4	PROPN	O	O
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
and	CCONJ	O	O
atazanavir	NOUN	O	I-Entity
are	VERB	O	O
recognized	VERB	O	O
CYP3A4	ADJ	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Pharmacokinetic	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
statins	NOUN	O	I-Entity
are	VERB	O	O
an	DET	O	O
important	ADJ	O	O
consideration	NOUN	O	O
for	ADP	O	O
assessing	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
potential	ADJ	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
requiring	VERB	O	O
the	DET	O	O
concurrent	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
statins	NOUN	O	I-Entity
and	CCONJ	O	O
CYP3A4	PROPN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
pravastatin	NOUN	O	I-Entity
,	PUNCT	O	O
fluvastatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
rosuvastatin	NOUN	O	I-Entity
carry	VERB	O	O
the	DET	O	O
lowest	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
;	PUNCT	O	O
atorvastatin	ADJ	O	I-Entity
carries	VERB	O	O
moderate	ADJ	O	O
risk	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
simvastatin	NOUN	O	I-Entity
and	CCONJ	O	O
lovastatin	NOUN	O	I-Entity
have	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
risk	NOUN	O	O
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
avoided	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
concomitant	ADJ	O	O
CYP3A4	PROPN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8558192)

Phase	NOUN	O	O
II	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
vinorelbine	NOUN	O	I-Entity
in	ADP	O	O
metastatic	ADJ	O	O
squamous	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
esophageal	ADJ	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

European	ADJ	O	O
Organization	PROPN	O	O
for	ADP	O	O
Research	PROPN	O	O
and	CCONJ	O	O
Treatment	PROPN	O	O
of	ADP	O	O
Cancer	PROPN	O	I-Entity
Gastrointestinal	PROPN	O	O
Treat	PROPN	O	O
Cancer	PROPN	O	I-Entity
Cooperative	PROPN	O	O
Group	PROPN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
response	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
vinorelbine	NOUN	O	I-Entity
(	PUNCT	O	O
VNB	PROPN	O	I-Entity
)	PUNCT	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
single	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
metastatic	ADJ	O	O
squamous	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
esophageal	ADJ	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

Thirty	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
prior	ADJ	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
16	NUM	O	O
pretreated	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
chemotherapy	NOUN	O	O
were	VERB	O	O
assessable	ADJ	O	O
for	ADP	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

VNB	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
weekly	ADV	O	O
as	ADP	O	O
a	DET	O	O
25-mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
short	ADJ	O	O
intravenous	ADJ	O	O
(	PUNCT	O	O
i.v	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O

VNB	NOUN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
zero	NUM	O	O
instances	NOUN	O	O
of	ADP	O	O
WHO	PROPN	O	O
grade	NOUN	O	O
4	NUM	O	O
nonhematologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

At	ADP	O	O
least	ADV	O	O
one	NUM	O	O
episode	NOUN	O	O
of	ADP	O	O
grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
4	NUM	O	O
granulocytopenia	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
59%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
grade	NOUN	O	O
2	NUM	O	O
or	CCONJ	O	O
3	NUM	O	O
infection	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
16%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
no	DET	O	O
toxic	ADJ	O	O
deaths	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

Other	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
rare	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
peripheral	ADJ	O	B-Entity
neurotoxicity	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
minor	ADJ	O	O
(	PUNCT	O	O
26%	NUM	O	O
grade	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
VNB	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
active	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
metastatic	ADJ	O	O
esophageal	ADJ	O	B-Entity
squamous	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

Given	VERB	O	O
its	ADJ	O	O
excellent	ADJ	O	O
tolerance	NOUN	O	O
profile	NOUN	O	O
and	CCONJ	O	O
low	ADJ	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
further	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
VNB	PROPN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11135224)

Paclitaxel	PROPN	O	I-Entity
,	PUNCT	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
gemcitabine	ADJ	O	I-Entity
combination	NOUN	O	O
chemotherapy	NOUN	O	O
within	ADP	O	O
a	DET	O	O
multidisciplinary	ADJ	O	O
therapeutic	ADJ	O	O
approach	NOUN	O	O
in	ADP	O	O
metastatic	NOUN	O	O
nonsmall	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

Cisplatin	PROPN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
chemotherapy	NOUN	O	O
combinations	NOUN	O	O
improve	VERB	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
and	CCONJ	O	O
survival	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
nonsmall	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
(	PUNCT	O	O
NSCLC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
feasibility	NOUN	O	O
,	PUNCT	O	O
response	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
paclitaxel	NOUN	O	I-Entity
,	PUNCT	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
gemcitabine	NOUN	O	I-Entity
combination	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
metastatic	ADJ	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
consecutive	ADJ	O	O
chemotherapy	NOUN	O	O
-	PUNCT	O	O
naive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
Stage	PROPN	O	O
IV	PROPN	O	O
NSCLC	PROPN	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
Eastern	PROPN	O	O
Cooperative	PROPN	O	O
Oncology	PROPN	O	O
Group	PROPN	O	O
performance	NOUN	O	O
status	NOUN	O	O
of	ADP	O	O
0	NUM	O	O
-	SYM	O	O
2	NUM	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
(	PUNCT	O	O
135	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
given	VERB	O	O
intravenously	ADV	O	O
in	ADP	O	O
3	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
Day	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
given	VERB	O	O
intravenously	ADV	O	O
in	ADP	O	O
6	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
Day	PROPN	O	O
1	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
gemcitabine	NOUN	O	I-Entity
(	PUNCT	O	O
800	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
given	VERB	O	O
intravenously	ADV	O	O
in	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
Days	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
,	PUNCT	O	O
every	DET	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
responding	VERB	O	O
patients	NOUN	O	O
were	VERB	O	O
scheduled	VERB	O	O
to	PART	O	O
receive	VERB	O	O
consolidation	NOUN	O	O
radiotherapy	ADJ	O	O
and	CCONJ	O	O
24	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
preplanned	VERB	O	O
second	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
chemotherapy	NOUN	O	O
after	ADP	O	O
disease	NOUN	O	O
progression	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
response	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
rates	NOUN	O	O
reported	VERB	O	O
refer	VERB	O	O
only	ADV	O	O
to	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
regimen	NOUN	O	O
given	VERB	O	O
.	PUNCT	O	O

All	ADJ	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
for	ADP	O	O
toxicity	NOUN	O	I-Entity
;	PUNCT	O	O
34	NUM	O	O
were	VERB	O	O
examinable	ADJ	O	O
for	ADP	O	O
response	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
154	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
dose	NOUN	O	O
intensity	NOUN	O	O
was	VERB	O	O
131	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
paclitaxel	NOUN	O	I-Entity
(	PUNCT	O	O
97.3%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
117	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m(2	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
97.3%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1378	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
gemcitabine	NOUN	O	I-Entity
(	PUNCT	O	O
86.2%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

World	PROPN	O	O
Health	PROPN	O	O
Organization	PROPN	O	O
Grade	PROPN	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
39.9%	NUM	O	O
and	CCONJ	O	O
11.4%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
one	NUM	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
death	NOUN	O	I-Entity
.	PUNCT	O	O

Nonhematologic	ADJ	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
mild	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
,	PUNCT	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
gemcitabine	NOUN	O	I-Entity
is	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
shows	VERB	O	O
high	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
metastatic	NOUN	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
treatment	NOUN	O	O
merits	VERB	O	O
further	ADJ	O	O
comparison	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
regimens	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8590259)

Evaluation	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
of	ADP	O	O
aponidine	ADJ	O	B-Entity
hydrochloride	NOUN	O	I-Entity
ophthalmic	NOUN	O	O
solution	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
of	ADP	O	O
apraclonidine	NOUN	O	I-Entity
in	ADP	O	O
20	NUM	O	O
normal	ADJ	O	O
volunteers	NOUN	O	O
by	ADP	O	O
instilling	VERB	O	O
a	DET	O	O
single	ADJ	O	O
drop	NOUN	O	O
of	ADP	O	O
1%	NUM	O	O
apraclonidine	NOUN	O	I-Entity
in	ADP	O	O
their	ADJ	O	O
right	ADJ	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ocular	ADJ	O	B-Entity
hypotensive	ADJ	O	I-Entity
effects	NOUN	O	O
were	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
for	ADP	O	O
apraclonidine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
eyes	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
also	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
for	ADP	O	O
contralateral	ADJ	O	O
eyes	NOUN	O	O
from	ADP	O	O
three	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
topical	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
1%	NUM	O	O
apraclonidine	NOUN	O	I-Entity
.	PUNCT	O	O

Decreases	NOUN	O	B-Entity
in	ADP	O	I-Entity
systolic	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
were	VERB	O	O
statistically	ADV	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
clinically	ADV	O	O
,	PUNCT	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Conjunctival	PROPN	O	B-Entity
blanching	NOUN	O	I-Entity
and	CCONJ	O	O
mydriasis	NOUN	O	I-Entity
were	VERB	O	O
commonly	ADV	O	O
found	VERB	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
elevations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
upper	ADJ	O	O
lid	NOUN	O	O
margin	NOUN	O	O
in	ADP	O	O
most	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
more	ADJ	O	O
than	ADP	O	O
2	NUM	O	O
mm	PROPN	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
noticeable	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
appearance	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
subject	NOUN	O	O
suffered	VERB	O	O
from	ADP	O	O
mechanical	ADJ	O	O
entropion	NOUN	O	I-Entity
and	CCONJ	O	O
marked	VERB	O	O
corneal	ADJ	O	B-Entity
abrasion	NOUN	O	I-Entity
3	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
instillation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2096243)

Carmofur	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
organic	ADJ	O	B-Entity
mental	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Organic	ADJ	O	B-Entity
mental	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
a	DET	O	O
29-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prognostic	ADJ	O	O
period	NOUN	O	O
after	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
carmofur	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
leukoencephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Symptoms	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
euphoria	NOUN	O	O
,	PUNCT	O	O
emotional	ADJ	O	O
lability	NOUN	O	O
and	CCONJ	O	O
puerile	ADJ	O	O
attitude	NOUN	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
were	VERB	O	O
diagnosed	VERB	O	O
as	ADP	O	O
organic	ADJ	O	B-Entity
personality	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
criteria	NOUN	O	O
defined	VERB	O	O
in	ADP	O	O
the	DET	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
III	PROPN	O	O
-	PUNCT	O	O
R.	PROPN	O	O
It	PRON	O	O
is	VERB	O	O
referred	VERB	O	O
to	ADP	O	O
as	ADP	O	O
a	DET	O	O
frontal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Consequently	ADV	O	O
,	PUNCT	O	O
carmofur	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
leukoencephalopathy	NOUN	O	I-Entity
may	VERB	O	O
uncommonly	ADV	O	O
result	VERB	O	O
in	ADP	O	O
organic	ADJ	O	B-Entity
personality	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
residual	ADJ	O	O
state	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
may	VERB	O	O
be	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
structural	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
to	ADP	O	I-Entity
the	DET	O	I-Entity
frontal	ADJ	O	I-Entity
lobe	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6209318)

International	ADJ	O	O
mexiletine	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
antiarrhythmic	ADJ	O	O
coronary	ADJ	O	O
trial	NOUN	O	O
:	PUNCT	O	O
I.	PROPN	O	O
Report	PROPN	O	O
on	ADP	O	O
arrhythmia	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
antiarrhythmic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sustained	ADJ	O	O
release	NOUN	O	O
form	NOUN	O	O
of	ADP	O	O
mexiletine	NOUN	O	I-Entity
(	PUNCT	O	O
Mexitil	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Perlongets	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
placebo	NOUN	O	O
trial	NOUN	O	O
in	ADP	O	O
630	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
recent	ADJ	O	O
documented	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Large	ADJ	O	O
differences	NOUN	O	O
,	PUNCT	O	O
regarded	VERB	O	O
as	ADP	O	O
statistically	ADV	O	O
significant	ADJ	O	O
,	PUNCT	O	O
between	ADP	O	O
the	DET	O	O
mexiletine	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
that	DET	O	O
end	NOUN	O	O
point	NOUN	O	O
at	ADP	O	O
months	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
trends	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
month	NOUN	O	O
12	NUM	O	O
.	PUNCT	O	O

These	DET	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
even	ADV	O	O
though	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
mexiletine	NOUN	O	I-Entity
levels	NOUN	O	O
obtained	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
generally	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
those	DET	O	O
observed	VERB	O	O
in	ADP	O	O
studies	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
used	VERB	O	O
the	DET	O	O
regular	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
more	ADJ	O	O
deaths	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
mexiletine	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
7.6%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
4.8%	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Previously	ADV	O	O
recognized	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
gastrointestinal	ADJ	O	B-Entity
problems	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
more	ADV	O	O
frequent	ADJ	O	O
in	ADP	O	O
the	DET	O	O
mexiletine	NOUN	O	I-Entity
group	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3615541)

Regional	ADJ	O	O
localization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antagonism	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
by	ADP	O	O
intracerebral	ADJ	O	O
calcitonin	NOUN	O	I-Entity
injections	NOUN	O	O
.	PUNCT	O	O

Calcitonin	PROPN	O	I-Entity
receptors	NOUN	O	O
are	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intracerebral	ADJ	O	O
infusions	NOUN	O	O
of	ADP	O	O
calcitonin	NOUN	O	I-Entity
can	VERB	O	O
produce	VERB	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
these	DET	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
are	VERB	O	O
decreases	NOUN	O	O
in	ADP	O	O
food	NOUN	O	O
intake	NOUN	O	O
and	CCONJ	O	O
decreases	VERB	O	O
in	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
previous	ADJ	O	O
experiments	NOUN	O	O
we	PRON	O	O
found	VERB	O	O
that	DET	O	O
decreases	VERB	O	O
in	ADP	O	O
food	NOUN	O	O
intake	NOUN	O	O
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
local	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
calcitonin	NOUN	O	I-Entity
into	ADP	O	O
several	ADJ	O	O
hypothalamic	NOUN	O	O
sites	NOUN	O	O
and	CCONJ	O	O
into	ADP	O	O
the	DET	O	O
nucleus	NOUN	O	O
accumbens	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
experiment	NOUN	O	O
calcitonin	NOUN	O	I-Entity
decreased	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
when	ADV	O	O
locally	ADV	O	O
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
same	ADJ	O	O
sites	NOUN	O	O
where	ADV	O	O
it	PRON	O	O
decreases	VERB	O	O
food	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
areas	NOUN	O	O
where	ADV	O	O
calcitonin	NOUN	O	I-Entity
is	VERB	O	O
most	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
decreasing	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
are	VERB	O	O
located	VERB	O	O
in	ADP	O	O
the	DET	O	O
hypothalamus	NOUN	O	O
and	CCONJ	O	O
nucleus	NOUN	O	O
accumbens	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
these	DET	O	O
areas	NOUN	O	O
are	VERB	O	O
the	DET	O	O
major	ADJ	O	O
sites	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
of	ADP	O	O
calcitonin	NOUN	O	I-Entity
in	ADP	O	O
inhibiting	VERB	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8953972)

Fatal	ADJ	O	O
intracranial	ADJ	O	B-Entity
bleeding	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
prehospital	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
paramedic	ADJ	O	O
misjudgment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
execution	NOUN	O	O
of	ADP	O	O
a	DET	O	O
protocol	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
allergic	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
pulmonary	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
with	ADP	O	O
wheezing	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
sudden	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	B-Entity
distress	NOUN	O	I-Entity
,	PUNCT	O	O
rash	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
medicine	NOUN	O	O
led	VERB	O	O
the	DET	O	O
two	NUM	O	O
paramedics	NOUN	O	O
on	ADP	O	O
the	DET	O	O
scene	NOUN	O	O
to	PART	O	O
administer	VERB	O	O
subcutaneous	ADJ	O	O
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

Subsequently	ADV	O	O
,	PUNCT	O	O
acute	ADJ	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
and	CCONJ	O	O
fatal	ADJ	O	O
subarachnoid	NOUN	O	B-Entity
hemorrhage	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

Epinephrine	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
proven	VERB	O	O
role	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
in	ADP	O	O
prehospital	NOUN	O	O
care	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
use	NOUN	O	O
by	ADP	O	O
paramedics	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
suspected	VERB	O	O
allergic	ADJ	O	B-Entity
reaction	NOUN	O	I-Entity
and	CCONJ	O	O
severe	ADJ	O	O
hypertension	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
viewed	VERB	O	O
with	ADP	O	O
caution	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3782049)

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
massive	ADJ	O	O
rhabdomyolysis	NOUN	O	I-Entity
following	VERB	O	O
molindone	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Rhabdomyolysis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
lethal	ADJ	O	O
syndrome	NOUN	O	O
that	ADJ	O	O
psychiatric	ADJ	O	I-Entity
patients	NOUN	O	O
seem	VERB	O	O
predisposed	ADJ	O	O
to	PART	O	O
develop	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
typical	ADJ	O	O
laboratory	NOUN	O	O
features	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
complications	NOUN	O	O
of	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
schizophrenic	ADJ	O	I-Entity
patient	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
to	PART	O	O
illustrate	VERB	O	O
massive	ADJ	O	O
rhabdomyolysis	NOUN	O	I-Entity
and	CCONJ	O	O
subsequent	ADJ	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
following	VERB	O	O
molindone	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Physicians	NOUN	O	O
who	NOUN	O	O
prescribe	VERB	O	O
molindone	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
reaction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9100294)

Cardiovascular	ADJ	O	B-Entity
alterations	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
fetuses	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

Preclinical	ADJ	O	O
toxicologic	ADJ	O	O
investigation	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
a	DET	O	O
new	ADJ	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
Ro	PROPN	O	B-Entity
40	NUM	O	I-Entity
-	SYM	O	I-Entity
5967	NUM	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
cardiovascular	ADJ	O	B-Entity
alterations	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
fetuses	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
during	ADP	O	O
organogenesis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
in	ADP	O	O
general	ADJ	O	O
induce	VERB	O	O
cardiovascular	NOUN	O	B-Entity
malformations	NOUN	O	I-Entity
indicating	VERB	O	O
a	DET	O	O
pharmacologic	ADJ	O	O
class	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
three	NUM	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
structure	NOUN	O	O
,	PUNCT	O	O
nifedipine	NOUN	O	I-Entity
,	PUNCT	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
verapamil	ADV	O	I-Entity
,	PUNCT	O	O
along	ADP	O	O
with	ADP	O	O
the	DET	O	O
new	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Pregnant	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
one	NUM	O	O
of	ADP	O	O
these	DET	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
during	ADP	O	O
the	DET	O	O
period	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
morphogenesis	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
offspring	NOUN	O	O
examined	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
20	NUM	O	O
of	ADP	O	O
gestation	NOUN	O	O
for	ADP	O	O
cardiovascular	ADJ	O	B-Entity
malformations	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
low	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiovascular	NOUN	O	B-Entity
malformations	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
each	DET	O	O
of	ADP	O	O
the	DET	O	O
four	NUM	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
incidence	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
only	ADV	O	O
for	ADP	O	O
verapamil	NOUN	O	I-Entity
and	CCONJ	O	O
nifedipine	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
four	NUM	O	O
agents	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
aortic	ADJ	O	O
arch	NOUN	O	O
branching	VERB	O	O
variants	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
significantly	ADV	O	O
increased	VERB	O	O
only	ADV	O	O
for	ADP	O	O
Ro	PROPN	O	B-Entity
40	NUM	O	I-Entity
-	PUNCT	O	I-Entity
5967	NUM	O	I-Entity
and	CCONJ	O	O
verapamil	ADV	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19889778)

Differential	ADJ	O	O
impact	NOUN	O	O
of	ADP	O	O
immune	ADJ	O	O
escape	NOUN	O	O
mutations	NOUN	O	O
G145R	PROPN	O	O
and	CCONJ	O	O
P120	PROPN	O	O
T	PROPN	O	O
on	ADP	O	O
the	DET	O	O
replication	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
e	PROPN	O	I-Entity
antigen	NOUN	O	I-Entity
-	PUNCT	O	O
positive	ADJ	O	O
and	CCONJ	O	O
-negative	ADJ	O	O
strains	NOUN	O	O
.	PUNCT	O	O

Immune	ADJ	O	O
escape	NOUN	O	O
variants	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HBV	PROPN	O	O
)	PUNCT	O	O
represent	VERB	O	O
an	DET	O	O
emerging	VERB	O	O
clinical	ADJ	O	O
challenge	NOUN	O	O
,	PUNCT	O	O
because	ADP	O	O
they	PRON	O	O
can	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
vaccine	NOUN	O	O
escape	NOUN	O	O
,	PUNCT	O	O
HBV	PROPN	O	O
reactivation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
failure	NOUN	O	O
of	ADP	O	O
diagnostic	ADJ	O	O
tests	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
systematically	ADV	O	O
analyzed	VERB	O	O
the	DET	O	O
functional	ADJ	O	O
impact	NOUN	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
prevalent	ADJ	O	O
immune	ADJ	O	O
escape	NOUN	O	O
variants	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
sG145R	NOUN	O	O
and	CCONJ	O	O
sP120	NOUN	O	O
T	NOUN	O	O
mutants	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
viral	ADJ	O	O
replication	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
antiviral	ADJ	O	O
drug	NOUN	O	O
susceptibility	NOUN	O	O
of	ADP	O	O
common	ADJ	O	O
treatment	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
mutants	NOUN	O	O
with	ADP	O	O
resistance	NOUN	O	O
to	ADP	O	O
lamivudine	NOUN	O	I-Entity
(	PUNCT	O	O
LAM	PROPN	O	I-Entity
)	PUNCT	O	O
and/or	CCONJ	O	O
HBeAg	PROPN	O	I-Entity
negativity	NOUN	O	O
.	PUNCT	O	O

Replication	NOUN	O	O
-	PUNCT	O	O
competent	ADJ	O	O
HBV	PROPN	O	O
strains	NOUN	O	O
with	ADP	O	O
sG145R	NOUN	O	O
or	CCONJ	O	O
sP120	NOUN	O	O
T	NOUN	O	O
and	CCONJ	O	O
LAM	PROPN	O	I-Entity
resistance	NOUN	O	O
(	PUNCT	O	O
rtM204I	NOUN	O	O
or	CCONJ	O	O
rtL180M	PUNCT	O	O

/	SYM	O	O
rtM204V	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
generated	VERB	O	O
on	ADP	O	O
an	DET	O	O
HBeAg	PROPN	O	I-Entity
-	PUNCT	O	O
positive	ADJ	O	O
and	CCONJ	O	O
an	DET	O	O
HBeAg	PROPN	O	I-Entity
-	PUNCT	O	O
negative	ADJ	O	O
background	NOUN	O	O
with	ADP	O	O
precore	NOUN	O	O
(	PUNCT	O	O
PC	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
basal	VERB	O	O
core	ADJ	O	O
promoter	NOUN	O	O
(	PUNCT	O	O
BCP	PROPN	O	O
)	PUNCT	O	O
mutants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sG145R	ADJ	O	O
mutation	NOUN	O	O
strongly	ADV	O	O
reduced	VERB	O	O
HBsAg	PROPN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
able	ADJ	O	O
to	PART	O	O
fully	ADV	O	O
restore	VERB	O	O
the	DET	O	O
impaired	ADJ	O	O
replication	NOUN	O	O
of	ADP	O	O
LAM	PROPN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
HBV	PROPN	O	O
mutants	NOUN	O	O
to	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
HBV	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
PC	NOUN	O	O
or	CCONJ	O	O
BCP	PROPN	O	O
mutations	NOUN	O	O
further	ADV	O	O
enhanced	VERB	O	O
viral	ADJ	O	O
replication	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
sP120	NOUN	O	O
T	PROPN	O	O
substitution	NOUN	O	O
also	ADV	O	O
impaired	VERB	O	O
HBsAg	PROPN	O	I-Entity
secretion	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
enhance	VERB	O	O
the	DET	O	O
replication	NOUN	O	O
of	ADP	O	O
LAM	PROPN	O	I-Entity
-	PUNCT	O	O
resistant	ADJ	O	O
clones	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
concomitant	ADJ	O	O
occurrence	NOUN	O	O
of	ADP	O	O
HBeAg	PROPN	O	I-Entity
negativity	NOUN	O	O
(	PUNCT	O	O
PC	PROPN	O	O
/	SYM	O	O
BCP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sP120	NOUN	O	O
T	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
LAM	PROPN	O	I-Entity
resistance	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
restoration	NOUN	O	O
of	ADP	O	O
replication	NOUN	O	O
to	ADP	O	O
levels	NOUN	O	O
of	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
HBV	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
clones	NOUN	O	O
with	ADP	O	O
combined	VERB	O	O
immune	ADJ	O	O
escape	NOUN	O	O
and	CCONJ	O	O
LAM	PROPN	O	I-Entity
resistance	NOUN	O	O
mutations	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
nucleotide	NOUN	O	I-Entity
analogues	NOUN	O	O
adefovir	VERB	O	I-Entity
and	CCONJ	O	O
tenofovir	VERB	O	I-Entity
remained	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
suppressing	VERB	O	O
viral	ADJ	O	O
replication	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15278670)

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
sevoflurane	NOUN	O	I-Entity
on	ADP	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
sevoflurane	NOUN	O	I-Entity
on	ADP	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
cats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
convulsive	ADJ	O	I-Entity
threshold	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
+	SYM	O	O
/-	PUNCT	O	O

l(-1	PUNCT	O	O
)	PUNCT	O	O
with	ADP	O	O
lidocaine	NOUN	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
mg.kg(-1).min(-1	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
increasing	VERB	O	O
significantly	ADV	O	O
to	ADP	O	O
66.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

l(-1	PUNCT	O	O
)	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
end	NOUN	O	O
-	PUNCT	O	O
tidal	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
sevoflurane	NOUN	O	I-Entity
was	VERB	O	O
0.8%	NUM	O	O
.	PUNCT	O	O

l(-1	PUNCT	O	O
)	PUNCT	O	O
)	PUNCT	O	O
during	ADP	O	O
1.6%	NUM	O	O
sevoflurane	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
from	ADP	O	O
that	DET	O	O
during	ADP	O	O
0.8%	NUM	O	O
sevoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
celling	VERB	O	O
effect	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
convulsive	ADJ	O	I-Entity
threshold	NOUN	O	O
between	ADP	O	O
sevoflurane	NOUN	O	I-Entity
and	CCONJ	O	O
enflurane	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
became	VERB	O	O
less	ADV	O	O
marked	ADJ	O	O
when	ADV	O	O
higher	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
sevoflurane	NOUN	O	I-Entity
or	CCONJ	O	O
enflurane	NOUN	O	I-Entity
were	VERB	O	O
administered	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
at	ADP	O	O
convulsions	NOUN	O	I-Entity
decreased	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
1.6%	NUM	O	O
sevoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
0.8%	NUM	O	O
and	CCONJ	O	O
1.6%	NUM	O	O
enflurane	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lidocaine	NOUN	O	I-Entity
concentrations	NOUN	O	O
measured	VERB	O	O
when	ADV	O	O
the	DET	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
became	VERB	O	O
70	NUM	O	O
mmHg	NOUN	O	O
.	PUNCT	O	O

Apamin	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
blocker	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
potassium	NOUN	O	I-Entity
channels	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
intracerebroventricularly	ADV	O	O
in	ADP	O	O
rats	NOUN	O	O
anesthetized	VERB	O	O
with	ADP	O	O
0.8%	NUM	O	O
sevoflurane	NOUN	O	I-Entity
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anticonvulsive	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Apamin	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
ng	NOUN	O	O
)	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
tendency	NOUN	O	O
to	PART	O	O
decrease	VERB	O	O
the	DET	O	O
convulsive	ADJ	O	I-Entity
threshold	NOUN	O	O
(	PUNCT	O	O
21.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
sevoflurane	NOUN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
convulsive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
but	CCONJ	O	O
carries	VERB	O	O
some	DET	O	O
risk	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
circulatory	ADJ	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17042910)

Anti	PROPN	O	O
-	PUNCT	O	O
oxidant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
atorvastatin	NOUN	O	I-Entity
in	ADP	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O
1	NUM	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity

(	PUNCT	O	O
Dex)-induced	VERB	O	I-Entity
hypertension	NOUN	O	I-Entity
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
endothelial	ADJ	O	O
dysfunction	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
deficiency	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
superoxide	NOUN	O	I-Entity
(	PUNCT	O	O
O2-	PROPN	O	I-Entity
)	PUNCT	O	O
production	NOUN	O	O
.	PUNCT	O	O

Atorvastatin	PROPN	O	I-Entity
(	PUNCT	O	O
Ato	PROPN	O	I-Entity
)	PUNCT	O	O
possesses	VERB	O	O
pleiotropic	ADJ	O	O
properties	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
improve	VERB	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
through	ADP	O	O
increased	VERB	O	O
availability	NOUN	O	O
of	ADP	O	O
NO	PROPN	O	I-Entity
and	CCONJ	O	O
reduced	VERB	O	O
O2-	ADJ	O	I-Entity
production	NOUN	O	O
in	ADP	O	O
various	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

,	PUNCT	O	O
Ato	PROPN	O	I-Entity
could	VERB	O	O
prevent	VERB	O	O
endothelial	ADJ	O	O

NO	DET	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
eNOS	PROPN	O	O
)	PUNCT	O	O

downregulation	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
O2-	PROPN	O	I-Entity
in	ADP	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
(	PUNCT	O	O
SD	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
,	PUNCT	O	O
thereby	ADV	O	O
reducing	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
Ato	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
in	ADP	O	O
drinking	NOUN	O	O
water	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
tap	VERB	O	O
water	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
,	PUNCT	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
saline	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
after	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
Ato	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
and	CCONJ	O	O
continued	VERB	O	O
for	ADP	O	O
11	NUM	O	O
-	SYM	O	O
13	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Endothelial	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
acetylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasorelaxation	NOUN	O	O
and	CCONJ	O	O
phenylephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasoconstriction	NOUN	O	O
in	ADP	O	O
aortic	ADJ	O	O
segments	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
Dex	PROPN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
SBP	PROPN	O	O
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
109	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
Ato	PROPN	O	I-Entity
+	PROPN	O	O
Dex	PROPN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
SBP	PROPN	O	O
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
113	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
SBP	PROPN	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
Dex	PRON	O	I-Entity
alone	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Endothelial	PROPN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
relaxation	NOUN	O	O
and	CCONJ	O	O
eNOS	NOUN	O	O
mRNA	NOUN	O	O
expression	NOUN	O	O
were	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
the	DET	O	O
Dex	PROPN	O	I-Entity
+	PROPN	O	O
Ato	PROPN	O	I-Entity
group	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
Dex	PROPN	O	I-Entity
only	ADV	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	PROPN	O	O
<	PROPN	O	O
0.05	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O

Aortic	ADJ	O	O
superoxide	NOUN	O	I-Entity
production	NOUN	O	O
was	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
Dex	PROPN	O	I-Entity
+	PROPN	O	O
Ato	PROPN	O	I-Entity
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
group	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
Dex	PRON	O	I-Entity
alone	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
Ato	PROPN	O	I-Entity
improved	VERB	O	O
endothelial	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
reduced	VERB	O	O
superoxide	NOUN	O	I-Entity
production	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
SBP	PROPN	O	O
in	ADP	O	O
Dex	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
SD	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11897407)

99mTc	NUM	O	B-Entity
-	PUNCT	O	I-Entity
glucarate	NOUN	O	I-Entity
for	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Infarct	PROPN	O	I-Entity
-	PUNCT	O	O
avid	ADJ	O	O
radiopharmaceuticals	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
for	ADP	O	O
rapid	ADJ	O	O
and	CCONJ	O	O
timely	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
used	VERB	O	O
to	PART	O	O
produce	VERB	O	O
infarction	NOUN	O	I-Entity
implies	VERB	O	O
artery	NOUN	O	O
ligation	NOUN	O	O
but	CCONJ	O	O
chemical	NOUN	O	O
induction	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
easily	ADV	O	O
obtained	VERB	O	O
with	ADP	O	O
isoproterenol	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
new	ADJ	O	O
infarct	NOUN	O	I-Entity
-	PUNCT	O	O
avid	NOUN	O	O
radiopharmaceutical	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
glucaric	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
prepared	VERB	O	O
in	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
radiopharmacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
INCMNSZ	PROPN	O	O
.	PUNCT	O	O

99mTc	NUM	O	B-Entity
-	PUNCT	O	I-Entity
glucarate	NOUN	O	I-Entity
was	VERB	O	O
easy	ADJ	O	O
to	PART	O	O
prepare	VERB	O	O
,	PUNCT	O	O
stable	ADJ	O	O
for	ADP	O	O
96	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
study	VERB	O	O
its	ADJ	O	O
biodistribution	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Histological	ADJ	O	O
studies	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
developed	VERB	O	O
an	DET	O	O
infarct	NOUN	O	I-Entity
18	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
isoproterenol	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
99mTc	NUM	O	B-Entity
-	PUNCT	O	I-Entity
glucarate	NOUN	O	I-Entity
administration	NOUN	O	O
the	DET	O	O
standardised	ADJ	O	O
heart	NOUN	O	O
uptake	NOUN	O	O
value	NOUN	O	O
S(h)UV	PROPN	O	O
was	VERB	O	O
4.7	NUM	O	O
in	ADP	O	O
infarcted	ADJ	O	O
rat	ADJ	O	O
heart	NOUN	O	O
which	ADJ	O	O
is	VERB	O	O
six	NUM	O	O
times	NOUN	O	O
more	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
normal	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
high	ADJ	O	O
image	NOUN	O	O
quality	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
high	ADJ	O	O
contrast	NOUN	O	O
images	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
humans	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
96	NUM	O	O
h	NOUN	O	O
stability	NOUN	O	O
makes	VERB	O	O
it	PRON	O	O
an	DET	O	O
ideal	ADJ	O	O
agent	NOUN	O	O
to	PART	O	O
detect	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
early	ADJ	O	O
cardiac	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9812111)

A	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
comparison	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
for	ADP	O	O
psychosis	NOUN	O	I-Entity
and	CCONJ	O	O
disruptive	ADJ	O	B-Entity
behaviors	NOUN	O	I-Entity
in	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
psychosis	NOUN	O	I-Entity
and	CCONJ	O	O
disruptive	ADJ	O	B-Entity
behaviors	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
6-week	NUM	O	O
random	ADJ	O	O
-	PUNCT	O	O
assignment	NOUN	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
(	PUNCT	O	O
phase	NOUN	O	O
A	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
2	NUM	O	O
-	SYM	O	O
3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
standard	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
0.50	NUM	O	O
-	SYM	O	O
0.75	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
low	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
71	NUM	O	O
outpatients	NOUN	O	O
with	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
subsequent	ADJ	O	O
6-week	NUM	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
crossover	ADJ	O	O
phase	NOUN	O	O
(	PUNCT	O	O
phase	NOUN	O	O
B	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
patients	NOUN	O	O
taking	VERB	O	O
standard-	ADJ	O	O
or	CCONJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
were	VERB	O	O
switched	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
taking	VERB	O	O
placebo	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
standard-	ADJ	O	O
or	CCONJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
60	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
completed	VERB	O	O
phase	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
standard	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
was	VERB	O	O
efficacious	ADJ	O	O
and	CCONJ	O	O
superior	ADJ	O	O
to	ADP	O	O
both	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
scores	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Brief	PROPN	O	O
Psychiatric	PROPN	O	O
Rating	PROPN	O	O
Scale	PROPN	O	O
psychosis	NOUN	O	I-Entity
factor	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
psychomotor	NOUN	O	B-Entity
agitation	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
phase	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
extrapyramidal	ADJ	O	B-Entity
signs	NOUN	O	I-Entity
tended	VERB	O	O
to	PART	O	O
be	VERB	O	O
greater	ADJ	O	O
with	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
dose	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
two	NUM	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
primarily	ADV	O	O
because	ADP	O	O
of	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
(	PUNCT	O	O
20%	NUM	O	O
)	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
signs	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
from	ADP	O	O
placebo	NOUN	O	O
on	ADP	O	O
any	DET	O	O
measure	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
or	CCONJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicated	VERB	O	O
a	DET	O	O
favorable	ADJ	O	O
therapeutic	NOUN	O	O
profile	NOUN	O	O
for	ADP	O	O
haloperidol	NOUN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
-	SYM	O	O
3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
developed	VERB	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
extrapyramidal	ADJ	O	B-Entity
signs	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
narrow	ADJ	O	O
therapeutic	ADJ	O	O
window	NOUN	O	O
observed	VERB	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
may	VERB	O	O
also	ADV	O	O
apply	VERB	O	O
to	ADP	O	O
other	ADJ	O	O
neuroleptics	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
psychosis	NOUN	O	I-Entity
and	CCONJ	O	O
disruptive	ADJ	O	B-Entity
behaviors	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15572383)

Individual	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
ACE	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
rats	NOUN	O	O
predict	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
man	NOUN	O	O
,	PUNCT	O	O
differences	NOUN	O	O
in	ADP	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	PROPN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
,	PUNCT	O	O
related	VERB	O	O
to	ADP	O	O
ACE	PROPN	O	O
(	PUNCT	O	O
I	NOUN	O	O
/	SYM	O	O
D	PROPN	O	O
)	PUNCT	O	O
genotype	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
renal	ADJ	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
predictive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
ACE	PROPN	O	O
activity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
adriamycin	ADJ	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Renal	ADJ	O	O
ACE	PROPN	O	O
activity	NOUN	O	O
(	PUNCT	O	O
Hip	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
His	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Leu	PROPN	O	I-Entity
cleavage	NOUN	O	O
by	ADP	O	O
cortical	ADJ	O	O
homogenates	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
renal	ADJ	O	O
biopsy	NOUN	O	O
in	ADP	O	O
27	NUM	O	O
adult	NOUN	O	O
male	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
of	ADP	O	O
recovery	NOUN	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
adriamycin	ADJ	O	I-Entity
[	PUNCT	O	O
1.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
intravenously	ADV	O	O
(	PUNCT	O	O
i.v	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
was	VERB	O	O
measured	VERB	O	O
every	DET	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
anticipated	VERB	O	O
,	PUNCT	O	O
adriamycin	ADV	O	I-Entity
elicited	VERB	O	O
nephrotic	ADJ	O	I-Entity
range	NOUN	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
renal	ADJ	O	B-Entity
interstitial	ADJ	O	I-Entity
damage	NOUN	O	I-Entity
and	CCONJ	O	O
mild	ADJ	O	O
focal	ADJ	O	B-Entity
glomerulosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

Baseline	ADJ	O	O
renal	ADJ	O	O
ACE	PROPN	O	O
positively	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
relative	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
proteinuria	NOUN	O	I-Entity
after	ADP	O	O
adriamycin	ADV	O	I-Entity
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.62	NUM	O	O
,	PUNCT	O	O
P<0.01	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
renal	ADJ	O	O
interstitial	ADJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
actin	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.49	NUM	O	O
,	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
interstitial	ADJ	O	O
macrophage	NOUN	O	O
influx	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.56	NUM	O	O
,	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
interstitial	ADJ	O	O
collagen	NOUN	O	O
III	PROPN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.53	NUM	O	O
,	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
glomerular	ADJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
actin	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.74	NUM	O	O
,	PUNCT	O	O
P<0.01	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
glomerular	ADJ	O	O
desmin	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.48	NUM	O	O
,	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ACE	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
focal	ADJ	O	B-Entity
glomerulosclerosis	NOUN	O	I-Entity
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.22	NUM	O	O
,	PUNCT	O	O
NS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Individual	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
ACE	PROPN	O	O
activity	NOUN	O	O
predict	VERB	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
outbred	ADJ	O	O
rat	NOUN	O	O
strain	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
supports	VERB	O	O
the	DET	O	O
assumption	NOUN	O	O
that	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
ACE	PROPN	O	O
activity	NOUN	O	O
predispose	VERB	O	O
to	ADP	O	O
a	DET	O	O
less	ADV	O	O
favourable	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7420681)

Clinical	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
of	ADP	O	O
tobramycin	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
.	PUNCT	O	O

Nearly	ADV	O	O
3.2	NUM	O	O
million	NUM	O	O
people	NOUN	O	O
in	ADP	O	O
this	DET	O	O
country	NOUN	O	O
receive	VERB	O	O
aminoglycoside	ADP	O	I-Entity
antibiotics	NOUN	O	O
annually	ADV	O	O
.	PUNCT	O	O

Gentamicin	PROPN	O	B-Entity
sulfate	NOUN	O	I-Entity
and	CCONJ	O	O
tobramycin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
continue	VERB	O	O
to	PART	O	O
demonstrate	VERB	O	O
ototoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
animal	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
62	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
confirmed	VERB	O	O
initial	ADJ	O	O
normal	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
treated	VERB	O	O
with	ADP	O	O
2	NUM	O	O
to	PART	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
of	ADP	O	O
gentamicin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
or	CCONJ	O	O
tobramycin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
seven	NUM	O	O
days	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
up	PART	O	O
prospectively	ADV	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
at	ADV	O	O
least	ADJ	O	O
a	DET	O	O
one	NUM	O	O
-	PUNCT	O	O
third	NOUN	O	O
reduction	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
62	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
other	ADJ	O	O
causes	NOUN	O	O
for	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
33	NUM	O	O
(	PUNCT	O	O
15%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
tobramycin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
16	NUM	O	O
of	ADP	O	O
29	NUM	O	O
(	PUNCT	O	O
55.2%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
had	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
gentamicin	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
more	ADJ	O	O
than	ADP	O	O
three	NUM	O	O
times	NOUN	O	O
as	ADV	O	O
often	ADV	O	O
as	ADP	O	O
was	VERB	O	O
tobramycin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12907309)

Neuroprotective	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
MPEP	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
mGluR5	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dopaminergic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
dopamine	NOUN	O	I-Entity
outflow	NOUN	O	O
and	CCONJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
hyperthermia	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
metabotropic	ADJ	O	O
glutamate	ADJ	O	I-Entity
receptor	NOUN	O	O
5	NUM	O	O
(	PUNCT	O	O
mGluR5	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
toxic	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
on	ADP	O	O
dopaminergic	ADJ	O	O
neurones	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
sc	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
five	NUM	O	O
times	NOUN	O	O
,	PUNCT	O	O
reduced	VERB	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
striatal	ADJ	O	O
tissue	NOUN	O	O
when	ADV	O	O
measured	VERB	O	O
72	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
injection	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
selective	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
mGluR5	NOUN	O	O
,	PUNCT	O	O
2-methyl-6-(phenylethynyl)pyridine	NUM	O	I-Entity
(	PUNCT	O	O
MPEP	NOUN	O	I-Entity
;	PUNCT	O	O
5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
when	ADV	O	O
administered	VERB	O	O
five	NUM	O	O
times	NOUN	O	O
immediately	ADV	O	O
before	ADP	O	O
each	DET	O	O
methamphetamine	NOUN	O	I-Entity
injection	NOUN	O	O
reversed	VERB	O	O
the	DET	O	O
above	ADV	O	O
-	PUNCT	O	O
mentioned	VERB	O	O
methamphetamine	NOUN	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
MPEP	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
)	PUNCT	O	O
injection	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
basal	NOUN	O	O
extracellular	ADJ	O	O
dopamine	NOUN	O	I-Entity
level	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
dopamine	NOUN	O	I-Entity
release	NOUN	O	O
stimulated	VERB	O	O
either	CCONJ	O	O
by	ADP	O	O
methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
sc	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
by	ADP	O	O
intrastriatally	ADV	O	O
administered	VERB	O	O
veratridine	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
microM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
transiently	ADV	O	O
diminished	VERB	O	O
the	DET	O	O
methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
sc)-induced	ADJ	O	O
hyperthermia	NOUN	O	I-Entity
and	CCONJ	O	O
reduced	ADJ	O	O
basal	ADJ	O	O
body	NOUN	O	O
temperature	NOUN	O	O
.	PUNCT	O	O

MPEP	PROPN	O	I-Entity
administered	VERB	O	O
into	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
at	ADP	O	O
high	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
microM	NOUN	O	O
)	PUNCT	O	O
increased	VERB	O	O
extracellular	ADP	O	O
dopamine	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
lower	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
-	SYM	O	O
100	NUM	O	O
microM	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
devoid	ADJ	O	O
of	ADP	O	O
any	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
blockade	NOUN	O	O
of	ADP	O	O
mGluR5	NOUN	O	O
by	ADP	O	O
MPEP	PROPN	O	I-Entity
may	VERB	O	O
protect	VERB	O	O
dopaminergic	ADJ	O	O
neurones	NOUN	O	O
against	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Neuroprotection	NOUN	O	O
rendered	VERB	O	O
by	ADP	O	O
MPEP	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dopamine	NOUN	O	I-Entity
efflux	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
the	DET	O	O
blockade	NOUN	O	O
of	ADP	O	O
extrastriatal	NOUN	O	O
mGluR5	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
hyperthermia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16680561)

Pharmacokinetics	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	B-Entity
HCl	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
with	ADP	O	O
cinacalcet	NOUN	O	B-Entity
HCl	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
vitro	NOUN	O	O
work	NOUN	O	O
has	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
cinacalcet	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
P450	PROPN	O	O
isoenzyme	NOUN	O	O
(	PUNCT	O	O
CYP	PROPN	O	O
)	PUNCT	O	O
2D6	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
cinacalcet	NOUN	O	I-Entity
on	ADP	O	O
CYP2D6	PROPN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
desipramine	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
probe	NOUN	O	O
substrate	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Seventeen	NUM	O	O
subjects	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
genotyped	VERB	O	O
as	ADP	O	O
CYP2D6	PROPN	O	O
extensive	ADJ	O	O
metabolizers	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
this	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
receive	VERB	O	O
a	DET	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
two	NUM	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
,	PUNCT	O	O
once	ADV	O	O
alone	ADV	O	O
and	CCONJ	O	O
once	ADV	O	O
after	ADP	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
cinacalcet	NOUN	O	I-Entity
(	PUNCT	O	O
90	NUM	O	O
mg	NUM	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Relative	ADJ	O	O
to	ADP	O	O
desipramine	NOUN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
mean	VERB	O	O
AUC	PROPN	O	O
and	CCONJ	O	O
C(max	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
increased	VERB	O	O
3.6-	NUM	O	O
and	CCONJ	O	O
1.8-fold	NUM	O	O
when	ADV	O	O
coadministered	VERB	O	O
with	ADP	O	O
cinacalcet	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
t	NOUN	O	O
(	PUNCT	O	O
1/2,z	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
was	VERB	O	O
longer	ADV	O	O
when	ADV	O	O
desipramine	NOUN	O	I-Entity
was	VERB	O	O
coadministered	VERB	O	O
with	ADP	O	O
cinacalcet	NOUN	O	I-Entity
(	PUNCT	O	O
21.0	NUM	O	O
versus	ADP	O	O
43.3	NUM	O	O
hs	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Fewer	ADJ	O	O
subjects	NOUN	O	O
reported	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
desipramine	NOUN	O	I-Entity
alone	ADV	O	O
than	ADP	O	O
when	ADV	O	O
receiving	VERB	O	O
desipramine	NOUN	O	I-Entity
with	ADP	O	O
cinacalcet	NOUN	O	I-Entity
(	PUNCT	O	O
33	NUM	O	O
versus	NOUN	O	O
86%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
frequent	ADJ	O	O
of	ADP	O	O
which	ADJ	O	O
(	PUNCT	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
headache	NOUN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
either	DET	O	O
desipramine	NOUN	O	I-Entity
or	CCONJ	O	O
cinacalcet	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
cinacalcet	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
CYP2D6	PROPN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
during	ADP	O	O
concomitant	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
cinacalcet	NOUN	O	I-Entity
,	PUNCT	O	O
dose	NOUN	O	O
adjustment	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
necessary	ADJ	O	O
for	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
demonstrate	VERB	O	O
a	DET	O	O
narrow	ADJ	O	O
therapeutic	ADJ	O	O
index	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
metabolized	VERB	O	O
by	ADP	O	O
CYP2D6	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (17532790)

Proteomic	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
striatal	ADJ	O	O
proteins	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
(	PUNCT	O	O
LID	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
among	ADP	O	O
the	DET	O	O
motor	NOUN	O	O
complications	NOUN	O	O
that	ADJ	O	O
arise	VERB	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
patients	NOUN	O	O
after	ADP	O	O
a	DET	O	O
prolonged	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
this	DET	O	O
day	NOUN	O	O
,	PUNCT	O	O
transcriptome	DET	O	O
analysis	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
LID	PROPN	O	I-Entity
[	PUNCT	O	O
Neurobiol	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
occurring	VERB	O	O
at	ADP	O	O
the	DET	O	O
protein	NOUN	O	O
level	NOUN	O	O
in	ADP	O	O
striatal	ADJ	O	O
samples	NOUN	O	O
obtained	VERB	O	O
from	ADP	O	O
the	DET	O	O
unilaterally	ADV	O	O
6-hydroxydopamine	NUM	O	I-Entity
-	PUNCT	O	O
lesion	NOUN	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
PD	PROPN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
,	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
or	CCONJ	O	O
bromocriptine	NOUN	O	I-Entity
using	VERB	O	O
two	NUM	O	O
-	PUNCT	O	O
dimensional	ADJ	O	O
difference	NOUN	O	O
gel	NOUN	O	O
electrophoresis	NOUN	O	O
and	CCONJ	O	O
mass	NOUN	O	O
spectrometry	NOUN	O	O
(	PUNCT	O	O
MS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
were	VERB	O	O
allocated	VERB	O	O
to	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
LID	PROPN	O	I-Entity
.	PUNCT	O	O

Out	ADP	O	O
of	ADP	O	O
these	DET	O	O
67	NUM	O	O
proteins	NOUN	O	O
,	PUNCT	O	O
LID	PROPN	O	I-Entity
significantly	ADV	O	O
changed	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
proteins	NOUN	O	O
:	PUNCT	O	O
alphabeta	NOUN	O	O
-	PUNCT	O	O
crystalin	NOUN	O	O
,	PUNCT	O	O
gamma	ADJ	O	O
-	PUNCT	O	O
enolase	NOUN	O	O
,	PUNCT	O	O
guanidoacetate	NOUN	O	O
methyltransferase	NOUN	O	O
,	PUNCT	O	O
vinculin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
proteasome	VERB	O	O
alpha-2	ADJ	O	O
subunit	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
provides	VERB	O	O
new	ADJ	O	O
insights	NOUN	O	O
into	ADP	O	O
the	DET	O	O
protein	NOUN	O	O
changes	VERB	O	O
occurring	VERB	O	O
in	PART	O	O
LID	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7582165)

Pseudo	PROPN	O	O
-	PUNCT	O	O
allergic	ADJ	O	B-Entity
reactions	NOUN	O	I-Entity
to	ADP	O	O
corticosteroids	NOUN	O	I-Entity
:	PUNCT	O	O
diagnosis	NOUN	O	O
and	CCONJ	O	O
alternatives	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
parenteral	ADJ	O	O
paramethasone	NOUN	O	I-Entity
(	PUNCT	O	O
Triniol	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
Sedionbel	PROPN	O	O
)	PUNCT	O	O
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
few	ADJ	O	O
minutes	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
presented	VERB	O	O
urticaria	NOUN	O	I-Entity
(	PUNCT	O	O
patients	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
conjunctivitis	NOUN	O	I-Entity
(	PUNCT	O	O
patient	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
examinations	NOUN	O	O
and	CCONJ	O	O
skin	NOUN	O	O
,	PUNCT	O	O
oral	ADJ	O	O
and	CCONJ	O	O
parenteral	ADJ	O	O
challenges	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
corticosteroids	NOUN	O	I-Entity
and	CCONJ	O	O
ELISA	PROPN	O	O
tests	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
skin	NOUN	O	O
and	CCONJ	O	O
ELISA	PROPN	O	O
tests	NOUN	O	O
with	ADP	O	O
paramethasone	NOUN	O	I-Entity
were	VERB	O	O
negative	ADJ	O	O
,	PUNCT	O	O
as	ADP	O	O
was	VERB	O	O
the	DET	O	O
prick	NOUN	O	O
test	NOUN	O	O
with	ADP	O	O
each	DET	O	O
of	ADP	O	O
its	ADJ	O	O
excipients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
carried	VERB	O	O
out	PART	O	O
oral	ADJ	O	O
and	CCONJ	O	O
parenteral	ADJ	O	O
challenges	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
corticosteroids	NOUN	O	I-Entity
and	CCONJ	O	O
found	VERB	O	O
intolerance	NOUN	O	O
to	ADP	O	O
some	DET	O	O
of	ADP	O	O
them	PRON	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
paramethasone	NOUN	O	I-Entity
caused	VERB	O	O
pseudoallergic	ADJ	O	O
reactions	NOUN	O	O
in	ADP	O	O
our	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Corticosteroids	NOUN	O	O
different	ADJ	O	O
from	ADP	O	O
paramethasone	NOUN	O	I-Entity
also	ADV	O	O
produced	VERB	O	O
hypersensitivity	ADJ	O	I-Entity
reactions	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
few	ADJ	O	O
of	ADP	O	O
them	PRON	O	O
were	VERB	O	O
tolerated	VERB	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pseudo	NOUN	O	O
-	PUNCT	O	O
allergy	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
paramethasone	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16787750)

Valproic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
induced	VERB	O	O
encephalopathy--19	PROPN	O	I-Entity
new	ADJ	O	O
cases	NOUN	O	O
in	ADP	O	O
Germany	PROPN	O	O
from	ADP	O	O
1994	NUM	O	O
to	ADP	O	O
2003	NUM	O	O
-	PUNCT	O	O
-a	NUM	O	O
side	NOUN	O	O
effect	NOUN	O	O
associated	VERB	O	O
to	ADP	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
therapy	NOUN	O	O
not	ADV	O	O
only	ADV	O	O
in	ADP	O	O
young	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

Valproic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
VPA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
broad	ADJ	O	O
-	PUNCT	O	O
spectrum	NOUN	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
usually	ADV	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
.	PUNCT	O	O

Rare	VERB	O	O
serious	ADJ	O	O
complications	NOUN	O	O
may	VERB	O	O
occur	VERB	O	O
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
haemorrhagic	ADJ	O	O
pancreatitis	NOUN	O	I-Entity
,	PUNCT	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
suppression	NOUN	O	I-Entity
,	PUNCT	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
typical	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
are	VERB	O	O
impaired	ADJ	O	B-Entity
consciousness	NOUN	O	I-Entity
,	PUNCT	O	O
sometimes	ADV	O	O
marked	VERB	O	O
EEG	PROPN	O	O
background	NOUN	O	O
slowing	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
seizure	NOUN	O	I-Entity
frequency	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
hyperammonemia	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
still	ADV	O	O
no	DET	O	O
proof	NOUN	O	O
of	ADP	O	O
causative	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
of	ADP	O	O
an	DET	O	O
association	NOUN	O	O
with	ADP	O	O
an	DET	O	O
assumed	ADJ	O	O
causal	ADJ	O	O
relation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
19	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
encephalopathy	NOUN	O	I-Entity
in	ADP	O	O
Germany	PROPN	O	O
from	ADP	O	O
the	DET	O	O
years	NOUN	O	O
1994	NUM	O	O
to	ADP	O	O
2003	NUM	O	O
,	PUNCT	O	O
none	NOUN	O	O
of	ADP	O	O
whom	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
published	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (3173180)

Haemolytic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
uraemic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
metronidazole	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
paper	NOUN	O	O
describes	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
children	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
the	DET	O	O
haemolytic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
uraemic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
metronidazole	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
metronidazole	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
aetiology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
haemolytic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
uraemic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
established	VERB	O	O
firmly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
sensitizing	VERB	O	O
tissues	NOUN	O	O
to	ADP	O	O
oxidation	NOUN	O	O
injury	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
reported	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
oxidation	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
haemolytic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
uraemic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
suggest	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
link	NOUN	O	O
between	ADP	O	O
metronidazole	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
some	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
the	DET	O	O
haemolytic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
uraemic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8996652)

Risk	NOUN	O	O
factors	NOUN	O	O
of	ADP	O	O
sensorineural	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
547	NUM	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
of	ADP	O	O
<	NUM	O	O
or	CCONJ	O	O
=	SYM	O	O
34	NUM	O	O
weeks	NOUN	O	O
gestation	NOUN	O	O
born	VERB	O	O
between	ADP	O	O
1987	NUM	O	O
and	CCONJ	O	O
1991	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
1.46%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
severe	ADJ	O	O
progressive	ADJ	O	O
and	CCONJ	O	O
bilateral	ADJ	O	O
sensorineural	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

Perinatal	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
of	ADP	O	O
infants	NOUN	O	O
with	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
two	NUM	O	O
control	NOUN	O	O
groups	NOUN	O	O
matched	VERB	O	O
for	ADP	O	O
gestation	NOUN	O	O
and	CCONJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
perinatal	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
observations	NOUN	O	O
demonstrated	VERB	O	O
an	DET	O	O
association	NOUN	O	O
of	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
perinatal	ADJ	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Ototoxicity	PROPN	O	I-Entity
appeared	VERB	O	O
closely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
prolonged	ADJ	O	O
administration	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
total	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ototoxic	ADJ	O	I-Entity
drugs	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
aminoglycosides	NOUN	O	I-Entity
and	CCONJ	O	O
furosemide	NOUN	O	I-Entity
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
strongly	ADV	O	O
recommend	VERB	O	O
to	ADP	O	O
prospectively	ADV	O	O
and	CCONJ	O	O
regularly	ADV	O	O
perform	VERB	O	O
audiologic	ADJ	O	O
assessment	NOUN	O	O
in	ADP	O	O
sick	ADJ	O	O
preterm	NOUN	O	O
children	NOUN	O	O
as	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
is	VERB	O	O
of	ADP	O	O
delayed	VERB	O	O
onset	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
most	ADJ	O	O
cases	NOUN	O	O
bilateral	ADJ	O	O
and	CCONJ	O	O
severe	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (84204)

Pharmacokinetic	PROPN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cimetidine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
.	PUNCT	O	O

15	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
that	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
investigated	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
mental	ADJ	O	O
status	NOUN	O	O
(	PUNCT	O	O
M.S.	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	O
and	CCONJ	O	O
hepatic	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
36	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
no	DET	O	O
M.S.	PROPN	O	O
change	VERB	O	O
on	ADP	O	O
cimetidine	NOUN	O	I-Entity
and	CCONJ	O	O
6	NUM	O	O
had	VERB	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
changes	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
6	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
both	DET	O	O
renal	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
liver	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
cimetidine	NOUN	O	I-Entity
trough	NOUN	O	O
-	PUNCT	O	O
concentrations	NOUN	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
1.25	NUM	O	O
microgram	NOUN	O	O
/	SYM	O	O
ml	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
:	PUNCT	O	O
serum	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
concentrations	NOUN	O	O
was	VERB	O	O
0.24:1	NUM	O	O
and	CCONJ	O	O
indicates	VERB	O	O
that	ADP	O	O
cimetidine	NOUN	O	I-Entity
passes	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
;	PUNCT	O	O
it	PRON	O	O
also	ADV	O	O
raises	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
M.S.	PROPN	O	O
changes	NOUN	O	O
are	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
blockade	NOUN	O	O
of	ADP	O	O
histamine	NOUN	O	I-Entity
H2-receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
likely	ADV	O	O
to	PART	O	O
have	VERB	O	O
both	DET	O	O
raised	VERB	O	O
trough	NOUN	O	O
-	PUNCT	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
are	VERB	O	O
those	DET	O	O
with	ADP	O	O
both	DET	O	O
severe	ADJ	O	O
renal	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
hepatic	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

They	PRON	O	O
should	VERB	O	O
be	VERB	O	O
closely	ADV	O	O
observed	ADJ	O	O
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
given	VERB	O	O
reduced	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9862868)

Different	ADJ	O	O
lobular	ADJ	O	O
distributions	NOUN	O	O
of	ADP	O	O
altered	VERB	O	O
hepatocyte	NOUN	O	O
tight	ADJ	O	O
junctions	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
intrahepatic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
extrahepatic	ADJ	O	I-Entity
cholestasis	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
hepatocyte	NOUN	O	O
TJs	NOUN	O	O
are	VERB	O	O
impaired	VERB	O	O
in	ADP	O	O
cholestasis	NOUN	O	I-Entity
,	PUNCT	O	O
attempts	NOUN	O	O
to	PART	O	O
localize	VERB	O	O
the	DET	O	O
precise	ADJ	O	O
site	NOUN	O	O
of	ADP	O	O
hepatocyte	NOUN	O	O
TJ	PROPN	O	O
damage	NOUN	O	O
by	ADP	O	O
freeze	NOUN	O	O
-	PUNCT	O	O
fracture	NOUN	O	O
electron	NOUN	O	O
microscopy	NOUN	O	O
have	VERB	O	O
produced	VERB	O	O
limited	ADJ	O	O
information	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
rat	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
intrahepatic	ADJ	O	B-Entity
cholestasis	NOUN	O	I-Entity
by	ADP	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
(	PUNCT	O	O
EE	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
extrahepatic	ADJ	O	B-Entity
cholestasis	NOUN	O	I-Entity
by	ADP	O	O
bile	NOUN	O	O
duct	NOUN	O	O
ligation	NOUN	O	O
(	PUNCT	O	O
BDL	PROPN	O	O
)	PUNCT	O	O
to	PART	O	O
precisely	ADV	O	O
determine	VERB	O	O
the	DET	O	O
site	NOUN	O	O
of	ADP	O	O
TJ	PROPN	O	O
damage	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
EE	PROPN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
immunostaining	VERB	O	O
for	ADP	O	O
7H6	NUM	O	O
and	CCONJ	O	O
ZO-1	NUM	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
seen	VERB	O	O
in	ADP	O	O
periportal	NOUN	O	O
hepatocytes	NOUN	O	O
after	ADP	O	O
BDL	PROPN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
distributed	VERB	O	O
more	ADV	O	O
diffusely	ADV	O	O
throughout	ADP	O	O
the	DET	O	O
lobule	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
to	PART	O	O
demonstrate	VERB	O	O
that	ADP	O	O
impairment	NOUN	O	O
of	ADP	O	O
hepatocyte	NOUN	O	O
TJs	PROPN	O	O
occurs	VERB	O	O
heterogenously	ADV	O	O
in	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
lobule	NOUN	O	O
after	ADP	O	O
BDL	PROPN	O	O
and	CCONJ	O	O
suggests	VERB	O	O
that	ADP	O	O
BDL	PROPN	O	O
and	CCONJ	O	O
EE	PROPN	O	I-Entity
treatments	NOUN	O	O
produce	VERB	O	O
different	ADJ	O	O
lobular	ADJ	O	O
distributions	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
paracellular	ADJ	O	O
permeability	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15515654)

Long	ADJ	O	O
term	NOUN	O	O
audiological	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
thalassemic	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
identify	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
monitor	VERB	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
young	ADJ	O	O
adults	NOUN	O	O
with	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
thalassemia	NOUN	O	I-Entity
major	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
desferrioxamine	NOUN	O	I-Entity
(	PUNCT	O	O
DFO	PROPN	O	I-Entity
)	PUNCT	O	O
chelation	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
-	PUNCT	O	O
60	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
,	PUNCT	O	O
5	NUM	O	O
-	SYM	O	O
6	NUM	O	O
days	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
six	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
then	ADV	O	O
reduced	VERB	O	O
to	ADP	O	O
40	NUM	O	O
-	SYM	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
the	DET	O	O
following	VERB	O	O
eight	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
21	NUM	O	O
out	ADP	O	O
of	ADP	O	O
104	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
20.2%	NUM	O	O
)	PUNCT	O	O
presented	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
frequency	NOUN	O	O
sensorineural	ADJ	O	B-Entity
hearing	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
(	PUNCT	O	O
SNHL	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
either	CCONJ	O	O
unilateral	ADJ	O	O
or	CCONJ	O	O
bilateral	ADJ	O	O
.	PUNCT	O	O

No	DET	O	O
ototoxic	ADJ	O	I-Entity
factor	NOUN	O	O
,	PUNCT	O	O
other	ADJ	O	O
than	ADP	O	O
DFO	PROPN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
SNHL	PROPN	O	I-Entity
presented	VERB	O	O
with	ADP	O	O
relatively	ADV	O	O
lower	ADJ	O	O
serum	NOUN	O	O
ferritin	NOUN	O	O
levels	NOUN	O	O
than	ADP	O	O
those	DET	O	O
with	ADP	O	O
normal	ADJ	O	O
hearing	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
with	ADP	O	O
SNHL	PROPN	O	I-Entity
were	VERB	O	O
submitted	VERB	O	O
to	ADP	O	O
DFO	PROPN	O	I-Entity
reduction	NOUN	O	O
or	CCONJ	O	O
temporary	ADJ	O	O
withdrawal	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
findings	NOUN	O	O
are	VERB	O	O
indicative	ADJ	O	O
of	ADP	O	O
DFO	PROPN	O	I-Entity
's	PART	O	O
contributing	VERB	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hearing	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

Regular	ADJ	O	O
audiologic	ADJ	O	O
evaluation	NOUN	O	O
is	VERB	O	O
imperative	ADJ	O	O
in	ADP	O	O
all	DET	O	O
thalassemic	ADJ	O	I-Entity
patients	NOUN	O	O
so	ADP	O	O
that	ADP	O	O
early	ADJ	O	O
changes	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
recognized	VERB	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
judiciously	ADV	O	O
adjusted	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
or	CCONJ	O	O
reverse	VERB	O	O
hearing	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2024540)

Design	NOUN	O	O
and	CCONJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
HYPREN	PROPN	O	O
-	PUNCT	O	O
trial	NOUN	O	O
:	PUNCT	O	O
safety	NOUN	O	O
of	ADP	O	O
enalapril	NOUN	O	I-Entity
and	CCONJ	O	O
prazosin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
phase	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	B-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
ACE	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
inhibitors	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
adjunctive	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
cases	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
have	VERB	O	O
occasionally	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ACE	PROPN	O	B-Entity
inhibitor	NOUN	O	I-Entity
enalapril	VERB	O	I-Entity
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
prazosin	NOUN	O	I-Entity
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
that	ADP	O	O
compared	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
symptomatic	ADJ	O	O
hypotension	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Trial	ADJ	O	O
medication	NOUN	O	O
was	VERB	O	O
2.5	NUM	O	O
mg	NUM	O	O
enalapril	NOUN	O	I-Entity
or	CCONJ	O	O
0.5	NUM	O	O
prazosin	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
enalapril	ADV	O	I-Entity
experienced	VERB	O	O
clinically	ADV	O	O
and	CCONJ	O	O
statistically	ADV	O	O
significantly	ADV	O	O
less	ADV	O	O
symptomatic	ADJ	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
5.2%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
prazosin	NOUN	O	I-Entity
(	PUNCT	O	O
12.9%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
enalapril	NOUN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
unreasonable	ADJ	O	O
to	PART	O	O
restrict	VERB	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
enalapril	NOUN	O	I-Entity
to	ADP	O	O
inpatients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12090760)

Antagonism	NOUN	O	O
between	ADP	O	O
interleukin	NOUN	O	O
3	NUM	O	O
and	CCONJ	O	O
erythropoietin	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
azidothymidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Azidothymidine	PROPN	O	I-Entity
(	PUNCT	O	O
AZT)-induced	VERB	O	I-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
reversed	VERB	O	O
by	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
IL-3	PROPN	O	O
(	PUNCT	O	O
fusion	NOUN	O	O
protein	NOUN	O	O
of	ADP	O	O
insulin	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
II	PROPN	O	O
(	PUNCT	O	O
IGF	PROPN	O	O
II	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
interleukin	NOUN	O	O
3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
interleukin	NOUN	O	O
3	NUM	O	O
(	PUNCT	O	O
IL-3	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
erythropoietin	NOUN	O	O
(	PUNCT	O	O
EPO	PROPN	O	O
)	PUNCT	O	O
are	VERB	O	O
known	VERB	O	O
to	PART	O	O
act	VERB	O	O
synergistically	ADV	O	O
on	ADP	O	O
hematopoietic	ADJ	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
,	PUNCT	O	O
injection	NOUN	O	O
of	ADP	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
IL-3	PROPN	O	O
and	CCONJ	O	O
EPO	PROPN	O	O
in	ADP	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
mice	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
red	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
EPO	PROPN	O	O
levels	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
IL-3	PROPN	O	O
or	CCONJ	O	O
EPO	PROPN	O	O
alone	ADV	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
thymidine	NOUN	O	I-Entity
incorporation	NOUN	O	O
into	ADP	O	O
both	DET	O	O
erythroid	NOUN	O	O
and	CCONJ	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
cultures	NOUN	O	O
pre	ADV	O	O
-	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
IGF	PROPN	O	O
-	PUNCT	O	O
IL-3	PROPN	O	O
and	CCONJ	O	O
EPO	PROPN	O	O
.	PUNCT	O	O

Endothelial	ADJ	O	O
cell	NOUN	O	O
culture	NOUN	O	O
supernatants	NOUN	O	O
separated	VERB	O	O
by	ADP	O	O
ultrafiltration	NOUN	O	O
and	CCONJ	O	O
ultracentrifugation	NOUN	O	O
from	ADP	O	O
cells	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
EPO	PROPN	O	O
and	CCONJ	O	O
IL-3	PROPN	O	O
significantly	ADV	O	O
reduced	VERB	O	O
thymidine	NOUN	O	I-Entity
incorporation	NOUN	O	O
into	ADP	O	O
erythroid	ADJ	O	O
cells	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
identical	ADJ	O	O
fractions	NOUN	O	O
obtained	VERB	O	O
from	ADP	O	O
the	DET	O	O
media	NOUN	O	O
of	ADP	O	O
cells	NOUN	O	O
cultured	VERB	O	O
with	ADP	O	O
EPO	PROPN	O	O
alone	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (7516729)

Interactive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
variations	NOUN	O	O
in	ADP	O	O
[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
and	CCONJ	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
on	ADP	O	O
rat	NOUN	O	O
atrial	ADJ	O	O
spontaneous	ADJ	O	O
frequency	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
varying	VERB	O	O
the	DET	O	O
extracellular	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
Na	PROPN	O	I-Entity
and	CCONJ	O	O
Ca	PROPN	O	I-Entity
(	PUNCT	O	O
[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
and	CCONJ	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
both	DET	O	O
,	PUNCT	O	O
the	DET	O	O
spontaneous	ADJ	O	O
beating	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
negative	ADJ	O	O
chronotropic	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
rat	NOUN	O	O
atria	NOUN	O	O
.	PUNCT	O	O

in	ADP	O	O
control	NOUN	O	O
Krebs	PROPN	O	O
-	PUNCT	O	O
Ringer	PROPN	O	O
containing	VERB	O	O
137	NUM	O	O
mM	NOUN	O	O
Na	PROPN	O	I-Entity
and	CCONJ	O	O
1.35	NUM	O	O
mM	NOUN	O	O
Ca	PROPN	O	I-Entity
(	PUNCT	O	O
N	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

3%	NUM	O	O
by	ADP	O	O
lowering	VERB	O	O
[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
to	ADP	O	O
78	NUM	O	O
mM	PROPN	O	O
(	PUNCT	O	O
LNa	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
23	NUM	O	O

[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
to	ADP	O	O
78	NUM	O	O
mM	NOUN	O	O
and	CCONJ	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
to	ADP	O	O
0.675	NUM	O	O
mM	PROPN	O	O
(	PUNCT	O	O
LNa+LCa	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
31	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

5%	NUM	O	O
by	ADP	O	O
lowering	VERB	O	O
[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
to	ADP	O	O
78	NUM	O	O

mM	PROPN	O	O
plus	CCONJ	O	O
increasing	VERB	O	O
[	PUNCT	O	O
Ca]o	NOUN	O	I-Entity
to	ADP	O	O
3.6	NUM	O	O
mM	PROPN	O	O
(	PUNCT	O	O
LNa+HCa	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
normal	ADJ	O	O
[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
,	PUNCT	O	O
decrease	NOUN	O	O
(	PUNCT	O	O
0.675	NUM	O	O
mM	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
increase	NOUN	O	O
(	PUNCT	O	O
3.6	NUM	O	O
mM	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
modify	VERB	O	O
BF	PROPN	O	O
;	PUNCT	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
ten	NUM	O	O
times	NOUN	O	O
(	PUNCT	O	O
0.135	PUNCT	O	O
mM	PROPN	O	O
of	ADP	O	O
normal	ADJ	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
was	VERB	O	O
effective	ADJ	O	O
to	PART	O	O
reduce	VERB	O	O
BF	NOUN	O	O
by	ADP	O	O
40	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
bradycardia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
verapamil	NOUN	O	I-Entity
was	VERB	O	O
potentiated	VERB	O	O
by	ADP	O	O
LNa	PROPN	O	O
,	PUNCT	O	O
LCa	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
HCa	PROPN	O	O
.	PUNCT	O	O

Independent	ADJ	O	O
but	CCONJ	O	O
not	ADV	O	O
additive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
Na	PROPN	O	I-Entity
and	CCONJ	O	O
Ca	PROPN	O	I-Entity
are	VERB	O	O
shown	VERB	O	O
by	ADP	O	O
decreases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
values	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	O
verapamil]o	NOUN	O	I-Entity
needed	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
BF	NOUN	O	O
by	ADP	O	O
30%	NUM	O	O
(	PUNCT	O	O
IC30	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
following	VERB	O	O
order	NOUN	O	O
of	ADP	O	O
inhibitory	ADJ	O	O
potency	NOUN	O	O
:	PUNCT	O	O
LNa	PROPN	O	O

The	DET	O	O
[	PUNCT	O	O
verapamil]o	ADP	O	I-Entity
that	DET	O	O
arrested	VERB	O	O
atrial	ADJ	O	O
beating	VERB	O	O
(	PUNCT	O	O
AC	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
potentiated	VERB	O	O
with	ADP	O	O
the	DET	O	O
order	NOUN	O	O
LNa	VERB	O	O
=	SYM	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
rat	NOUN	O	O
atrial	ADV	O	O
spontaneous	ADJ	O	O
beating	NOUN	O	O
is	VERB	O	O
more	ADJ	O	O
dependent	ADJ	O	O
on	ADP	O	O
[	PUNCT	O	O
Na]o	PROPN	O	I-Entity
than	ADP	O	O
on	ADP	O	O
[	PUNCT	O	O
Ca]o	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
+	X	O	O
/-	PUNCT	O	O

Also	ADV	O	O
the	DET	O	O
enhancement	NOUN	O	O
of	ADP	O	O
verapamil	ADJ	O	I-Entity
effects	NOUN	O	O
on	ADP	O	O
atrial	ADJ	O	O
beating	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
pronounced	ADJ	O	O
at	ADP	O	O
LNa	PROPN	O	O
than	ADP	O	O
at	ADP	O	O
LCa.(ABSTRACT	PROPN	O	O
TRUNCATED	PROPN	O	O
AT	PROPN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (2802551)

Sodium	NOUN	O	I-Entity
status	NOUN	O	O
influences	VERB	O	O
chronic	ADJ	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
nephrotoxic	ADJ	O	I-Entity
potential	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
intraperitoneally	ADV	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
depleted	VERB	O	O
,	PUNCT	O	O
normal	ADJ	O	O
-	PUNCT	O	O
salt	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
salt	NOUN	O	O
-	PUNCT	O	O
loaded	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
depleted	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
amphotericin	NOUN	O	B-Entity
B	NOUN	O	I-Entity
decreased	VERB	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
linearly	ADV	O	O
with	ADP	O	O
time	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
85%	NUM	O	O
reduction	NOUN	O	O
by	ADP	O	O
week	NOUN	O	O
3	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
normal	ADJ	O	O
-	PUNCT	O	O
salt	NOUN	O	O
rats	NOUN	O	O
creatinine	VERB	O	I-Entity
clearance	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
but	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
lesser	ADJ	O	O
extent	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
loaded	VERB	O	O
rats	NOUN	O	O
creatinine	VERB	O	I-Entity
clearance	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
43%	NUM	O	O
at	ADP	O	O
week	NOUN	O	O
3	NUM	O	O
.	PUNCT	O	O

All	DET	O	O
rats	NOUN	O	O
in	ADP	O	O
the	DET	O	O
sodium	NOUN	O	I-Entity
-	PUNCT	O	O
depleted	VERB	O	O
group	NOUN	O	O
had	VERB	O	O
histopathological	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
patchy	ADJ	O	O
tubular	ADJ	O	O
cytoplasmic	ADJ	O	O
degeneration	NOUN	O	O
in	ADP	O	O
tubules	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
any	DET	O	O
normal	ADJ	O	O
-	PUNCT	O	O
salt	NOUN	O	O
or	CCONJ	O	O
salt	NOUN	O	O
-	PUNCT	O	O
loaded	VERB	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Concentrations	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	NOUN	O	I-Entity
in	ADP	O	O
plasma	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
among	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
at	ADP	O	O
any	DET	O	O
time	NOUN	O	O
during	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kidneys	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
depleted	VERB	O	O
and	CCONJ	O	O
normal	ADJ	O	O
-	PUNCT	O	O
salt	NOUN	O	O
rats	NOUN	O	O
than	ADP	O	O
those	DET	O	O
in	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
loaded	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
plasma	NOUN	O	O
/	SYM	O	O
kidney	NOUN	O	O
ratios	NOUN	O	O
of	ADP	O	O
21	NUM	O	O
,	PUNCT	O	O
14	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
8	NUM	O	O
in	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
depleted	VERB	O	O
,	PUNCT	O	O
normal	ADJ	O	O
-	PUNCT	O	O
salt	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
salt	NOUN	O	O
-	PUNCT	O	O
loaded	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
reductions	NOUN	O	O
in	ADP	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
and	CCONJ	O	O
renal	NOUN	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
accumulation	NOUN	O	O
after	ADP	O	O
chronic	ADJ	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
administration	NOUN	O	O
were	VERB	O	O
enhanced	VERB	O	O
by	ADP	O	O
salt	NOUN	O	O
depletion	NOUN	O	O
and	CCONJ	O	O
attenuated	VERB	O	O
by	ADP	O	O
sodium	NOUN	O	I-Entity
loading	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19346865)

Reversible	ADJ	O	O
inferior	ADJ	O	B-Entity
colliculus	NOUN	O	I-Entity
lesion	NOUN	O	I-Entity
in	ADP	O	O
metronidazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
:	PUNCT	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
findings	NOUN	O	O
on	ADP	O	O
diffusion	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
and	CCONJ	O	O
fluid	ADJ	O	O
attenuated	ADJ	O	O
inversion	NOUN	O	O
recovery	NOUN	O	O
imaging	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
This	DET	O	O
is	VERB	O	O
to	PART	O	O
present	VERB	O	O
reversible	ADJ	O	O
inferior	ADJ	O	B-Entity
colliculus	NOUN	O	I-Entity
lesions	NOUN	O	I-Entity
in	ADP	O	O
metronidazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
to	PART	O	O
focus	VERB	O	O
on	ADP	O	O
the	DET	O	O
diffusion	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
DWI	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fluid	ADJ	O	O
attenuated	ADJ	O	O
inversion	NOUN	O	O
recovery	NOUN	O	O
(	PUNCT	O	O
FLAIR	PROPN	O	O
)	PUNCT	O	O
imaging	VERB	O	O
.	PUNCT	O	O

From	ADP	O	O
November	PROPN	O	O
2005	NUM	O	O
to	ADP	O	O
September	PROPN	O	O
2007	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
diagnosed	VERB	O	O
as	ADP	O	O
having	VERB	O	O
metronidazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
(	PUNCT	O	O
age	NOUN	O	O
range	NOUN	O	O
;	PUNCT	O	O
43	NUM	O	O
-	PUNCT	O	O
78	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

They	PRON	O	O
had	VERB	O	O
been	VERB	O	O
taking	VERB	O	O
metronidazole	NOUN	O	I-Entity
(	PUNCT	O	O
total	ADJ	O	O
dosage	NOUN	O	O
,	PUNCT	O	O
45	NUM	O	O
-	SYM	O	O
120	NUM	O	O
g	NOUN	O	O
;	PUNCT	O	O
duration	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
days	NOUN	O	O
to	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
treat	VERB	O	O
the	DET	O	O
infection	NOUN	O	I-Entity
in	ADP	O	O
various	ADJ	O	O
organs	NOUN	O	O
.	PUNCT	O	O

Follow	VERB	O	O
-	PUNCT	O	O
up	PART	O	O
MRIs	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
from	ADP	O	O
third	ADJ	O	O
to	ADP	O	O
14th	ADJ	O	O
days	NOUN	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
metronidazole	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

All	ADJ	O	O
the	DET	O	O
lesions	NOUN	O	O
in	ADP	O	O
dentate	NOUN	O	O
,	PUNCT	O	O
inferior	ADJ	O	O
colliculus	NOUN	O	O
,	PUNCT	O	O
pons	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
medullas	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
resolved	VERB	O	O
completely	ADV	O	O
on	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
MRIs	NOUN	O	O
in	ADP	O	O
5	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
of	ADP	O	O
them	PRON	O	O
,	PUNCT	O	O
corpus	NOUN	O	O
callosal	NOUN	O	B-Entity
lesion	NOUN	O	I-Entity
persisted	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Reversible	ADJ	O	O
inferior	ADJ	O	B-Entity
colliculus	NOUN	O	I-Entity
lesions	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
the	DET	O	O
characteristic	NOUN	O	O
for	ADP	O	O
metronidazole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
encephalopathy	NOUN	O	I-Entity
,	PUNCT	O	O
next	ADV	O	O
to	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
nucleus	NOUN	O	O
involvement	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2334618)

infusions	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
regional	ADJ	O	O
analgesia	NOUN	O	O
by	ADP	O	O
extradural	ADJ	O	O
block	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
respiratory	ADJ	O	O
apnoea	NOUN	O	I-Entity
was	VERB	O	O
compared	VERB	O	O
between	ADP	O	O
five	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
continuous	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

infusion	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
73.6	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
five	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
continuous	ADJ	O	O
extradural	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
0.25%	NUM	O	O
bupivacaine	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
192	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
24-h	NOUN	O	O
period	NOUN	O	O
following	VERB	O	O
upper	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Monitoring	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
airflow	NOUN	O	O
detection	NOUN	O	O
by	ADP	O	O
a	DET	O	O
carbon	NOUN	O	B-Entity
dioxide	NOUN	O	I-Entity
analyser	NOUN	O	O
,	PUNCT	O	O
chest	NOUN	O	O
wall	NOUN	O	O
movement	NOUN	O	O
detected	VERB	O	O
by	ADP	O	O
pneumatic	ADJ	O	O
capsules	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
continuous	ADJ	O	O
electrocardiograph	NOUN	O	O
recorded	VERB	O	O
with	ADP	O	O
a	DET	O	O
Holter	PROPN	O	O
ambulatory	NOUN	O	O
monitor	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
obstructive	ADJ	O	B-Entity
(	PUNCT	O	I-Entity
P	NOUN	O	I-Entity
less	ADJ	O	I-Entity
than	ADP	O	I-Entity
0.05	NUM	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
central	ADJ	O	I-Entity
apnoea	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
occurred	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
morphine	NOUN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
also	ADV	O	O
a	DET	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
tachyarrhythmias	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
ventricular	ADJ	O	B-Entity
ectopic	NOUN	O	I-Entity
beats	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
morphine	NOUN	O	I-Entity
infusion	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8864707)

Magnetic	ADJ	O	O
resonance	NOUN	O	O
volumetry	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cerebellum	NOUN	O	O
in	ADP	O	O
epileptic	ADJ	O	I-Entity
patients	NOUN	O	O
after	ADP	O	O
phenytoin	NOUN	O	I-Entity
overdosages	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
phenytoin	NOUN	O	I-Entity
medication	NOUN	O	O
and	CCONJ	O	O
cerebellar	ADJ	O	B-Entity
atrophy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
experienced	VERB	O	O
clinical	ADJ	O	O
intoxication	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
linear	NOUN	O	O
regression	NOUN	O	O
we	PRON	O	O
found	VERB	O	O
that	ADP	O	O
no	DET	O	O
correlation	NOUN	O	O
exists	VERB	O	O
between	ADP	O	O
seizure	NOUN	O	I-Entity
duration	NOUN	O	O
,	PUNCT	O	O
elevation	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
serum	NOUN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
cerebellar	ADJ	O	O
volume	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
regression	NOUN	O	O
for	ADP	O	O
the	DET	O	O
daily	ADJ	O	O
dosage	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
cerebellar	NOUN	O	O
volume	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
correlation	NOUN	O	O
of	ADP	O	O
these	DET	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
phenytoin	NOUN	O	I-Entity
overdosage	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
necessarily	ADV	O	O
result	VERB	O	O
in	ADP	O	O
cerebellar	NOUN	O	B-Entity
atrophy	NOUN	O	I-Entity
and	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
unlikely	ADJ	O	O
that	ADP	O	O
phenytoin	NOUN	O	I-Entity
medication	NOUN	O	O
was	VERB	O	O
the	DET	O	O
only	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
cerebellar	ADJ	O	B-Entity
atrophy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Quantitative	ADJ	O	O
morphometric	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cerebellum	NOUN	O	O
provide	VERB	O	O
valuable	ADJ	O	O
insights	NOUN	O	O
into	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
cerebellar	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12589964)

Evaluation	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
troponin	NOUN	O	O
I	PRON	O	O
and	CCONJ	O	O
T	PROPN	O	O
levels	NOUN	O	O
as	ADP	O	O
markers	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
rats	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
relationship	NOUN	O	O
with	ADP	O	O
echocardiographic	ADJ	O	O
and	CCONJ	O	O
histological	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O

Cardiac	PROPN	O	O
troponins	NOUN	O	O
I	PRON	O	O
(	PUNCT	O	O
cTnI	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
T	PROPN	O	O
(	PUNCT	O	O
cTnT	PROPN	O	O
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
highly	ADV	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
specific	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
diagnostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
cTnI	NOUN	O	O
and	CCONJ	O	O
cTnT	NOUN	O	O
for	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX)-induced	VERB	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
we	PRON	O	O
examined	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
serial	ADJ	O	O
cTnI	PROPN	O	O
and	CCONJ	O	O
cTnT	PROPN	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
monitored	VERB	O	O
by	ADP	O	O
echocardiography	NOUN	O	O
and	CCONJ	O	O
histological	ADJ	O	O
examinations	NOUN	O	O
in	ADP	O	O
this	DET	O	O
model	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
DOX	PROPN	O	I-Entity
,	PUNCT	O	O
i.v	PROPN	O	O
.	PUNCT	O	O

By	ADP	O	O
using	VERB	O	O
transthoracic	NOUN	O	O
echocardiography	NOUN	O	O
,	PUNCT	O	O
anterior	ADJ	O	O
and	CCONJ	O	O
posterior	ADJ	O	O
wall	NOUN	O	O
thickness	NOUN	O	O
,	PUNCT	O	O
LV	PROPN	O	O
diameters	NOUN	O	O
and	CCONJ	O	O
LV	PROPN	O	O
fractional	ADJ	O	O
shortening	NOUN	O	O
(	PUNCT	O	O
FS	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
all	DET	O	O
rats	NOUN	O	O
before	ADP	O	O
DOX	PROPN	O	I-Entity
or	CCONJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
weeks	NOUN	O	O
6	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
after	ADP	O	O
treatment	NOUN	O	O
in	ADP	O	O
all	DET	O	O
surviving	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Histology	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
rats	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
DOX	PROPN	O	I-Entity
dose	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
all	DET	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Eighteen	NUM	O	O
of	ADP	O	O
the	DET	O	O
DOX	PROPN	O	I-Entity
rats	NOUN	O	O
died	VERB	O	O
prematurely	ADV	O	O
of	ADP	O	O
general	ADJ	O	O
toxicity	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
9-week	NUM	O	O
period	NOUN	O	O
.	PUNCT	O	O

/	SYM	O	O
BW	PROPN	O	O
significantly	ADV	O	O
increased	VERB	O	O
,	PUNCT	O	O
whereas	ADP	O	O
LV	PROPN	O	O
FS	PROPN	O	O
was	VERB	O	O
decreased	VERB	O	O
after	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
DOX	PROPN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
p<0.001	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Histological	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
hearts	NOUN	O	O
from	ADP	O	O
all	DET	O	O
rats	NOUN	O	O
given	VERB	O	O
DOX	PROPN	O	I-Entity
revealed	VERB	O	O
significant	ADJ	O	O
slight	ADJ	O	O
degrees	NOUN	O	O
of	ADP	O	O
perivascular	NOUN	O	O
and	CCONJ	O	O
interstitial	ADJ	O	O
fibrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Only	ADV	O	O
five	NUM	O	O
of	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
exhibited	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
very	ADV	O	O
slight	ADJ	O	O
perivascular	ADJ	O	O
fibrosis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
cTnT	PROPN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
DOX	PROPN	O	I-Entity
rats	NOUN	O	O
after	ADP	O	O
cumulative	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
7.5	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
p<0.05	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

/	SYM	O	O
kg	X	O	O
DOX	PROPN	O	I-Entity
.	PUNCT	O	O

and	CCONJ	O	O
cTnT	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
DOX	PROPN	O	I-Entity
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
p=0.006	NOUN	O	O
,	PUNCT	O	O
0.007	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

cTnI	NOUN	O	O
(	PUNCT	O	O
ng	INTJ	O	O
/	SYM	O	O
ml	INTJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
mass	NOUN	O	O
and	CCONJ	O	O
CK	PROPN	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
in	ADP	O	O
DOX	PROPN	O	I-Entity
rats	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Among	ADP	O	O
markers	NOUN	O	O
of	ADP	O	O
ischemic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
after	ADP	O	O
DOX	PROPN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
cTnT	PROPN	O	O
showed	VERB	O	O
the	DET	O	O
greatest	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
detect	VERB	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
assessed	VERB	O	O
by	ADP	O	O
echocardiographic	ADJ	O	O
detection	NOUN	O	O
and	CCONJ	O	O
histological	ADJ	O	O
changes	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
discrepancy	NOUN	O	O
between	ADP	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
cTnI	NOUN	O	O
and	CCONJ	O	O
cTnT	NOUN	O	O
after	ADP	O	O
DOX	PROPN	O	I-Entity
,	PUNCT	O	O
probably	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
heterogeneity	NOUN	O	O
in	ADP	O	O
cross	NOUN	O	O
-	PUNCT	O	O
reactivities	NOUN	O	O
of	ADP	O	O
mAbs	PROPN	O	O
to	ADP	O	O
various	ADJ	O	O
cTnI	PROPN	O	O
and	CCONJ	O	O
cTnT	PROPN	O	O
forms	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
likely	ADJ	O	O
that	ADP	O	O
cTnT	PROPN	O	O
in	ADP	O	O
rats	NOUN	O	O
after	ADP	O	O
DOX	PROPN	O	I-Entity
indicates	VERB	O	O
cell	NOUN	O	O
damage	NOUN	O	O
determined	VERB	O	O
by	ADP	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
injury	NOUN	O	O
induced	VERB	O	O
and	CCONJ	O	O
that	ADP	O	O
cTnT	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
marker	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prediction	NOUN	O	O
of	ADP	O	O
experimentally	ADV	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
possibly	ADV	O	O
for	ADP	O	O
cardioprotective	ADJ	O	O
experiments	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11263551)

Calcineurin	PROPN	O	O
-	PUNCT	O	O
inhibitor	NOUN	O	O
induced	VERB	O	O
pain	NOUN	O	I-Entity
syndrome	NOUN	O	O
(	PUNCT	O	O
CIPS	PROPN	O	I-Entity
)	PUNCT	O	O
:	PUNCT	O	O
a	DET	O	O
severe	ADJ	O	O
disabling	VERB	O	O
complication	NOUN	O	O
after	ADP	O	O
organ	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Bone	PROPN	O	O
pain	NOUN	O	I-Entity
after	ADP	O	O
transplantation	NOUN	O	O
is	VERB	O	O
a	DET	O	O
frequent	ADJ	O	O
complication	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
several	ADJ	O	O
diseases	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
strategies	NOUN	O	O
depend	VERB	O	O
on	ADP	O	O
the	DET	O	O
correct	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Nine	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
their	ADJ	O	O
feet	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
registered	VERB	O	O
after	ADP	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
demonstrated	VERB	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
oedema	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
painful	ADJ	O	O
bones	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
explained	VERB	O	O
by	ADP	O	O
other	ADJ	O	O
diseases	NOUN	O	O
causing	VERB	O	O
foot	NOUN	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
like	ADP	O	O
reflex	NOUN	O	B-Entity
sympathetic	ADJ	O	I-Entity
dystrophy	NOUN	O	I-Entity
,	PUNCT	O	O
polyneuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
Morton	PROPN	O	B-Entity
's	PART	O	I-Entity
neuralgia	NOUN	O	I-Entity
,	PUNCT	O	O
gout	NOUN	O	I-Entity
,	PUNCT	O	O
osteoporosis	NOUN	O	I-Entity
,	PUNCT	O	O
avascular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
intermittent	ADJ	O	B-Entity
claudication	NOUN	O	I-Entity
,	PUNCT	O	O
orthopaedic	ADJ	O	O
foot	NOUN	O	B-Entity
deformities	NOUN	O	I-Entity
,	PUNCT	O	O
stress	NOUN	O	B-Entity
fractures	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hyperparathyroidism	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
cyclosporine-	NOUN	O	I-Entity
or	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
trough	NOUN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
relief	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Calcineurin	PROPN	O	O
-	PUNCT	O	O
inhibitor	NOUN	O	O
Induced	PROPN	O	O
Pain	PROPN	O	I-Entity
Syndrome	PROPN	O	O
(	PUNCT	O	O
CIPS	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
but	CCONJ	O	O
severe	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
or	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
accurately	ADV	O	O
diagnosed	VERB	O	O
by	ADP	O	O
its	ADJ	O	O
typical	ADJ	O	O
presentation	NOUN	O	O
,	PUNCT	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
scans	NOUN	O	O
.	PUNCT	O	O

Incorrect	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
syndrome	NOUN	O	O
will	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
quality	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
CIPS	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10520387)

The	DET	O	O
haemodynamic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
ephedrine	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
ASA	PROPN	O	O
groups	NOUN	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
marked	ADJ	O	O
vasodilator	NOUN	O	O
and	CCONJ	O	O
negative	ADJ	O	O
inotropic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
are	VERB	O	O
disadvantages	NOUN	O	O
in	ADP	O	O
frail	ADJ	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
adding	VERB	O	O
different	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
to	ADP	O	O
propofol	NOUN	O	I-Entity
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
obtund	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
haemodynamic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
adding	VERB	O	O
15	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
or	CCONJ	O	O
25	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
to	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
control	NOUN	O	O
in	ADP	O	O
40	NUM	O	O
ASA	PROPN	O	O
3/4	NUM	O	O
patients	NOUN	O	O
over	ADP	O	O
60	NUM	O	O
years	NOUN	O	O
presenting	VERB	O	O
for	ADP	O	O
genito	NOUN	O	O
-	PUNCT	O	O
urinary	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
to	ADP	O	O
propofol	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
obtunding	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
to	ADP	O	O
propofol	VERB	O	I-Entity
at	ADP	O	O
all	ADV	O	O
doses	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
marked	VERB	O	O
tachycardia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
occasionally	ADV	O	O
reaching	VERB	O	O
high	ADJ	O	O
levels	NOUN	O	O
in	ADP	O	O
individual	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Due	ADP	O	O
to	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
this	DET	O	O
tachycardia	NOUN	O	I-Entity
inducing	VERB	O	O
myocardial	NOUN	O	B-Entity
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
would	VERB	O	O
not	ADV	O	O
recommend	VERB	O	O
the	DET	O	O
use	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
of	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
ephedrine	NOUN	O	I-Entity
/	SYM	O	O
propofol	NOUN	O	I-Entity
/	SYM	O	O
mixtures	NOUN	O	O
studied	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (230316)

Neurotoxicity	NOUN	O	I-Entity
of	ADP	O	O
halogenated	VERB	O	B-Entity
hydroxyquinolines	NOUN	O	I-Entity
:	PUNCT	O	O
clinical	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
reported	VERB	O	O
outside	ADP	O	O
Japan	PROPN	O	O
.	PUNCT	O	O

An	DET	O	O
analysis	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
of	ADP	O	O
220	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
possible	ADJ	O	O
neurotoxic	ADJ	O	I-Entity
reactions	NOUN	O	O
to	ADP	O	O
halogenated	VERB	O	B-Entity
hydroxyquinolines	NOUN	O	I-Entity
reported	VERB	O	O
from	ADP	O	O
outside	ADP	O	O
Japan	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
80	NUM	O	O
cases	NOUN	O	O
insufficient	ADJ	O	O
information	NOUN	O	O
was	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
adequate	ADJ	O	O
comment	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
29	NUM	O	O
a	DET	O	O
relationship	NOUN	O	O
to	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
clioquinol	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
remainder	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
relationship	NOUN	O	O
to	ADP	O	O
clioquinol	NOUN	O	I-Entity
was	VERB	O	O
considered	VERB	O	O
probable	ADJ	O	O
in	ADP	O	O
42	NUM	O	O
and	CCONJ	O	O
possible	ADJ	O	O
in	ADP	O	O
69	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
six	NUM	O	O
of	ADP	O	O
the	DET	O	O
probable	ADJ	O	O
cases	NOUN	O	O
the	DET	O	O
neurological	ADJ	O	B-Entity
disturbance	NOUN	O	I-Entity
consisted	VERB	O	O
of	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
reversible	ADJ	O	O
encephalopathy	NOUN	O	I-Entity
usually	ADV	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
clioquinol	NOUN	O	I-Entity
over	ADP	O	O
a	DET	O	O
short	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
manifestation	NOUN	O	O
,	PUNCT	O	O
observed	VERB	O	O
in	ADP	O	O
15	NUM	O	O
further	ADJ	O	O
cases	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
isolated	ADJ	O	O
optic	NOUN	O	B-Entity
atrophy	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
most	ADV	O	O
frequently	ADV	O	O
found	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
,	PUNCT	O	O
many	DET	O	O
of	ADP	O	O
whom	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
clioquinol	NOUN	O	I-Entity
as	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
acrodermatitis	NOUN	O	B-Entity
enteropathica	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
cases	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
myelopathy	ADJ	O	I-Entity
,	PUNCT	O	O
visual	ADJ	O	B-Entity
disturbance	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
manifestation	NOUN	O	O
.	PUNCT	O	O

Isolated	VERB	O	O
myelopathy	NOUN	O	I-Entity
or	CCONJ	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
these	DET	O	O
manifestations	NOUN	O	O
occurring	VERB	O	O
together	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
infrequent	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
all	DET	O	O
manifestations	NOUN	O	O
(	PUNCT	O	O
except	ADP	O	O
toxic	ADJ	O	O
encephalopathy	NOUN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
usually	ADV	O	O
subacute	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
subsequent	ADJ	O	O
partial	ADJ	O	O
recovery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
full	ADJ	O	O
syndrome	NOUN	O	O
of	ADP	O	O
subacute	NOUN	O	O
myelo	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
optic	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
frequent	ADJ	O	O
in	ADP	O	O
women	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
they	PRON	O	O
tended	VERB	O	O
to	PART	O	O
have	VERB	O	O
taken	VERB	O	O
greater	ADJ	O	O
quantities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11807648)

Epileptic	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
following	VERB	O	O
cortical	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
fibrin	NOUN	O	O
sealants	NOUN	O	O
containing	VERB	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
synthetic	ADJ	O	O
fibrinolysis	NOUN	O	O
inhibitors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
tranexamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
tAMCA	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
substitutes	NOUN	O	O
for	ADP	O	O
aprotinin	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
tAMCA	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
cause	VERB	O	O
epileptic	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
wanted	VERB	O	O
to	PART	O	O
study	VERB	O	O
whether	ADP	O	O
tAMCA	PROPN	O	I-Entity
retains	VERB	O	O
its	ADJ	O	O
convulsive	ADJ	O	I-Entity
action	NOUN	O	O
if	ADP	O	O
incorporated	VERB	O	O
into	ADP	O	O
a	DET	O	O
FS	NOUN	O	O
.	PUNCT	O	O

FS	NOUN	O	O
containing	VERB	O	O
aprotinin	NOUN	O	O
or	CCONJ	O	O
different	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
tAMCA	PROPN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
-	SYM	O	O
47.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
applied	VERB	O	O
to	ADP	O	O
the	DET	O	O
pial	ADJ	O	O
surface	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
of	ADP	O	O
anaesthetized	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

FS	NOUN	O	O
containing	VERB	O	O
tAMCA	PROPN	O	I-Entity
caused	VERB	O	O
paroxysmal	ADJ	O	O
brain	NOUN	O	O
activity	NOUN	O	O
which	ADJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
distinct	ADJ	O	O
convulsive	ADJ	O	I-Entity
behaviours	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
these	DET	O	O
seizures	NOUN	O	I-Entity
increased	VERB	O	O
with	ADP	O	O
increasing	VERB	O	O
concentration	NOUN	O	O
of	ADP	O	O
tAMCA	PROPN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
FS	PROPN	O	O
containing	VERB	O	O
47.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
tAMCA	NOUN	O	I-Entity
evoked	VERB	O	O
generalized	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
in	ADP	O	O
all	DET	O	O
tested	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
n=6	PUNCT	O	O
)	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
lowest	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
tAMCA	PROPN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
only	ADV	O	O
evoked	VERB	O	O
brief	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
jerk	NOUN	O	O
-	PUNCT	O	O
correlated	VERB	O	O
convulsive	ADJ	O	I-Entity
potentials	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
of	ADP	O	O
6	NUM	O	O
rats	NOUN	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
:	PUNCT	O	O
Tranexamic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
retains	VERB	O	O
its	ADJ	O	O
convulsive	ADJ	O	I-Entity
action	NOUN	O	O
within	ADP	O	O
FS	PROPN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
FS	PROPN	O	O
containing	VERB	O	O
tAMCA	PROPN	O	I-Entity
for	ADP	O	O
surgery	NOUN	O	O
within	ADP	O	O
or	CCONJ	O	O
close	ADV	O	O
to	ADP	O	O
the	DET	O	O
CNS	PROPN	O	O
may	VERB	O	O
pose	VERB	O	O
a	DET	O	O
substantial	ADJ	O	O
risk	NOUN	O	O
to	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14596845)

A	DET	O	O
diet	NOUN	O	O
promoting	VERB	O	O
sugar	NOUN	O	B-Entity
dependency	NOUN	O	I-Entity
causes	VERB	O	O
behavioral	ADJ	O	B-Entity
cross	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sensitization	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
low	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

Previous	ADJ	O	O
research	NOUN	O	O
in	ADP	O	O
this	DET	O	O
laboratory	NOUN	O	O
has	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
a	DET	O	O
diet	NOUN	O	O
of	ADP	O	O
intermittent	ADJ	O	O
excessive	ADJ	O	O
sugar	NOUN	O	O
consumption	NOUN	O	O
produces	VERB	O	O
a	DET	O	O
state	NOUN	O	O
with	ADP	O	O
neurochemical	ADJ	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
similarities	NOUN	O	O
to	ADP	O	O
drug	NOUN	O	B-Entity
dependency	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
whether	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
on	ADP	O	O
various	ADJ	O	O
regimens	NOUN	O	O
of	ADP	O	O
sugar	NOUN	O	O
access	NOUN	O	O
would	VERB	O	O
show	VERB	O	O
behavioral	ADJ	O	B-Entity
cross	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
sensitization	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
low	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
30-min	NUM	O	O
baseline	NOUN	O	O
measure	NOUN	O	O
of	ADP	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
animals	NOUN	O	O
were	VERB	O	O
maintained	VERB	O	O
on	ADP	O	O
a	DET	O	O
cyclic	ADJ	O	O
diet	NOUN	O	O
of	ADP	O	O
12-h	NUM	O	O
deprivation	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
12-h	NUM	O	O
access	NOUN	O	O
to	ADP	O	O
10%	NUM	O	O
sucrose	NOUN	O	I-Entity
solution	NOUN	O	O
and	CCONJ	O	O
chow	NOUN	O	O
pellets	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
h	NOUN	O	O
access	NOUN	O	O
starting	VERB	O	O
4	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dark	ADJ	O	O
period	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
21	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
a	DET	O	O
single	ADJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
animals	NOUN	O	O
that	ADJ	O	O
had	VERB	O	O
experienced	VERB	O	O
cyclic	ADJ	O	O
sucrose	NOUN	O	I-Entity
and	CCONJ	O	O
chow	NOUN	O	O
were	VERB	O	O
hyperactive	ADJ	O	I-Entity
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
four	NUM	O	O
control	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
ad	NOUN	O	O
libitum	NOUN	O	O
10%	NUM	O	O
sucrose	NOUN	O	I-Entity
and	CCONJ	O	O
chow	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
amphetamine	NOUN	O	I-Entity
injection	NOUN	O	O
,	PUNCT	O	O
cyclic	ADJ	O	O
chow	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
amphetamine	NOUN	O	I-Entity
injection	NOUN	O	O
,	PUNCT	O	O
ad	NOUN	O	O
libitum	NOUN	O	O
chow	NOUN	O	O
with	ADP	O	O
amphetamine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
cyclic	ADJ	O	O
10%	NUM	O	O
sucrose	NOUN	O	I-Entity
and	CCONJ	O	O
chow	NOUN	O	O
with	ADP	O	O
a	DET	O	O
saline	ADJ	O	O
injection	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
diet	NOUN	O	O
comprised	VERB	O	O
of	ADP	O	O
alternating	VERB	O	O
deprivation	NOUN	O	O
and	CCONJ	O	O
access	NOUN	O	O
to	ADP	O	O
a	DET	O	O
sugar	NOUN	O	O
solution	NOUN	O	O
and	CCONJ	O	O
chow	NOUN	O	O
produces	VERB	O	O
bingeing	VERB	O	O
on	ADP	O	O
sugar	NOUN	O	O
that	ADJ	O	O
leads	VERB	O	O
to	ADP	O	O
a	DET	O	O
long	ADJ	O	O
lasting	ADJ	O	O
state	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
,	PUNCT	O	O
possibly	ADV	O	O
due	ADP	O	O
to	ADP	O	O
a	DET	O	O
lasting	ADJ	O	O
alteration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dopamine	NOUN	O	I-Entity
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6666578)

D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
angiopathy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
aortic	ADJ	O	O
permeability	NOUN	O	O
to	ADP	O	O
albumin	VERB	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
ultrastructure	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vessel	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
(	PUNCT	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
pen	NOUN	O	I-Entity
)	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
or	CCONJ	O	O
42	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

TEM	PROPN	O	O
revealed	VERB	O	O
extensive	ADJ	O	O
elastolysis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
arterial	ADJ	O	O
wall	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
pen	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
an	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
crosslink	NOUN	O	O
formation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aorta	NOUN	O	O
/	PUNCT	O	O
serum	NOUN	O	O
-	PUNCT	O	O
ratio	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
radioactive	ADJ	O	O
build	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
24	NUM	O	O
and	CCONJ	O	O
48	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
131I	NUM	O	O
-	PUNCT	O	O
HSA	PROPN	O	O
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
pen	NOUN	O	I-Entity
for	ADP	O	O
42	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
an	DET	O	O
impeded	VERB	O	O
transmural	ADJ	O	O
transport	NOUN	O	O
of	ADP	O	O
tracer	NOUN	O	O
which	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
a	DET	O	O
steric	ADJ	O	O
exclusion	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
abundant	ADJ	O	O
hyaluronate	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
endothelial	ADJ	O	O
ultrastructure	NOUN	O	O
was	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
pen	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
aortic	ADJ	O	O
131I	NUM	O	O
-	PUNCT	O	O
HSA	PROPN	O	O
radioactivity	NOUN	O	O
or	CCONJ	O	O
aorta	NOUN	O	O
/	SYM	O	O
serum	NOUN	O	O
-	PUNCT	O	O
ratio	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
between	ADP	O	O
experimental	ADJ	O	O
and	CCONJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
10	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
tracer	NOUN	O	O
injection	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
permeability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
endothelial	ADJ	O	O
barrier	NOUN	O	O
to	ADP	O	O
albumin	NOUN	O	O
remained	VERB	O	O
unaffected	ADJ	O	O
by	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
pen	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
support	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
pen	NOUN	O	I-Entity
may	VERB	O	O
induce	VERB	O	O
a	DET	O	O
fibroproliferative	ADJ	O	O
response	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
aorta	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
by	ADP	O	O
an	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
linking	VERB	O	O
of	ADP	O	O
collagen	NOUN	O	O
and	CCONJ	O	O
elastin	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11279304)

Brain	VERB	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
is	VERB	O	O
a	DET	O	O
predictor	NOUN	O	O
of	ADP	O	O
anthracycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Anthracyclines	NOUN	O	I-Entity
are	VERB	O	O
effective	ADJ	O	O
antineoplastic	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
they	PRON	O	O
frequently	ADV	O	O
cause	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiotoxicity	NOUN	O	I-Entity
of	ADP	O	O
conventional	ADJ	O	O
anthracycline	NOUN	O	I-Entity
therapy	NOUN	O	O
highlights	VERB	O	O
a	DET	O	O
need	NOUN	O	O
to	PART	O	O
search	VERB	O	O
for	ADP	O	O
methods	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
highly	ADV	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
capable	ADJ	O	O
of	ADP	O	O
predicting	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
measured	VERB	O	O
the	DET	O	O
plasma	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
(	PUNCT	O	O
BNP	PROPN	O	O
)	PUNCT	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
BNP	PROPN	O	O
might	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
a	DET	O	O
simple	ADJ	O	O
diagnostic	ADJ	O	O
indicator	NOUN	O	O
of	ADP	O	O
anthracycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
leukemia	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
daunorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DNR)-containing	VERB	O	I-Entity
regimen	NOUN	O	O
.	PUNCT	O	O

Thirteen	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
leukemia	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
DNR	PROPN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
diagnosed	VERB	O	O
as	ADP	O	O
having	VERB	O	O
subclinical	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
BNP	PROPN	O	O
in	ADP	O	O
all	ADJ	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
subclinical	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
increased	VERB	O	O
above	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
limit	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
pg	NOUN	O	O
/	SYM	O	O
ml	PROPN	O	O
)	PUNCT	O	O
before	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
or	CCONJ	O	O
subclinical	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
by	ADP	O	O
radionuclide	NOUN	O	O
angiography	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
BNP	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
increase	VERB	O	O
in	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
without	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
given	VERB	O	O
DNR	PROPN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
at	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
700	NUM	O	O
mg	NOUN	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
plasma	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
ANP	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
always	ADV	O	O
increase	VERB	O	O
in	ADP	O	O
all	ADJ	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
subclinical	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
preliminary	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
BNP	PROPN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
as	ADP	O	O
an	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
sensitive	ADJ	O	O
indicator	NOUN	O	O
of	ADP	O	O
anthracycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19884587)

Antibacterial	ADJ	O	O
medication	NOUN	O	O
use	NOUN	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
and	CCONJ	O	O
risk	NOUN	O	O
of	ADP	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
:	PUNCT	O	O
National	PROPN	O	O
Birth	PROPN	O	B-Entity
Defects	PROPN	O	I-Entity
Prevention	PROPN	O	O
Study	PROPN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
estimate	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
antibacterial	ADJ	O	O
medications	NOUN	O	O
and	CCONJ	O	O
selected	VERB	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
.	PUNCT	O	O

Population	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
,	PUNCT	O	O
multisite	NOUN	O	O
,	PUNCT	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
pregnancies	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
1	NUM	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
30	NUM	O	O
eligible	ADJ	O	O
major	ADJ	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
identified	VERB	O	O
via	ADP	O	O
birth	NOUN	O	B-Entity
defect	NOUN	O	I-Entity
surveillance	NOUN	O	O
programs	NOUN	O	O
in	ADP	O	O
10	NUM	O	O
states	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
13	NUM	O	O
155	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
women	NOUN	O	O
randomly	ADV	O	O
selected	VERB	O	O
from	ADP	O	O
the	DET	O	O
same	ADJ	O	O
geographical	ADJ	O	O
regions	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
4941	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Odds	NOUN	O	O
ratios	NOUN	O	O
(	PUNCT	O	O
ORs	PROPN	O	O
)	PUNCT	O	O
measuring	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
antibacterial	ADJ	O	O
use	NOUN	O	O
and	CCONJ	O	O
selected	VERB	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
adjusted	VERB	O	O
for	ADP	O	O
potential	ADJ	O	O
confounders	NOUN	O	O
.	PUNCT	O	O

Sulfonamides	NOUN	O	I-Entity
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
anencephaly	NOUN	O	I-Entity
(	PUNCT	O	O
adjusted	VERB	O	O
OR	PROPN	O	O
[	PUNCT	O	O
AOR	PROPN	O	O
]	PUNCT	O	O
=	SYM	O	O
3.4	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	PROPN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
1.3	NUM	O	O
-	SYM	O	O
8.8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hypoplastic	NOUN	O	B-Entity
left	VERB	O	I-Entity
heart	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
3.2	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.3	NUM	O	O
-	SYM	O	O
7.6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
coarctation	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
aorta	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
2.7	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.3	NUM	O	O
-	SYM	O	O
5.6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
choanal	ADJ	O	B-Entity
atresia	NOUN	O	I-Entity

(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
8.0	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
2.7	NUM	O	O
-	SYM	O	O
23.5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
transverse	ADJ	O	B-Entity
limb	NOUN	O	I-Entity
deficiency	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
2.5	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.0	NUM	O	O
-	SYM	O	O
5.9	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
diaphragmatic	ADJ	O	B-Entity
hernia	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
2.4	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.1	NUM	O	O
-	SYM	O	O
5.4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nitrofurantoins	NOUN	O	I-Entity
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
anophthalmia	NOUN	O	I-Entity
or	CCONJ	O	O
microphthalmos	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
3.7	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.1	NUM	O	O
-	SYM	O	O
12.2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hypoplastic	NOUN	O	B-Entity
left	VERB	O	I-Entity
heart	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
4.2	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.9	NUM	O	O
-	SYM	O	O
9.1	NUM	O	O
)	PUNCT	O	O

,	PUNCT	O	O
atrial	ADJ	O	B-Entity
septal	ADJ	O	I-Entity
defects	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
1.9	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
1.1	NUM	O	O
-	SYM	O	O
3.4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cleft	VERB	O	B-Entity
lip	NOUN	O	I-Entity
with	ADP	O	O
cleft	NOUN	O	B-Entity
palate	NOUN	O	I-Entity
(	PUNCT	O	O
AOR	PROPN	O	O
=	SYM	O	O
2.1	NUM	O	O
;	PUNCT	O	O

Other	ADJ	O	O
antibacterial	ADJ	O	O
agents	NOUN	O	O
that	ADJ	O	O
showed	VERB	O	O
associations	NOUN	O	O
included	VERB	O	O
erythromycins	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
defects	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
penicillins	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
defect	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cephalosporins	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
defect	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
quinolones	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
defect	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Reassuringly	ADV	O	O
,	PUNCT	O	O
penicillins	NOUN	O	I-Entity
,	PUNCT	O	O
erythromycins	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cephalosporins	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
used	VERB	O	O
commonly	ADV	O	O
by	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
many	ADJ	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
.	PUNCT	O	O

Sulfonamides	NOUN	O	I-Entity
and	CCONJ	O	O
nitrofurantoins	NOUN	O	I-Entity
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
several	ADJ	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
need	NOUN	O	O
for	ADP	O	O
additional	ADJ	O	O
scrutiny	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3970039)

Incidence	NOUN	O	O
of	ADP	O	O
neoplasms	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
exposed	VERB	O	O
to	ADP	O	O
different	ADJ	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

Immunosuppressive	ADJ	O	O
drugs	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
used	VERB	O	O
during	ADP	O	O
the	DET	O	O
last	ADJ	O	O
30	NUM	O	O
years	NOUN	O	O
in	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
drugs	NOUN	O	O
commonly	ADV	O	O
used	VERB	O	O
are	VERB	O	O
cyclophosphamide	NOUN	O	I-Entity
and	CCONJ	O	O
chlorambucil	NOUN	O	I-Entity
(	PUNCT	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
azathioprine	NOUN	O	I-Entity
(	PUNCT	O	O
purine	ADJ	O	I-Entity
analogue	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
methotrexate	NOUN	O	I-Entity
(	PUNCT	O	O
folic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
analogue	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
evidence	NOUN	O	O
that	ADP	O	O
all	DET	O	O
four	NUM	O	O
immunosuppressive	ADJ	O	O
drugs	NOUN	O	O
can	VERB	O	O
reduce	VERB	O	O
synovitis	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
disease	NOUN	O	O
activity	NOUN	O	O
almost	ADV	O	O
always	ADV	O	O
recurs	ADV	O	O
after	ADP	O	O
therapy	NOUN	O	O
is	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
have	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
nonlymphocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
both	DET	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
and	CCONJ	O	O
azathioprine	NOUN	O	I-Entity
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
Hodgkin	PROPN	O	I-Entity
's	PART	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

Cyclophosphamide	NOUN	O	I-Entity
therapy	NOUN	O	O
increases	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
bladder	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
have	VERB	O	O
been	VERB	O	O
several	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
studies	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
azathioprine	NOUN	O	I-Entity
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
most	ADJ	O	O
of	ADP	O	O
the	DET	O	O
common	ADJ	O	O
cancers	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
increased	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
malignancy	NOUN	O	I-Entity
in	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
are	VERB	O	O
still	ADV	O	O
being	VERB	O	O
collected	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
until	ADP	O	O
further	ADJ	O	O
information	NOUN	O	O
is	VERB	O	O
available	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
immunosuppressive	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
reserved	VERB	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
progressive	ADJ	O	O
disease	NOUN	O	O
or	CCONJ	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
complications	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (424937)

Patterns	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
methyldopa	NOUN	O	I-Entity
.	PUNCT	O	O

Twelve	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
methyldopa	NOUN	O	I-Entity
were	VERB	O	O
seen	VERB	O	O
between	ADP	O	O
1967	NUM	O	O
and	CCONJ	O	O
1977	NUM	O	O
.	PUNCT	O	O

Jaundice	PROPN	O	I-Entity
with	ADP	O	O
tender	NOUN	O	O
hepatomegaly	NOUN	O	I-Entity
,	PUNCT	O	O
usually	ADV	O	O
preceded	VERB	O	O
by	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
malaise	NOUN	O	O
,	PUNCT	O	O
anorexia	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
associated	VERB	O	O
with	ADP	O	O
upper	ADJ	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
an	DET	O	O
invariable	ADJ	O	O
finding	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Biochemical	ADJ	O	O
liver	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
indicated	VERB	O	O
hepatocellular	ADJ	O	O
necrosis	NOUN	O	I-Entity
and	CCONJ	O	O
correlated	VERB	O	O
with	ADP	O	O
histopathological	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
spectrum	NOUN	O	O
of	ADP	O	O
which	ADJ	O	O
ranged	VERB	O	O
from	ADP	O	O
fatty	ADJ	O	B-Entity
change	NOUN	O	I-Entity
and	CCONJ	O	O
focal	ADJ	O	O
hepatocellular	ADJ	O	O
necrosis	NOUN	O	I-Entity
to	ADP	O	O
massive	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Most	ADJ	O	O
patients	NOUN	O	O
showed	VERB	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
acute	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
or	CCONJ	O	O
chronic	ADJ	O	B-Entity
active	ADJ	O	I-Entity
hepatitis	NOUN	O	I-Entity
with	ADP	O	O
associated	VERB	O	O
cholestasis	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
died	VERB	O	O
,	PUNCT	O	O
having	VERB	O	O
presented	VERB	O	O
in	ADP	O	O
hepatic	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
another	DET	O	O
,	PUNCT	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
taking	VERB	O	O
methyldopa	NOUN	O	I-Entity
for	ADP	O	O
7	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
slower	ADJ	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
resolution	NOUN	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
remaining	VERB	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
series	NOUN	O	O
developed	VERB	O	O
fulminant	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
when	ADV	O	O
the	DET	O	O
drug	NOUN	O	O
was	VERB	O	O
accidentally	ADV	O	O
recommenced	VERB	O	O
1	NUM	O	O
year	NOUN	O	O
after	ADP	O	O
a	DET	O	O
prior	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
methyldopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
latter	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
2	NUM	O	O
others	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
causal	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
methyldopa	NOUN	O	I-Entity
and	CCONJ	O	O
hepatic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
was	VERB	O	O
proved	VERB	O	O
with	ADP	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
within	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
re	ADP	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8643971)

A	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
/	SYM	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
plus	CCONJ	O	O
cisplatin	NOUN	O	I-Entity
as	ADP	O	O
first	ADV	O	O
-	PUNCT	O	O
line	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
head	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
cancers	NOUN	O	I-Entity
:	PUNCT	O	O
preliminary	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

Improved	ADJ	O	O
outcomes	NOUN	O	O
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
head	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
carcinomas	NOUN	O	I-Entity
require	VERB	O	O
investigations	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
drugs	NOUN	O	O
for	ADP	O	O
induction	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Preliminary	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
an	DET	O	O
Eastern	PROPN	O	O
Cooperative	PROPN	O	O
Oncology	PROPN	O	O
Group	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
single	ADJ	O	O
-	PUNCT	O	O
agent	NOUN	O	O
paclitaxel	NOUN	O	I-Entity
(	PUNCT	O	O
Taxol	PROPN	O	I-Entity
;	PUNCT	O	O
Bristol	PROPN	O	O
-	PUNCT	O	O
Myers	PROPN	O	O
Squibb	PROPN	O	O
Company	PROPN	O	O
,	PUNCT	O	O
Princeton	PROPN	O	O
,	PUNCT	O	O
NJ	PROPN	O	O
)	PUNCT	O	O
reported	VERB	O	O
a	DET	O	O
37%	NUM	O	O
response	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
head	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
paclitaxel	NOUN	O	I-Entity
/	SYM	O	O
cisplatin	NOUN	O	I-Entity
combination	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
successfully	ADV	O	O
and	CCONJ	O	O
has	VERB	O	O
significantly	ADV	O	O
improved	VERB	O	O
median	ADJ	O	O
response	NOUN	O	O
duration	NOUN	O	O
in	ADP	O	O
ovarian	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
initiated	VERB	O	O
a	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
/	SYM	O	O
II	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
response	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
escalating	VERB	O	O
paclitaxel	ADJ	O	I-Entity
doses	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
fixed	VERB	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cisplatin	NOUN	O	I-Entity
with	ADP	O	O
granulocyte	ADJ	O	O
colony	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
factor	NOUN	O	O
support	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
untreated	ADJ	O	O
locally	ADV	O	O
advanced	ADJ	O	O
inoperable	ADJ	O	O
head	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

Primary	ADJ	O	O
tumor	NOUN	O	I-Entity
sites	NOUN	O	O
were	VERB	O	O
oropharynx	ADJ	O	O
,	PUNCT	O	O
10	NUM	O	O
patients	NOUN	O	O
;	PUNCT	O	O
hypopharynx	NOUN	O	O
,	PUNCT	O	O
four	NUM	O	O
;	PUNCT	O	O
larynx	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
;	PUNCT	O	O
oral	ADJ	O	O
cavity	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
;	PUNCT	O	O
unknown	ADJ	O	O
primary	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
nasal	ADJ	O	O
cavity	NOUN	O	O
and	CCONJ	O	O
parotid	NOUN	O	O
gland	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
each	DET	O	O
.	PUNCT	O	O

Of	ADP	O	O
20	NUM	O	O
patients	NOUN	O	O
evaluable	ADJ	O	O
for	ADP	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
four	NUM	O	O
had	VERB	O	O
stage	NOUN	O	O
III	PROPN	O	O
and	CCONJ	O	O
16	NUM	O	O
had	VERB	O	O
stage	NOUN	O	O
IV	PROPN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
,	PUNCT	O	O
given	VERB	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
for	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
cycles	NOUN	O	O
,	PUNCT	O	O
consisted	VERB	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
by	ADP	O	O
3-hour	NUM	O	O
infusion	NOUN	O	O
followed	VERB	O	O
the	DET	O	O
next	ADJ	O	O
day	NOUN	O	O
by	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
75	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
levels	NOUN	O	O
incorporate	VERB	O	O
escalating	VERB	O	O
paclitaxel	NOUN	O	I-Entity
doses	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intrapatient	NOUN	O	O
escalations	NOUN	O	O
within	ADP	O	O
a	DET	O	O
given	VERB	O	O
dose	NOUN	O	O
level	NOUN	O	O
are	VERB	O	O
permitted	VERB	O	O
if	ADP	O	O
toxicity	NOUN	O	I-Entity
permits	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
paclitaxel	NOUN	O	I-Entity
doses	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m2	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
,	PUNCT	O	O
granulocyte	ADJ	O	O
colony	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
factor	NOUN	O	O
5	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	ADV	O	O
/	SYM	O	O
d	PROPN	O	O
is	VERB	O	O
given	VERB	O	O
(	PUNCT	O	O
days	NOUN	O	O
4	NUM	O	O
through	ADP	O	O
12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Alopecia	PROPN	O	I-Entity
,	PUNCT	O	O
paresthesias	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
arthralgias	VERB	O	I-Entity

/	SYM	O	O
myalgias	NOUN	O	I-Entity
have	VERB	O	O
occurred	VERB	O	O
frequently	ADV	O	O
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
one	NUM	O	O
exception	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
grade	NOUN	O	O
3	NUM	O	O
myalgia	NOUN	O	I-Entity
)	PUNCT	O	O
they	PRON	O	O
have	VERB	O	O
been	VERB	O	O
grade	NOUN	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
.	PUNCT	O	O

No	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
hematologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
seen	VERB	O	O
.	PUNCT	O	O

Paclitaxel	PROPN	O	I-Entity
/	SYM	O	O
cisplatin	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
first	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
regimen	NOUN	O	O
for	ADP	O	O
locoregionally	ADV	O	O
advanced	ADJ	O	O
head	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
neck	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
continued	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O

Results	NOUN	O	O
thus	ADV	O	O
far	ADV	O	O
suggest	VERB	O	O
no	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
effect	NOUN	O	O
for	ADP	O	O
paclitaxel	NOUN	O	I-Entity
doses	NOUN	O	O
above	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2224762)

A	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
study	NOUN	O	O
of	ADP	O	O
4'-0-tetrahydropyranyladriamycin	PROPN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
Phase	NOUN	O	O
I	PRON	O	O
study	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
(	PUNCT	O	O
IV	PROPN	O	O
)	PUNCT	O	O
bolus	NOUN	O	O
4'-0-tetrahydropyranyladriamycin	NUM	O	I-Entity
(	PUNCT	O	O
Pirarubicin	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
done	VERB	O	O
in	ADP	O	O
55	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
good	ADJ	O	O
performance	NOUN	O	O
status	NOUN	O	O
with	ADP	O	O
refractory	ADJ	O	O
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
had	VERB	O	O
minimal	ADJ	O	O
prior	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
good	ADJ	O	O
risk	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
23	NUM	O	O
had	VERB	O	O
extensive	ADJ	O	O
prior	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
poor	ADJ	O	O
risk	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
six	NUM	O	O
had	VERB	O	O
renal	NOUN	O	B-Entity
and/or	CCONJ	O	I-Entity
hepatic	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
was	VERB	O	O
transient	ADJ	O	O
noncumulative	ADJ	O	O
granulocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Less	ADV	O	O
frequent	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
included	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
mild	ADJ	O	O
alopecia	NOUN	O	I-Entity
,	PUNCT	O	O
phlebitis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
mucositis	NOUN	O	I-Entity
.	PUNCT	O	O

Myelosuppression	PROPN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	O
analyses	NOUN	O	O
in	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
revealed	VERB	O	O
Pirarubicin	PROPN	O	I-Entity
plasma	NOUN	O	O
T	PROPN	O	O
1/2	NUM	O	O
alpha	NOUN	O	O
(	PUNCT	O	O
+	X	O	O
/-	PUNCT	O	O

Adriamycinol	PROPN	O	I-Entity
,	PUNCT	O	O
doxorubicin	NOUN	O	I-Entity
,	PUNCT	O	O
adriamycinone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
tetrahydropyranyladriamycinol	NOUN	O	I-Entity
were	VERB	O	O
the	DET	O	O
metabolites	NOUN	O	O
detected	VERB	O	O
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
was	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	PART	O	O
10%	NUM	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
metabolites	NOUN	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
Pirarubicin	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
hours	NOUN	O	O
was	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	PART	O	O
10%	NUM	O	O
.	PUNCT	O	O

Activity	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
mesothelioma	NOUN	O	I-Entity
,	PUNCT	O	O
leiomyosarcoma	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
basal	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2440413)

Differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
hexachlorocyclohexane	NOUN	O	I-Entity
(	PUNCT	O	O
lindane	NOUN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
pharmacologically	ADV	O	O
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Gamma	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
hexachlorocyclohexane	PROPN	O	I-Entity
(	PUNCT	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
active	ADJ	O	O
ingredient	NOUN	O	O
of	ADP	O	O
the	DET	O	O
insecticide	NOUN	O	O
lindane	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
decrease	VERB	O	O
seizure	NOUN	O	I-Entity
threshold	NOUN	O	O
to	ADP	O	O
pentylenetrazol	NOUN	O	O
(	PUNCT	O	O
PTZ	PROPN	O	I-Entity
)	PUNCT	O	O
3	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
gamma	VERB	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
and	CCONJ	O	O
conversely	ADV	O	O
increase	VERB	O	O
threshold	NOUN	O	O
to	ADP	O	O
PTZ	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
gamma	VERB	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
(	PUNCT	O	O
Vohland	PROPN	O	O
et	PROPN	O	O
al	PROPN	O	O
.	PUNCT	O	O
1981	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
other	ADJ	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
inducing	VERB	O	O
agents	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
intraperitoneal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
80	NUM	O	O
mg	NUM	O	O

/	SYM	O	O
kg	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
hour	NOUN	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
inducing	VERB	O	O
agents	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
,	PUNCT	O	O
regardless	ADV	O	O
of	ADP	O	O
their	ADJ	O	O
mechanism	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
a	DET	O	O
differential	ADJ	O	O
response	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Seizure	NOUN	O	I-Entity
activity	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
PTZ	PROPN	O	I-Entity
and	CCONJ	O	O
picrotoxin	NOUN	O	I-Entity
(	PUNCT	O	O
PTX	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
3-mercaptopropionic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
MPA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
bicuculline	NOUN	O	I-Entity
(	PUNCT	O	O
BCC	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
methyl	NOUN	O	B-Entity
6,7-dimethoxy-4-ethyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
B	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
carboline-3-carboxylate	NOUN	O	I-Entity
(	PUNCT	O	O
DMCM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
strychnine	NOUN	O	I-Entity
(	PUNCT	O	O
STR	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
vitro	NOUN	O	O
,	PUNCT	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
,	PUNCT	O	O
pentylenetetrazol	NOUN	O	I-Entity
and	CCONJ	O	O
picrotoxin	NOUN	O	I-Entity
were	VERB	O	O
shown	VERB	O	O
to	PART	O	O
inhibit	VERB	O	O
3H	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
TBOB	NOUN	O	I-Entity
binding	VERB	O	O
in	ADP	O	O
mouse	NOUN	O	O
whole	ADJ	O	O
brain	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
IC50	PROPN	O	O
values	NOUN	O	O
of	ADP	O	O
4.6	NUM	O	O
,	PUNCT	O	O
404	NUM	O	O
and	CCONJ	O	O
9.4	NUM	O	O
microM	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

MPA	PROPN	O	I-Entity
,	PUNCT	O	O
BCC	PROPN	O	I-Entity
,	PUNCT	O	O
DMCM	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
STR	PROPN	O	I-Entity
showed	VERB	O	O
no	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
3H	NUM	O	B-Entity
-	PUNCT	O	I-Entity
TBOB	PROPN	O	I-Entity
(	PUNCT	O	O
t	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
butyl	NOUN	O	I-Entity
bicyclo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
orthobenzoate	NOUN	O	I-Entity
)	PUNCT	O	O
binding	VERB	O	O
at	ADP	O	O
concentrations	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
micron	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pharmacological	ADJ	O	O
challenge	NOUN	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
tolerance	NOUN	O	O
may	VERB	O	O
occur	VERB	O	O
to	ADP	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
PTZ	PROPN	O	I-Entity
and	CCONJ	O	O
PTX	PROPN	O	I-Entity
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
,	PUNCT	O	O
since	ADP	O	O
the	DET	O	O
response	NOUN	O	O
to	PART	O	O
only	ADV	O	O
these	DET	O	O
two	NUM	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
inducing	VERB	O	O
agents	NOUN	O	O
is	VERB	O	O
decreased	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
in	ADP	O	O
vitro	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
site	NOUN	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
HCH	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
GABA	PROPN	O	I-Entity
-	PUNCT	O	O
A	PROPN	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
linked	VERB	O	O
chloride	NOUN	O	O
channel	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12483326)

Severe	ADJ	O	O
ocular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
orbital	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
after	ADP	O	O
intracarotid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
for	ADP	O	O
recurrent	ADJ	O	O
glioblastomas	NOUN	O	I-Entity
.	PUNCT	O	O

Glioblastoma	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
malignant	ADJ	O	B-Entity
tumor	NOUN	O	I-Entity
that	ADJ	O	O
occurs	VERB	O	O
in	ADP	O	O
the	DET	O	O
cerebrum	NOUN	O	O
during	ADP	O	O
adulthood	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
glioblastoma	NOUN	O	I-Entity
sometimes	ADV	O	O
have	VERB	O	O
intracarotid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
carcinostatics	NOUN	O	O
added	VERB	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

Generally	ADV	O	O
,	PUNCT	O	O
carboplatin	NOUN	O	I-Entity
is	VERB	O	O
said	VERB	O	O
to	PART	O	O
have	VERB	O	O
milder	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
than	ADP	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
whose	ADJ	O	O
ocular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
orbital	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
are	VERB	O	O
well	ADV	O	O
known	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
experienced	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
ocular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
orbital	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
after	ADP	O	O
intracarotid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
infrequently	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
58-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
received	VERB	O	O
an	DET	O	O
intracarotid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
for	ADP	O	O
recurrent	ADJ	O	O
glioblastomas	NOUN	O	I-Entity
in	ADP	O	O
his	ADJ	O	O
left	ADJ	O	O
temporal	ADJ	O	O
lobe	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
complained	VERB	O	O
of	ADP	O	O
pain	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
visual	ADJ	O	I-Entity
disturbance	NOUN	O	I-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
ipsilateral	ADJ	O	I-Entity
eye	NOUN	O	I-Entity
30	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Various	ADJ	O	O
ocular	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
findings	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
carboplatin	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
were	VERB	O	O
seen	VERB	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
corticosteroids	NOUN	O	O
and	CCONJ	O	O
glycerin	NOUN	O	I-Entity
for	ADP	O	O
6	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
intraocular	NOUN	O	O
pressure	NOUN	O	O
elevation	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
secondary	ADJ	O	O
acute	ADJ	O	O
angle	NOUN	O	O
-	PUNCT	O	O
closure	NOUN	O	O
glaucoma	NOUN	O	I-Entity
decreased	VERB	O	O
and	CCONJ	O	O
ocular	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
diminished	VERB	O	O
,	PUNCT	O	O
inexorable	ADJ	O	O
papilledema	NOUN	O	I-Entity
and	CCONJ	O	O
exudative	ADJ	O	O
retinal	ADJ	O	B-Entity
detachment	NOUN	O	I-Entity
continued	VERB	O	O
for	ADP	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
6	NUM	O	O
weeks	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
diffuse	VERB	O	O
chorioretinal	ADJ	O	B-Entity
atrophy	NOUN	O	I-Entity
with	ADP	O	O
optic	NOUN	O	B-Entity
atrophy	NOUN	O	I-Entity
occurred	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
vision	NOUN	O	O
in	ADP	O	O
his	ADJ	O	O
left	ADJ	O	O
eye	NOUN	O	O
was	VERB	O	O
lost	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
When	ADV	O	O
performing	VERB	O	O
intracarotid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
must	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
its	ADJ	O	O
potentially	ADV	O	O
blinding	ADJ	O	O
ocular	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1664218)

Phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
amsacrine	ADJ	O	I-Entity
analogue	NOUN	O	O
CI-921	PROPN	O	I-Entity
(	PUNCT	O	O
NSC	PROPN	O	B-Entity
343499	NUM	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
small	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

CI-921	PROPN	O	I-Entity
(	PUNCT	O	O
NSC	PROPN	O	B-Entity
343499	NUM	O	I-Entity
;	PUNCT	O	O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino	NUM	O	B-Entity
]	PUNCT	O	I-Entity
-N,5-dimethyl-	NUM	O	I-Entity
4-acridinecarboxamide	NOUN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
topoisomerase	NOUN	O	O
II	NUM	O	O
poison	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
experimental	ADJ	O	O
antitumour	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
administered	VERB	O	O
by	ADP	O	O
15	NUM	O	O
min	NOUN	O	O
infusion	NOUN	O	O
to	ADP	O	O
16	NUM	O	O
evaluable	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
small	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
NSCLC	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
7	NUM	O	O
with	ADP	O	O
no	DET	O	O
prior	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
9	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
relapse	NOUN	O	O
following	VERB	O	O
surgery	NOUN	O	O
/	SYM	O	O
radiotherapy	ADJ	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
(	PUNCT	O	O
648	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
divided	VERB	O	O
over	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
repeated	VERB	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
determined	VERB	O	O
by	ADP	O	O
phase	NOUN	O	O
I	PRON	O	O
trial	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
histology	NOUN	O	O
comprised	VERB	O	O
squamous	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
(	PUNCT	O	O
11	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
adenocarcinoma	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mixed	ADJ	O	O
histology	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bronchio	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alveolar	ADJ	O	I-Entity
carcinoma	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
large	ADJ	O	O
cell	NOUN	O	O
undifferentiated	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Neutropenia	PROPN	O	I-Entity
grade	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
3	NUM	O	O
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
15	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
infections	NOUN	O	I-Entity
with	ADP	O	O
recovery	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
grand	ADJ	O	O
mal	ADJ	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Grade	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
2	NUM	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	VERB	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
66%	NUM	O	O
courses	NOUN	O	O
and	CCONJ	O	O
phlebitis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
arm	NOUN	O	O
in	ADP	O	O
37%	NUM	O	O
.	PUNCT	O	O

1	NUM	O	O
patient	NOUN	O	O
with	ADP	O	O
squamous	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
achieved	VERB	O	O
a	DET	O	O
partial	ADJ	O	O
response	NOUN	O	O
lasting	VERB	O	O
5	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Further	ADV	O	O
testing	VERB	O	O
in	ADP	O	O
this	DET	O	O
and	CCONJ	O	O
other	ADJ	O	O
tumour	NOUN	O	I-Entity
types	NOUN	O	O
using	VERB	O	O
multiple	ADJ	O	O
daily	ADJ	O	O
schedules	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18809400)

Alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
prevents	VERB	O	O
mitochondrial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
and	CCONJ	O	O
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
experimental	ADJ	O	O
chemotherapy	NOUN	O	O
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
investigates	VERB	O	O
if	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
is	VERB	O	O
neuroprotective	ADJ	O	O
against	ADP	O	O
chemotherapy	NOUN	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
if	ADP	O	O
mitochondrial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
plays	VERB	O	O
a	DET	O	O
critical	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
toxic	ADJ	O	B-Entity
neurodegenerative	ADJ	O	I-Entity
cascade	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
if	ADP	O	O
neuroprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
depend	VERB	O	O
on	ADP	O	O
mitochondria	ADJ	O	O
protection	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
an	DET	O	O
in	ADP	O	O
vitro	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
induced	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
that	ADJ	O	O
closely	ADV	O	O
mimic	VERB	O	O
the	DET	O	O
in	ADP	O	O
vivo	NOUN	O	O
condition	NOUN	O	O
by	ADP	O	O
exposing	VERB	O	O
primary	ADJ	O	O
cultures	NOUN	O	O
of	ADP	O	O
dorsal	NOUN	O	O
root	NOUN	O	O
ganglion	NOUN	O	O
(	PUNCT	O	O
DRG	PROPN	O	O
)	PUNCT	O	O
sensory	ADJ	O	O
neurons	NOUN	O	O
to	ADP	O	O
paclitaxel	VERB	O	I-Entity
and	CCONJ	O	O
cisplatin	VERB	O	I-Entity
,	PUNCT	O	O
two	NUM	O	O
widely	ADV	O	O
used	ADJ	O	O
and	CCONJ	O	O
highly	ADV	O	O
effective	ADJ	O	O
chemotherapeutic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
approach	NOUN	O	O
allowed	VERB	O	O
investigating	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
preventing	VERB	O	O
axonal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
and	CCONJ	O	O
apoptosis	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
function	NOUN	O	O
and	CCONJ	O	O
ultrastructural	ADJ	O	O
morphology	NOUN	O	O
of	ADP	O	O
mitochondria	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
toxic	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
both	DET	O	O
cisplatin	NOUN	O	I-Entity
and	CCONJ	O	O
paclitaxel	NOUN	O	I-Entity
cause	NOUN	O	O
early	ADJ	O	O
mitochondrial	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
with	ADP	O	O
loss	NOUN	O	O
of	ADP	O	O
membrane	NOUN	O	O
potential	NOUN	O	O
and	CCONJ	O	O
induction	NOUN	O	O
of	ADP	O	O
autophagic	ADJ	O	O
vacuoles	NOUN	O	O
in	ADP	O	O
neurons	NOUN	O	O
.	PUNCT	O	O

Alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
exerts	VERB	O	O
neuroprotective	ADJ	O	O
effects	NOUN	O	O
against	ADP	O	O
chemotherapy	NOUN	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
sensory	ADJ	O	O
neurons	NOUN	O	O
:	PUNCT	O	O
it	PRON	O	O
rescues	VERB	O	O
the	DET	O	O
mitochondrial	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
induces	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
frataxin	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
essential	ADJ	O	O
mitochondrial	NOUN	O	O
protein	NOUN	O	O
with	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
oxidant	NOUN	O	O
and	CCONJ	O	O
chaperone	NOUN	O	O
properties	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
mitochondrial	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
early	ADJ	O	O
common	ADJ	O	O
event	NOUN	O	O
both	DET	O	O
in	ADP	O	O
paclitaxel	NOUN	O	I-Entity
and	CCONJ	O	O
cisplatin	NOUN	O	I-Entity
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
protects	VERB	O	O
sensory	ADJ	O	O
neurons	NOUN	O	O
through	ADP	O	O
its	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
oxidant	NOUN	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	O
regulatory	ADJ	O	O
functions	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
inducing	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
frataxin	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lipoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
might	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
peripheral	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
encourage	VERB	O	O
further	ADJ	O	O
confirmatory	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17020434)

Optimising	VERB	O	O
stroke	NOUN	O	I-Entity
prevention	NOUN	O	O
in	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
valvular	ADJ	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

Atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
substantial	ADJ	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Pooled	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
trials	NOUN	O	O
comparing	VERB	O	O
antithrombotic	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
warfarin	NOUN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	I-Entity
by	ADP	O	O
62%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
aspirin	NOUN	O	I-Entity
alone	ADV	O	O
reduces	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
by	ADP	O	O
22%	NUM	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
warfarin	NOUN	O	I-Entity
is	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
aspirin	NOUN	O	I-Entity
in	ADP	O	O
preventing	VERB	O	O
strokes	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
relative	ADJ	O	O
risk	NOUN	O	O
reduction	NOUN	O	O
of	ADP	O	O
36%	NUM	O	O
.	PUNCT	O	O

Ximelagatran	PROPN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
oral	ADJ	O	O
direct	ADJ	O	O
thrombin	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
as	ADV	O	O
efficient	ADJ	O	O
as	ADP	O	O
vitamin	NOUN	O	B-Entity
K	PROPN	O	I-Entity
antagonist	NOUN	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
embolic	ADJ	O	B-Entity
events	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
has	VERB	O	O
been	VERB	O	O
recently	ADV	O	O
withdrawn	VERB	O	O
because	ADP	O	O
of	ADP	O	O
abnormal	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
function	NOUN	O	I-Entity
tests	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ACTIVE	PROPN	O	O
-	PUNCT	O	O
W	PROPN	O	O
(	PUNCT	O	O
Atrial	ADJ	O	B-Entity
Fibrillation	PROPN	O	I-Entity
Clopidogrel	PROPN	O	I-Entity
Trial	PROPN	O	O
with	ADP	O	O
Irbesartan	PROPN	O	I-Entity
for	ADP	O	O
Prevention	PROPN	O	O
of	ADP	O	O
Vascular	PROPN	O	O
Events	PROPN	O	O
)	PUNCT	O	O
study	NOUN	O	O
has	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
warfarin	NOUN	O	I-Entity
is	VERB	O	O
superior	ADJ	O	O
to	PART	O	O
platelet	VERB	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
clopidogrel	NOUN	O	I-Entity
plus	CCONJ	O	O
aspirin	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
af	ADP	O	O
embolic	ADJ	O	B-Entity
events	NOUN	O	I-Entity
.	PUNCT	O	O

Idraparinux	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
Factor	PROPN	O	O
Xa	PROPN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
being	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

Angiotensin	PROPN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitors	NOUN	O	O
and	CCONJ	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
receptor	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
drugs	NOUN	O	O
hold	VERB	O	O
promise	NOUN	O	O
in	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
through	ADP	O	O
cardiac	ADJ	O	B-Entity
remodelling	NOUN	O	I-Entity
.	PUNCT	O	O

Preliminary	ADJ	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
statins	NOUN	O	I-Entity
could	VERB	O	O
interfere	VERB	O	O
with	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
recurrence	NOUN	O	O
after	ADP	O	O
electrical	ADJ	O	O
cardioversion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3865016)

Interaction	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
with	ADP	O	O
antineoplastic	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
synergistic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
etoposide	ADV	O	I-Entity
and	CCONJ	O	O
cyclosporin	VERB	O	B-Entity
A	DET	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
T	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
lymphocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
in	ADP	O	O
relapse	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
concomitant	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
etoposide	ADV	O	I-Entity
and	CCONJ	O	O
cyclosporin	VERB	O	B-Entity
A	DET	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
eradication	NOUN	O	O
of	ADP	O	O
hitherto	ADV	O	O
refractory	ADJ	O	O
leukemic	ADJ	O	B-Entity
infiltration	NOUN	O	I-Entity
of	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
mental	ADJ	O	O
confusion	NOUN	O	I-Entity
and	CCONJ	O	O
progressive	ADJ	O	O
hyperbilirubinemia	NOUN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
point	NOUN	O	O
to	ADP	O	O
an	DET	O	O
enhancement	NOUN	O	O
not	ADV	O	O
only	ADV	O	O
of	ADP	O	O
antineoplastic	ADJ	O	O
effects	NOUN	O	O
but	CCONJ	O	O
also	ADV	O	O
of	ADP	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
normal	ADJ	O	O
tissues	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
demonstrates	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
that	ADP	O	O
the	DET	O	O
pharmacodynamic	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
confined	VERB	O	O
strictly	ADV	O	O
to	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
functions	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3629586)

The	DET	O	O
hematologic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cefonicid	NOUN	O	I-Entity
and	CCONJ	O	O
cefazedone	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
potential	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
cephalosporin	NOUN	O	I-Entity
hematotoxicity	NOUN	O	I-Entity
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Cephalosporin	PROPN	O	I-Entity
antibiotics	NOUN	O	O
cause	VERB	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
hematologic	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
in	ADP	O	O
man	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pathogeneses	NOUN	O	O
and	CCONJ	O	O
hematopathology	NOUN	O	O
of	ADP	O	O
which	ADJ	O	O
remain	VERB	O	O
poorly	ADV	O	O
characterized	VERB	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
a	DET	O	O
need	NOUN	O	O
for	ADP	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
defined	VERB	O	O
animal	NOUN	O	O
model	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
these	DET	O	O
blood	NOUN	O	B-Entity
dyscrasias	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
four	NUM	O	O
subacute	NOUN	O	O
toxicity	NOUN	O	I-Entity
studies	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
cefonicid	NOUN	O	I-Entity
or	CCONJ	O	O
cefazedone	NOUN	O	I-Entity
to	ADP	O	O
beagle	NOUN	O	O
dogs	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
after	ADP	O	O
1	NUM	O	O
-	SYM	O	O
3	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
nonregenerative	ADJ	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
compromising	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cytopenias	NOUN	O	I-Entity
and	CCONJ	O	O
occurred	VERB	O	O
in	ADP	O	O
approximately	ADV	O	O
50%	NUM	O	O
of	ADP	O	O
dogs	NOUN	O	O
receiving	VERB	O	O
400	NUM	O	O
-	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	VERB	O	O
cefonicid	NOUN	O	I-Entity
or	CCONJ	O	O
540	NUM	O	O
-	SYM	O	O
840	NUM	O	O
mg	NUM	O	O

/	SYM	O	O
kg	ADV	O	O
cefazedone	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
three	NUM	O	O
cytopenias	NOUN	O	I-Entity
were	VERB	O	O
completely	ADV	O	O
reversible	ADJ	O	O
following	VERB	O	O
cessation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
time	NOUN	O	O
required	VERB	O	O
for	ADP	O	O
recovery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
erythron	NOUN	O	O
(	PUNCT	O	O
approximately	ADV	O	O
1	NUM	O	O
month	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
considerably	ADV	O	O
longer	ADV	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
granulocytes	NOUN	O	O
and	CCONJ	O	O
platelets	NOUN	O	O
(	PUNCT	O	O
hours	NOUN	O	O
to	ADP	O	O
a	DET	O	O
few	ADJ	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Upon	ADP	O	O
rechallenge	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
cephalosporin	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
hematologic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
was	VERB	O	O
reproduced	VERB	O	O
in	ADP	O	O
most	ADJ	O	O
dogs	NOUN	O	O
tested	VERB	O	O
;	PUNCT	O	O
cefonicid	NOUN	O	I-Entity
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
cefazedone)-treated	VERB	O	I-Entity
dogs	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
substantially	ADV	O	O
reduced	VERB	O	O
induction	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
,	PUNCT	O	O
along	ADP	O	O
with	ADP	O	O
the	DET	O	O
rapid	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
decline	NOUN	O	O
in	ADP	O	O
red	ADJ	O	O
cell	NOUN	O	O
mass	ADJ	O	O
parameters	NOUN	O	O
of	ADP	O	O
affected	VERB	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
suggests	VERB	O	O
that	ADP	O	O
a	DET	O	O
hemolytic	ADJ	O	I-Entity
component	NOUN	O	O
complicated	VERB	O	O
the	DET	O	O
red	ADJ	O	O
cell	NOUN	O	O
production	NOUN	O	O
problem	NOUN	O	O
and	CCONJ	O	O
that	DET	O	O
multiple	ADJ	O	O
toxicologic	ADJ	O	O
mechanisms	NOUN	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
cytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
cefonicid	NOUN	O	I-Entity
or	CCONJ	O	O
cefazedone	NOUN	O	I-Entity
to	ADP	O	O
dogs	NOUN	O	O
can	VERB	O	O
induce	VERB	O	O
hematotoxicity	NOUN	O	I-Entity
similar	ADJ	O	O
to	ADP	O	O
the	DET	O	O
cephalosporin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
blood	NOUN	O	B-Entity
dyscrasias	NOUN	O	I-Entity
described	VERB	O	O
in	ADP	O	O
man	NOUN	O	O
and	CCONJ	O	O
thus	ADV	O	O
provides	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
studying	VERB	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
these	DET	O	O
disorders	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (150790)

A	DET	O	O
pyridoxine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
behavioral	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
unmasked	VERB	O	O
by	ADP	O	O
isoniazid	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
3-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
had	VERB	O	O
behavioral	ADJ	O	B-Entity
deterioration	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
hyperkinesis	NOUN	O	I-Entity
,	PUNCT	O	O
irritability	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sleeping	VERB	O	B-Entity
difficulties	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
isoniazid	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
pharmacologic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
pyridoxine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
a	DET	O	O
disappearance	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
discontinuing	VERB	O	O
isoniazid	NOUN	O	I-Entity
therapy	NOUN	O	O
a	DET	O	O
similar	ADJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
behavior	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
that	DET	O	O
was	VERB	O	O
controlled	VERB	O	O
by	ADP	O	O
pyridoxine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
placebo	NOUN	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
niacinamide	ADV	O	I-Entity
was	VERB	O	O
as	ADV	O	O
effective	ADJ	O	O
as	ADP	O	O
pyridoxine	NOUN	O	I-Entity
.	PUNCT	O	O

Periodic	ADJ	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
pyridoxine	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
return	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hyperkinesis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
level	NOUN	O	O
of	ADP	O	O
pyridoxal	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
was	VERB	O	O
normal	ADJ	O	O
during	ADP	O	O
the	DET	O	O
periods	NOUN	O	O
of	ADP	O	O
relapse	NOUN	O	O
.	PUNCT	O	O

Metabolic	ADJ	O	O
studies	NOUN	O	O
suggested	VERB	O	O
a	DET	O	O
block	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kynurenine	NOUN	O	I-Entity
pathway	NOUN	O	O
of	ADP	O	O
tryptophan	DET	O	I-Entity
metabolism	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
followed	VERB	O	O
for	ADP	O	O
six	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
has	VERB	O	O
required	VERB	O	O
pharmacologic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
pyridoxine	NOUN	O	I-Entity
to	PART	O	O
control	VERB	O	O
her	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10579464)

A	DET	O	O
selective	ADJ	O	O
dopamine	NOUN	O	I-Entity
D4	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
NRA0160	PROPN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
preclinical	ADJ	O	O
neuropharmacological	ADJ	O	O
profile	NOUN	O	O
.	PUNCT	O	O

NRA0160	PROPN	O	I-Entity
,	PUNCT	O	O
5	NUM	O	B-Entity
-	SYM	O	I-Entity
[	PUNCT	O	I-Entity
2-	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
4-	X	O	I-Entity
(	PUNCT	O	I-Entity
3	NUM	O	I-Entity
-	SYM	O	I-Entity
fluorobenzylidene	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
piperidin-1-yl	PUNCT	O	I-Entity
)	PUNCT	O	I-Entity
ethyl	NOUN	O	I-Entity
]	PUNCT	O	I-Entity
-	PUNCT	O	I-Entity
4	NUM	O	I-Entity
-(4-fluorophenyl	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
thiazole-2-carboxamide	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
a	DET	O	O
high	ADJ	O	O
affinity	NOUN	O	O
for	ADP	O	O
human	NOUN	O	O
cloned	VERB	O	O
dopamine	NOUN	O	I-Entity
D4.2	PROPN	O	O
,	PUNCT	O	O
D4.4	PROPN	O	O
and	CCONJ	O	O
D4.7	PROPN	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
Ki	PROPN	O	O
values	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
,	PUNCT	O	O
0.9	NUM	O	O
and	CCONJ	O	O
2.7	NUM	O	O
nM	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

NRA0160	PROPN	O	I-Entity
is	VERB	O	O
over	ADV	O	O
20,000fold	NUM	O	O
more	ADJ	O	O
potent	ADJ	O	O
at	ADP	O	O
the	DET	O	O
dopamine	NOUN	O	I-Entity
D4.2	PROPN	O	O
receptor	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
human	NOUN	O	O
cloned	VERB	O	O
dopamine	NOUN	O	I-Entity
D2L	PROPN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

NRA0160	PUNCT	O	I-Entity
has	VERB	O	O
negligible	ADJ	O	O
affinity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
human	NOUN	O	O
cloned	VERB	O	O
dopamine	NOUN	O	I-Entity
D3	PROPN	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
Ki=39	PROPN	O	O
nM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rat	NOUN	O	O
serotonin	NOUN	O	I-Entity
(	PUNCT	O	O
5-HT)2A	ADJ	O	I-Entity
receptors	NOUN	O	O
(	PUNCT	O	O
Ki=180	PROPN	O	O
nM	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
rat	NOUN	O	O
alpha1	NOUN	O	O
adrenoceptor	NOUN	O	O
(	PUNCT	O	O
Ki=237	PROPN	O	O
nM	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

NRA0160	PROPN	O	I-Entity
and	CCONJ	O	O
clozapine	NOUN	O	I-Entity
antagonized	VERB	O	O
locomotor	NOUN	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
MAP	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

NRA0160	PROPN	O	I-Entity
and	CCONJ	O	O
clozapine	NOUN	O	I-Entity
antagonized	VERB	O	O
MAP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
stereotyped	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
their	ADJ	O	O
effects	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
exceed	VERB	O	O
50%	NUM	O	O
inhibition	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
at	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
dose	NOUN	O	O
given	VERB	O	O
.	PUNCT	O	O

NRA0160	PROPN	O	I-Entity
and	CCONJ	O	O
clozapine	NOUN	O	I-Entity
significantly	ADV	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
their	ADJ	O	O
effects	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
exceed	VERB	O	O
50%	NUM	O	O
induction	NOUN	O	O
even	ADV	O	O
at	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
dose	NOUN	O	O
given	VERB	O	O
.	PUNCT	O	O

NRA0160	PROPN	O	I-Entity
and	CCONJ	O	O
clozapine	NOUN	O	I-Entity
significantly	ADV	O	O
reversed	VERB	O	O
the	DET	O	O
disruption	NOUN	O	O
of	ADP	O	O
prepulse	ADJ	O	O
inhibition	NOUN	O	O
(	PUNCT	O	O
PPI	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
apomorphine	NOUN	O	I-Entity
.	PUNCT	O	O

NRA0160	PUNCT	O	I-Entity
and	CCONJ	O	O

clozapine	NOUN	O	I-Entity
significantly	ADV	O	O
shortened	VERB	O	O
the	DET	O	O
phencyclidine	NOUN	O	I-Entity
(	PUNCT	O	O
PCP)-induced	PROPN	O	I-Entity
prolonged	ADJ	O	O
swimming	NOUN	O	O
latency	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
in	ADP	O	O
a	DET	O	O
water	NOUN	O	O
maze	NOUN	O	O
task	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
NRA0160	PROPN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
unique	ADJ	O	O
antipsychotic	ADJ	O	O
activities	NOUN	O	O
without	ADP	O	O
the	DET	O	O
liability	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
typical	ADJ	O	O
of	ADP	O	O
classical	ADJ	O	O
antipsychotics	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3496378)

Prolonged	VERB	O	O
cholestasis	NOUN	O	I-Entity
after	ADP	O	O
troleandomycin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
troleandomycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatitis	NOUN	O	I-Entity
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
prolonged	ADJ	O	O
anicteric	ADJ	O	O
cholestasis	NOUN	O	I-Entity
.	PUNCT	O	O

Jaundice	PROPN	O	I-Entity
occurred	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
troleandomycin	NOUN	O	I-Entity
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
hypereosinophilia	NOUN	O	I-Entity
.	PUNCT	O	O

Jaundice	PROPN	O	I-Entity
disappeared	VERB	O	O
within	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
but	CCONJ	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
prolonged	ADJ	O	O
anicteric	NOUN	O	O
cholestasis	NOUN	O	I-Entity
marked	VERB	O	O
by	ADP	O	O
pruritus	NOUN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
alkaline	ADJ	O	O
phosphatase	NOUN	O	O
and	CCONJ	O	O
gammaglutamyltransferase	NOUN	O	O
activities	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
pruritus	NOUN	O	I-Entity
disappeared	VERB	O	O
within	ADP	O	O
19	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
liver	NOUN	O	O
tests	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
27	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
prolonged	VERB	O	O
cholestasis	NOUN	O	I-Entity
can	VERB	O	O
follow	VERB	O	O
troleandomycin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3076126)

Lovastatin	PROPN	O	I-Entity
and	CCONJ	O	O
simvastatin	NOUN	O	I-Entity
are	VERB	O	O
the	DET	O	O
2	NUM	O	O
best	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
members	NOUN	O	O
of	ADP	O	O
the	DET	O	O
class	NOUN	O	O
of	ADP	O	O
hypolipidaemic	ADJ	O	O
agents	NOUN	O	O
known	VERB	O	O
as	ADP	O	O
HMG	PROPN	O	O
CoA	PROPN	O	O
reductase	NOUN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
experience	NOUN	O	O
with	ADP	O	O
lovastatin	NOUN	O	I-Entity
includes	VERB	O	O
over	ADP	O	O
5000	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
700	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
experience	NOUN	O	O
with	ADP	O	O
simvastatin	NOUN	O	I-Entity
includes	VERB	O	O
over	ADP	O	O
3500	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
whom	NOUN	O	O
350	NUM	O	O
have	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
18	NUM	O	O
months	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
.	PUNCT	O	O

Lovastatin	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
marketed	VERB	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
for	ADP	O	O
over	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
agents	NOUN	O	O
show	VERB	O	O
substantial	ADJ	O	O
clinical	ADJ	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
reductions	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
cholesterol	NOUN	O	I-Entity
of	ADP	O	O
over	ADP	O	O
30%	NUM	O	O
and	CCONJ	O	O
in	ADP	O	O
LDL	PROPN	O	O
-	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
of	ADP	O	O
40%	NUM	O	O
in	ADP	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Modest	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
HDL	PROPN	O	O
-	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
levels	NOUN	O	O
of	ADP	O	O
about	ADV	O	O
10%	NUM	O	O
are	VERB	O	O
also	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

Minor	PROPN	O	O
elevations	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
levels	NOUN	O	O
are	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
about	ADP	O	O
5%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Myopathy	PROPN	O	I-Entity
,	PUNCT	O	O
associated	VERB	O	O
in	ADP	O	O
some	DET	O	O
cases	NOUN	O	O
with	ADP	O	O
myoglobinuria	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
2	NUM	O	O
cases	NOUN	O	O
with	ADP	O	O
transient	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
rarely	ADV	O	O
reported	VERB	O	O
with	ADP	O	O
lovastatin	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
concomitantly	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
cyclosporin	NOUN	O	I-Entity
,	PUNCT	O	O
gemfibrozil	NOUN	O	I-Entity
or	CCONJ	O	O
niacin	ADV	O	I-Entity
.	PUNCT	O	O

Lovastatin	PROPN	O	I-Entity
and	CCONJ	O	O
simvastatin	NOUN	O	I-Entity
are	VERB	O	O
both	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
agents	NOUN	O	O
for	ADP	O	O
lowering	VERB	O	O
elevated	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
cholesterol	NOUN	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
wider	ADJ	O	O
use	NOUN	O	O
confirms	VERB	O	O
their	ADJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
will	VERB	O	O
gain	VERB	O	O
increasing	VERB	O	O
importance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
approach	NOUN	O	O
to	ADP	O	O
hypercholesterolaemia	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
consequences	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2894766)

Sulfasalazine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
lupus	NOUN	O	B-Entity
erythematosus	NOUN	O	I-Entity
.	PUNCT	O	O

Pneumonitis	PROPN	O	I-Entity
,	PUNCT	O	O
bilateral	ADJ	O	O
pleural	ADJ	O	B-Entity
effusions	NOUN	O	I-Entity
,	PUNCT	O	O
echocardiographic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
tamponade	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
positive	ADJ	O	O
autoantibodies	NOUN	O	O
developed	VERB	O	O
in	ADP	O	O
a	DET	O	O
43-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
was	VERB	O	O
receiving	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
sulfasalazine	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	O
ulcerative	ADJ	O	B-Entity
colitis	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sulfasalazine	NOUN	O	I-Entity
and	CCONJ	O	O
completion	NOUN	O	O
of	ADP	O	O
a	DET	O	O
six	NUM	O	O
-	PUNCT	O	O
week	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
corticosteroids	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
problems	NOUN	O	O
resolved	VERB	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
to	PART	O	O
six	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
sulfasalazine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
lupus	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
manifested	VERB	O	O
with	ADP	O	O
serositis	NOUN	O	I-Entity
and	CCONJ	O	O
pulmonary	ADJ	O	O
parenchymal	NOUN	O	O
involvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
joint	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Physicians	NOUN	O	O
who	NOUN	O	O
use	VERB	O	O
sulfasalazine	NOUN	O	I-Entity
to	PART	O	O
treat	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
inflammatory	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
signs	NOUN	O	O
of	ADP	O	O
sulfasalazine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
lupus	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1549199)

Optimization	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
single	ADJ	O	O
correct	ADJ	O	O
starting	VERB	O	O
dose	NOUN	O	O
for	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
many	ADJ	O	O
individuals	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
started	VERB	O	O
on	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
25/100	NUM	O	O
or	CCONJ	O	O
controlled	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
formula	NOUN	O	O
,	PUNCT	O	O
following	VERB	O	O
the	DET	O	O
general	ADJ	O	O
rule	NOUN	O	O
not	ADV	O	O
to	PART	O	O
attempt	VERB	O	O
to	PART	O	O
titrate	VERB	O	O
carbidopa	NOUN	O	I-Entity
-	PUNCT	O	O
levodopa	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
point	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
normality	NOUN	O	O
,	PUNCT	O	O
"	PUNCT	O	O
which	ADJ	O	O
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
emerging	VERB	O	O
difficulties	NOUN	O	O
require	VERB	O	O
a	DET	O	O
reassessment	NOUN	O	O
of	ADP	O	O
therapeutic	ADJ	O	O
approaches	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
dosage	NOUN	O	O
adjustment	NOUN	O	O
or	CCONJ	O	O
introduction	NOUN	O	O
of	ADP	O	O
a	DET	O	O
dopamine	NOUN	O	I-Entity
agonist	NOUN	O	O
.	PUNCT	O	O

Other	ADJ	O	O
possible	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
--	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
gastrointestinal	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
,	PUNCT	O	O
orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
,	PUNCT	O	O
sleep	VERB	O	B-Entity
disturbances	NOUN	O	I-Entity
or	CCONJ	O	O
parasomnias	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
--	PUNCT	O	O
also	ADV	O	O
require	VERB	O	O
carefully	ADV	O	O
monitored	ADJ	O	O
individual	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Nonpharmacologic	ADJ	O	O
concerns	NOUN	O	O
can	VERB	O	O
help	VERB	O	O
the	DET	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patient	NOUN	O	O
achieve	VERB	O	O
and	CCONJ	O	O
maintain	VERB	O	O
optimal	ADJ	O	O
functioning	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
daily	ADJ	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
involvement	NOUN	O	O
with	ADP	O	O
support	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (88336)

Alpha	NOUN	O	O
and	CCONJ	O	O
beta	NOUN	O	O
coma	NOUN	O	I-Entity
in	ADP	O	O
drug	NOUN	O	O
intoxication	NOUN	O	O
uncomplicated	VERB	O	O
by	ADP	O	O
cerebral	ADJ	O	B-Entity
hypoxia	NOUN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
rendered	VERB	O	O
comatose	ADJ	O	I-Entity
or	CCONJ	O	O
stuporous	ADJ	O	I-Entity
by	ADP	O	O
drug	NOUN	O	O
intoxication	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
who	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
hypoxic	ADJ	O	O
,	PUNCT	O	O
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
chlormethiazole	NOUN	O	I-Entity
for	ADP	O	O
alcohol	NOUN	O	I-Entity
withdrawal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
took	VERB	O	O
a	DET	O	O
suicidal	ADJ	O	O
overdose	NOUN	O	I-Entity
of	ADP	O	O
nitrazepam	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
nitrazepam	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
and	CCONJ	O	O
two	NUM	O	O
of	ADP	O	O
those	DET	O	O
with	ADP	O	O
chlormethiazole	ADJ	O	I-Entity
intoxication	NOUN	O	O
conformed	VERB	O	O
to	ADP	O	O
the	DET	O	O
criteria	NOUN	O	O
of	ADP	O	O
'	PUNCT	O	O
alpha	ADJ	O	O
coma	NOUN	O	I-Entity
'	PUNCT	O	O
,	PUNCT	O	O
showing	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
generalized	ADJ	O	O
or	CCONJ	O	O
frontally	ADV	O	O
predominant	ADJ	O	O
alpha	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
EEG	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
fourth	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
unconscious	ADJ	O	O
after	ADP	O	O
chlormethiazole	ADJ	O	I-Entity
administration	NOUN	O	O
exhibite	ADV	O	O
generalized	ADJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
slow	ADJ	O	O
beta	NOUN	O	O
range	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
four	NUM	O	O
recovered	VERB	O	O
completely	ADV	O	O
without	ADP	O	O
neurological	ADJ	O	B-Entity
sequelae	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
offending	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
similarities	NOUN	O	O
between	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
structural	ADJ	O	O
lesions	NOUN	O	O
and	CCONJ	O	O
pharmacological	ADJ	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
stem	VERB	O	O
reticular	ADJ	O	O
formation	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
in	ADP	O	O
both	DET	O	O
situations	NOUN	O	O
disturbed	VERB	O	O
reticulo	NOUN	O	O
-	PUNCT	O	O
thalamic	ADJ	O	O
interactions	NOUN	O	O
are	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	O
coma	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
when	ADV	O	O
this	DET	O	O
electroencephalographic	ADJ	O	O
and	CCONJ	O	O
behavioural	ADJ	O	O
picture	NOUN	O	O
is	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
drug	NOUN	O	O
intoxication	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
significant	ADJ	O	O
hypoxaemia	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
favourable	ADJ	O	O
outcome	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
anticipated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (18544179)

Omitting	VERB	O	O
fentanyl	NOUN	O	I-Entity
reduces	VERB	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
without	ADP	O	O
increasing	VERB	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
after	ADP	O	O
sevoflurane	NOUN	O	I-Entity
for	ADP	O	O
day	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
advantages	NOUN	O	O
of	ADP	O	O
induction	NOUN	O	O
and	CCONJ	O	O
maintenance	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
sevoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
occurs	VERB	O	O
frequently	ADV	O	O
.	PUNCT	O	O

Fentanyl	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
commonly	ADV	O	O
used	VERB	O	O
supplement	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
this	DET	O	O
,	PUNCT	O	O
although	ADP	O	O
it	PRON	O	O
may	VERB	O	O
also	ADV	O	O
improve	VERB	O	O
analgesia	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
and	CCONJ	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
sevoflurane	NOUN	O	I-Entity
anaesthesia	NOUN	O	O
in	ADP	O	O
216	NUM	O	O
adult	NOUN	O	O
day	NOUN	O	O
surgery	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
either	DET	O	O
receive	VERB	O	O
or	CCONJ	O	O
not	ADV	O	O
receive	VERB	O	O
1	NUM	O	O
1	NUM	O	O
fentanyl	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
a	DET	O	O
third	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
dexamethasone	NOUN	O	I-Entity
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
fentanyl	NOUN	O	I-Entity
.	PUNCT	O	O

Omission	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
overall	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
vomiting	NOUN	O	I-Entity
and/or	CCONJ	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
nausea	NOUN	O	I-Entity
prior	ADV	O	O
to	PART	O	O
discharge	NOUN	O	O
from	ADP	O	O
20%	NUM	O	O
and	CCONJ	O	O
17%	NUM	O	O
with	ADP	O	O
fentanyl	NOUN	O	I-Entity
and	CCONJ	O	O
fentanyl	NOUN	O	I-Entity
-	PUNCT	O	O
dexamethasone	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
to	ADP	O	O
5%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.013	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
had	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
or	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
.	PUNCT	O	O

Combining	VERB	O	O
the	DET	O	O
two	NUM	O	O
fentanyl	NOUN	O	I-Entity
groups	NOUN	O	O
revealed	VERB	O	O
further	ADV	O	O
significant	ADJ	O	O
benefits	NOUN	O	O
from	ADP	O	O
the	DET	O	O
avoidance	NOUN	O	O
of	ADP	O	O
opioids	NOUN	O	O
,	PUNCT	O	O
reducing	VERB	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
and	CCONJ	O	O
nausea	NOUN	O	I-Entity
prior	ADV	O	O
to	PART	O	O
discharge	VERB	O	O
from	ADP	O	O
35%	NUM	O	O
and	CCONJ	O	O
33%	NUM	O	O
to	ADP	O	O
22%	NUM	O	O
and	CCONJ	O	O
19%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.049	NUM	O	O
and	CCONJ	O	O
P	NOUN	O	O
=	SYM	O	O
0.035	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
while	ADP	O	O
nausea	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
h	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
from	ADP	O	O
42%	NUM	O	O
to	ADP	O	O
27%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.034	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
severity	NOUN	O	O
and	CCONJ	O	O
analgesic	NOUN	O	O
requirements	NOUN	O	O
were	VERB	O	O
unaffected	VERB	O	O
by	ADP	O	O
the	DET	O	O
omission	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
.	PUNCT	O	O

Fentanyl	PROPN	O	I-Entity
did	VERB	O	O
reduce	VERB	O	O
minor	ADJ	O	O
intraoperative	ADJ	O	O
movement	NOUN	O	O
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
sevoflurane	NOUN	O	I-Entity
-	PUNCT	O	O
sparing	VERB	O	O
effect	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
respiratory	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
,	PUNCT	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
fentanyl	NOUN	O	I-Entity
exacerbated	VERB	O	O
postoperative	ADJ	O	B-Entity
nausea	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
vomiting	NOUN	O	I-Entity
without	ADP	O	O
an	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
postoperative	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
also	ADV	O	O
had	VERB	O	O
adverse	ADJ	O	O
cardiorespiratory	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
unnecessary	ADJ	O	O
and	CCONJ	O	O
possibly	ADV	O	O
detrimental	ADJ	O	O
supplement	NOUN	O	O
to	ADP	O	O
sevoflurane	NOUN	O	I-Entity
in	ADP	O	O
day	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18186898)

Renal	ADJ	O	B-Entity
Fanconi	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
myopathy	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
:	PUNCT	O	O

drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
mitochondrial	ADJ	O	B-Entity
cytopathy	NOUN	O	I-Entity
?	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
15-yr	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
orthotopic	ADJ	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Tacrolimus	PROPN	O	I-Entity
,	PUNCT	O	O
MMF	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
steroids	NOUN	O	I-Entity
were	VERB	O	O
given	VERB	O	O
as	ADP	O	O
immunosuppressant	NOUN	O	O
.	PUNCT	O	O

Lamivudine	PROPN	O	I-Entity
was	VERB	O	O
added	VERB	O	O
because	ADP	O	O
of	ADP	O	O
de	X	O	O
nova	X	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
infection	NOUN	O	I-Entity
during	ADP	O	O
her	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
yr	NOUN	O	O
after	ADP	O	O
transplantation	NOUN	O	O
she	PRON	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
Fanconi	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
with	ADP	O	O
severe	ADJ	O	O
metabolic	NOUN	O	B-Entity
acidosis	NOUN	O	I-Entity
,	PUNCT	O	O
hypophosphatemia	NOUN	O	I-Entity
,	PUNCT	O	O
glycosuria	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
aminoaciduria	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
tacrolimus	NOUN	O	I-Entity
was	VERB	O	O
suspected	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
late	ADJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
transplant	NOUN	O	O
renal	NOUN	O	O
acidosis	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
replaced	VERB	O	O
by	ADP	O	O
sirolimus	NOUN	O	I-Entity
,	PUNCT	O	O
acidosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
electrolyte	NOUN	O	O
imbalance	NOUN	O	O
got	VERB	O	O
worse	ADJ	O	O
.	PUNCT	O	O

Proximal	ADJ	O	O
muscle	NOUN	O	B-Entity
weakness	NOUN	O	I-Entity
has	VERB	O	O
developed	VERB	O	O
during	ADP	O	O
her	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

Fanconi	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
myopathy	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
well	ADV	O	O
recognized	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mitochondrial	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
and	CCONJ	O	O
caused	VERB	O	O
by	ADP	O	O
depletion	NOUN	O	O
of	ADP	O	O
mtDNA	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
's	PART	O	O
tubular	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
myopathy	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
resulted	VERB	O	O
from	ADP	O	O
mitochondrial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
which	ADJ	O	O
is	VERB	O	O
triggered	VERB	O	O
by	ADP	O	O
tacrolimus	NOUN	O	I-Entity
and	CCONJ	O	O
augmented	VERB	O	O
by	ADP	O	O
lamivudine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16867021)

Antipsychotic	ADJ	O	O
-	PUNCT	O	O
like	ADJ	O	O
profile	NOUN	O	O
of	ADP	O	O
thioperamide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
H3-receptor	NOUN	O	O
antagonist	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Experimental	PROPN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
evidence	NOUN	O	O
points	VERB	O	O
to	ADP	O	O
a	DET	O	O
role	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
histaminergic	ADJ	O	O
system	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
histamine	NOUN	O	I-Entity
H(3)-receptor	PROPN	O	O
ligands	VERB	O	O
on	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
climbing	VERB	O	O
behavior	NOUN	O	O
and	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
activities	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Catalepsy	PROPN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
while	ADP	O	O
apomorphine	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

(	PUNCT	O	B-Entity
R)-alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylhistamine	NOUN	O	I-Entity
(	PUNCT	O	O
RAMH	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
5	NUM	O	O
microg	NOUN	O	O
i.c.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
thioperamide	NOUN	O	I-Entity
(	PUNCT	O	O
THP	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
per	ADP	O	O
se	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
THP	PROPN	O	I-Entity
(	PUNCT	O	O
3.75	NUM	O	O
,	PUNCT	O	O
7.5	NUM	O	O
and	CCONJ	O	O
15	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
1	NUM	O	O

h	X	O	O
prior	ADV	O	O
to	ADP	O	O
haloperidol	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
catalepsy	ADJ	O	I-Entity
times	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
RAMH	PROPN	O	I-Entity
significantly	ADV	O	O
reversed	VERB	O	O
such	ADJ	O	O
an	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
THP	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RAMH	PROPN	O	I-Entity
per	X	O	O
se	X	O	O
showed	VERB	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
locomotor	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
distance	NOUN	O	O
traveled	VERB	O	O
and	CCONJ	O	O
average	ADJ	O	O
speed	NOUN	O	O
but	CCONJ	O	O
THP	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

On	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
,	PUNCT	O	O
THP	PROPN	O	I-Entity
(	PUNCT	O	O
3.75	NUM	O	O
and	CCONJ	O	O
7.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
RAMH	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
microg	NOUN	O	O
i.c.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
could	VERB	O	O
partially	ADV	O	O
reverse	VERB	O	O
such	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
THP	PROPN	O	I-Entity
(	PUNCT	O	O
3.75	NUM	O	O
mg	PROPN	O	O

Climbing	VERB	O	O
behavior	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
apomorphine	NOUN	O	I-Entity
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
THP	PROPN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
an	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
reversed	VERB	O	O
in	ADP	O	O
presence	NOUN	O	O
of	ADP	O	O
RAMH	PROPN	O	I-Entity
.	PUNCT	O	O

THP	PROPN	O	I-Entity
exhibited	VERB	O	O
an	DET	O	O
antipsychotic	ADJ	O	O
-	PUNCT	O	O
like	ADJ	O	O
profile	NOUN	O	O
by	ADP	O	O
potentiating	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
reducing	VERB	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
and	CCONJ	O	O
reducing	VERB	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
climbing	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Such	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
THP	PROPN	O	I-Entity
were	VERB	O	O
reversed	VERB	O	O
by	ADP	O	O
RAMH	PROPN	O	I-Entity
indicating	VERB	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
histamine	NOUN	O	I-Entity
H(3)-receptors	NOUN	O	O
.	PUNCT	O	O

Findings	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
H(3)-receptor	NOUN	O	O
antagonists	NOUN	O	O
in	ADP	O	O
improving	VERB	O	O
the	DET	O	O
refractory	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (14976857)

Transient	PROPN	O	O
platypnea	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
orthodeoxia	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
propafenone	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
young	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
Ebstein	PROPN	O	B-Entity
's	PART	O	I-Entity
anomaly	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
report	NOUN	O	O
we	PRON	O	O
describe	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
37-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
white	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
Ebstein	PROPN	O	B-Entity
's	PART	O	I-Entity
anomaly	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
syndrome	NOUN	O	O
called	VERB	O	O
platypnea	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
orthodeoxia	NOUN	O	I-Entity
,	PUNCT	O	O
characterized	VERB	O	O
by	ADP	O	O
massive	ADJ	O	O
right	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
left	VERB	O	O
interatrial	ADJ	O	O
shunting	VERB	O	O
with	ADP	O	O
transient	ADJ	O	O
profound	ADJ	O	O
hypoxia	NOUN	O	I-Entity
and	CCONJ	O	O
cyanosis	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
shunt	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
via	ADP	O	O
a	DET	O	O
patent	NOUN	O	B-Entity
foramen	NOUN	O	I-Entity
ovale	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
pulmonary	ADJ	O	O
artery	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
probably	ADV	O	O
precipitated	VERB	O	O
by	ADP	O	O
a	DET	O	O
propafenone	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
drug	NOUN	O	O
caused	VERB	O	O
biventricular	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
due	ADP	O	O
to	ADP	O	O
its	ADJ	O	O
negative	ADJ	O	O
inotropic	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
its	ADJ	O	O
peripheral	ADJ	O	O
vasodilatory	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11745184)

A	DET	O	O
Phase	NOUN	O	O
II	NUM	O	O
trial	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
plus	CCONJ	O	O
WR-2721	PROPN	O	I-Entity
(	PUNCT	O	O
amifostine	NOUN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
Eastern	PROPN	O	O
Cooperative	PROPN	O	O
Oncology	PROPN	O	O
Group	PROPN	O	O
Study	PROPN	O	O
(	PUNCT	O	O
E8188	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Cisplatin	PROPN	O	I-Entity
has	VERB	O	O
minimal	ADJ	O	O
antitumor	NOUN	O	O
activity	NOUN	O	O
when	ADV	O	O
used	VERB	O	O
as	ADP	O	O
second-	NOUN	O	O
or	CCONJ	O	O
third	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

Older	ADJ	O	O
reports	NOUN	O	O
suggest	VERB	O	O
an	DET	O	O
objective	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
8%	NUM	O	O
when	ADV	O	O
60	NUM	O	O
-	SYM	O	O
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
is	VERB	O	O
administered	VERB	O	O
every	DET	O	O
3	NUM	O	O
-	SYM	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
effect	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxicities	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
e.g.	NOUN	O	O
,	PUNCT	O	O
nephrotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
ototoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
neurotoxicity	NOUN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
limited	VERB	O	O
its	ADJ	O	O
use	NOUN	O	O
as	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
for	ADP	O	O
breast	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

WR-2721	PUNCT	O	I-Entity

or	CCONJ	O	O
amifostine	NOUN	O	I-Entity
initially	ADV	O	O
was	VERB	O	O
developed	VERB	O	O
to	PART	O	O
protect	VERB	O	O
military	ADJ	O	O
personnel	NOUN	O	O
in	ADP	O	O
the	DET	O	O
event	NOUN	O	O
of	ADP	O	O
nuclear	ADJ	O	O
war	NOUN	O	O
.	PUNCT	O	O

Amifostine	PROPN	O	I-Entity
subsequently	ADV	O	O
was	VERB	O	O
shown	VERB	O	O
to	PART	O	O
protect	VERB	O	O
normal	ADJ	O	O
tissues	NOUN	O	O
from	ADP	O	O
the	DET	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
alkylating	VERB	O	B-Entity
agents	NOUN	O	I-Entity
and	CCONJ	O	O
cisplatin	NOUN	O	I-Entity
without	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
antitumor	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Early	ADJ	O	O
trials	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
and	CCONJ	O	O
amifostine	NOUN	O	I-Entity
also	ADV	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
ototoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
neuropathy	NOUN	O	I-Entity
were	VERB	O	O
reduced	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
Phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
plus	CCONJ	O	O
amifostine	NOUN	O	I-Entity
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
progressive	ADJ	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
one	NUM	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
more	ADJ	O	O
than	ADP	O	O
one	NUM	O	O
,	PUNCT	O	O
chemotherapy	NOUN	O	O
regimen	NOUN	O	O
for	ADP	O	O
metastatic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
amifostine	NOUN	O	I-Entity
,	PUNCT	O	O
910	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
intravenously	ADV	O	O
over	ADP	O	O
15	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
completion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
amifostine	NOUN	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
cisplatin	ADJ	O	I-Entity
120	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
over	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
hydration	NOUN	O	O
and	CCONJ	O	O
mannitol	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

Neurologic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
52%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Seven	NUM	O	O
different	ADJ	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
while	ADP	O	O
receiving	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
and	CCONJ	O	O
amifostine	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
overall	ADJ	O	O
response	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
16%	NUM	O	O
.	PUNCT	O	O

Neither	DET	O	O
a	DET	O	O
tumor	NOUN	O	I-Entity
-	PUNCT	O	O
protective	ADJ	O	O
effect	NOUN	O	O
nor	CCONJ	O	O
reduced	VERB	O	O
toxicity	NOUN	O	I-Entity
to	ADP	O	O
normal	ADJ	O	O
tissues	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
amifostine	NOUN	O	I-Entity
to	ADP	O	O
cisplatin	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3985451)

Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
iliopsoas	NOUN	O	O
hemorrhage	NOUN	O	I-Entity
with	ADP	O	O
subsequent	ADJ	O	O
femoral	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
palsy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
28-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
on	ADP	O	O
chronic	ADJ	O	O
warfarin	NOUN	O	I-Entity
therapy	NOUN	O	O
who	NOUN	O	O
sustained	VERB	O	O
a	DET	O	O
minor	ADJ	O	O
muscle	NOUN	O	B-Entity
tear	NOUN	O	I-Entity
and	CCONJ	O	O
developed	VERB	O	O
increasing	VERB	O	O
pain	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
flexure	NOUN	O	O
contracture	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
right	ADJ	O	O
hip	NOUN	O	O
.	PUNCT	O	O

Surgical	ADJ	O	O
exploration	NOUN	O	O
revealed	VERB	O	O
an	DET	O	O
iliopsoas	NOUN	O	O
hematoma	NOUN	O	I-Entity
and	CCONJ	O	O
femoral	ADJ	O	O
nerve	NOUN	O	B-Entity
entrapment	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
a	DET	O	O
femoral	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
palsy	NOUN	O	I-Entity
and	CCONJ	O	O
partial	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
of	ADP	O	I-Entity
quadriceps	NOUN	O	I-Entity
functions	NOUN	O	I-Entity
.	PUNCT	O	O

Anticoagulant	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
femoral	ADJ	O	B-Entity
nerve	NOUN	O	I-Entity
palsy	NOUN	O	I-Entity
represents	VERB	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
;	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
severe	ADJ	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
inguinal	ADJ	O	O
region	NOUN	O	O
,	PUNCT	O	O
varying	VERB	O	O
degrees	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
sensory	ADJ	O	I-Entity
impairment	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
flexure	NOUN	O	O
contracture	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
involved	ADJ	O	O
extremity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3750012)

Myasthenia	PROPN	O	B-Entity
gravis	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
penicillamine	NOUN	O	I-Entity
and	CCONJ	O	O
chloroquine	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
described	VERB	O	O
a	DET	O	O
unique	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
reversible	ADJ	O	O
and	CCONJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
myasthenia	NOUN	O	B-Entity
gravis	NOUN	O	I-Entity
after	ADP	O	O
penicillamine	NOUN	O	I-Entity
and	CCONJ	O	O
chloroquine	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
antibodies	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
detectable	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
time	NOUN	O	O
course	NOUN	O	O
was	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
an	DET	O	O
autoimmune	ADJ	O	O
process	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1130930)

Nephrotoxicity	PROPN	O	I-Entity
of	ADP	O	O
combined	VERB	O	O
cephalothin	NOUN	O	I-Entity
-	PUNCT	O	O
gentamicin	NOUN	O	I-Entity
regimen	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
characterized	VERB	O	O
clinically	ADV	O	O
by	ADP	O	O
acute	ADJ	O	O
oliguric	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
they	PRON	O	O
were	VERB	O	O
receiving	VERB	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
cephalothin	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
given	VERB	O	O
this	DET	O	O
drug	NOUN	O	O
regimen	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
observed	VERB	O	O
very	ADV	O	O
carefully	ADV	O	O
for	ADP	O	O
early	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
given	VERB	O	O
this	DET	O	O
regimen	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19356307)

Components	NOUN	O	O
of	ADP	O	O
lemon	NOUN	O	O
essential	ADJ	O	O
oil	NOUN	O	O
attenuate	NOUN	O	O
dementia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
dementia	NOUN	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
s	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
limonene	NOUN	O	I-Entity
and	CCONJ	O	O
s	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
perillyl	NOUN	O	I-Entity
alcohol	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
using	VERB	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
PA	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
open	ADJ	O	O
field	NOUN	O	O
habituation	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
OFH	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
lemon	NOUN	O	O
essential	ADJ	O	O
oils	NOUN	O	O
showed	VERB	O	O
strong	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
improve	VERB	O	O
memory	NOUN	O	B-Entity
impaired	VERB	O	I-Entity
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
s	PUNCT	O	B-Entity
-	PUNCT	O	I-Entity
perillyl	NOUN	O	I-Entity
alcohol	NOUN	O	I-Entity
relieved	VERB	O	O
the	DET	O	O
deficit	NOUN	O	B-Entity
of	ADP	O	I-Entity
associative	ADJ	O	I-Entity
memory	NOUN	O	I-Entity
in	ADP	O	O
PA	PROPN	O	O
only	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
improve	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
associative	ADJ	O	O
memory	NOUN	O	O
significantly	ADV	O	O
in	ADP	O	O
OFH	PROPN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
neurotransmitter	NOUN	O	O
concentration	NOUN	O	O
in	ADP	O	O
some	DET	O	O
brain	NOUN	O	O
regions	NOUN	O	O
on	ADP	O	O
the	DET	O	O
test	NOUN	O	O
day	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
dopamine	NOUN	O	I-Entity
concentration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vehicle	NOUN	O	O
/	SYM	O	O
scopolamine	NOUN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
vehicle	NOUN	O	O
/	SYM	O	O
vehicle	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
phenomenon	NOUN	O	O
was	VERB	O	O
reversed	VERB	O	O
when	ADV	O	O
s	VERB	O	B-Entity
-	PUNCT	O	I-Entity
limonene	NOUN	O	I-Entity
or	CCONJ	O	O
s	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
perillyl	NOUN	O	I-Entity
alcohol	NOUN	O	I-Entity
were	VERB	O	O
administered	VERB	O	O
before	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15957009)

The	DET	O	O
selective	ADJ	O	O
5-HT6	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
Ro4368554	NOUN	O	I-Entity
restores	VERB	O	O
memory	NOUN	O	O
performance	NOUN	O	O
in	ADP	O	O
cholinergic	NOUN	O	O
and	CCONJ	O	O
serotonergic	ADJ	O	O
models	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	B-Entity
deficiency	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Antagonists	NOUN	O	O
at	ADP	O	O
serotonin	NOUN	O	I-Entity
type	NOUN	O	O
6	NUM	O	O
(	PUNCT	O	O
5-HT(6	NUM	O	I-Entity
)	PUNCT	O	O
)	PUNCT	O	O
receptors	NOUN	O	O
show	VERB	O	O
activity	NOUN	O	O
in	ADP	O	O
models	NOUN	O	O
of	ADP	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
underlying	VERB	O	O
mechanism(s	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
not	ADV	O	O
well	ADV	O	O
understood	VERB	O	O
,	PUNCT	O	O
these	DET	O	O
effects	NOUN	O	O
may	VERB	O	O
involve	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
acetylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
ACh	PROPN	O	I-Entity
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
sought	VERB	O	O
to	PART	O	O
characterize	VERB	O	O
the	DET	O	O
cognitive	ADJ	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
5-HT(6	PROPN	O	I-Entity
)	PUNCT	O	O
antagonist	NOUN	O	O
Ro4368554	NOUN	O	I-Entity
(	PUNCT	O	O
3-benzenesulfonyl-7-(4-methyl	NUM	O	B-Entity
-	PUNCT	O	I-Entity
piperazin-1-yl)1H	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
indole	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
object	NOUN	O	O
recognition	NOUN	O	O
task	NOUN	O	O
employing	VERB	O	O
a	DET	O	O
cholinergic	NOUN	O	O
(	PUNCT	O	O
scopolamine	NOUN	O	I-Entity
pretreatment	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
serotonergic-	NOUN	O	O
(	PUNCT	O	O
tryptophan	NOUN	O	I-Entity
(	PUNCT	O	O
TRP	PROPN	O	I-Entity
)	PUNCT	O	O
depletion	NOUN	O	O
)	PUNCT	O	O
deficient	ADJ	O	O
model	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
compared	VERB	O	O
its	ADJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
acetylcholinesterase	NOUN	O	O
inhibitor	NOUN	O	O
metrifonate	NOUN	O	I-Entity
.	PUNCT	O	O

Initial	ADJ	O	O
testing	NOUN	O	O
in	ADP	O	O
a	DET	O	O
time	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
forgetting	VERB	O	O
task	NOUN	O	O
employing	VERB	O	O
a	DET	O	O
24-h	NUM	O	O
delay	NOUN	O	O
between	ADP	O	O
training	NOUN	O	O
and	CCONJ	O	O
testing	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
metrifonate	NOUN	O	I-Entity
improved	VERB	O	O
object	NOUN	O	O
recognition	NOUN	O	O
(	PUNCT	O	O
at	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
Ro4368554	PROPN	O	I-Entity
was	VERB	O	O
inactive	ADJ	O	O
.	PUNCT	O	O

Both	DET	O	O
,	PUNCT	O	O
Ro4368554	PROPN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
intraperitoneally	ADV	O	O
(	PUNCT	O	O
i.p	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
metrifonate	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O

,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
reversed	VERB	O	O
memory	NOUN	O	B-Entity
deficits	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
TRP	PROPN	O	I-Entity
depletion	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
p.o	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
Ro4368554	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
improve	VERB	O	O
a	DET	O	O
time	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
retention	NOUN	O	O
deficit	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
reversed	VERB	O	O
a	DET	O	O
cholinergic	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
serotonergic	ADJ	O	O
memory	NOUN	O	B-Entity
deficit	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
both	DET	O	O
mechanisms	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
facilitation	NOUN	O	O
of	ADP	O	O
object	NOUN	O	O
memory	NOUN	O	O
by	ADP	O	O
Ro4368554	PROPN	O	I-Entity
and	CCONJ	O	O
,	PUNCT	O	O
possibly	ADV	O	O
,	PUNCT	O	O
other	ADJ	O	O
5-HT(6	NUM	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15899738)

Lone	NOUN	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
creatine	NOUN	O	I-Entity
monohydrate	ADJ	O	O
supplementation	NOUN	O	O
.	PUNCT	O	O

Atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
in	ADP	O	O
young	ADJ	O	O
patients	NOUN	O	O
without	ADP	O	O
structural	ADJ	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
is	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
,	PUNCT	O	O
reversible	ADJ	O	O
causes	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
identified	VERB	O	O
and	CCONJ	O	O
resolved	VERB	O	O
.	PUNCT	O	O

Thyroid	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
,	PUNCT	O	O
illicit	ADJ	O	O
drug	NOUN	O	O
or	CCONJ	O	O
stimulant	NOUN	O	O
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
acute	ADJ	O	B-Entity
alcohol	NOUN	O	I-Entity
intoxication	NOUN	O	I-Entity
are	VERB	O	O
among	ADP	O	O
these	DET	O	O
causes	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
30-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Caucasian	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
came	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
in	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
with	ADP	O	O
rapid	ADJ	O	O
ventricular	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

His	ADJ	O	O
medical	ADJ	O	O
history	NOUN	O	O
was	VERB	O	O
unremarkable	ADJ	O	O
,	PUNCT	O	O
except	ADP	O	O
for	ADP	O	O
minor	ADJ	O	O
fractures	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
fingers	NOUN	O	O
and	CCONJ	O	O
foot	NOUN	O	O
.	PUNCT	O	O

Thyroid	ADJ	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
hormone	NOUN	O	O
,	PUNCT	O	O
magnesium	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
potassium	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
within	ADP	O	O
normal	ADJ	O	O
limits	NOUN	O	O
,	PUNCT	O	O
urine	ADJ	O	O
drug	NOUN	O	O
screen	NOUN	O	O
was	VERB	O	O
negative	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
was	VERB	O	O
denied	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
questioned	VERB	O	O
about	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
herbal	ADJ	O	O
products	NOUN	O	O
and	CCONJ	O	O
supplements	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	I-Entity
monohydrate	NOUN	O	O
was	VERB	O	O
revealed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
,	PUNCT	O	O
anticoagulated	VERB	O	O
with	ADP	O	O
unfractionated	ADJ	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
given	VERB	O	O
intravenous	ADJ	O	O
diltiazem	NOUN	O	I-Entity
for	ADP	O	O
rate	NOUN	O	O
control	NOUN	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
amiodarone	NOUN	O	I-Entity
for	ADP	O	O
rate	NOUN	O	O
and	CCONJ	O	O
rhythm	NOUN	O	O
control	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
discharged	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
he	PRON	O	O
was	VERB	O	O
receiving	VERB	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
plans	NOUN	O	O
for	ADP	O	O
echocardiography	NOUN	O	O
and	CCONJ	O	O
nuclear	ADJ	O	O
imaging	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
perfusion	NOUN	O	O
.	PUNCT	O	O

Exogenous	ADJ	O	O
creatine	NOUN	O	I-Entity
is	VERB	O	O
used	VERB	O	O
by	ADP	O	O
athletes	NOUN	O	O
to	PART	O	O
theoretically	ADV	O	O
improve	VERB	O	O
exercise	NOUN	O	O
performance	NOUN	O	O
.	PUNCT	O	O

Vegetarians	NOUN	O	O
may	VERB	O	O
also	ADV	O	O
take	VERB	O	O
creatine	NOUN	O	I-Entity
to	PART	O	O
replace	VERB	O	O
what	NOUN	O	O
they	PRON	O	O
are	VERB	O	O
not	ADV	O	O
consuming	VERB	O	O
from	ADP	O	O
meat	NOUN	O	O
,	PUNCT	O	O
fish	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
animal	NOUN	O	O
products	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
anecdotal	ADJ	O	O
reports	NOUN	O	O
have	VERB	O	O
linked	VERB	O	O
creatine	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
arrhythmia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15863244)

Comparison	NOUN	O	O
of	ADP	O	O
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
selective	ADJ	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
cyclooxygenase-2	NOUN	O	O
inhibitors	NOUN	O	O
in	ADP	O	O
CRL:(WI)WUBR	PROPN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
--	PUNCT	O	O
DFU	PROPN	O	I-Entity
and	CCONJ	O	O
piroxicam	ADJ	O	I-Entity
study	NOUN	O	O
.	PUNCT	O	O

Unlike	ADP	O	O
general	ADJ	O	O
toxicity	NOUN	O	I-Entity
data	NOUN	O	O
,	PUNCT	O	O
their	ADJ	O	O
prenatal	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
extensively	ADV	O	O
studied	VERB	O	O
before	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
experiment	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
(	PUNCT	O	O
piroxicam	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
selective	ADJ	O	O
(	PUNCT	O	O
DFU	PROPN	O	I-Entity
;	PUNCT	O	O
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl	NUM	O	B-Entity
)	PUNCT	O	I-Entity
phenyl-2(5H)-furanon	NOUN	O	I-Entity
)	PUNCT	O	O
COX-2	ADJ	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Doses	NOUN	O	O
were	VERB	O	O
set	VERB	O	O
at	ADP	O	O
0.3	NUM	O	O
,	PUNCT	O	O
3.0	NUM	O	O
and	CCONJ	O	O
30.0mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
piroxicam	NOUN	O	I-Entity
and	CCONJ	O	O
0.2	NUM	O	O
,	PUNCT	O	O
2.0	NUM	O	O
and	CCONJ	O	O
20.0mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
DFU	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pooled	ADJ	O	O
statistical	ADJ	O	O
analysis	NOUN	O	O
for	ADP	O	O
ventricular	ADJ	O	B-Entity
septal	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
VSD	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
midline	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
MD	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
defects	NOUN	O	I-Entity
was	VERB	O	O
performed	VERB	O	O
for	ADP	O	O
rat	NOUN	O	O
fetuses	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
piroxicam	NOUN	O	I-Entity
,	PUNCT	O	O
selective	ADJ	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
COX-2	NOUN	O	O
inhibitor	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
present	ADJ	O	O
and	CCONJ	O	O
historic	ADJ	O	O
data	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Maternal	ADJ	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
intrauterine	ADJ	O	B-Entity
growth	NOUN	O	I-Entity
retardation	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
increase	NOUN	O	B-Entity
of	ADP	O	I-Entity
external	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
skeletal	ADJ	O	I-Entity
variations	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
piroxicam	NOUN	O	I-Entity
.	PUNCT	O	O

Decrease	NOUN	O	O
of	ADP	O	O
fetal	ADJ	O	O
length	NOUN	O	O
was	VERB	O	O
the	DET	O	O
only	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DFU	PROPN	O	I-Entity
developmental	ADJ	O	O
toxicity	NOUN	O	I-Entity
observed	VERB	O	O
in	ADP	O	O
pups	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
compound	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Lack	NOUN	O	O
of	ADP	O	O
teratogenicity	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
piroxicam	NOUN	O	I-Entity
and	CCONJ	O	O
DFU	PROPN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Unlike	ADP	O	O
DFU	PROPN	O	I-Entity
,	PUNCT	O	O
piroxicam	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
highly	ADV	O	O
toxic	ADJ	O	O
to	ADP	O	O
the	DET	O	O
dams	NOUN	O	O
.	PUNCT	O	O

Prenatal	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
selective	ADJ	O	O
COX-2	PROPN	O	O
inhibitors	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
septal	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
midline	NOUN	O	I-Entity
defects	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
historic	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12921865)

Protective	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
against	ADP	O	O
cocaine	NOUN	O	I-Entity
kindled	VERB	O	O
-	PUNCT	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
demonstrate	VERB	O	O
pharmacological	ADJ	O	O
actions	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
relevance	NOUN	O	O
for	ADP	O	O
a	DET	O	O
host	NOUN	O	O
of	ADP	O	O
neurological	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
psychiatric	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

They	PRON	O	O
offer	VERB	O	O
protection	NOUN	O	O
against	ADP	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
models	NOUN	O	O
and	CCONJ	O	O
seem	VERB	O	O
to	PART	O	O
inhibit	VERB	O	O
certain	ADJ	O	O
stages	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	B-Entity
dependence	NOUN	O	I-Entity
in	ADP	O	O
preclinical	ADJ	O	O
assessments	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
two	NUM	O	O
endogenous	ADJ	O	O
and	CCONJ	O	O
one	NUM	O	O
synthetic	ADJ	O	O
neuroactive	ADJ	O	O
steroid	NOUN	O	I-Entity
that	ADJ	O	O
positively	ADV	O	O
modulate	VERB	O	O
the	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
)	PUNCT	O	O
receptor	NOUN	O	O
against	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
the	DET	O	O
convulsant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
engendered	VERB	O	O
by	ADP	O	O
repeated	VERB	O	O
cocaine	NOUN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
seizure	NOUN	O	I-Entity
kindling	VERB	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Allopregnanolone	PROPN	O	I-Entity
(	PUNCT	O	O
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
hydroxy-5alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
pregnanolone	NOUN	O	I-Entity
(	PUNCT	O	O
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
hydroxy-5beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
ganaxolone	NOUN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
synthetic	ADJ	O	O
derivative	NOUN	O	O
of	ADP	O	O
allopregnanolone	NOUN	O	I-Entity
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
hydroxy-3beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
methyl-5alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
their	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
suppress	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
(	PUNCT	O	O
anticonvulsant	ADJ	O	O
effect	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
development	NOUN	O	O
(	PUNCT	O	O
antiepileptogenic	ADJ	O	O
effect	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
kindled	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
male	NOUN	O	O
,	PUNCT	O	O
Swiss	PROPN	O	O
-	PUNCT	O	O
Webster	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Kindled	VERB	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
daily	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
60	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
cocaine	NOUN	O	I-Entity
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
of	ADP	O	O
these	DET	O	O
positive	ADJ	O	O
GABA(A	NOUN	O	I-Entity
)	PUNCT	O	O
modulators	NOUN	O	O
suppressed	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
kindled	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
only	ADV	O	O
allopregnanolone	NOUN	O	I-Entity
and	CCONJ	O	O
ganaxolone	NOUN	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
kindling	VERB	O	O
.	PUNCT	O	O

Allopregnanolone	PROPN	O	I-Entity
and	CCONJ	O	O
pregnanolone	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
ganaxolone	NOUN	O	I-Entity
,	PUNCT	O	O
also	ADV	O	O
reduced	VERB	O	O
cumulative	ADJ	O	O
lethality	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
kindling	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
some	DET	O	O
neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
attenuate	VERB	O	O
convulsant	NOUN	O	O
and	CCONJ	O	O
sensitizing	VERB	O	O
properties	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
add	VERB	O	O
to	ADP	O	O
a	DET	O	O
growing	VERB	O	O
literature	NOUN	O	O
on	ADP	O	O
their	ADJ	O	O
potential	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
the	DET	O	O
modulation	NOUN	O	O
of	ADP	O	O
effects	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
of	ADP	O	O
abuse	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12584269)

Kidney	PROPN	O	O
function	NOUN	O	O
and	CCONJ	O	O
morphology	NOUN	O	O
after	ADP	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
cyclosporine	NOUN	O	B-Entity
A	NOUN	O	I-Entity
,	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
and	CCONJ	O	O
sirolimus	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Sirolimus	PROPN	O	I-Entity
(	PUNCT	O	O
SRL	PROPN	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
supplement	VERB	O	O
calcineurin	ADJ	O	O
inhibitors	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
organ	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
are	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
SRL	PROPN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
act	VERB	O	O
differently	ADV	O	O
displaying	VERB	O	O
only	ADJ	O	O
minor	ADJ	O	O
nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
this	DET	O	O
question	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
open	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
protocols	NOUN	O	O
where	ADV	O	O
SRL	PROPN	O	I-Entity
was	VERB	O	O
combined	VERB	O	O
with	ADP	O	O
a	DET	O	O
calcineurin	ADJ	O	O
inhibitor	NOUN	O	O
indications	NOUN	O	O
of	ADP	O	O
a	DET	O	O
synergistic	ADJ	O	O
nephrotoxic	NOUN	O	I-Entity
effect	NOUN	O	O
were	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
examine	VERB	O	O
further	ADV	O	O
the	DET	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
morphological	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kidneys	NOUN	O	O
of	ADP	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
either	DET	O	O
cyclosporine	NOUN	O	B-Entity
A	DET	O	I-Entity
(	PUNCT	O	O
CsA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
(	PUNCT	O	O
FK506	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
SRL	PROPN	O	I-Entity
as	ADP	O	O
monotherapies	NOUN	O	O
or	CCONJ	O	O
in	ADP	O	O
different	ADJ	O	O
combinations	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
For	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
CsA	PROPN	O	I-Entity
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
given	VERB	O	O
orally	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
FK506	PROPN	O	I-Entity
3.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
given	VERB	O	O
orally	ADV	O	O
)	PUNCT	O	O
or	CCONJ	O	O
SRL	PROPN	O	I-Entity
0.4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
given	VERB	O	O
intraperitoneally	ADV	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
once	ADV	O	O
a	DET	O	O
day	NOUN	O	O
as	ADP	O	O
these	DET	O	O
doses	NOUN	O	O
have	VERB	O	O
earlier	ADJ	O	O
been	VERB	O	O
found	VERB	O	O
to	PART	O	O
achieve	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
immunosuppressive	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
morphological	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kidneys	NOUN	O	O
included	VERB	O	O
a	DET	O	O
semi	NOUN	O	O
-	PUNCT	O	O
quantitative	ADJ	O	O
scoring	NOUN	O	O
system	NOUN	O	O
analysing	VERB	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
striped	ADJ	O	O
fibrosis	NOUN	O	I-Entity
,	PUNCT	O	O
subcapsular	ADJ	O	O
fibrosis	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
basophilic	NOUN	O	O
tubules	NOUN	O	O
,	PUNCT	O	O
plus	CCONJ	O	O
an	DET	O	O
additional	ADJ	O	O
stereological	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
grade	NOUN	O	O
of	ADP	O	O
fibrosis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
stained	VERB	O	O
with	ADP	O	O
Sirius	PROPN	O	O
Red	PROPN	O	O
.	PUNCT	O	O

CsA	NOUN	O	I-Entity
,	PUNCT	O	O
FK506	PROPN	O	I-Entity
and	CCONJ	O	O
SRL	PROPN	O	I-Entity
all	DET	O	O
significantly	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
GFR	PROPN	O	O
.	PUNCT	O	O

A	DET	O	O
further	ADJ	O	O
deterioration	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
when	ADV	O	O
CsA	PROPN	O	I-Entity
was	VERB	O	O
combined	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
FK506	PROPN	O	I-Entity
or	CCONJ	O	O
SRL	PROPN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
GFR	PROPN	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
FK506	PROPN	O	I-Entity
plus	CCONJ	O	O
SRL	PROPN	O	I-Entity
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
single	ADJ	O	O
substances	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
semi	NOUN	O	O
-	PUNCT	O	O
quantitative	ADJ	O	O
scoring	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
worst	ADJ	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
CsA	PROPN	O	I-Entity
plus	CCONJ	O	O
SRL	PROPN	O	I-Entity
(	PUNCT	O	O
P<0.001	PROPN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
grade	NOUN	O	O
of	ADP	O	O
fibrosis	NOUN	O	I-Entity
also	ADV	O	O
showed	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
proportion	NOUN	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
P<0.02	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
FK506	PROPN	O	I-Entity
plus	CCONJ	O	O
SRL	PROPN	O	I-Entity
combination	NOUN	O	O
showed	VERB	O	O
only	ADV	O	O
a	DET	O	O
marginally	ADV	O	O
higher	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
fibrosis	NOUN	O	I-Entity
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
P=0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
rat	NOUN	O	O
study	NOUN	O	O
demonstrated	VERB	O	O
a	DET	O	O
synergistic	ADJ	O	O
nephrotoxic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
CsA	PROPN	O	I-Entity
plus	CCONJ	O	O
SRL	PROPN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
FK506	PROPN	O	I-Entity
plus	CCONJ	O	O
SRL	PROPN	O	I-Entity
was	VERB	O	O
better	ADV	O	O
tolerated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (10406016)

Effect	NOUN	O	O
of	ADP	O	O
fucoidan	ADJ	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
collagenase	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Inflammatory	ADJ	O	O
cells	NOUN	O	O
are	VERB	O	O
postulated	VERB	O	O
to	PART	O	O
mediate	VERB	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
following	VERB	O	O
ischemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

Intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
more	ADJ	O	O
inflammation	NOUN	O	I-Entity
than	ADP	O	O
ischemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
the	DET	O	O
sulfated	VERB	O	O
polysaccharide	NOUN	O	O
fucoidan	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
inflammatory	ADJ	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
bacterial	ADJ	O	O
collagenase	NOUN	O	O
into	ADP	O	O
the	DET	O	O
caudate	NOUN	O	O
nucleus	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
seven	NUM	O	O
day	NOUN	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
fucoidan	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
h-1	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hematoma	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
vivo	NOUN	O	O
by	ADP	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
.	PUNCT	O	O

Fucoidan	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
exhibited	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
impaired	ADJ	O	B-Entity
blood	NOUN	O	I-Entity
clotting	NOUN	O	I-Entity
and	CCONJ	O	O
hemodilution	NOUN	O	I-Entity
,	PUNCT	O	O
had	VERB	O	O
larger	ADJ	O	O
hematomas	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
tended	VERB	O	O
to	PART	O	O
have	VERB	O	O
less	ADJ	O	O
inflammation	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
vicinity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hematoma	NOUN	O	I-Entity
after	ADP	O	O
three	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
showed	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
rapid	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
week	NOUN	O	O
following	VERB	O	O
hemorrhage	NOUN	O	I-Entity
and	CCONJ	O	O
better	ADJ	O	O
memory	NOUN	O	O
retention	NOUN	O	O
in	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
white	ADJ	O	B-Entity
matter	NOUN	O	I-Entity
edema	NOUN	O	I-Entity
and	CCONJ	O	O
eventual	ADJ	O	O
neuronal	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
adjacent	ADJ	O	O
to	ADP	O	O
the	DET	O	O
hematoma	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Investigation	NOUN	O	O
of	ADP	O	O
more	ADV	O	O
specific	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
hemodiluting	VERB	O	O
agents	NOUN	O	O
are	VERB	O	O
warranted	VERB	O	O
in	ADP	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3403780)

Paracetamol	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
coma	NOUN	O	I-Entity
,	PUNCT	O	O
metabolic	NOUN	O	B-Entity
acidosis	NOUN	O	I-Entity
,	PUNCT	O	O
renal	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
metabolic	NOUN	O	B-Entity
acidosis	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
following	VERB	O	O
paracetamol	NOUN	O	I-Entity
ingestion	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3101906)

Hepatic	ADJ	O	O
reactions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
ketoconazole	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
Kingdom	PROPN	O	O
.	PUNCT	O	O

Ketoconazole	PROPN	O	I-Entity
was	VERB	O	O
introduced	VERB	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
Kingdom	PROPN	O	O
in	ADP	O	O
1981	NUM	O	O
.	PUNCT	O	O

By	ADP	O	O
November	PROPN	O	O
1984	NUM	O	O
the	DET	O	O
Committee	PROPN	O	O
on	ADP	O	O
Safety	PROPN	O	O
of	ADP	O	O
Medicines	PROPN	O	O
had	VERB	O	O
received	VERB	O	O
82	NUM	O	O
reports	NOUN	O	O
of	ADP	O	O
possible	ADJ	O	O
hepatotoxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
five	NUM	O	O
deaths	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
75	NUM	O	O
cases	NOUN	O	O
that	ADJ	O	O
had	VERB	O	O
been	VERB	O	O
adequately	ADV	O	O
followed	VERB	O	O
up	PART	O	O
suggested	VERB	O	O
that	ADP	O	O
16	NUM	O	O
,	PUNCT	O	O
including	VERB	O	O
three	NUM	O	O
deaths	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
probably	ADV	O	O
related	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
age	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
16	NUM	O	O
probable	ADJ	O	O
cases	NOUN	O	O
was	VERB	O	O
57.9	NUM	O	O
,	PUNCT	O	O
with	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
being	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
women	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
before	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
jaundice	NOUN	O	I-Entity
was	VERB	O	O
61	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
liver	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
suggested	VERB	O	O
hepatocellular	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
63%	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
rest	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
mixed	ADJ	O	O
pattern	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
histological	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
often	ADV	O	O
showed	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
cholestasis	NOUN	O	I-Entity
.	PUNCT	O	O

Allergic	ADJ	O	O
manifestations	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
rash	NOUN	O	I-Entity
and	CCONJ	O	O
eosinophilia	NOUN	O	I-Entity
were	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

Hepatitis	PROPN	O	I-Entity
was	VERB	O	O
usually	ADV	O	O
reversible	ADJ	O	O
when	ADV	O	O
treatment	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
returning	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
after	ADP	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
3.1	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
of	ADP	O	O
the	DET	O	O
three	NUM	O	O
deaths	NOUN	O	I-Entity
probably	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
ketoconazole	NOUN	O	I-Entity
treatment	NOUN	O	O
the	DET	O	O
drug	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
continued	VERB	O	O
after	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
jaundice	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
monitoring	NOUN	O	O
at	ADP	O	O
regular	ADJ	O	O
intervals	NOUN	O	O
for	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
is	VERB	O	O
advised	VERB	O	O
during	ADP	O	O
long	ADJ	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
ketoconazole	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
possible	ADJ	O	O
serious	ADJ	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9088814)

Combined	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
prolonged	VERB	O	O
prostaglandin	NOUN	O	B-Entity
E1-induced	PROPN	O	I-Entity
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
haemodilution	NOUN	O	I-Entity
on	ADP	O	O
human	ADJ	O	O
hepatic	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Combined	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
prolonged	VERB	O	O
prostaglandin	NOUN	O	B-Entity
E1	PROPN	O	I-Entity

(	PUNCT	O	O
PGE1)-induced	VERB	O	I-Entity
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
haemodilution	NOUN	O	I-Entity
on	ADP	O	O
hepatic	ADJ	O	O
function	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
hip	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
one	NUM	O	O
of	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
;	PUNCT	O	O
those	DET	O	O
in	ADP	O	O
group	NOUN	O	O
A	PROPN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
those	DET	O	O
in	ADP	O	O
group	NOUN	O	O
B	PROPN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
haemodilution	NOUN	O	I-Entity
alone	ADV	O	O
and	CCONJ	O	O
those	DET	O	O
in	ADP	O	O
group	NOUN	O	O
C	PROPN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
both	DET	O	O
controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
haemodilution	NOUN	O	I-Entity
.	PUNCT	O	O

Haemodilution	NOUN	O	I-Entity
in	ADP	O	O
groups	NOUN	O	O
B	PROPN	O	O
and	CCONJ	O	O
C	PROPN	O	O
was	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
withdrawing	VERB	O	O
approximately	ADV	O	O
1000	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
and	CCONJ	O	O
replacing	VERB	O	O
it	PRON	O	O
with	ADP	O	O
the	DET	O	O
same	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
dextran	NOUN	O	I-Entity
solution	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
final	ADJ	O	O
haematocrit	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
21	NUM	O	O
or	CCONJ	O	O
22%	NUM	O	O
.	PUNCT	O	O

Controlled	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
groups	NOUN	O	O
A	PROPN	O	O
and	CCONJ	O	O
C	PROPN	O	O
was	VERB	O	O
induced	VERB	O	O
with	ADP	O	O
PGE1	PROPN	O	I-Entity
to	PART	O	O
maintain	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
at	ADP	O	O
55	NUM	O	O
mmHg	NOUN	O	O
for	ADP	O	O
180	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

Measurements	NOUN	O	O
included	VERB	O	O
arterial	ADJ	O	O
ketone	NOUN	O	O
body	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
AKBR	PROPN	O	O
,	PUNCT	O	O
aceto	ADV	O	B-Entity
-	PUNCT	O	I-Entity
acetate/3-hydroxybutyrate	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
hepatic	ADJ	O	O
function	NOUN	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
C	PROPN	O	O
,	PUNCT	O	O
AKBR	PROPN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
at	ADP	O	O
120	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
-40%	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
180	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
-49%	PROPN	O	O
)	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
at	ADP	O	O
60	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
-32%	PROPN	O	O
)	PUNCT	O	O
after	ADP	O	O
recovery	NOUN	O	O
of	ADP	O	O
normotension	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
SGOT	PROPN	O	O
,	PUNCT	O	O
SGPT	PROPN	O	O
,	PUNCT	O	O
LDH	PROPN	O	O
and	CCONJ	O	O
total	ADJ	O	O
bilirubin	NOUN	O	I-Entity
showed	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
after	ADP	O	O
operation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
prolonged	ADJ	O	O
combination	NOUN	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
120	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
PGE1-induced	PROPN	O	I-Entity
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
moderate	ADJ	O	O
haemodilution	NOUN	O	I-Entity
would	VERB	O	O
cause	VERB	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
hepatic	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20880751)

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
:	PUNCT	O	O
filling	VERB	O	O
the	DET	O	O
bench	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
bedside	NOUN	O	O
gap	NOUN	O	O
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
most	ADV	O	O
effective	ADJ	O	O
drug	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
dopamine	NOUN	O	I-Entity
precursor	NOUN	O	O
is	VERB	O	O
complicated	VERB	O	O
by	ADP	O	O
highly	ADV	O	O
disabling	VERB	O	O
fluctuations	NOUN	O	O
and	CCONJ	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
preclinical	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
findings	NOUN	O	O
suggest	VERB	O	O
pulsatile	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
striatal	ADJ	O	O
postsynaptic	ADJ	O	O
receptors	NOUN	O	O
as	ADP	O	O
a	DET	O	O
key	ADJ	O	O
mechanism	NOUN	O	O
underlying	VERB	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
,	PUNCT	O	O
their	ADJ	O	O
pathogenesis	NOUN	O	O
is	VERB	O	O
still	ADV	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
recent	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
evidence	NOUN	O	O
from	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
has	VERB	O	O
provided	VERB	O	O
important	ADJ	O	O
information	NOUN	O	O
to	PART	O	O
understand	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
specific	ADJ	O	O
receptor	NOUN	O	O
and	CCONJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
receptor	NOUN	O	O
molecular	ADJ	O	O
mechanisms	NOUN	O	O
underlying	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
dyskinetic	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
.	PUNCT	O	O

Recent	ADJ	O	O
preclinical	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
data	NOUN	O	O
from	ADP	O	O
promising	VERB	O	O
lines	NOUN	O	O
of	ADP	O	O
research	NOUN	O	O
focus	NOUN	O	O
on	ADP	O	O
the	DET	O	O
differential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
presynaptic	ADJ	O	O
versus	ADP	O	O
postsynaptic	ADJ	O	O
mechanisms	NOUN	O	O
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
subtypes	NOUN	O	O
,	PUNCT	O	O
ionotropic	NOUN	O	O
and	CCONJ	O	O
metabotropic	ADJ	O	O
glutamate	NOUN	O	I-Entity
receptors	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
dopaminergic	NOUN	O	O
neurotransmitter	NOUN	O	O
systems	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20080419)

Prevention	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
reorganization	NOUN	O	O
of	ADP	O	O
hippocampal	ADJ	O	O
functions	NOUN	O	O
by	ADP	O	O
transplantation	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
therapeutic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
mononuclear	ADJ	O	O
cells	NOUN	O	O
(	PUNCT	O	O
BMCs	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

BMCs	NOUN	O	O
obtained	VERB	O	O
from	ADP	O	O
green	ADJ	O	O
fluorescent	ADJ	O	O
protein	NOUN	O	O
(	PUNCT	O	O
GFP	PROPN	O	O
)	PUNCT	O	O
transgenic	ADJ	O	O
mice	NOUN	O	O
or	CCONJ	O	O
rats	NOUN	O	O
were	VERB	O	O
transplanted	VERB	O	O
intravenously	ADV	O	O
after	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
SE	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Spontaneous	ADJ	O	B-Entity
recurrent	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
(	PUNCT	O	O
SRS	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
monitored	VERB	O	O
using	VERB	O	O
Racine	PROPN	O	O
's	PART	O	O
seizure	NOUN	O	I-Entity
severity	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
of	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
in	ADP	O	O
the	DET	O	O
saline	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
epileptic	ADJ	O	I-Entity
control	NOUN	O	O
group	NOUN	O	O
developed	VERB	O	O
SRS	PROPN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
none	NOUN	O	O
of	ADP	O	O
the	DET	O	O
BMC	PROPN	O	O
-	PUNCT	O	O
treated	VERB	O	O
epileptic	ADJ	O	I-Entity
animals	NOUN	O	O
had	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
short	ADJ	O	O
term	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
transplantation	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
regardless	ADV	O	O
of	ADP	O	O
the	DET	O	O
BMC	PROPN	O	O
source	NOUN	O	O
.	PUNCT	O	O

Over	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
chronic	ADJ	O	O
phase	NOUN	O	O
(	PUNCT	O	O
120	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
transplantation	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
only	ADV	O	O
25%	NUM	O	O
of	ADP	O	O
BMC	PROPN	O	O
-	PUNCT	O	O
treated	VERB	O	O
epileptic	ADJ	O	I-Entity
animals	NOUN	O	O
had	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
lower	ADJ	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
epileptic	ADJ	O	I-Entity
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
hippocampal	ADJ	O	O
Schaeffer	PROPN	O	O
collateral	NOUN	O	O
-	PUNCT	O	O
CA1	PROPN	O	O
synapses	NOUN	O	O
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
potentiation	NOUN	O	O
was	VERB	O	O
preserved	VERB	O	O
in	ADP	O	O
BMC	PROPN	O	O
-	PUNCT	O	O
transplanted	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
epileptic	ADJ	O	I-Entity
controls	NOUN	O	O
.	PUNCT	O	O

cells	NOUN	O	O
were	VERB	O	O
rarely	ADV	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
brains	NOUN	O	O
of	ADP	O	O
transplanted	VERB	O	O
epileptic	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
BMCs	NOUN	O	O
can	VERB	O	O
prevent	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
reduce	VERB	O	O
neuronal	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
influence	VERB	O	O
the	DET	O	O
reorganization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
neuronal	ADJ	O	O
network	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19445921)

Cardioprotective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
salvianolic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
A	NOUN	O	I-Entity
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
cardioprotective	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
salvianolic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
A	NOUN	O	I-Entity
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Isoproterenol	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
lactate	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
,	PUNCT	O	O
aspartate	ADJ	O	I-Entity
transaminase	NOUN	O	O
,	PUNCT	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
and	CCONJ	O	O
malondialdehyde	NOUN	O	I-Entity
and	CCONJ	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
activities	NOUN	O	O
of	ADP	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
,	PUNCT	O	O
catalase	NOUN	O	O
and	CCONJ	O	O
glutathione	NOUN	O	I-Entity
peroxidase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
mitochondrial	ADJ	O	O
respiratory	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
characterized	VERB	O	O
by	ADP	O	O
decreased	VERB	O	O
respiratory	ADJ	O	O
control	NOUN	O	O
ratio	NOUN	O	O
and	CCONJ	O	O
ADP	PROPN	O	I-Entity
/	SYM	O	O
O	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
salvianolic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
A	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
significantly	ADV	O	O
attenuated	ADJ	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
and	CCONJ	O	O
improved	ADJ	O	O
mitochondrial	ADJ	O	O
respiratory	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
salvianolic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
A	NOUN	O	I-Entity
against	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
further	ADV	O	O
confirmed	VERB	O	O
by	ADP	O	O
histopathological	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
salvianolic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
A	NOUN	O	I-Entity
possessing	VERB	O	O
antioxidant	ADJ	O	O
activity	NOUN	O	O
has	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
protective	ADJ	O	O
effect	NOUN	O	O
against	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18439803)

Acute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
N-(2-propylpentanoyl)urea	PROPN	O	I-Entity
on	ADP	O	O
hippocampal	ADJ	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
neurotransmitters	NOUN	O	O
in	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizure	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
anticonvulsant	ADJ	O	O
activity	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
hippocampal	ADJ	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
neurotransmitters	NOUN	O	O
(	PUNCT	O	O
glutamate	NOUN	O	I-Entity
,	PUNCT	O	O
aspartate	NOUN	O	I-Entity
,	PUNCT	O	O
glycine	NOUN	O	I-Entity
and	CCONJ	O	O
GABA	PROPN	O	I-Entity
)	PUNCT	O	O
of	ADP	O	O
N-(2-propylpentanoyl)urea	PROPN	O	I-Entity
(	PUNCT	O	O
VPU	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
its	ADJ	O	O
parent	NOUN	O	O
compound	NOUN	O	O
,	PUNCT	O	O
valproic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
VPA	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

VPU	PROPN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
potent	ADJ	O	O
than	ADP	O	O
VPA	PROPN	O	I-Entity
,	PUNCT	O	O
exhibiting	VERB	O	O
the	DET	O	O
median	ADJ	O	O
effective	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
ED(50	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
49	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
in	ADP	O	O
protecting	VERB	O	O
rats	NOUN	O	O
against	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizure	NOUN	O	I-Entity
whereas	ADP	O	O
the	DET	O	O
corresponding	VERB	O	O
value	NOUN	O	O
for	ADP	O	O
VPA	PROPN	O	I-Entity
was	VERB	O	O
322	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
vivo	NOUN	O	O
microdialysis	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
an	DET	O	O
intraperitoneal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
induced	VERB	O	O
a	DET	O	O
pronounced	ADJ	O	O
increment	NOUN	O	O
of	ADP	O	O
hippocampal	ADJ	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
aspartate	NOUN	O	I-Entity
whereas	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
on	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
glycine	NOUN	O	I-Entity
and	CCONJ	O	O
GABA	PROPN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
either	DET	O	O
VPU	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
and	CCONJ	O	O
100	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
VPA	PROPN	O	I-Entity
(	PUNCT	O	O
300	NUM	O	O
and	CCONJ	O	O
600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
completely	ADV	O	O
abolished	VERB	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
evoked	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
extracellular	ADJ	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
aspartate	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
on	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
GABA	PROPN	O	I-Entity
and	CCONJ	O	O
glycine	NOUN	O	I-Entity
but	CCONJ	O	O
less	ADJ	O	O
than	ADP	O	O
a	DET	O	O
drastic	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
aspartate	ADJ	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
the	DET	O	O
finding	NOUN	O	O
that	ADJ	O	O
VPU	PROPN	O	I-Entity
and	CCONJ	O	O
VPA	PROPN	O	I-Entity
could	VERB	O	O
protect	VERB	O	O
the	DET	O	O
animals	NOUN	O	O
against	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizure	NOUN	O	I-Entity
it	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
inhibitory	NOUN	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
neurotransmitters	NOUN	O	O
was	VERB	O	O
comparatively	ADV	O	O
minor	ADJ	O	O
and	CCONJ	O	O
offset	VERB	O	O
by	ADP	O	O
a	DET	O	O
pronounced	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
aspartate	NOUN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
like	ADP	O	O
VPA	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
finding	NOUN	O	O
that	ADJ	O	O
VPU	PROPN	O	I-Entity
could	VERB	O	O
drastically	ADV	O	O
reduce	VERB	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
aspartate	NOUN	O	I-Entity
should	VERB	O	O
account	VERB	O	O
,	PUNCT	O	O
at	ADP	O	O
least	ADJ	O	O
partly	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
its	ADJ	O	O
anticonvulsant	ADJ	O	O
activity	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizure	NOUN	O	I-Entity
in	ADP	O	O
experimental	ADJ	O	O
animals	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17919553)

Acute	PROPN	O	O
hepatitis	NOUN	O	I-Entity
attack	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
telithromycin	VERB	O	I-Entity
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
:	PUNCT	O	O
Antibiotic	ADJ	O	O
-	PUNCT	O	O
associated	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
is	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

With	ADP	O	O
widespread	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
antimicrobial	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
occurs	VERB	O	O
frequently	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
among	ADP	O	O
adverse	ADJ	O	B-Entity
drug	NOUN	O	I-Entity
reactions	NOUN	O	I-Entity
,	PUNCT	O	O
idiosyncratic	ADJ	O	O
reactions	NOUN	O	O
are	VERB	O	O
the	DET	O	O
most	ADV	O	O
serious	ADJ	O	O
.	PUNCT	O	O

Hospital	PROPN	O	O
Emergency	PROPN	O	O
Department	PROPN	O	O
,	PUNCT	O	O
Istanbul	PROPN	O	O
,	PUNCT	O	O
Turkey	PROPN	O	O
,	PUNCT	O	O
with	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
'	PART	O	O
history	NOUN	O	O
of	ADP	O	O
jaundice	NOUN	O	I-Entity
,	PUNCT	O	O
malaise	NOUN	O	O
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
had	VERB	O	O
been	VERB	O	O
prescribed	VERB	O	O
telithromycin	ADV	O	I-Entity
400	NUM	O	O
mg	NUM	O	O
/	SYM	O	O

d	X	O	O
PO	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
an	DET	O	O
upper	ADJ	O	B-Entity
respiratory	ADJ	O	I-Entity
tract	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
7	NUM	O	O
days	NOUN	O	O
prior	ADV	O	O
.	PUNCT	O	O

Admission	NOUN	O	O
laboratory	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
as	ADP	O	O
follows	VERB	O	O
:	PUNCT	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
,	PUNCT	O	O
67	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
reference	NOUN	O	O
range	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
37	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
aspartate	ADJ	O	I-Entity
aminotransferase	NOUN	O	O
,	PUNCT	O	O
98	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
40	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
alkaline	ADJ	O	O
phosphatase	NOUN	O	O
,	PUNCT	O	O
513	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
270	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
gamma	ADJ	O	O
-	PUNCT	O	O
glutamyltransferase	NOUN	O	O
,	PUNCT	O	O
32	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
7	NUM	O	O
-	SYM	O	O
49	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
amylase	NOUN	O	O
,	PUNCT	O	O
46	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
220	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
total	ADJ	O	O
bilirubin	NOUN	O	I-Entity
,	PUNCT	O	O
20.1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	NOUN	O	O
(	PUNCT	O	O
0.2	NUM	O	O
-	SYM	O	O
1.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
direct	ADJ	O	O
bilirubin	NOUN	O	I-Entity
,	PUNCT	O	O
14.8	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
(	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
0.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
albumin	NOUN	O	O
,	PUNCT	O	O
4.7	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
(	PUNCT	O	O
3.5	NUM	O	O
-	SYM	O	O
5.4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
toxin	NOUN	O	O
,	PUNCT	O	O
alcohol	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
other	ADJ	O	O
drugs	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
suffered	VERB	O	O
a	DET	O	O
previous	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
of	ADP	O	O
unknown	ADJ	O	O
origin	NOUN	O	O
,	PUNCT	O	O
"	PUNCT	O	O
that	ADJ	O	O
occurred	VERB	O	O
after	ADP	O	O
telithromycin	NOUN	O	I-Entity
usage	NOUN	O	O
.	PUNCT	O	O

Telithromycin	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
of	ADP	O	O
the	DET	O	O
ketolide	NOUN	O	O
antibacterials	NOUN	O	O
to	PART	O	O
receive	VERB	O	O
US	PROPN	O	O
Food	PROPN	O	O
and	CCONJ	O	O
Drug	PROPN	O	O
Administration	PROPN	O	O
approval	NOUN	O	O
for	ADP	O	O
clinical	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
infrequent	ADJ	O	O
and	CCONJ	O	O
usually	ADV	O	O
reversible	ADJ	O	O
severe	ADJ	O	O
hepatic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
a	DET	O	O
score	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
on	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
adverse	ADJ	O	B-Entity
drug	NOUN	O	I-Entity
reaction	NOUN	O	I-Entity
probability	NOUN	O	O
scale	NOUN	O	O
,	PUNCT	O	O
telithromycin	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
probable	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pathological	ADJ	O	O
findings	NOUN	O	O
suggested	VERB	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
toxic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Recurrence	NOUN	O	O
of	ADP	O	O
hepatitis	ADJ	O	I-Entity
attack	NOUN	O	O
might	VERB	O	O
have	VERB	O	O
been	VERB	O	O
avoided	VERB	O	O
if	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
incident	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
communicated	VERB	O	O
to	ADP	O	O
the	DET	O	O
attending	VERB	O	O
physician	NOUN	O	O
who	NOUN	O	O
prescribed	VERB	O	O
telithromycin	X	O	I-Entity
the	DET	O	O
second	ADJ	O	O
time	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
hepatitis	NOUN	O	I-Entity
probably	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
telithromycin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15632880)

Spironolactone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
and	CCONJ	O	O
hyperkalemia	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
previous	ADJ	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
evaluating	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
spironolactone	NOUN	O	I-Entity
in	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
patients	NOUN	O	O
reported	VERB	O	O
a	DET	O	O
low	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
(	PUNCT	O	O
2%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
(	PUNCT	O	O
0%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Because	ADP	O	O
treatments	NOUN	O	O
for	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
have	VERB	O	O
changed	VERB	O	O
since	ADP	O	O
the	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
spironolactone	NOUN	O	I-Entity
were	VERB	O	O
reported	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
these	DET	O	O
complications	NOUN	O	O
may	VERB	O	O
differ	VERB	O	O
in	ADP	O	O
current	ADJ	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
therefore	ADV	O	O
sought	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
associations	NOUN	O	O
of	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
in	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
spironolactone	NOUN	O	I-Entity
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
case	NOUN	O	O
control	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
spironolactone	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

Cases	NOUN	O	O
were	VERB	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
hyperkalemia	NOUN	O	I-Entity
(	PUNCT	O	O
K(+	PROPN	O	I-Entity
)	PUNCT	O	O

>	X	O	O
5.0	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity

(	PUNCT	O	O
Cr	PROPN	O	I-Entity
>	PROPN	O	O
or=2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O

Sixty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
of	ADP	O	O
926	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
7.2%	NUM	O	O
)	PUNCT	O	O
required	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
spironolactone	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
hyperkalemia	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
33	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
34	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
hyperkalemia	NOUN	O	I-Entity
were	VERB	O	O
older	ADJ	O	O
and	CCONJ	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
diabetes	NOUN	O	I-Entity
,	PUNCT	O	O
had	VERB	O	O
higher	ADJ	O	O
baseline	NOUN	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
baseline	NOUN	O	O
potassium	NOUN	O	I-Entity
supplement	NOUN	O	O
doses	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blockers	NOUN	O	O
than	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
134	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
had	VERB	O	O
lower	ADJ	O	O
baseline	NOUN	O	O
body	NOUN	O	O
weight	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
baseline	NOUN	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
required	VERB	O	O
higher	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
loop	NOUN	O	O
diuretics	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
thiazide	NOUN	O	I-Entity
diuretics	NOUN	O	O
than	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Spironolactone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperkalemia	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
are	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
our	ADJ	O	O
clinical	ADJ	O	O
experience	NOUN	O	O
than	ADP	O	O
reported	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (11773892)

End	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
ESRD	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
orthotopic	ADJ	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
OLTX	PROPN	O	O
)	PUNCT	O	O
using	VERB	O	O
calcineurin	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
immunotherapy	NOUN	O	O
:	PUNCT	O	O

The	DET	O	O
calcineurin	NOUN	O	O
inhibitors	VERB	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
are	VERB	O	O
both	DET	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
had	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
presenting	VERB	O	O
after	ADP	O	O
OLTX	PROPN	O	O
with	ADP	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
ESRD	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
examines	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
and	CCONJ	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CRF	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
OLTX	PROPN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
Controls	PROPN	O	O
,	PUNCT	O	O
no	DET	O	O
CRF	PROPN	O	I-Entity
or	CCONJ	O	O
ESRD	PROPN	O	I-Entity
,	PUNCT	O	O
n=748	NUM	O	O
;	PUNCT	O	O
CRF	PROPN	O	I-Entity
,	PUNCT	O	O
sustained	VERB	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
>	SYM	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dl	NOUN	O	O
,	PUNCT	O	O
n=41	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
ESRD	PROPN	O	I-Entity
,	PUNCT	O	O
n=45	PROPN	O	O
.	PUNCT	O	O

Groups	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
for	ADP	O	O
preoperative	ADJ	O	O
laboratory	NOUN	O	O
variables	NOUN	O	O
,	PUNCT	O	O
diagnosis	NOUN	O	O
,	PUNCT	O	O
postoperative	ADJ	O	O
variables	NOUN	O	O
,	PUNCT	O	O
survival	NOUN	O	O
,	PUNCT	O	O
type	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
survival	NOUN	O	O
from	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
13	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
OLTX	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
was	VERB	O	O
18.1%	NUM	O	O
(	PUNCT	O	O
CRF	PROPN	O	I-Entity
8.6%	NUM	O	O
and	CCONJ	O	O
ESRD	PROPN	O	I-Entity
9.5%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
CRF	PROPN	O	I-Entity
and	CCONJ	O	O
ESRD	PROPN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
higher	ADJ	O	O
preoperative	ADJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
greater	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatorenal	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
higher	ADJ	O	O
percentage	NOUN	O	O
requirement	NOUN	O	O
for	ADP	O	O
dialysis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
3	NUM	O	O
months	NOUN	O	O
postoperatively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
higher	ADJ	O	O
1-year	ADJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
.	PUNCT	O	O

Multivariate	PROPN	O	O
stepwise	NOUN	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
using	VERB	O	O
preoperative	NOUN	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
variables	NOUN	O	O
identified	VERB	O	O
that	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
average	ADJ	O	O
at	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
weeks	NOUN	O	O
postoperatively	ADV	O	O
were	VERB	O	O
independent	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
CRF	PROPN	O	I-Entity
or	CCONJ	O	O
ESRD	PROPN	O	I-Entity
with	ADP	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
of	ADP	O	O
2.6	NUM	O	O
,	PUNCT	O	O
2.2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.6	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
survival	NOUN	O	O
from	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
OLTX	PROPN	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
among	ADP	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
by	ADP	O	O
year	NOUN	O	O
13	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
survival	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
ESRD	PROPN	O	I-Entity
was	VERB	O	O
only	ADV	O	O
28.2%	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
54.6%	NUM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
developing	VERB	O	O
ESRD	PROPN	O	I-Entity
had	VERB	O	O
a	DET	O	O
6-year	ADJ	O	O
survival	NOUN	O	O
after	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
of	ADP	O	O
27%	NUM	O	O
for	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
receiving	VERB	O	O
hemodialysis	NOUN	O	O
versus	ADP	O	O
71.4%	NUM	O	O
for	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
developing	VERB	O	O
ESRD	PROPN	O	I-Entity
who	NOUN	O	O
subsequently	ADV	O	O
received	VERB	O	O
kidney	NOUN	O	O
transplants	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
more	ADJ	O	O
than	ADP	O	O
10	NUM	O	O
years	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
OLTX	PROPN	O	O
have	VERB	O	O
CRF	PROPN	O	I-Entity
and	CCONJ	O	O
ESRD	PROPN	O	I-Entity
at	ADP	O	O
a	DET	O	O
high	ADJ	O	O
rate	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
ESRD	PROPN	O	I-Entity
decreases	VERB	O	O
survival	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
those	DET	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
dialysis	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	NOUN	O	O
develop	VERB	O	O
ESRD	NOUN	O	I-Entity
have	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
preoperative	NOUN	O	O
and	CCONJ	O	O
1-year	NUM	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
are	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
hepatorenal	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
at	ADP	O	O
various	ADJ	O	O
times	NOUN	O	O
postoperatively	ADV	O	O
is	VERB	O	O
more	ADV	O	O
predictive	ADJ	O	O
of	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
CRF	PROPN	O	I-Entity
or	CCONJ	O	O
ESRD	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10835440)

Effect	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
nimodipine	NOUN	O	I-Entity
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
after	ADP	O	O
acute	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Intravenous	PROPN	O	O
Nimodipine	PROPN	O	I-Entity
West	PROPN	O	O
European	PROPN	O	O
Stroke	PROPN	O	I-Entity
Trial	PROPN	O	O
(	PUNCT	O	O
INWEST	PROPN	O	O
)	PUNCT	O	O
found	VERB	O	O
a	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
nimodipine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
(	PUNCT	O	O
BP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
unfavorable	ADJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
sought	VERB	O	O
to	PART	O	O
confirm	VERB	O	O
this	DET	O	O
correlation	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
prognostic	ADJ	O	O
variables	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
investigate	VERB	O	O
outcome	NOUN	O	O
in	ADP	O	O
subgroups	NOUN	O	O
with	ADP	O	O
increasing	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
BP	PROPN	O	B-Entity
reduction	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
ischemic	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
(	PUNCT	O	O
within	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
consecutively	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	VERB	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n=100	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
1	NUM	O	O
mg	INTJ	O	O
/	SYM	O	O
h	INTJ	O	O
(	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
)	PUNCT	O	O

nimodipine	NOUN	O	I-Entity
(	PUNCT	O	O
n=101	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
h	PROPN	O	O
(	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
)	PUNCT	O	O
nimodipine	NOUN	O	I-Entity
(	PUNCT	O	O
n=94	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nimodipine	PROPN	O	I-Entity
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
systolic	NOUN	O	I-Entity
BP	PROPN	O	I-Entity
(	PUNCT	O	O
SBP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diastolic	ADJ	O	O
BP	PROPN	O	O
(	PUNCT	O	O
DBP	PROPN	O	O
)	PUNCT	O	O
from	ADP	O	O
baseline	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
few	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
multivariate	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
DBP	PROPN	O	B-Entity
reduction	NOUN	O	I-Entity
and	CCONJ	O	O
worsening	VERB	O	O
of	ADP	O	O
the	DET	O	O
neurological	ADJ	O	O
score	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
for	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
beta=0.49	NOUN	O	O
,	PUNCT	O	O
P=0	PROPN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
DBP	PROPN	O	B-Entity
reduction	NOUN	O	I-Entity
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
20%	NUM	O	O
in	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
group	NOUN	O	O
had	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
increased	VERB	O	O
adjusted	VERB	O	O
OR	PROPN	O	O
for	ADP	O	O
the	DET	O	O
compound	NOUN	O	O
outcome	NOUN	O	O
variable	ADJ	O	O
death	NOUN	O	I-Entity
or	CCONJ	O	O
dependency	NOUN	O	O

(	PUNCT	O	O
n	ADV	O	O
/	SYM	O	O
N=25/26	PROPN	O	O
,	PUNCT	O	O
OR	PROPN	O	O
10	NUM	O	O
.	PUNCT	O	O
16	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
1.02	NUM	O	O
to	ADP	O	O
101.74	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
death	NOUN	O	I-Entity
alone	ADV	O	O
(	PUNCT	O	O
n	ADV	O	O
/	SYM	O	O
N=9/26	PROPN	O	O
,	PUNCT	O	O
OR	PROPN	O	O
4.336	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.131	NUM	O	O
16.619	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
all	DET	O	O
placebo	NOUN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
/	SYM	O	O
N=62/92	PROPN	O	O
and	CCONJ	O	O
14/92	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DBP	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
SBP	PROPN	O	O
,	PUNCT	O	O
reduction	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
neurological	ADJ	O	O
worsening	NOUN	O	O
after	ADP	O	O
the	DET	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
nimodipine	NOUN	O	I-Entity
after	ADP	O	O
acute	ADJ	O	B-Entity
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

For	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
nimodipine	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
results	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
conclusive	ADJ	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
confirm	VERB	O	O
or	CCONJ	O	O
exclude	VERB	O	O
a	DET	O	O
neuroprotective	ADJ	O	O
property	NOUN	O	O
of	ADP	O	O
nimodipine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9523805)

Transient	ADJ	O	B-Entity
neurologic	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
after	ADP	O	O
spinal	ADJ	O	O
anesthesia	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
lower	ADJ	O	O
incidence	NOUN	O	O
with	ADP	O	O
prilocaine	NOUN	O	I-Entity
and	CCONJ	O	O
bupivacaine	NOUN	O	I-Entity
than	ADP	O	O
with	ADP	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Recent	ADJ	O	O
evidence	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
transient	ADJ	O	B-Entity
neurologic	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
(	PUNCT	O	O
TNSs	PROPN	O	I-Entity
)	PUNCT	O	O
frequently	ADV	O	O
follow	VERB	O	O
lidocaine	NOUN	O	I-Entity
spinal	ADJ	O	O
anesthesia	NOUN	O	O
but	CCONJ	O	O
are	VERB	O	O
infrequent	ADJ	O	O
with	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
identification	NOUN	O	O
of	ADP	O	O
a	DET	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
to	PART	O	O
substitute	VERB	O	O
for	ADP	O	O
lidocaine	NOUN	O	I-Entity
for	ADP	O	O
brief	ADJ	O	O
surgical	ADJ	O	O
procedures	NOUN	O	O
remains	VERB	O	O
an	DET	O	O
important	ADJ	O	O
goal	NOUN	O	O
.	PUNCT	O	O

Prilocaine	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
amide	ADJ	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
with	ADP	O	O
a	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
compares	VERB	O	O
prilocaine	NOUN	O	I-Entity
with	ADP	O	O
lidocaine	NOUN	O	I-Entity
and	CCONJ	O	O
bupivacaine	NOUN	O	I-Entity
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
and	CCONJ	O	O
relative	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
TNSs	NOUN	O	I-Entity
.	PUNCT	O	O

2%	NUM	O	O
lidocaine	NOUN	O	I-Entity
in	ADP	O	O
7.5%	NUM	O	O
glucose	NOUN	O	I-Entity
,	PUNCT	O	O
2%	NUM	O	O
prilocaine	NOUN	O	I-Entity
in	ADP	O	O
7.5%	NUM	O	O
glucose	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
0.5%	NUM	O	O
bupivacaine	NOUN	O	I-Entity
in	ADP	O	O
7.5%	NUM	O	O
glucose	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
evening	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
TNSs	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
physician	NOUN	O	O
unaware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
administered	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
details	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anesthetic	ADJ	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
of	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
lidocaine	NOUN	O	I-Entity
experienced	ADJ	O	O
TNSs	NOUN	O	I-Entity
,	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
prilocaine	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
them	PRON	O	O
,	PUNCT	O	O
and	CCONJ	O	O
none	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
bupivacaine	NOUN	O	I-Entity
had	VERB	O	O
TNSs	NOUN	O	I-Entity
.	PUNCT	O	O

Times	NOUN	O	O
to	ADP	O	O
ambulate	VERB	O	O
and	CCONJ	O	O
to	PART	O	O
void	VERB	O	O
were	VERB	O	O
similar	ADJ	O	O
after	ADP	O	O
lidocaine	NOUN	O	I-Entity
and	CCONJ	O	O
prilocaine	NOUN	O	I-Entity
(	PUNCT	O	O
150	NUM	O	O
vs.	ADP	O	O
165	NUM	O	O
min	NOUN	O	O
and	CCONJ	O	O
238	NUM	O	O
vs.	ADP	O	O
253	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
but	CCONJ	O	O
prolonged	VERB	O	O
after	ADP	O	O
bupivacaine	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
and	CCONJ	O	O
299	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O

Prilocaine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
preferable	ADJ	O	O
to	PART	O	O
lidocaine	VERB	O	I-Entity
for	ADP	O	O
short	ADJ	O	O
surgical	ADJ	O	O
procedures	NOUN	O	O
because	ADP	O	O
it	PRON	O	O
has	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
but	CCONJ	O	O
a	DET	O	O
lower	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
TNSs	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9245658)

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
in	ADP	O	O
smoking	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
activates	VERB	O	O
the	DET	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
this	DET	O	O
way	NOUN	O	O
could	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Animal	ADJ	O	O
studies	NOUN	O	O
and	CCONJ	O	O
mechanistic	ADJ	O	O
studies	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
nicotine	NOUN	O	I-Entity
could	VERB	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
accelerating	VERB	O	O
atherosclerosis	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
evidence	NOUN	O	O
among	ADP	O	O
humans	NOUN	O	O
is	VERB	O	O
too	ADV	O	O
inadequate	ADJ	O	O
to	PART	O	O
be	VERB	O	O
definitive	ADJ	O	O
about	ADP	O	O
such	ADJ	O	O
an	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Almost	ADV	O	O
certainly	ADV	O	O
,	PUNCT	O	O
nicotine	NOUN	O	I-Entity
via	ADP	O	O
its	ADJ	O	O
hemodynamic	ADJ	O	O
effects	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
acute	ADJ	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
current	ADJ	O	O
evidence	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
are	VERB	O	O
much	ADV	O	O
less	ADV	O	O
important	ADJ	O	O
than	ADP	O	O
are	VERB	O	O
the	DET	O	O
prothrombotic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cigarette	NOUN	O	O
smoking	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
carbon	NOUN	O	B-Entity
monoxide	NOUN	O	I-Entity
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
enhance	VERB	O	O
thrombosis	NOUN	O	I-Entity
among	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
pipe	NOUN	O	O
smokers	NOUN	O	O
and	CCONJ	O	O
people	NOUN	O	O
using	VERB	O	O
transdermal	ADJ	O	O
nicotine	NOUN	O	I-Entity
support	NOUN	O	O
the	DET	O	O
idea	NOUN	O	O
that	ADP	O	O
toxins	NOUN	O	O
other	ADJ	O	O
than	ADP	O	O
nicotine	NOUN	O	I-Entity
are	VERB	O	O
the	DET	O	O
most	ADV	O	O
important	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
dose	NOUN	O	O
response	NOUN	O	O
for	ADP	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
flat	ADJ	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
if	ADP	O	O
nicotine	NOUN	O	I-Entity
is	VERB	O	O
involved	VERB	O	O
,	PUNCT	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
seen	VERB	O	O
with	ADP	O	O
relatively	ADV	O	O
low	ADJ	O	O
-	PUNCT	O	O
level	NOUN	O	O
cigarette	NOUN	O	O
exposures	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9034419)

Seizure	NOUN	O	I-Entity
resulting	VERB	O	O
from	ADP	O	O
a	DET	O	O
venlafaxine	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
venlafaxine	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
40-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
major	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
took	VERB	O	O
an	DET	O	O
overdose	NOUN	O	I-Entity
of	ADP	O	O
venlafaxine	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
apparent	ADJ	O	O
suicide	NOUN	O	O
attempt	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
26	NUM	O	O
venlafaxine	NOUN	O	I-Entity
50-mg	NUM	O	O
tablets	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
witnessed	VERB	O	O
generalized	ADJ	O	O
seizure	NOUN	O	I-Entity
.	PUNCT	O	O

She	PRON	O	O
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
medical	ADJ	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
,	PUNCT	O	O
venlafaxine	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
further	ADJ	O	O
sequelae	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
venlafaxine	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
that	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
generalized	ADJ	O	O
seizure	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
nonoverdose	NOUN	O	O
pharmacokinetics	NOUN	O	O
and	CCONJ	O	O
pharmacodynamics	NOUN	O	O
of	ADP	O	O
venlafaxine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
potential	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
available	ADJ	O	O
interventions	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
emergent	ADJ	O	O
therapy	NOUN	O	O
was	VERB	O	O
instituted	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
venlafaxine	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
generalized	ADJ	O	O
seizure	NOUN	O	I-Entity
but	CCONJ	O	O
elicited	VERB	O	O
no	DET	O	O
further	ADV	O	O
sequelae	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8829025)

Effect	PROPN	O	O
of	ADP	O	O
nifedipine	NOUN	O	I-Entity
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
receiving	VERB	O	O
tacrolimus	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
nifedipine	NOUN	O	I-Entity
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
tacrolimus	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
between	ADP	O	O
January	PROPN	O	O
1992	NUM	O	O
and	CCONJ	O	O
January	PROPN	O	O
1996	NUM	O	O
.	PUNCT	O	O

Two	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
tacrolimus	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
group	NOUN	O	O
comprising	VERB	O	O
hypertensive	ADJ	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
nifedipine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
comprising	VERB	O	O
nonhypertensive	ADJ	O	O
patients	NOUN	O	O
not	ADV	O	O
receiving	VERB	O	O
nifedipine	NOUN	O	I-Entity
.	PUNCT	O	O

Nifedipine	PROPN	O	I-Entity
significantly	ADV	O	O
improved	VERB	O	O
kidney	NOUN	O	O
function	NOUN	O	O
as	ADP	O	O
indicated	VERB	O	O
by	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
lowering	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
observed	VERB	O	O
positive	ADJ	O	O
impact	NOUN	O	O
of	ADP	O	O
nifedipine	NOUN	O	I-Entity
on	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
nephrotoxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
tacrolimus	NOUN	O	I-Entity
in	ADP	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
factor	NOUN	O	O
in	ADP	O	O
selecting	VERB	O	O
an	DET	O	O
agent	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8437969)

Sinus	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
continuous	ADJ	O	O
-	PUNCT	O	O
infusion	NOUN	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
intermittent	ADJ	O	O
intravenous	ADJ	O	O
infusions	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
is	VERB	O	O
infrequently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
bradyarrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
40-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
leukemia	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
history	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
developed	VERB	O	O
recurrent	ADJ	O	O
,	PUNCT	O	O
brief	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
apparent	ADJ	O	O
sinus	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
continuous	ADJ	O	O
-	PUNCT	O	O
infusion	NOUN	O	O
cimetidine	NOUN	O	I-Entity
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
hour	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
arrhythmias	NOUN	O	I-Entity
were	VERB	O	O
temporally	ADV	O	O
related	VERB	O	O
to	ADP	O	O
cimetidine	NOUN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
disappeared	VERB	O	O
after	ADP	O	O
dechallenge	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
recur	VERB	O	O
during	ADP	O	O
ranitidine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
sinus	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
continuous	ADJ	O	O
-	PUNCT	O	O
infusion	NOUN	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7890216)

Composition	NOUN	O	O
of	ADP	O	O
gall	NOUN	O	B-Entity
bladder	NOUN	O	I-Entity
stones	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
octreotide	NOUN	O	I-Entity
:	PUNCT	O	O
response	NOUN	O	O
to	ADP	O	O
oral	ADJ	O	O
ursodeoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Octreotide	PROPN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
acromegaly	NOUN	O	I-Entity
,	PUNCT	O	O
induces	VERB	O	O
gall	NOUN	O	B-Entity
bladder	NOUN	O	I-Entity
stones	NOUN	O	I-Entity
in	ADP	O	O
13	NUM	O	O
-	PUNCT	O	O
60%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
knowledge	NOUN	O	O
of	ADP	O	O
stone	NOUN	O	O
composition	NOUN	O	O
is	VERB	O	O
essential	ADJ	O	O
for	ADP	O	O
studies	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
pathogenesis	NOUN	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
was	VERB	O	O
investigated	VERB	O	O
by	ADP	O	O
direct	ADJ	O	O
and	CCONJ	O	O
indirect	ADJ	O	O
methods	NOUN	O	O
in	ADP	O	O
14	NUM	O	O
octreotide	ADV	O	I-Entity
treated	VERB	O	O
acromegalic	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
gall	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
.	PUNCT	O	O

Chemical	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
gall	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
retrieved	VERB	O	O
at	ADP	O	O
cholecystectomy	NOUN	O	O
from	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
that	ADP	O	O
they	PRON	O	O
contained	VERB	O	O
71%	NUM	O	O
and	CCONJ	O	O
87%	NUM	O	O
cholesterol	NOUN	O	I-Entity
by	ADP	O	O
weight	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
12	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
localised	VERB	O	O
computed	VERB	O	O
tomography	NOUN	O	O
of	ADP	O	O
the	DET	O	O
gall	NOUN	O	O
bladder	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
eight	NUM	O	O
had	VERB	O	O
stones	NOUN	O	O
with	ADP	O	O
maximum	ADJ	O	O
attenuation	NOUN	O	O
scores	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
100	NUM	O	O
Hounsfield	PROPN	O	O
units	NOUN	O	O
(	PUNCT	O	O
values	NOUN	O	O
of	ADP	O	O
<	SYM	O	O
100	NUM	O	O
HU	PROPN	O	O
predict	ADJ	O	O
cholesterol	NOUN	O	I-Entity
rich	ADJ	O	O
,	PUNCT	O	O
dissolvable	ADJ	O	O
stones	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
six	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
supersaturated	VERB	O	O
bile	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
(	PUNCT	O	O
SEM	PROPN	O	O
)	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
saturation	NOUN	O	O
index	NOUN	O	O
of	ADP	O	O
1.19	NUM	O	O
(	PUNCT	O	O
0.08	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
range	NOUN	O	O
1.01	NUM	O	O
-	SYM	O	O
1.53	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
had	VERB	O	O
abnormally	ADV	O	O
rapid	ADJ	O	O
cholesterol	NOUN	O	I-Entity
microcrystal	ADJ	O	O
nucleation	NOUN	O	O
times	NOUN	O	O
(	PUNCT	O	O
<	SYM	O	O
4	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
1	NUM	O	O
-	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whilst	NOUN	O	O
in	ADP	O	O
four	NUM	O	O

,	PUNCT	O	O
the	DET	O	O
bile	NOUN	O	O
contained	VERB	O	O
cholesterol	NOUN	O	I-Entity
microcrystals	NOUN	O	O
immediately	ADV	O	O
after	ADP	O	O
sampling	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
12	NUM	O	O
patients	NOUN	O	O
considered	VERB	O	O
for	ADP	O	O
oral	ADJ	O	O
ursodeoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
UDCA	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
had	VERB	O	O
a	DET	O	O
blocked	VERB	O	O
cystic	NOUN	O	O
duct	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
not	ADV	O	O
started	VERB	O	O
on	ADP	O	O
UDCA	PROPN	O	I-Entity
while	ADP	O	O
one	NUM	O	O
was	VERB	O	O
lost	VERB	O	O
to	PART	O	O
follow	VERB	O	O
up	PART	O	O
.	PUNCT	O	O

n	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
gall	NOUN	O	B-Entity
stone	NOUN	O	I-Entity
dissolution	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
their	ADJ	O	O
stones	NOUN	O	O
were	VERB	O	O
cholesterol	NOUN	O	I-Entity
rich	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
corresponds	VERB	O	O
,	PUNCT	O	O
by	ADP	O	O
actuarial	ADJ	O	O
(	PUNCT	O	O
life	NOUN	O	O
table	NOUN	O	O
)	PUNCT	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
combined	ADJ	O	O
gall	NOUN	O	B-Entity
stone	NOUN	O	I-Entity
dissolution	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
58.3	NUM	O	O
(	PUNCT	O	O
15.9%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
octreotide	ADV	O	I-Entity
induced	VERB	O	O
gall	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
are	VERB	O	O
generally	ADV	O	O
small	ADJ	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cholesterol	NOUN	O	I-Entity
rich	ADJ	O	O
although	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
common	ADJ	O	O
with	ADP	O	O
spontaneous	ADJ	O	O
gall	NOUN	O	B-Entity
stone	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
presentation	NOUN	O	O
some	DET	O	O
patients	NOUN	O	O
will	VERB	O	O
have	VERB	O	O
a	DET	O	O
blocked	VERB	O	O
cystic	NOUN	O	O
duct	NOUN	O	O
and	CCONJ	O	O
some	DET	O	O
gall	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
containing	VERB	O	O
calcium	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7468724)

Cardiovascular	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
terbutaline	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
preterm	NOUN	O	B-Entity
labor	NOUN	O	I-Entity
.	PUNCT	O	O

Severe	ADJ	O	O
cardiovascular	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
eight	NUM	O	O
of	ADP	O	O
160	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
terbutaline	NOUN	O	I-Entity
for	ADP	O	O
preterm	NOUN	O	B-Entity
labor	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7199841)

Neurologic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
subarachnoid	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
2-chloroprocaine	NUM	O	B-Entity
-	PUNCT	O	I-Entity
CE	PROPN	O	I-Entity
,	PUNCT	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
pH	NOUN	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
neurologic	ADJ	O	O
consequences	NOUN	O	O
of	ADP	O	O
deliberate	ADJ	O	O
subarachnoid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
large	ADJ	O	O
volumes	NOUN	O	O
of	ADP	O	O
2-chloroprocaine	NUM	O	B-Entity
-	PUNCT	O	I-Entity
CE	PROPN	O	I-Entity
in	ADP	O	O
experimental	ADJ	O	O
animals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
pH	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
total	ADJ	O	O
volume	NOUN	O	O
as	ADP	O	O
potential	ADJ	O	O
factors	NOUN	O	O
in	ADP	O	O
causing	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
65	NUM	O	O
dogs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
received	VERB	O	O
injections	NOUN	O	O
in	ADP	O	O
the	DET	O	O
subarachnoid	ADJ	O	O
space	NOUN	O	O
as	ADP	O	O
follows	VERB	O	O
:	PUNCT	O	O
6	NUM	O	O
to	PART	O	O
8	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
(	PUNCT	O	O

N	PROPN	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2-chloroprocaine	NUM	O	B-Entity
-	PUNCT	O	I-Entity
CE	PROPN	O	I-Entity
(	PUNCT	O	O
N	CCONJ	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
low	ADJ	O	O
pH	NOUN	O	O
normal	ADJ	O	O
saline	ADJ	O	O
(	PUNCT	O	O
pH	PROPN	O	O
3.0	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
N	PROPN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
20	NUM	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
subarachnoid	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
2-chloroprocaine	NUM	O	B-Entity
-	PUNCT	O	I-Entity
CE	PROPN	O	I-Entity
seven	NUM	O	O
(	PUNCT	O	O
35%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
hind	ADJ	O	O
-	PUNCT	O	O
limb	NOUN	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
normal	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
titrated	VERB	O	O
to	ADP	O	O
a	DET	O	O
pH	NOUN	O	O
3.0	NUM	O	O
developed	VERB	O	O
hind	ADJ	O	O
-	PUNCT	O	O
limb	NOUN	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
15	NUM	O	O
spinal	ADJ	O	O
cords	NOUN	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
2-chloroprocaine	NUM	O	B-Entity
-	PUNCT	O	I-Entity
CE	PROPN	O	I-Entity
,	PUNCT	O	O
13	NUM	O	O
showed	VERB	O	O
subpial	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
nerve	NOUN	O	O
roots	NOUN	O	O
and	CCONJ	O	O
subarachnoid	ADJ	O	O
vessels	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
spinal	ADJ	O	O
cords	NOUN	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
low	ADJ	O	O
pH	NOUN	O	O
normal	ADJ	O	O
saline	ADJ	O	O
(	PUNCT	O	O
pH	PROPN	O	O
3.0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
show	VERB	O	O
abnormal	ADJ	O	O
findings	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6640832)

Early	ADV	O	O
adjuvant	NOUN	O	O
adriamycin	ADJ	O	I-Entity
in	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
multicenter	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
110	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
superficial	ADJ	O	O
transitional	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
bladder	NOUN	O	I-Entity
.	PUNCT	O	O

Adriamycin	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg/50	NUM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
intravesically	ADV	O	O
within	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
TA	PROPN	O	O
-	PUNCT	O	O
T1	PROPN	O	O
(	PUNCT	O	O
O	INTJ	O	O
-	PUNCT	O	O
A	PROPN	O	O
)	PUNCT	O	O
bladder	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
24	NUM	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
chemical	ADJ	O	O
cystitis	NOUN	O	I-Entity
was	VERB	O	O
severe	ADJ	O	O
enough	ADV	O	O
for	ADP	O	O
them	PRON	O	O
to	PART	O	O
drop	VERB	O	O
out	ADP	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
recurrences	NOUN	O	O
,	PUNCT	O	O
27	NUM	O	O
were	VERB	O	O
T1	PROPN	O	O
tumors	NOUN	O	I-Entity
while	ADP	O	O
five	NUM	O	O
progressed	VERB	O	O
to	ADP	O	O
more	ADV	O	O
highly	ADV	O	O
invasive	ADJ	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
free	ADJ	O	O
of	ADP	O	O
recurrence	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
year	NOUN	O	O
,	PUNCT	O	O
80%	NUM	O	O
remained	VERB	O	O
tumor	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
during	ADP	O	O
the	DET	O	O
2-	NOUN	O	O
to	PART	O	O
3-year	VERB	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
Adriamycin	PROPN	O	I-Entity
appears	VERB	O	O
obvious	ADJ	O	O
and	CCONJ	O	O
might	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
itself	PRON	O	O
,	PUNCT	O	O
the	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
repeated	VERB	O	O
instillations	NOUN	O	O
after	ADP	O	O
TUR	PROPN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
.	PUNCT	O	O


-DOCSTART- (3560096)

Hyperkalemia	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sulindac	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Hyperkalemia	PROPN	O	I-Entity
has	VERB	O	O
recently	ADV	O	O
been	VERB	O	O
recognized	VERB	O	O
as	ADP	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
nonsteroidal	NOUN	O	O
antiinflammatory	ADJ	O	O
agents	NOUN	O	O
(	PUNCT	O	O
NSAID	PROPN	O	O
)	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
indomethacin	NOUN	O	I-Entity
.	PUNCT	O	O

Several	ADJ	O	O
recent	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
stressed	VERB	O	O
the	DET	O	O
renal	NOUN	O	O
sparing	NOUN	O	O
features	NOUN	O	O
of	ADP	O	O
sulindac	NOUN	O	I-Entity
,	PUNCT	O	O
owing	VERB	O	O
to	ADP	O	O
its	ADJ	O	O
lack	NOUN	O	O
of	ADP	O	O
interference	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	O
prostacyclin	NOUN	O	I-Entity
synthesis	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
4	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
hyperkalemia	NOUN	O	I-Entity
ranging	VERB	O	O
from	ADP	O	O
6.1	NUM	O	O
to	ADP	O	O
6.9	NUM	O	O
mEq	PROPN	O	O
/	SYM	O	O
l	NOUN	O	O
developed	VERB	O	O
within	ADP	O	O
3	NUM	O	O
to	PART	O	O
8	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
sulindac	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
of	ADP	O	O
them	PRON	O	O
normal	ADJ	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
levels	NOUN	O	O
reached	VERB	O	O
within	ADP	O	O
2	NUM	O	O
to	PART	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
stopping	VERB	O	O
sulindac	NOUN	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
no	DET	O	O
other	ADJ	O	O
medications	NOUN	O	O
known	VERB	O	O
to	PART	O	O
effect	VERB	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
had	VERB	O	O
been	VERB	O	O
given	VERB	O	O
concomitantly	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
course	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
is	VERB	O	O
suggestive	ADJ	O	O
of	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
-	PUNCT	O	O
and	CCONJ	O	O
-	PUNCT	O	O
effect	NOUN	O	O
relationship	NOUN	O	O
between	ADP	O	O
sulindac	NOUN	O	I-Entity
and	CCONJ	O	O
hyperkalemia	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
initial	ADJ	O	O
hopes	NOUN	O	O
that	ADJ	O	O
sulindac	VERB	O	I-Entity
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
adverse	ADJ	O	O
renal	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
NSAID	PROPN	O	O
are	VERB	O	O
probably	ADV	O	O
not	ADV	O	O
justified	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3358181)

Ventricular	PROPN	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
during	ADP	O	O
cesarean	ADJ	O	O
section	NOUN	O	O
after	ADP	O	O
ritodrine	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
illustrates	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
ritodrine	NOUN	O	I-Entity
for	ADP	O	O
preterm	NOUN	O	B-Entity
labor	NOUN	O	I-Entity
may	VERB	O	O
risk	VERB	O	O
interactions	NOUN	O	O
between	ADP	O	O
the	DET	O	O
residual	ADJ	O	O
betamimetic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
ritodrine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
anesthetics	NOUN	O	O
during	ADP	O	O
cesarean	ADJ	O	O
section	NOUN	O	O
.	PUNCT	O	O

Such	ADJ	O	O
interactions	NOUN	O	O
may	VERB	O	O
result	VERB	O	O
in	ADP	O	O
serious	ADJ	O	O
cardiovascular	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
even	ADV	O	O
after	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
ritodrine	NOUN	O	I-Entity
.	PUNCT	O	O

Preoperative	ADJ	O	O
assessment	NOUN	O	O
should	VERB	O	O
focus	VERB	O	O
on	ADP	O	O
cardiovascular	ADJ	O	O
status	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
level	NOUN	O	O
.	PUNCT	O	O

Careful	ADJ	O	O
fluid	ADJ	O	O
administration	NOUN	O	O
and	CCONJ	O	O
cautious	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
titrated	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
are	VERB	O	O
advised	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
delivery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
infant	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
should	VERB	O	O
be	VERB	O	O
no	DET	O	O
contraindication	NOUN	O	O
to	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
an	DET	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
vasopressor	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
phenylephrine	NOUN	O	I-Entity
to	PART	O	O
treat	VERB	O	O
hypotensive	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2887062)

Immunohistochemical	ADJ	O	O
,	PUNCT	O	O
electron	ADJ	O	O
microscopic	ADJ	O	O
and	CCONJ	O	O
morphometric	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
prolactinomas	NOUN	O	I-Entity
after	ADP	O	O
bromocriptine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
clarify	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
bromocriptine	NOUN	O	I-Entity
on	ADP	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
immunohistochemical	ADJ	O	O
,	PUNCT	O	O
ultrastructural	ADJ	O	O
and	CCONJ	O	O
morphometrical	ADJ	O	O
analyses	NOUN	O	O
were	VERB	O	O
applied	VERB	O	O
to	ADP	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
1	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
bromocriptine	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
of	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Golgi	PROPN	O	O
cisternae	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
lowered	VERB	O	O
serum	NOUN	O	O
prolactin	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
bromocriptine	NOUN	O	I-Entity
treatment	NOUN	O	O
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
an	DET	O	O
impaired	ADJ	O	O
secretion	NOUN	O	O
of	ADP	O	O
prolactin	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
decreasing	VERB	O	O
numbers	NOUN	O	O
of	ADP	O	O
cytoplasmic	ADJ	O	O
microtubules	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
at	ADP	O	O
this	DET	O	O
time	NOUN	O	O
were	VERB	O	O
well	ADV	O	O
granulated	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
vesiculated	VERB	O	O
rough	ADJ	O	O
endoplasmic	NOUN	O	O
reticulum	NOUN	O	O
and	CCONJ	O	O
markedly	ADV	O	O
dilated	VERB	O	O
Golgi	PROPN	O	O
cisternae	NOUN	O	O
.	PUNCT	O	O

Electron	PROPN	O	O
microscopical	ADJ	O	O
immunohistochemistry	NOUN	O	O
revealed	VERB	O	O
positive	ADJ	O	O
reaction	NOUN	O	O
products	NOUN	O	O
noted	VERB	O	O
on	ADP	O	O
the	DET	O	O
secretory	NOUN	O	O
granules	NOUN	O	O
,	PUNCT	O	O
Golgi	PROPN	O	O
cisternae	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
endoplasmic	ADJ	O	O
reticulum	NOUN	O	O
of	ADP	O	O
the	DET	O	O
untreated	ADJ	O	O
rat	NOUN	O	O
prolactinoma	NOUN	O	I-Entity
cells	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
only	ADV	O	O
secretory	ADJ	O	O
granules	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
positive	ADJ	O	O
reaction	NOUN	O	O
products	NOUN	O	O
for	ADP	O	O
prolactin	NOUN	O	O
6	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
bromocriptine	NOUN	O	I-Entity
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adenoma	NOUN	O	I-Entity
cells	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
volume	NOUN	O	O
density	NOUN	O	O
of	ADP	O	O
secretory	NOUN	O	O
granules	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
volume	NOUN	O	O
densities	NOUN	O	O
of	ADP	O	O
rough	ADJ	O	O
endoplasmic	ADJ	O	O
reticulum	NOUN	O	O
and	CCONJ	O	O
microtubules	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
morphometric	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
bromocriptine	NOUN	O	I-Entity
inhibits	VERB	O	O
protein	NOUN	O	O
synthesis	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
bringing	VERB	O	O
about	PART	O	O
a	DET	O	O
disturbance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prolactin	NOUN	O	O
secretion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2425813)

On	ADP	O	O
two	NUM	O	O
paradoxical	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
of	ADP	O	O
prednisolone	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
ribosomal	ADJ	O	O
RNA	PROPN	O	O
biosyntheses	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
.	PUNCT	O	O

Liver	PROPN	O	B-Entity
enlargement	NOUN	O	I-Entity
and	CCONJ	O	O
muscle	NOUN	O	B-Entity
wastage	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
following	VERB	O	O
the	DET	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
prednisolone	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
view	NOUN	O	O
supports	VERB	O	O
the	DET	O	O
contention	NOUN	O	O
that	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
and	CCONJ	O	O
muscle	NOUN	O	O
are	VERB	O	O
independent	ADJ	O	O
sites	NOUN	O	O
of	ADP	O	O
prednisolone	NOUN	O	I-Entity
action	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2375138)

Possible	ADJ	O	O
intramuscular	ADJ	O	O
midazolam	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
cardiorespiratory	NOUN	O	B-Entity
arrest	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	I-Entity
.	PUNCT	O	O

Midazolam	PROPN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
is	VERB	O	O
commonly	ADV	O	O
used	VERB	O	O
for	ADP	O	O
dental	ADJ	O	O
or	CCONJ	O	O
endoscopic	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
generally	ADV	O	O
consisted	VERB	O	O
safe	ADJ	O	O
when	ADV	O	O
given	VERB	O	O
intramuscularly	ADV	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
respiratory	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
cardiovascular	ADJ	O	I-Entity
depression	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
describes	VERB	O	O
the	DET	O	O
first	ADJ	O	O
published	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
cardiorespiratory	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
intramuscular	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
midazolam	NOUN	O	I-Entity
.	PUNCT	O	O

Information	NOUN	O	O
regarding	VERB	O	O
midazolam	NOUN	O	I-Entity
use	NOUN	O	O
is	VERB	O	O
reviewed	VERB	O	O
to	PART	O	O
provide	VERB	O	O
recommendation	NOUN	O	O
for	ADP	O	O
safe	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2265898)

Serial	ADJ	O	O
epilepsy	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
levodopa	NOUN	O	B-Entity
/	SYM	O	I-Entity
carbidopa	NOUN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
on	ADP	O	O
hemodialysis	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
similar	ADJ	O	O
clinical	ADJ	O	O
features	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
:	PUNCT	O	O
both	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
hemodialysis	NOUN	O	O
for	ADP	O	O
many	ADJ	O	O
years	NOUN	O	O
but	CCONJ	O	O
recently	ADV	O	O
begun	VERB	O	O
on	ADP	O	O
a	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
flux	NOUN	O	O
dialyzer	NOUN	O	O
;	PUNCT	O	O
both	DET	O	O
had	VERB	O	O
been	VERB	O	O
receiving	VERB	O	O
a	DET	O	O
carbidopa	NOUN	O	B-Entity
/	SYM	O	I-Entity
levodopa	NOUN	O	I-Entity
preparation	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
both	DET	O	O
had	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
hallucinosis	NOUN	O	I-Entity
and	CCONJ	O	O
recurrent	ADJ	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
refractory	ADJ	O	O
to	ADP	O	O
anticonvulsants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
patient	NOUN	O	O
died	VERB	O	O
without	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
second	ADJ	O	O
patient	NOUN	O	O
had	VERB	O	O
a	DET	O	O
dramatic	ADJ	O	O
recovery	NOUN	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
B6	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2071257)

Effect	PROPN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
glyceryl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
phosphorylcholine	NOUN	O	I-Entity
on	ADP	O	O
amnesia	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
to	PART	O	O
test	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
glycerylphosphorylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
GFC	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
ten	NUM	O	O
day	NOUN	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
GFC	PROPN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
p.o	NOUN	O	O
.	PUNCT	O	O

,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
eleventh	ADJ	O	O
day	NOUN	O	O
either	CCONJ	O	O
scopolamine	NOUN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
i.m	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
able	ADJ	O	O
to	PART	O	O
antagonize	VERB	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
attention	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1592014)

Seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
metabolite	NOUN	O	O
benzoylecgonine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
half	NOUN	O	O
-	PUNCT	O	O
life	NOUN	O	O
(	PUNCT	O	O
t1/2	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
is	VERB	O	O
relatively	ADV	O	O
short	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
consequences	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
use	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
strokes	NOUN	O	I-Entity
,	PUNCT	O	O
can	VERB	O	O
occur	VERB	O	O
hours	NOUN	O	O
after	ADP	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
led	VERB	O	O
us	PRON	O	O
to	PART	O	O
hypothesize	VERB	O	O
that	ADP	O	O
a	DET	O	O
metabolite	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
some	DET	O	O
of	ADP	O	O
those	DET	O	O
delayed	VERB	O	O
sequelae	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
potential	NOUN	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
metabolite	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
benzoylecgonine	NOUN	O	I-Entity
(	PUNCT	O	O
BE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
to	PART	O	O
cause	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
separate	ADJ	O	O
equimolar	ADJ	O	O
doses	NOUN	O	O
(	PUNCT	O	O
0.2	NUM	O	O
and	CCONJ	O	O
0.4	NUM	O	O
mumol	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
either	DET	O	O
cocaine	NOUN	O	I-Entity
or	CCONJ	O	O
BE	VERB	O	I-Entity
were	VERB	O	O
injected	VERB	O	O
ventricularly	ADV	O	O
in	ADP	O	O
unanesthetized	ADJ	O	O
juvenile	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Treated	VERB	O	O
rats	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
evaluated	VERB	O	O
for	ADP	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
latency	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
seizure	NOUN	O	I-Entity
pattern	NOUN	O	O
or	CCONJ	O	O
for	ADP	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
without	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

BE	VERB	O	I-Entity
-	PUNCT	O	O
Induced	PROPN	O	O
seizures	NOUN	O	I-Entity
occurred	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
and	CCONJ	O	O
had	VERB	O	O
significantly	ADV	O	O
longer	ADJ	O	O
latencies	NOUN	O	O
than	ADP	O	O
those	DET	O	O
induced	VERB	O	O
by	ADP	O	O
equimolar	ADJ	O	O
amounts	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Whereas	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
best	ADV	O	O
characterized	VERB	O	O
as	ADP	O	O
brief	NOUN	O	O
,	PUNCT	O	O
generalized	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tonic	NOUN	O	O
and	CCONJ	O	O
resulted	VERB	O	O
in	ADP	O	O
death	NOUN	O	I-Entity
,	PUNCT	O	O
those	DET	O	O
induced	VERB	O	O
by	ADP	O	O
BE	PROPN	O	I-Entity
were	VERB	O	O
prolonged	VERB	O	O
,	PUNCT	O	O
often	ADV	O	O
multiple	ADJ	O	O
and	CCONJ	O	O
mixed	ADJ	O	O
in	ADP	O	O
type	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
rarely	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
death	NOUN	O	I-Entity
.	PUNCT	O	O

Electrical	ADJ	O	O
recordings	NOUN	O	O
from	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
rhythmic	ADJ	O	O
progression	NOUN	O	O
in	ADP	O	O
EEG	PROPN	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
voltage	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
seizure	NOUN	O	I-Entity
expression	NOUN	O	O
.	PUNCT	O	O

BE	VERB	O	I-Entity
-	PUNCT	O	O
Injected	VERB	O	O
rats	NOUN	O	O
that	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
seizures	NOUN	O	I-Entity
had	VERB	O	O
significantly	ADV	O	O
more	ADJ	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
than	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
animals	NOUN	O	O
without	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
finding	NOUN	O	O
that	ADJ	O	O
cocaine-	X	O	I-Entity
and	CCONJ	O	O
BE	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
differ	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
respects	NOUN	O	O
suggests	VERB	O	O
more	ADJ	O	O
than	ADP	O	O
one	NUM	O	O
mechanism	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
emphasizes	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
cocaine	NOUN	O	I-Entity
metabolite	NOUN	O	O
,	PUNCT	O	O
BE	VERB	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1436384)

Protection	NOUN	O	O
against	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
toward	ADP	O	O
striatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
neurons	NOUN	O	O
in	ADP	O	O
rodents	NOUN	O	O
by	ADP	O	O
LY274614	PROPN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
excitatory	NOUN	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
antagonist	NOUN	O	O
.	PUNCT	O	O

LY274614	NOUN	O	I-Entity
,	PUNCT	O	O
3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr	NUM	O	B-Entity
oisoquinoline-3-	ADJ	O	I-Entity
carboxylic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
as	ADP	O	O
a	DET	O	O
potent	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
the	DET	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O

subtype	NOUN	O	O
of	ADP	O	O
glutamate	ADJ	O	I-Entity
receptor	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
its	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
antagonize	VERB	O	O
the	DET	O	O
prolonged	ADJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
by	ADP	O	O
amphetamine	NOUN	O	I-Entity
in	ADP	O	O
iprindole	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

dose	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-amphetamine	NUM	O	I-Entity
hemisulfate	NOUN	O	O
,	PUNCT	O	O
given	VERB	O	O
to	ADP	O	O
rats	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
iprindole	NOUN	O	I-Entity
,	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
persistent	ADJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
1	NUM	O	O
week	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
prolonged	ADJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
was	VERB	O	O
antagonized	VERB	O	O
by	ADP	O	O
dizocilpine	NOUN	O	I-Entity
(	PUNCT	O	O
MK-801	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
non	ADV	O	O
-	PUNCT	O	O
competitive	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
by	ADP	O	O
LY274614	PROPN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
competitive	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
LY274614	PROPN	O	I-Entity
was	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	NOUN	O	O
,	PUNCT	O	O
being	VERB	O	O
maximum	ADJ	O	O
at	ADP	O	O
10	NUM	O	O
-	SYM	O	O
40	NUM	O	O
mgkg	NOUN	O	O
(	PUNCT	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
dose	NOUN	O	O
of	ADP	O	O
LY274614	PROPN	O	I-Entity
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
antagonizing	VERB	O	O
the	DET	O	O
depletion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
when	ADV	O	O
given	VERB	O	O
as	ADV	O	O
long	ADV	O	O
as	ADP	O	O
8	NUM	O	O
hr	PRON	O	O
prior	ADV	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
when	ADV	O	O
given	VERB	O	O
24	NUM	O	O
hr	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

Depletion	PROPN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
antagonized	VERB	O	O
when	ADV	O	O
LY274614	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
;	PUNCT	O	O
LY274614	PROPN	O	I-Entity
protected	VERB	O	O
when	ADV	O	O
given	VERB	O	O
up	PART	O	O
to	ADP	O	O
4	NUM	O	O
hr	NOUN	O	O
after	ADV	O	O
but	CCONJ	O	O
not	ADV	O	O
when	ADV	O	O
given	VERB	O	O
8	NUM	O	O
or	CCONJ	O	O
24	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
prolonged	ADJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
given	VERB	O	O
multiple	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
antagonized	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
and	CCONJ	O	O
completely	ADV	O	O
by	ADP	O	O
LY274614	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
strengthen	VERB	O	O
the	DET	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
neurotoxic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
and	CCONJ	O	O
related	VERB	O	O
compounds	NOUN	O	O
toward	ADP	O	O
nigrostriatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
neurons	NOUN	O	O
involves	VERB	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
LY274614	ADV	O	I-Entity
is	VERB	O	O
an	DET	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
lasting	VERB	O	O
in	ADP	O	O
vivo	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1085609)

Neonatal	ADJ	O	O
pyridoxine	NOUN	O	I-Entity
responsive	ADJ	O	O
convulsions	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
isoniazid	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
17-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
infant	NOUN	O	O
on	ADP	O	O
isoniazid	NOUN	O	I-Entity
therapy	NOUN	O	O

13	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
daily	ADV	O	O
from	ADP	O	O
birth	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
maternal	ADJ	O	O
tuberculosis	NOUN	O	I-Entity
was	VERB	O	O
admitted	VERB	O	O
after	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
clonic	ADJ	O	B-Entity
fits	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
fits	NOUN	O	I-Entity
ceased	VERB	O	O
within	ADP	O	O
4	NUM	O	O
hours	NOUN	O	O
of	ADP	O	O
administering	VERB	O	O
intramuscular	ADJ	O	O
pyridoxine	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
an	DET	O	O
aetiology	NOUN	O	O
of	ADP	O	O
pyridoxine	ADJ	O	I-Entity
deficiency	NOUN	O	O
secondary	NOUN	O	O
to	ADP	O	O
isoniazid	VERB	O	I-Entity
medication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (809711)

Reversal	NOUN	O	O
by	ADP	O	O
phenylephrine	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
nitroglycerin	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Nitroglycerin	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
elevation	NOUN	O	O
during	ADP	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
effect	NOUN	O	O
potentiated	VERB	O	O
in	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
by	ADP	O	O
agents	NOUN	O	O
that	ADJ	O	O
reverse	VERB	O	O
nitroglycerin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
nitroglycerin	NOUN	O	I-Entity
and	CCONJ	O	O
phenylephrine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
transmural	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarctions	NOUN	O	I-Entity
received	VERB	O	O
intravenous	ADJ	O	O
nitroglycerin	NOUN	O	I-Entity
,	PUNCT	O	O
sufficient	ADJ	O	O
to	PART	O	O
reduce	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
from	ADP	O	O
107	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

SigmaST	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
sum	NOUN	O	O
of	ADP	O	O
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
elevations	NOUN	O	O
in	ADP	O	O
16	NUM	O	O
precordial	NOUN	O	O
leads	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.02	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
intravenous	ADJ	O	O
nitroglycerin	NOUN	O	I-Entity
.	PUNCT	O	O

Subsequent	ADJ	O	O
addition	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
sufficient	ADJ	O	O
to	PART	O	O
re	VERB	O	O
-	PUNCT	O	O
elevate	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
to	ADP	O	O
106	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
addition	NOUN	O	O
of	ADP	O	O
phenylephrine	NOUN	O	I-Entity
to	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
beneficial	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
myocardial	ADJ	O	I-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20621845)

Elevation	NOUN	O	O
of	ADP	O	O
ADAM10	PROPN	O	O
,	PUNCT	O	O
ADAM17	PROPN	O	O
,	PUNCT	O	O
MMP-2	PROPN	O	O
and	CCONJ	O	O
MMP-9	PROPN	O	O
expression	NOUN	O	O
with	ADP	O	O
media	NOUN	O	O
degeneration	NOUN	O	O
features	VERB	O	O
CaCl2-induced	PROPN	O	I-Entity
thoracic	ADP	O	B-Entity
aortic	ADJ	O	I-Entity
aneurysm	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
establish	VERB	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
thoracic	NOUN	O	B-Entity
aortic	ADJ	O	I-Entity
aneurysm	NOUN	O	I-Entity
(	PUNCT	O	O
TAA	PROPN	O	I-Entity
)	PUNCT	O	O
by	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
(	PUNCT	O	O
CaCl(2))-induced	VERB	O	I-Entity
arterial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
a	DET	O	O
disintegrin	NOUN	O	O
and	CCONJ	O	O
metalloproteinase	NOUN	O	O
(	PUNCT	O	O
ADAM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
matrix	NOUN	O	O
metalloproteinases	NOUN	O	O
(	PUNCT	O	O
MMPs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
endogenous	ADJ	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
TIMPs	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
TAA	PROPN	O	I-Entity
formation	NOUN	O	O
.	PUNCT	O	O

Thoracic	PROPN	O	O
aorta	NOUN	O	O
of	ADP	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
was	VERB	O	O
exposed	VERB	O	O
to	ADP	O	O
0.5	NUM	O	O
M	PROPN	O	O
CaCl(2	PROPN	O	B-Entity
)	PUNCT	O	I-Entity
or	CCONJ	O	O
normal	ADJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
NaCl	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
12weeks	NUM	O	O
,	PUNCT	O	O
animals	NOUN	O	O
were	VERB	O	O
euthanized	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
CaCl(2)-treated	PROPN	O	I-Entity
,	PUNCT	O	O
CaCl(2)-untreated	PROPN	O	I-Entity
(	PUNCT	O	O
n=12	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O

NaCl	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
aortic	ADJ	O	O
segments	NOUN	O	O
(	PUNCT	O	O
n=12	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
histological	ADJ	O	O
and	CCONJ	O	O
molecular	ADJ	O	O
assessments	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
similar	ADJ	O	O
external	ADJ	O	O
diameters	NOUN	O	O
among	ADP	O	O
CaCl(2)-treated	VERB	O	I-Entity
,	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
CaCl(2)-treated	PROPN	O	I-Entity
and	CCONJ	O	O
NaCl	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
segments	NOUN	O	O
,	PUNCT	O	O
aneurymal	ADJ	O	O
alteration	NOUN	O	O
(	PUNCT	O	O
n=6	NOUN	O	O
,	PUNCT	O	O
50%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
media	NOUN	O	O
degeneration	NOUN	O	O
with	ADP	O	O
regional	ADJ	O	O
disruption	NOUN	O	O
,	PUNCT	O	O
fragmentation	NOUN	O	O
of	ADP	O	O
elastic	ADJ	O	O
fiber	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
collagen	NOUN	O	O
deposition	NOUN	O	O
(	PUNCT	O	O
n=12	NOUN	O	O
,	PUNCT	O	O
100%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
demonstrated	VERB	O	O
in	ADP	O	O
CaCl(2)-treated	VERB	O	I-Entity
segments	NOUN	O	O
.	PUNCT	O	O

MMP-2	NOUN	O	O
,	PUNCT	O	O
MMP-9	PROPN	O	O
,	PUNCT	O	O
ADAM-10	PROPN	O	O
and	CCONJ	O	O
ADAM-17	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
were	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
CaCl(2)-treated	VERB	O	I-Entity
segments	NOUN	O	O
(	PUNCT	O	O
all	DET	O	O
p<0.01	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
trends	NOUN	O	O
of	ADP	O	O
elevation	NOUN	O	O
in	ADP	O	O
CaCl(2)-untreated	VERB	O	I-Entity
segments	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
NaCl	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
segments	NOUN	O	O
.	PUNCT	O	O

Immunohistochemistry	PROPN	O	O
displayed	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
expressions	NOUN	O	O
of	ADP	O	O
MMP-2	PROPN	O	O
,	PUNCT	O	O
MMP-9	PROPN	O	O
,	PUNCT	O	O
ADAM-10	PROPN	O	O
and	CCONJ	O	O
ADAM-17	PROPN	O	O
(	PUNCT	O	O
all	DET	O	O
p<0.01	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
intima	NOUN	O	O
and	CCONJ	O	O
media	NOUN	O	O
for	ADP	O	O
CaCl(2)-treated	ADJ	O	I-Entity
segments	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
establishes	VERB	O	O
a	DET	O	O
TAA	PROPN	O	I-Entity
model	NOUN	O	O
by	ADP	O	O
periarterial	ADJ	O	O
CaCl(2	PROPN	O	B-Entity
)	PUNCT	O	I-Entity
exposure	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
demonstrates	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
elevation	NOUN	O	O
of	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
MMP-2	PROPN	O	O
,	PUNCT	O	O
MMP-9	PROPN	O	O
,	PUNCT	O	O
ADAM10	PROPN	O	O
and	CCONJ	O	O
ADAM17	PROPN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	O
remodeling	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19843802)

Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
heart	NOUN	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
acute	ADJ	O	O
right	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
requiring	VERB	O	O
continuous	ADJ	O	O
venovenous	ADJ	O	O
hemodiafiltration	NOUN	O	O
(	PUNCT	O	O
CVVHDF	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Increasing	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
catecholamines	NOUN	O	I-Entity
,	PUNCT	O	O
sedatives	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
muscle	NOUN	O	O
relaxants	NOUN	O	O
administered	VERB	O	O
through	ADP	O	O
a	DET	O	O
central	ADJ	O	O
venous	ADJ	O	O
catheter	NOUN	O	O
were	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
bolus	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
injected	VERB	O	O
through	ADP	O	O
an	DET	O	O
alternative	NOUN	O	O
catheter	NOUN	O	O
provoked	VERB	O	O
a	DET	O	O
hypertensive	ADJ	O	I-Entity
crisis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
catheters	NOUN	O	O
were	VERB	O	O
changed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hemodynamics	NOUN	O	O
stabilized	VERB	O	O
at	ADP	O	O
lower	ADJ	O	O
catecholamine	NOUN	O	I-Entity
doses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19473225)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
glutamate	NOUN	O	I-Entity
supplementation	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
protect	VERB	O	O
against	ADP	O	O
peripheral	ADJ	O	B-Entity
neurotoxicity	NOUN	O	I-Entity
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
.	PUNCT	O	O

Toxic	ADJ	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
is	VERB	O	O
still	ADV	O	O
a	DET	O	O
significant	ADJ	O	O
limiting	VERB	O	O
factor	NOUN	O	O
for	ADP	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
paclitaxel	NOUN	O	I-Entity
(	PUNCT	O	O
PAC	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
although	ADP	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
closely	ADV	O	O
related	ADJ	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
glutamine	NOUN	O	I-Entity
were	VERB	O	O
claimed	VERB	O	O
to	PART	O	O
ameliorate	VERB	O	O
PAC	PROPN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
pilot	NOUN	O	O
trial	NOUN	O	O
aimed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
glutamate	ADJ	O	I-Entity
supplementation	NOUN	O	O
for	ADP	O	O
preventing	VERB	O	O
PAC	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
double	ADV	O	O
-	PUNCT	O	O
blinded	VERB	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
electro	NOUN	O	O
-	PUNCT	O	O
diagnostic	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
ovarian	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
analysis	NOUN	O	O
following	VERB	O	O
six	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
PAC	PROPN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
regimen	NOUN	O	O
:	PUNCT	O	O
23	NUM	O	O
had	VERB	O	O
been	VERB	O	O
supplemented	VERB	O	O
by	ADP	O	O
glutamate	NOUN	O	I-Entity
all	ADV	O	O
along	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
times	NOUN	O	O
500	NUM	O	O
mg	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
G	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
20	NUM	O	O
had	VERB	O	O
received	VERB	O	O
a	DET	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
P	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
signs	NOUN	O	O
or	CCONJ	O	O
symptoms	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
although	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
symptoms	NOUN	O	O
presented	VERB	O	O
mostly	ADV	O	O
with	ADP	O	O
lower	ADJ	O	O
scores	NOUN	O	O
of	ADP	O	O
severity	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
G.	PROPN	O	O

However	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
difference	NOUN	O	O
reached	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
only	ADV	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
reported	VERB	O	O
pain	NOUN	O	I-Entity
sensation	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.011	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
leads	VERB	O	O
to	ADP	O	O
the	DET	O	O
conclusion	NOUN	O	O
that	ADP	O	O
glutamate	NOUN	O	I-Entity
supplementation	NOUN	O	O
at	ADP	O	O
the	DET	O	O
chosen	ADJ	O	O
regimen	NOUN	O	O
fails	VERB	O	O
to	PART	O	O
protect	VERB	O	O
against	ADP	O	O
peripheral	ADJ	O	B-Entity
neurotoxicity	NOUN	O	I-Entity
of	ADP	O	O
PAC	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19387625)

Attentional	ADJ	O	O
modulation	NOUN	O	O
of	ADP	O	O
perceived	VERB	O	O
pain	NOUN	O	I-Entity
intensity	NOUN	O	O
in	ADP	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
secondary	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

Perceived	VERB	O	O
pain	NOUN	O	I-Entity
intensity	NOUN	O	O
is	VERB	O	O
modulated	VERB	O	O
by	ADP	O	O
attention	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
that	ADP	O	O
how	ADV	O	O
pain	ADJ	O	I-Entity
intensity	NOUN	O	O
ratings	NOUN	O	O
are	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
attention	NOUN	O	O
in	ADP	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
secondary	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
show	VERB	O	O
that	ADP	O	O
perceived	VERB	O	O
pain	NOUN	O	I-Entity
intensity	NOUN	O	O
in	ADP	O	O
secondary	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
is	VERB	O	O
decreased	VERB	O	O
when	ADV	O	O
attention	NOUN	O	O
is	VERB	O	O
distracted	VERB	O	O
away	ADV	O	O
from	ADP	O	O
the	DET	O	O
painful	ADJ	O	O
pinprick	NOUN	O	O
stimulus	NOUN	O	O
with	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
task	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
found	VERB	O	O
that	ADP	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
attentional	ADJ	O	O
modulation	NOUN	O	O
in	ADP	O	O
secondary	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
is	VERB	O	O
very	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
untreated	ADJ	O	O
,	PUNCT	O	O
control	ADJ	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
,	PUNCT	O	O
showing	VERB	O	O
no	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
capsaicin	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
attentional	ADJ	O	O
modulation	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
secondary	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
attention	NOUN	O	O
might	VERB	O	O
affect	VERB	O	O
mechanical	ADJ	O	O
pain	NOUN	O	I-Entity
through	ADP	O	O
independent	ADJ	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19211690)

Testosterone	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
upregulation	NOUN	O	O
of	ADP	O	O
intrarenal	ADJ	O	O
angiotensinogen	NOUN	O	O
in	ADP	O	O
Dahl	PROPN	O	O
salt	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
more	ADJ	O	O
salt	NOUN	O	I-Entity
sensitive	ADJ	O	O
in	ADP	O	O
men	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
premenopausal	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Dahl	PROPN	O	O
salt	NOUN	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
rats	NOUN	O	O
(	PUNCT	O	O
DS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
salt	NOUN	O	I-Entity
(	PUNCT	O	O
HS	PROPN	O	O
)	PUNCT	O	O
diet	NOUN	O	O
increases	VERB	O	O
BP	PROPN	O	O
more	ADV	O	O
in	ADP	O	O
males	NOUN	O	O
than	ADP	O	O
females	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
the	DET	O	O
systemic	ADJ	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
suppressed	VERB	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
HS	PROPN	O	O
in	ADP	O	O
male	NOUN	O	O
DS	PROPN	O	O
,	PUNCT	O	O
intrarenal	ADJ	O	O
angiotensinogen	NOUN	O	O
expression	NOUN	O	O
is	VERB	O	O
increased	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
intrarenal	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
ANG	PROPN	O	O
II	PROPN	O	O
are	VERB	O	O
not	ADV	O	O
suppressed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
hypothesis	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
that	ADP	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
sexual	ADJ	O	O
dimorphism	NOUN	O	O
in	ADP	O	O
HS	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
upregulation	NOUN	O	O
of	ADP	O	O
intrarenal	ADJ	O	O
angiotensinogen	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
testosterone	NOUN	O	I-Entity
that	ADJ	O	O
also	ADV	O	O
causes	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
BP	PROPN	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
a	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
salt	NOUN	O	I-Entity
(	PUNCT	O	O
LS	PROPN	O	O
)	PUNCT	O	O
diet	NOUN	O	O
,	PUNCT	O	O
male	ADJ	O	O
DS	PROPN	O	O
had	VERB	O	O
higher	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
intrarenal	ADJ	O	O
angiotensinogen	NOUN	O	O
mRNA	NOUN	O	O
than	ADP	O	O
females	NOUN	O	O
.	PUNCT	O	O

HS	PROPN	O	O
diet	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
wk	PART	O	O
caused	VERB	O	O
a	DET	O	O
progressive	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
BP	PROPN	O	O
,	PUNCT	O	O
protein	NOUN	O	O
and	CCONJ	O	O
albumin	NOUN	O	O
excretion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
glomerular	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
in	ADP	O	O
male	NOUN	O	O
DS	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
attenuated	VERB	O	O
by	ADP	O	O
castration	NOUN	O	O
.	PUNCT	O	O

Testosterone	NOUN	O	I-Entity
replacement	NOUN	O	O
in	ADP	O	O
castrated	VERB	O	O
DS	NOUN	O	O
rats	NOUN	O	O
increased	VERB	O	O
BP	PROPN	O	O
,	PUNCT	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
upregulation	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
angiotensinogen	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
HS	PROPN	O	O
diet	NOUN	O	O
.	PUNCT	O	O

Testosterone	NOUN	O	I-Entity
contributes	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
male	NOUN	O	O
DS	PROPN	O	O
rats	NOUN	O	O
on	ADP	O	O
HS	PROPN	O	O
diet	NOUN	O	O
possibly	ADV	O	O
through	ADP	O	O
upregulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intrarenal	ADJ	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18703024)

Prenatal	ADJ	O	O
protein	NOUN	O	O
deprivation	NOUN	O	O
alters	VERB	O	O
dopamine	NOUN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
behaviors	NOUN	O	O
and	CCONJ	O	O
dopaminergic	ADJ	O	O
and	CCONJ	O	O
glutamatergic	ADJ	O	O
receptor	NOUN	O	O
binding	NOUN	O	O
.	PUNCT	O	O

Epidemiological	ADJ	O	O
evidence	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
prenatal	ADJ	O	O
nutritional	ADJ	O	O
deprivation	NOUN	O	O
may	VERB	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
was	VERB	O	O
to	PART	O	O
use	VERB	O	O
an	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
prenatal	ADJ	O	O
protein	NOUN	O	O
deprivation	NOUN	O	O
on	ADP	O	O
behaviors	NOUN	O	O
and	CCONJ	O	O
receptor	NOUN	O	O
binding	VERB	O	O
with	ADP	O	O
relevance	NOUN	O	O
to	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
that	ADP	O	O
prenatally	ADV	O	O
protein	NOUN	O	O
deprived	ADJ	O	O
(	PUNCT	O	O
PD	PROPN	O	O
)	PUNCT	O	O
female	ADJ	O	O
rats	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
increased	VERB	O	O
stereotypic	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
apomorphine	VERB	O	I-Entity
and	CCONJ	O	O
an	DET	O	O
increased	VERB	O	O
locomotor	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
in	ADP	O	O
adulthood	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
or	CCONJ	O	O
MK-801-induced	ADJ	O	I-Entity
locomotion	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
following	VERB	O	O
PD	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
PD	PROPN	O	O
female	ADJ	O	O
rats	NOUN	O	O
showed	VERB	O	O
increased	VERB	O	O
(	PUNCT	O	O
3)H	NUM	O	I-Entity
-	PUNCT	O	O
MK-801	PROPN	O	I-Entity
binding	VERB	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
and	CCONJ	O	O
hippocampus	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

PD	PROPN	O	O
female	ADJ	O	O
rats	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
increased	VERB	O	O
(	PUNCT	O	O
3)H	NUM	O	I-Entity
-	PUNCT	O	O
haloperidol	NOUN	O	I-Entity
binding	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
dopamine	NOUN	O	I-Entity
transporter	NOUN	O	O
binding	VERB	O	O
in	ADP	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
behavior	NOUN	O	O
or	CCONJ	O	O
receptor	NOUN	O	O
binding	VERB	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
PD	PROPN	O	O
males	NOUN	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
(	PUNCT	O	O
3)H	NUM	O	I-Entity
-	PUNCT	O	O
MK-801	PROPN	O	I-Entity
binding	VERB	O	O
in	ADP	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
prenatal	ADJ	O	O
nutritional	ADJ	O	B-Entity
deficiency	NOUN	O	I-Entity
enhances	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
schizophrenia	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
also	ADV	O	O
have	VERB	O	O
implications	NOUN	O	O
for	ADP	O	O
developmental	ADJ	O	O
processes	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
differential	ADJ	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
drugs	NOUN	O	O
of	ADP	O	O
abuse	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18631865)

inhibitors	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
proteinuria	NOUN	O	I-Entity
:	PUNCT	O	O
mechanisms	NOUN	O	O
,	PUNCT	O	O
significance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
management	NOUN	O	O
.	PUNCT	O	O

Massive	ADJ	O	O
urinary	ADJ	O	O
protein	NOUN	O	O
excretion	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
conversion	NOUN	O	O
from	ADP	O	O
calcineurin	ADJ	O	O
inhibitors	NOUN	O	O
to	ADP	O	O
mammalian	ADJ	O	O
target	NOUN	O	O
of	ADP	O	O
rapamycin	NOUN	O	I-Entity
(	PUNCT	O	O
mToR	PROPN	O	O
)	PUNCT	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
sirolimus	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
allograft	NOUN	O	I-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
proteinuria	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
predictive	ADJ	O	O
factor	NOUN	O	O
of	ADP	O	O
poor	ADJ	O	O
transplantation	NOUN	O	O
outcome	NOUN	O	O
,	PUNCT	O	O
many	ADJ	O	O
studies	NOUN	O	O
focused	VERB	O	O
on	ADP	O	O
this	DET	O	O
adverse	ADJ	O	O
event	NOUN	O	O
during	ADP	O	O
the	DET	O	O
past	ADJ	O	O
years	NOUN	O	O
.	PUNCT	O	O

Whether	ADP	O	O
proteinuria	NOUN	O	I-Entity
was	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
sirolimus	NOUN	O	I-Entity
or	CCONJ	O	O
only	ADV	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
calcineurin	NOUN	O	O
inhibitors	NOUN	O	O
withdrawal	NOUN	O	O
remained	VERB	O	O
unsolved	ADJ	O	O
until	ADP	O	O
high	ADJ	O	O
range	NOUN	O	O
proteinuria	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
observed	VERB	O	O
during	ADP	O	O
sirolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
islet	NOUN	O	O
transplantation	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
sirolimus	NOUN	O	I-Entity
de	X	O	O
novo	X	O	O
.	PUNCT	O	O

Podocyte	PROPN	O	O
injury	NOUN	O	O
and	CCONJ	O	O
focal	ADJ	O	O
segmental	ADJ	O	O
glomerulosclerosis	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
mToR	PROPN	O	O
inhibition	NOUN	O	O
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
pathways	NOUN	O	O
underlying	VERB	O	O
these	DET	O	O
lesions	NOUN	O	O
remain	VERB	O	O
hypothetic	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
discuss	VERB	O	O
herein	ADV	O	O
the	DET	O	O
possible	ADJ	O	O
mechanisms	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
significance	NOUN	O	O
of	ADP	O	O
mToR	PROPN	O	O
blockade	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18162529)

Hypothalamic	PROPN	O	O
prolactin	NOUN	O	O
receptor	NOUN	O	O
messenger	NOUN	O	O
ribonucleic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
prolactin	NOUN	O	O
signaling	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hyperprolactinemic	ADJ	O	I-Entity
inhibition	NOUN	O	O
of	ADP	O	O
pulsatile	NOUN	O	O
luteinizing	VERB	O	O
hormone	NOUN	O	O
secretion	NOUN	O	O
are	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
estradiol	NOUN	O	I-Entity
.	PUNCT	O	O

Hyperprolactinemia	NOUN	O	I-Entity
can	VERB	O	O
reduce	VERB	O	O
fertility	NOUN	O	O
and	CCONJ	O	O
libido	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
first	ADV	O	O
tested	VERB	O	O
whether	ADP	O	O
chronic	ADJ	O	O
hyperprolactinemia	NOUN	O	I-Entity
inhibited	VERB	O	O
two	NUM	O	O
neuroendocrine	ADJ	O	O
parameters	NOUN	O	O
necessary	ADJ	O	O
for	ADP	O	O
female	ADJ	O	O
fertility	NOUN	O	O
:	PUNCT	O	O
pulsatile	NOUN	O	O
LH	PROPN	O	O
secretion	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
LH	PROPN	O	O
surge	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
hyperprolactinemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
dopamine	NOUN	O	I-Entity
antagonist	NOUN	O	O
sulpiride	NOUN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
40%	NUM	O	O
reduction	NOUN	O	O
LH	PROPN	O	O
pulse	NOUN	O	O
frequency	NOUN	O	O
in	ADP	O	O
ovariectomized	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
low	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
estradiol	NOUN	O	I-Entity
.	PUNCT	O	O

Sulpiride	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
a	DET	O	O
steroid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
LH	PROPN	O	O
surge	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
GnRH	PROPN	O	O
neurons	NOUN	O	O
activated	VERB	O	O
during	ADP	O	O
the	DET	O	O
surge	NOUN	O	O
.	PUNCT	O	O

Estradiol	PROPN	O	I-Entity
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
influence	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
long	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
prolactin	NOUN	O	O
receptors	NOUN	O	O
(	PUNCT	O	O
PRL	PROPN	O	O
-	PUNCT	O	O
R	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
components	NOUN	O	O
of	ADP	O	O
prolactin	NOUN	O	O
's	PART	O	O
signaling	VERB	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
test	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
estrogen	NOUN	O	I-Entity
increases	NOUN	O	O
PRL	PROPN	O	O
-	PUNCT	O	O
R	PROPN	O	O
expression	NOUN	O	O
and	CCONJ	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
prolactin	VERB	O	O
,	PUNCT	O	O
we	PRON	O	O
next	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
estradiol	NOUN	O	I-Entity
greatly	ADV	O	O
augments	VERB	O	O
prolactin	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
STAT5	PROPN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

Lastly	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
measured	VERB	O	O
PRL	PROPN	O	O
-	PUNCT	O	O
R	PROPN	O	O
and	CCONJ	O	O
suppressor	NOUN	O	O
of	ADP	O	O
cytokine	NOUN	O	O
signaling	VERB	O	O
(	PUNCT	O	O
SOCS-1	NOUN	O	O
and	CCONJ	O	O
-3	NOUN	O	O
and	CCONJ	O	O
CIS	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
reflect	VERB	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
prolactin	NOUN	O	O
signaling	VERB	O	O
)	PUNCT	O	O
mRNAs	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
sulpiride	VERB	O	I-Entity
and	CCONJ	O	O
estradiol	VERB	O	I-Entity
.	PUNCT	O	O

Sulpiride	PROPN	O	I-Entity
induced	VERB	O	O
only	ADV	O	O
SOCS-1	PROPN	O	O
in	ADP	O	O
the	DET	O	O
medial	ADJ	O	O
preoptic	ADJ	O	O
area	NOUN	O	O
,	PUNCT	O	O
where	ADV	O	O
GnRH	PROPN	O	O
neurons	NOUN	O	O
are	VERB	O	O
regulated	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
arcuate	NOUN	O	O
nucleus	NOUN	O	O
and	CCONJ	O	O
choroid	NOUN	O	O
plexus	NOUN	O	O
,	PUNCT	O	O
PRL	PROPN	O	O
-	PUNCT	O	O
R	PROPN	O	O
,	PUNCT	O	O
SOCS-3	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
CIS	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
induced	VERB	O	O
.	PUNCT	O	O

Estradiol	PROPN	O	I-Entity
enhanced	VERB	O	O
these	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
SOCS-3	PROPN	O	O
and	CCONJ	O	O
CIS	PROPN	O	O
.	PUNCT	O	O

Interestingly	ADV	O	O
,	PUNCT	O	O
estradiol	NOUN	O	I-Entity
also	ADV	O	O
induced	VERB	O	O
PRL	PROPN	O	O
-	PUNCT	O	O
R	PROPN	O	O
,	PUNCT	O	O
SOCS-3	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
CIS	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
independently	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
GnRH	PROPN	O	O
pulse	NOUN	O	O
frequency	NOUN	O	O
is	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
hyperprolactinemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
steroid	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
also	ADV	O	O
provide	VERB	O	O
evidence	NOUN	O	O
for	ADP	O	O
estradiol	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
and	CCONJ	O	O
brain	ADJ	O	O
region	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
PRL	PROPN	O	O
-	PUNCT	O	O
R	PROPN	O	O
expression	NOUN	O	O
and	CCONJ	O	O
signaling	VERB	O	O
responses	NOUN	O	O
by	ADP	O	O
prolactin	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17879945)

Estrogen	NOUN	O	O
prevents	VERB	O	O
cholesteryl	NOUN	O	B-Entity
ester	NOUN	O	I-Entity
accumulation	NOUN	O	O
in	ADP	O	O
macrophages	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
HIV	PROPN	O	O
protease	NOUN	O	O
inhibitor	NOUN	O	O
ritonavir	NOUN	O	I-Entity
.	PUNCT	O	O

Individuals	NOUN	O	O
with	ADP	O	O
HIV	PROPN	O	O
can	VERB	O	O
now	ADV	O	O
live	VERB	O	O
long	ADJ	O	O
lives	NOUN	O	O
with	ADP	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
that	ADJ	O	O
often	ADV	O	O
includes	VERB	O	O
protease	NOUN	O	O
inhibitors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
ritonavir	NOUN	O	I-Entity
.	PUNCT	O	O

Many	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
develop	VERB	O	O
negative	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
premature	ADJ	O	B-Entity
atherosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
previously	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
ritonavir	NOUN	O	I-Entity
treatment	NOUN	O	O
increases	VERB	O	O
atherosclerotic	ADJ	O	B-Entity
lesion	NOUN	O	I-Entity
formation	NOUN	O	O
in	ADP	O	O
male	ADJ	O	O
mice	NOUN	O	O
to	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
extent	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
female	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
monocytes	NOUN	O	O
isolated	VERB	O	O
from	ADP	O	O
ritonavir	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
females	NOUN	O	O
had	VERB	O	O
less	ADJ	O	O
cholesteryl	NOUN	O	B-Entity
ester	NOUN	O	I-Entity
accumulation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
investigated	VERB	O	O
the	DET	O	O
molecular	ADJ	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
female	ADJ	O	O
hormones	NOUN	O	O
influence	NOUN	O	O
cholesterol	NOUN	O	I-Entity
metabolism	NOUN	O	O
in	ADP	O	O
macrophages	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
HIV	PROPN	O	O
protease	NOUN	O	O
inhibitor	NOUN	O	O
ritonavir	NOUN	O	I-Entity
.	PUNCT	O	O

Briefly	NOUN	O	O
,	PUNCT	O	O
cells	NOUN	O	O
were	VERB	O	O
differentiated	VERB	O	O
for	ADP	O	O
72	NUM	O	O
h	NOUN	O	O
with	ADP	O	O
100	NUM	O	O
nM	ADJ	O	O
PMA	PROPN	O	O
to	PART	O	O
obtain	VERB	O	O
a	DET	O	O
macrophage	NOUN	O	O
-	PUNCT	O	O
like	ADJ	O	O
phenotype	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
nM	NUM	O	O
17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
estradiol	NOUN	O	I-Entity
(	PUNCT	O	O
E2	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
100	NUM	O	O
nM	ADJ	O	O
progesterone	NOUN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
(	PUNCT	O	O
0.01%	NUM	O	O
ethanol	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Cells	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
30	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
ml	CCONJ	O	O
ritonavir	NOUN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
aggregated	VERB	O	O
LDL	PROPN	O	O
for	ADP	O	O
24	NUM	O	O
h.	PROPN	O	O
Cell	PROPN	O	O
extracts	NOUN	O	O
were	VERB	O	O
harvested	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lipid	ADJ	O	O
or	CCONJ	O	O
total	ADJ	O	O
RNA	PROPN	O	O
was	VERB	O	O
isolated	VERB	O	O
.	PUNCT	O	O

E2	NOUN	O	I-Entity
decreased	VERB	O	O
the	DET	O	O
accumulation	NOUN	O	O
of	ADP	O	O
cholesteryl	NOUN	O	B-Entity
esters	NOUN	O	I-Entity
in	ADP	O	O
macrophages	NOUN	O	O
following	VERB	O	O
ritonavir	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Ritonavir	PROPN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
scavenger	NOUN	O	O
receptor	NOUN	O	O
,	PUNCT	O	O
CD36	PROPN	O	O
mRNA	PROPN	O	O
,	PUNCT	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
uptake	NOUN	O	O
of	ADP	O	O
LDL	PROPN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
ritonavir	ADJ	O	I-Entity
treatment	NOUN	O	O
selectively	ADV	O	O
increased	VERB	O	O
the	DET	O	O
relative	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
PPARgamma	PROPN	O	O
mRNA	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
transcription	NOUN	O	O
factor	NOUN	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
CD36	PROPN	O	O
mRNA	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
E2	NOUN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
these	DET	O	O
increases	NOUN	O	O
at	ADP	O	O
the	DET	O	O
mRNA	PROPN	O	O
level	NOUN	O	O
.	PUNCT	O	O

E2	NOUN	O	I-Entity
did	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
significantly	ADV	O	O
suppress	VERB	O	O
CD36	PROPN	O	O
protein	NOUN	O	O
levels	NOUN	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
fluorescent	ADJ	O	O
immunocytochemistry	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
data	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
E2	PROPN	O	I-Entity
modifies	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
CD36	PROPN	O	O
at	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
monocyte	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
macrophages	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
reduced	VERB	O	O
cholesteryl	NOUN	O	B-Entity
ester	NOUN	O	I-Entity
accumulation	NOUN	O	O
following	VERB	O	O
ritonavir	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17437408)

Upregulation	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
expression	NOUN	O	O
of	ADP	O	O
P	NOUN	O	O
-	PUNCT	O	O
glycoprotein	NOUN	O	O
in	ADP	O	O
MRP2-deficient	PROPN	O	O
TR(-	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
resembles	VERB	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
up	PART	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
efflux	NOUN	O	O
transporter	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
using	VERB	O	O
this	DET	O	O
strategy	NOUN	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
MRP2	PROPN	O	O
in	ADP	O	O
brain	NOUN	O	O
access	NOUN	O	O
of	ADP	O	O
antiepileptic	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
AEDs	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
recently	ADV	O	O
reported	VERB	O	O
that	ADP	O	O
phenytoin	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
substrate	NOUN	O	O
for	ADP	O	O
MRP2	PROPN	O	O
in	ADP	O	O
the	DET	O	O
BBB	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparable	ADJ	O	O
overexpression	NOUN	O	O
of	ADP	O	O
Pgp	PROPN	O	O
in	ADP	O	O
the	DET	O	O
BBB	PROPN	O	O
was	VERB	O	O
obtained	VERB	O	O
after	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Experiments	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Pgp	PROPN	O	O
substrate	NOUN	O	O
phenobarbital	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
selective	ADJ	O	O
Pgp	PROPN	O	O
inhibitor	NOUN	O	O
tariquidar	NOUN	O	I-Entity
in	ADP	O	O
TR(-	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
substantiated	VERB	O	O
that	ADP	O	O
Pgp	PROPN	O	O
is	VERB	O	O
functional	ADJ	O	O
and	CCONJ	O	O
compensates	VERB	O	O
for	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
MRP2	PROPN	O	O
in	ADP	O	O
the	DET	O	O
BBB	PROPN	O	O
.	PUNCT	O	O

Because	ADP	O	O
such	ADJ	O	O
a	DET	O	O
compensatory	NOUN	O	O
mechanism	NOUN	O	O
most	ADV	O	O
likely	ADJ	O	O
occurs	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
injury	NOUN	O	B-Entity
to	ADP	O	I-Entity
the	DET	O	I-Entity
brain	NOUN	O	I-Entity
from	ADP	O	O
cytotoxic	ADJ	O	O
compounds	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
data	NOUN	O	O
substantiate	VERB	O	O
the	DET	O	O
concept	NOUN	O	O
that	ADP	O	O
MRP2	PROPN	O	O
performs	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
BBB	PROPN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
TR(-	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
are	VERB	O	O
an	DET	O	O
interesting	ADJ	O	O
tool	NOUN	O	O
to	PART	O	O
study	VERB	O	O
consequences	NOUN	O	O
of	ADP	O	O
overexpression	NOUN	O	O
of	ADP	O	O
Pgp	PROPN	O	O
in	ADP	O	O
the	DET	O	O
BBB	PROPN	O	O
on	ADP	O	O
access	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
the	DET	O	O
need	NOUN	O	O
of	ADP	O	O
inducing	VERB	O	O
seizures	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
Pgp	PROPN	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
events	NOUN	O	O
for	ADP	O	O
this	DET	O	O
purpose	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17242861)

Use	NOUN	O	O
of	ADP	O	O
chromosome	NOUN	O	O
substitution	NOUN	O	O
strains	NOUN	O	O
to	PART	O	O
identify	VERB	O	O
seizure	NOUN	O	I-Entity
susceptibility	NOUN	O	O
loci	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Seizure	PROPN	O	I-Entity
susceptibility	NOUN	O	O
varies	VERB	O	O
among	ADP	O	O
inbred	ADJ	O	O
mouse	NOUN	O	O
strains	NOUN	O	O
.	PUNCT	O	O

Chromosome	ADJ	O	O
substitution	NOUN	O	O
strains	NOUN	O	O
(	PUNCT	O	O
CSS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADJ	O	O
a	DET	O	O
single	ADJ	O	O
chromosome	NOUN	O	O
from	ADP	O	O
one	NUM	O	O
inbred	ADJ	O	O
strain	NOUN	O	O
(	PUNCT	O	O
donor	NOUN	O	O
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
transferred	VERB	O	O
onto	ADP	O	O
a	DET	O	O
second	ADJ	O	O
strain	NOUN	O	O
(	PUNCT	O	O
host	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
repeated	VERB	O	O
backcrossing	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
identify	VERB	O	O
quantitative	ADJ	O	O
trait	NOUN	O	O
loci	NOUN	O	O
(	PUNCT	O	O
QTLs	PROPN	O	O
)	PUNCT	O	O
that	DET	O	O
contribute	VERB	O	O
to	ADP	O	O
seizure	NOUN	O	I-Entity
susceptibility	NOUN	O	O
.	PUNCT	O	O

QTLs	NOUN	O	O
for	ADP	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
pilocarpine	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
,	PUNCT	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
CSS	PROPN	O	O
have	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
been	VERB	O	O
used	VERB	O	O
to	PART	O	O
localize	VERB	O	O
seizure	NOUN	O	I-Entity
susceptibility	NOUN	O	O
genes	NOUN	O	O
.	PUNCT	O	O

CSS	PROPN	O	O
panel	NOUN	O	O
to	PART	O	O
localize	VERB	O	O
genes	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
pilocarpine	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
/	SYM	O	O
J	PROPN	O	O
were	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
pilocarpine	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

B6	ADP	O	O
mice	NOUN	O	O
were	VERB	O	O
resistant	ADJ	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
slower	ADJ	O	O
to	PART	O	O
reach	VERB	O	O
stages	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
A	DET	O	O
/	SYM	O	O
J	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

CSS	NOUN	O	O
mapping	NOUN	O	O
suggests	VERB	O	O
seizure	NOUN	O	I-Entity
susceptibility	NOUN	O	O
loci	NOUN	O	O
on	ADP	O	O
mouse	NOUN	O	O
Chromosomes	NOUN	O	O
10	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
.	PUNCT	O	O

This	DET	O	O
approach	NOUN	O	O
provides	VERB	O	O
a	DET	O	O
framework	NOUN	O	O
for	ADP	O	O
identifying	VERB	O	O
potentially	ADV	O	O
novel	ADJ	O	O
homologous	ADJ	O	O
candidate	NOUN	O	O
genes	NOUN	O	O
for	ADP	O	O
human	ADJ	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16337777)

Investigation	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	O
involvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

Mitochondrial	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
several	ADJ	O	O
aspects	NOUN	O	O
of	ADP	O	O
epileptogenesis	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
energy	NOUN	O	O
generation	NOUN	O	O
,	PUNCT	O	O
control	NOUN	O	O
of	ADP	O	O
cell	NOUN	O	O
death	NOUN	O	I-Entity
,	PUNCT	O	O
neurotransmitter	ADJ	O	O
synthesis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
free	ADJ	O	O
radical	ADJ	O	O
(	PUNCT	O	O
FR	PROPN	O	O
)	PUNCT	O	O
production	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
increased	VERB	O	O
generation	NOUN	O	O
of	ADP	O	O
FR	NOUN	O	O
during	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
would	VERB	O	O
be	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
provoke	VERB	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
mtDNA	PROPN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
c	NOUN	O	O
oxidase	NOUN	O	O
(	PUNCT	O	O
CCO	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
complex	ADJ	O	O
IV	PROPN	O	O
of	ADP	O	O
the	DET	O	O
respiratory	ADJ	O	O
chain	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
evidences	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
previously	ADV	O	O
published	VERB	O	O
studies	NOUN	O	O
,	PUNCT	O	O
our	ADJ	O	O
results	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
FRs	PROPN	O	O
,	PUNCT	O	O
generated	VERB	O	O
during	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
determined	VERB	O	O
important	ADJ	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
mtDNA	PROPN	O	O
,	PUNCT	O	O
in	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
CCO	PROPN	O	O
-	PUNCT	O	O
I	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
CCO	PROPN	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15859940)

Causes	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
kidney	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Thrombotic	PROPN	O	B-Entity
microangiopathy	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
problem	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
following	VERB	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
postrenal	ADJ	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
is	VERB	O	O
often	ADV	O	O
a	DET	O	O
reflection	NOUN	O	O
of	ADP	O	O
hemolytic	ADJ	O	B-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
causes	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
recipients	NOUN	O	O
and	CCONJ	O	O
discuss	VERB	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
causes	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
during	ADP	O	O
a	DET	O	O
1-year	NUM	O	O
period	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
June	PROPN	O	O
2003	NUM	O	O
to	ADP	O	O
June	PROPN	O	O
2004	NUM	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
King	PROPN	O	O
Fahad	PROPN	O	O
National	PROPN	O	O
Guard	PROPN	O	O
Hospital	PROPN	O	O
in	ADP	O	O
Riyadh	PROPN	O	O
,	PUNCT	O	O
Saudi	PROPN	O	O
Arabia	PROPN	O	O
,	PUNCT	O	O
by	ADP	O	O
reviewing	VERB	O	O
the	DET	O	O
slides	NOUN	O	O
of	ADP	O	O
all	DET	O	O
transplant	NOUN	O	O
biopsies	NOUN	O	O

Five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Three	NUM	O	O
cases	NOUN	O	O
were	VERB	O	O
related	VERB	O	O
to	ADP	O	O
cyclosporine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
case	NOUN	O	O
was	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
both	DET	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
fifth	ADJ	O	O
case	NOUN	O	O
had	VERB	O	O
features	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
an	DET	O	O
antiphospholipid	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	B-Entity
lupus	NOUN	O	I-Entity
erythematosus	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
-	PUNCT	O	O
frequent	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
hemolytic	ADJ	O	B-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
following	VERB	O	O
renal	ADJ	O	O
transplantation	NOUN	O	O
is	VERB	O	O
recurrence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hemolytic	ADJ	O	B-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

cyclosporine	NOUN	O	I-Entity
,	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
)	PUNCT	O	O

toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
procoagulant	ADJ	O	O
status	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
antibody	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
rejection	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
the	DET	O	O
most	ADV	O	O
-	PUNCT	O	O
frequent	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
was	VERB	O	O
drug	NOUN	O	O
related	VERB	O	O
,	PUNCT	O	O
secondary	ADJ	O	O
mainly	ADV	O	O
to	ADP	O	O
cyclosporine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
the	DET	O	O
percentage	NOUN	O	O
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
(	PUNCT	O	O
20%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (15188772)

Severe	ADV	O	O
reversible	ADJ	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
systolic	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
diastolic	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
accidental	ADJ	O	O
iatrogenic	ADJ	O	O
epinephrine	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

Catecholamine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
chronic	ADJ	O	O
excess	NOUN	O	O
of	ADP	O	O
endogenous	ADJ	O	O
catecholamines	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
recognized	VERB	O	O
for	ADP	O	O
decades	NOUN	O	O
as	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
reports	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
acute	ADJ	O	O
iatrogenic	ADJ	O	O
overdose	NOUN	O	I-Entity
are	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
35-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
whose	ADJ	O	O
cervix	NOUN	O	O
uteri	NOUN	O	O
was	VERB	O	O
inadvertently	ADV	O	O
injected	VERB	O	O
with	ADP	O	O
8	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
developed	VERB	O	O
myocardial	ADJ	O	B-Entity
stunning	ADJ	O	I-Entity
that	DET	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
severe	ADJ	O	O
hemodynamic	ADJ	O	O
compromise	NOUN	O	O
,	PUNCT	O	O
profound	ADJ	O	O
,	PUNCT	O	O
albeit	ADP	O	O
transient	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
systolic	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
diastolic	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
only	ADV	O	O
modestly	ADV	O	O
elevated	VERB	O	O
biochemical	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15130900)

Urinary	ADJ	O	B-Entity
bladder	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
:	PUNCT	O	O

risks	NOUN	O	O
and	CCONJ	O	O
relation	NOUN	O	O
to	PART	O	O
cyclophosphamide	VERB	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
assess	VERB	O	O
and	CCONJ	O	O
characterise	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
its	ADJ	O	O
relation	NOUN	O	O
to	ADP	O	O
cyclophosphamide	VERB	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
In	ADP	O	O
the	DET	O	O
population	NOUN	O	O
based	VERB	O	O
,	PUNCT	O	O
nationwide	ADJ	O	O
Swedish	ADJ	O	O
Inpatient	PROPN	O	O
Register	PROPN	O	O
a	DET	O	O
cohort	NOUN	O	O
of	ADP	O	O
1065	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
,	PUNCT	O	O
1969	NUM	O	O
-	SYM	O	O
95	NUM	O	O
,	PUNCT	O	O
was	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

Through	ADP	O	O
linkage	NOUN	O	O
with	ADP	O	O
the	DET	O	O
Swedish	PROPN	O	O
Cancer	PROPN	O	I-Entity
Register	PROPN	O	O
,	PUNCT	O	O
all	DET	O	O
subjects	NOUN	O	O
in	ADP	O	O
this	DET	O	O
cohort	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

Nested	VERB	O	O
within	ADP	O	O
the	DET	O	O
cohort	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
matched	VERB	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
and	CCONJ	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
using	VERB	O	O
odds	NOUN	O	O
ratios	NOUN	O	O
(	PUNCT	O	O
ORs	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
relative	ADJ	O	O
risk	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
cohort	NOUN	O	O
the	DET	O	O
cumulative	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
after	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
relative	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
estimated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
cumulative	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
among	ADP	O	O
cases	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
11	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
25	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
113	NUM	O	O
g	NOUN	O	O
and	CCONJ	O	O
25	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
doubled	VERB	O	O
for	ADP	O	O
every	DET	O	O
10	NUM	O	O
g	NOUN	O	O
increment	NOUN	O	O
in	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
OR	CCONJ	O	O
=	SYM	O	O
2.0	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
(	PUNCT	O	O
CI	PROPN	O	O
)	PUNCT	O	O
0.8	NUM	O	O
to	ADP	O	O
4.9	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
cohort	NOUN	O	O
reached	VERB	O	O
10%	NUM	O	O
16	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
was	VERB	O	O
(	PUNCT	O	O
non	ADV	O	O
-	PUNCT	O	O
significantly	ADV	O	O
)	PUNCT	O	O
twice	ADV	O	O
as	ADV	O	O
common	ADJ	O	O
as	ADP	O	O
expected	VERB	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
relationship	NOUN	O	O
between	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
high	ADJ	O	O
cumulative	ADJ	O	O
risks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
cohort	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
operating	VERB	O	O
even	ADV	O	O
before	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12707296)

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
transport	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
with	ADP	O	O
cortisol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
deficient	ADJ	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
-	PUNCT	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
system	NOUN	O	O
is	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
cortisol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
investigate	VERB	O	O
whether	ADP	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
uptake	NOUN	O	O
contribute	VERB	O	O
to	ADP	O	O
this	DET	O	O
deficiency	NOUN	O	O
.	PUNCT	O	O

Hydrocortisone	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
orally	ADV	O	O
every	DET	O	O
6	NUM	O	O
hours	NOUN	O	O
for	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
a	DET	O	O
5-day	NUM	O	O
fixed	VERB	O	O
-	PUNCT	O	O
salt	NOUN	O	O
diet	NOUN	O	O
(	PUNCT	O	O
150	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
d	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
uptake	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
mononuclear	NOUN	O	O
cells	NOUN	O	O
incubated	VERB	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
to	ADP	O	O
300	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
incorporating	VERB	O	O
100	NUM	O	O
nmol	NOUN	O	O
/	SYM	O	O

L	PROPN	O	O
[	PUNCT	O	B-Entity
3H]-l	NUM	O	I-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
minutes	NOUN	O	O
at	ADP	O	O
37	NUM	O	O
degrees	NOUN	O	O
C.	ADJ	O	O
Forearm	PROPN	O	O
[	PUNCT	O	B-Entity
3H]-L	NUM	O	I-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
extraction	NOUN	O	O
was	VERB	O	O
calculated	VERB	O	O
after	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	B-Entity
3H]-L	NUM	O	I-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
brachial	ADJ	O	O
artery	NOUN	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
nCi	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
for	ADP	O	O
80	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

Deep	ADJ	O	O
forearm	NOUN	O	O
venous	ADJ	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
determination	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
extraction	NOUN	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
cortisol	NOUN	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
raised	VERB	O	O
during	ADP	O	O
the	DET	O	O
active	ADJ	O	O
phase	NOUN	O	O
(	PUNCT	O	O
323+/-43	NOUN	O	O
to	ADP	O	O
1082+/-245	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O

Neither	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
transport	NOUN	O	O
into	ADP	O	O
mononuclear	NOUN	O	O
cells	NOUN	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
vs	ADP	O	O
active	ADJ	O	O
,	PUNCT	O	O
26.3+/-3.6	NUM	O	O
vs	ADP	O	O
29.0+/-2.1	NUM	O	O

pmol/10	NOUN	O	O
000	NUM	O	O
cells	NOUN	O	O
per	ADP	O	O
5	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
at	ADP	O	O
an	DET	O	O
l	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
concentration	NOUN	O	O
of	ADP	O	O
300	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
nor	CCONJ	O	O
L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
extraction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
forearm	NOUN	O	O
(	PUNCT	O	O
at	ADP	O	O
80	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
vs	ADP	O	O
active	ADJ	O	O
,	PUNCT	O	O
1	NUM	O	O
868	NUM	O	O
904+/-434	NUM	O	O
962	NUM	O	O
vs	ADP	O	O
2	NUM	O	O
013	NUM	O	O
910+/-770	NUM	O	O
619	NUM	O	O
disintegrations	NOUN	O	O
per	ADP	O	O
minute	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
cortisol	NOUN	O	I-Entity
treatment	NOUN	O	O
;	PUNCT	O	O

ie	CCONJ	O	O
,	PUNCT	O	O
that	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	ADJ	O	I-Entity
uptake	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
cortisol	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
cortisol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increases	NOUN	O	B-Entity
in	ADP	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
abnormalities	NOUN	O	O
in	ADP	O	O
the	DET	O	O
l	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
transport	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12695819)

MR	NOUN	O	O
imaging	NOUN	O	O
with	ADP	O	O
quantitative	ADJ	O	O
diffusion	NOUN	O	O
mapping	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
organ	NOUN	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
objective	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
brain	NOUN	O	O
MR	NOUN	O	O
imaging	NOUN	O	O
findings	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
utility	NOUN	O	O
of	ADP	O	O
diffusion	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
(	PUNCT	O	O
DW	PROPN	O	O
)	PUNCT	O	O
imaging	NOUN	O	O
in	ADP	O	O
organ	NOUN	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
neurologic	ADJ	O	O
symptoms	NOUN	O	O
during	ADP	O	O
tacrolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Brain	NOUN	O	O
MR	PROPN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
DW	PROPN	O	O
imaging	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
prospectively	ADV	O	O
performed	VERB	O	O
in	ADP	O	O
14	NUM	O	O
organ	ADJ	O	O
transplant	NOUN	O	O
patients	NOUN	O	O
receiving	VERB	O	O
tacrolimus	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
neurologic	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
14	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
(	PUNCT	O	O
35.7%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
white	ADJ	O	B-Entity
matter	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
,	PUNCT	O	O

1	NUM	O	O
(	PUNCT	O	O
7.1%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
putaminal	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
8	NUM	O	O
(	PUNCT	O	O
57.1%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
normal	ADJ	O	O
findings	NOUN	O	O
on	ADP	O	O
initial	ADJ	O	O
MR	PROPN	O	O
images	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
5	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
white	ADJ	O	B-Entity
matter	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
,	PUNCT	O	O
4	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
80.0%	NUM	O	O
)	PUNCT	O	O
showed	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
normal	ADJ	O	O
ADC	PROPN	O	O
values	NOUN	O	O
on	ADP	O	O
initial	ADJ	O	O
MR	PROPN	O	O
images	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
showed	VERB	O	O
complete	ADJ	O	O
resolution	NOUN	O	O
on	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
images	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
remaining	VERB	O	O
1	NUM	O	O
patient	NOUN	O	O
(	PUNCT	O	O
20.0%	NUM	O	O
)	PUNCT	O	O
showed	VERB	O	O
lower	ADJ	O	O
than	ADP	O	O
normal	ADJ	O	O
ADC	PROPN	O	O
value	NOUN	O	O
and	CCONJ	O	O
showed	VERB	O	O
incomplete	ADJ	O	O
resolution	NOUN	O	O
with	ADP	O	O
cortical	ADJ	O	B-Entity
laminar	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Diffusion	NOUN	O	O
-	PUNCT	O	O
weighted	VERB	O	O
imaging	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
predicting	VERB	O	O
the	DET	O	O
outcomes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lesions	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12596116)

Octreotide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypoxemia	NOUN	O	I-Entity
and	CCONJ	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
premature	ADJ	O	O
neonates	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
report	VERB	O	O
2	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
premature	ADJ	O	O
neonates	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
enterocutaneous	ADJ	O	O
fistula	NOUN	O	I-Entity
complicating	VERB	O	O
necrotizing	VERB	O	B-Entity
enterocolitis	NOUN	O	I-Entity
.	PUNCT	O	O

Pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
developed	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
somatostatin	ADJ	O	O
analogue	NOUN	O	O
,	PUNCT	O	O
octreotide	NOUN	O	I-Entity
,	PUNCT	O	O
to	PART	O	O
enhance	VERB	O	O
resolution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
fistula	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11875660)

Sequential	ADJ	O	O
observations	NOUN	O	O
of	ADP	O	O
exencephaly	NOUN	O	I-Entity
and	CCONJ	O	O
subsequent	ADJ	O	O
morphological	ADJ	O	O
changes	NOUN	O	O
by	ADP	O	O
mouse	NOUN	O	O
exo	NOUN	O	O
utero	NOUN	O	O
development	NOUN	O	O
system	NOUN	O	O
:	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
transformation	NOUN	O	O
from	ADP	O	O
exencephaly	NOUN	O	I-Entity
to	ADP	O	O
anencephaly	NOUN	O	I-Entity
.	PUNCT	O	O

Anencephaly	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
to	PART	O	O
develop	VERB	O	O
from	ADP	O	O
exencephaly	NOUN	O	I-Entity
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
little	ADJ	O	O
direct	ADJ	O	O
experimental	ADJ	O	O
evidence	NOUN	O	O
to	PART	O	O
support	VERB	O	O
this	DET	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
transformation	NOUN	O	O
remains	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
the	DET	O	O
exencephaly	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
5-azacytidine	NUM	O	I-Entity
at	ADP	O	O
embryonic	ADJ	O	O
day	NOUN	O	O
13.5	NUM	O	O
(	PUNCT	O	O
E13.5	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
let	VERB	O	O
the	DET	O	O
embryos	NOUN	O	O
develop	VERB	O	O
exo	NOUN	O	O
utero	NOUN	O	O
until	ADP	O	O
E18.5	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
re	ADP	O	O
-	PUNCT	O	O
observed	VERB	O	O
the	DET	O	O
same	ADJ	O	O
embryos	NOUN	O	O
at	ADP	O	O
E18.5	PROPN	O	O
.	PUNCT	O	O

We	PRON	O	O
confirmed	VERB	O	O
several	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
transformation	NOUN	O	O
from	ADP	O	O
exencephaly	NOUN	O	I-Entity
to	ADP	O	O
anencephaly	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
many	ADJ	O	O
cases	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
exencephalic	ADJ	O	I-Entity
brain	NOUN	O	O
tissue	NOUN	O	O
was	VERB	O	O
preserved	VERB	O	O
with	ADP	O	O
more	ADV	O	O
or	CCONJ	O	O
less	ADJ	O	O
reduction	NOUN	O	O
during	ADP	O	O
this	DET	O	O
period	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
analyze	VERB	O	O
the	DET	O	O
transformation	NOUN	O	O
patterns	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
classified	VERB	O	O
the	DET	O	O
exencephaly	NOUN	O	I-Entity
by	ADP	O	O
size	NOUN	O	O
and	CCONJ	O	O
shape	NOUN	O	O
of	ADP	O	O
the	DET	O	O
exencephalic	ADJ	O	I-Entity
tissue	NOUN	O	O
into	ADP	O	O
several	ADJ	O	O
types	NOUN	O	O
at	ADP	O	O
E13.5	PROPN	O	O
and	CCONJ	O	O
E18.5	PROPN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
found	VERB	O	O
that	ADP	O	O
the	DET	O	O
transformation	NOUN	O	O
of	ADP	O	O
exencephalic	ADJ	O	I-Entity
tissue	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
simply	ADV	O	O
size	VERB	O	O
-	PUNCT	O	O
dependent	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
anencephaly	NOUN	O	I-Entity
at	ADP	O	O
E18.5	PROPN	O	O
resulted	VERB	O	O
from	ADP	O	O
embryos	NOUN	O	O
with	ADP	O	O
a	DET	O	O
large	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
exencephalic	ADJ	O	I-Entity
tissue	NOUN	O	O
at	ADP	O	O
E13.5	PROPN	O	O
.	PUNCT	O	O

Microscopic	ADJ	O	O
observation	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
configuration	NOUN	O	O
of	ADP	O	O
exencephaly	NOUN	O	I-Entity
at	ADP	O	O
E13.5	PROPN	O	O
,	PUNCT	O	O
frequent	ADJ	O	O
hemorrhaging	NOUN	O	I-Entity
and	CCONJ	O	O
detachment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neural	ADJ	O	O
plate	NOUN	O	O
from	ADP	O	O
surface	NOUN	O	O
ectoderm	NOUN	O	O
in	ADP	O	O
the	DET	O	O
exencephalic	ADJ	O	I-Entity
head	NOUN	O	O
at	ADP	O	O
E15.5	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
multiple	ADJ	O	O
modes	NOUN	O	O
of	ADP	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
exencephalic	ADJ	O	I-Entity
tissue	NOUN	O	O
at	ADP	O	O
E18.5	PROPN	O	O
.	PUNCT	O	O

From	ADP	O	O
observations	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vasculature	NOUN	O	O
,	PUNCT	O	O
altered	VERB	O	O
distribution	NOUN	O	O
patterns	NOUN	O	O
of	ADP	O	O
vessels	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
the	DET	O	O
exencephalic	ADJ	O	I-Entity
head	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
overgrowth	NOUN	O	O
of	ADP	O	O
the	DET	O	O
exencephalic	ADJ	O	I-Entity
neural	ADJ	O	O
tissue	NOUN	O	O
causes	VERB	O	O
the	DET	O	O
altered	ADJ	O	O
distribution	NOUN	O	O
patterns	NOUN	O	O
of	ADP	O	O
vessels	NOUN	O	O
,	PUNCT	O	O
subsequent	ADJ	O	O
peripheral	ADJ	O	O
circulatory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and/or	CCONJ	O	O
hemorrhaging	VERB	O	I-Entity
in	ADP	O	O
various	ADJ	O	O
parts	NOUN	O	O
of	ADP	O	O
the	DET	O	O
exencephalic	ADJ	O	I-Entity
head	NOUN	O	O
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
the	DET	O	O
multiple	ADJ	O	O
modes	NOUN	O	O
of	ADP	O	O
tissue	NOUN	O	O
reduction	NOUN	O	O
during	ADP	O	O
transformation	NOUN	O	O
from	ADP	O	O
exencephaly	NOUN	O	I-Entity
to	ADP	O	O
anencephaly	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11166519)

Acute	PROPN	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
:	PUNCT	O	O
differential	NOUN	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
inbred	ADJ	O	O
mouse	NOUN	O	O
strains	NOUN	O	O
.	PUNCT	O	O

Mature	ADJ	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
mice	NOUN	O	O
from	ADP	O	O
six	NUM	O	O
inbred	ADJ	O	O
stains	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
behavioral	ADJ	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
was	VERB	O	O
injected	VERB	O	O
ip	ADV	O	O
over	ADP	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
doses	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
-	SYM	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
behavior	NOUN	O	O
was	VERB	O	O
monitored	VERB	O	O
for	ADP	O	O
20	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

Seizure	ADJ	O	I-Entity
end	NOUN	O	O
points	NOUN	O	O
included	VERB	O	O
latency	NOUN	O	O
to	ADP	O	O
forelimb	NOUN	O	O
or	CCONJ	O	O
hindlimb	NOUN	O	O
clonus	NOUN	O	O
,	PUNCT	O	O
latency	NOUN	O	O
to	ADP	O	O
clonic	VERB	O	O
running	VERB	O	O
seizure	NOUN	O	I-Entity
and	CCONJ	O	O
latency	NOUN	O	O
to	ADP	O	O
jumping	VERB	O	O
bouncing	VERB	O	O
seizure	NOUN	O	I-Entity
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
determined	VERB	O	O
in	ADP	O	O
hippocampus	NOUN	O	O
and	CCONJ	O	O
cortex	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
sensitive	ADJ	O	O
and	CCONJ	O	O
resistant	ADJ	O	O
strains	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
these	DET	O	O
murine	ADJ	O	O
strains	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
investigating	VERB	O	O
genetic	ADJ	O	O
influences	NOUN	O	O
on	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8701950)

Microangiopathic	ADJ	O	B-Entity
hemolytic	ADJ	O	I-Entity
anemia	NOUN	O	I-Entity
complicating	VERB	O	O
FK506	PROPN	O	I-Entity
(	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
3	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
microangiopathic	ADJ	O	B-Entity
hemolytic	ADJ	O	I-Entity
anemia	NOUN	O	I-Entity
(	PUNCT	O	O
MAHA	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
2	NUM	O	O
solid	ADJ	O	O
organ	ADJ	O	O
recipients	NOUN	O	O
under	ADP	O	O
FK506	PROPN	O	I-Entity
(	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
cases	NOUN	O	O
,	PUNCT	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
FK506	PROPN	O	I-Entity
and	CCONJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
plasma	NOUN	O	O
exchange	NOUN	O	O
,	PUNCT	O	O
fresh	ADJ	O	O
frozen	ADJ	O	O
plasma	NOUN	O	O
replacement	NOUN	O	O
,	PUNCT	O	O
corticosteroids	NOUN	O	I-Entity
,	PUNCT	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dipyridamole	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
resolution	NOUN	O	O
of	ADP	O	O
MAHA	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
,	PUNCT	O	O
reintroduction	NOUN	O	O
of	ADP	O	O
FK506	PROPN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
rapid	ADJ	O	O
recurrence	NOUN	O	O
of	ADP	O	O
MAHA	PROPN	O	I-Entity
.	PUNCT	O	O

FK506-associated	VERB	O	I-Entity
MAHA	PROPN	O	I-Entity
is	VERB	O	O
probably	ADV	O	O
rare	ADJ	O	O
but	CCONJ	O	O
physicians	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
severe	ADJ	O	O
complication	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
experience	NOUN	O	O
and	CCONJ	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
FK506	PROPN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
seem	VERB	O	O
to	PART	O	O
cross	VERB	O	O
-	PUNCT	O	O
react	VERB	O	O
with	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	PROPN	O	I-Entity
(	PUNCT	O	O
CyA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
immuno	NOUN	O	O
-	PUNCT	O	O
suppressive	ADJ	O	O
drug	NOUN	O	O
already	ADV	O	O
known	VERB	O	O
to	PART	O	O
induce	VERB	O	O
MAHA	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7292072)

Variant	NOUN	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
in	ADP	O	O
desipramine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
variant	NOUN	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
desipramine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Unusual	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
are	VERB	O	O
repetitive	ADJ	O	O
group	NOUN	O	O
beating	NOUN	O	O
,	PUNCT	O	O
progressive	ADJ	O	O
shortening	NOUN	O	O
of	ADP	O	O
the	DET	O	O
R	NOUN	O	O
-	PUNCT	O	O
R	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
progressive	ADJ	O	O
widening	NOUN	O	O
of	ADP	O	O
the	DET	O	O
QRS	PROPN	O	O
complex	ADJ	O	O
with	ADP	O	O
eventual	ADJ	O	O
failure	NOUN	O	O
of	ADP	O	O
intraventricular	ADJ	O	O
conduction	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
direction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
QRS	PROPN	O	O
axis	NOUN	O	O
.	PUNCT	O	O

Recognition	PROPN	O	O
of	ADP	O	O
variant	NOUN	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
is	VERB	O	O
important	ADJ	O	O
because	ADP	O	O
therapy	NOUN	O	O
differs	VERB	O	O
from	ADP	O	O
that	DET	O	O
of	ADP	O	O
classic	ADJ	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (4027862)

Desipramine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
delirium	NOUN	O	I-Entity
at	ADP	O	O
"	PUNCT	O	O
subtherapeutic	ADJ	O	O
"	PUNCT	O	O
concentrations	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
elderly	ADJ	O	O
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
low	ADJ	O	O
dose	NOUN	O	O
Desipramine	NOUN	O	I-Entity
developed	VERB	O	O
a	DET	O	O
delirium	NOUN	O	I-Entity
while	ADP	O	O
her	ADJ	O	O
plasma	NOUN	O	O
level	NOUN	O	O
was	VERB	O	O
in	ADP	O	O
the	DET	O	O
"	PUNCT	O	O
subtherapeutic	ADJ	O	O
"	PUNCT	O	O
range	NOUN	O	O
.	PUNCT	O	O

Delirium	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
tricyclic	ADJ	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
,	PUNCT	O	O
can	VERB	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
tricyclics	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
anticholinergic	ADJ	O	O
potency	NOUN	O	O
.	PUNCT	O	O

Therapeutic	ADJ	O	O
ranges	NOUN	O	O
for	ADP	O	O
antidepressants	NOUN	O	I-Entity
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
derived	VERB	O	O
from	ADP	O	O
general	ADJ	O	O
adult	NOUN	O	O
population	NOUN	O	O
studies	NOUN	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
appropriate	ADJ	O	O
for	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (2484011)

Mouse	PROPN	O	O
strain	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
on	ADP	O	O
motility	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
biogenic	ADJ	O	O
amines	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
injected	VERB	O	O
i.p	PRON	O	O
.	PUNCT	O	O

in	ADP	O	O
6	NUM	O	O
increments	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
each	DET	O	O
over	ADP	O	O
30	NUM	O	O
hr	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
mouse	NOUN	O	O
motility	NOUN	O	O
and	CCONJ	O	O
whole	ADJ	O	O
brain	NOUN	O	O
content	NOUN	O	O
of	ADP	O	O
selected	VERB	O	O
biogenic	ADJ	O	O
amines	NOUN	O	I-Entity
and	CCONJ	O	O
major	ADJ	O	O
metabolites	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
4	NUM	O	O
strains	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Amantadine	ADJ	O	I-Entity
treatment	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
biphasic	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
mouse	NOUN	O	O
motility	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
initial	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
depressed	ADJ	O	I-Entity
locomotor	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
all	DET	O	O
mouse	NOUN	O	O
strains	NOUN	O	O
studied	VERB	O	O
with	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
being	VERB	O	O
the	DET	O	O
most	ADV	O	O
sensitive	ADJ	O	O
.	PUNCT	O	O

Subsequent	ADJ	O	O
amantadine	NOUN	O	I-Entity
treatments	NOUN	O	O
produced	VERB	O	O
enhancement	NOUN	O	O
of	ADP	O	O
motility	NOUN	O	O
from	ADP	O	O
corresponding	VERB	O	O
control	NOUN	O	O
in	ADP	O	O
all	DET	O	O
mouse	NOUN	O	O
strains	NOUN	O	O
with	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
being	VERB	O	O
the	DET	O	O
least	ADJ	O	O
sensitive	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
from	ADP	O	O
corresponding	VERB	O	O
controls	NOUN	O	O
in	ADP	O	O
all	DET	O	O
strains	NOUN	O	O
studied	VERB	O	O
,	PUNCT	O	O
except	ADP	O	O
for	ADP	O	O
the	DET	O	O
ICR	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
an	DET	O	O
overnight	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
period	NOUN	O	O
following	VERB	O	O
the	DET	O	O
fourth	ADJ	O	O
amantadine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Readministration	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
,	PUNCT	O	O
after	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
overnight	ADJ	O	O
period	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
motility	NOUN	O	O
from	ADP	O	O
respective	ADJ	O	O
saline	ADJ	O	O
control	NOUN	O	O
in	ADP	O	O
all	DET	O	O
strains	NOUN	O	O
with	ADP	O	O
exception	NOUN	O	O
of	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
where	ADV	O	O
suppression	NOUN	O	B-Entity
of	ADP	O	I-Entity
motility	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
amantadine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
whole	ADJ	O	O
brain	NOUN	O	O
dopamine	NOUN	O	I-Entity
levels	NOUN	O	O
but	CCONJ	O	O
decreased	VERB	O	O
the	DET	O	O
amounts	NOUN	O	O
of	ADP	O	O
3,4-dihydroxyphenylacetic	NUM	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
saline	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

Conversely	ADV	O	O
,	PUNCT	O	O
brain	NOUN	O	O
normetanephrine	ADJ	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
saline	ADJ	O	O
control	NOUN	O	O
by	ADP	O	O
amantadine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
strain	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
on	ADP	O	O
motility	NOUN	O	O
and	CCONJ	O	O
indicate	VERB	O	O
a	DET	O	O
differential	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
and	CCONJ	O	O
multiple	ADJ	O	O
dose	NOUN	O	O
regimens	NOUN	O	O
used	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mouse	NOUN	O	O
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
sensitive	ADJ	O	O
strain	NOUN	O	O
and	CCONJ	O	O
could	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
the	DET	O	O
strain	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
for	ADP	O	O
evaluating	VERB	O	O
the	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
amantadine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
biochemical	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
biogenic	ADJ	O	O
amines	NOUN	O	I-Entity
of	ADP	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mouse	NOUN	O	O
strain	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
probable	ADJ	O	O
decrease	NOUN	O	O
of	ADP	O	O
catecholamine	NOUN	O	I-Entity
turnover	NOUN	O	O
rate	NOUN	O	O
and/or	CCONJ	O	O
metabolism	NOUN	O	O
by	ADP	O	O
monoamine	NOUN	O	O
oxidase	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
resulting	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
O	PROPN	O	O
-	PUNCT	O	O
methylation	NOUN	O	O
of	ADP	O	O
norepinephrine	NOUN	O	I-Entity
which	ADJ	O	O
may	VERB	O	O
account	VERB	O	O
for	ADP	O	O
a	DET	O	O
behavioral	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
amantadine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
BALB	PROPN	O	O
/	SYM	O	O
C	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2396046)

No	DET	O	O
enhancement	NOUN	O	O
by	ADP	O	O
phenobarbital	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
hepatocarcinogenicity	NOUN	O	O
of	ADP	O	O
a	DET	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
diet	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
experiment	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
test	VERB	O	O
whether	ADP	O	O
inclusion	NOUN	O	O
of	ADP	O	O
phenobarbital	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
diet	NOUN	O	O
would	VERB	O	O
increase	VERB	O	O
the	DET	O	O
hepatocarcinogenicity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diet	NOUN	O	O
.	PUNCT	O	O

semipurified	VERB	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
or	CCONJ	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
supplemented	VERB	O	O
diets	NOUN	O	O
,	PUNCT	O	O
containing	VERB	O	O
or	CCONJ	O	O
not	ADV	O	O
0.06%	NUM	O	O
phenobarbital	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
hepatic	ADJ	O	O
preneoplastic	NOUN	O	O
nodules	NOUN	O	O
or	CCONJ	O	O
hepatocellular	ADJ	O	B-Entity
carcinomas	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
fed	VERB	O	O
the	DET	O	O
plain	ADJ	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
supplemented	VERB	O	O
diet	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
one	NUM	O	O
preneoplastic	NOUN	O	O
nodule	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
two	NUM	O	O
rats	NOUN	O	O
fed	VERB	O	O
the	DET	O	O
same	ADJ	O	O
diet	NOUN	O	O
containing	VERB	O	O
phenobarbital	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
preneoplastic	ADJ	O	O
nodules	NOUN	O	O
and	CCONJ	O	O
of	ADP	O	O
hepatocellular	ADJ	O	B-Entity
carcinomas	NOUN	O	I-Entity
was	VERB	O	O
10%	NUM	O	O
and	CCONJ	O	O
37%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
fed	VERB	O	O
the	DET	O	O
plain	ADJ	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
diet	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
17%	NUM	O	O
and	CCONJ	O	O
30%	NUM	O	O
,	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
fed	VERB	O	O
the	DET	O	O
phenobarbital	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
diet	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
evinced	VERB	O	O
no	DET	O	O
enhancement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hepatocarcinogenicity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
choline	NOUN	O	I-Entity
-	PUNCT	O	O
devoid	ADJ	O	O
diet	NOUN	O	O
by	ADP	O	O
phenobarbital	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2008831)

Effect	NOUN	O	O
of	ADP	O	O
direct	ADJ	O	O
intracoronary	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
methylergonovine	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
intracoronary	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
methylergonovine	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
21	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
and	CCONJ	O	O
22	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
atypical	ADJ	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
others	NOUN	O	O
without	ADP	O	O
angina	NOUN	O	B-Entity
pectoris	NOUN	O	I-Entity
(	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Methylergonovine	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
continuously	ADV	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
min	VERB	O	O
up	PART	O	O
to	PART	O	O
50	NUM	O	O
micrograms	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
,	PUNCT	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
was	VERB	O	O
provoked	VERB	O	O
at	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
28	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
neither	CCONJ	O	O
ischemic	ADJ	O	O
ST	NOUN	O	O
change	NOUN	O	O
nor	CCONJ	O	O
localized	ADJ	O	O
spasm	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
spasm	NOUN	O	I-Entity
provocation	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
use	VERB	O	O
an	DET	O	O
intracoronary	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
a	DET	O	O
relatively	ADV	O	O
low	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
methylergonovine	NOUN	O	I-Entity
,	PUNCT	O	O
have	VERB	O	O
a	DET	O	O
high	ADJ	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
vasoreactivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
right	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
greater	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
coronary	ADJ	O	O
arteries	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1732369)

Dobutamine	PROPN	O	I-Entity
stress	NOUN	O	O
echocardiography	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
sensitive	ADJ	O	O
indicator	NOUN	O	O
of	ADP	O	O
diminished	VERB	O	O
myocardial	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
asymptomatic	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
survivors	NOUN	O	O
of	ADP	O	O
childhood	NOUN	O	O
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Doxorubicin	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
anticancer	NOUN	O	O
chemotherapeutic	ADJ	O	O
agent	NOUN	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
develop	VERB	O	O
a	DET	O	O
more	ADV	O	O
sensitive	ADJ	O	O
echocardiographic	ADJ	O	O
screening	NOUN	O	O
test	NOUN	O	O
for	ADP	O	O
cardiac	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
doxorubicin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
cohort	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
dobutamine	NOUN	O	I-Entity
infusion	NOUN	O	O
to	PART	O	O
differentiate	VERB	O	O
asymptomatic	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
survivors	NOUN	O	O
of	ADP	O	O
childhood	NOUN	O	O
cancer	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
doxorubicin	NOUN	O	I-Entity
from	ADP	O	O
healthy	ADJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
treated	VERB	O	O
from	ADP	O	O
1.6	NUM	O	O
to	ADP	O	O
14.3	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
5.3	NUM	O	O
)	PUNCT	O	O
before	ADP	O	O
this	DET	O	O
study	NOUN	O	O
with	ADP	O	O
27	NUM	O	O
to	PART	O	O
532	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
196	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
echocardiographic	ADJ	O	O
data	NOUN	O	O
from	ADP	O	O
12	NUM	O	O
normal	ADJ	O	O
age	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
control	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Graded	VERB	O	O
dobutamine	NOUN	O	I-Entity
infusions	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
,	PUNCT	O	O
2.5	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	ADP	O	O
per	ADP	O	O
min	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Dobutamine	ADJ	O	I-Entity
infusion	NOUN	O	O
at	ADP	O	O
10	NUM	O	O
micrograms	NOUN	O	O

The	DET	O	O
most	ADV	O	O
important	ADJ	O	O
findings	NOUN	O	O
were	VERB	O	O
that	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
values	NOUN	O	O
in	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
end	VERB	O	O
-	PUNCT	O	O
systolic	NOUN	O	O
left	VERB	O	O
ventricular	ADJ	O	O
posterior	ADJ	O	O
wall	NOUN	O	O
dimension	NOUN	O	O
and	CCONJ	O	O
percent	NOUN	O	O
of	ADP	O	O
left	VERB	O	O
ventricular	ADJ	O	O
posterior	ADJ	O	O
wall	NOUN	O	O
thickening	VERB	O	O
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
were	VERB	O	O
decreased	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
study	NOUN	O	O
and	CCONJ	O	O
these	DET	O	O
findings	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
clearly	ADV	O	O
delineated	VERB	O	O
with	ADP	O	O
dobutamine	NOUN	O	I-Entity
stimulation	NOUN	O	O
.	PUNCT	O	O

End	NOUN	O	O
-	PUNCT	O	O
systolic	NOUN	O	O
left	VERB	O	O
ventricular	ADJ	O	O
posterior	ADJ	O	O
wall	NOUN	O	O
dimension	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
for	ADP	O	O
the	DET	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
was	VERB	O	O
11	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

End	NOUN	O	O
-	PUNCT	O	O
systolic	NOUN	O	O
left	VERB	O	O
ventricular	ADJ	O	O
posterior	ADJ	O	O
wall	NOUN	O	O
dimension	NOUN	O	O
at	ADP	O	O
the	DET	O	O
5-micrograms	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
min	NOUN	O	O
dobutamine	NOUN	O	I-Entity
infusion	NOUN	O	O
for	ADP	O	O
the	DET	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
was	VERB	O	O
14.1	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O


-DOCSTART- (234669)

Effects	NOUN	O	O
of	ADP	O	O
aminophylline	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
initiating	VERB	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
during	ADP	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiac	PROPN	O	B-Entity
arrhythmias	NOUN	O	I-Entity
have	VERB	O	O
frequently	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
additive	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
pharmacologic	ADJ	O	O
agents	NOUN	O	O
in	ADP	O	O
precipitating	VERB	O	O
cardiac	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
has	VERB	O	O
only	ADV	O	O
recently	ADV	O	O
been	VERB	O	O
emphasized	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
aminophylline	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
threshold	NOUN	O	O
during	ADP	O	O
normal	ADJ	O	O
acid	NOUN	O	O
-	PUNCT	O	O
base	NOUN	O	O
conditions	NOUN	O	O
and	CCONJ	O	O
during	ADP	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
anesthetized	VERB	O	O
open	ADJ	O	O
chest	NOUN	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
threshold	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
passing	VERB	O	O
a	DET	O	O
gated	ADJ	O	O
train	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
constant	ADJ	O	O
current	ADJ	O	O
pulses	NOUN	O	O
through	ADP	O	O
the	DET	O	O
ventricular	ADJ	O	O
myocardium	NOUN	O	O
during	ADP	O	O
the	DET	O	O
vulnerable	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardiac	ADJ	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
aminophylline	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
threshold	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
30	NUM	O	O
to	PART	O	O
40	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
when	ADV	O	O
pH	NOUN	O	O
and	CCONJ	O	O
partial	ADJ	O	O
pressures	NOUN	O	O
of	ADP	O	O
oxygen	NOUN	O	I-Entity
(	PUNCT	O	O
PO2	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
carbon	NOUN	O	B-Entity
dioxide	NOUN	O	I-Entity
(	PUNCT	O	O
CO2	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
kept	VERB	O	O
within	ADP	O	O
normal	ADJ	O	O
limits	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
hypoventilation	NOUN	O	I-Entity
(	PUNCT	O	O
pH	PROPN	O	O
7.05	NUM	O	O
to	ADP	O	O
7.25	NUM	O	O
;	PUNCT	O	O
PC02	PROPN	O	O
70	NUM	O	O
to	ADP	O	O
100	NUM	O	O
mm	PROPN	O	O

P02	PROPN	O	O
20	NUM	O	O
to	PART	O	O
40	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
infusion	NOUN	O	O
of	ADP	O	O
aminophylline	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
even	ADV	O	O
greater	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
threshold	NOUN	O	O
to	ADP	O	O
60	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
experiments	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
although	ADP	O	O
many	ADJ	O	O
factors	NOUN	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
in	ADP	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
pharmacologic	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
aminophylline	ADV	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
role	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16740173)

Case	NOUN	O	O
report	NOUN	O	O
:	PUNCT	O	O
acute	ADJ	O	O
unintentional	ADJ	O	O
carbachol	NOUN	O	I-Entity
intoxication	NOUN	O	O
.	PUNCT	O	O

INTRODUCTION	NOUN	O	O
:	PUNCT	O	O
Intoxications	NOUN	O	O
with	ADP	O	O
carbachol	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
muscarinic	ADJ	O	O
cholinergic	ADJ	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
are	VERB	O	O
rare	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
an	DET	O	O
interesting	ADJ	O	O
case	NOUN	O	O
investigating	VERB	O	O
a	DET	O	O
(	PUNCT	O	O
near	ADP	O	O
)	PUNCT	O	O
fatal	ADJ	O	O
poisoning	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
son	NOUN	O	O
of	ADP	O	O
an	DET	O	O
84-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
discovered	VERB	O	O
a	DET	O	O
newspaper	NOUN	O	O
report	NOUN	O	O
stating	VERB	O	O
clinical	ADJ	O	O
success	NOUN	O	O
with	ADP	O	O
plant	NOUN	O	O
extracts	NOUN	O	O
in	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mode	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
was	VERB	O	O
said	VERB	O	O
to	PART	O	O
be	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
synthetic	ADJ	O	O
compound	NOUN	O	O
'	PUNCT	O	O
carbamylcholin	NOUN	O	I-Entity
'	PUNCT	O	O
;	PUNCT	O	O
that	DET	O	O
is	VERB	O	O
,	PUNCT	O	O
carbachol	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
bought	VERB	O	O
25	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
carbachol	NOUN	O	I-Entity
as	ADP	O	O
pure	ADJ	O	O
substance	NOUN	O	O
in	ADP	O	O
a	DET	O	O
pharmacy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
father	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
400	NUM	O	O
to	ADP	O	O
500	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Carbachol	PROPN	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Minutes	NOUN	O	O
after	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
sweating	VERB	O	O
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
finally	ADV	O	O
collapsed	VERB	O	O
.	PUNCT	O	O

Bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
cholinergic	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
asystole	NOUN	O	I-Entity
occurred	VERB	O	O
.	PUNCT	O	O

Initial	ADJ	O	O
cardiopulmonary	ADJ	O	O
resuscitation	NOUN	O	O
and	CCONJ	O	O
immediate	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
adrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
epinephrine	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
atropine	NOUN	O	I-Entity
and	CCONJ	O	O
furosemide	NOUN	O	I-Entity
was	VERB	O	O
successful	ADJ	O	O
.	PUNCT	O	O

Further	ADJ	O	O
signs	NOUN	O	O
were	VERB	O	O
hyperhidrosis	NOUN	O	I-Entity
,	PUNCT	O	O
hypersalivation	NOUN	O	I-Entity
,	PUNCT	O	O
bronchorrhoea	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
severe	ADJ	O	O
miosis	NOUN	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
electrocardiographic	ADJ	O	O
finding	NOUN	O	O
was	VERB	O	O
atrio	ADV	O	B-Entity
-	PUNCT	O	I-Entity
ventricular	ADJ	O	I-Entity
dissociation	NOUN	O	I-Entity
.	PUNCT	O	O

High	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
atropine	NOUN	O	I-Entity
(	PUNCT	O	O
up	ADP	O	O
to	PART	O	O
50	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
adrenaline	NOUN	O	I-Entity
and	CCONJ	O	O
dopamine	NOUN	O	I-Entity
were	VERB	O	O
necessary	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
increased	VERB	O	O
dyspnoea	NOUN	O	I-Entity
and	CCONJ	O	O
bronchospasm	NOUN	O	I-Entity
necessitated	VERB	O	O
reintubation	NOUN	O	O
.	PUNCT	O	O

Respiratory	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
was	VERB	O	O
further	ADV	O	O
worsened	VERB	O	O
by	ADP	O	O
Proteus	PROPN	O	B-Entity
mirabilis	ADJ	O	I-Entity
infection	NOUN	O	I-Entity
and	CCONJ	O	O
severe	ADJ	O	O
bronchoconstriction	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
next	ADJ	O	O
day	NOUN	O	O
he	PRON	O	O
died	VERB	O	O
,	PUNCT	O	O
probably	ADV	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Serum	PROPN	O	O
samples	NOUN	O	O
from	ADP	O	O
the	DET	O	O
first	ADJ	O	O
and	CCONJ	O	O
second	ADJ	O	O
days	NOUN	O	O
contained	VERB	O	O
3.6	NUM	O	O
and	CCONJ	O	O
1.9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
l	NOUN	O	O
carbachol	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
analytical	ADJ	O	O
method	NOUN	O	O
for	ADP	O	O
the	DET	O	O
determination	NOUN	O	O
of	ADP	O	O
carbachol	NOUN	O	I-Entity
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
developed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
analysed	ADJ	O	O
carbachol	NOUN	O	I-Entity
concentration	NOUN	O	O
exceeded	VERB	O	O
the	DET	O	O
supposed	VERB	O	O
serum	NOUN	O	O
level	NOUN	O	O
resulting	VERB	O	O
from	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
dose	NOUN	O	O
by	ADP	O	O
a	DET	O	O
factor	NOUN	O	O
of	ADP	O	O
130	NUM	O	O
to	ADP	O	O
260	NUM	O	O
.	PUNCT	O	O

Especially	ADV	O	O
in	ADP	O	O
old	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
intensivists	NOUN	O	O
should	VERB	O	O
consider	VERB	O	O
intoxications	NOUN	O	O
(	PUNCT	O	O
with	ADP	O	O
cholinergics	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
cardiovascular	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12464714)

Crossover	PROPN	O	O
comparison	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
preference	NOUN	O	O
for	ADP	O	O
rizatriptan	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
versus	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
migraine	NOUN	O	I-Entity
.	PUNCT	O	O

Rizatriptan	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
5-HT(1B/1D	NOUN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
with	ADP	O	O
rapid	ADJ	O	O
oral	ADJ	O	O
absorption	NOUN	O	O
and	CCONJ	O	O
early	ADJ	O	O
onset	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
randomized	ADJ	O	O
double-	ADJ	O	O
blind	ADJ	O	O
crossover	ADJ	O	O
outpatient	NOUN	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
preference	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
rizatriptan	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
tablet	NOUN	O	O
to	ADP	O	O
2	NUM	O	O
ergotamine	NOUN	O	I-Entity
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
caffeine	NOUN	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
tablets	NOUN	O	O
in	ADP	O	O
439	NUM	O	O
patients	NOUN	O	O
treating	VERB	O	O
a	DET	O	O
single	ADJ	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
with	ADP	O	O
each	DET	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
patients	NOUN	O	O
expressing	VERB	O	O
a	DET	O	O
preference	NOUN	O	O
(	PUNCT	O	O
89.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
more	ADJ	O	O
than	ADP	O	O
twice	ADV	O	O
as	ADV	O	O
many	ADJ	O	O
preferred	VERB	O	O
rizatriptan	NOUN	O	I-Entity
to	ADP	O	O
ergotamine	VERB	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
69.9	NUM	O	O
vs.	X	O	O
30.1%	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Faster	ADJ	O	O
relief	NOUN	O	O
of	ADP	O	O
headache	NOUN	O	I-Entity
was	VERB	O	O
the	DET	O	O
most	ADV	O	O
important	ADJ	O	O
reason	NOUN	O	O
for	ADP	O	O
preference	NOUN	O	O
,	PUNCT	O	O
cited	VERB	O	O
by	ADP	O	O
67.3%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
preferring	VERB	O	O
rizatriptan	NOUN	O	I-Entity
and	CCONJ	O	O
54.2%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
preferred	VERB	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
co	NOUN	O	O
-	PUNCT	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
of	ADP	O	O
being	VERB	O	O
pain	NOUN	O	I-Entity
free	ADJ	O	O
at	ADP	O	O
2	NUM	O	O
h	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
in	ADP	O	O
favor	NOUN	O	O
of	ADP	O	O
rizatriptan	NOUN	O	I-Entity
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
pain	NOUN	O	I-Entity
free	ADJ	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
rizatriptan	NOUN	O	I-Entity
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
24.3%	NUM	O	O
treated	VERB	O	O
with	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rizatriptan	VERB	O	I-Entity
being	VERB	O	O
superior	ADJ	O	O
within	ADP	O	O
1	NUM	O	O
h	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Headache	NOUN	O	I-Entity
relief	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
h	NOUN	O	O
was	VERB	O	O
75.9%	NUM	O	O
for	ADP	O	O
rizatriptan	NOUN	O	I-Entity
and	CCONJ	O	O
47.3%	NUM	O	O
for	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O

p	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
rizatriptan	NOUN	O	I-Entity
being	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
ergotamine	VERB	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
within	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
dosing	VERB	O	O
.	PUNCT	O	O

Almost	ADV	O	O
36%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
rizatriptan	NOUN	O	I-Entity
were	VERB	O	O
pain	NOUN	O	I-Entity
free	ADJ	O	O
at	ADP	O	O
2	NUM	O	O
h	PROPN	O	O
and	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
recurrence	NOUN	O	O
or	CCONJ	O	O
need	NOUN	O	O
for	ADP	O	O
additional	ADJ	O	O
medication	NOUN	O	O
within	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
20%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	PUNCT	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Rizatriptan	PROPN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
ergotamine	VERB	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
proportions	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
vomiting	VERB	O	I-Entity
,	PUNCT	O	O
phonophobia	NOUN	O	I-Entity
or	CCONJ	O	O
photophobia	NOUN	O	I-Entity
and	CCONJ	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
function	NOUN	O	O
2	NUM	O	O
h	X	O	O
after	ADP	O	O
drug	NOUN	O	O
intake	NOUN	O	O
(	PUNCT	O	O

More	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
(	PUNCT	O	O
completely	ADV	O	O
,	PUNCT	O	O
very	ADV	O	O
or	CCONJ	O	O
somewhat	ADV	O	O
)	PUNCT	O	O
satisfied	ADJ	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
rizatriptan	NOUN	O	I-Entity
(	PUNCT	O	O
69.8%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
at	ADP	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
38.6%	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Recurrence	NOUN	O	O
rates	NOUN	O	O
were	VERB	O	O
31.4%	NUM	O	O
with	ADP	O	O
rizatriptan	NOUN	O	I-Entity
and	CCONJ	O	O
15.3%	NUM	O	O
with	ADP	O	O
ergotamine	NOUN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
(	PUNCT	O	O
incidence	NOUN	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
5%	NUM	O	O
in	ADP	O	O
one	NUM	O	O
group	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
rizatriptan	NOUN	O	I-Entity
and	CCONJ	O	O
ergotamine	VERB	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
dizziness	NOUN	O	I-Entity
(	PUNCT	O	O
6.7	NUM	O	O
and	CCONJ	O	O
5.3%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
4.2	NUM	O	O
and	CCONJ	O	O
8.5%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
somnolence	NOUN	O	I-Entity
(	PUNCT	O	O
5.5	NUM	O	O
and	CCONJ	O	O
2.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (6203452)

Thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
antineoplastic	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
carcinoma	NOUN	O	I-Entity
developed	VERB	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
(	PUNCT	O	O
characterized	VERB	O	O
by	ADP	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
,	PUNCT	O	O
microangiopathic	ADJ	O	B-Entity
hemolytic	ADJ	O	I-Entity
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
usually	ADV	O	O
thrombocytopenia	VERB	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
bleomycin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
vinca	NOUN	O	B-Entity
alkaloid	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
had	VERB	O	O
thrombotic	ADJ	O	B-Entity
thrombocytopenic	ADJ	O	I-Entity
purpura	NOUN	O	I-Entity
,	PUNCT	O	O
three	NUM	O	O
the	DET	O	O
hemolytic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
an	DET	O	O
apparent	ADJ	O	O
forme	NOUN	O	O
fruste	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
of	ADP	O	O
these	DET	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Histologic	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
tissue	NOUN	O	O
showed	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
intravascular	ADJ	O	B-Entity
coagulation	NOUN	O	I-Entity
,	PUNCT	O	O
primarily	ADV	O	O
affecting	VERB	O	O
the	DET	O	O
small	ADJ	O	O
arteries	NOUN	O	O
,	PUNCT	O	O
arterioles	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
glomeruli	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
tumor	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
or	CCONJ	O	O
had	VERB	O	O
only	ADV	O	O
a	DET	O	O
small	ADJ	O	O
tumor	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
thrombotic	ADJ	O	B-Entity
microangiopathy	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Diagnosis	NOUN	O	O
of	ADP	O	O
this	DET	O	O
potentially	ADV	O	O
fatal	ADJ	O	O
complication	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
delayed	VERB	O	O
or	CCONJ	O	O
missed	VERB	O	O
if	ADP	O	O
renal	ADJ	O	O
tissue	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
smear	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
examined	VERB	O	O
,	PUNCT	O	O
because	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
ascribed	VERB	O	O
to	ADP	O	O
cisplatin	VERB	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
to	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
suppression	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20528871)

Salvage	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
nelarabine	NOUN	O	I-Entity
,	PUNCT	O	O
etoposide	ADV	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
relapsed	VERB	O	O
/	SYM	O	O
refractory	ADJ	O	O
paediatric	NOUN	O	O
T	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
cell	NOUN	O	I-Entity
lymphoblastic	ADJ	O	I-Entity
leukaemia	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
d	NOUN	O	O
of	ADP	O	O
nelarabine	NOUN	O	I-Entity
(	PUNCT	O	O
AraG	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
5	NUM	O	O
d	NOUN	O	O
of	ADP	O	O
etoposide	NOUN	O	I-Entity
(	PUNCT	O	O
VP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CPM	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
prophylactic	ADJ	O	O
intrathecal	ADJ	O	O
chemotherapy	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
salvage	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
seven	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
refractory	NOUN	O	O
or	CCONJ	O	O
relapsed	VERB	O	O
T	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
cell	NOUN	O	I-Entity
leukaemia	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
attributable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
AraG	PROPN	O	I-Entity
included	VERB	O	O
Grade	PROPN	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
sensory	NOUN	O	O
and	CCONJ	O	O
motor	NOUN	O	O
neuropathy	NOUN	O	I-Entity
and	CCONJ	O	O
musculoskeletal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Haematological	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
greater	ADJ	O	O
for	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
than	ADP	O	O
AraG	PROPN	O	I-Entity
alone	ADV	O	O
,	PUNCT	O	O
although	ADP	O	O
median	ADJ	O	O
time	NOUN	O	O
to	ADP	O	O
neutrophil	NOUN	O	O
and	CCONJ	O	O
platelet	NOUN	O	O
recovery	NOUN	O	O
was	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
other	ADJ	O	O
salvage	NOUN	O	O
therapies	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
some	DET	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
combined	VERB	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
five	NUM	O	O
of	ADP	O	O
the	DET	O	O
seven	NUM	O	O
went	VERB	O	O
into	ADP	O	O
complete	ADJ	O	O
remission	NOUN	O	O
after	ADP	O	O
one	NUM	O	O
or	CCONJ	O	O
two	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
AraG	PROPN	O	I-Entity
/	SYM	O	O
VP	PROPN	O	I-Entity
/	SYM	O	O
CPM	PROPN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
experience	NOUN	O	O
supports	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
giving	VERB	O	O
AraG	PROPN	O	I-Entity
as	ADP	O	O
salvage	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
synchrony	NOUN	O	O
with	ADP	O	O
etoposide	NOUN	O	I-Entity
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
neurological	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
must	VERB	O	O
be	VERB	O	O
closely	ADV	O	O
monitored	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11672959)

The	DET	O	O
3-week	NUM	O	O
sulphasalazine	NOUN	O	I-Entity
syndrome	NOUN	O	O
strikes	NOUN	O	O
again	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
34-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
lady	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
constellation	NOUN	O	O
of	ADP	O	O
dermatitis	NOUN	O	I-Entity
,	PUNCT	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
lymphadenopathy	NOUN	O	I-Entity
and	CCONJ	O	O
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
beginning	VERB	O	O
on	ADP	O	O
the	DET	O	O
17th	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
a	DET	O	O
course	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
sulphasalazine	NOUN	O	I-Entity
for	ADP	O	O
sero	NOUN	O	O
-	PUNCT	O	O
negative	ADJ	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

Cervical	ADJ	O	O
and	CCONJ	O	O
inguinal	ADJ	O	O
lymph	ADJ	O	O
node	NOUN	O	O
biopsies	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
features	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
necrotising	NOUN	O	O
lymphadenitis	NOUN	O	I-Entity
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
erythrophagocytosis	NOUN	O	O
and	CCONJ	O	O
prominent	ADJ	O	O
eosinophilic	NOUN	O	O
infiltrates	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
viral	ADJ	O	O
inclusion	NOUN	O	O
bodies	NOUN	O	O
,	PUNCT	O	O
suggestive	ADJ	O	O
of	ADP	O	O
an	DET	O	O
adverse	ADJ	O	B-Entity
drug	NOUN	O	I-Entity
reaction	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
week	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
fulminant	ADJ	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
nuclear	ADJ	O	O
autoantibodies	NOUN	O	O
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
other	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
autoimmunity	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
accompanied	VERB	O	O
by	ADP	O	O
multi	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
organ	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
sepsis	NOUN	O	I-Entity
,	PUNCT	O	O
supervened	VERB	O	O
.	PUNCT	O	O

Post	PROPN	O	O
-	PUNCT	O	O
mortem	NOUN	O	O
examination	NOUN	O	O
showed	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
massive	ADJ	O	B-Entity
hepatocellular	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
acute	ADJ	O	O
hypersensitivity	NOUN	O	O
myocarditis	NOUN	O	I-Entity
,	PUNCT	O	O
focal	ADJ	O	O
acute	ADJ	O	O
tubulo	NOUN	O	O
-	PUNCT	O	O
interstitial	ADJ	O	O
nephritis	NOUN	O	I-Entity
and	CCONJ	O	O
extensive	ADJ	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
malignancy	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
thought	VERB	O	O
that	ADP	O	O
the	DET	O	O
clinico	NOUN	O	O
-	PUNCT	O	O
pathological	ADJ	O	O
features	NOUN	O	O
and	CCONJ	O	O
chronology	NOUN	O	O
of	ADP	O	O
this	DET	O	O
case	NOUN	O	O
bore	VERB	O	O
the	DET	O	O
hallmarks	NOUN	O	O
of	ADP	O	O
the	DET	O	O
so	ADV	O	O
-	PUNCT	O	O
called	VERB	O	O
"	PUNCT	O	O
3-week	X	O	O
sulphasalazine	NOUN	O	I-Entity
syndrome	NOUN	O	O
"	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
rare	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
often	ADV	O	O
fatal	ADJ	O	O
,	PUNCT	O	O
immunoallergic	ADJ	O	O
reaction	NOUN	O	O
to	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11928786)

Bupropion	PROPN	O	I-Entity
(	PUNCT	O	O
Zyban	PROPN	O	I-Entity
)	PUNCT	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Bupropion	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
monocyclic	ADJ	O	O
antidepressant	NOUN	O	I-Entity
structurally	ADV	O	O
related	VERB	O	O
to	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

Zyban	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
formulation	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
recently	ADV	O	O
released	VERB	O	O
in	ADP	O	O
Ireland	PROPN	O	O
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
smoking	NOUN	O	O
cessation	NOUN	O	O
aid	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
6	NUM	O	O
months	NOUN	O	O
since	ADP	O	O
it	PRON	O	O
's	VERB	O	O
introduction	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
overdose	NOUN	O	I-Entity
cases	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	ADP	O	O
The	DET	O	O
National	PROPN	O	O
Poisons	PROPN	O	O
Information	PROPN	O	O
Centre	PROPN	O	O
.	PUNCT	O	O

8	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Common	ADJ	O	O
features	NOUN	O	O
included	VERB	O	O
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
drowsiness	NOUN	O	O
,	PUNCT	O	O
hallucinations	NOUN	O	I-Entity
and	CCONJ	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
severe	ADJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
one	NUM	O	O
patient	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
resuscitated	VERB	O	O
following	VERB	O	O
a	DET	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
31	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
female	NOUN	O	O
who	NOUN	O	O
required	VERB	O	O
admission	NOUN	O	O
to	ADP	O	O
the	DET	O	O
Intensive	PROPN	O	O
Care	PROPN	O	O
Unit	PROPN	O	O
for	ADP	O	O
ventilation	NOUN	O	O
and	CCONJ	O	O
full	ADJ	O	O
supportive	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
following	VERB	O	O
ingestion	NOUN	O	O
of	ADP	O	O
13.5	NUM	O	O
g	NOUN	O	O
bupropion	NOUN	O	I-Entity
.	PUNCT	O	O

Recurrent	NOUN	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
diazepam	NOUN	O	I-Entity
and	CCONJ	O	O
broad	ADJ	O	O
complex	ADJ	O	O
tachycardia	NOUN	O	I-Entity
was	VERB	O	O
successfully	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
adenosine	NOUN	O	I-Entity
.	PUNCT	O	O

Zyban	PROPN	O	I-Entity
caused	VERB	O	O
significant	ADJ	O	O
neurological	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
cardiovascular	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
overdose	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7977601)

Survey	NOUN	O	O
of	ADP	O	O
complications	NOUN	O	O
of	ADP	O	O
indocyanine	NOUN	O	B-Entity
green	ADJ	O	I-Entity
angiography	NOUN	O	O
in	ADP	O	O
Japan	PROPN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
indocyanine	NOUN	O	B-Entity
green	ADJ	O	I-Entity
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
fundus	NOUN	O	O
angiography	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
sent	VERB	O	O
a	DET	O	O
questionnaire	NOUN	O	O
concerning	VERB	O	O
complications	NOUN	O	O
of	ADP	O	O
indocyanine	NOUN	O	B-Entity
green	ADJ	O	I-Entity
to	ADP	O	O
32	NUM	O	O
institutions	NOUN	O	O
in	ADP	O	O
Japan	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
were	VERB	O	O
selected	VERB	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
client	NOUN	O	O
list	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Topcon	PROPN	O	O
Company	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
manufactures	VERB	O	O
the	DET	O	O
indocyanine	NOUN	O	B-Entity
green	ADJ	O	I-Entity
fundus	NOUN	O	O
camera	NOUN	O	O
.	PUNCT	O	O

Ophthalmologists	NOUN	O	O
at	ADP	O	O
15	NUM	O	O
institutions	NOUN	O	O
responded	VERB	O	O
,	PUNCT	O	O
reporting	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
3,774	NUM	O	O
indocyanine	NOUN	O	B-Entity
green	ADJ	O	I-Entity
angiograms	NOUN	O	O
performed	VERB	O	O
on	ADP	O	O
2,820	NUM	O	O
patients	NOUN	O	O
between	ADP	O	O
June	PROPN	O	O
1984	NUM	O	O
and	CCONJ	O	O
September	PROPN	O	O
1992	NUM	O	O
.	PUNCT	O	O

Before	ADP	O	O
angiography	NOUN	O	O
,	PUNCT	O	O
intradermal	ADJ	O	O
or	CCONJ	O	O
intravenous	ADJ	O	O
indocyanine	NOUN	O	B-Entity
green	ADJ	O	I-Entity
testing	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
was	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
13	NUM	O	O
of	ADP	O	O
15	NUM	O	O
institutions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dosage	NOUN	O	O
of	ADP	O	O
indocyanine	NOUN	O	B-Entity
green	ADJ	O	I-Entity
used	VERB	O	O
for	ADP	O	O
angiography	NOUN	O	O
varied	VERB	O	O
from	ADP	O	O
25	NUM	O	O
to	PART	O	O
75	NUM	O	O
mg	INTJ	O	O
,	PUNCT	O	O
depending	VERB	O	O
upon	ADP	O	O
the	DET	O	O
institution	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
13	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
(	PUNCT	O	O
0.34%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ten	NUM	O	O
of	ADP	O	O
which	ADJ	O	O
were	VERB	O	O
mild	ADJ	O	O
reactions	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
exanthema	NOUN	O	I-Entity
,	PUNCT	O	O
urtication	NOUN	O	I-Entity
,	PUNCT	O	O
itchiness	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
urgency	NOUN	O	O
to	ADP	O	O
defecate	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
require	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
recorded	VERB	O	O
were	VERB	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
vein	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
required	VERB	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
hypotensive	NOUN	O	I-Entity
patients	NOUN	O	O
required	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
shock	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
frequency	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
indocyanine	VERB	O	B-Entity
green	ADJ	O	I-Entity
with	ADP	O	O
the	DET	O	O
previously	ADV	O	O
reported	VERB	O	O
frequency	NOUN	O	O
of	ADP	O	O
such	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
fluorescein	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
indicated	VERB	O	O
that	ADP	O	O
indocyanine	NOUN	O	B-Entity
green	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
as	ADP	O	O
fluorescein	NOUN	O	I-Entity
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
angiography	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19300402)

Bradykinin	NOUN	O	I-Entity
receptors	NOUN	O	O
antagonists	NOUN	O	O
and	CCONJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
inhibitors	NOUN	O	O
in	ADP	O	O
vincristine	NOUN	O	I-Entity
and	CCONJ	O	O
streptozotocin	NOUN	O	I-Entity
induced	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
in	ADP	O	O
chemotherapy	NOUN	O	O
and	CCONJ	O	O
diabetic	ADJ	O	B-Entity
neuropathy	ADJ	O	I-Entity
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

NO	DET	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
L	PROPN	O	O
-	PUNCT	O	O
NOArg	PROPN	O	O
;	PUNCT	O	O
1.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
relatively	ADV	O	O
selective	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
inducible	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
L	PROPN	O	O
-	PUNCT	O	O
NIL	PROPN	O	O
;	PUNCT	O	O
1.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
relatively	ADV	O	O
specific	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
neuronal	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
7-NI	NUM	O	O
;	PUNCT	O	O
0.1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
antihyperalgesic	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
selective	ADJ	O	O
antagonists	NOUN	O	O
of	ADP	O	O
B2	NOUN	O	O
and	CCONJ	O	O
B1	NOUN	O	O
receptors	NOUN	O	O
:	PUNCT	O	O
D	NOUN	O	O
-	PUNCT	O	O
Arg-[Hyp3,Thi5,D	PROPN	O	O
-	PUNCT	O	O
Tic7,Oic8	PROPN	O	O
]	PUNCT	O	O
bradykinin	NOUN	O	I-Entity
(	PUNCT	O	O
HOE	PROPN	O	B-Entity
140	NUM	O	I-Entity
;	PUNCT	O	O
70	NUM	O	O
nmol	NOUN	O	O
/	SYM	O	O
kg	X	O	O
ip	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
des	X	O	B-Entity
Arg10	X	O	I-Entity
HOE	PROPN	O	I-Entity
140	NUM	O	I-Entity
(	PUNCT	O	O
70	NUM	O	O
nmol	NOUN	O	O
/	SYM	O	O
kg	X	O	O

ip	PUNCT	O	O
)	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
model	NOUN	O	O
of	ADP	O	O
diabetic	ADJ	O	B-Entity
(	PUNCT	O	I-Entity
streptozotocin	ADV	O	I-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
toxic	ADJ	O	I-Entity
(	PUNCT	O	I-Entity
vincristine	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
)	PUNCT	O	I-Entity
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	I-Entity
thresholds	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
using	VERB	O	O
mechanical	ADJ	O	O
stimuli	NOUN	O	O
--	PUNCT	O	O
the	DET	O	O
modification	NOUN	O	O
of	ADP	O	O
the	DET	O	O
classic	ADJ	O	O
paw	NOUN	O	O
withdrawal	NOUN	O	O
test	NOUN	O	O
described	VERB	O	O
by	ADP	O	O
Randall	PROPN	O	O
-	PUNCT	O	O
Selitto	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
paper	NOUN	O	O
confirm	VERB	O	O
that	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
receptors	NOUN	O	O
and	CCONJ	O	O
inducible	ADJ	O	O

NO	DET	O	I-Entity
synthase	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
neuronal	ADJ	O	O

NO	PROPN	O	I-Entity
synthase	NOUN	O	O
activity	NOUN	O	O
reduces	VERB	O	O
diabetic	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

both	DET	O	O
HOE	PROPN	O	B-Entity
140	NUM	O	I-Entity
and	CCONJ	O	O
des	NOUN	O	B-Entity
Arg10	PROPN	O	I-Entity
HOE	PROPN	O	I-Entity
140	NUM	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
also	ADV	O	O
shown	VERB	O	O
that	ADP	O	O
both	DET	O	O
products	NOUN	O	O
of	ADP	O	O
inducible	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
and	CCONJ	O	O
neuronal	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
activation	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
bradykinin	NOUN	O	I-Entity
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
vincristine	NOUN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
L	PROPN	O	O
-	PUNCT	O	O
NOArg	PROPN	O	O
and	CCONJ	O	O
7-NI	PROPN	O	O
but	CCONJ	O	O
not	ADV	O	O
L	NOUN	O	O
-	PUNCT	O	O
NIL	PROPN	O	O
intensify	VERB	O	O
antihyperalgesic	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
HOE	PROPN	O	B-Entity
140	NUM	O	I-Entity
or	CCONJ	O	O
des	X	O	B-Entity
-	PUNCT	O	I-Entity
Arg10HOE	PROPN	O	I-Entity
140	NUM	O	I-Entity
in	ADP	O	O
toxic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Results	NOUN	O	O
of	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
B1	PROPN	O	O
and	CCONJ	O	O
B2	NOUN	O	O
receptors	NOUN	O	O
are	VERB	O	O
engaged	VERB	O	O
in	ADP	O	O
transmission	NOUN	O	O
of	ADP	O	O
nociceptive	ADJ	O	O
stimuli	NOUN	O	O
in	ADP	O	O
both	DET	O	O
diabetic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
toxic	ADJ	O	I-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
,	PUNCT	O	O
inducible	ADJ	O	O

NO	DET	O	I-Entity
synthase	NOUN	O	O
participates	VERB	O	O
in	ADP	O	O
pronociceptive	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
vincristine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
bradykinin	NOUN	O	I-Entity
seemed	VERB	O	O
to	PART	O	O
activate	VERB	O	O
neuronal	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
concomitant	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
bradykinin	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
and	CCONJ	O	O
NO	DET	O	I-Entity
synthase	NOUN	O	O
inhibitors	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
alleviation	NOUN	O	O
of	ADP	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
hospital	NOUN	O	O
care	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15325671)

Cardiac	PROPN	O	B-Entity
toxicity	NOUN	O	I-Entity
observed	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Cyclophosphamide	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
alkylating	VERB	O	O
agent	NOUN	O	O
given	VERB	O	O
frequently	ADV	O	O
as	ADP	O	O
a	DET	O	O
component	NOUN	O	O
of	ADP	O	O
many	ADJ	O	O
conditioning	NOUN	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
nonhematological	ADJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxicity	NOUN	O	I-Entity
is	VERB	O	O
cardiomyopathy	ADJ	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
combined	VERB	O	O
paclitaxel	NOUN	O	I-Entity
,	PUNCT	O	O
melphalan	NOUN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cyclophosphamide	NOUN	O	I-Entity
,	PUNCT	O	O
thiotepa	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
carboplatin	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
triple	ADJ	O	O
sequential	ADJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
regimen	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Analysis	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
61	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
-	PUNCT	O	O
responsive	ADJ	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
receiving	VERB	O	O
96-h	NUM	O	O
infusional	ADJ	O	O
cyclophosphamide	NOUN	O	I-Entity
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
triple	ADJ	O	O
sequential	ADJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
regimen	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
association	NOUN	O	O
between	ADP	O	O
presence	NOUN	O	O
of	ADP	O	O
peritransplant	NOUN	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CHF	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
following	VERB	O	O
pretreatment	NOUN	O	O
characteristics	NOUN	O	O
:	PUNCT	O	O
presence	NOUN	O	O
of	ADP	O	O
electrocardiogram	NOUN	O	O
(	PUNCT	O	O
EKG	PROPN	O	O
)	PUNCT	O	O
abnormalities	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
prior	ADJ	O	O
cardiac	ADJ	O	O
history	NOUN	O	O
,	PUNCT	O	O
smoking	NOUN	O	O
,	PUNCT	O	O
diabetes	VERB	O	B-Entity
mellitus	NOUN	O	I-Entity
,	PUNCT	O	O
prior	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
anthracyclines	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
left	ADV	O	O
-	PUNCT	O	O
sided	ADJ	O	O
chest	NOUN	O	O
irradiation	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
of	ADP	O	O
61	NUM	O	O
women	NOUN	O	O
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
clinically	ADV	O	O
reversible	ADJ	O	O
grade	NOUN	O	O
3	NUM	O	O
CHF	PROPN	O	I-Entity
following	VERB	O	O
infusional	ADJ	O	O
cyclophosphamide	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
median	ADJ	O	O
percent	NOUN	O	O
decline	NOUN	O	O
in	ADP	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
of	ADP	O	O
31%	NUM	O	O
.	PUNCT	O	O

Incidence	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
is	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
previous	ADJ	O	O
recorded	VERB	O	O
literature	NOUN	O	O
.	PUNCT	O	O

Older	ADJ	O	O
age	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
CHF	PROPN	O	I-Entity
development	NOUN	O	O
;	PUNCT	O	O
with	ADP	O	O
median	ADJ	O	O
ages	NOUN	O	O
for	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
patients	NOUN	O	O
developing	VERB	O	O
CHF	PROPN	O	I-Entity
of	ADP	O	O
45	NUM	O	O
and	CCONJ	O	O
59	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Routine	ADJ	O	O
EKG	PROPN	O	O
monitoring	NOUN	O	O
during	ADP	O	O
infusional	ADJ	O	O
cyclophosphamide	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
predict	VERB	O	O
CHF	PROPN	O	I-Entity
development	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9746003)

Inappropriate	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
and	CCONJ	O	O
vigabatrin	NOUN	O	I-Entity
in	ADP	O	O
typical	ADJ	O	O
absence	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Carbamazepine	PROPN	O	I-Entity
and	CCONJ	O	O
vigabatrin	NOUN	O	I-Entity
are	VERB	O	O
contraindicated	VERB	O	O
in	ADP	O	O
typical	ADJ	O	O
absence	NOUN	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
18	NUM	O	O
consecutive	ADJ	O	O
referrals	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
resistant	ADJ	O	O
typical	ADJ	O	O
absences	NOUN	O	O
only	ADV	O	O
,	PUNCT	O	O
eight	NUM	O	O
were	VERB	O	O
erroneously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
carbamazepine	NOUN	O	I-Entity
either	CCONJ	O	O
as	ADP	O	O
monotherapy	NOUN	O	O
or	CCONJ	O	O
as	ADP	O	O
an	DET	O	O
add	NOUN	O	O
-	PUNCT	O	O
on	PART	O	O
.	PUNCT	O	O

Vigabatrin	PROPN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
children	NOUN	O	O
.	PUNCT	O	O

Frequency	PROPN	O	O
of	ADP	O	O
absences	NOUN	O	O
increased	VERB	O	O
in	ADP	O	O
four	NUM	O	O
children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
carbamazepine	NOUN	O	I-Entity
and	CCONJ	O	O
two	NUM	O	O
of	ADP	O	O
these	DET	O	O
developed	VERB	O	O
myoclonic	ADJ	O	B-Entity
jerks	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
resolved	VERB	O	O
on	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
.	PUNCT	O	O

Absences	NOUN	O	O
were	VERB	O	O
aggravated	VERB	O	O
in	ADP	O	O
both	DET	O	O
cases	NOUN	O	O
where	ADV	O	O
vigabatrin	NOUN	O	I-Entity
was	VERB	O	O
added	VERB	O	O
on	ADP	O	O
to	ADP	O	O
concurrent	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Optimal	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
the	DET	O	O
absences	NOUN	O	O
was	VERB	O	O
achieved	VERB	O	O
with	ADP	O	O
sodium	NOUN	O	B-Entity
valproate	NOUN	O	I-Entity
,	PUNCT	O	O
lamotrigine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
ethosuximide	ADV	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1992636)

Hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
omeprazole	NOUN	O	I-Entity
.	PUNCT	O	O

Omeprazole	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
drug	NOUN	O	O
designed	VERB	O	O
to	PART	O	O
block	VERB	O	O
the	DET	O	O
final	ADJ	O	O
step	NOUN	O	O
in	ADP	O	O
the	DET	O	O
acid	NOUN	O	O
secretory	NOUN	O	O
process	NOUN	O	O
within	ADP	O	O
the	DET	O	O
parietal	ADJ	O	O
cell	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	VERB	O	O
extremely	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
peptic	ADJ	O	B-Entity
ulcer	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
reflux	NOUN	O	B-Entity
esophagitis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Zollinger	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Ellison	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
clinical	ADJ	O	O
experience	NOUN	O	O
with	ADP	O	O
omeprazole	NOUN	O	I-Entity
is	VERB	O	O
still	ADV	O	O
limited	ADJ	O	O
,	PUNCT	O	O
many	ADJ	O	O
controlled	VERB	O	O
studies	NOUN	O	O
have	VERB	O	O
established	VERB	O	O
the	DET	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
safety	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
serious	ADJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
adverse	ADJ	O	O
reaction	NOUN	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
omeprazole	NOUN	O	I-Entity
:	PUNCT	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
weakness	NOUN	O	O
,	PUNCT	O	O
lethargy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
shortness	NOUN	O	B-Entity
of	ADP	O	I-Entity
breath	NOUN	O	I-Entity
2	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
starting	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
omeprazole	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
her	ADJ	O	O
hematocrit	NOUN	O	O
had	VERB	O	O
decreased	VERB	O	O
from	ADP	O	O
44.1%	NUM	O	O
to	ADP	O	O
20.4%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
she	PRON	O	O
had	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
direct	ADJ	O	O
Coombs	PROPN	O	O
antiglobulin	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
elevated	ADJ	O	O
indirect	ADJ	O	O
bilirubin	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
she	PRON	O	O
discontinued	VERB	O	O
the	DET	O	O
omeprazole	NOUN	O	I-Entity
,	PUNCT	O	O
her	ADJ	O	O
hemoglobin	NOUN	O	O
and	CCONJ	O	O
hematocrit	NOUN	O	O
gradually	ADV	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
omeprazole	NOUN	O	I-Entity
caused	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
is	VERB	O	O
uncertain	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
physicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
alerted	VERB	O	O
to	ADP	O	O
this	DET	O	O
possible	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8387218)

The	DET	O	O
use	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
didanosine	NOUN	O	I-Entity
(	PUNCT	O	O
ddI	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
HIV	PROPN	O	B-Entity
antibody	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
positive	ADJ	O	I-Entity
individuals	NOUN	O	O
intolerant	ADJ	O	O
to	ADP	O	O
zidovudine	NOUN	O	I-Entity
(	PUNCT	O	O
AZT	PROPN	O	I-Entity
)	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
fifty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
patients	NOUN	O	O
intolerant	ADJ	O	O
to	ADP	O	O
zidovudine	NOUN	O	I-Entity
(	PUNCT	O	O
AZT	PROPN	O	I-Entity
)	PUNCT	O	O
received	VERB	O	O
didanosine	NOUN	O	I-Entity
(	PUNCT	O	O
ddI	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
maximum	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
12.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
.	PUNCT	O	O

Seventy	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
major	ADJ	O	O
opportunistic	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
whilst	ADV	O	O
on	ADP	O	O
therapy	NOUN	O	O
;	PUNCT	O	O
this	DET	O	O
was	VERB	O	O
the	DET	O	O
first	ADJ	O	O
AIDS	PROPN	O	I-Entity
diagnosis	NOUN	O	O
in	ADP	O	O
17	NUM	O	O
.	PUNCT	O	O

+	CCONJ	O	O
lymphocyte	NOUN	O	O
subset	NOUN	O	O
count	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
AIDS	PROPN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
a	DET	O	O
more	ADV	O	O
significant	ADJ	O	O
rise	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
those	DET	O	O
with	ADP	O	O
earlier	ADJ	O	O
stages	NOUN	O	O
of	ADP	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
reactions	NOUN	O	O
possibly	ADV	O	O
attributable	ADJ	O	O
to	ADP	O	O
didanosine	NOUN	O	I-Entity
were	VERB	O	O
common	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
was	VERB	O	O
diarrhoea	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
in	ADP	O	O
19	NUM	O	O
individuals	NOUN	O	O
.	PUNCT	O	O

Peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
12	NUM	O	O
patients	NOUN	O	O
and	CCONJ	O	O
pancreatitis	NOUN	O	I-Entity
in	ADP	O	O
six	NUM	O	O
.	PUNCT	O	O

Thirteen	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
raised	VERB	O	O
serum	NOUN	O	O
amylase	NOUN	O	O
without	ADP	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Seven	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
glucose	NOUN	O	B-Entity
tolerance	NOUN	O	I-Entity
curves	VERB	O	I-Entity
characteristic	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	I-Entity
but	CCONJ	O	O
these	DET	O	O
were	VERB	O	O
mild	ADJ	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
require	VERB	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
on	ADP	O	O
ceasing	VERB	O	O
didanosine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20698227)

Can	VERB	O	O
angiogenesis	NOUN	O	O
be	VERB	O	O
a	DET	O	O
target	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
ribavirin	NOUN	O	I-Entity
associated	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
?	PUNCT	O	O

Recently	ADV	O	O
ribavirin	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
found	VERB	O	O
to	PART	O	O
inhibit	VERB	O	O
angiogenesis	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
angiogenesis	NOUN	O	O
inhibitors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
sunitinib	NOUN	O	I-Entity
and	CCONJ	O	O
sorafenib	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
found	VERB	O	O
to	PART	O	O
cause	VERB	O	O
acute	ADJ	O	O
hemolysis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
hemoglobin	NOUN	O	O
,	PUNCT	O	O
haptoglobin	NOUN	O	O
and	CCONJ	O	O
angiogenesis	NOUN	O	O
soluble	ADJ	O	O
markers	NOUN	O	O
which	ADJ	O	O
are	VERB	O	O
modifiable	ADJ	O	O
and	CCONJ	O	O
can	VERB	O	O
help	VERB	O	O
in	ADP	O	O
developing	VERB	O	O
strategies	NOUN	O	O
against	ADP	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Fourteen	NUM	O	O
patients	NOUN	O	O
chronically	ADV	O	B-Entity
infected	VERB	O	I-Entity
with	ADP	O	I-Entity
hepatitis	NOUN	O	I-Entity
C	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
alpha	NOUN	O	I-Entity
2a	NUM	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
with	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
angiogenesis	NOUN	O	O
factors	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
by	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
investigating	VERB	O	O
a	DET	O	O
link	NOUN	O	O
between	ADP	O	O
angiogenesis	NOUN	O	O
soluble	ADJ	O	O
markers	NOUN	O	O
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
induced	VERB	O	O
anemia	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hepatitis	NOUN	O	B-Entity
C	NOUN	O	I-Entity
and	CCONJ	O	O
we	PRON	O	O
could	VERB	O	O
not	ADV	O	O
find	VERB	O	O
any	DET	O	O
relation	NOUN	O	O
.	PUNCT	O	O

Future	ADJ	O	O
research	NOUN	O	O
with	ADP	O	O
larger	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
to	PART	O	O
find	VERB	O	O
out	PART	O	O
modifiable	ADJ	O	O
factors	NOUN	O	O
that	ADJ	O	O
will	VERB	O	O
improve	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20477932)

Cocaine	NOUN	O	I-Entity
causes	VERB	O	O
memory	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
learning	VERB	O	I-Entity
impairments	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
:	PUNCT	O	O
involvement	NOUN	O	O
of	ADP	O	O
nuclear	ADJ	O	O
factor	NOUN	O	O
kappa	NOUN	O	O
B	PROPN	O	O
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
by	ADP	O	O
topiramate	NOUN	O	I-Entity
.	PUNCT	O	O

Different	ADJ	O	O
mechanisms	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
for	ADP	O	O
cocaine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
including	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
oxidative	ADJ	O	O
status	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
induced	VERB	O	O
-	PUNCT	O	O
behaviour	NOUN	O	O
is	VERB	O	O
poorly	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

Nuclear	ADJ	O	O
factor	NOUN	O	O
kappa	NOUN	O	O
B	PROPN	O	O
(	PUNCT	O	O
NFkappaB	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
sensor	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
participates	VERB	O	O
in	ADP	O	O
memory	NOUN	O	O
formation	NOUN	O	O
that	ADJ	O	O
could	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
drug	NOUN	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
addiction	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
NFkappaB	PROPN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
neuronal	ADJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
nNOS	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
,	PUNCT	O	O
spatial	ADJ	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
topiramate	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
previously	ADV	O	O
proposed	VERB	O	O
therapy	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	B-Entity
addiction	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
an	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

NFkappaB	ADJ	O	O
activity	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
in	ADP	O	O
the	DET	O	O
frontal	NOUN	O	O
cortex	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
GSH	PROPN	O	I-Entity
concentration	NOUN	O	O
and	CCONJ	O	O
glutathione	NOUN	O	I-Entity
peroxidase	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
nNOS	DET	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
.	PUNCT	O	O

Memory	NOUN	O	O
retrieval	NOUN	O	O
of	ADP	O	O
experiences	NOUN	O	O
acquired	VERB	O	O
prior	ADV	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
administration	NOUN	O	O
was	VERB	O	O
impaired	ADJ	O	O
and	CCONJ	O	O
negatively	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
NFkappaB	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
frontal	NOUN	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
learning	VERB	O	O
of	ADP	O	O
new	ADJ	O	O
tasks	NOUN	O	O
was	VERB	O	O
enhanced	VERB	O	O
and	CCONJ	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
nNOS	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
decrease	NOUN	O	O
of	ADP	O	O
glutathione	NOUN	O	I-Entity
peroxidase	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
evidence	NOUN	O	O
for	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
mechanistic	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
and	CCONJ	O	O
nitrosative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
NFkappaB	PROPN	O	O
in	ADP	O	O
the	DET	O	O
alterations	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Topiramate	PROPN	O	I-Entity
prevented	VERB	O	O
all	ADJ	O	O
the	DET	O	O
alterations	NOUN	O	O
observed	VERB	O	O
,	PUNCT	O	O
showing	VERB	O	O
novel	NOUN	O	O
neuroprotective	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9495837)

Antinociceptive	ADJ	O	O
and	CCONJ	O	O
antiamnesic	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
the	DET	O	O
presynaptic	ADJ	O	O
cholinergic	NOUN	O	O
amplifier	NOUN	O	O
PG-9	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
antinociceptive	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
3	NUM	O	B-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
tropyl	NOUN	O	I-Entity
2-(p	NUM	O	I-Entity
-	PUNCT	O	I-Entity
bromophenyl)propionate	NOUN	O	I-Entity
[	PUNCT	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	NOUN	O	I-Entity
]	PUNCT	O	O
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
40	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
s.c	NOUN	O	O
.	PUNCT	O	O

(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	PROPN	O	I-Entity
antinociception	NOUN	O	O
peaked	VERB	O	O
15	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
slowly	ADV	O	O
diminished	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
antinociception	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	PROPN	O	I-Entity
was	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
the	DET	O	O
unselective	ADJ	O	O
muscarinic	NOUN	O	O
antagonist	NOUN	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
M1-selective	ADJ	O	O
antagonists	NOUN	O	O
pirenzepine	VERB	O	I-Entity
and	CCONJ	O	O
dicyclomine	VERB	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
acetylcholine	NOUN	O	I-Entity
depletor	NOUN	O	O
hemicholinium-3	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
the	DET	O	O
opioid	ADJ	O	O
antagonist	NOUN	O	O
naloxone	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acidB	PROPN	O	I-Entity
antagonist	NOUN	O	O
3-aminopropyl	NUM	O	B-Entity
-	PUNCT	O	I-Entity
diethoxy	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
phosphinic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
H3	PROPN	O	O
agonist	NOUN	O	O
R-(alpha)-methylhistamine	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
D2	PROPN	O	O
antagonist	NOUN	O	O
quinpirole	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
5-hydroxytryptamine4	ADJ	O	I-Entity
antagonist	NOUN	O	O
2-methoxy-4-amino-5-chlorobenzoic	NUM	O	B-Entity
acid	NOUN	O	I-Entity
2-(diethylamino)ethyl	NUM	O	I-Entity
ester	NOUN	O	I-Entity
hydrochloride	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
5-hydroxytryptamin1A	ADJ	O	I-Entity
antagonist	NOUN	O	O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine	NUM	O	I-Entity
hydrobromide	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
polyamines	NOUN	O	O
depletor	NOUN	O	O
reserpine	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
postulated	VERB	O	O
that	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	PROPN	O	I-Entity
exerted	VERB	O	O
an	DET	O	O
antinociceptive	ADJ	O	O
effect	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
a	DET	O	O
central	ADJ	O	O
potentiation	NOUN	O	O
of	ADP	O	O
cholinergic	ADJ	O	O
transmission	NOUN	O	O
.	PUNCT	O	O

(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
40	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
able	ADJ	O	O
to	PART	O	O
prevent	VERB	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
dicyclomine	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	NUM	O	O
kg-1	NUM	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
mouse	NOUN	O	O
passive	ADJ	O	O
-	PUNCT	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Affinity	NOUN	O	O
profiles	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	NOUN	O	I-Entity
for	ADP	O	O
muscarinic	ADJ	O	O
receptor	NOUN	O	O
subtypes	NOUN	O	O
,	PUNCT	O	O
determined	VERB	O	O
by	ADP	O	O
functional	ADJ	O	O
studies	NOUN	O	O
(	PUNCT	O	O
rabbit	NOUN	O	O
vas	X	O	O
deferens	VERB	O	O
for	ADP	O	O
M1	PROPN	O	O
,	PUNCT	O	O
guinea	NOUN	O	O
pig	NOUN	O	O
atrium	NOUN	O	O
for	ADP	O	O
M2	PROPN	O	O
,	PUNCT	O	O

,	PUNCT	O	O
have	VERB	O	O
shown	VERB	O	O
an	DET	O	O
M4/M1	ADJ	O	O
selectivity	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
10.2	NUM	O	O
that	ADJ	O	O
might	VERB	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
antinociception	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
amnesic	ADJ	O	I-Entity
effect	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-PG-9	PROPN	O	I-Entity
through	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
acetylcholine	NOUN	O	I-Entity
extracellular	ADJ	O	O
levels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
antinociceptive	NOUN	O	O
and	CCONJ	O	O
antiamnesic	ADJ	O	O
dose	NOUN	O	O
range	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
+	CCONJ	O	O
/-)-PG-9	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
impair	VERB	O	O
mouse	NOUN	O	O
performance	NOUN	O	O
evaluated	VERB	O	O
by	ADP	O	O
the	DET	O	O
rota	NOUN	O	O
-	PUNCT	O	O
rod	NOUN	O	O
test	NOUN	O	O
and	CCONJ	O	O
Animex	PROPN	O	O
apparatus	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1468485)

Hyperbaric	ADJ	O	O
oxygen	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
intractable	ADJ	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
intractable	ADJ	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
Wegener	PROPN	O	B-Entity
's	PART	O	I-Entity
granulomatosis	NOUN	O	I-Entity
.	PUNCT	O	O

Conservative	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
bladder	NOUN	O	O
irrigation	NOUN	O	O
with	ADP	O	O
physiological	ADJ	O	O
saline	NOUN	O	O
and	CCONJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	B-Entity
F2	NUM	O	I-Entity
alpha	NOUN	O	I-Entity
,	PUNCT	O	O
failed	VERB	O	O
to	PART	O	O
totally	ADV	O	O
control	VERB	O	O
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
used	VERB	O	O
hyperbaric	ADJ	O	O
oxygen	NOUN	O	I-Entity
at	ADP	O	O
an	DET	O	O
absolute	ADJ	O	O
pressure	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
atm	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
days	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
for	ADP	O	O
8	NUM	O	O
consecutive	ADJ	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
bleeding	NOUN	O	I-Entity
ceased	VERB	O	O
completely	ADV	O	O
by	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
remained	VERB	O	O
free	ADJ	O	O
of	ADP	O	O
hematuria	NOUN	O	I-Entity
thereafter	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
future	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
form	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
can	VERB	O	O
offer	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
alternative	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1009330)

The	DET	O	O
results	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
the	DET	O	O
degradation	NOUN	O	O
product	NOUN	O	O
p	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
choloroaniline	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
a	DET	O	O
significant	ADJ	O	O
factor	NOUN	O	O
in	ADP	O	O
chlorhexidine	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
digluconate	NOUN	O	I-Entity
associated	VERB	O	O
erosive	ADJ	O	O
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
high	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
kanamycin	NOUN	O	I-Entity
-	PUNCT	O	O
colistin	NOUN	O	I-Entity
and	CCONJ	O	O
povidone	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
iodine	NOUN	O	I-Entity
irrigations	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
erosive	ADJ	O	O
cystitis	NOUN	O	I-Entity
and	CCONJ	O	O
suggested	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
complication	NOUN	O	O
with	ADP	O	O
human	ADJ	O	O
usage	NOUN	O	O
.	PUNCT	O	O

Picloxydine	ADJ	O	I-Entity
irrigations	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
erosive	ADJ	O	O
cystitis	NOUN	O	I-Entity
but	CCONJ	O	O
further	ADJ	O	O
studies	NOUN	O	O
would	VERB	O	O
have	VERB	O	O
to	PART	O	O
be	VERB	O	O
performed	VERB	O	O
before	ADP	O	O
it	PRON	O	O
could	VERB	O	O
be	VERB	O	O
recommended	VERB	O	O
for	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
urological	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (347884)

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
sixty	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
trated	VERB	O	O
with	ADP	O	O
bromperidol	NOUN	O	I-Entity
first	ADV	O	O
in	ADP	O	O
open	ADJ	O	O
conditions	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
then	ADV	O	O
on	ADP	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
basis	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
substance	NOUN	O	O
.	PUNCT	O	O

Nine	NUM	O	O
patients	NOUN	O	O
exhibited	VERB	O	O
mild	ADJ	O	O
to	ADP	O	O
moderate	ADJ	O	O
extrapyramidal	ADJ	O	B-Entity
concomitant	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
;	PUNCT	O	O
no	DET	O	O
other	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
study	NOUN	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
both	DET	O	O
substances	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
psychotic	ADJ	O	B-Entity
syndromes	NOUN	O	I-Entity
belonging	VERB	O	I-Entity
predominantly	ADV	O	I-Entity
to	ADP	O	I-Entity
the	DET	O	I-Entity
schizophrenia	NOUN	O	I-Entity
group	NOUN	O	I-Entity
.	PUNCT	O	O

Certain	ADJ	O	O
clues	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
,	PUNCT	O	O
seem	VERB	O	O
to	PART	O	O
be	VERB	O	O
indicative	ADJ	O	O
of	ADP	O	O
the	DET	O	O
superiority	NOUN	O	O
of	ADP	O	O
bromperidol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20667451)

Curcumin	PROPN	O	I-Entity
ameliorates	VERB	O	O
cognitive	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
in	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
administered	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
antiepileptic	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
are	VERB	O	O
well	ADV	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
on	ADP	O	O
chronic	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
free	ADJ	O	O
radical	ADJ	O	O
generation	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
as	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
important	ADJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
by	ADP	O	O
antiepileptic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Curcumin	PROPN	O	I-Entity
has	VERB	O	O
shown	VERB	O	O
antioxidant	ADJ	O	O
,	PUNCT	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
and	CCONJ	O	O
neuro	ADJ	O	O
-	PUNCT	O	O
protective	ADJ	O	O
properties	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
curcumin	NOUN	O	I-Entity
administration	NOUN	O	O
on	ADP	O	O
phenobarbitone-	ADJ	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	O
interactions	NOUN	O	O
of	ADP	O	O
curcumin	NOUN	O	I-Entity
with	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
,	PUNCT	O	O
whole	ADJ	O	O
brain	NOUN	O	O
malondialdehyde	NOUN	O	I-Entity
and	CCONJ	O	O
reduced	VERB	O	O
glutathione	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
estimated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
for	ADP	O	O
21days	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
learning	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
an	DET	O	O
increased	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Concomitant	ADJ	O	O
curcumin	NOUN	O	I-Entity
administration	NOUN	O	O
prevented	VERB	O	O
the	DET	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
decreased	VERB	O	O
the	DET	O	O
increased	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
these	DET	O	O
antiepileptic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Curcumin	PROPN	O	I-Entity
co	X	O	O
-	PUNCT	O	O
administration	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
any	DET	O	O
significant	ADJ	O	O
alteration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
both	DET	O	O
phenobarbitone	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
carbamazepine	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
curcumin	NOUN	O	I-Entity
has	VERB	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
mitigating	VERB	O	O
the	DET	O	O
deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
cognitive	ADJ	O	I-Entity
functions	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
damage	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
without	ADP	O	O
significantly	ADV	O	O
altering	VERB	O	O
their	ADJ	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
curcumin	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
potential	ADJ	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
adjuvant	NOUN	O	O
to	ADP	O	O
phenobarbitone	NOUN	O	I-Entity
and	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19767176)

Pyrrolidine	NOUN	O	B-Entity
dithiocarbamate	NOUN	O	I-Entity
protects	VERB	O	O
the	DET	O	O
piriform	NOUN	O	O
cortex	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

Pyrrolidine	PROPN	O	B-Entity
dithiocarbamate	NOUN	O	I-Entity
(	PUNCT	O	O
PDTC	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
a	DET	O	O
dual	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
as	ADP	O	O
an	DET	O	O
antioxidant	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
transcription	NOUN	O	O
factor	NOUN	O	O
kappa	NOUN	O	O
-	PUNCT	O	O
beta	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
,	PUNCT	O	O
production	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
NF	PROPN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
have	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
severe	ADJ	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
different	ADJ	O	O
sub	NOUN	O	O
-	PUNCT	O	O
regions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
surrounding	VERB	O	O
cortices	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
PDTC	PROPN	O	I-Entity
on	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
cell	NOUN	O	O
loss	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
and	CCONJ	O	O

piriform	NOUN	O	O
cortex	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
fractionated	VERB	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

PDTC	PROPN	O	I-Entity
before	ADV	O	O
and	CCONJ	O	O
following	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
to	ADP	O	O
100%	NUM	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
PDTC	PROPN	O	I-Entity
(	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
exert	VERB	O	O
major	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
a	DET	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
or	CCONJ	O	O
the	DET	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
vehicle	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
caused	VERB	O	O
pronounced	ADJ	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
piriform	NOUN	O	O
cortex	NOUN	O	O
comprising	VERB	O	O
both	DET	O	O
pyramidal	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
interneurons	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
PDTC	PROPN	O	I-Entity
treatment	NOUN	O	O
almost	ADV	O	O
completely	ADV	O	O
protected	VERB	O	O
from	ADP	O	O
lesions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
piriform	NOUN	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
neuronal	ADJ	O	O
density	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
hilar	ADJ	O	O
formation	NOUN	O	O
was	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
vehicle-	NOUN	O	O
and	CCONJ	O	O
PDTC	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
following	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
NF	PROPN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
inhibitor	NOUN	O	O
and	CCONJ	O	O
antioxidant	NOUN	O	O
PDTC	PROPN	O	I-Entity
protected	VERB	O	O
the	DET	O	O
piriform	NOUN	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
hilar	ADJ	O	O
neuronal	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
might	VERB	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
generation	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
and	CCONJ	O	O
activation	NOUN	O	O
of	ADP	O	O
NF	PROPN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
plays	VERB	O	O
a	DET	O	O
more	ADV	O	O
central	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
cortex	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
hilus	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
future	ADJ	O	O
investigations	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
exactly	ADV	O	O
analyze	VERB	O	O
the	DET	O	O
biochemical	ADJ	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
PDTC	PROPN	O	I-Entity
exerted	VERB	O	O
its	ADJ	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
piriform	NOUN	O	O
cortex	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16330293)

Safety	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
a	DET	O	O
nicotine	NOUN	O	I-Entity
lozenge	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
gum	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
smokers	NOUN	O	O
with	ADP	O	O
underlying	ADJ	O	O
medical	ADJ	O	O
conditions	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
12-week	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Nicotine	NOUN	O	I-Entity
polacrilex	NOUN	O	O
lozenges	VERB	O	O
deliver	VERB	O	O
25%	NUM	O	O
to	PART	O	O
27%	NUM	O	O
more	ADJ	O	O
nicotine	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
equivalent	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
polacrilex	NOUN	O	O
gum	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
increased	VERB	O	O
nicotine	NOUN	O	I-Entity
exposure	NOUN	O	O
from	ADP	O	O
the	DET	O	O
lozenge	NOUN	O	O
has	VERB	O	O
raised	VERB	O	O
questions	NOUN	O	O
about	ADP	O	O
the	DET	O	O
relative	ADJ	O	O
safety	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lozenge	NOUN	O	O
and	CCONJ	O	O
gum	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
profiles	NOUN	O	O
of	ADP	O	O
the	DET	O	O
4-mg	NUM	O	O
nicotine	NOUN	O	I-Entity
lozenge	NOUN	O	O
and	CCONJ	O	O
4-mg	NUM	O	O
nicotine	NOUN	O	I-Entity
gum	NOUN	O	O
in	ADP	O	O
smokers	NOUN	O	O
with	ADP	O	O
selected	VERB	O	O
label	NOUN	O	O
-	PUNCT	O	O
restricted	VERB	O	O
diseases	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
a	DET	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
smokers	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
hypertension	NOUN	O	I-Entity
not	ADV	O	O
controlled	VERB	O	O
by	ADP	O	O
medication	NOUN	O	O
,	PUNCT	O	O
and/or	CCONJ	O	O
diabetes	VERB	O	B-Entity
mellitus	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
in	ADP	O	O
a	DET	O	O
1:1	NUM	O	O
ratio	NOUN	O	O
to	PART	O	O
receive	VERB	O	O
the	DET	O	O
4-mg	NUM	O	O
nicotine	NOUN	O	I-Entity
lozenge	NOUN	O	O
or	CCONJ	O	O
4-mg	NUM	O	O
nicotine	NOUN	O	I-Entity
gum	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
nicotine	NOUN	O	I-Entity
lozenge	NOUN	O	O
and	CCONJ	O	O
nicotine	NOUN	O	I-Entity
gum	NOUN	O	O
were	VERB	O	O
equally	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
despite	ADP	O	O
increased	VERB	O	O
nicotine	NOUN	O	I-Entity
exposure	NOUN	O	O
from	ADP	O	O
the	DET	O	O
lozenge	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
17.2%	NUM	O	O
and	CCONJ	O	O
16.1%	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
-3.7	PROPN	O	O
to	ADP	O	O
6.0	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hiccups	NOUN	O	I-Entity
(	PUNCT	O	O
10.7%	NUM	O	O
and	CCONJ	O	O
6.6%	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
0.5	NUM	O	O
to	ADP	O	O
7.8	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	I-Entity
(	PUNCT	O	O
8.7%	NUM	O	O
and	CCONJ	O	O
9.9%	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
Cl	PROPN	O	O
,	PUNCT	O	O
-5.0	PROPN	O	O
to	ADP	O	O
2.6	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
4-mg	NUM	O	O
nicotine	NOUN	O	I-Entity
lozenge	NOUN	O	O
and	CCONJ	O	O
4-mg	NUM	O	O
nicotine	NOUN	O	I-Entity
gum	NOUN	O	O
had	VERB	O	O
comparable	ADJ	O	O
safety	NOUN	O	O
profiles	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
label	NOUN	O	O
-	PUNCT	O	O
restricted	VERB	O	O
medical	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14568327)

Development	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
parkinsonian	ADJ	O	I-Entity
monkeys	NOUN	O	O
may	VERB	O	O
depend	VERB	O	O
upon	ADP	O	O
rate	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	O
onset	NOUN	O	O
and/or	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
(	PUNCT	O	O
LIDs	PROPN	O	I-Entity
)	PUNCT	O	O
present	VERB	O	O
a	DET	O	O
major	ADJ	O	O
problem	NOUN	O	O
for	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
management	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Due	ADP	O	O
to	ADP	O	O
the	DET	O	O
interdependence	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
populations	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
difficult	ADJ	O	O
to	PART	O	O
independently	ADV	O	O
examine	VERB	O	O
factors	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
influence	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
LIDs	NOUN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
macaque	ADJ	O	O
monkeys	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
parkinsonism	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
degree	NOUN	O	O
to	PART	O	O
which	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	O
progression	NOUN	O	O
,	PUNCT	O	O
symptom	NOUN	O	O
severity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
response	NOUN	O	O
to	ADP	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
LIDs	NOUN	O	I-Entity
.	PUNCT	O	O

MPTP	PROPN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
rapid	ADJ	O	O
symptom	NOUN	O	O
onset	NOUN	O	O
and	CCONJ	O	O
short	ADJ	O	O
symptom	NOUN	O	O
duration	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
developed	VERB	O	O
dyskinesia	NOUN	O	I-Entity
between	ADP	O	O
11	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
levodopa	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
monkeys	NOUN	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
MPTP	PROPN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
slow	ADJ	O	O
symptom	NOUN	O	O
progression	NOUN	O	O
and/or	CCONJ	O	O
long	ADJ	O	O
symptom	ADJ	O	O
duration	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
resistant	ADJ	O	O
to	ADP	O	O
developing	VERB	O	O
LIDs	NOUN	O	I-Entity
(	PUNCT	O	O
e.g.	ADV	O	O
,	PUNCT	O	O
dyskinesia	NOUN	O	I-Entity
developed	VERB	O	O
no	DET	O	O
sooner	ADJ	O	O
than	ADP	O	O
146	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
levodopa	NOUN	O	I-Entity
administration	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
animals	NOUN	O	O
were	VERB	O	O
similarly	ADV	O	O
symptomatic	ADJ	O	O
at	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
similar	ADJ	O	O
therapeutic	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
distinct	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
propensity	NOUN	O	O
to	PART	O	O
develop	VERB	O	O
LIDs	NOUN	O	I-Entity
in	ADP	O	O
monkeys	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
rates	NOUN	O	O
of	ADP	O	O
symptom	NOUN	O	O
progression	NOUN	O	O
or	CCONJ	O	O
symptom	NOUN	O	O
durations	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
levodopa	NOUN	O	I-Entity
and	CCONJ	O	O
demonstrate	VERB	O	O
the	DET	O	O
value	NOUN	O	O
of	ADP	O	O
these	DET	O	O
models	NOUN	O	O
for	ADP	O	O
further	ADV	O	O
studying	VERB	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
LIDs	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11250767)

Propylthiouracil	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
perinuclear	NOUN	O	O
-	PUNCT	O	O
staining	VERB	O	O
antineutrophil	NOUN	O	O
cytoplasmic	ADJ	O	O
autoantibody	NOUN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
vasculitis	NOUN	O	I-Entity
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
pericarditis	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
manifesting	VERB	O	O
with	ADP	O	O
pericarditis	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
present	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
with	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
in	ADP	O	O
whom	NOUN	O	O
a	DET	O	O
syndrome	NOUN	O	O
of	ADP	O	O
pericarditis	NOUN	O	I-Entity
,	PUNCT	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
glomerulonephritis	NOUN	O	I-Entity
developed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
25-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
febrile	ADJ	O	B-Entity
illness	NOUN	O	I-Entity
and	CCONJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
pericarditis	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
confirmed	VERB	O	O
by	ADP	O	O
biopsy	NOUN	O	O
.	PUNCT	O	O

Propylthiouracil	PROPN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
withdrawn	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
she	PRON	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
1-month	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
prednisone	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
alleviated	VERB	O	O
her	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
literature	NOUN	O	O
review	NOUN	O	O
revealed	VERB	O	O
no	DET	O	O
prior	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
pericarditis	NOUN	O	I-Entity
in	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
MPO	PROPN	O	O
pANCA	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
vasculitis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
propylthio-	ADJ	O	B-Entity
uracil	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Pericarditis	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
manifestation	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
attributable	ADJ	O	O
to	ADP	O	O
propylthio-	VERB	O	B-Entity
uracil	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11206082)

Two	NUM	O	O
mouse	NOUN	O	O
lines	NOUN	O	O
selected	VERB	O	O
for	ADP	O	O
differential	NOUN	O	O
sensitivities	NOUN	O	O
to	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
carboline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
are	VERB	O	O
also	ADV	O	O
differentially	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
various	ADJ	O	O
pharmacological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O

Two	NUM	O	O
mouse	NOUN	O	O
lines	NOUN	O	O
were	VERB	O	O
selectively	ADV	O	O
bred	VERB	O	O
according	VERB	O	O
to	ADP	O	O
their	ADJ	O	O
sensitivity	NOUN	O	O
(	PUNCT	O	O
BS	PROPN	O	O
line	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
resistance	NOUN	O	O
(	PUNCT	O	O
BR	PROPN	O	O
line	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
methyl	NOUN	O	B-Entity
beta	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
carboline-3-carboxylate	NOUN	O	I-Entity
(	PUNCT	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
CCM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inverse	NOUN	O	O
agonist	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
benzodiazepine	NOUN	O	I-Entity
site	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
characterize	VERB	O	O
both	DET	O	O
lines	NOUN	O	O
'	PART	O	O
sensitivities	NOUN	O	O
to	ADP	O	O
various	ADJ	O	O
physiological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
ligands	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
measured	VERB	O	O
diazepam	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anxiolysis	NOUN	O	O
with	ADP	O	O
the	DET	O	O
elevated	VERB	O	O
plus	CCONJ	O	O
-	PUNCT	O	O
maze	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
diazepam	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sedation	NOUN	O	O
by	ADP	O	O
recording	VERB	O	O
the	DET	O	O
vigilance	NOUN	O	O
states	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
picrotoxin-	ADJ	O	I-Entity
and	CCONJ	O	O
pentylenetetrazol	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
presented	VERB	O	O
here	ADV	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
differential	ADJ	O	O
sensitivities	NOUN	O	O
of	ADP	O	O
BS	PROPN	O	O
and	CCONJ	O	O
BR	PROPN	O	O
lines	NOUN	O	O
to	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
CCM	PROPN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
extended	VERB	O	O
to	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
picrotoxin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
pentylenetetrazol	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
a	DET	O	O
genetic	ADJ	O	O
selection	NOUN	O	O
of	ADP	O	O
a	DET	O	O
general	ADJ	O	O
sensitivity	NOUN	O	O
and	CCONJ	O	O
resistance	NOUN	O	O
to	ADP	O	O
several	ADJ	O	O
ligands	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11027905)

Analgesic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
ketamine	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
morphine	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
not	ADV	O	O
responsive	ADJ	O	O
to	ADP	O	O
morphine	NOUN	O	I-Entity
is	VERB	O	O
often	ADV	O	O
problematic	ADJ	O	O
.	PUNCT	O	O

Animal	PROPN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
ketamine	NOUN	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
improving	VERB	O	O
opioid	ADJ	O	O
analgesia	NOUN	O	O
in	ADP	O	O
difficult	ADJ	O	O
pain	NOUN	O	I-Entity
syndromes	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
slow	ADJ	O	O
bolus	NOUN	O	O
of	ADP	O	O
subhypnotic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
(	PUNCT	O	O
0.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
or	CCONJ	O	O
0.50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
10	NUM	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
whose	ADJ	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
unrelieved	ADJ	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
intensity	NOUN	O	O
on	ADP	O	O
a	DET	O	O
0	NUM	O	O
to	PART	O	O
10	NUM	O	O
numerical	ADJ	O	O
scale	NOUN	O	O
;	PUNCT	O	O

nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
drowsiness	NOUN	O	O
,	PUNCT	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dry	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
scale	NOUN	O	O
from	ADP	O	O
0	NUM	O	O
to	ADP	O	O
3	NUM	O	O
(	PUNCT	O	O
not	ADV	O	O
at	ADV	O	O
all	ADV	O	O
,	PUNCT	O	O
slight	ADJ	O	O
,	PUNCT	O	O
a	DET	O	O
lot	NOUN	O	O
,	PUNCT	O	O
awful	ADJ	O	O
)	PUNCT	O	O
;	PUNCT	O	O
Mini	PROPN	O	O
-	PUNCT	O	O
Mental	PROPN	O	O
State	PROPN	O	O
Examination	PROPN	O	O
(	PUNCT	O	O
MMSE	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
0	NUM	O	O
-	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
before	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
T0	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T30	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
60	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T60	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
120	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T120	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
180	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
T180	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
saline	ADJ	O	O
solution	NOUN	O	O
,	PUNCT	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
intensity	NOUN	O	O
in	ADP	O	O
almost	ADV	O	O
all	ADJ	O	O
the	DET	O	O
patients	NOUN	O	O
at	ADP	O	O
both	DET	O	O
doses	NOUN	O	O
.	PUNCT	O	O

Hallucinations	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
4	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
unpleasant	ADJ	O	O
sensation	NOUN	O	O
(	PUNCT	O	O
"	PUNCT	O	O
empty	ADJ	O	O
head	NOUN	O	O
"	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
reported	VERB	O	O
by	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
episodes	NOUN	O	O
reversed	VERB	O	O
after	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
1	NUM	O	O
mg	NUM	O	O
intravenously	ADV	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
drowsiness	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
more	ADJ	O	O
marked	ADJ	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
0.50	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
MMSE	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
at	ADP	O	O
T30	PROPN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
0.50	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
can	VERB	O	O
improve	VERB	O	O
morphine	NOUN	O	I-Entity
analgesia	NOUN	O	O
in	ADP	O	O
difficult	ADJ	O	O
pain	NOUN	O	I-Entity
syndromes	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
studies	NOUN	O	O
of	ADP	O	O
prolonged	VERB	O	O
ketamine	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9334596)

Endocrine	NOUN	O	O
screening	VERB	O	O
in	ADP	O	O
1,022	NUM	O	O
men	NOUN	O	O
with	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
:	PUNCT	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
and	CCONJ	O	O
cost	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
strategy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
reviewed	VERB	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
testosterone	NOUN	O	I-Entity
and	CCONJ	O	O
prolactin	NOUN	O	O
determination	NOUN	O	O
in	ADP	O	O
1,022	NUM	O	O
patients	NOUN	O	O
referred	VERB	O	O
because	ADP	O	O
of	ADP	O	O
erectile	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
compared	VERB	O	O
the	DET	O	O
data	NOUN	O	O
with	ADP	O	O
history	NOUN	O	O
,	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
examination	NOUN	O	O
,	PUNCT	O	O
other	ADJ	O	O
etiological	ADJ	O	O
investigations	NOUN	O	O
and	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
endocrine	NOUN	O	O
therapy	NOUN	O	O
to	PART	O	O
refine	VERB	O	O
the	DET	O	O
rules	NOUN	O	O
of	ADP	O	O
cost	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
endocrine	NOUN	O	O
screening	VERB	O	O
and	CCONJ	O	O
to	PART	O	O
pinpoint	VERB	O	O
actual	ADJ	O	O
responsibility	NOUN	O	O
for	ADP	O	O
hormonal	ADJ	O	O
abnormalities	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
:	PUNCT	O	O
Testosterone	NOUN	O	I-Entity
and	CCONJ	O	O
prolactin	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
radioimmunoassay	NOUN	O	O
.	PUNCT	O	O

Every	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
screened	VERB	O	O
for	ADP	O	O
testosterone	NOUN	O	I-Entity
and	CCONJ	O	O
451	NUM	O	O
were	VERB	O	O
screened	VERB	O	O
for	ADP	O	O
prolactin	NOUN	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
low	ADJ	O	B-Entity
sexual	ADJ	O	I-Entity
desire	NOUN	O	I-Entity
,	PUNCT	O	O
gynecomastia	NOUN	O	I-Entity
or	CCONJ	O	O
testosterone	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
4	NUM	O	O
ng./ml	NUM	O	O
.	PUNCT	O	O

Prolactin	ADJ	O	O
results	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
a	DET	O	O
previous	ADJ	O	O
personal	ADJ	O	O
cohort	NOUN	O	O
of	ADP	O	O
1,340	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
systematic	ADJ	O	O
prolactin	NOUN	O	O
determination	NOUN	O	O
.	PUNCT	O	O

Main	ADJ	O	O
clinical	ADJ	O	O
criteria	NOUN	O	O
tested	VERB	O	O
regarding	VERB	O	O
efficiency	NOUN	O	O
in	ADP	O	O
hormone	NOUN	O	O
determination	NOUN	O	O
were	VERB	O	O
low	ADJ	O	B-Entity
sexual	ADJ	O	I-Entity
desire	NOUN	O	I-Entity
,	PUNCT	O	O
small	ADJ	O	O
testes	NOUN	O	O
and	CCONJ	O	O
gynecomastia	NOUN	O	I-Entity
.	PUNCT	O	O

Endocrine	NOUN	O	O
therapy	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
testosterone	NOUN	O	B-Entity
heptylate	NOUN	O	I-Entity
or	CCONJ	O	O
human	ADJ	O	O
chorionic	NOUN	O	O
gonadotropin	NOUN	O	O
for	ADP	O	O
hypogonadism	NOUN	O	I-Entity
and	CCONJ	O	O
bromocriptine	NOUN	O	I-Entity
for	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

Testosterone	NOUN	O	I-Entity
was	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
3	NUM	O	O
ng./ml	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
repeatedly	ADV	O	O
low	ADJ	O	O
testosterone	NOUN	O	I-Entity
increased	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
(	PUNCT	O	O
4%	NUM	O	O
before	ADP	O	O
age	NOUN	O	O
50	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
9%	NUM	O	O
50	NUM	O	O
years	NOUN	O	O
or	CCONJ	O	O
older	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
pituitary	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
were	VERB	O	O
discovered	VERB	O	O
after	ADP	O	O
testosterone	NOUN	O	I-Entity
determination	NOUN	O	O
.	PUNCT	O	O

Most	ADJ	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
low	ADJ	O	O
testosterone	NOUN	O	I-Entity
levels	NOUN	O	O
seemed	VERB	O	O
to	ADP	O	O
result	VERB	O	O
from	ADP	O	O
nonorganic	ADJ	O	O
hypothalamic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
because	ADP	O	O
of	ADP	O	O
normal	ADJ	O	O
serum	NOUN	O	O
luteinizing	VERB	O	O
hormone	NOUN	O	O
and	CCONJ	O	O
prolactin	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
have	VERB	O	O
only	ADV	O	O
a	DET	O	O
small	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
(	PUNCT	O	O
definite	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
only	ADV	O	O
16	NUM	O	O
of	ADP	O	O
44	NUM	O	O
[	PUNCT	O	O
36%	NUM	O	O
]	PUNCT	O	O
after	ADP	O	O
androgen	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
normal	ADJ	O	O
morning	NOUN	O	O
or	CCONJ	O	O
nocturnal	ADJ	O	O
erections	NOUN	O	O
in	ADP	O	O
30%	NUM	O	O
and	CCONJ	O	O
definite	ADJ	O	O
vasculogenic	ADJ	O	O
contributions	NOUN	O	O
in	ADP	O	O
42%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Determining	VERB	O	O
testosterone	NOUN	O	I-Entity
only	ADV	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
low	ADJ	O	B-Entity
sexual	ADJ	O	I-Entity
desire	NOUN	O	I-Entity
or	CCONJ	O	O
abnormal	ADJ	O	O
physical	ADJ	O	O
examination	NOUN	O	O
would	VERB	O	O
have	VERB	O	O
missed	VERB	O	O
40%	NUM	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
testosterone	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
37%	NUM	O	O
of	ADP	O	O
those	DET	O	O
subsequently	ADV	O	O
improved	VERB	O	O
by	ADP	O	O
androgen	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
1	NUM	O	O
prolactinoma	NOUN	O	I-Entity
was	VERB	O	O
discovered	VERB	O	O
.	PUNCT	O	O

in	ADP	O	O
1.86%	NUM	O	O
of	ADP	O	O
1,821	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
prolactinomas	NOUN	O	I-Entity
in	ADP	O	O
7	NUM	O	O
,	PUNCT	O	O
0.38%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Bromocriptine	PROPN	O	I-Entity
was	VERB	O	O
definitely	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
cases	NOUN	O	O
with	ADP	O	O
prolactin	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
35	NUM	O	O
ng./ml	NOUN	O	O
.	PUNCT	O	O

Testosterone	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
in	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
50%	NUM	O	O
of	ADP	O	O
cases	NOUN	O	O
with	ADP	O	O
prolactin	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
35	NUM	O	O
ng./ml	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
prevalences	NOUN	O	O
and	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
testosterone	NOUN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
prolactin	NOUN	O	O
in	ADP	O	O
erectile	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
can	VERB	O	O
not	ADV	O	O
justify	VERB	O	O
their	ADJ	O	O
routine	ADJ	O	O
determination	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
cost	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
screening	NOUN	O	O
strategies	NOUN	O	O
recommended	VERB	O	O
so	ADV	O	O
far	ADV	O	O
missed	VERB	O	O
40	NUM	O	O
to	ADP	O	O
50%	NUM	O	O
of	ADP	O	O
cases	NOUN	O	O
improved	VERB	O	O
with	ADP	O	O
endocrine	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
pituitary	ADJ	O	B-Entity
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
now	ADV	O	O
advocate	VERB	O	O
that	DET	O	O
before	ADP	O	O
age	NOUN	O	O
50	NUM	O	O
years	NOUN	O	O
testosterone	NOUN	O	I-Entity
be	VERB	O	O
determined	VERB	O	O
only	ADV	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
low	ADJ	O	B-Entity
sexual	ADJ	O	I-Entity
desire	NOUN	O	I-Entity
and	CCONJ	O	O
abnormal	ADJ	O	O
physical	ADJ	O	O
examination	NOUN	O	O
but	CCONJ	O	O
that	ADP	O	O
it	PRON	O	O
be	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
all	DET	O	O
men	NOUN	O	O
older	ADJ	O	O
than	ADP	O	O
50	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Prolactin	PROPN	O	O
should	VERB	O	O
be	VERB	O	O
determined	VERB	O	O
only	ADV	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
low	ADJ	O	B-Entity
sexual	ADJ	O	I-Entity
desire	NOUN	O	I-Entity
,	PUNCT	O	O
gynecomastia	NOUN	O	I-Entity
and/or	CCONJ	O	O
testosterone	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
4	NUM	O	O
ng./ml	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8595686)

Thiopentone	NOUN	O	I-Entity
pretreatment	NOUN	O	O
for	ADP	O	O
propofol	NOUN	O	I-Entity
injection	NOUN	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
ambulatory	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
propofol	NOUN	O	I-Entity
injection	NOUN	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
ambulatory	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
allocated	VERB	O	O
to	PART	O	O
receive	VERB	O	O
one	NUM	O	O
of	ADP	O	O
three	NUM	O	O
treatments	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
C	PROPN	O	O
received	VERB	O	O
2	NUM	O	O
ml	ADP	O	O
normal	ADJ	O	O
saline	NOUN	O	O
,	PUNCT	O	O
Group	PROPN	O	O
L	PROPN	O	O
,	PUNCT	O	O
2	NUM	O	O
ml	NOUN	O	O
,	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
2%	NUM	O	O
(	PUNCT	O	O
40	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Group	PROPN	O	O
T	PROPN	O	O
,	PUNCT	O	O
2	NUM	O	O
ml	CCONJ	O	O

thiopentone	NOUN	O	I-Entity
2.5%	NUM	O	O
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Venous	ADJ	O	O
discomfort	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
VAS	PROPN	O	O
)	PUNCT	O	O
5	NUM	O	O
-	SYM	O	O
15	NUM	O	O
sec	NOUN	O	O
after	ADP	O	O
commencing	VERB	O	O
propofol	ADJ	O	I-Entity
administration	NOUN	O	O
using	VERB	O	O
an	DET	O	O
infusion	NOUN	O	O
pump	NOUN	O	O
(	PUNCT	O	O
rate	NOUN	O	O
1000	NUM	O	O
micrograms.kg-1.min-1	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
consciousness	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
60	NUM	O	O
-	SYM	O	O
90	NUM	O	O
sec	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
VAS	PROPN	O	O
scores	NOUN	O	O
for	ADP	O	O
recall	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
recovery	NOUN	O	O
room	NOUN	O	O
were	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
VAS	PROPN	O	O
scores	NOUN	O	O
during	ADP	O	O
induction	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.7045	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Assessing	VERB	O	O
their	ADJ	O	O
overall	ADJ	O	O
satisfaction	NOUN	O	O
,	PUNCT	O	O
89.7%	NUM	O	O
would	VERB	O	O
choose	VERB	O	O
propofol	ADJ	O	I-Entity
anaesthesia	NOUN	O	O
again	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
lidocaine	NOUN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
propofol	ADJ	O	I-Entity
injection	NOUN	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
ambulatory	ADJ	O	O
patients	NOUN	O	O
whereas	ADP	O	O
thiopentone	NOUN	O	I-Entity
only	ADV	O	O
reduces	VERB	O	O
its	ADJ	O	O
severity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6466532)

glycopyrrolate	NOUN	O	I-Entity
and	CCONJ	O	O
atropine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
arrhythmias	NOUN	O	I-Entity
following	VERB	O	O
repeated	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
glycopyrrolate	NOUN	O	I-Entity
5	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
micrograms	NOUN	O	O
kg-1	NOUN	O	O
and	CCONJ	O	O
atropine	NOUN	O	I-Entity
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
micrograms	NOUN	O	O
kg-1	ADJ	O	O

immediately	ADV	O	O
before	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
prevent	VERB	O	O
arrhythmia	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
following	VERB	O	O
repeated	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
included	VERB	O	O
for	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
dose	NOUN	O	O
range	NOUN	O	O
of	ADP	O	O
glycopyrrolate	NOUN	O	I-Entity
and	CCONJ	O	O
atropine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
of	ADP	O	O
50%	NUM	O	O
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
the	DET	O	O
frequency	NOUN	O	O
with	ADP	O	O
the	DET	O	O
active	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Bradycardia	PROPN	O	I-Entity
(	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
to	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
50	NUM	O	O
beat	NOUN	O	O
min-1	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
prevented	VERB	O	O
when	ADV	O	O
the	DET	O	O
larger	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
either	DET	O	O
active	ADJ	O	O
drug	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
recommended	VERB	O	O
that	ADP	O	O
either	DET	O	O
glycopyrrolate	NOUN	O	I-Entity
10	NUM	O	O
micrograms	NOUN	O	O
kg-1	NOUN	O	O
or	CCONJ	O	O
atropine	NOUN	O	I-Entity
20	NUM	O	O
micrograms	NOUN	O	O
kg-1	SYM	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

should	VERB	O	O
immediately	ADV	O	O
precede	VERB	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
children	NOUN	O	O
,	PUNCT	O	O
if	ADP	O	O
the	DET	O	O
repeated	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
suxamethonium	NOUN	O	I-Entity
is	VERB	O	O
anticipated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (6308277)

Reduction	NOUN	O	O
in	ADP	O	O
caffeine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
by	ADP	O	O
acetaminophen	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
allegedly	ADV	O	O
consumed	VERB	O	O
100	NUM	O	O
tablets	NOUN	O	O
of	ADP	O	O
an	DET	O	O
over	ADP	O	O
-	PUNCT	O	O
the	DET	O	O
-	PUNCT	O	O
counter	NOUN	O	O
analgesic	NOUN	O	O
containing	VERB	O	O
sodium	NOUN	O	B-Entity
acetylsalicylate	NOUN	O	I-Entity
,	PUNCT	O	O
caffeine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
acetaminophen	NOUN	O	I-Entity
displayed	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
CNS	PROPN	O	O
stimulation	NOUN	O	O
despite	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
175	NUM	O	O
micrograms	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
per	ADP	O	O
mL	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
salicylates	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
augment	VERB	O	O
the	DET	O	O
stimulatory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
CNS	PROPN	O	O
,	PUNCT	O	O
attention	NOUN	O	O
was	VERB	O	O
focused	VERB	O	O
on	ADP	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
52	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
reduced	VERB	O	O
the	DET	O	O
CNS	PROPN	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
caffeine	NOUN	O	I-Entity
.	PUNCT	O	O

Studies	NOUN	O	O
in	ADP	O	O
DBA/2J	PROPN	O	O
mice	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
:	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
increased	VERB	O	O
the	DET	O	O
interval	NOUN	O	O
between	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
300	NUM	O	O
to	PART	O	O
450	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
IP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
convulsions	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
factor	NOUN	O	O
of	ADP	O	O
about	ADV	O	O
two	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
2	PUNCT	O	O
)	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
75	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
reduced	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
audiogenic	NOUN	O	O
seizures	NOUN	O	I-Entity
produced	VERB	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
12.5	NUM	O	O
to	PART	O	O
75	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
IP	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
sound	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
12.5	NUM	O	O
or	CCONJ	O	O
25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADP	O	O
caffeine	NOUN	O	I-Entity
was	VERB	O	O
reduced	VERB	O	O
from	ADP	O	O
50	NUM	O	O
to	PART	O	O
5%	NUM	O	O
by	ADP	O	O
acetaminophen	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
,	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
modify	VERB	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
maximal	ADJ	O	O
electroshock	NOUN	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
the	DET	O	O
convulsant	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
pentylenetetrezol	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
(	PUNCT	O	O
tests	NOUN	O	O
performed	VERB	O	O
by	ADP	O	O
the	DET	O	O
Anticonvulsant	PROPN	O	O
Screening	PROPN	O	O
Project	PROPN	O	O
of	ADP	O	O
NINCDS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Acetaminophen	PROPN	O	I-Entity
(	PUNCT	O	O
up	ADV	O	O
to	ADP	O	O
150	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
retard	VERB	O	O
the	DET	O	O
incorporation	NOUN	O	O
of	ADP	O	O
radioactive	ADJ	O	O
adenosine	NOUN	O	I-Entity
into	ADP	O	O
ATP	PROPN	O	I-Entity
in	ADP	O	O
slices	NOUN	O	O
of	ADP	O	O
rat	NOUN	O	O
cerebral	ADJ	O	O
cortex	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
the	DET	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
acetaminophen	NOUN	O	I-Entity
antagonizes	VERB	O	O
the	DET	O	O
actions	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
CNS	PROPN	O	O
remains	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (2870085)

Flestolol	PROPN	O	I-Entity
:	PUNCT	O	O

Flestolol	PROPN	O	I-Entity
(	PUNCT	O	O
ACC-9089	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
nonselective	ADJ	O	O
,	PUNCT	O	O
competitive	ADJ	O	O
,	PUNCT	O	O
ultra	ADV	O	O
-	PUNCT	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	NOUN	O	O
blocking	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
any	DET	O	O
intrinsic	ADJ	O	O
sympathomimetic	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Flestolol	PROPN	O	I-Entity
is	VERB	O	O
metabolized	VERB	O	O
by	ADP	O	O
plasma	NOUN	O	O
esterases	NOUN	O	O
and	CCONJ	O	O
has	VERB	O	O
an	DET	O	O
elimination	NOUN	O	O
half	NOUN	O	O
-	PUNCT	O	O
life	NOUN	O	O
of	ADP	O	O
approximately	ADV	O	O
6.5	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
infusion	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
flestolol	NOUN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
at	ADP	O	O
the	DET	O	O
effective	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
dose	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
up	ADP	O	O
to	PART	O	O
seven	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Flestolol	ADJ	O	I-Entity
blood	NOUN	O	O
concentrations	NOUN	O	O
increased	VERB	O	O
linearly	ADV	O	O
with	ADP	O	O
increasing	VERB	O	O
dose	NOUN	O	O
and	CCONJ	O	O
good	ADJ	O	O
correlation	NOUN	O	O
exists	VERB	O	O
between	ADP	O	O
blood	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
flestolol	NOUN	O	I-Entity
and	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
blockade	NOUN	O	O
.	PUNCT	O	O

Flestolol	PROPN	O	I-Entity
produced	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
attenuation	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Electrophysiologic	PROPN	O	O
and	CCONJ	O	O
hemodynamic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
flestolol	NOUN	O	I-Entity
are	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
other	ADJ	O	O
beta	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
beta	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
flestolol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
effects	NOUN	O	O
reverse	VERB	O	O
rapidly	ADV	O	O
(	PUNCT	O	O
within	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
following	VERB	O	O
discontinuation	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
short	ADJ	O	O
half	NOUN	O	O
-	PUNCT	O	O
life	NOUN	O	O
.	PUNCT	O	O

Flestolol	PROPN	O	I-Entity
effectively	ADV	O	O
reduced	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
supraventricular	ADJ	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
unstable	ADJ	O	B-Entity
angina	NOUN	O	I-Entity
,	PUNCT	O	O
flestolol	ADJ	O	I-Entity
infusion	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
in	ADP	O	O
controlling	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
flestolol	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potent	ADJ	O	O
,	PUNCT	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
ultra	ADV	O	O
-	PUNCT	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	NOUN	O	O
blocking	VERB	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
flestolol	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
critical	ADJ	O	O
care	NOUN	O	O
setting	VERB	O	O
is	VERB	O	O
currently	ADV	O	O
undergoing	VERB	O	O
investigation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1639466)

Adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
nitrendipine	NOUN	O	I-Entity
on	ADP	O	O
nephrosclerosis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
renovascular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
6-week	NUM	O	O
treatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
nitrendipine	NOUN	O	I-Entity
or	CCONJ	O	O
the	DET	O	O
angiotensin	NOUN	O	I-Entity
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
enalapril	NOUN	O	I-Entity
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
albuminuria	NOUN	O	I-Entity
,	PUNCT	O	O
renal	ADJ	O	O
hemodynamics	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
morphology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nonclipped	ADJ	O	O
kidney	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
two	NUM	O	O
-	PUNCT	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
clip	NOUN	O	O
renovascular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Six	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
clipping	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
renal	ADJ	O	O
artery	NOUN	O	O
,	PUNCT	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
(	PUNCT	O	O
178	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

4	PUNCT	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
untreated	ADJ	O	O
hypertensive	ADJ	O	I-Entity
controls	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
8)	NUM	O	O
,	PUNCT	O	O
enalapril	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
8)	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
nitrendipine	ADV	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
(	PUNCT	O	O

Enalapril	PROPN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
nitrendipine	ADJ	O	I-Entity
reduced	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
significantly	ADV	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
plasma	NOUN	O	O
flow	NOUN	O	O
increased	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
albumin	DET	O	O
excretion	NOUN	O	O
and	CCONJ	O	O
glomerulosclerosis	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
after	ADP	O	O
enalapril	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
nitrendipine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
albuminuria	NOUN	O	I-Entity
increased	VERB	O	O
from	ADP	O	O
12.8	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

9	NUM	O	O
mg/24	NOUN	O	O
hr	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
controls	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
glomerulosclerosis	NOUN	O	I-Entity
index	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
nitrendipine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
controls	NOUN	O	O
(	PUNCT	O	O
0.38	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
glomerular	ADJ	O	O
size	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
the	DET	O	O
nitrendipine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
14.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.17	NUM	O	O
10(-3	NUM	O	O
)	PUNCT	O	O
mm2	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
enalapril	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
11.5	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

mm2	PUNCT	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
controls	NOUN	O	O
(	PUNCT	O	O
12.1	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O


-DOCSTART- (1527456)

Treatment	NOUN	O	O
of	ADP	O	O
tinnitus	NOUN	O	I-Entity
by	ADP	O	O
intratympanic	ADJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
lignocaine	NOUN	O	I-Entity
(	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
)	PUNCT	O	O
2	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
through	ADP	O	O
ventilation	NOUN	O	O
tubes	NOUN	O	O
.	PUNCT	O	O

Idiopathic	PROPN	O	B-Entity
subjective	ADJ	O	I-Entity
tinnitus	NOUN	O	I-Entity
(	PUNCT	O	O
IST	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
obscure	ADJ	O	O
otological	ADJ	O	O
pathologies	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
paper	NOUN	O	O
presents	VERB	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
IST	NOUN	O	I-Entity
by	ADP	O	O
intratympanic	ADJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
lignocaine	NOUN	O	I-Entity
(	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
)	PUNCT	O	O
2	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
through	ADP	O	O
a	DET	O	O
grommet	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
five	NUM	O	O
weekly	ADJ	O	O
courses	NOUN	O	O
.	PUNCT	O	O

Fifty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
intractable	ADJ	O	O
tinnitus	NOUN	O	I-Entity
entered	VERB	O	O
this	DET	O	O
therapeutic	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
nine	NUM	O	O
finished	VERB	O	O
all	DET	O	O
five	NUM	O	O
courses	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
tinnitus	NOUN	O	I-Entity
was	VERB	O	O
almost	ADV	O	O
completely	ADV	O	O
abolished	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
all	ADJ	O	O
the	DET	O	O
nine	NUM	O	O
patients	NOUN	O	O
the	DET	O	O
decompensated	ADJ	O	O
tinnitus	NOUN	O	I-Entity
changed	VERB	O	O
to	ADP	O	O
a	DET	O	O
compensated	VERB	O	O
one	NUM	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
warned	VERB	O	O
about	ADP	O	O
the	DET	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
vertigo	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
subsides	VERB	O	O
gradually	ADV	O	O
with	ADP	O	O
every	DET	O	O
new	ADJ	O	O
instillation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
tinnitus	NOUN	O	I-Entity
may	VERB	O	O
not	ADV	O	O
disappear	VERB	O	O
but	CCONJ	O	O
will	VERB	O	O
be	VERB	O	O
alleviated	VERB	O	O
,	PUNCT	O	O
enabling	VERB	O	O
them	PRON	O	O
to	PART	O	O
cope	VERB	O	O
more	ADV	O	O
easily	ADV	O	O
with	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
and	CCONJ	O	O
lead	VERB	O	O
a	DET	O	O
more	ADV	O	O
normal	ADJ	O	O
life	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (220563)

Perhexiline	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
and	CCONJ	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Peripheral	PROPN	O	B-Entity
neuropathy	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
noted	VERB	O	O
as	ADP	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
perhexiline	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
drug	NOUN	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
France	PROPN	O	O
(	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
angina	NOUN	O	B-Entity
pectoris	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
marked	ADJ	O	O
slowing	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
nerve	NOUN	O	O
conduction	NOUN	O	O
velocity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
electromyographic	ADJ	O	O
changes	NOUN	O	O
imply	VERB	O	O
mainly	ADV	O	O
a	DET	O	O
demyelinating	VERB	O	B-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
underlying	VERB	O	O
mechanism	NOUN	O	O
causing	VERB	O	O
the	DET	O	O
neuropathy	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
yet	ADV	O	O
fully	ADV	O	O
known	VERB	O	O
,	PUNCT	O	O
although	ADP	O	O
some	DET	O	O
evidence	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
lipid	ADJ	O	O
storage	NOUN	O	O
process	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (137340)

Effect	NOUN	O	O
of	ADP	O	O
humoral	ADJ	O	O
modulators	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
locomotor	NOUN	O	I-Entity
activity	NOUN	O	I-Entity
of	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
humoral	ADJ	O	O
modulators	NOUN	O	O
on	ADP	O	O
the	DET	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
locomotor	NOUN	O	I-Entity
activity	NOUN	O	I-Entity
of	ADP	O	O
mice	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
HC1	PROPN	O	O
produced	VERB	O	O
a	DET	O	O
marked	ADJ	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
locomotor	NOUN	O	I-Entity
activity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
was	VERB	O	O
potentiated	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
attenuated	VERB	O	O
by	ADP	O	O
physostigmine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
methscopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
neostigmine	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
do	VERB	O	O
not	ADV	O	O
penetrate	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
,	PUNCT	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
hyperactivity	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyltyrosine	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

,	PUNCT	O	O
one	NUM	O	O
hour	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
tyrosine	NOUN	O	I-Entity
hydroxylase	NOUN	O	O
,	PUNCT	O	O
significantly	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
-	PUNCT	O	O
increasing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
p	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
chlorophenylalamine	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
X	PROPN	O	O
320	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

,	PUNCT	O	O
24	NUM	O	O
hr	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
serotonin	NOUN	O	I-Entity
depletor	NOUN	O	O
,	PUNCT	O	O
caused	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
-	PUNCT	O	O
increasing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
are	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
catecholamines	NOUN	O	I-Entity
from	ADP	O	O
adrenergic	ADJ	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

And	CCONJ	O	O
the	DET	O	O
results	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
morphine	NOUN	O	I-Entity
acts	VERB	O	O
by	ADP	O	O
retarding	VERB	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
acetylcholine	NOUN	O	I-Entity
at	ADP	O	O
some	DET	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
synapses	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
also	ADV	O	O
suggested	VERB	O	O
from	ADP	O	O
collected	VERB	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
-	PUNCT	O	O
increasing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
are	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
mechanisms	NOUN	O	O
different	ADJ	O	O
from	ADP	O	O
those	DET	O	O
which	ADJ	O	O
mediate	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
-	PUNCT	O	O
increasing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9931093)

Mechanisms	PROPN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506-induced	NUM	O	I-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

-Tacrolimus	PROPN	O	I-Entity
(	PUNCT	O	O
FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
powerful	ADJ	O	O
,	PUNCT	O	O
widely	ADV	O	O
used	ADJ	O	O
immunosuppressant	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
utility	NOUN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
is	VERB	O	O
complicated	VERB	O	O
by	ADP	O	O
substantial	ADJ	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
clarify	VERB	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506-induced	NUM	O	I-Entity
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
the	DET	O	O
chronic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
on	ADP	O	O
the	DET	O	O
synthesis	NOUN	O	O
of	ADP	O	O
endothelin-1	PROPN	O	O
(	PUNCT	O	O
ET-1	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
mRNA	PROPN	O	O
of	ADP	O	O
ET-1	PROPN	O	O
and	CCONJ	O	O
endothelin	ADV	O	O
-	PUNCT	O	O
converting	VERB	O	O
enzyme-1	NOUN	O	O
(	PUNCT	O	O
ECE-1	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
endothelial	ADJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
eNOS	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
mRNA	PROPN	O	O
of	ADP	O	O
eNOS	PROPN	O	O
and	CCONJ	O	O
C	PROPN	O	O
-	PUNCT	O	O
type	NOUN	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
(	PUNCT	O	O
CNP	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
rat	NOUN	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
specific	ADJ	O	O
endothelin	NOUN	O	O
type	NOUN	O	O
A	DET	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
FR	PROPN	O	B-Entity
139317	NUM	O	I-Entity
on	ADP	O	O
FK	PROPN	O	B-Entity
506-induced	NUM	O	I-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
,	PUNCT	O	O
5	NUM	O	O
mg	PRON	O	O
.	PUNCT	O	O

FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
decreased	VERB	O	O
eNOS	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
eNOS	PROPN	O	O
mRNA	PROPN	O	O
in	ADP	O	O
the	DET	O	O
aorta	NOUN	O	O
(	PUNCT	O	O
48%	NUM	O	O
and	CCONJ	O	O
55%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
FR	PROPN	O	B-Entity
139317	NUM	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

d-1	PUNCT	O	O
)	PUNCT	O	O
prevented	VERB	O	O
FK	PROPN	O	B-Entity
506-induced	NUM	O	I-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
FK	PROPN	O	B-Entity
506	NUM	O	I-Entity
may	VERB	O	O
increase	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
not	ADV	O	O
only	ADV	O	O
by	ADP	O	O
increasing	VERB	O	O
ET-1	ADJ	O	O
production	NOUN	O	O
but	CCONJ	O	O
also	ADV	O	O
by	ADP	O	O
decreasing	VERB	O	O
NO	DET	O	I-Entity
synthesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vasculature	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20633755)

Suxamethonium	PROPN	O	I-Entity
induced	VERB	O	O
prolonged	ADJ	O	O
apnea	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
receiving	VERB	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Suxamethonium	PROPN	O	I-Entity
causes	VERB	O	O
prolonged	ADJ	O	O
apnea	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
pseudocholinesterase	NOUN	O	O
enzyme	NOUN	O	O
gets	VERB	O	O
deactivated	VERB	O	O
by	ADP	O	O
organophosphorus	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
OP	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
poisons	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
present	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
incident	NOUN	O	O
in	ADP	O	O
a	DET	O	O
severely	ADV	O	O
depressed	ADJ	O	I-Entity
patient	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ECT	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Prolonged	VERB	O	O
apnea	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
case	NOUN	O	O
ensued	ADV	O	O
because	ADP	O	O
the	DET	O	O
information	NOUN	O	O
about	ADP	O	O
suicidal	ADJ	O	O
attempt	NOUN	O	O
by	ADP	O	O
OP	NOUN	O	B-Entity
compound	NOUN	O	I-Entity
was	VERB	O	O
concealed	VERB	O	O
from	ADP	O	O
the	DET	O	O
treating	VERB	O	O
team	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20067456)

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adjunctive	ADJ	O	O
bupropion	NOUN	O	I-Entity
on	ADP	O	O
male	ADJ	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
selective	ADJ	O	B-Entity
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	I-Entity
inhibitor	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
and	CCONJ	O	O
randomized	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
adjunctive	ADJ	O	O
bupropion	NOUN	O	I-Entity
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
(	PUNCT	O	O
SR	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
male	ADJ	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
(	PUNCT	O	O
SD	PROPN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
selective	ADJ	O	B-Entity
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	I-Entity
inhibitor	NOUN	O	I-Entity
(	PUNCT	O	O
SSRI	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
as	ADP	O	O
SD	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
SSRIs	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
most	ADV	O	O
effective	ADJ	O	O
treatments	NOUN	O	O
have	VERB	O	O
yet	ADV	O	O
to	PART	O	O
be	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
randomized	ADJ	O	O
sample	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
234	NUM	O	O
euthymic	ADJ	O	O
men	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
some	DET	O	O
type	NOUN	O	O
of	ADP	O	O
SSRI	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
men	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
bupropion	NOUN	O	I-Entity
SR	PROPN	O	O
(	PUNCT	O	O
150	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
,	PUNCT	O	O
117	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
twice	ADV	O	O
daily	ADV	O	O
,	PUNCT	O	O
117	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
the	DET	O	O
Clinical	PROPN	O	O
Global	ADJ	O	O
Impression	NOUN	O	O
-	PUNCT	O	O
Sexual	ADJ	O	O
Function	PROPN	O	O
(	PUNCT	O	O
CGI	PROPN	O	O
-	PUNCT	O	O
SF	PROPN	O	O
;	PUNCT	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
International	PROPN	O	O
Index	PROPN	O	O
of	ADP	O	O
Erectile	PROPN	O	O
Function	PROPN	O	O
(	PUNCT	O	O
IIEF	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Arizona	PROPN	O	O
Sexual	PROPN	O	O
Experience	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
ASEX	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Erectile	PROPN	O	B-Entity
Dysfunction	PROPN	O	I-Entity
Inventory	PROPN	O	O
of	ADP	O	O
Treatment	PROPN	O	O
Satisfaction	PROPN	O	O
(	PUNCT	O	O
EDITS	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
secondary	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
(	PUNCT	O	O
sd	NOUN	O	O
)	PUNCT	O	O
scores	NOUN	O	O
for	ADP	O	O
CGI	PROPN	O	O
-	PUNCT	O	O
SF	PROPN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
,	PUNCT	O	O
i.e.	X	O	O
better	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
bupropion	NOUN	O	I-Entity
SR	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
2.4	NUM	O	O
(	PUNCT	O	O
1.2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
3.9	NUM	O	O
(	PUNCT	O	O
1.1	NUM	O	O
)	PUNCT	O	O

Men	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
bupropion	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
IIEF	PROPN	O	O
score	NOUN	O	O
(	PUNCT	O	O
54.4%	NUM	O	O
vs	ADP	O	O
1.2%	NUM	O	O
;	PUNCT	O	O
P=	PROPN	O	O
0.003	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
five	NUM	O	O
different	ADJ	O	O
domains	NOUN	O	O
of	ADP	O	O
the	DET	O	O
IIEF	PROPN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
ASEX	PROPN	O	O
scores	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
,	PUNCT	O	O
i.e.	X	O	O
better	ADV	O	O
,	PUNCT	O	O
among	ADP	O	O
men	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
bupropion	NOUN	O	I-Entity
than	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
15.5	NUM	O	O
(	PUNCT	O	O
4.3	NUM	O	O
)	PUNCT	O	O
vs	ADP	O	O
21.5	NUM	O	O
(	PUNCT	O	O
4.7	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P=	PROPN	O	O
0.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
EDITS	PROPN	O	O
scores	NOUN	O	O
were	VERB	O	O
67.4	NUM	O	O
(	PUNCT	O	O
10.2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
bupropion	NOUN	O	I-Entity
and	CCONJ	O	O
36.3	NUM	O	O
(	PUNCT	O	O
11.7	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P=	PROPN	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
linear	NOUN	O	O
regression	NOUN	O	O
analyses	VERB	O	O
the	DET	O	O
CGI	PROPN	O	O
-	PUNCT	O	O
SF	PROPN	O	O
score	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
significantly	ADV	O	O
by	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
SD	PROPN	O	I-Entity
,	PUNCT	O	O
type	NOUN	O	O
of	ADP	O	O
SSRI	PROPN	O	I-Entity
used	VERB	O	O
and	CCONJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

Bupropion	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
male	NOUN	O	O
SD	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
SSRIs	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
empirical	ADJ	O	O
support	NOUN	O	O
for	ADP	O	O
conducting	VERB	O	O
a	DET	O	O
further	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18464113)

Lamivudine	PROPN	O	I-Entity
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
reactivation	NOUN	O	O
in	ADP	O	O
hepatitis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
B	NOUN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
(	PUNCT	O	O
HBSAG	PROPN	O	I-Entity
)	PUNCT	O	O
seropositive	ADJ	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
undergoing	VERB	O	O
cytotoxic	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HBV	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
worldwide	ADV	O	O
.	PUNCT	O	O

Cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
chronic	ADJ	O	O
carriers	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
have	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
hepatic	ADJ	O	B-Entity
complication	NOUN	O	I-Entity
rate	NOUN	O	O
while	ADP	O	O
receiving	VERB	O	O
cytotoxic	NOUN	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
CT	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
has	VERB	O	O
mainly	ADV	O	O
been	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
HBV	PROPN	O	O
reactivation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
solid	ADJ	O	O
and	CCONJ	O	O
hematological	ADJ	O	B-Entity
malignancies	NOUN	O	I-Entity
with	ADP	O	O
chronic	ADJ	O	O
HBV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
received	VERB	O	O
the	DET	O	O
antiviral	ADJ	O	O
agent	NOUN	O	O
lamivudine	NOUN	O	I-Entity
prior	ADV	O	O

and	CCONJ	O	O
during	ADP	O	O
CT	PROPN	O	O
compared	VERB	O	O
with	ADP	O	O
historical	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
receive	VERB	O	O
lamivudine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
objectives	NOUN	O	O
were	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
in	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
reactivation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
diminishing	VERB	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
during	ADP	O	O
CT	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
prophylactic	ADJ	O	O
lamivudin	NOUN	O	I-Entity
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
historical	ADJ	O	O
controls	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
50	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
CT	PROPN	O	O
without	ADP	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
our	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=	SYM	O	O
50	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
21	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
42%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
established	VERB	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Twelve	NUM	O	O
(	PUNCT	O	O
24%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
them	PRON	O	O
were	VERB	O	O
evaluated	VERB	O	O
as	ADP	O	O
severe	ADJ	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
group	NOUN	O	O
severe	ADJ	O	O
hepatitis	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
(	PUNCT	O	O
2.7%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.006	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mean	ADJ	O	O
ALT	PROPN	O	O
values	NOUN	O	O
revealed	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
mean	ADJ	O	O
alanine	ADJ	O	I-Entity
aminotransferase	NOUN	O	O
(	PUNCT	O	O
ALT	PROPN	O	O
)	PUNCT	O	O
values	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
than	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
group	NOUN	O	O
;	PUNCT	O	O
154:64	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.32	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
prophylactic	ADJ	O	O
lamivudine	NOUN	O	I-Entity
significantly	ADV	O	O
decreases	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
HBV	PROPN	O	O
reactivation	NOUN	O	O
and	CCONJ	O	O
overall	ADJ	O	O
morbidity	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
immunosuppressive	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
most	ADV	O	O
appropriate	ADJ	O	O
nucleoside	NOUN	O	I-Entity
or	CCONJ	O	O
nucleotide	ADJ	O	I-Entity
analogue	NOUN	O	O
for	ADP	O	O
antiviral	ADJ	O	O
prophylaxis	NOUN	O	O
during	ADP	O	O
CT	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
optimal	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
after	ADP	O	O
completion	NOUN	O	O
of	ADP	O	O
CT	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (18308784)

Ginsenoside	PROPN	O	B-Entity
Rg1	PROPN	O	I-Entity
restores	VERB	O	O
the	DET	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
learning	VERB	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
morphine	NOUN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Rg1	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
ginsenoside	NOUN	O	I-Entity
extracted	VERB	O	O
from	ADP	O	O
Panax	PROPN	O	O
ginseng	NOUN	O	O
,	PUNCT	O	O
could	VERB	O	O
ameliorate	VERB	O	O
spatial	ADJ	O	O
learning	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
Rg1	PROPN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
agent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
Rg1	NOUN	O	I-Entity
on	ADP	O	O
learning	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
by	ADP	O	O
chronic	ADJ	O	O
morphine	NOUN	O	I-Entity
administration	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
mechanism	NOUN	O	O
responsible	ADJ	O	O
for	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Male	NOUN	O	O
rats	NOUN	O	O
were	VERB	O	O
subcutaneously	ADV	O	O
injected	VERB	O	O
with	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
twice	ADJ	O	O
a	DET	O	O
day	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
hour	NOUN	O	O
intervals	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Rg1	PROPN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
intraperitoneally	ADV	O	O
injected	VERB	O	O
2	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
second	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
once	ADV	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
Morphine	PROPN	O	I-Entity
/	SYM	O	O
Rg1	PROPN	O	I-Entity
decreased	VERB	O	O
escape	NOUN	O	O
latency	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
the	DET	O	O
time	NOUN	O	O
spent	VERB	O	O
in	ADP	O	O
platform	NOUN	O	O
quadrant	NOUN	O	O
and	CCONJ	O	O
entering	VERB	O	O
frequency	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
implantation	NOUN	O	O
of	ADP	O	O
electrodes	NOUN	O	O
and	CCONJ	O	O
electrophysiological	ADJ	O	O
recording	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
Rg1	PROPN	O	I-Entity
restored	VERB	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
potentiation	NOUN	O	O
(	PUNCT	O	O
LTP	PROPN	O	O
)	PUNCT	O	O
impaired	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
both	CCONJ	O	O
freely	ADV	O	O
moving	VERB	O	O
and	CCONJ	O	O
anaesthetised	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
electrophysiological	ADJ	O	O
recording	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
Rg1	PROPN	O	I-Entity
restored	VERB	O	O
the	DET	O	O
LTP	PROPN	O	O
in	ADP	O	O
slices	NOUN	O	O
from	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
changed	VERB	O	O
LTP	PROPN	O	O
in	ADP	O	O
the	DET	O	O
slices	NOUN	O	O
from	ADP	O	O
normal	ADJ	O	O
saline-	NOUN	O	O
or	CCONJ	O	O
morphine	NOUN	O	I-Entity
/	SYM	O	O
Rg1-treated	VERB	O	I-Entity
rats	NOUN	O	O
;	PUNCT	O	O
this	DET	O	O
restoration	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
MK801	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
Rg1	PROPN	O	I-Entity
may	VERB	O	O
significantly	ADV	O	O
improve	VERB	O	O
the	DET	O	O
spatial	ADJ	O	O
learning	NOUN	O	O
capacity	NOUN	O	O
impaired	VERB	O	O
by	ADP	O	O
chonic	ADJ	O	O
morphine	NOUN	O	I-Entity
administration	NOUN	O	O
and	CCONJ	O	O
restore	VERB	O	O
the	DET	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
inhibited	VERB	O	O
LTP	PROPN	O	O
.	PUNCT	O	O

This	DET	O	O
effect	NOUN	O	O
is	VERB	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
dependent	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17931375)

A	DET	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
subcutaneous	ADJ	O	O
heparin	NOUN	O	I-Entity
injection	NOUN	O	O
on	ADP	O	O
bruising	VERB	O	I-Entity
and	CCONJ	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	PART	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
injection	NOUN	O	O
duration	NOUN	O	O
on	ADP	O	O
bruising	VERB	O	I-Entity
and	CCONJ	O	O
pain	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
subcutaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
different	ADJ	O	O
methods	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
bruising	ADJ	O	I-Entity
and	CCONJ	O	O
pain	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
subcutaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
widely	ADV	O	O
studied	VERB	O	O
and	CCONJ	O	O
described	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
injection	NOUN	O	O
duration	NOUN	O	O
on	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
bruising	VERB	O	I-Entity
and	CCONJ	O	O
pain	NOUN	O	I-Entity
is	VERB	O	O
little	ADJ	O	O
documented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
sample	NOUN	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
50	NUM	O	O
patients	NOUN	O	O
to	PART	O	O
whom	NOUN	O	O
subcutaneous	ADJ	O	O
heparin	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

Heparin	PROPN	O	I-Entity
was	VERB	O	O
injected	VERB	O	O
over	ADP	O	O
10	NUM	O	O
seconds	NOUN	O	O
on	ADP	O	O
the	DET	O	O
right	ADJ	O	O
abdominal	ADJ	O	O
site	NOUN	O	O
and	CCONJ	O	O
30	NUM	O	O
seconds	NOUN	O	O
on	ADP	O	O
the	DET	O	O
left	ADJ	O	O
abdominal	ADJ	O	O
site	NOUN	O	O
.	PUNCT	O	O

Injections	NOUN	O	O
areas	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
bruising	VERB	O	I-Entity
at	ADP	O	O
48	NUM	O	O
and	CCONJ	O	O
72	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
each	DET	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Dimensions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bruising	VERB	O	I-Entity
on	ADP	O	O
the	DET	O	O
heparin	NOUN	O	I-Entity
applied	VERB	O	O
areas	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
transparent	ADJ	O	O
millimetric	ADJ	O	O
measuring	VERB	O	O
paper	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
VAS	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
measure	VERB	O	O
pain	NOUN	O	I-Entity
intensity	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
stop	NOUN	O	O
-	PUNCT	O	O
watch	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
time	VERB	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
bruising	VERB	O	I-Entity
occurrence	NOUN	O	O
was	VERB	O	O
64%	NUM	O	O
with	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
seconds	NOUN	O	O
duration	NOUN	O	O
and	CCONJ	O	O
42%	NUM	O	O
in	ADP	O	O
the	DET	O	O
30-second	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
determined	VERB	O	O
that	ADP	O	O
the	DET	O	O
size	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bruising	NOUN	O	I-Entity
was	VERB	O	O
smaller	ADJ	O	O
in	ADP	O	O
the	DET	O	O
30-second	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
intensity	NOUN	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
period	NOUN	O	O
were	VERB	O	O
statistically	ADV	O	O
significantly	ADV	O	O
lower	ADJ	O	O
for	ADP	O	O
the	DET	O	O
30-second	NOUN	O	O
injection	NOUN	O	O
than	ADP	O	O
for	ADP	O	O
the	DET	O	O
10-second	ADJ	O	O
injection	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
It	PRON	O	O
was	VERB	O	O
determined	VERB	O	O
that	ADP	O	O
injection	NOUN	O	O
duration	NOUN	O	O
had	VERB	O	O
an	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
bruising	VERB	O	I-Entity
and	CCONJ	O	O
pain	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
.	PUNCT	O	O

PRACTICE	NOUN	O	O
:	PUNCT	O	O
When	ADV	O	O
administering	VERB	O	O
subcutaneous	ADJ	O	O
heparin	NOUN	O	I-Entity
injections	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
extend	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15649445)

Acute	PROPN	O	O
reserpine	NOUN	O	I-Entity
and	CCONJ	O	O
subchronic	ADJ	O	O
haloperidol	NOUN	O	I-Entity
treatments	NOUN	O	O
change	VERB	O	O
synaptosomal	ADJ	O	O
brain	NOUN	O	O
glutamate	NOUN	O	I-Entity
uptake	NOUN	O	O
and	CCONJ	O	O
elicit	VERB	O	O
orofacial	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Reserpine-	PROPN	O	I-Entity
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
orofacial	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
are	VERB	O	O
putative	ADJ	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
(	PUNCT	O	O
TD	NOUN	O	I-Entity
)	PUNCT	O	O
whose	ADJ	O	O
pathophysiology	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
related	VERB	O	O
to	ADP	O	O
free	ADJ	O	O
radical	ADJ	O	O
generation	NOUN	O	O
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
induced	VERB	O	O
orofacial	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
by	ADP	O	O
acute	ADJ	O	O
reserpine	NOUN	O	I-Entity
and	CCONJ	O	O
subchronic	ADJ	O	O
haloperidol	NOUN	O	I-Entity
administration	NOUN	O	O
to	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Reserpine	ADJ	O	I-Entity
injection	NOUN	O	O
(	PUNCT	O	O
one	NUM	O	O
dose	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
mg	NUM	O	O

Haloperidol	PROPN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
one	NUM	O	O
dose	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
once	ADV	O	O
a	DET	O	O
week	NOUN	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
observation	NOUN	O	O
,	PUNCT	O	O
glutamate	NOUN	O	I-Entity
uptake	NOUN	O	O
by	ADP	O	O
segments	NOUN	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
was	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
decreased	ADJ	O	O
glutamate	NOUN	O	I-Entity
uptake	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
subcortical	ADJ	O	O
parts	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
reserpine	NOUN	O	I-Entity
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
.	PUNCT	O	O

Importantly	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
glutamate	NOUN	O	I-Entity
uptake	NOUN	O	O
correlates	VERB	O	O
negatively	ADV	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
orofacial	ADJ	O	B-Entity
diskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
early	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
glutamate	NOUN	O	I-Entity
transport	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
vacuous	ADJ	O	O
chewing	NOUN	O	O
movements	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14698717)

Acute	PROPN	O	B-Entity
psychosis	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
phenytoin	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
nonepileptic	ADJ	O	O
patient	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
psychosis	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
is	VERB	O	O
usually	ADV	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
the	DET	O	O
epileptic	ADJ	O	I-Entity
brain	NOUN	O	O
substratum	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
antiepileptic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
nonepileptic	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
psychosis	NOUN	O	I-Entity
following	VERB	O	O
phenytoin	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
trigeminal	ADJ	O	B-Entity
neuralgia	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
the	DET	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
that	ADJ	O	O
occur	VERB	O	O
following	VERB	O	O
phenytoin	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
some	DET	O	O
epileptic	ADJ	O	I-Entity
patients	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
direct	ADJ	O	O
result	NOUN	O	O
of	ADP	O	O
medication	NOUN	O	O
,	PUNCT	O	O
unrelated	ADJ	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12617329)

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
gum	NOUN	O	B-Entity
Arabic	PROPN	O	I-Entity
on	ADP	O	O
gentamicin	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
preliminary	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
work	NOUN	O	O
we	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
gum	NOUN	O	B-Entity
Arabic	ADJ	O	I-Entity
on	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
gentamicin	NOUN	O	I-Entity
(	PUNCT	O	O
GM	PROPN	O	I-Entity
)	PUNCT	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

kg	NOUN	O	O
of	ADP	O	O
distilled	VERB	O	O
water	NOUN	O	O
and	CCONJ	O	O
5%	NUM	O	O
w	PROPN	O	O
/	SYM	O	O
v	ADP	O	O
cellulose	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
gum	NOUN	O	B-Entity
Arabic	PROPN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mL	PROPN	O	O
/	SYM	O	O

kg	NOUN	O	O
of	ADP	O	O
a	DET	O	O
10%	NUM	O	O
w	PROPN	O	O
/	SYM	O	O
v	ADP	O	O
aqueous	ADJ	O	O
suspension	NOUN	O	O
of	ADP	O	O
gum	NOUN	O	B-Entity
Arabic	ADJ	O	I-Entity
powder	NOUN	O	O
,	PUNCT	O	O
orally	ADV	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
gum	NOUN	O	B-Entity
Arabic	PROPN	O	I-Entity
concomitantly	ADV	O	O
with	ADP	O	O
GM	PROPN	O	I-Entity
(	PUNCT	O	O
80mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
/	SYM	O	O
day	NOUN	O	O
intramuscularly	ADV	O	O
,	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
last	ADJ	O	O
six	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
period	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nephrotoxicity	PROPN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
the	DET	O	O
concentrations	NOUN	O	O
of	ADP	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
urea	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
glutathione	NOUN	O	I-Entity
(	PUNCT	O	O
GSH	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
light	ADJ	O	O
microscopic	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	O
sections	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
concomitant	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
gum	NOUN	O	B-Entity
Arabic	PROPN	O	I-Entity
and	CCONJ	O	O
GM	PROPN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
urea	NOUN	O	I-Entity
by	ADP	O	O
about	ADV	O	O
183	NUM	O	O
and	CCONJ	O	O
239%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
432	NUM	O	O
and	CCONJ	O	O
346%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
cellulose	NOUN	O	O
and	CCONJ	O	O
GM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
decreased	VERB	O	O
that	ADP	O	O
of	ADP	O	O
cortical	ADJ	O	O
GSH	PROPN	O	I-Entity
by	ADP	O	O
21%	NUM	O	O
(	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
27%	NUM	O	O
in	ADP	O	O
the	DET	O	O
cellulose	NOUN	O	O
plus	CCONJ	O	O
GM	PROPN	O	I-Entity
group	NOUN	O	O
)	PUNCT	O	O

The	DET	O	O
GM	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
proximal	ADJ	O	O
tubular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
slightly	ADV	O	O
less	ADV	O	O
severe	ADJ	O	O
in	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
GM	PROPN	O	I-Entity
together	ADV	O	O
with	ADP	O	O
gum	NOUN	O	B-Entity
Arabic	PROPN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
those	DET	O	O
given	VERB	O	O
GM	PROPN	O	I-Entity
and	CCONJ	O	O
cellulose	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
could	VERB	O	O
be	VERB	O	O
inferred	VERB	O	O
that	ADP	O	O
gum	NOUN	O	B-Entity
Arabic	ADJ	O	I-Entity
treatment	NOUN	O	O
has	VERB	O	O
induced	VERB	O	O
a	DET	O	O
modest	ADJ	O	O
amelioration	NOUN	O	O
of	ADP	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
histological	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
indices	NOUN	O	O
of	ADP	O	O
GM	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Further	ADJ	O	O
work	NOUN	O	O
is	VERB	O	O
warranted	VERB	O	O
on	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
on	ADP	O	O
renal	ADJ	O	O
functional	ADJ	O	O
aspects	NOUN	O	O
in	ADP	O	O
models	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
mechanism(s	NOUN	O	O
)	PUNCT	O	O
involved	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (12523465)

Visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
zonisamide	NOUN	O	I-Entity
.	PUNCT	O	O

Zonisamide	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
broad	ADJ	O	O
-	PUNCT	O	O
spectrum	NOUN	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
various	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
an	DET	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
three	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
complex	ADJ	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
and	CCONJ	O	O
altered	VERB	O	O
mental	ADJ	O	O
status	NOUN	O	O
after	ADP	O	O
zonisamide	NOUN	O	I-Entity
treatment	NOUN	O	O
was	VERB	O	O
begun	VERB	O	O
or	CCONJ	O	O
its	ADJ	O	O
dosage	NOUN	O	O
increased	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
three	NUM	O	O
had	VERB	O	O
been	VERB	O	O
diagnosed	VERB	O	O
earlier	ADV	O	O
with	ADP	O	O
epilepsy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
electroencephalogram	NOUN	O	O
(	PUNCT	O	O
EEG	PROPN	O	O
)	PUNCT	O	O

During	ADP	O	O
monitoring	VERB	O	O
,	PUNCT	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
EEG	PROPN	O	O
readings	NOUN	O	O
,	PUNCT	O	O
nor	CCONJ	O	O
did	VERB	O	O
video	NOUN	O	O
recording	NOUN	O	O
capture	NOUN	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
described	VERB	O	O
events	NOUN	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
experienced	VERB	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
before	ADP	O	O
this	DET	O	O
event	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
only	ADJ	O	O
recent	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
their	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
the	DET	O	O
introduction	NOUN	O	O
or	CCONJ	O	O
increased	VERB	O	O
dosage	NOUN	O	O
of	ADP	O	O
zonisamide	NOUN	O	I-Entity
.	PUNCT	O	O

Until	ADP	O	O
then	ADV	O	O
,	PUNCT	O	O
clinicians	NOUN	O	O
need	VERB	O	O
to	PART	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
possible	ADJ	O	O
complication	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
zonisamide	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11961407)

GLEPP1	ADJ	O	O
receptor	NOUN	O	O
tyrosine	NOUN	O	I-Entity
phosphatase	NOUN	O	O
(	PUNCT	O	O
Ptpro	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
rat	NOUN	O	O
PAN	PROPN	O	I-Entity
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Glomerular	ADJ	O	O
epithelial	ADJ	O	O
protein	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
GLEPP1	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
podocyte	NOUN	O	O
receptor	NOUN	O	O
membrane	NOUN	O	O
protein	NOUN	O	O
tyrosine	NOUN	O	I-Entity
phosphatase	NOUN	O	O
located	VERB	O	O
on	ADP	O	O
the	DET	O	O
apical	ADJ	O	O
cell	NOUN	O	O
membrane	NOUN	O	O
of	ADP	O	O
visceral	ADJ	O	O
glomerular	ADJ	O	O
epithelial	ADJ	O	O
cell	NOUN	O	O
and	CCONJ	O	O
foot	NOUN	O	O
processes	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
better	ADV	O	O
understand	VERB	O	O
the	DET	O	O
utility	NOUN	O	O
of	ADP	O	O
GLEPP1	PROPN	O	O
as	ADP	O	O
a	DET	O	O
marker	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
amount	NOUN	O	O
and	CCONJ	O	O
distribution	NOUN	O	O
of	ADP	O	O
GLEPP1	PROPN	O	O
protein	NOUN	O	O
and	CCONJ	O	O
mRNA	PRON	O	O
were	VERB	O	O
examined	VERB	O	O
by	ADP	O	O
immunohistochemistry	NOUN	O	O
,	PUNCT	O	O
Western	ADJ	O	O
blot	NOUN	O	O
and	CCONJ	O	O
RNase	PROPN	O	O
protection	NOUN	O	O
assay	NOUN	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
podocyte	NOUN	O	O
injury	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Puromycin	PROPN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
nephrosis	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
single	ADJ	O	O
intraperitoneal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
,	PUNCT	O	O
20	NUM	O	O
mg/100	NOUN	O	O
g	NOUN	O	O
BW	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tissues	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
at	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
11	NUM	O	O
,	PUNCT	O	O
21	NUM	O	O
,	PUNCT	O	O
45	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
and	CCONJ	O	O
126	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
PAN	PROPN	O	I-Entity
injection	NOUN	O	O
so	ADP	O	O
as	ADP	O	O
to	PART	O	O
include	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
acute	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
foot	NOUN	O	O
process	NOUN	O	O
effacement	NOUN	O	O
(	PUNCT	O	O
days	NOUN	O	O
5	NUM	O	O
-	SYM	O	O
11	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
chronic	ADJ	O	O
phase	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
glomerulosclerosis	NOUN	O	I-Entity
(	PUNCT	O	O
days	NOUN	O	O
45	NUM	O	O
-	SYM	O	O
126	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
GLEPP1	PROPN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
unlike	ADP	O	O
podocalyxin	NOUN	O	O
,	PUNCT	O	O
reflects	VERB	O	O
podocyte	ADJ	O	O
injury	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
PAN	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9401499)

Ticlopidine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
:	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
Chinese	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
ticlopidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
were	VERB	O	O
reported	VERB	O	O
and	CCONJ	O	O
another	DET	O	O
13	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
English	ADJ	O	O
literature	NOUN	O	O
were	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

Agranulocytosis	NOUN	O	I-Entity
occurred	VERB	O	O
3	NUM	O	O
-	SYM	O	O
20	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
ticlopidine	NOUN	O	I-Entity
,	PUNCT	O	O
so	ADV	O	O
frequent	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
white	ADJ	O	O
cell	NOUN	O	O
count	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O

There	ADV	O	O
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
no	DET	O	O
direct	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
or	CCONJ	O	O
duration	NOUN	O	O
used	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
suppression	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	NOUN	O	O
for	ADP	O	O
ticlopidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
with	ADP	O	O
colony	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
factors	NOUN	O	O
seemed	VERB	O	O
to	PART	O	O
have	VERB	O	O
little	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
5	NUM	O	O
of	ADP	O	O
the	DET	O	O
6	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
concurrent	ADJ	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
died	VERB	O	O
,	PUNCT	O	O
should	VERB	O	O
alert	VERB	O	O
clinicians	NOUN	O	O
to	PART	O	O
be	VERB	O	O
more	ADV	O	O
cautious	ADJ	O	O
when	ADV	O	O
using	VERB	O	O
these	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
simultaneously	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (2273650)

Facilitation	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
retrieval	NOUN	O	O
by	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
test	NOUN	O	O
morphine	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
state	NOUN	O	O
dependency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
step	NOUN	O	O
-	PUNCT	O	O
through	ADP	O	O
type	NOUN	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
learning	VERB	O	O
test	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Amnesia	PROPN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
cycloheximide	NOUN	O	I-Entity
were	VERB	O	O
reversed	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
given	VERB	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
test	NOUN	O	O
trial	NOUN	O	O
(	PUNCT	O	O
pre	NOUN	O	O
-	PUNCT	O	O
test	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pre	ADV	O	O
-	PUNCT	O	O
test	NOUN	O	O
morphine	NOUN	O	I-Entity
also	ADV	O	O
facilitated	VERB	O	O
the	DET	O	O
memory	NOUN	O	O
retrieval	NOUN	O	O
in	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
administered	VERB	O	O
naloxone	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
training	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
pre	X	O	O
-	PUNCT	O	O
test	NOUN	O	O
scopolamine	NOUN	O	I-Entity
partially	ADV	O	O
reversed	VERB	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
significantly	ADV	O	O
;	PUNCT	O	O
and	CCONJ	O	O
pre	VERB	O	O
-	PUNCT	O	O
test	NOUN	O	O
cycloheximide	NOUN	O	I-Entity
failed	VERB	O	O
to	PART	O	O
reverse	VERB	O	O
the	DET	O	O
cycloheximide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
facilitation	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
retrieval	NOUN	O	O
by	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
test	NOUN	O	O
morphine	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
the	DET	O	O
direct	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
rather	ADV	O	O
than	ADP	O	O
a	DET	O	O
state	NOUN	O	O
dependent	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10683478)

Apomorphine	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
nonselective	ADJ	O	O
dopamine	NOUN	O	B-Entity
agonist	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
selected	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
its	ADJ	O	O
biphasic	ADJ	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
hypothermia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
produce	VERB	O	O
distinct	ADJ	O	O
changes	NOUN	O	O
to	ADP	O	O
dopamine	NOUN	O	I-Entity
turnover	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rodent	NOUN	O	O
brain	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
such	ADJ	O	O
experiments	NOUN	O	O
there	ADV	O	O
is	VERB	O	O
evidence	NOUN	O	O
that	ADP	O	O
characterization	NOUN	O	O
and	CCONJ	O	O
detection	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
activity	NOUN	O	O
in	ADP	O	O
rodents	NOUN	O	O
critically	ADV	O	O
depends	VERB	O	O
upon	ADP	O	O
the	DET	O	O
test	NOUN	O	O
conditions	NOUN	O	O
employed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
detection	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
was	VERB	O	O
facilitated	VERB	O	O
by	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
acclimatization	NOUN	O	O
to	ADP	O	O
the	DET	O	O
test	NOUN	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
test	NOUN	O	O
conditions	NOUN	O	O
can	VERB	O	O
impact	VERB	O	O
upon	ADP	O	O
other	ADJ	O	O
physiological	ADJ	O	O
responses	NOUN	O	O
to	PART	O	O
apomorphine	VERB	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypothermia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
apomorphine	ADV	O	I-Entity
produced	VERB	O	O
qualitatively	ADV	O	O
different	ADJ	O	O
responses	NOUN	O	O
under	ADP	O	O
novel	NOUN	O	O
conditions	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
those	DET	O	O
behaviors	NOUN	O	O
elicited	VERB	O	O
in	ADP	O	O
the	DET	O	O
home	NOUN	O	O
test	NOUN	O	O
cage	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
apomorphine	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotion	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
prominent	ADJ	O	O
in	ADP	O	O
the	DET	O	O
novel	NOUN	O	O
exploratory	ADJ	O	O
box	NOUN	O	O
.	PUNCT	O	O

Dopamine	PROPN	O	I-Entity
turnover	NOUN	O	O
ratios	NOUN	O	O
(	PUNCT	O	O
DOPAC	PROPN	O	I-Entity
:	PUNCT	O	O
DA	NOUN	O	I-Entity
and	CCONJ	O	O
HVA	PROPN	O	I-Entity
:	PUNCT	O	O

DA	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
those	DET	O	O
animals	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
the	DET	O	O
exploratory	ADJ	O	O
box	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
their	ADJ	O	O
home	NOUN	O	O
cage	NOUN	O	O
counterparts	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
apomorphine	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
reductions	NOUN	O	O
in	ADP	O	O
striatal	ADJ	O	O
dopamine	NOUN	O	I-Entity
turnover	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
both	DET	O	O
novel	NOUN	O	O
and	CCONJ	O	O
home	NOUN	O	O
cage	NOUN	O	O
environments	NOUN	O	O
.	PUNCT	O	O


